2017”N

  • ’˜‘
    1. ‘«—§—YˆêDÅVƒKƒCƒhƒ‰ƒCƒ“€‹’ ¬Ž™‰È f’fEŽ¡—ÃŽwj ‰ü’ù‘æ2”ŁD‰““¡•¶•v•Ò. “Œ‹ž: ’†ŽR‘“X; 2017. ‹}«×‹CŠÇŽx‰ŠDp516-9.
    2. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj 2017”N“x”ŁDŽRŒû“O, –kŒŽŒõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. ¬Ž™‚Ì‹CŠÇŽxšb‘§D p1386-8.
    3. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒŽŒõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽŸŠ³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. p1360-1.
    4. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒŽŒõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽŸŠ³Š³ŽÒ‚Ì”DPEoŽY‚Ì“K‰žEŠÇ—. p429.
    5. ŽíŽsq’ˆ. _Œo“à‰È Clinical Question & Pearls _ŒoŠŽõÇ. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2017. ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚É‚æ‚é”]Ç‚Í‚Ç‚Ì‚æ‚€‚ɐf’f‚µ‚ÄŽ¡—µ‚œ‚ç‚æ‚¢‚Å‚µ‚å‚€‚©H p116-20.
    6. œA–ìŒbˆê, Žs“c•™Žq. f’fƒ‚ƒ_ƒŠƒeƒB‚Æ‚µ‚Ă̐S‹Ø•a—. ˜aò“OEœA]“¹º•Ò. “Œ‹ž: “ì]“°; 2017. 3ÍuS”ì‘å‚ðŽå•a‘Ô‚Æ‚·‚鎟Š³v-2uƒŠƒ\ƒ\[ƒ€iƒ‰ƒCƒ\ƒ][ƒ€j•av-d)uS‹Øãk–§‰»áŠQv. p136-8.
    7. œA–ìŒbˆê, Žs“c•™Žq. ƒKƒCƒhƒ‰ƒCƒ“‚ƍŐV•¶Œ£‚ÅŠw‚ԏ¬Ž™‰ÈŠwƒŒƒrƒ…[2016-17. “Œ‹ž: ‘‡ˆãŠwŽÐ; 2017. S‹ØŽŸŠ³. P313-25.
    8. œA–ìŒbˆê, Žs“c•™Žq. ÅVƒKƒCƒhƒ‰ƒCƒ“€‹’@¬Ž™‰Èf’fEŽ¡—ÃŽwj. “Œ‹ž: ’†ŽR‘“X; 2017. ŒÇ—§«¶Žºãk–§‰»áŠQ. P673?5.
    9. œA–ìŒbˆê, Žs“c•™Žq.¬Ž™—Տ°ŒŸž‚̃z?ƒCƒ“ƒg2017.¬Ž™“à‰È49i‘j. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2017. zŠÂŠíŽŸŠ³. p713- 732.
    10. œA–ìŒbˆê, Žs“c•™Žq. ìè•a‚Ì•aˆöŒ€‹†ŠT˜_@ŠCŠO‚ÌŒ€‹†‚©‚ç@“ú–{ìè•aŠw‰ï•aˆöŒŸ“¢¬ˆÏˆõ‰ï•Ò “ú–{ìè•aŠw‰ïŽ––±‹Ç 2017; p44-9.
    11. Œ“c’ŒŽ÷, Žs“c•™Žq. f’fƒ‚ƒ_ƒŠƒeƒB‚Æ‚µ‚Ă̐S‹Ø•a—. ˜aò“OEœA]“¹º•Ò. “Œ‹ž: “ì]“°; 2017. 2ÍuSŠg‘å‚ðŽå•a‘Ô‚Æ‚·‚鎟Š³v-7uDanon•av. p168-71.
    12. Œ“c’Œ“¿. “ú–{¬Ž™ŠŽõÇŠw‰ïi•Òj“úíf—Âɖ𗧂¬Ž™ŠŽõÇƒ}ƒjƒ…ƒAƒ‹2017. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2017. ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒ„ƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“. p426-33.
    13. ˆÉ“¡–õ“TD‚±‚±‚ª‚·‚²‚¢I•xŽR‘åŠw•‘®•a‰@‚̍ŐVŽ¡—ÁD•xŽR‘åŠw•‘®•a‰@•Ò’˜D“Œ‹ž: ƒoƒŠƒ…[ƒƒfƒBƒJƒ‹; 2017.uŒoŒû–Ɖu—Ö@v‚É‚æ‚éH•šƒAƒŒƒ‹ƒM[‚ÌŽ¡—ÁDp70-1.
    14. ’‡‰ª‰pK, Žs“c•™Žq. zŠÂŠíŽŸŠ³ ÅV‚ÌŽ¡—à 2018-2019. “Œ‹ž: “ì]“°; FontanŽèpŒã‚̉“ŠuŠúŠÇ—. p225-8.
  • ŒŽ’˜
    1. Makimoto M, Kawasaki Y, Inomata S, Tamura K, Yoshida T. Early upper lip pressure ulcer in a preterm neonate. Pediatr Int. 2017 May; 59(5): 633-4.
    2. Nakaoka S, Kawasaki Y, Inomata S, Makimoto M, Yoshida T. Caffeine toxicity in a preterm neonate. Pediatr Neonatol. 2017 Aug; 58(4): 380-1.
    3. Hoshino A, Okada S, Yoshida K, Nishida N, Okuno Y, Ueno H, Yamashita M, Okano T, Tsumura M, Nishimura S, Sakata S, Kobayashi M, Nakamura H, Kamizono J, Mitsui-Sekinaka K, Ichimura T, Ohga S, Nakazawa Y, Takagi M, Imai K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Kojima S, Nonoyama S, Morio T, Kanegane H. Abnormal hematopoiesis and autoimmunity in human subjects with germline IKZF1 mutations. J Allergy Clin Immunol. 2017 Jul; 140(1): 223-31.
    4. Wang C, Takasaki A, Watanabe Ozawa S, Nakaoka H, Okabe M, Miyao N, Saito K, Ibuki K, Hirono K, Yoshimura N, Yu X, Ichida F. Long-Term Prognosis of Patients With Left Ventricular Noncompaction@- Comparison Between Infantile and Juvenile Types. Circ J. 2017 Apr 25; 81(5): 694-700.
    5. Wang C, Yu X, Ichida F. Survival in Young Patients With Noncompaction May Not Only Depend on Cardiac But Also on Neuromuscular Comorbidity - Reply. Circ J. 2017 Jul 25; 81(8): 1239.
    6. Wang C, Hata Y, Hirono K, Takasaki A, Ozawa SW, Nakaoka H, Saito K, Miyao N, Okabe M, Ibuki K, Nishida N, Origasa H, Yu X, Bowles NE, Ichida F; for LVNC Study Collaborators. A Wide and Specific Spectrum of Genetic Variants and Genotype-Phenotype Correlations Revealed by Next-Generation Sequencing in Patients with Left Ventricular Noncompaction.J Am Heart Assoc. 2017 Aug 30; 6(9).
    7. Ikawa Y, Nishimura R, Araki R, Noguchi K, Muraoka M, Fukuda M, Fujiki T, Kuroda R, Mase S, Maeba H, Nomura K, Yachie A. Pathognomonic serum cytokine profiles identify life-threatening langerhans cell histiocytosis. Br J Haematol. 2017 Feb; 176(3): 495-497.
    8. Yamaguchi Y, Mizumaki K, Hata Y, Sakamoto T, Nakatani Y, Kataoka N, Ichida F, Inoue H, Nishida N. Latent pathogenicity of the G38S polymorphism of KCNE1 K+ channel modulator. Heart Vessels. 2017 Feb; 32(2): 186-192.
    9. Straus R, Rose T, Flint SM, Klotsche J, Haupl T, Peck-Radosavljevic M, Yoshida T, Kyogoku C, Flechsig A, Becker AM, Dao KH, Radbruch A, Burmester GR, Lyons PA, Davis LS, Hiepe F, Grutzkau A, Biesen R. Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. J Mol Med (Berl). 2017 Jul;95(7):753-765.
    10. Aonuma K, Shiga T, Atarashi H, Doki K, Echizen H, Hagiwara N, Hasegawa J, Hayashi H, Hirao K, Ichida F, Ikeda T, Maeda Y, Matsumoto N, Sakaeda T, Shimizu W, Sugawara M, Totsuka K, Tsuchishita Y, Ueno K, Watanabe E, Hashiguchi M, Hirata S, Kasai H, Matsumoto Y, Nogami A, Sekiguchi Y, Shinohara T, Sugiyama A, Sumitomo N, Suzuki A, Takahashi N, Yukawa E, Homma M, Horie M, Inoue H, Ito H, Miura T, Ohe T, Shinozaki K, Tanaka K; Japanese Circulation Society and the Japanese Society of Therapeutic Drug Monitoring Joint Working Group. Guidelines for Therapeutic Drug Monitoring of Cardiovascular Drugs Clinical Use of Blood Drug Concentration Monitoring (JCS 2015)@- Digest Version. Circ J. 2017 Mar 24; 81(4): 581-612.
    11. Yoshida K, Adachi Y, Sasaki M, Akashi M, Itazawa T, Ohya Y, Odajima H, Akasawa A. Ultraviolet index is associated with childhood eczema prevalence: Sex and age differences. Pediatr Allergy Immunol. 2017 Jun; 28(4): 391-3.
    12. Chida A, Inai K, Sato H, Shimada E, Nishizawa T, Shimada M, Furutani M, Furutani Y, Kawamura Y, Sugimoto M, Ishihara J, Fujiwara M, Soga T, Kawana M, Fuji S, Tateno S, Kuraishi K, Kogaki S, Nishimura M, Ayusawa M, Ichida F, Yamazawa H, Matsuoka R, Nonoyama S, Nakanishi T. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. Heart Vessels. 2017 Jun; 32(6): 700-7.
    13. Kimura M, Ito Y, Shimomura M, Morishita H, Meguro T, Adachi Y, Seto S. Cytokine profile after oral food challenge in infants with food protein-induced enterocolitis syndrome. Allergol Int. 2017 Jul; 66(3): 452-7.
    14. Fujino N, Yoshimuta T, Ichida F, Kinugawa K, Usuda K, Kitayama M, Ino H, Kawashiri MA, Tada H, Mizuno S, Hayashi K, Takemura H, Yamagishi M; all the members of the Japanese Circulation Society in Hokuriku District. Overview of the 81st Annual Scientific Meeting of the Japanese Circulation Society@- Cardiovascular Medicine for the Next Generation. Circ J. 2017 Aug 25; 81(9): 1261-7.
    15. Hosoki K, Redding D, Itazawa T, Chakraborty A, Tapryal N, Qian S, Qi H, Aguilera-Aguirre L, Brasier AR, Phani VS, Hazra TK, Boldogh I, Sur S. Innate mechanism of pollen- and cat dander-induced oxidative stress and DNA damage in the airways. J Allergy Clin Immunol. 2017 Nov; 140(5): 1436-9.e5.
    16. Takatsuki S, Ogata S, Ishii M, Yokozawa M, Ono M, Fujiwara M, Ida H, Motomura H, Moriuchi H, Taketazu M, Kawamura Y, Kawano T, Izumi T, Shiono J, Tsuchiya S, Tsuchiya K, Goushi T, Ichida F, Saji T. Low risk of treatment resistance in Down syndrome with Kawasaki disease. Pediatr Int. 2017 Dec; 59(12): 1236-9.
    17. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ‘ºãIŒ[, ‘«—§—Yˆê. H•šƒAƒŒƒ‹ƒM[Ž™‚š‚æ‚Ñ‚»‚Ì•ÛŒìŽÒ‚ɑ΂·‚éƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËŠíiƒGƒsƒyƒ“Rj‚ðŽg—p‚·‚é“KØ‚ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“xD“ú–{¬Ž™—Տ°ƒAƒŒƒ‹ƒM[Šw‰ïŽGŽ@(in press)r–؁@®, ŽsìŒõ‘Ÿ˜Y, ŒŽR˜aF, V’ÃŒ’—T, ŽR–{„Žm, ŽíŽsq’ˆ, ’·‘º•q¶, ’߁@’qŒõ, ”~ŒŽ@ŽÀ, —¢Œ©@º. ¬Ž™ˆã—Ï]Ž–ŽÒ‚Ì”]Ž€‚š‚æ‚Ñ‘ŸŠíˆÚA‚ÉŠÖ‚·‚éˆÓŽ¯’²ž(‘æ“ñ‰ñ). “ú–{¬Ž™‹~‹}ˆãŠw‰ïŽGŽ 2017 16(1): 111-5.
    18. Ž›‰ºV‘Ÿ˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•œ, ’†Œ•q—Y, Žs“c•™Žq. WilliamsÇŒóŒQ‚É“Á’¥“I‚ȐSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µ‚œELNˆâ“`ŽqˆÙíÇ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2017 July 121(7): 1179-83.
    19. ˆ¢•”@~, Œ“c’Œ“¿, X–ìŽÑˆßŽq. ‰º—ŸÇŠ³Ž™‚ɃEƒCƒ‹ƒXRŒŽŒŸžiƒƒ^ƒEƒCƒ‹ƒXAƒmƒƒEƒCƒ‹ƒXAƒAƒfƒmƒEƒCƒ‹ƒXj‚ðŽÀŽ{‚·‚邱‚Ƃ̐¥”ñ. ¬Ž™‰È—Տ°@2017 Mar 70(3): 402-5.
  • Ç—á•ñ
    1. ˜a“c‘ñ–ç, ŽíŽsq’ˆ, rˆä”ü•ä, ’†—ÑŒºˆê, ‘«—§—Yˆê. high-flow nasal cannula —Ö@‰º‚ɍq‹ó”À‘—‚ðs‚Á‚œdÇˆô“ª“Ç‚Ì“ûŽ™—á. ‹~‹}ˆãŠw@2017 Mar 41(3): 364-8.
    2. Ž›‰ºV‘Ÿ˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•œ, ’†Œ•q—Y, Žs“c•™Žq. WilliamsÇŒóŒQ‚É“Á’¥“I‚ȐSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µ‚œELNˆâ“`ŽqˆÙíÇ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2017 July 121(7): 1179-83.
    3. ›“c^–ç, •œŠâ–ŸŽq, “c’†•ü”ü, ”ÂàVŽõŽq, ‘«—§—Yˆê. •ÂÇ«‡–°Žž–³ŒÄ‹z‚ª‹^‚í‚ê‚œ‡–°Žž—VsÇ‚ÌDownÇŒóŒQ‚Ì1—á. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ 2017 June 28(1): 3-8.
    4. â“c“ÞûŽ, ‹Ž–{ˆè•v, ŽÄ“c@K, ‹à“c@®, “c’†•ü”ü, ‘«—§—Yˆê. V¶Ž™Šú‚æ‚è“TŒ^“I‚ȗՏ°Çó‚ð’悵‘Šúf’f‚ª‰Â”\‚Å‚ ‚Á‚œ”玿Œ`¬ˆÙí‚𔺂Á‚œ’†ŠuŽ‹_ŒoˆÙŒ`¬Ç‚Ì‚P—á. ¬Ž™‰È—Տ° 2017 May 70(5): 679-84.
  • ‘à
    1. ‘«—§—YˆêD¬Ž™ƒAƒŒƒ‹ƒM[‚̃gƒsƒbƒNƒX@ŠÂ‹«‚Ə¬Ž™‚̃AƒŒƒ‹ƒM[D“ú–{¬Ž™‰Èˆã‰ï‰ï•ñ 2017 54:32-4.
    2. ‘«—§—YˆêD¬Ž™‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒvD¬Ž™‰È—Տ° 2017; 70:2041-5.
    3. ‘«—§—Yˆê. •ÛˆçŒ»ê‚ł̐H•šƒAƒŒƒ‹ƒM[Ž™‚ւ̑Ήž. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 26-8.
    4. ‘«—§—Yˆê. Žq‚Ç‚à‚Æ‘å‹C ŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[. Žq‚Ç‚à‚ÌŒ’N‰ÈŠw 2017 Jan 16(1): 7-11.
    5. ‘«—§—Yˆê. ¬Ž™šb‘§‚̃tƒFƒmƒ^ƒCƒv. ƒAƒŒƒ‹ƒM[@2017 Jan 66(1): 1-8.
    6. ‘«—§—Yˆê. ”ì–ž‚Ə¬Ž™šb‘§. ƒAƒŒƒ‹ƒM[@2017 Aug 66(8): 977-983.
    7. ‘«—§—Yˆê. “û—cŽ™šb–‚̃tƒFƒmƒ^ƒCƒv•ª—Þ. ¬Ž™“à‰È@2017 Jan 49(1): 43-46.
    8. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[‚©‚ç‚Ý‚œŒÄ‹zŠíŽŸŠ³. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ@2017 June 28(1): 28-32.
    9. ‘«—§—Yˆê. ƒAƒJƒfƒ~ƒbƒNƒXƒLƒ‹‚𖁂­. ž“ǂ̃|ƒCƒ“ƒgD“ú–{¬Ž™—Տ°ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 15: 408-11.
    10. ‘«—§—YˆêD“û—cŽ™‚Ìšb–‚̊ӕʂƎ¡—ÁD“ú–{¬Ž™Žš•@ˆôA‰È 2017 38:326-9.
    11. –q–{—D”ü. NICU“ü‰@Ž™‚ւ̃Jƒ“ƒKƒ‹[ƒPƒA.ŽüŽYŠú‚É‚š‚¯‚éƒtƒ@ƒ~ƒŠ[ƒZƒ“ƒ^[ƒhƒPƒA. ŽüŽYŠúˆãŠw; 2017 Jan; 47(1): 90-2.
    12. ŽíŽsq’ˆ. ¬Ž™‹~‹}‚©‚猩‚œ•ÛˆçŽ{Ý‚ÌŠë‹@ŠÇ—. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 29-31.
    13. ŽíŽsq’ˆ. ¬Ž™‹~‹}‚©‚猩‚œ•ÛˆçŽ{Ý‚ÌŠë‹@ŠÇ—. •Ûˆç‚Æ•ÛŒ’. 2017 Jan ; 23(1): 29-31.ŽíŽsq’ˆ. y’¥Œó‚©‚猩”²‚¯!¬Ž™‹~‹}ŽŸŠ³@‰Ÿ‚³‚Š‚Ä‚š‚«‚œ‚¢Še’¥Œó‚Ì•a‘ԂƑΉžƒXƒLƒ‹z šq“f. Jmed mook 2017 52: 101-9.
    14. ŽíŽsq’ˆ. ¬Ž™dÇS•s‘SŽ¡—Â̌»ó‚Ə«—ˆ@‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒ»ó‚Ə¬Ž™‰Èˆã‚Ì–ðŠ„. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 2017 33(2): 91-9.
    15. ŽíŽsq’ˆ. ”]Ž€‚Æ‚±‚Ç‚à‚Ì–œ‚Ə¬Ž™‰Èˆã. “ú–{¬Ž™‰Èˆã‰ï‰ï•ñ 2017 54: 44-7.
    16. œA–ìŒbˆê, Žs“c•™Žq. u“KØ‚ÈŠwZS‘ŸŒŸf|Œ©“Š‚µ‚Ä‚Í‚¢‚¯‚È‚¢ƒ|ƒCƒ“ƒg‚ÆŠÇ—v. TŠ§“ú–{ˆãŽ–V•ñ . p - .
    17. ˆÉ“¡–õ“TDÁ‰»ŠÇƒAƒŒƒ‹ƒM[‚̃tƒFƒmƒ^ƒCƒvE—Տ°‘œD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 31:1-6.
    18. ˆÉ“¡–õ“TDH•šƒAƒŒƒ‹ƒM[‚Ì—U”­Çó?dÇ“x”»’è‚ƑΉž?@H•šƒAƒŒƒ‹ƒM[Œ€‹†‰ïŽ2017 17(2):102-9.
    19. ˆÉ“¡–õ“TDH•šƒAƒŒƒ‹ƒM[‚Ì—U”­Çó‚̏dÇ“x•]‰¿‚ƃAƒiƒtƒBƒ‰ƒLƒV[‚ւ̑ΉžD“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 2017 15:1-7.
    20. ˆÉ“¡–õ“T, ŠC˜VàVŒ³GDH•šƒAƒŒƒ‹ƒM[ƒKƒCƒhƒ‰ƒCƒ“2016 Çó‚̏dÇ“x”»’è‚ƑΏǗÖ@D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2017 31:740-6.
    21. Œ“c’Œ“¿. ƒEƒCƒ‹ƒXŠŽõÇ\Å‹ß‚Ì“®ŒüEƒgƒsƒbƒNƒX. ‘“à‚Řb‘è‚ÌŠŽõÇ\f’f‚ÆŽ¡—Á@ƒqƒgƒRƒƒiƒEƒCƒ‹ƒX. ¬Ž™“à‰È; 2017 49(11): 1659-63.
    22. ¬àVˆ»‰À, Žs“c•™Žq. ”DPE•ª•ØŽž‚ÌŒŒs“®‘Ô‚ðŠÜ‚Þ•ê‘̂̕ω»@Heart View 2017 21: 26-30.
    23. “c‘ºŒ«‘Ÿ˜Y, ‹g“cär. ‚¿‚å‚Á‚Æ‹C‚É‚È‚éV¶Ž™-”À‘—‚·‚ׂ«”»’f‚Í?@–³ŒÄ‹z”­ì. ŽüŽYŠúˆãŠw; 2017 Oct; 47(10): 1275-8.

  • 2017”NŠw‰ï•ñ
    1. Itazawa T, Hosoki K, Sur S. Cat Dander Extract Directly Stimulates B Cell to Induce Class Switch. 73th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2017 Mar 3-6; Atlanta(USA).
    2. Itazawa T, Hosoki K, Boldogh I, Sur S. Cat Dander Extract Requires Myd88 to Induce Innate Neutrophil Recruitment, and Allergic Sensitization and Allergic Airway Inflammation. 72th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2017 Mar 3-6; Atlanta(USA).
    3. Ichida F. The Zebras in Pediatric Cardiology. A National Registry of Rare Cardiac Disease in Children. The 51th Annual Meeting of AEPC; 2017 Mar 30; Lyon(France). (Invited Lecture)
    4. Hirono K, Hata Y, Ozawa S, Wang C, Toda T, Momoi N, Inuzuka R, Hiroki N, Sakaguchi H, Kurosaki K, Okabe M, Miyao N, Nakaoka H, Ibuki K, Saito K, Nishida N, Ichida F. Phenotype-Genotype correlations in the fetal patients with left ventricular noncompaction. The 13th Japan-China-Korea Pediatric Heart Forum with Asian Pacific Symposium; 2017 July 9; Hamamatsu.
    5. Ichida F. Clinical and molecular mechanism of left ventricular noncompaction. Scientific sessions of AHA; 2017 Nov. 14; Anaheim(U.S.A) (Invited Lecture)
    6. ’‡‰ª²’qŽqC‹v•ÛŸ”VC˜a“c‘ñ–çC“c’†•ü”üCŽíŽsq’ˆC‘«—§—Yˆê.@ƒ}ƒCƒRƒvƒ‰ƒYƒ}ŠŽõŒã‚É‹}«¬”]Žž’²Ç‚𗈂œ‚µ‚œ‚P—áD‘æ71‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï; 2017 Feb 5; ‹à‘ò.
    7. ¬àVˆ»‰À, ’‡‰ª‰pK, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, ’––”’qŽÀ, •Ä“c@“N, –F‘º’ŒŽ÷. ‘ÙŽ™Šú‚ɐf’f‚µŽèp‰î“ü‚ð‘I‘ð‚µ‚œ‚ªAŒ‹‰Ê‹~–œ‚Å‚«‚È‚©‚Á‚œŽOë•Ù•ÂœA”x“®–¬•ÂœASŽº’†ŠuŒ‡‘¹AŽå—v‘Ì”x‘€•›“®–¬iMAPCAj‚É—Œ”x‚̐æ“V«”x‹C“¹ŠïŒ`iCPAMj‚ª‡•¹‚µ‚œˆê—á. ‘æ23‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ï; 2017 Mar 3-4; “Œ‹ž.
    8. ŽíŽsq’ˆ. ƒ[ƒŠƒ“ƒOƒŠƒXƒg‚ð—˜—p‚µ‚œW’cÐŠQŽž‚É‚š‚¯‚é‹Ù‹}ˆã—Ïî•ñŠÇ—ƒVƒXƒeƒ€‚̍lŽ@. ‘æ44‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï; 2017 Mar 9-11; ŽD–y.
    9. Žs“c•™Žq. “Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚̗Տ°``Ç—á•ñ‚©‚çˆâ“`Žq‰ðÍ‚Ü‚Å20”NŠÔ‚ÌŒ€‹†‚©‚猩‚Š‚œ‚à‚́`. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2017 Mar 12; •xŽR.
    10. ”ª–؍GŽq, ¬àVˆ»‰À, ’‡‰ª‰pK, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq. ‚΂¿Žw‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ”x“®Ã–¬á‘‚Ì1—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2017 Mar 12; •xŽR.
    11. ’·‰ªvG, Œ“cŒ\Œá, ˆÉ—Ç•”m, ’JŒûçq, ×–ì—RŽ—Žq, ã–ì˜a”V, “ˆ”öˆ»Žq, “ŒŽROK, “¡“cC•œ, “ñ’J@•, ŒÜ\—’“o, ”šèŠì–F, ’ށ@_”V, Œ“c’Œ“¿, ’†’Ø‹v”T, –쑺ŒbŽq. ”jÓÔŒŒ‹…E•nŒŒ‚ð”F‚߁AVitB12‹zŽûáŠQ‚É‚æ‚鋐Ô‰è‹…«•nŒŒ‚Ɛf’f‚µ‚œ’Z’°ÇŒóŒQ‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2017 Mar 12; •xŽR.
    12. ‘Ÿ“cˆÀF, Œ“c’Œ“¿, ’†’Ø‹v”T, –쑺ŒbŽq, ‘«—§—Yˆê, à_“‡@ä, ùŒŽ³Ž. “÷‰èŽî—l•a•Ï‚𔺂¢AŽ©‘R‘ޏk‚ƍđ‘å‚ð”F‚ß‚œcŠuƒZƒ~ƒm[ƒ}‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2017 Mar 12; •xŽR.
    13. œA–ìŒbˆê. ‰ï’·“Á•ÊŠé‰æuzŠÂŠí—̈æ“«‹H­ŽŸŠ³‚̍Ž•ž‚É‚Þ‚¯‚āv Left Ventricular Non-compaction. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2017 Mar 17-19; ‹à‘ò.
    14. œA–ìŒbˆê, Žs“c•™Žq. uƒJ?ƒCƒg?ƒ‰ƒCƒ“‰ðà3v2014-2015”N“xŠˆ“® ŠwZS‘ŸŒŸf‚̃J?ƒCƒg?ƒ‰ƒCƒ“ 4. S‹ØÇES‹Ø‰Š‚ÌŠÇ—. ‘æ81‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2017 Mar 17-19; ‹à‘ò.
    15. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€@‚±‚Ç‚à‚Ì–ò@“K³Žg—pAˆÀ‘S«‚Æ“Y•t•¶‘‚Ì‚Í‚ŽŠÔ‚Å ‚±‚Ç‚à‚ɑ΂·‚éOTCˆã–ò•i“K³Žg—p‰º‚É‚Ä”­Ç‚µ‚œƒIƒsƒIƒCƒh’†“Å. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    16. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€@¬Ž™S‘ŸˆÚA‚̍‘ÛƒVƒ“ƒ|ƒWƒEƒ€ “ú–{‚É‚š‚¯‚éŽq‚Ç‚à‚Ì”]Ž€‚ƐS‘ŸˆÚA. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    17. ŽíŽsq’ˆ, ”ª–ؐMˆê, ‰ª“cr‘¥. ƒƒNƒ`ƒ“ÚŽí‚ðs‚í‚È‚¢‰Æ‘°‚œ‚¿‚ւ̃Aƒvƒ[ƒ``u‰‰‰ïŠJÃ‚ƃAƒ“ƒP[ƒgŒ‹‰Ê‚̉ðÍ‚ð’Ê‚µ‚ā`. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    18. Žs“c•™Žq. “Á•ÊŠé‰æuæ”y‚ÉŠw‚ÔƒLƒƒƒŠƒA‚̐ςݕûEŠˆ‚©‚µ•ûv’nˆæˆã—ÂðŽx‚Š‚鏗«ˆãŽt‚ÌŠˆ–ô‚ðŽx‰‡‚·‚é•xŽR‘åŠw‚ÌŽŽ‚Ý. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    19. Žs“c•™Žq. •ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€@‘Û“I‚ȏ¬Ž™zŠÂŠíŒ€‹†‚ðŠw‚ԌߌãuS‹Øãk–§‰»áŠQ‚Ì•ªŽqˆâ“`ˆãŠwv. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    20. ˆÉ“¡–õ“TDƒVƒ“ƒ|ƒWƒEƒ€uH•šƒAƒŒƒ‹ƒM[ƒKƒCƒhƒ‰ƒCƒ“2016FÇó‚̏dÇ“x”»’è‚ƑΏˆ—Ö@ ?ƒAƒhƒŒƒiƒŠƒ“‚Æ•¹—p‹ÖŠõ–ò‚ɂ‚¢‚Ä-v. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    21. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•šƒAƒŒƒ‹ƒM[‚ɑ΂·‚éƒGƒsƒyƒ“‚Ì“K³Žg—p‚Ì•]‰¿. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    22. ”ª–؍GŽq, ŽíŽsq’ˆ, ˜a“c‘ñ–ç, ’‡‰ª²’qŽq, “c’†•ü”ü, ‘«—§—Yˆê. ”]Žº• oƒVƒƒƒ“ƒg‚©‚ç‚̐‘‰tÌŽæ‚É‚æ‚é‚Æ l‚Š‚ç‚ê‚é• o“àŠŽõ‚Ì‚P—á. ‘æ120‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2017 Apr 14-16; “Œ‹ž.
    23. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™‚Ìšb–‚̊ӕʂƎ¡—Áv. ‘æ12‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï; 2017 June 2-3; ‰F“s‹{.
    24. ˆÉ“¡–õ“T, ‰ª•””üŒb, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[«•@‰Š‚ªŒÄ‹CˆêŽ_‰»’‚‘f‘ª’è‚É—^‚Š‚éƒCƒ“ƒpƒNƒg. ‘æ12‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï; 2017 June 2-3; ‰F“s‹{.
    25. ‘«—§—YˆêD“Á•ÊŠé‰æ1u–k—€‚©‚ç‚Ì”­M@¬Ž™ƒAƒŒƒ‹ƒM[‚̃gƒsƒbƒNƒXFŠÂ‹«‚Ə¬Ž™‚̃AƒŒƒ‹ƒM[v. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    26. ”ª–ؐMˆê, ŒÜ\—’“o, ‘ºãIŒ[, Ë“ckŠî, ¬ŒIˆºŽq, “ˆ”ö@’q, ŽíŽsq’ˆ. •xŽRŒ§‚É‚š‚¯‚鍂“x‚̈ã—ÓIƒj[ƒY‚̍‚‚¢áŠQŽ™ŽÒ‚Ö‚ÌŽx‰‡‘̐§‚Ö‚Þ‚¯‚ā|ˆã—Ïî•ñƒlƒbƒgƒ[ƒN\’z‚É‚Þ‚¯‚ā|. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    27. ”ª–ؐMˆê, ŒÜ\—’“o, ‘ºã”ü–çŽq, ‘ºãIŒ[, ”öã—mˆê, ‰ª•”@Œh, Ë“ckŠî, “ˆ”ö@’q, ŽíŽsq’ˆ. •xŽRŽs‚É‚š‚¯‚é’nˆæ¬Ž™‰Èˆã‚Ə‰Šú‹~‹}f—Ñ̐§‚ɂ‚¢‚Ä. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    28. ŽíŽsq’ˆ. ‹³ˆçƒZƒ~ƒi[uƒƒNƒ`ƒ“ÚŽí‚ðçSçO‚·‚é‰Æ‘°‚œ‚¿v. ‘æ28‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2017 June 10-11; •xŽR.
    29. ìú±—TŽq, ¬–ì—m•ã, “c‘ºŒ«‘Ÿ˜Y, ŒˆäŽOŽ}, ‹g“cär. o¶Œã‚̃XƒeƒƒCƒh“Š—^‚ªC³18ƒ•ŒŽŽž‚̐_ŒoŠw“I—\Œã‚É—^‚Š‚é‰e‹¿. ‘æ59‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2017 June 15-17; ‘åã.
    30. •œŠâ–ŸŽqC“c’†•ü”ü, ‹{@ˆêŽu, ŒˆäŽOŽ}, Žs“c•™Žq, ‘«—§—Yˆê. æ“V«SŽŸŠ³Ž™‚Ì“û—cŽ™‚Ì”­’BŽw”‚ÆŠw“¶Šú‚Ì’m”\Žw”EŠwKŽx‰‡‚Ì—L–³‚Í‘ŠŠÖ‚·‚éD‘æ59‰ñ“ú–{¬Ž™_ŒoŠw‰ïŠwpW‰ï; 2017 June 15-17; ‘åã.
    31. ˆÉ“¡–õ“T, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[FV¶Ž™“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚Ì•‰‰×ŽŽŒ±Ž{sŽž‚ÌŒoŽž“IƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹v. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    32. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËiƒGƒsƒyƒ“Rj‚ðŽg—p‚·‚é“KØ‚ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚š‚æ‚ÑŽè‹Z”\—Í‚Ì’²ž. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    33. ŽRŒ³ƒŽq, “n•Ó—S‹I, •£àV—³–ç, ˆÉ“¡–õ“T, ‘«—§—Yˆê. ƒVƒCƒ^ƒP‚ƃzƒEƒŒƒ“ƒ\ƒE‚É‚æ‚éH•šˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[iFDEIAj‚̈ê—á. ‘æ66‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïŠwp‘å‰ï; 2017 June 16-18; “Œ‹ž.
    34. ŽíŽsq’ˆ. ’n•û‘åŠw‚É‚š‚¯‚鏬Ž™‹~‹}. ‘æ31‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2017 June 23-25; “Œ‹ž.
    35. ˜a“c—DŽq, –x]’åŽu, ˜a“c‘ñ–ç, “c’†•ü”ü, ˆÉ“¡–õ“T, ŽíŽsq’ˆ, ‘«—§—Yˆê. Ý‘î—×{’†‚ɉ¡–ä‹Ø—Z‰ðÇE‹}«t•s‘S‚𔭏ǂµ‚œdÇSgáŠQŽ™(ŽÒ)‚Ì1—á. ‘æ38‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2017 July 2; •xŽR.
    36. Žs“c•™Žq. ‚”öÜŽóÜ‹L”Ou‰‰uS‹Øãk–§‰»áŠQ@Ç—á•ñ‚©‚çˆâ“`Žq‰ðÍ‚Ü‚Å20”NŠÔ‚ÌŒ€‹†‚©‚猩‚Š‚œ‚à‚́v. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.
    37. œA–ìŒbˆê. ‹³ˆçƒZƒ~ƒi[ ‚±‚±‚Ü‚Ä?’m‚Á‚Ä‚š‚«‚œ‚¢S‹ØÇ:?u1.‰ð–U‚©‚番ŽqˆãŠw‚Ü‚Ä??v. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.
    38. âV“¡˜a—R, œA–ìŒbˆê, ‰ª•”^Žq, ‹{”ö¬–Ÿ, ¬àVˆ»‰À, Žs“c•™Žq. V407I-BMP10•ÏˆÙ‚͐S‹Ø‚Ì•ª‰»‚š‚æ‚Ñ‘B‚ðáŠQ‚µA¶ŽºS‹Øãk–§‰»áŠQ‚ÌŒŽˆö‚Æ‚È‚é‚©‚à‚µ‚ê‚È‚¢. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.(“ú–{¬Ž™zŠÂŠíŠw‰ï‰ï’·Ü)
    39. ’‡‰ª‰pK, ‰ª•”^Žq, ‹{”ö¬–Ÿ, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘q‹Ž£“ß, ŽR–{@Œ’, rˆäˆêˆ®, Ò“¡—F”ü, àF’J®Šó, ’·à_q‰i, ˆÉ“¡’å‘¥, X@Œõˆê. S‘ŸMRI‚ð—p‚¢‚œ¶ŽºS‹Øãk–§‰»áŠQ(LVNC)‚̐SŽº‹@”\‰ðÍ. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.
    40. ‰ª•”^Žq, ‹{”ö¬–Ÿ, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ’¹’Ë‘å‰î, Â–ؐ³Æ, –F‘º’ŒŽ÷. ìè•aœëŠ³Œã‚Ƀy[ƒXƒ[ƒJ[SŽºè‡’l‚̏㏞‚ð”F‚ß‚œŽOë•Ù•ÂœEFontanpŒã‚Ì“Ž•s‘SÇŒóŒQ‚Ì1—á. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.
    41. ‹{”ö¬–Ÿ, ‰ª•”^Žq, ’‡‰ª‰pK, Ö“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™–«“Á’莟•aƒŒƒ|ƒWƒgƒŠ[‚ÉŠî‚­ƒAƒ“ƒP[ƒgŒ‹‰Ê‚©‚ç‚Ý‚œ¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°‘œ. ‘æ53‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2017 July 7-9; •lŒ.
    42. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê. ¬Ž™‚É‚š‚¯‚éƒOƒ‹ƒp[ƒ‹19S‚É‚æ‚鏬”žƒAƒŒƒ‹ƒM[‚ÌŒo‰ßF¬l—á‚Æ”äŠr‚µ‚Ä. ‘æ41‰ñ“ú–{¬Ž™”畆‰ÈŠw‰ï; 2017 July 8-9; •Ÿˆä.
    43. ‹g“cär, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü. V¶Ž™Šú‚ÉŽèp‚ð—v‚µ‚œæ“V«SŽŸŠ³Ž™‚Ì—\Œã Žèp‚ðs‚Á‚œæ“V«SŽŸŠ³Ž™‚É‚š‚¯‚é3Î‚̐_Œo”­’B—\Œã. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    44. “c‘ºŒ«‘Ÿ˜Y, ’––”’qŽÀ, ìú±—TŽq, –q–{—D”ü, •Ä“c“¿Žq, •Ä“c@“N, ‹g“cär. •aŒŽ”÷¶•š‚É‚æ‚éŽq‹{“à‰ŠÇ‚Æ–«”xŽŸŠ³”­Ç‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    45. ‘Ÿ“cˆÀF, ìú±—TŽq, ’––”’qŽÀ, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü, ‹g“cär. “–‰@‚ŃxƒoƒVƒYƒ}ƒuÉŽq‘Ì’ŽË“±“üŒã‚ÌROPŽ¡—ÂɊւ·‚錟“¢. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l.
    46. ˆÀ“cˆê•œ, “c‘ºŒ«‘Ÿ˜Y, ’––”’q”ü, ìú±—TŽq, –q–{—D”ü, ‹g“cär. ŒoŽž“I‚È“ª•”’Ž‰¹”g‚É‚æ‚èf’f‚ÉŽŠ‚Á‚œV¶Ž™”][Ç‚Ì1—á. ‘æ53‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2017 July 16-18; ‰¡•l
    47. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. ÅdÇ¬”žƒAƒŒƒ‹ƒM[Š³ŽÒ‚ɑ΂·‚é’ZŠú“ü‰@ŒoŒû–Ɖu—Ö@“±“ü‚ÌŽŽ‚Ý. ‘æ34‰ñ“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2017 July 22-23; ‘å’Ã.
    48. ‘«—§—zŽq, ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—YˆêDƒvƒŠƒbƒNƒeƒXƒg‚ÅŒŽˆö‚ðŠm’è‚Å‚«‚œƒiƒbƒcƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì2Ç—á. ‘æ34‰ñ“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2017 July 22-23; ‘å’Ã.
    49. ’·‰ªvG, ‹{”ö¬–Ÿ, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê. ‹CŠÇ‹·ó‚É‚æ‚éŒJ‚è•Ô‚·‹C“¹ŠŽõÇE–³‹C”x‚ɑ΂µ, NIPPV“±“ü‚Å“ü‰@‚Ì•p“x‚ªŒž­‚µ, •aó‚̉ü‘P‚ðŒ©‚œˆê—á. ‘æ53‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2017 Aug 20; ‹à‘ò.
    50. ”ª–ؐMˆê, Ë“ckŠî, “ˆ”ö@’q, –xìT“ñ˜Y, ŽíŽsq’ˆ. ‘æ27‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2017 Sep 2-3; ŽOd.
    51. ¬àVˆ»‰À, Ö“¡@—I, ‹{”ö¬–Ÿ, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, Â–ؐ³Æ, –F‘º’ŒŽ÷. 22q11.2Œ‡ŽžÇŒóŒQ‚ɍ‡•¹‚µ‚œƒtƒ@ƒ[Žl’¥ÇŒ^”x“®–¬•ÙŒ‡‘¹A¶”x“®–¬ŒÇ—§Ç‚̈ê—á. ‘æ45‰ñ–k—€¬Ž™zŠÂŠíŠw‰ï; 2017 Sep 9; ‹à‘ò.
    52. ”ª–ؐMˆê, ŽíŽsq’ˆ, ŒàVƒŽq, Œ“c@“µ, —щÀ“ÞŽq, ‚–؉€”ü, ‰±–{çŽj. •xŽRˆã—ÃŒ—‚É‚š‚¯‚鏬Ž™ˆã—ÓIƒPƒAŽÀKŒ€C‰ï‚̏[ŽÀ‚É‚Þ‚¯‚Ä‚ÌŽæ‚è‘g‚Ý‚Æ•xŽRŒ§‚É‚š‚¯‚édÇSgáŠQŽ™(ŽÒ)‚Ö‚Ì’nˆæŽx‰‡‘̐§\’z‚ɂ‚¢‚Ä. ‘æ43‰ñdÇSgáŠQŽ™Šw‰ï; 2017 Sep 29-30; å‘ä.
    53. –q–{—D”ü, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘Ÿ˜Y, ‹g“cär. Bayley“û—cŽ™”­’BƒXƒP[ƒ‹III‚ð—p‚¢‚œ‹É’áo¶‘̏dSGAŽ™‚Ì3ÎŽž_ŒoŠw“I—\Œã. ‘æ62‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2017 Oct 12-14; ‘å‹{.
    54. ìú±—TŽq, ’––”’qŽÀ, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü, ‹g“cär. Šç–ʁEŠáâ|“àŒŒŠÇŽî‚ɑ΂µƒvƒƒvƒ‰ƒmƒ[ƒ‹“à•ž—Ö@‚ðs‚Á‚œ‹É’áo¶‘̏dŽ™‚Ì1—á. ‘æ62‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2017 Oct 12-14; ‘å‹{.
    55. ¬àVˆ»‰À, ‰ª•”^Žq, ‹{”ö¬–Ÿ, âV“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, Â–ؐ³Æ, –F‘º’ŒŽ÷. ‰EŽº’áŒ`¬‚ƐSŽº’†•”•ÂÇ«”ì‘åŒ^S‹ØÇ‚ð‡•¹‚µ‚œ¬Ž™‚̈ê—á. ‘æ26‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2017 Oct 14; ‘q•~.
    56. œA–ìŒbˆê, Žðˆä••F, ¬àVˆ»‰À, ”š—R‹IŽq, Œ“c’Œ“¿, ‰ª•”^Žq, ‹{”ö¬–Ÿ, âV“¡˜a—R, –F‘º’ŒŽ÷, Œ“c®Ž÷, Žs“c•™Žq. MYH7ˆâ“`Žq•ÏˆÙ‚ÆCD36ˆâ“`Žq•ÏˆÙ‚ªŒ©‚¢‚Ÿ‚³‚ê‚œS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ26‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2017 Oct 14; ‘q•~.
    57. ‰ª•”^Žq, œA–ìŒbˆê, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, –؉ºkŽj, ‚èˆê˜N. ìè•a‹}«Šú‚É‚š‚¯‚élong noncoding RNA‚Ì”­Œ»‰ðÍ. ‘æ37‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ï; 2017 Oct 27-28; “Œ‹ž.
    58. ‘«—§—zŽq, ”óŒû@Žû, ’†—ÑŒºˆê, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p. ¬Ž™‚Ì‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚ÉŠÖ‚·‚é•êe‚Ì’mŽ¯‚ɉe‹¿‚ð—^‚Š‚éˆöŽqD‘æ50‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2017 Nov 10-11; “Œ‹ž.
    59. ”ª–ؐMˆê, ‘«—§—Yˆê, •Ä“c“N–ç, ¬Ÿº³ŽŸ, “¡“cC•œ. •xŽRŽs‚Ì’nˆæƒNƒŠƒjƒbƒN‚É‚š‚¯‚é“û—cŽ™‚̌ċzŠíƒEƒCƒ‹ƒXŠw“I’²ž ‘æ‚Q•ñ. ‘æ50‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2017 Nov 10-11; “Œ‹ž.
    60. œA–ìŒbˆê, Žðˆä••F, ¬àVˆ»‰À, ”š—R‹IŽq, Œ“c’Œ“¿, ‰ª•”^Žq, ‹{”ö¬–Ÿ, âV“¡˜a—R, –F‘º’ŒŽ÷, Œ“c®Ž÷, Žs“c•™Žq. A novel MYH7 and CD36 gene variants in a fetus with left ventricular noncompaction; crosstalk between beta myosin heavy chain and fatty acid translocase deteriorates heart failure after surgical intervention. “ú–{l—Þˆâ“`Šw‰ï‘æ62‰ñ‘å‰ï; 2017 Nov 15-18; _ŒË.
    61. ˆÉ“¡–õ“T. ‹³ˆçƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2017`–ò•š—Ö@‚̃|ƒCƒ“ƒgF’·ŠúŠÇ—‚Ì–ò•š—Ö@‚̉ü’ù`‰œ‚ª•Ï‚í‚Á‚œ‚Ì‚©A•Ï‚Š‚œ‚Ì‚©H`. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    62. ˆÉ“¡–õ“T, ‘ê‘ò‘ô–€, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uJPGL2017‰ü’ù”Ł@ƒL[ƒGƒbƒZƒ“ƒXF’·ŠúŠÇ—‚ÉŠÖ‚·‚é–ò•š—Ö@. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    63. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê. u•ÛˆçŠ‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[‘ΉžƒKƒCƒhƒ‰ƒCƒ“vŒã5”NŠÔ‚Ì•xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚鏜‹ŽH‘Ήž‚̕ω». ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    64. ˆÉ“¡–õ“T, ‰º‘º^‹B, –Ø‘ºŒõ–Ÿ, ‘«—§—Yˆê. Food protein induced enterocolitis syndrome (FPIES) ‚Ì•‰‰×ŽŽŒ±Ž{sŽž‚ÌŒoŽž“IƒTƒCƒgƒJƒCƒ“ƒvƒƒtƒ@ƒCƒ‹. ‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{. (—DG‰‰‘èÜ)
    65. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ‘«—§—zŽq, ’†—ÑŒºˆê, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[, ‚”ö@Š², ‘«—§—Yˆê. ƒGƒsƒyƒ“Žg—p‚̃^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚ÉŠÖ‚·‚é’²ž`1”NŒã‚Ì•]‰¿`D‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{.
    66. Œ–쐳’m, ŒÜ\—’—²•v, ‘«—§—YˆêD—Տ°“IŽ¡–ü‚ÉŽŠ‚Á‚œšb‘§¬Ž™—á‚É‚š‚¯‚é‹C“¹‰ß•q«EŒÄ‹z‹@”\‚ÌŒŸ“¢D‘æ54‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2017 Nov 18-19; ‰F“s‹{. (Å—DG‰‰‘èÜ)
    67. œA–ìŒbˆê, ‹{”ö¬–Ÿ, ‰ª•”^Žq, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ”š—R‹IŽq, Œ“c®Ž÷. ‰ï’·—v–]‰‰‘èu¬Ž™S‹ØŽŸŠ³‚Æ•s®–¬v‘æ22‰ñ“ú–{¬Ž™S“dŠw‰ïŠwpW‰ï; 2017 Nov 24-25; “¿“‡.
    68. ꎓ¡@—I, –쑺ŒbŽq, ’ށ@_”V, ‘«—§—Yˆê, ìè—TŽq, ‹g“cär, •Ÿ“cD, Ý“cK‘Ÿ˜Y. ŒŒ—F•aB•ÛˆöŽÒ”D•w‚̏oŽYŒoŒ±@-ŽY•wl‰È, ŒŒ‰t“à‰È, ¬Ž™‰È, –ƒŒ‰È, –òÜ•”‚É‚æ‚é˜AŒg. ‘æ321‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2017 Dec 10; ‹à‘ò.

    2016”N

  • ’˜‘
    1. Hirono K, Ichida F. Kawasaki Disease: Current Understanding of Mechanism and Evidence-based Treatment. Saji B.T., Newburger J.W., Burns J.C., Takahashi M. (Eds.), 2016. Evidences of endothelial damage in acute stage.; p335-40. Springer, Japan.
    2. Hiraiwa A, Ibuki K, Watanabe K, Matsui M, Yoshimura N, Ichida F. -The growth of the brain- edited by Matsui M, Oishi K, Yamashita A. Aichi: Ichiryusyobou; 2016 Neurodevelopmental outcomes in children with congenital heart disease. How humans evolved supersize brains. p11-8.
    3. Kawasaki Y, Matsui M, Yoshida. T. -The growth of the brain- edited by Matsui M, Oishi K, Yamashita A. Aichi: Ichiryusyobou; 2016 Neurodevelopmental outcomes in children with congenital heart disease. Early Assessment of brain by MRImaging segmentation in small-for-gestational-age infants. P2-5.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[ƒ}[ƒ`‚ð’f‚ ?ƒKƒCƒhƒ‰ƒCƒ“€‹’‚É‚æ‚éŠg‘å—\–h- rì_ˆê•Ò. ‘åã: ˆã–òƒWƒƒ[ƒiƒ‹; 2016. ƒoƒCƒIƒ}[ƒJ[iFeNO‚ðŠÜ‚ށj‚É‚æ‚èšb‘§”­Ç‚Í—\’m‚Å‚«‚é‚©H; p101-6.
    5. ‘«—§—Yˆê. ‘‡¬Ž™ˆã—ÃJƒ“ƒpƒjƒA ê–åˆã‚ª“š‚Š‚éƒAƒŒƒ‹ƒM[ŽŸŠ³ Q&A. “cŒŽ‘ì_•Ò. “Œ‹ž: ’†ŽR‘“X; 2016. ¬Ž™‚Ìšb‘§‚ŃŠƒ‚ƒfƒŠƒ“ƒO‚Í‹N‚±‚è‚Ü‚·‚©H‹z“üƒXƒeƒƒCƒh‚̓Šƒ‚ƒfƒŠƒ“ƒO—}§‚É—LŒø‚Å‚·‚©H; p78-9.
    6. ‘«—§—YˆêD¡“ú‚ÌŽ¡—ÃŽwj 2016”N“x”ŁDŽRŒû“O, –kŒŽŒõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2016. ¬Ž™‚Ì‚©‚ºÇŒóŒQDp1404-6.
    7. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒŽŒõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽŸŠ³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. P1360-1.
    8. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj-2017”N”Å. ŽRŒû“O, –kŒŽŒõ’j•Ò. “Œ‹ž: ˆãŠw‘‰@; 2017. SŽŸŠ³Š³ŽÒ‚Ì”DPEoŽY‚Ì“K‰žEŠÇ—. P429.
    9. Žs“c•™Žq.ŠwZS‘ŸŒŸf‚̃KƒCƒhƒ‰ƒCƒ“i2016”N”Łj“ú–{zŠÂŠíŠw‰ïE“ú–{¬Ž™zŠÂŠíŠw‰ï‡“¯ƒKƒCƒhƒ‰ƒCƒ“. “Œ‹ž: ˆê”ÊŽÐ’c–@l“ú–{zŠÂŠíŠw‰ï; 2016. S‹ØÇ, S‹Ø‰Š‚ÌŠÇ—. p57-60.
    10. ‹g“cär. ‚±‚±‚Ü‚ÅŽg‚Š‚éV¶Ž™E¬Ž™‚̃pƒ‹ƒXƒIƒLƒVƒƒgƒŠ. ×–ì@–ΕÒ. ‘åã: ƒƒfƒBƒJo”Å; 2016 ‡–°–ò‚ðŽg‚Á‚œˆ’uEŒŸžŽž; p112-8.
    11. ŽíŽsq’ˆ, ‹{˜e—˜’j. ƒ|ƒPƒbƒg”ŃJƒ‰[“à‰ÈŠw. –å˜e@F, ‰iˆä—ÇŽO•Ò. “Œ‹ž: Œ‘º‘“X; 2016. ŒŽ”­«–Ɖu•s‘SÇŒóŒQ@1D‰t«–Ɖu•s‘S‚ðŽå‚Æ‚·‚鎟Š³. P1321-3.
    12. ¬àVˆ»‰À, Žs“c•™Žq. SƒGƒR[ƒnƒ“ƒhƒuƒbƒN@S•s‘S. ’|’†@Ž•Ò. ‹ž“s: ‹à–F“°; 2016. S‹Øãk–§‰»áŠQ. P219-26.
    13. ¬àVˆ»‰À, Žs“c•™Žq. S‘Ÿ‚ðŽç‚é. S‘Ÿ•a‚Ì‚±‚Ç‚à‚ðŽç‚ée‚̉ï•Ò. “Œ‹ž: Œõ—zƒƒfƒBƒA; 2016. pŒã‹N‚±‚è‚€‚é–â‘è‚Æ“à‰È“IŽ¡—Ã.S‘Ÿ•a‚ÌŽ¡—Ã: p155-61.
    14. ¬àVˆ»‰À, Žs“c•™Žq. S‘Ÿ‚ðŽç‚é. S‘Ÿ•a‚Ì‚±‚Ç‚à‚ðŽç‚ée‚̉ï•Ò. “Œ‹ž: Œõ—zƒƒfƒBƒA; 2016. “úí¶Šˆ. æ“V«SŽŸŠ³‚Æ”­’BáŠQ; p186-90.
    15. ˆÉ“¡–õ“T. ‘‡¬Ž™ˆã—ÃJƒ“ƒpƒjƒAFê–åˆã‚ª“š‚Š‚éƒAƒŒƒ‹ƒM[ŽŸŠ³Q&A. “cŒŽ‘ì_•Ò. “Œ‹ž: ’†ŽR‘“X; 2016. ƒAƒiƒtƒBƒ‰ƒLƒV[‚̐f’f‚Ə‰ŠúŽ¡—Ẫ|ƒCƒ“ƒg‚́H: p228-31.
    16. “cŒû‰ë“o, Žs“c•™Žq. ¬Ž™‚̈â“`Šw“IŒŸžEf’fEƒJƒEƒ“ƒZƒŠƒ“ƒO@ŽÀ‘HƒP[ƒXƒtƒ@ƒCƒ‹. ‰œŽRŒÕ”V, ŽR–{rŽŠ•Ò. @ “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2016. ƒ[ƒtƒ@ƒŠƒ“‚ÌŽ¡—ÁE“Š—^—Ê—\‘ª. p163-5.
  • ŒŽ’˜
    1. Hirono K, Hata Y, Miyao N, Nakaoka H, Saito K, Ibuki K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Nishida N, Ichida F. Anomalous origin of the right coronary artery evaluated with multidetector computed tomography and its clinical relevance. J Cardiol. 2016 Sep; 68(3): 196-201.
    2. Saito K, Nakaoka H, Takasaki I, Hirono K, Yamamoto S, Kinoshita K, Miyao N, Ibuki K, Ozawa S, Watanabe K, Bowles NE, Ichida F. MicroRNA-93 may control vascular endothelial growth factor A in circulating peripheral blood mononuclear cells in acute Kawasaki disease. Pediatr Res. 2016 Sep; 80(3): 425-32.
    3. Miyazaki A, Oguri A, Ichida F. Non-high-density lipoprotein cholesterol as a cardiovascular risk screening tool in children. Pediatr Int. 2016 Jun; 58(6): 439-44.
    4. Hashimoto I, Watanabe K, Ichida F. Right to Left Ventricular Diameter Ratio ?0.42 is the Warning Flag for Suspecting Atrial Septal Defect in Preschool Children: Age- and Body Surface Area-Related Reference Values Determined by M-Mode Echocardiography. Pediatr Cardiol. Apr; 37(4): 704-13.
    5. Kodo K, Ong SG, Jahanbani F, Termglinchan V, Hirono K, InanlooRahatloo K, Ebert AD, Shukla P, Abilez OJ, Churko JM, Karakikes I, Jung G, Ichida F, Wu SM, Snyder MP, Bernstein D, Wu JC. iPSC-derived cardiomyocytes reveal abnormal TGF-ƒÀ signalling in left ventricular non-compaction cardiomyopathy. Nat Cell Biol. 2016 Oct; 18(10): 1031-42.
    6. Yoshida K, Sasaki M, Adachi Y, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with the severity of childhood rhinoconjunctivitis. Allergol Int. 2016 Apr; 65(2): 166-71.
    7. Sato K, Sato Y, Nagao M, Shimojo N, Yoshihara S, Adachi Y, Kameda M, Terada A, Fujisawa T; Best ACT Investigators. Development and validation of asthma questionnaire for assessing and achieving best control in preschool-age children. Pediatr Allergy Immunol. 2016 May; 27(3): 307-12.
    8. Kanatani KT, Hamazaki K, Inadera H, Sugimoto N, Shimizu A, Noma H, Onishi K, Takahashi Y, Itazawa T, Egawa M, Sato K, Go T, Ito I, Kurozawa Y, Konishi I, Adachi Y, Nakayama T; Japan Environment & Children's Study Group. Effect of desert dust exposure on allergic symptoms: A natural experiment in Japan. Ann Allergy Asthma Immunol. 2016 May; 116(5): 425-430.e7
    9. Hosoki K, Itazawa T, Boldogh I, Sur S. Neutrophil recruitment by allergens contribute to allergic sensitization and allergic inflammation . Curr Opin Allergy Clin Immunol. 2016 Feb; 16(1): 45-50.
    10. Hosoki K, Boldogh I, Aguilera-Aguirre L, Sun Q, Itazawa T, Hazra T, Brasier AR, Kurosky A, Sur S. Myeloid differentiation protein 2 facilitates pollen- and cat dander-induced innate and allergic airway inflammation. J Allergy Clin Immunol. 2016 May; 137(5): 1506-1513.e2.
    11. Kobayashi T, Fuse S, Sakamoto N, Mikami M, Ogawa S, Hamaoka K, Arakaki Y, Nakamura T, Nagasawa H, Kato T, Jibiki T, Iwashima S, Yamakawa M, Ohkubo T, Shimoyama S, Aso K, Sato S, Saji T; Z Score Project Investigators. A new Z score curve of the coronary arterial internal diameter using the lambda-mu-sigma method in a pediatric population. J Am Soc Echocardiogr. 2016 Aug; 29(8): 794-801.e29.
    12. Matsuura H, Ichida F, Saji T, Ogawa S, Waki K, Kaneko M, Tahara M, Soga T, Ono Y, Yasukochi S. Clinical features of acute and fulminant myocarditis in children - 2nd Nationwide survey by Japanese society of pediatric cardiology and cardiac surgery. Circ J. 2016 Oct 25; 80(11): 2362-8.
    13. Okuma Y, Suda K, Nakaoka H, Katsube Y, Mitani Y, Yoshikane Y, Ichida F, Matsushita T, Shichino H, Shiraishi I, Abe J, Hiroe M, Yoshida T, Imanaka-Yoshida K. Serum Tenascin-C as a novel predictor for risk of coronary artery lesion and resistance to intravenous immunoglobulin in Kawasaki disease - A multicenter retrospective study. Circ J. 2016 Oct 25; 80(11): 2376-81.
    14. Ochiai R, Kato H, Akiyama N, Ichida F, Yao A, Inuzuka R, Niwa K, Shiraishi I, Nakanishi T. Nationwide survey of the transfer of adults with congenital heart disease from pediatric cardiology departments to adult congenital heart disease centers in Japan. Circ J. 2016 Apr 25; 80(5): 1242-50.
    15. Gaynor JW, Stopp C, Wypij D, Andropoulos DB, Atallah J, Atz AM, Beca J, Donofrio MT, Duncan K, Ghanayem NS, Goldberg CS, Hovels-Gurich H, Ichida F, Jacobs JP, Justo R, Latal B, Li JS, Mahle WT, McQuillen PS, Menon SC, Pemberton VL, Pike NA, Pizarro C, Shekerdemian LS, Synnes A, Williams I, Bellinger DC, Newburger JW. Impact of operative and postoperative factors on neurodevelopmental outcomes after cardiac operations. Ann Thorac Surg. 2016 Sep; 102(3): 843-9.
    16. Hata Y, Kinoshita K, Mizumaki K, Yamaguchi Y, Hirono K, Ichida F, Takasaki A, Mori H, Nishida N. Postmortem genetic analysis of sudden unexplained death syndrome under 50 years of age: A next-generation sequencing study. Heart Rhythm. 2016 Jul; 13(7): 1544-51.
    17. Akashi K, Mezawa H, Tabata Y, Atsuta J, Tokuda R, Kawada Y, Kitamura T, Murasugi H, Ito H, Tabata M, Shirao K, Sato S, Nishimura H, Fujiwara M, Masuda K, Arakawa H, Adachi Y, Yoshihara S, Fujisawa T, Katsunuma T. Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study). Allergol Int. 2016 Jul; 65(3): 306-11.
    18. Nakamura S, Watanabe N, Yoshimura N, Ozawa S, Hirono K, Ichida F, Taguchi M. A model analysis for dose-response relationship of warfarin in Japanese children: An introduction of the SIZE parameter. Drug Metab Pharmacokinet. 2016 Jun; 31(3): 234-41.
    19. Hachiya A, Motoki N, Akazawa Y, Matsuzaki S, Hirono K, Hata Y, Nishida N, Ichida F, Koike K. Left ventricular non-compaction revealed by aortic regurgitation due to Kawasaki disease in a boy with LDB3 mutation. Pediatr Int. 2016 Aug; 58(8): 797-800.
    20. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Hide M, Akasawa A. Environmental factors associated with childhood eczema: Findings from a national web-based survey. Allergol Int. 2016 Oct; 65(4): 420-424.
    21. Kimura M, Ito Y, Tokunaga F, Meguro T, Shimomura M, Morishita H, Seto S. Increased C-reactive protein and fever in Japanese infants with food protein-induced enterocolitis syndrome. Pediatr Int. 2016 Sep; 58(9): 826-30.
    22. ˜a“c‘ñ–ç,@”ÂàVŽõŽq,@à_“¹”ü‹I,@”óŒû@Žû,@ˆÉ“¡–õ“T,@’†—ÑŒºˆê,@‰ª•””üŒb,@‘«—§—zŽq,@‘«—§—Yˆê.@¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚̏dÇ“x‚È‚ç‚тɏǏó‚Ì’ö“x‚Ì•]‰¿‚É‚š‚¯‚évisual analog scale‚Ì—L—p«. ¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ @2016 30: 642-50.
    23. ‹{@ˆêŽu, “c’‡çH, “c’†•ü”ü. Šw—îŠú”­’BáŠQE’m“IáŠQŽ™‚Ì“ñŽŸáŠQ‡•¹‚ÌŒŸ“¢. ‚Æ‚â‚Ü”­’B•ŸŽƒŠw”N•ñ. 2016 Jul 7:23-98.
    24. X‚±‚ž‚Š, ìú±—TŽq, –q–{—D”ü, ’|‘º‹žŽq, “c‘ºŒ«‘Ÿ˜Y, ‹g“cär. HLAR‘Ì‚É‚æ‚Á‚ÄŒŒ¬”’ቺ‚ª‘J‰„‚µ‚œV¶Ž™“¯Ží–Ɖu«ŒŒ¬”ÂŒž­Ç‚̈ê—á. “ú–{ŽüŽYŠúV¶Ž™ˆãŠw‰ïŽGŽ 2016 Dec 52(4): 1220-3.
  • Ç—á•ñ
    1. Yoshida Y, Hirono K, Nakamura K, Suzuki T, Hata Y, Nishida N. A novel ACTC1 gene mutation in a young boy with left ventricular noncompaction and arrhythmias. Heart Rhythm Case Report 2016 2: 92?7.
    2. ꎓ¡@—I, Œ“c’Œ“¿, –쑺ŒbŽq, ‘«—§—Yˆê, ‹àŒ“O˜a. ‹}«œ‘«”’ŒŒ•aiAML M0j‚ɐæs‚µ‚œœ‘“÷Žî‚Ì1—á. “ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŽGŽ@2016 53(3): 300-4.
    3. ‘ŠJË•œ, ¶…ŠÑl, –x]’åŽu, ’†’Ø‹v”T, ŽÂèŒ’‘Ÿ˜Y, ‘剮®Žq, ¯Ži‘׍O. ƒrƒj[ƒ‹‘܂ِ̈H‚É‚æ‚è’°•ÂÇ‚𔭏ǂµ‚œŽ©•ÂÇ‚Ì1—á. ¬Ž™‰È—Տ° 2016 July 69(7): 1243-7.
  • ‘à
    1. Ichida F. Management and treatment of hypertrophic cardiomyopathy in children. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circ J 2016 80:753-74.
    2. Katsunuma T, Adachi Y, Miura K, Teramoto T, Fujisawa T, Ohya Y, Futamura M, Imai T, Kondo N. Care of children with allergic diseases following major disasters. Pediatr Allergy Immunol. 2016 Jun; 27(4): 425.
    3. ‘«—§—Yˆê. ŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[. Žq‚Ç‚à‚ÌŒ’N‰ÈŠw 2016 16(1): 7-11.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[ŽŸŠ³‚Ì‚·‚ׂāF“ûŽ™Šú‚Ìšb‘§‚Æšb–Â. “ú–{ˆãŽt‰ïŽGŽ@2016 June 145: S170-1.
    5. ‘«—§—Yˆê. Ž„‚ÌŽ¡—Á@¬Ž™‰È@ƒGƒrƒfƒ“ƒX‚ÉŠî‚¢‚œ¬Ž™šb‘§‚Ì’·ŠúŠÇ—. ƒAƒŒƒ‹ƒM[‚̗Տ° 2016 May 36(5): 473-5.
    6. ‘«—§—Yˆê. “ÁWu¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚€‚Æ‚«EŽg‚€‚ׂ«‚Å‚È‚¢‚Æ‚«F‹CŠÇŽxšb‘§‚ƃXƒeƒƒCƒh“à•ž–òv. ¬Ž™‰È 2016 57(13):1092-3.
    7. ‘«—§—Yˆê. “ÁWu¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚€‚Æ‚«EŽg‚€‚ׂ«‚Å‚È‚¢‚Æ‚«F‹CŠÇŽxšb‘§‚Æ‹z“üƒXƒeƒƒCƒh–òv. ¬Ž™‰È 2016 57(13):1590-1.
    8. ‘«—§—Yˆê. ƒg[ƒ^ƒ‹ƒPƒA‚ð‚ß‚Ž‚·ƒAƒŒƒ‹ƒM[f—ÁF¬Ž™ƒAƒŒƒ‹ƒM[ŽŸŠ³‚Ì“Á’¥‚Æ’ˆÓ“_D“ú–{“à‰ÈŠw‰ïŽGŽ 2016 105:1952-7.
    9. ‘«—§—Yˆê. “ÁWu¬Ž™ƒAƒŒƒ‹ƒM[ŽŸŠ³‚̐V’mŽ¯F˜@Žq‚Ç‚à‚̃AƒŒƒ‹ƒM[‚Í‚Ç‚ñ‚Ç‚ñ•Ï‰»‚µ‚Ä‚¢‚év. ƒAƒŒƒ‹ƒM[E–Ɖu 2016 Mar 23(4): 483-6.
    10. œA–ìŒbˆê, Žs“c•™Žq. –«SŽŸŠ³. S‹ØÇ. ¬Ž™‰È—Տ°2016 May 69(4): 617-22.
    11. œA–ìŒbˆê, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚ð‚Ç‚Ì‚æ‚€‚ɐf’f‚·‚é‚©. Heart View 2016. Feb 20(2): 121-31.
    12. ’†—ÑŒºˆê. ƒCƒ“ƒpƒ‹ƒXƒIƒVƒƒƒgƒŠ[iIOSj‚Ì“Á’¥‚ƗՏ°‰ž—p. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽGŽ 2016 27: 58-62.
    13. ¬àVˆ»‰À, Žs“c•™Žq. ŠwZS‘ŸŒŸf‚ð—Տ°‚ɐ¶‚©‚·. ŒÄ‹z‚ƏzŠÂ2016 7: 718-24.
    14. ¬àVˆ»‰À, Žs“c•™Žq. S•s‘S‚ƃÀŽÕ’f–ò.u¬Ž™“úíf—Âł»‚Ì–ò‚ðŽg‚€‚Æ‚«EŽg‚€‚ׂ«‚Å‚È‚¢Žžv. ¬Ž™‰È2016 57(13): 1636-7.
    15. ˆÉ“¡–õ“T. ¬Ž™ƒAƒŒƒ‹ƒM[ŽŸŠ³‚̃tƒFƒmƒ^ƒCƒv. ƒAƒŒƒ‹ƒM[E–Ɖu 2016 Mar 23(4): 494-501.
    16. Œ“c’Œ“¿, Î‰HàV‰f”ü, ‘q‹ŽK–ç, Œã“¡Œ€œ, ²“¡—F‹I. ¬Ž™×‹Û«’°‰Š‚ð‹^‚Á‚œ‚Æ‚«‚ɍR‹Û–ò‚ð“Š—^‚·‚é‚©? ¬Ž™‰È—Տ° 69(2): 291-5.
    17. ìè—TŽq, ‹g“cär. ”sŒŒÇE‘–Œ‰ŠE”x‰Š.yŽüŽYŠúˆãŠw•KC’mŽ¯(‘æ8”Å)zV¶Ž™•Ò (Part V)`V¶Ž™. ŽüŽYŠúˆãŠw 2016 46(‘): 619-21.
    18. ’––”’qŽÀ, ‹g“cär. GBSŠŽõÇ.yŽüŽYŠúˆãŠw•KC’mŽ¯(‘æ8”Å)zV¶Ž™•Ò (Part V)`V¶Ž™. ŽüŽYŠúˆãŠw 2016 46(‘): 622-4.

  • 2016”NŠw‰ï•ñ
    1. Itazawa T, Hosoki K, Boldogh I, Sur S. Cat Dander Extract Requires Myd88 to Induce Innate Neutrophil Recruitment, and Allergic Sensitization and Allergic Airway Inflammation. 72th Annual Meeting of American Academy of Allergy, Asthma and Clinical Immunology; 2016 Mar 4-7; Los Angels, USA.
    2. Saito K, Mayhew C, Stanton L, Towbin JA, Purevjav E. Generation of induced pluripotent stem cells from Epstein-Barr Virus immortalized lymphoblastoid cell lines using Episomal vectors. The Experimental Biology 2016 Meeting; 2016 Apr 2-6; San Diego, USA.
    3. Hirono K, Takasaki A, Hata Y, Okabe M, Nakaoka H, Ibuki K, Ozawa S, Nishida N, Ichida F. Clinical features and prognosis of pediatic patients with left ventricular noncompaction. European society for cardiology congress 2016; 2016 Aug 26-30; Rome.
    4. Adachi Y. Environmental factors and allergy in children. Joint Congress of Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI) and Asia Pacific Association of Pediatric Allergy, Respirology & Immunology (APAPARI) 2016; 2016 Oct 16-20; Kuala Lumpur, Malaysia. (Invited Speech)
    5. Ichida F. Clinical features of left ventricular noncompaction: long-term clinical course and genetic background. The 6th APPCS; 2016 22; Shanghai. (Invited Lecture)
    6. Nakaoka H, Hirono K, Okabe M, Miyao N, Saito K, Ibuki K, Ozawa S, Takahashi K, Ichida F. Endothelial microparticles modulate vasculitis during the acute phase of Kawasaki Disease. The 89th Scientific sessions of AHA 2016; 2016 Nov 12-16; New Orleans, USA. (CVDY Outstanding research award)
    7. Hirono K, Wang C, Hata Y, Takasaki A, Ozawa S, Nakaoka H, Okabe M, Miyao N, Saito K, Nishida N, Ichida F. Long-term prognosis of the pediatric patients with Left Ventricular Noncompaction. 2nd International Congress of Cardiomyopathies and Heart Failure 2016; 2016 Dec 2-4; Kyoto.
    8. ‘ŠJË•œ, ’‡‰ª²’qŽq, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. R‚Ä‚ñ‚©‚ñ–ò‚ª‘tŒ÷‚µ‚œŽüŠú«šq“fÇ‚Ì“ûŽ™—á. ‘æ69‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï; 2016 Feb 7; ‹à‘ò.
    9. ŽíŽsq’ˆ, àF’JLŽq. ¬Ž™”]Ž€Ž–—á‚ɑ΂µ‚Ä’·‹——£”À‘—‚ðs‚Á‚œˆê—á. ‘æ43‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï; 2016 Feb 12-14; _ŒË.
    10. ŽíŽsq’ˆ, àF’JLŽq. OTCˆã–ò•i‚ÉŠÜ‚Ü‚ê‚éƒWƒqƒhƒƒRƒfƒCƒ“‚ُ̈í‘ãŽÓ‚É‹Nˆö‚µ‚œ¬Ž™ƒIƒsƒIƒCƒh’†“Å. ‘æ43‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï; 2016 Feb 12-14; _ŒË.
    11. ¬àVˆ»‰À, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ‘ÙŽ™Šú‚©‚ç’ǐՂµAo¶Œã‘Šú‚ÉŠO‰È“IØœ‚ðs‚Á‚œ‰E–[“àŒŒŠÇŽî‚̈ê—á. ‘æ22‰ñ‘ÙŽ™S‘Ÿ•aŠw‰ï; 2016 Feb 19-20; “Œ‹ž.
    12. ’‡‰ª²’qŽq, ìú±—TŽq, Â–Ø—•Žq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. CPK‚̏㏞‚©‚獂ƒJƒtƒFƒCƒ“ŒŒÇ‚ª”»–Ÿ‚µ‚œ‘ŽYŽ™‚̈ê—á. ‘æ316‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2016 Mar 13; •xŽR.
    13. Hirono K, Hata Y, Takasaki A, Miyao N, Nakaoka H, Ibuki K, Ozawa S, Nishida N, Ichida F. Clinical and genetic characteristics in the fetal patients with left ventricular noncompaction. ‘æ80‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï; 2016 Mar 18-20; å‘ä.
    14. ŽíŽsq’ˆ, “c’†•ü”ü, ûüè–ƒ”ü, âV“¡@—I, ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u‘I‘ðŽˆ’ñŽŠ‚̈Ӌ`‚Æ•‹yŒ[”­Šˆ“®F6Î–¢–ž”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒoŒ±‚©‚çl‚Š‚é‘I‘ðŽˆ’ñŽŠ‚̈Ӌ`vD‘æ49‰ñ“ú–{—Տ°tˆÚAŠw‰ï; 2016 Mar 23-25; •ÄŽq.
    15. ‘«—§—Yˆê. ‘‡ƒVƒ“ƒ|ƒWƒEƒ€uŽq‹Ÿ‚̊‹«‚ÆŒ’N‚ðl‚Š‚é -ƒGƒRƒ`ƒ‹’²ž‚ÉŠú‘Ò‚·‚邱‚Æ-FŽq‚Ç‚à‚̊‹«‚ƃAƒŒƒ‹ƒM[v. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    16. ŽíŽsq’ˆ, ’ÒŒûŠì‘ã—², ‚‹ŽŒŠ‘ã. ‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹ŸŒoŒ±3Ž{Ý‚É‚š‚¯‚éî•ñ‚Ì‹€—L‚Æ–â‘è‰ðŒˆ‚ÉŒü‚¯‚Ä‚Ì’ñŒŸ. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    17. ŽíŽsq’ˆ, ŒŽR˜aF, ˆäoŒ’‘Ÿ˜Y, ‘Ÿ“c–M—Y, Ž…’ŒŽ÷, ŽR”š‰À“Ä, ”~ŒŽ@ŽÀ, ŽsìŒõ‘Ÿ˜Y, ‹Êˆä@_, Ž›ˆä@Ÿ. “ú–{¬Ž™‰ÈŠw‰ï”ŏ¬Ž™‹~‹}‘h¶ƒR[ƒXiŠJ”­’†jƒR[ƒX‚Ì–ÚŽw‚·ƒRƒ“ƒZƒvƒg(ˆÄ). ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    18. ’––”’qŽÀ, ìú±—TŽq, ¬‰Y@Ž, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‰Á‰·‰ÁŽŒ‚—¬—Ê•@ƒJƒjƒ…[ƒŒ‚ÌŽg—p‚ōݑîˆÚs‚Å‚«‚œ–«”xŽŸŠ³‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    19. ’‡‰ª²’qŽq, “c’†•ü”ü, ‘ŠJãĕœ, Ž›‰ºV‘Ÿ˜Y, “ú”ä‘å—º, Œˆä@—I, •z‘º°, ŽíŽsq’ˆ, ‘«—§—Yˆê. OTCˆã–ò•i‚Ì“K³Žg—pŒã‚ɃIƒsƒIƒCƒh’†“Å‚ÉŽŠ‚Á‚œ—Ž™—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    20. ‘ŠJË•œ, “c’†•ü”ü, ’‡‰ª²’qŽq, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. R‚Ä‚ñ‚©‚ñ–ò‚ª‘tŒ÷‚µ‚œŽüŠú«šq“fÇ‚Ì“ûŽ™—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    21. ‘ºã«Œ[, Œ“c’Œ“¿, ’†’Ø‹v”T, ŽíŽsq’ˆ, –쑺ŒbŽq, ‘«—§—Yˆê. ‹}Œƒ‚Ȉӎ¯áŠQ‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ‹}«’P‹…«”’ŒŒ•a(M5a)‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    22. ›“c^–ç, ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ƒ}ƒJƒ_ƒ~ƒAƒiƒbƒc‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚̏¬Ž™—á. -ƒiƒbƒc—ÞƒAƒŒƒ‹ƒM[‚̐f’fEŠÇ—‚ɂ‚¢‚Ă̍lˆÄ-. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    23. rˆä”ü•ä, ˜a“c‘ñ–ç, ŽíŽsq’ˆ, ˆÀì@“µ, ›“c^–ç, ’†—ÑŒºˆê, ‘«—§—Yˆê, ’ß“cŽu, ’·’Jì‹v–í. ŒÀ‹Ç«”’”çÇ‚ɍ‡•¹‚µ‚œdÇˆô“ª“Ç‚̈ê—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    24. Ž…@”V, “c‘ºŒ«‘Ÿ˜Y, ¬‰Y@Ž, ’––”’qŽÀ, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‘ÙŽ™f’f‚³‚ê‚œæ“V«‰E”xŒ‡‘¹Ç‚Ì1—á. ‘æ119‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2016 May 13-15; ŽD–y.
    25. ‘ŠJË•œ, “c’†•ü”ü, •œŠâ–ŸŽq, “n•Ó—S‹I, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ‚—tŽ_ŒŒÇ‚ð”F‚ß‚œd“xž_‰^“®”­’B’x‰„‚̏—Ž™—á. ‘æ58‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2016 June 3-5; “Œ‹ž.
    26. ”ª–ؐMˆê, ŒÜ\—’“o, ”šèŠì–F, ‰ª•”@Œh, ‘ºãIŒ[, Ë“ckŠî, “ˆ”ö@’q, ‘«—§—Yˆê, ‚–؉€, —щÀ“ÞŽq, ‰±–{çŽj. •xŽRŽs‚É‚š‚¯‚鏬Ž™ˆã—ÓIƒPƒAŽÀ‹ZŒ€C‰ï‚ɂ‚¢‚Ä. ‘æ1•ñ. ‘æ27‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ïƒtƒH[ƒ‰ƒ€; 2016 June 11-12; •ÄŽq.
    27. –xìT“ñ˜Y, ’†“ˆ“ÖŽq, Ž®¯WŽq, •œŠâ–ŸŽq, ’‡‰ª‰pK, ¬‰Y@Ž, ’†’Ø‹v”T, ”óŒû@Žû, ‹{@ˆêŽu, ŽR“cŒbŽq, ˆ¢•Û@Ä, ’†—ÑŒºˆê, “¡“cC•œ, ŽíŽsq’ˆ, ŒÜ\—’“o. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ7‰ñ“ú–{ƒvƒ‰ƒCƒ}ƒŠEƒPƒA˜A‡Šw‰ï; 2016 June 11-12; “Œ‹ž.
    28. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•šƒAƒŒƒ‹ƒM[(Šî‘b@‚»‚Ì‚Ù‚©) Œ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚É‚š‚¯‚éŒ{—‘RŒŽ“ÁˆÙ“I§Œä«T×–E‚ÌŒŸo•û–@‚ÌŠm—§. ‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 June 17-19; “Œ‹ž.
    29. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§‚ÌŽ¡—ÁEŠÇ— ƒAƒŒƒ‹ƒM[«•@‰Š‚É‚æ‚鏬Ž™‹CŠÇŽxšb‘§‚Ö‚Ì‹Gß–ˆ‚̉e‹¿. ‘æ65‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 June 17-19; “Œ‹ž.
    30. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –F‘º’ŒŽ÷. S–[’†ŠuŒ‡‘¹Ç(ASD)‚ɑ΂·‚éŒo”ç“I•Âœp‚ÌŒoŒ±‚Æ“–‰@‚É‚š‚¯‚鏬Ž™ASDŽ¡—Â̌»ó. ‘æ132‰ñ“ú–{zŠÂŠíŠw‰ï–k—€’n•û‰ï; 2016 June 26; ‹à‘ò.
    31. Â“‡—DŽq, ˜a“c‘ñ–ç, ŽíŽsq’ˆ. dÇˆô“ª“Ç‚ɑ΂µ‚Ä High-flow nasal cannula —Ö@‚ð—p‚¢‚œq‹ó”À‘—. ‘æ30‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2016 July 1-2; å‘ä.
    32. œA–ìŒbˆê, Žs“c˜HŽq. ƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“FŠwZS‘ŸŒŸf‚̈Ӌ`FŠeSŽŸŠ³–ˆ‚̃AƒEƒgƒJƒ€‚©‚ç’T‚é. uS‹ØÇv. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    33. œA–ìŒbˆê. ƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€F¬Ž™zŠÂŠí—̈æ‚É‚š‚¯‚éiPS×–E‚ð—p‚¢‚œŒ€‹†‚ÌŒ»ó.uS‹ØÇv. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    34. ˆÉŒ\“ñ˜Y, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, –F‘º’ŒŽ÷, Žs“c•™Žq. æ“V«SŽŸŠ³Ž™‚ÌŠw“¶Šú’m”\Žw”‚Æ“û—cŽ™Šú‚Ì”­’BŽw”‚ÌŠÖŒW. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    35. ¬àVˆ»‰À, ‹{”ö¬–Ÿ, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq, Œ”ö’C˜N, “úŒG’qŒ›, –F‘º’ŒŽ÷. ‘”xÃ–¬ŠÒ—¬ˆÙíA”xÃ–¬•ÂÇ‚ð‡•¹‚µ‚œ¶S’áŒ`¬‚ɑ΂µA’iŠK“IŽèp‚ðs‚¢2SŽºC•œ‚É“ž’B‚µ‚œˆê—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    36. ’‡‰ª‰pK, ‰ª•”^Žq, ‹{”ö¬–Ÿ, ˆÉŒ\“ñ˜Y, âV“¡˜a—R, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„.@‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    37. ‰ª•”^Žq, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. MDCTŒŸž‚ª—L—p‚Å‚ ‚Á‚œ‰EŠ¥“®–¬‹NŽnˆÙí‚Ì3Žèp—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    38. ‹{”ö¬–Ÿ, ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ¬Ž™SŽŸŠ³‚ɑ΂·‚éƒgƒ‹ƒoƒvƒ^ƒ“‚ÌŽg—pŒoŒ±‚Æ—LŒø«AˆÀ‘S«‚ÌŒŸ“¢. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    39. ꎓ¡@—I, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ‘ÙŽ™•p”‚Å”­Œ©‚³‚êA¶Œã•p”Ž¡—Âɓïa‚µ‚œS–[•p”(AT)‡•¹–[ŽºƒŠƒGƒ“ƒgƒŠ[«•p”(AVRT)‚̈ê—á. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    40. ‹Ž–{ˆè•v, ˆÉŒ\“ñ˜Y. 3DƒGƒR[ƒf[ƒ^‚©‚ç‚Ì3D printing‚ÉŒü‚¯‚œŽŽ‚Ý. ‘æ52‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï ; 2016 July 6-8; “Œ‹ž.
    41. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê, ŽÄ“c@K, ”óŒû@Žû,@•£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[,@”öã—mˆê, ‚”ö@Š², à_“¹”ü‹I. ƒAƒhƒŒƒiƒŠƒ“Ž©ŒÈ’ŽËŠí(ƒGƒsƒyƒ“R)‚Í“KØ‚ÉŽg—p‚Å‚«‚é‚©? ?Š³ŽÒE•ÛŒìŽÒ‚ɑ΂·‚é‘Ζʒ²ž‚©‚ç?. ‘æ36‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2016 July 10; •xŽR.
    42. ”ª–؍GŽq, ’‡‰ª²’qŽq, ˜a“c‘ñ–ç, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. ˆÓŽ¯áŠQ‚ª‘J‰„‚µ‚œDravetÇŒóŒQ‚̈ê—á. ‘æ36‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2016 July 10; •xŽR.
    43. ‹g“cär. ƒVƒ“ƒ|ƒWƒEƒ€uNCPR2015‚̕ύX“_‚Æ‚±‚ê‚Ü‚Å‚Ì“ú–{‚Å‚ÌŽÀÑ ƒgƒŒ[ƒjƒ“ƒOƒTƒCƒg‚ðŽ‚œ‚È‚¢Œ§‚Å‚ÌNCPRuK‰ï‚ÌŽ–‹Æ‚ÌŒ»ó‚Æ–â‘è“_v. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 Jul 16-18;•xŽR.
    44. ìè—TŽq, ’‡‰ª²’qŽq, Â–Ø—•Žq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. CPKãž‚ðŒ_‹@‚ɍ‚ƒJƒtƒFƒCƒ“ŒŒÇ‚Ɛf’f‚µ‚œ‘ŽYŽ™‚̈ê—á. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    45. “c‘ºŒ«‘Ÿ˜Y, ŽR–{’ŒŠ°, ’©“c—T‹M, ›@ÊŽq, ŠâŒ©—TŽq, ŒŽ“c–Ÿ‰À, ‘同@‘, “c’†—TŽq, Žsê”ŽK. ƒKƒ“ƒVƒNƒƒrƒ‹‚É‚æ‚鎡—Âð—v‚µ‚œŒã“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‚Ì’Ž’áo¶‘̏dŽ™2Ç—á. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    46. ’––”’qŽÀ, “c‘ºŒ«‘Ÿ˜Y, ’‡‰ª²’qŽq, ìè—TŽq, –q–{—D”ü, ‹g“cär. ’è—Ê“I’Ž‰¹”g–@‚Å‘ª’肵‚œ‘ŽYŽ™‚̍œ—Ê. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    47. ’‡‰ª²’qŽq, Â–Ø—•Žq, ìú±—TŽq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. –¢nŽ™–Ô–ŒÇ‚Ɛ¶Œã1‚©ŒŽŠÔ‚̑̏d‘‰Á‚ÌŠÖ˜A. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2016 July 16-18; •xŽR.
    48. ‘«—§—Yˆê. ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€uRIgER‘̗Ö@‚̍¡Œã‚̃KƒCƒhƒ‰ƒCƒ“‚ł̈ʒu‚¯‚ðl‚Š‚éFRIgER‘̗Ö@‚̍¡Œã‚̃KƒCƒhƒ‰ƒCƒ“‚ł̈ʒu‚¯v. ‘æ33‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2016 July 16-17; å‘ä.
    49. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—Yˆê. ƒOƒ‹ƒp[ƒ‹19S‚É‚æ‚鏬”žƒAƒŒƒ‹ƒM[F“–‰È‚É‚š‚¯‚鐬l”­Ç—á‚Æ”äŠr‚µ‚œ¬Ž™—á‚Ì“Á’¥. ‘æ33‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2016 July 16-17; å‘ä.
    50. ’‡‰ª²’qŽq, Â–Ø—•Žq, ìú±—TŽq, ’––”’qŽÀ, –q–{—D”ü, ‹g“cär. –¢nŽ™–Ô–ŒÇ‚Ɛ¶Œã1‚©ŒŽŠÔ‚̑̏d‘‰Á‚ÌŠÖ˜A. ‘æ52‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; July 16-18; •xŽR.
    51. ‹v•ÛŸ”VCìú±—TŽqCˆÉ“Œ‰ë”üC’––”’qŽÀC“c‘ºŒ«‘Ÿ˜YC–q–{—D”üC‹g“cär. MRSA‹ÛŒŒÇ‚É•¹”­‚µ‚œèò•”“î•”‘gDŠŽõÇ‚Ì‘ŽYŽ™—á. ‘æ52‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2016 Aug 21; Šò•Œ.
    52. ”ª–ؐMˆê, ŒÜ\—’“o, ‘ºãIŒ[, Ë“ckŠî, “ˆ”ö@’q, ŽíŽsq’ˆ, ‘«—§—Yˆê. •xŽRŽsŽžŠÔŠO¬Ž™‹~‹}‘Ήž‚Ö‚Ì20”NŠÔ‚̐„ˆÚ‚Ə¬Ž™‰Èˆã‚̏¬Ž™‰Šú•]‰¿Œ€CƒR[ƒX‚Ö‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ‘æ26‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; Aug 27-28; ì.
    53. ¬‰Y@Ž, ŒÜ\—’“o, ŽíŽsq’ˆ, “¡“cC•œ, ‹{@ˆêŽu, –xìT“ñ˜Y, ˆ¢•Û@Ä, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, ’†—ÑŒºˆê, ’†’Ø‹v”T, ’‡‰ª‰pK, •œŠâ–ŸŽq, –x]’åŽu, Ž®¯ÍŽq, ’†“ˆ“ÖŽq. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ26‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; Aug 27-28; ì.
    54. ŽíŽsq’ˆ, ‚‹ŽŒŠ‘ã. ‚±‚Ç‚à‚Ì”]Ž€‰º‘ŸŠí’ñ‹ŸŒoŒ±3Ž{Ý‚É‚š‚¯‚é–â‘è“_‚Ì‹€—L‚ƍ¡Œã‚̉ۑè. ‘æ52‰ñ“ú–{ˆÚAŠw‰ï; 2016 Sep 29-Oct 1; “Œ‹ž.
    55. ’‡‰ª‰pK, œA–ìŒbˆê, ‰ª•”^Žq, ‹{”ö¬–Ÿ, ˆÉŒ\“ñû¶, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„. ‘æ36‰ñ“ú–{ìè•aŠw‰ï; 2016 Sep30-Oct1; ‰¡•l.
    56. ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, •Ä“c“¿Žq, •Ä“c@“N, Ö“¡@Ž , ’†“ˆ—²•F. –UŒŸ‚āJ—ŒSŽº‚ɐüˆÛ‰»‚ƐΊD‰»‚ð”F‚ß‘ÙŽ™S‹Øãk–§‰»áŠQ‚©J‹^‚í‚ê‚œˆê—á. ‘æ25‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2016 Oct 8; “Œ‹ž.
    57. œA–ìŒbˆê, ‰€@ô, ‰ª•”^Žq, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñû¶, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. S‹Øãk–§‰»áŠQ‚̏¬Ž™Š³ŽÒ‚É‚š‚¯‚é—\Œã - S‘Ÿ’Ž‰¹”gŒŸž‚ÌŠÏ“_‚©‚ç ?.‘æ25‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2016 Oct 8; “Œ‹ž.
    58. ‘«—§—Yˆê. ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€ušb‘§ƒGƒ“ƒhƒ^ƒCƒv‚ÆŽ¡—ÁF‘œ—l«‚ðl—¶‚µ‚œ¬Ž™šb‘§‚Ì’·ŠúŠÇ—v. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    59. ˆÉ“¡–õ“T. ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚Ì•a‘ԉ𖟂ւ̃Aƒvƒ[ƒ`FV¶Ž™E“ûŽ™Á‰»ŠÇƒAƒŒƒ‹ƒM[‚̃tƒFƒmƒ^ƒCƒvE—Տ°‘œv. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    60. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. H•šƒAƒŒƒ‹ƒM[‚Ì‘ŠŽžŒ^—U”­Çó‚É‚š‚¯‚édÇ“x•]‰¿@ƒAƒiƒtƒBƒ‰ƒLƒV[ƒKƒCƒhƒ‰ƒCƒ“‚̏dÇ“x•ª—Þ‚ÉŠî‚­ƒAƒhƒŒƒiƒŠƒ“‹Ø“÷’ŽË‚Ì“K³Žg—p‚ɂ‚¢‚Ä. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    61. ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê, ŽÄ“c K, ”óŒû Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‘ºãIŒ[, ”öã —mˆê, ‚”ö@Š², à_“¹”ü‹I. ƒGƒsƒyƒ“Äˆ•ûŽž‚ÌŽè‹Z”\—Í‚š‚æ‚ÑŽ©ŒÈ’ŽË‚Ì“KØ‚ȃ^ƒCƒ~ƒ“ƒO‚Ì—‰ð“x‚ð•]‰¿‚·‚é‚œ‚߂̃c[ƒ‹‚̍쐬. ‘æ53‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2016 Oct 8-9; ŒQ”n.
    62. ‘«—§—Yˆê. ‰ï’·u‰‰uƒAƒŒƒ‹ƒM[‚©‚猩‚œ¬Ž™‚̌ċzŠíŽŸŠ³v. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    63. ‘«—§—zŽq, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F. •xŽRŒ§‚É‚š‚¯‚é2Î–¢–žŽ™‚Ì•ÛŒìŽÒ‚Ì‹C“¹ˆÙ•š‚ÌŽ–ŒÌ—\–h‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²ž?2010”N‚Æ‚Ì”äŠr?. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    64. ’––”’qŽÀ, ìè—TŽq, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. Ý‘î‰Á‰·‰ÁŽŒ‚—¬—Ê•@ƒJƒjƒ…[ƒŒ‚Å‘Þ‰@‚µ‚Š‚œ–«”xŽŸŠ³‚Ì1—á. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    65. ”ª–ؐMˆê, ‘«—§—Yˆê. •xŽRŽs‚Ì’nˆæƒNƒŠƒjƒbƒN‚É‚š‚¯‚é“û—cŽ™‚̌ċzŠíƒEƒCƒ‹ƒXŠw“I’²ž‚©‚炱‚Ç‚à‚Ì‚©‚ºÇŒóŒQ‚ðl‚Š‚é. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    66. Œ–쐳’m, ‘«—§—Yˆê, ŒÜ\—’—²•v. ŽvtŠú‚É‚š‚¯‚é”ì–žó‘Ԃ̐„ˆÚ‚Ə¬Ž™šb‘§‚̗Տ°Œo‰ßE‹C“¹‰ß•q«‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚Ä. ‘æ49‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2016 Oct 28-29; •xŽR.
    67. ‘ºã«Œ[, ‘ŠJË•œ, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. ¬Ž™ƒGƒ`ƒŒƒ“ƒOƒŠƒR[ƒ‹’†“łɑ΂µ‚ÄŒŒ‰t“§Í‚ƃzƒƒsƒ][ƒ‹‚Ì•¹—p‚ª—LŒø‚Å‚ ‚Á‚œˆê—á. ‘æ44‰ñ“ú–{‹~‹}ˆãŠw‰ï; 2016 Nov 17-19; “Œ‹ž.
    68. –q–{—D”ü, ’––”’qŽÀ, ìú±—TŽq, “c‘ºŒ«‘Ÿ˜Y, ‹g“cär. •ê‘Ì—r…”÷¶•š”|—{Œ‹‰Ê‚ƐV¶Ž™–«”xŽŸŠ³”­ÇƒŠƒXƒN‚Æ‚ÌŠÖ˜A. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    69. ìú±—TŽq, –q–{—D”ü, ’––”’qŽÀ, “c‘ºŒ«‘Ÿ˜Y, –q–{—D”ü, ‹g“cär. ‹É’áo¶‘̏dŽ™‚É‚š‚¯‚é3DMRI‚ð—p‚¢‚œ”]—e—Ê‚Æ“ªˆÍ‚ÌŠÖ˜A«. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    70. “c‘ºŒ«‘Ÿ˜Y, ’––”’qŽÀ, ìú±—TŽq, –q–{—D”ü, ‹g“cär. ƒ‰ƒ{‚ÌŒ©–{ŽsF’è—Ê“I’Ž‰¹”g–@‚ð—p‚¢‚œ‘ŽYŽ™‚̍œ—Ê‘ª’è/3ŽŸŒ³MRI‚ð—p‚¢‚œ”]’è—Ê•]‰¿‚Ɛ_ŒoŠw“I”­’B. ‘æ61‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ï; 2016 Dec 1-3; ‘åã.
    71. ”ª–؍GŽq, ¬àVˆ»‰À, ’‡‰ª‰pK, ꎓ¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq. ‚΂¿Žw‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ”x“®Ã–¬á‘‚Ì‚P—á. ‘æ318‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2016 Dec 12; ‹à‘ò.
    72. –쑺ŒbŽq, ’ށ@_”V, ¯–쌰G, ‹àŒ“O˜a, •è–M˜a, •l“cG—Y, •“c@•q. “–‰@‚ÅŒoŒ±‚µ‚œ’†•_Œo”ñ’èŒ^ŠïŒ`Žî—l/ƒ‰ƒuƒhƒCƒhŽîᇁiAT/RTj‚Ì3—á. ‘æ58‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï; 2016 Dec 15-17; “Œ‹ž.

    2015”N

  • ’˜‘
    1. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–f—ÃKƒCƒh. “¿ŽRŒ€ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ‹C“¹ˆÙ•š; p45-9.
    2. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–f—ÃKƒCƒh. “¿ŽRŒ€ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ‹z“ü—Ö@; p111-7.
    3. ‘«—§—Yˆê. ‚æ‚­‚í‚©‚éŽq‚Ç‚à‚Ìšb–f—ÃKƒCƒh. “¿ŽRŒ€ˆê•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2015. ƒGƒLƒXƒp[ƒgƒAƒCƒYF2TŠÔ‘O‚Ƀs[ƒiƒbƒc‚ðH‚ׂĂނ¹‚œŽq‚Ç‚à‚ª”­”M‚Æšb–‚𔭏ǂµ‚œê‡A‚·‚®ê–å•a‰@‚ɏЉ‚ׂ«‚©H; p170.
    4. ‘«—§—Yˆê. ¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ‹CŠÇŽxšb‘§@”­ì‚ÌŽ¡—Ã. p302-4.
    5. ‘«—§—Yˆê. 34th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@‹CŠÇŽxšb‘§‚Æ‚»‚ÌŽü•Ó ?Å‹ß‚̘b‘è-.‘«—§@–ž‘Œ•Ò.@“Œ‹ž: ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å; 2015. ¬Ž™ŒyÇšb‘§‚É‚š‚¯‚éICSŠÔŒ‡“Š—^‚̐¥”ñFCON‚Ì—§ê‚©‚ç; p7-9.
    6. ‘«—§—Yˆê. uŒÄ‹zvƒGƒbƒZƒ“ƒVƒƒƒ‹ƒYƒGƒbƒZƒ“ƒVƒƒƒ‹ƒY ?ŒÄ‹zŠíŽŸŠ³‚̃sƒbƒgƒtƒH[ƒ‹-.•Ÿ’n‹`”V•, Š€ŒŽ@‚•Ò. “Œ‹ž: ˆê”ÊŽÐ’c–@l ŒÄ‹zŒ€‹†; 2015. “û—cŽ™šb‘§. p102-5.
    7. ‘«—§—Yˆê. ¡“ú‚ÌŽ¡—ÃŽwj 2015”N“x”ŁDŽRŒû@“O, –kŒŽŒõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ¬Ž™‚Ì‚©‚ºÇŒóŒQD p1288-9.
    8. Žs“c•™Žq. ¡“ú‚̐f’fŽwji‘æ7”Łj. ‹ààVˆê˜YE‰iˆä—ÇŽO•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. ‘ŸŒÛƒoƒ`Žw; p250-1.
    9. Žs“c•™Žq. ¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. S“à–ŒüˆÛ’e«Ç; p525-6.
    10. Žs“c•™Žq. ƒlƒ‹ƒ\ƒ“¬Ž™‰ÈŠw@ŒŽ’˜‘æ19”Å. ŒÜ\—’—²‘Œ•Ò. “Œ‹ž: ƒGƒ‹ƒ[ƒrƒAEƒWƒƒƒpƒ“; 2015. S‹Ø‚ƐS–Œ‚ÌŽŸŠ³; p1890-1900.
    11. Žs“c•™Žq. ¬læ“V«SŽŸŠ³ƒp[ƒtƒFƒNƒgƒKƒCƒh. Ô–Ø’õ“ñAˆÉ“¡@_•Ò. “Œ‹ž: •¶Œõ“°; 2015. ¬læ“V«SŽŸŠ³‚Ì‘SgŠÇ—@3.ž_ES—Šw“IƒAƒvƒ[ƒ`; p252-5.
    12. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj 2015”N“x”ŁDŽRŒû@“O, –kŒŽŒõ•v•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. SŽŸŠ³‚ðŽ‚ÂŽ™“¶E¶“k‚ÌŠwZŠÇ—‰º‚Å‚ÌŽæ‚舵‚¢•û; p1410-3.
    13. ‹g“cär. ‚æ‚­‚í‚©‚éV¶Ž™‚ÌŒŒ‰tƒKƒX: ŽüŽYŠúƒXƒ^ƒbƒt‚Ì‚œ‚ß‚Ì. ×–ì–Ώt•Ò. ‘åã: ƒƒfƒBƒJo”Å; 2015.ŒŒ‰tƒKƒX‘ª’è‚ÉŽg—p‚·‚é‹@Ší‚Æ•ªÍŒ‹‰Ê‚ÌŒ©•û‚ð’m‚ë‚€!; p90-6.
    14. ”ÂàVŽõŽq, ‘«—§—Yˆê. ¬Ž™‰È—Տ°ƒsƒNƒVƒX‡D”N‘ã•ÊƒAƒŒƒ‹ƒM[ŽŸŠ³‚ւ̑Ήž. ŒÜ\—’—²AŠC˜VàVŒ³G•Ò. “Œ‹ž: ’†ŽR‘“X; 2015. “ûŽ™šb‘§‚Ì’·ŠúŠÇ—; p110-3.
    15. ”ÂàVŽõŽq. ¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ16”Å. ‘åŠÖ••F‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2015. –³‹C”x, ’†—tÇŒóŒQ; p422-4.
    16. ŽíŽsq’ˆ. Žq‚Ç‚à‚ð‚ ‚ž‚©‚él‚Ì‚œ‚ß‚Ì‹~–œƒ}ƒjƒ…ƒAƒ‹. “ú–{¬Ž™‘h¶Œ€‹†‹@\, ŽíŽsq’ˆŠÄC. “Œ‹ž: ŠwŒ€ƒƒfƒBƒJƒ‹GŽÐ; 2015.
    17. ˆÉŒ\“ñ˜Y, Žs“c•™Žq. Annual reviewzŠÂŠí2015. ¬Žºˆê¬, ²’n@•×‘Œ•Ò. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2015. æ“V«SŽŸŠ³Ž™‚Ì”]zŠÂ‚Æ‚»‚ÌŒã‚̏¬Ž™Šú‚̍‚ŽŸ‹@”\”­’B;p248-57.
    18. ˆÉŒ\“ñ˜Y, Žs“c•™Žq. ƒi[ƒX‚Ì“à‰ÈŠw. ²’n@•×‘Œ•Ò. “Œ‹ž: ’†ŠOˆãŠwŽÐ; 2015. æ“V«SŽŸŠ³ ‘å“®–¬•Ù‹·óA‘å“®–¬kóÇAƒAƒCƒ[ƒ“ƒƒ“ƒQƒ‹ÇŒóŒQAƒtƒ@ƒ[Žl’¥ÇA‘匌ŠÇ“]ˆÊÇ; p391-4.
    19. ”óŒû@Žû, ‘«—§—Yˆê. uŒÄ‹zvƒGƒbƒZƒ“ƒVƒƒƒ‹ƒYƒGƒbƒZƒ“ƒVƒƒƒ‹ƒY ?ŒÄ‹zŠíŽŸŠ³‚̃sƒbƒgƒtƒH[ƒ‹-.•Ÿ’n‹`”V•, Š€ŒŽ@‚•Ò. “Œ‹ž: ˆê”ÊŽÐ’c–@l ŒÄ‹zŒ€‹†; 2015. ¬Ž™‚É‚š‚¯‚é‹C“¹ˆÙ•šDp150-3.
  • ŒŽ’˜
    1. Hirono K and Ichida F. Utility of TNF-ƒ¿ as a biomarker and the possibility of anti-TNF-ƒ¿ therapy for Kawasaki Diseases. Pediat Therapeut 2015; 5: 257.
    2. Nishida N, Yang X, Takasaki I, Imai K, Kato K, Inoue Y, Imamura T, Miyashita R, Kato F, Yamaide A, Mori M, Saito S, Hara J, Adachi Y, Miyawaki T, Kanegane H. Dysgammaglobulinemia assciated with a hypomorphic XIAP mutation. J Invest Allerg Clin 2015; 25(3): 205-13.
    3. Tamura K, Ikutani M, Yoshida T, Tanaka-Hayashi A, Yanagibashi T, Inoue R, Nagai Y, Adachi Y, Miyawaki T, Takatsu K, Mori H. Increased production of intestinal immunoglobulins in Syntenin-1-deficient mice. Immunobiology. 2015 May; 220(5):597-604.
    4. Hoshino A, Okuno Y, Migita M, Ban H, Yang X, Kiyokawa N, Adachi Y, Kojima S, Ohara O, Kanegane H. X-Linked Agammaglobulinemia Associated with B-Precursor Acute Lymphoblastic Leukemia. J Clin Immunol. 2015 Feb;35(2):108-11.
    5. Watanabe K, Hashimoto I, Ibuki K, Okabe M, Kaneda H, Ichida F. Evaluation of Right Ventricular Function Using Single-Beat Three-Dimensional Echocardiography in Neonate. Pediatr Cardiol. 2015 Jun;36(5):918-24.
    6. Inomata S, Yoshida T, Koura U, Tamura K, Hatasaki K, Imamura H, Mase D, Kigawa M, Adachi Y, Inadera H. Effect of preterm birth on growth and cardiovascular disease risk at school age. Pediatr Int. 2015 Dec; 57(6): 1126-30.
    7. Yang X, Nishida N, Zhao Z, Kanegane H. Advances inunderstanding the pathogenesis of Epstein-barr virus-assosiated lymphoproliferative disorders. Iran J Allergy Asthma Immunol 2015 Oct 14: 462-471.
    8. Nomura Y, Momoi N, Hirono K, Hata Y, Takasaki A, Nishida N, Ichida F. A novel MYH7 gene mutation in a fetus with left ventricular noncompaction. Can J Cardiol. 2015 Jan;31(1):103.e1-3.
    9. Takahiro R, Nakamura S, Kohno H, Yoshimura N, Nakamura T, Ozawa S, Hirono K, Ichida F, Taguchi M. Contribution of CYP3A Isoforms to Dealkylation of PDE5 Inhibitors: A Comparison between Sildenafil N-Demethylation and Tadalafil Demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
    10. Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, Nishida N, Kanegane H, Wada T, Yachie A, Ohara O, Morio T, Notarangelo LD, Imai K, Nonoyama S. RAG1 Deficiency May Present Clinically as Selective IgA Deficiency. J Clin Immunol. 2015 Apr;35(3):280-8.
    11. Heresco-Levy U, Durrant AR, Ermilov M, Javitt DC, Miya K, Mori H. Clinical and electrophysiological effects of D-serine in a schizophrenia patient positive for anti-N-methyl-D-aspartate receptor antibodies. Biol Psychiatry. 2015 Mar 15;77(6):e27-9.
    12. Gaynor JW, Stopp C, Wypij D, Andropoulos DB, Atallah J, Atz AM, Beca J, Donofrio MT, Duncan K, Ghanayem NS, Goldberg CS, Hovels-Gurich H, Ichida F, Jacobs JP, Justo R, Latal B, Li JS, Mahle WT, McQuillen PS, Menon SC, Pemberton VL, Pike NA, Pizarro C, Shekerdemian LS, Synnes A, Williams I, Bellinger DC, Newburger JW; International Cardiac Collaborative on Neurodevelopment (ICCON) Investigators. Neurodevelopmental outcomes after cardiac surgery in infancy. Pediatrics. 2015 May;135(5):816-25.
    13. Kuroda M, Shimizu M, Inoue N, Ikeno I, Nakagawa H, Yokoi A, Niida Y, Konishi M, Kaneda H, Igarashi N, Yamahana J, Taneichi H, Kanegane H, Ito M, Saito S, Furuichi K, Wada T, Nakagawa M, Yokoyama H, Yachie A. Serum tau protein as a marker of disease activity in enterohemorrhagic Escherichia coli O111-induced hemolytic uremic syndrome. Neurochem Int. 2015 Jun-Jul;85-86:24-30.
    14. Iwaki R, Higuma T, Ichida F, Yoshimura N. Follow-Up of Persistent Tracheal Stenosis After Surgery for a Double Aortic Arch. World J Pediatr Congenit Heart Surg. 2015 Jul;6(3):458-61.
    15. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with asthma control in children: findings from a national web-based survey. Pediatr Allergy Immunol. 2014 Dec; 25(8): 804-9.
    16. Kimura M, Meguro T, Ito Y, Tokunaga F, Hashiguchi A, Seto S. Close positive correlation between the lymphocyte response to hen ggg white and house dust mites in Infants with atopic dermatitis. Int Arch Allergy Immunol 2015 166: 161-9.
    17. Uda S, Matsui M, Tanaka C, Uematsu A, Miura K, Kawana I, Noguchi K: Normal development of human brain white matter from infancy to early adulthood: a diffusion tensor imaging study. Dev Neurosci. 2015 37: 182-194.
    18. Tanaka-Arakawa MM, Matsui M, Tanaka C, Uematsu A, Uda S, Miura K, Sakai T, Noguchi K: Developmental changes in the corpus callosum from infancy to early adulthood: A structural magnetic resonance imaging study. PLoS One 2015 10(3): e0118760.
    19. ŽíŽsq’ˆ. Šó­_ŒoŠŽõÇ ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚É‚æ‚é‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Ð헪. NEUROINFECTION 2015 20: 34-39.
    20. ˆÉ“¡–õ“T, X‰º‰p–Ÿ, ‰º‘º^‹B, “¿‰iˆè, –ڍ•ŒhÍ, £ŒËŽk˜Y, –Ø‘ºŒõ–ŸDŒ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚Ì•‰‰×ŽŽŒ±—U”­Çó‚ÉŠî‚­ŠK‘w•ÊƒNƒ‰ƒXƒ^[‰ðÍ. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2015 29: 270-7.
  • Ç—á•ñ
    1. Hoshino A, Nomura K, Hamashima T, Isobe T, Seki M, Hiwatari M, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Takita J, Kanegane H. Aggressive transformation of anaplastic large cell lymphoma with increased number of ALK-translocated chromosomes. Int J Hematol. 2015 Feb;101(2):198-202.
    2. Yang X, Hoshino A, Taga T, Kunitsu T, Ikeda Y, Yasumi T, Yoshida K, Wada T, Miyake K, Kubota T, Okuno Y, Muramatsu H, Adachi Y, Miyano S, Ogawa S, Kojima S, Kanegane H. A Female Patient with Incomplete Hemophagocytic Lymphohistiocytosis Caused by a Heterozygous XIAP Mutation Associated with Non-Random X-Chromosome Inactivation Skewed Towards the Wild-Type XIAP Allele. J Clin Immunol. 2015 Apr;35(3):244-8.
    3. Kawasaki Y, Makimoto M, Nomura K, Hoshino A, Hamashima T, Hiwatari M, Nakazawa A, Takita J, Yoshida T, Kanegane H. Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. Clin Case Rep. 2015 Mar;3(3):145-9.
    4. Koura U, Horikawa S, Okabe M, Kawasaki Y, Makimoto M, Mizuta K, Yoshida T. Successful treatment of hemochromatosis with renal tubular dysgenesis in a preterm infant. Clin Case Rep. 2015 Aug;3(8):690-3.
    5. –쑺ŒbŽq, ¯–쌰G, ‰ª“cˆÀO, ŽRè@“O, âV“¡Ÿ•F, ×ì@•à, ‹àŒ“O˜a. • ’ɁE•Ö”é‚ð‰”­Çó‚Æ‚µ‚œ¬Ž™‘å’°‚ª‚ñ‚Ì1—á. ¬Ž™‰È 2015 56(6): 863-7.
    6. –xìT“ñ˜Y, ‹{”ö¬–Ÿ, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ˜˜]Ò’ŏnjóŒQ‚É”º‚Á‚œ˜ƒwƒ‹ƒjƒA. “ú–{¬Ž™‰ÈŠw‰ïŽ@2015 July 119(7): 1118-1123.
  • ‘à
    1. ‘«—§—YˆêDPro/Con Ž†ã“¢˜_@‹z“üƒXƒeƒƒCƒh–ò‚ÌŠÔŒ‡“Š—^‚̐¥”ñ‚ɂ‚¢‚Ä Con‚Ì—§ê‚©‚çDšb‘§ 2015 28(1): 88-90.
    2. ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒv‚ÆŽ¡—Ð헪. ƒAƒŒƒ‹ƒM[E–Ɖu 2015 22:1562-7.
    3. ‘«—§—Yˆê. ¬Ž™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“iJPGLj‚̍ĕ]‰¿‚Æ“W–]FŠCŠO‚̃KƒCƒhƒ‰ƒCƒ“‚©‚ç‚Ý‚œJPGL‚̍ĕ]‰¿‚Æ“W–]. ƒAƒŒƒ‹ƒM[EŒÄ‹z 2015 22:1088-96.
    4. ‘«—§—Yˆê. ì—p‹@˜‚©‚çl‚Š‚é–ò•š—Ö@Fšb‘§. ¬Ž™‰È@56(3): 279-84.
    5. ‘«—§—Yˆê. ¬Ž™ŒÄ‹zŠíŽŸŠ³‚ð‚ ‚È‚Ç‚é‚ȁIFŒ©’Œ‚·‚ׂ«–òÜiƒeƒIƒtƒBƒŠƒ“»ÜARƒqƒXƒ^ƒ~ƒ“–òj ¬Ž™‰Èf—à 2015 July 78(7): 953-8.
    6. ‘«—§—Yˆê. ƒtƒFƒmƒ^ƒCƒv•ª—Þ‚Æ‘Šú‰î“ü. “ú–{¬Ž™ŒÄ‹zŠíŠw‰ïŽ 2015 26(1): 116-9.
    7. ‘«—§—Yˆê. Å‹ß‚̏¬Ž™‹CŠÇŽxšb‘§f—Á@‚æ‚è‚æ‚¢ƒRƒ“ƒgƒ[ƒ‹ƒŒƒxƒ‹‚ð–ÚŽw‚µ‚āD•xŽR‘åŠwˆãŠw‰ïŽ 2015 25: 50-3.
    8. ‘«—§—Yˆê, ”óŒû@Žû. ŽŸŠ³‚©‚ç‚Ý‚é‰æ‘œf’f‚̐i‚ß•ûE“Ç‚Ý•ûF‹C“¹ˆÙ•šD¬Ž™‰Èf—Ã(‘) 2015 78:s111-5.
    9. ‘«—§—Yˆê, ‹à’J‹v”üŽq. ‰©»‚ƃAƒŒƒ‹ƒM[DƒAƒŒƒ‹ƒM[‚̗Տ°. 2015 35: 1043-6.
    10. Žs“c•™Žq. Žá”NŽÒ‚Ì”ì‘åŒ^S‹ØÇ‚Æ‚»‚ÌŠÓ•ÊŽŸŠ³. ŒÄ‹z‚ƏzŠÂ 2015 63:173-8.
    11. Žs“c•™Žq. S‹Øãk–§‰»áŠQ‚̐f’f–@w¬Ž™zŠÂŠíf—Â̂¢‚܁x ¬Ž™“à‰È 2015 2: 220-4.
    12. Žs“c•™Žq. S‹Ø‰ŠES–Œ‰ŠwŽ„‚̏ˆ•û2015x ¬Ž™‰È—Տ° 2015 68: 637-43.
    13. Žs“c•™Žq. S‹Øãk–§‰»áŠQ@S‘Ÿ 2015 47: 637-44.
    14. ‹g“cär. V¶Ž™•Ò@³ŠúŽYŽ™‚Ì”ñ‹Ù’£«‹C‹¹‚ÌŽ¡—Â͂ǂ€‚·‚é‚©? ŽüŽYŠúˆãŠw 2015 45(3): 337-9.
    15. ‹g“cär, –q–{—D”ü. ƒsƒ“ƒ|ƒCƒ“ƒg¬Ž™ˆã—Á@V‚µ‚¢ŽŸŠ³ŠT”O‚ÆŠÇ—‚ÌŒ©’Œ‚µ@Late pretermŽ™‚Ì–â‘è“_. ¬Ž™“à‰È 2015 47(3): 371-4.
    16. –q–{—D”ü. NICU‘Þ‰@Œã‚̃tƒHƒ[ƒAƒbƒvƒVƒXƒeƒ€. ¬Ž™‰È 56(10): 1617-24.
    17. ”ÂàVŽõŽq. šb‘§Š³Ž™‚Ö‚Ì‹z“üŽw“±‚̃|ƒCƒ“ƒg. ¬Ž™‰È 2015 July 56(7)1001-7.
    18. œA–ìŒbˆê, Žs“c•™Žq. ”ì‘åŒ^S‹ØÇ—Þ‰ŽŸŠ³i“Á’èS‹ØÇjŒÄ‹z‚ƏzŠÂ 2015 63: 631-6.
    19. ‰ª“c–ƒ‘ã, –Ζì—R‹M, ‹g“cär. šM“ûó‘Ô. ƒyƒŠƒlƒCƒ^ƒ‹ƒPƒA 34(7): 690-3.

  • 2015”NŠw‰ï•ñ
    1. Hirono K, Nakaoka H, Ibuki K, Ozawa S, Ichida F. The role of BMP10 during differentiating cardiomyocyte derived from iPSCs. ;2015 Jan 13-
    2. Nakaoka H, Hirono K, Ibuki K, Ozawa S, Ichida F. Increased circulating endothelial microparticles in the acute phase of Kawasaki Disease. 11th International Kawasaki Disease Symposium; 2015 Feb 3-6; Hawaii.
    3. Itazawa T, Hamamichi M, Higuchi O, Nakabayashi M, Okabe Y, Adachi SA, Adachi Y. Clinical usefulness of visual analogue scale to monitor symptoms of allergic rhinitis in children. 71th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2015 Feb 20-24; Houston, USA.
    4. Kusabiraki S., Watanabe Y., Taneichi H., Tanaka T., Tanaka C., Miya K., Mori H., Adachi Y. A case of boy with anti-NMDAR encephalitis treated with additional high-dose corticosteroid therapy.
    5. Ichida F. Insights into etiology and pathogenesis of childhood cardiomyopathy. The 5th Congress of the Asia Pacific Pediatric Cardiology Society; 2014 Mar. 7-9; New Delhi. (invited Lecture)
    6. Higuchi O, Itazawa T, Adachi YS, Hamamichi M, Nakabayashi M, Ito Y, Wada T, Yamamoto J, Murakami G, Adachi Y. Component-specific IgE and IgG4 levels in milk allergy children tolerated baked milk products. XXIV World Allergy Congress; 2015 Oct 14-17; Seoul, Korea.
    7. Nakaoka H, Hirono K, Takasaki I, Yamamoto S, Kinoshita K, Takasaki A, Miyao N, Saito K, Ibuki K, Ozawa S, Ichida F. Increased circulating endothelial microparticles in the acute phase of Kawasaki Disease. The 88th Scientific sessions of AHA 2015; 2015 Nov 7-11; Orlando, Florida, U.S.A.
    8. Takasaki A, Ozawa S, Miyao N, Nakaoka H, Ibuki K, Hirono K, Yoshimura N, Ichida F. Clinical Features and Prognosis of Patients with Left Ventricular Noncompaction Cardiomyopathy: A Comparison between Infantile and Juvenile Types. The 88th Scientific sessions of AHA 2015; 2015 Nov 7-11; Orlando, Florida, U.S.A.
    9. •œŠâ–ŸŽq, ì‡”ü•ä, ’·‰ªvG, ‘q–{@’, “c’†•ü”ü, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê, ’‡‰ª²’qŽq, ”óŒû@Žû. BickerstaffŒ^”]Š²”]‰Š‚ƍl‚Š‚ç‚ê‚œ‚PÎ—Ž™—á. ‘æ67‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï; 2015 Feb 1; ‹à‘ò.
    10. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹Û”]Ç‚É‚š‚¯‚éƒoƒCƒ^ƒ‹ƒTƒCƒ“‚̕ω». ‘æ42‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï; Feb 9-11; “Œ‹ž.
    11. ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq, –q–{—D”ü, ‹g“cär, •Ä“c@“N, ꎓ¡@Ž . ‘ÙŽ™Šú‚ɉES•s‘S‚É‚Ä‹C•t‚©‚ê‚œ¶ŽºS‹Øãk–§‰»áŠQ‚Ì3—á. ‘æ21‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï; Feb 13; “Œ‹ž.
    12. ‘q–{@’, •œŠâ–ŸŽq, ‘ŠJË•œ, “n•Ó—S‹I, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ‰ß‹Ž5”NŠÔi2009`2014”Nj‚É“–‰È‚ÅŽ¡—Âðs‚Á‚œÛHáŠQŠ³ŽÒ‚ɂ‚¢‚Ä. ‘æ313‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2015 March 8; ‹à‘ò.
    13. ŽíŽsq’ˆ, ŒÜ\—’“o, “¡“cC•œ, ‹{@ˆêŽu, –xìT“ñ˜Y, ˆ¢•Û@Ä, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, ’†—ÑŒºˆê, ’†’Ø‹v”T, ¬‰Y@Ž, ’‡‰ª‰pK, •œŠâ–ŸŽq, Ž®¯ÍŽq. •xŽR¬Ž™‰Šúf—ÁiTOPjƒR[ƒX‚ÌŠJ”­. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    14. •l“¹”ü‹I, ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—zŽq, ‘«—§—Yˆê. ŒoŒûH•š•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚̏dÇ“x‚Æ“ÁˆÙ“IIgER‘̉¿‚š‚æ‚Ñ‘•‰‰×—Ê‚Æ‚ÌŠÖŒW. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    15. ‘ŠJË•œ, ¶…ŠÑl, –x]’åŽu, ’†’Ø‹v”T, ŽÂèŒ’‘Ÿ˜Y, ¯Ži‘׍O. ƒrƒj[ƒ‹Žè‘܂ِ̈H‚É‚æ‚é’°•ÂÇ‚𔭏ǂµ‚œŽ©•ÂÇ‚Ì‚P—á. ‘æ118‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2015 Apr 17-19; ‘åã.
    16. Hirono K, Takasaki A, Hata Y, Nakaoka H, Ibuki K, Ozawa S, Sekine M, Yoshimura N, Nishida N, Ichida F. Sarcomere gene mutations in the patients with left ventricular noncompaction. ‘æ79‰ñ“ú–{zŠÂŠíŠw‰ï; 2015 Apr 24-26; ‘åã.
    17. ˜a“c‘ñ–ç, ”ÂàVŽõŽq, •l“¹”ü‹I, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚̏Ǐ󃂃jƒ^ƒŠƒ“ƒO‚É‚š‚¯‚éVAS(visual analog scale)‚Ì—L—p«. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    18. ˆÉ“¡–õ“TAX‰º‰p–ŸA‰º‘º^‹BA“¿‰iˆèA–ڍ•ŒhÍA£ŒËŽk˜YA–Ø‘ºŒõ–ŸDŒ{—‘ƒAƒŒƒ‹ƒM[Š³ŽÒ‚É‚š‚¯‚éŠK‘w“IƒNƒ‰ƒXƒ^[‰ðÍ‚É‚æ‚éÁ‰»ŠÇƒAƒŒƒ‹ƒM[—lƒtƒFƒmƒ^ƒCƒv‚Ì“¯’è. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    19. ˆÉ“¡–õ“TAX‰º‰p–ŸA“¿‰iˆèA–ڍ•ŒhÍA£ŒËŽk˜YA–Ø‘ºŒõ–ŸD5Î‚ÅŽÀŽ{‚µ‚œ‹“û•‰‰×ŽŽŒ±‚Å”sŒŒÇ—lÇó‚ð’悵‚œÁ‰»ŠÇƒAƒŒƒ‹ƒM[.. ‘æ64‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 May 26-28; “Œ‹ž.
    20. •œŠâ–ŸŽq, “c’†•ü”ü, ‘q–{@’, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê. Žá”N«“Á”­«ŠÖß‰Š‚̉Á—Ã’†‚ɏ¬”]•a•Ï‚𔺂€‰Â‹t«”]—À–c‘å•”•a•Ï‚ð—L‚·‚éŒyÇ”]‰ŠE”]ÇiM‚dRSj‚𔭏ǂµ‚œˆê—á. ‘æ57‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2015 May 28-30; ‘åã.
    21. “c’†•ü”ü, ‹{@ˆêŽu, ‘ŠJË•œ, •œŠâ–ŸŽq, “n•Ó—S‹I, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê, Vˆä“c—v. PNKPˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œ¬“ªÇ‚̈ê’jŽ™—á. ‘æ57‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2015 May 28-30; ‘åã.
    22. ŽíŽsq’ˆ. ƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™‹~–œ‹~‹}‚ÌŒ»ó‚Æ“W–]v’n•û‚É‚š‚¯‚éd“﬎™f—Ñ̐§?Šë‹@“IW’cŠŽõ‚©‚ç‚̍lŽ@. ‘æ18‰ñ“ú–{—Տ°‹~‹}ˆãŠw‰ï; June 4-6; •xŽR.
    23. ŽíŽsq’ˆ, âV“¡@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ‘«—§—Yˆê. ¬Ž™I––Šúˆã—Âɂš‚¢‚Ä•K—v‚È‚±‚Ɓ`”]Ž€‰º’·‹——£”À‘—‚ÌŒoŒ±‚ð’Ê‚µ‚ā` ‘æ29‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2015 June 12-13; ‘å‹{.
    24. âV“¡@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê. “ûŽ™dÇƒ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éR‚¯‚¢‚ê‚ñ–ò‚Ì‘I‘ð. ‘æ29‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï; 2015 June 12-13; ‘å‹{.
    25. Ž›‰ºV‘Ÿ˜Y, Œˆä@—I, ‘ŠJË•œ, ’‡‰ª²’qŽq, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê, ²‹vŠÔ—FŽq, H‰ª’ŒŽ÷, ŒKŽR’Œ–ç. L”Í‚É‚í‚œ‚é”]Ã–¬“ŽŒŒð‚ð”F‚ß‚œƒx[ƒ`ƒFƒbƒg•a‚̈ê—á. ‘æ314‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2015 June 14; ‹à‘ò.
    26. ‘«—§—zŽq, ˜a“c‘ñ–ç, •l“¹”ü‹I, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê. ƒs[ƒiƒbƒcƒAƒŒƒ‹ƒM[‚É‚š‚¯‚éŠeŽíƒRƒ“ƒ|[ƒlƒ“ƒg‚ɑ΂·‚é“ÁˆÙ“IIgER‘Ì‚ÌŒŸ“¢. ‘æ32‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2015 June 20-21; ‰¡•l.
    27. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uŠÂ‹«‰˜õ‚ÌŒ»ó‚Ƒ΍ôF‰©»‚ɂ‚¢‚āv ‘æ46‰ñ“ú–{E‹ÆEŠÂ‹«ƒAƒŒƒ‹ƒM[Šw‰ï; 2015 July 3-4; “Œ‹ž.
    28. ‹g“cär, “c‘ºŒ«‘Ÿ˜Y, â“c“ޏ, ìè—TŽq, –q–{—D”ü. NICU“à‚É‚š‚¯‚éƒJƒ“ƒKƒ‹[ƒPƒA‚̕ꎙ‚ւ̉e‹¿. -‘Á‰tƒAƒ~ƒ‰[ƒ[‚É‚æ‚é•]‰¿- ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    29. â“c“ޏ, “c‘ºŒ«‘Ÿ˜Y, ìè—TŽq, –q–{—D”ü, ‹g“cär, “ñ’J@•, ”šèŠì–F. 18ƒgƒŠƒ\ƒ~[Ž™‚̍ݑîˆÚs‚ÉŠÖ‚·‚錟“¢. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    30. ’·‰ªvG, â“c“ޏ, “c‘ºŒ«‘Ÿ˜Y, ìè—TŽq, –q–{—D”ü, ‹g“cär. ‹}«Šú‚ɕꎙŠÔ—AŒŒÇŒóŒQ‚Æ‚ÌŠÓ•Ê‚ª¢“ï‚Å‚ ‚Á‚œDiamond-Blackfan•nŒŒ‚Ì1—á. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    31. X‚±‚ž‚Š,@’|‘º‹žŽq, ìè—TŽq, –q–{—D”ü, “c‘ºŒ«‘Ÿ˜Y, ‹g“cär, ˆÉ“¡ŽÀ, •Ä“c@“N. ŒŒ¬”’ቺ‚ª‘J‰„‚µ‚œHLAR‘Ì‚É‚æ‚éV¶Ž™“¯Ží–Ɖu«ŒŒ¬”ÂŒž­Ç‚̈ê—á. ‘æ51‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï; 2015 July 10-12; •Ÿ‰ª.
    32. ‘ŠJË•œ, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. DownÇŒóŒQ‚É”º‚€ÇŒó«WestÇŒóŒQ‚Ì6—á‚É‚š‚¯‚é‰uŠw“IŒŸ“¢. ‘æ8‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï“ŒŠCE–k—€’n•û‰ï; 2015 July 11; •xŽR.
    33. ˆÉ“¡–õ“T, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, à_“¹”ü‹I, ”‘òŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê. •xŽR‘åŠw‚É‚š‚¯‚éŒoŒû–Ɖu—Ö@‚ðŽ{s‚µ‚Ä‚¢‚鎙‚ÌŒo‰ß‚ɂ‚¢‚Ä. ‘æ34‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2015 July 12; ‚‰ª.
    34. œA–ìŒbˆê, ”š—R‹IŽq, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ‚è–ƒ”ü, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Œ“c®Ž÷, Žs“c•™Žq. ‘ÙŽ™ŠúEV¶Ž™Šú”­Ç‚̍¶ŽºS‹Øãk–§‰»áŠQ‚É‚š‚¯‚é—Տ°ˆâ“`Šw“IŒŸ“¢. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    35. ’‡‰ª‰pK, œA–ìŒbˆê, ‚è–ƒ”ü, ‹{”ö¬–Ÿ, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq(EMPs)‚Ì–ðŠ„. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2015 July 16-18; “Œ‹ž.
    36. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. Ž©Œ±—á3Ç—á‚©‚猩‚œV¶Ž™S‹Øãk–§‰»áŠQ‚̗Տ°“I“Á’¥. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    37. ‰ª•”^Žq, ‹Ž–{ˆè•v, “n•Óˆê—m, ãšŒhˆê˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚éIVIGŽ{s‘OŒã‚ÌIgG’l‚ÆŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ51‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï 2015 July 16-18; “Œ‹ž.
    38. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™šb‘§‚É‚š‚¯‚é‹z“üƒXƒeƒƒCƒh–ò‚̈ʒu‚¯v. ‘æ25‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï 2015 Aug 22-23; å‘ä.
    39. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒƒ^ƒ{ƒŠƒbƒNÇŒóŒQ‚Æšb‘§“‰»F¬Ž™”ì–ž‚Æšb‘§“‰»v. ‘æ25‰ñ‘Ûšb‘§“ú–{E–kƒAƒWƒA•”‰ï 2015 Sep 3-4; ‰¡•l.
    40. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€ ’j—‹€“¯ŽQ‰æ„iƒ_ƒCƒoƒVƒeƒC\‚ÌŽæ‚è‘g‚Ý. •xŽR‘åŠw‚É‚š‚¯‚鏗«Œ€‹†ŽÒŽx‰‡‚Æ’j—‹€“¯ŽQ‰æ‚ÌŽæ‚è‘g‚Ý. “ú–{ƒZƒ‰ƒ~ƒbƒN‹Š‰ï‘æ28‰ñH‹GƒVƒ“ƒ|ƒWƒEƒ€ 2015 Sep 17; •xŽR.
    41. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€@zŠÂŠíˆã—ÃŒ»ê‚Å‚Ì’j—‹€“¯ŽQ‰æ‚ð‚Ç‚Ì‚æ‚€‚ɐi‚ß‚é‚©H ƒ[ƒNƒ‰ƒCƒtƒoƒ‰ƒ“ƒX‚ðŽx‚Š‚é`•xŽR‘åŠw‚Å‚ÌŽæ‚è‘g‚݁`. ‘æ63‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï 2015 Sep 18-20; ‰¡•l.
    42. ŽíŽsq’ˆ. 6Î–¢–ž”]Ž€‰º‘ŸŠí’ñ‹Ÿ‚ÌŒoŒ±‚©‚çl‚Š‚éŽq‚Ç‚à‚̏I––Šúˆã—Ã. ‘æ51‰ñ“ú–{ˆÚAŠw‰ï 2015 Oct 1-3; ŒF–{.
    43. –q–{—D”ü. ƒVƒ“ƒ|ƒWƒEƒ€ •xŽRŒ§‚É‚š‚¯‚鏬Ž™Ý‘îˆã—Â̌»ó‚ƉۑèF¬Ž™Ý‘îˆã—ÁG‘—‚èo‚·‘€‚ÌŒ»ó‚Æ–â‘è“_. ‘æ54‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï. 2015 Oct 4; •xŽR.
    44. Ž›‰ºV‘Ÿ˜Y, Œˆä@—I, ‘ŠJË•œ, ’‡‰ª²’qŽq, “c’†•ü”ü, ŽíŽsq’ˆ, ‘«—§—Yˆê, ²‹vŠÔ—FŽq, H‰ª’ŒŽ÷, ŒKŽR’Œ–ç. L”Í‚È”]Ã–¬“ŽŒŒð‚ð’悵‚œŒŒŠÇŒ^ƒx[ƒ`ƒFƒbƒg•a‚̈ê—á. ‘æ25‰ñ“ú–{¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïEŠwpW‰ï; 2015 Oct 9-11; ‹à‘ò.
    45. ’‡‰ª‰pK, œA–ìŒbˆê, ‚èˆê˜N, ŽR–{œŽm, ‚è–ƒ”ü, ‹{”ö¬–Ÿ, ˆÉŒ\“ñ˜Y, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚錌ŠÇ“à”ç×–E—R—ˆ‚ÌŒŒŠÇ”÷¬—±Žq (EMPs) ‚Ì–ðŠ„. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡ .
    46. ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ‰“ŠuŠú‚É‘œ”­«‚Ì‹‘å––œ“®–¬áŽ‚š‚æ‚Ñ‹‘劥“®–¬áŽ‚ª”F‚ß‚ç‚ê‚œ•s‘SŒ^ìè•a‚̈ê—á. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡.
    47. ‰ª•”^Žq, ‹Ž–{ˆè•v, ²‹vŠÔ—FŽq, “n•Óˆê—m, ãšŒhˆê˜Y, ’‡‰ª‰pK, œA–ìŒbˆê, Žs“c•™Žq. ìè•a‹}«Šú‚É‚š‚¯‚é IVIG ‘OŒã‚ÌŒŒŽ IgG ‚̕ω»‚ÆŽ¡—Ôœ‰ž«‚ÌŒŸ“¢. ‘æ35‰ñ“ú–{ìè•aŠw‰ï 2015 Oct 9-10; Ž­Ž™“‡.
    48. ‹g“cär, â“c“ޏ, “c‘ºŒ«‘Ÿ˜Y, ìè—TŽq, –q–{—D”ü, “ñ’J•, ”šèŠì–F. Ý‘îˆã—Âֈڍs‚Å‚«‚œ18ƒgƒŠƒ\ƒ~[Ž™‚ɂ‚¢‚Ä‚ÌŒŸ“¢. “ú–{l—Þˆâ“`Šw‰ï‘æ60‰ñ‘å‰ï 2015 Oct 14-17; “Œ‹ž.
    49. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb–‚ɂš‚¯‚郍ƒCƒRƒgƒŠƒGƒ“Žó—e‘̝hR–ò‚Ì–ðŠ„v. ‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    50. ’†—ÑŒºˆê.@ƒVƒ“ƒ|ƒWƒEƒ€u”x‹@”\ŒŸž —‰ð‚ð[‚ß‚ÄŠˆ—p‚·‚é‚œ‚߂ɁFƒCƒ“ƒpƒ‹ƒXƒIƒVƒƒƒgƒŠ[iIOSj‚Ì“Á’¥‚ƗՏ°‰ž—pv. ‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    51. ”óŒû@Žû, ’‡‰ª²’qŽq, ‰ª•”^Žq, ²‹vŠÔ—FŽq, ¬ìŽŸ˜Y, ãšŒhˆê˜Y, ¡‘º”Ž–Ÿ, ŒE“c”Ž“¹, ’†—ÑŒºˆê, ‘«—§—Yˆê.@–³ä°–ŒŒ^ƒCƒ“ƒtƒ‹ƒGƒ“ƒU‹Û‚É‚æ‚èdÇ”x‰Š‚ð‹N‚±‚µ‚œ‚Pƒ–ŒŽŽ™‚Ì2Ç—á.@‘æ48‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï 2015 Oct 23-24; ‘q•~.
    52. –q–{—D”ü, ’|‘º‹žŽq, ¬‰Y@Ž, â“c“ޏ, ìè—TŽq, “c‘ºŒ«‘Ÿ˜Y, ‹g“cär. ‹U«’°•ÂÇ‚ð’悵‚œæ“VŒ^‹Ø‹­’Œ«ƒWƒXƒgƒƒtƒB[‚Ì’Ž’áo¶‘̏dŽ™—á. ‘æ60‰ñ“ú–{V¶Ž™¬ˆçˆãŠw‰ïŠwpW‰ï 2015 Oct 23-25; ·‰ª.
    53. œA–ìŒbˆê, ”š—R‹IŽq, “ˆäL, ˆŒ‘ò@‰q, ˆ¢•”•S‡Žq, ’ÒˆäM”V, —с@ŠÂ, âŒû•œ”n, ˆ¢•”’‰˜N, ‹{”ö¬–Ÿ, ‚è–ƒ”ü, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Œ“c®Ž÷, Žs“c•™Žq. TAZˆâ“`Žq•ÏˆÙ‚𔺂€¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°ˆâ“`Šw“IŒŸ“¢. ‘æ24‰ñ¬Ž™S‹ØŽŸŠ³Šw‰ïŠwpW‰ï 2015 Oct 24; ‘åã.
    54. ûüú±–ƒ”ü, ¬àVˆ»‰À, ‹{”ö¬–Ÿ, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚Ì“ûŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚̗Տ°‘œ‚ÌŒŸ“¢. ‘æ24‰ñ¬Ž™S‹ØŽŸŠ³Šw‰ïŠwpW‰ï 2015 Oct 24; ‘åã.
    55. ‘«—§—Yˆê. ‹³ˆçƒZƒ~ƒi[u¬Ž™šb‘§@?‘ŠúŽ¡—Éî“ü‚ª‚à‚œ‚ç‚·‚à‚̂Ƃ́H-v ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    56. Higuchi O, Itazawa T, Adachi YS, Hamamichi M, Nakabayashi M, Ito Y, Wada T, Yamamoto J, Murakami G, Adachi Y. Component-specific IgE and IgG4 in milk allergy children performed oral baked milk-containing food challenge. ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    57. Ž›‰ºV‘Ÿ˜Y, ”ÂàVŽõŽq, ’†—ÑŒºˆê, ˜a“c‘ñ–ç, ˆÉ“¡–õ“T, à_“¹”ü‹I, ‘«—§—zŽq, “c“ˆ’ŒÆ, ‘«—§—Yˆê. ¬”ž‚š‚æ‚уÖ-5ƒOƒŠƒAƒWƒ““ÁˆÙ“IIgER‘̉A«‚Å‚ ‚Á‚œ¬”žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á. ‘æ52‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï 2015 Nov 21-22; “Þ—Ç.
    58. –쑺ŒbŽq, Œ“c’Œ“¿, ‘«—§—Yˆê, ‹àŒ“O˜a, ’Ø“c‰ëm, ‰““¡ˆê•œ, ‹gè’qˆê. ‰ºˆô“ªŒŽ”­‹Øã”çŠà‚Ì2Î’jŽ™—á. ‘æ57‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŠwpW‰ï 2015 Nov 27-29; ŽR—œ.
    59. Ž…@”V, “c‘ºŒ«‘Ÿ˜Y, ¬‰Y@Ž, ’––”’qŽÀ, ìè—TŽq, –q–{—D”ü, ‹g“cär, ‘«—§—Yˆê. ‘ÙŽ™f’f‚³‚ê‚œæ“V«‰E”xŒ‡‘¹Ç‚Ì1—á. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï 2015 Dec 13; ‹à‘ò.
    60. ”ª–ؐMˆê, Ë“ckŠî, “ˆ”ö@’q, –xìT“ñ˜Y, ŽíŽsq’ˆ. ’nˆæ¬Ž™‰È‚É‚š‚¯‚鏬Ž™‰Šú‹~‹}Œ€C‚Ö‚Ì‚Æ‚è‚­‚݁[¬Ž™‹}•Ï‘Ήž@•]‰¿”FŽ¯ˆÀ’艻ƒvƒƒOƒ‰ƒ€(PEARS)‚Ì‘ÌŒ±‚ð’Ê‚µ‚ÄŠw‚ñ‚Ÿ‚±‚Ɓ[. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï 2015 Dec 13; ‹à‘ò.
    61. ¬‰Y@Ž, ŽíŽsq’ˆ, ‹{@ˆêŽu, ’†—ÑŒºˆê, ’†’Ø‹v”T, ’‡‰ª‰pK, •œŠâ–ŸŽq, ŒÜ\—’“o, “¡“cC•œ, –xìT“ñ˜Y,@ˆ¢•ÛÄ, Ž®¯ÍŽq, ’†“ˆ“ÖŽq, ŽR“cŒbŽq, ”óŒû@Žû, ‹à“c@®, –x]’åŽu. •xŽR¬Ž™‰Šúf—ÃR[ƒX(TOPƒR[ƒX)‚ÌŠJ”­‚ÆŠˆ“®•ñ. ‘æ315‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï 2015 Dec 13; ‹à‘ò.

    2014”N

  • ’˜‘
    1. ‘«—§—YˆêD¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—1Dw¬Ž™“à‰Èxw¬Ž™ŠO‰Èx•ÒWˆÏˆõ‰ï‹€•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014D‹¹–Œ‰ŠD81-83.
    2. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2014”N”Å. •ŸˆäŽŸ–î‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014. æ“V«SŽŸŠ³‚Ì’áŽ_‘f”­ì. 1246-7.
    3. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2014”N”Å. •ŸˆäŽŸ–î‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2014. æ“V«SŽŸŠ³i“à‰Èj. 411-2.
    4. Žs“c•™Žq. RSƒEƒCƒ‹ƒXŠŽõÇ‚˜ƒpƒŠƒrƒYƒ}ƒuData Book. “í“c@‘•Ò. ‘åã: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ƒpƒŠƒrƒYƒ}ƒu“Š—^‚̈Ӌ`@¬Ž™zŠÂŠí‰È‚Ì—§ê‚©‚ç. 50-1.@
    5. Žs“c•™Žq. ¬Ž™‰Èf—Áu¬Ž™‚ÌŽ¡—ÃŽwjvˆä“c”ŽK•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2014. ”ì‘åŒ^S‹ØÇ. 369-70.
    6. Žs“c•™Žq. ¬Ž™‰Èf—Áu¬Ž™‚ÌŽ¡—ÃŽwjvˆä“c”ŽK•Ò. “Œ‹ž: f’f‚ÆŽ¡—ÃŽÐ; 2014. Šg’£Œ^S‹ØÇ. 371-2.
    7. Žs“c•™Žq. æ“V«SŽŸŠ³. ’†àV@œ•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. Šg’£Œ^S‹ØÇ. 378-84.
    8. Žs“c•™Žq. æ“V«SŽŸŠ³. ’†àV@œ•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ”ì‘åŒ^S‹ØÇ. 385-96.
    9. Žs“c•™Žq. æ“V«SŽŸŠ³. ’†àV@œ•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. S‹Øãk–§‰»áŠQ. 397-403.
    10. Žs“c•™Žq. ¬Ž™“à‰È‘Š§†@•a‘Ԑ¶—‚h. ŒÜ\—’—²‘Œ•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2014. FS‹Øãk–§‰»áŠQ. 432-7.
    11. Žs“c•™Žq. ¬læ“V«SŽŸŠ³. ’O‰HŒöˆê˜Y•Ò. “Œ‹ž: ƒƒf²ƒJƒ‹ƒrƒ…[ŽÐ; 2014. ˆâ“`ŽqˆÙíAõF‘ُ̈í. 8-12.
    12. œA–ìŒbˆê, Žs“c•™Žq. ìè•a‚Ì‚·‚ׂÄ. Îˆä³_•Ò, “Œ‹ž: ’†ŽR‘“X; 2014. ƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@. 112-5.
    13. “n•Óˆê—m, Žs“c•™Žq. ‚í‚©‚è‚â‚·‚¢“à‰ÈŠwi‘æ4”Łj. ˆä‘º—T•v‘Œ•Ò. “Œ‹ž: •¶Œõ“°; 2014. æ“V«SŽŸŠ³@zŠÂŠíŽŸŠ³. 118-28.
  • ŒŽ’˜
    1. Kanegane H, Imai K, Yamada M, Takada H, Ariga T, Bexon M, Rojavin M, Hu W, Kobayashi M, Lawo JP, Nonoyama S, Hara T, Miyawaki T. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014 Feb; 34(2): 204-11.
    2. Hirono K, Sekine M, Shiba N, Hayashi S, Nakaoka H, Ibuki K, Saito K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Kitajima I, Ichida F. N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of Fallot. Circ J 2014 Feb 25; 78(3): 693-700.
    3. Hirono K, Ibuki K, Tomita H. Percutaneous catheter aspiration thrombectomy for the occluded stents of pulmonary artery in children with single ventricle physiology after fontan surgery. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1153-6.
    4. Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev. 2014 Sep; 36(8): 645-52.
    5. Yoshida T, Takasaki I, Kanegane H, Inomata S, Ito Y, Tamura K, Makimoto M, Saito S, Yoshimoto Y, Miyawaki T. Intrauterine growth restriction modifies gene expressionprofiling in cord blood. Pediatr Int. 2014 Aug; 56(4): 559-65.
    6. Hoshino A, Shimizu M, Matsukura H, Sakaki-Nakatsubo H, Nomura K, Miyawaki T, Kanegane H. Allogeneic Bone Marrow transplantation appears to ameliorate IgA nephropathy in a patient with X-linked thrombocytopenia. J Clin Immunol. 2014 Jan; 34(1): 53-7.
    7. Hoshino A, Imai K, Ohshima Y, Yasutomi M, Kasai M, Terai M, Ishigaki K, Morio T, Miyawaki T, Kanegane H. Pneumothorax in patients with severe combined immunodeficiency. Pediatr Int. 2014 Aug; 56(4): 510-4.
    8. Yoshida K, Adachi Y, Sasaki M, Furukawa M, Itazawa T, Hashimoto K, Odajima H, Akasawa A. Test-retest reliability of the International Study of Asthma and Allergies in Childhood questionnaire for a web-based survey. Ann Allergy Asthma Immunol. 2014 Feb; 112(2): 181-2.
    9. Wada T, Kanegane H, Ohta K, Katoh F, Imamura T, Nakazawa Y, Miyashita R, Hara J, Hamamoto K, Yang X, Filipovich AH, Marsh RA, Yachie A. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014 Jan; 65(1): 74-8.
    10. Hata Y, Mori H, Tanaka A, Fujita Y, Shimomura T, Tabata T, Kinoshita K, Yamaguchi Y, Ichida F, Kominato Y, Ikeda N, Nishida N. Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death. Int J Legal Med. 2014 Jan; 128(1): 105-15.
    11. Horino S, Sasahara Y, Sato M, Niizuma H, Kumaki S, Abukawa D, Sato A, Imaizumi M, Kanegane H, Kamachi Y, Sasaki S, Terui K, Ito E, Kobayashi I, Ariga T, Tsuchiya S, Kure S. Selective expansion of donor-derived regulatory T cells after allogeneic bone marrow transplantation in a patient with IPEX syndrome. Pediatr Transplant. 2014 Feb; 18(1): E25-30.
    12. Kanatani KT, Okumura M, Tohno S, Adachi Y, Sato K, Nakayama T. Indoor particle counts during Asian dust events under everyday conditions at an apartment in Japan. Environ Health Prev Med. 2014 Jan; 19(1): 81-8.
    13. Kanatani KT, Adachi Y, Sugimoto N, Noma H, Onishi K, Hamazaki K, Takahashi Y, Ito I, Egawa M, Sato K, Go T, Kurozawa Y, Inadera H, Konishi I, Nakayama T. Birth cohort study on the effects of desert dust exposure on childrenfs health: protocol of an adjunct study of the Japan Environment & Childrenfs Study. BMJ Open 2014; 4: e004863
    14. Takanashi J, Taneichi H, Misaki T, Yahata Y, Okumura A, Ishida YI, Miyawaki T, Okabe N, Sata T, Mizuguchi M. Clinical and radiologic features of encephalopathy during 2011 E coli O111 outbreak in Japan. Neurology. 2014 Feb 18; 82(7): 564-72.
    15. Kobayashi S, Taki T, Nagoshi H, Chinen Y, Yokokawa Y, Kanegane H, Matsumoto Y, Kuroda J, Horiike S, Nishida K, Taniwaki M. Identification of novel fusion genes with 28S ribosomal DNA in hematologic malignancies. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group. Int J Oncol. 2014 Apr; 44(4): 1193-8.
    16. Shimizu M, Kuroda M, Inoue N, Konishi M, Igarashi N, Taneichi H, Kanegane H, Ito M, Saito S, Yachie A. Extensive serum biomarker analysis in patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine. 2014 Mar; 66(1): 1-6.
    17. Horie A. Ishida K, Shibata K, Taguchi M, Ozawa A, Hirono K, Ichida F, Hashimoto Y. Pharmacokinetic variability of flecainide in younger Japanese patients and mechanisms for renal excretion and intestinal absorption. Biopharm Drug Dispos. Apr; 35(3): 145-53.
    18. Kinoshita K, Komatsu T, Nishide K, Hata Y, Hisajima N, Takahashi H, Kimoto K, Aonuma K, Tsushima E, Tabata T, Yoshida T, Mori H, Nishida K, Yamaguchi Y, Ichida F, Fukurotani K, Inoue H, Nishida N. A590T mutation in KCNQ1 C-terminal helix D decreases IKs channel trafficking and function but not Yotiao interaction. J Mol Cell Cardiol. 2014 Jul; 72: 273-80.
    19. Yamaguchi Y, Nishide K, Kato M, Hata Y, Mizumaki K, Kinoshita K, Nonobe Y, Tabata T, Sakamoto T, Kataoka N, Nakatani Y, Ichida F, Mori H, Fukurotani K, Inoue H, Nishida N. Glycine/Serine Polymorphism at Position 38 Influences KCNE1 Subunit's Modulatory Actions on Rapid and Slow Delayed Rectifier K+ Currents. Circ J 2014 Feb 25; 78(3): 610-8.
    20. Mitani Y, Ohta K, Ichida F, Nii M, Arakaki Y, Ushinohama H, Takahashi T, Ohashi H, Yodoya N, Fujii E, Ishikura K, Tateno S, Sato S, Suzuki T, Higaki T, Iwamoto M, Yoshinaga M, Nagashima M, Sumitomo N. Circumstances and Outcomes of Out-Of-Hospital Cardiac Arrest in Elementary and Middle School Students in the Era of Public-Access Defibrillation. Circ J 2014 Feb 25; 78(3): 701-7.
    21. Kogawa K, Sato H, Asano T, Ohga S, Kudo K, Morimoto A, Ohta S, Wakiguchi H, Kanegane H, Oda M, Ishii E. Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: Report of the Japan Histiocytosis Study Group. Pediatr Blood Cancer. 2014 Jul; 61(7): 1257-62.
    22. Murakami Y, Honjo S, Odajima H, Adachi Y, Yoshida K, Ohya Y, Akasawa A. Exercise-induced wheezing among Japanese pre-school children and pupils. Allergol Int. 2014 Jun; 63(2): 251-9.
    23. Yabal M, Muller N, Adler H, Knies N, Gros CJ, Damgaard RB, Kanegane H, Ringelhan M, Kaufmann T, Heikenwalder M, Strasser A, Gros O, Ruland J, Peschel C, Gyrd-Hansen M, Jost PJ. XIAP Restricts TNF- and RIP3-Dependent Cell Death and Inflammasome Activation. Cell Rep. 2014 Jun; 7(6): 1796-808.
    24. Kubagawa H, Oka S, Kubagawa Y, Torii I, Takayama E, Kang DW, Jones D, Nishida N, Miyawaki T, Bertoli LF, Sanders SK, Honjo K. The Long Elusive IgM Fc Receptor, FcƒÊR. J Clin Immunol. 2014 Jul; 34 Suppl 1: 35-45.
    25. Bowles NE, Arrington CB, Hirono K, Nakamura T, Ngo L, Wee YS, Ichida F, Weis JH. Kawasaki disease patients homozygous for the rs12252-C variant of interferon-induced transmembrane protein-3 are significantly more likely to develop coronary artery lesions. Mol Genet Genomic Med. 2014 Jul; 2(4): 356-61.
    26. Tabata T, Yamaguchi Y, Hata Y, Ichida F, Mori H. Modification of KCNH2-Encoded cardiac potassium channels by KCNE1 polymorphism. Circ J. 2014 Aug 25; 78(9): 2331.
    27. van Zelm MC, Bartol SJ, Driessen GJ, Mascart F, Reisli I, Franco JL, Wolska-Kusnierz B, Kanegane H, Boon L, van Dongen JJ, van der Burg M. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. J Allergy Clin Immunol. 2014 Jul; 134(1): 135-144.e7
    28. Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H, Ashida A, Kaname S, Taneichi H, Tang J, Ohnishi M; Study group for establishing guidelines for the diagnosis and therapy of hemolytic uremic syndrome. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol. 2014 Aug; 18(4): 525-57.
    29. Hamasaki Y, Kohno Y, Ebisawa M, Kondo N, Nishima S, Nishimuta T, Morikawa A, Aihara Y, Akasawa A, Adachi Y, Arakawa H, Ikebe T, Ichikawa K, Inoue T, Iwata T, Urisu A, Ohya Y, Okada K, Odajima H, Katsunuma T, Kameda M, Kurihara K, Sakamoto T, Shimojo N, Suehiro Y, Tokuyama K, Nambu M, Fujisawa T, Matsui T, Matsubara T, Mayumi M, Mochizuki H, Yamaguchi K, Yoshihara S.@ Japanese pediatric guideline for the treatment and management of bronchial asthma 2012.@Pediatr Int. 2014 Aug; 56(4): 441-50.
    30. Kato M, Saitsu H, Murakami Y, Kikuchi K, Watanabe S, Iai M, Miya K, Matsuura R, Takayama R, Ohba C, Nakashima M, Tsurusaki Y, Miyake N, Hamano S, Osaka H, Hayasaka K, Kinoshita T, Matsumoto N. PIGA mutations cause early-onset epileptic encephalopathies and distinctive features. Neurology. 2014 May 6; 82(18): 1587-96.
    31. Kohno H, Ichida F, Hirono K, Ozawa S, Yoshimura N, Nakamura T, Akita C, Ishida K, Taguchi M. Plasma Concentrations of Tadalafil in Children With Pulmonary Arterial Hypertension. Ther Drug Monit. 2014 Oct; 36(5): 576-83.
    32. Yoshida K, Adachi Y, Sasaki M, Furukawa M, Itazawa T, Hashimoto K, Odajima H, Akasawa A. Time-dependent variation in the responses to the Web-based ISAAC questionnaire. Ann Allergy Asthma Immunol. 2014 Nov; 113(5): 539-43.
    33. Katagiri M, Miya K, Matsui M. Difficulty of crossmodal processing in individuals with autism spectrum disorders: An audio-visual gap/overlap paradigm studyDRes Autism Spectrum Disorders 2014; 8: 424-31.
    34. Aguilar C, Lenoir C, Lambert N, Begue B, Brousse N, Canioni D, Berrebi D, Roy M, Gerart S, Chapel H, Schwerd T, Siproudhis L, Schappi M, Al-Ahmari A, Mori M, Yamaide A, Galicier L, Neven B, Routes J, Uhlig HH, Koletzko S, Patel S, Kanegane H, Picard C, Fischer A, Bensussan NC, Ruemmele F, Hugot JP, Latour S. Characterization of Crohn disease in X-linked inhibitor of apoptosis-deficient male patients and female symptomatic carriers. J Allergy Clin Immunol. 2014 Nov;134(5):1131-41.
    35. Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K. Cost-Minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency. Clin Ther. 2014 Nov 1;36(11):1616-24.
    36. Sasaki M, Yoshida K, Adachi Y, Furukawa M, Itazawa T, Odajima H, Saito H, Akasawa A. Factors associated with asthma control in children: findings from a national web-based survey. Pediatr Allergy Immunol. 2014 Dec;25(8):804-9.
    37. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê.@ •ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‘Ήž‚Ì10”NŠÔ‚̕ω»- •xŽRŒ§‚É‚š‚¯‚é•œ¬13”N“x‚Æ18”N“x’²ž‚Æ‚Ì”äŠr-@“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@2014 28(5): 806-13.
    38. ŽíŽsq’ˆ, ˜ZŽÔ@’, ‘Ÿ“c–M—Y, ¬Œ“¹—Y, ‰œ‘º²‹v, ‚—œˆê, …Œû@‰ë, ‹{˜e—˜’j. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠŽõ‚É‚š‚¯‚éŠë‹@‘Ήž. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2014;118(7): 1103-1108.
    39. •œŠâ–ŸŽq, ˜a“c‘ñ–ç, ’†’Ø‹v”T, ŽÂèŒ’‘Ÿ˜Y, ‹{˜e—˜’j, ‘«—§—Yˆê. ŠÈˆÕ…“¹‚ð‰î‚µ‚œYersinia enterocolitica ŠŽõÇ‚̏W’c”­¶.“ú–{¬Ž™‰ÈŠw‰ïŽ@2014; 118(12): 1738-1741.
    40. Î‘º–šŽq, ŽR“c‘œŽq, ŽR“c‚ ‚·‚©, ‹àŒ“O˜a. Žq‹Ÿ‚ƉƑ°‚̖ڐü‚ōl‚Š‚œƒvƒŒƒCƒ‹[ƒ€ì¬‚Ì‹L˜^. ¬Ž™‰È. 2014;@55(4): 443-8.
    41. •x“c@‰p, ŽRŠÝ³–Ÿ, Žs“c•™Žq, â–{ŠìŽO˜Y, ò“c’ŒŒÈ, žwŠ_‚Žj, “yˆä¯ŽO˜Y, ˆÀ‰Í“à ãà, Šâ–{^—, ˆŒàV@‰q. ¬Ž™zŠÂŠíê–åˆã§“x‚É‚š‚¯‚éC—ûŽ{ÝEŽ{ÝŒQ‚Ì”NŽž•ñ:2011,2012”N•ñ‚Ì‚Ü‚Æ‚ß. ¬Ž™zŠÂŠíŠw‰ïŽGŽ@2014; 30: 431-5.
  • Ç—á•ñ
    1. Kawasaki Y, Makimoto M, Nomura K, Hoshino A, Hamashima T, Hiwatari M, Nakazawa A, Takita J, Yoshida T, Kanegane H. Neonatal acute megakaryoblastic leukemia mimicking congenital neuroblastoma. Clinical Case Reports 2014; DOI: 10.1002/ ccr3.183.
    2. Koura U, Sakaki-Nakatsubo H, Otsubo K, Nomura K, Oshima K, Ohara O, Wada T, Yachie A, Imai K, Morio T, Miyawaki T, Kanegane H. Successful treatment of systemic cytomegalovirus infection in severe combined immunodeficiency using allogeneic bone marrow transplantation followed by adoptive immunotherapy.@ J Investig Allergol Clin Immunol. 2014; 24(3): 200-2.
    3. Hoshino A, Nomura K, Kanegane H. Graft versus tumor effect against neuroblastoma: a case report with long-term survival and a review of the literature. J Hematopoietic cell Transplantation 2014 3(3): 93-96.
    4. Hoshino A, Nomura K, Noguchi K, Kanegane H. Relapsed leukemia without peripheral blood abnormalities and clinical symptoms detected on MRI. Pediatr Int. 2014 Oct; 56(5): 798.
    5. Yamagami K, Miyashita T, Nakamura T, Shirano M, Nakamura T, Kameda K, Nishijima M, Imanishi M, Yang X, Kanegane H. Campylobacter fetus Bacteremia with Purulent Pleurisy in a Young Adult with Primary Hypogammaglobulinemia. Intern Med. 2014; 53(11): 1221-5.
    6. Hata Y, Kinoshita K, Miya K, Hirono K, Ichida F, Yoshida K, Nishida N. An autopsy case of infantile-onset vanishing white matter disease related to an EIF2B2 mutation (V85E) in a hemizygous region. Int J Clin Exp Pathol. 2014 May; 7(6): 3355-62.
    7. Miyatake S, Koshimizu E, Hayashi YK, Miya K, Shiina M, Nakashima M, Tsurusaki Y, Miyake N, Saitsu H, Ogata K, Nishino I, Matsumoto N. Deep sequencing detects very-low-grade somatic mosaicism in the unaffected mother of siblings with nemaline myopathy. Neuromuscul Disord. 2014 Jul; 24(7): 642-7.
    8. Mizawa M, Makino T, Norisugi O, Hara H, Shimizu K, Nomura K, Kanegane H, Nojima T, Shimizu T. Primary cutaneous Ewing sarcoma following metastasis to the bone and lymph nodes. Br J Dermatol. 2014 Sep; 171(3): 660-2.
    9. ¬‰Y@Ž, –xìT“ñ˜Y, ìè—TŽq, –q–{—D”ü, ‘«—§—Yˆê, ‹g“cär. –Ú‚ÅŒ©‚鏬Ž™‰È. Autopsy imaging‚Őf’f‚µ‚œcerebro-costo-mandibular syndrome‚Ì1—á. ¬Ž™‰È 2014 Sep; 55(10): 1365-6.
    10. ”öèO“T, –“sŽq, ŽíŽsq’ˆ, “¹‹ïL_, —с@“ÄŽu. —ŒŠá‚Ì‹}Œƒ‚ÈŽ‹—͒ቺ‚ð‚«‚œ‚µ,ƒXƒeƒƒCƒhŽ¡—Âɂæ‚è‰ü‘P‚ð‚Ý‚œŽ‹Œð³‰Š‚Ì1—á. —Տ°Šá‰È2014; 68: 545-51.
  • ‘à
    1. ‘«—§—YˆêDƒvƒƒRƒ“ƒfƒBƒx[ƒg2@ICSŠÔŒ‡“Š—^‚̐¥”ñ Con‚Ì—§ê‚©‚çD “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 2014; 28(1): 75-80.
    2. ‘«—§—YˆêD‹C“¹ŠŽõ‚Æ“û—cŽ™Šú‚Ìšb–Dƒ`ƒƒƒCƒ‹ƒhƒwƒ‹ƒX 2014; 17: 244-7.
    3. ‘«—§—YˆêD¬Ž™‚É‚š‚¯‚é‹z“üƒXƒeƒƒCƒh—Ö@‚̐V“WŠJ`‹z“üƒXƒeƒƒCƒhŠÔŒ‡‹z“ü‚ÌŒ»ó‚Ə«—ˆ“W–]D‹z“ü—Ö@ 2014; 6: 54-8.
    4. ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[ƒ}[ƒ`‚©‚ç‚Ý‚œšb‘§‚Ö‚Ì‘Šú‰î“üD¬Ž™‰È 2014; 55: 1463-7.
    5. ‘«—§—YˆêD¬Ž™‹CŠÇŽxšb‘§‚Æ•@‰Š‚ÌŠÖŒWD“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï‰ïŽ 2014; 35(3): 222-5.
    6. ‘«—§—Yˆê. ‹CŠÇŽxšb‘§Ž¡—ẪXƒeƒbƒvƒ_ƒEƒ“DAir 2014 13(3): 4-5.
    7. ‘«—§—Yˆê, “¡àV—²•v. ÐŠQŽž‚Ì‚±‚Ç‚à‚̃AƒŒƒ‹ƒM[ŽŸŠ³‘Ήžƒpƒ“ƒŒƒbƒg. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@2014; 27(5): 739-42.
    8. ‘«—§—Yˆê, ‹à’J‹v”üŽq. ¬Ž™šb‘§‚Æ‘å‹C‰˜õDRespiratory Trends@2014; 4:16-7.
    9. ‘«—§—Yˆê, ”óŒû@Žû. One airway, one disease‚Æšb–ÂŽŸŠ³‚̐V‚µ‚¢•ª—ށD¬Ž™‰ÈŠwƒŒƒNƒ`ƒƒ[@2014; 4:467-73.
    10. ‘«—§—Yˆê, ”óŒû@Žû, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘Ÿ“c–M—Y, ”ª–ؐMˆê. ¬Ž™‚É‚š‚¯‚é‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚É‚Þ‚¯‚āDŠO—ˆ¬Ž™‰È 2014; 17: 81-5.
    11. ‘«—§—YˆêA‹à’J‹v”üŽqD‹CŠÇŽxšb‘§‚ÌŽ©‘R—ð‚ƃAƒEƒgƒOƒ[F”­ÇE‘ˆ«‚É‚š‚¯‚é‘å‹C‰˜õE—±Žqó•šŽ¿‚Ì–ðŠ„Dšb‘§ 2014; 27: 152-6.
    12. Ichida F. Cardiovascular Events in Pregnancy With Hypertrophic Cardiomyopathy. Circ J. 2014 Sep 25; 78(10): 2386-7.
    13. Žs“c•™Žq. Cardiomyopathy: progress in diagnosis and treatments. Topics: II. Secondary cardiomyopathy; 5. Noncompaction of the ventricular myocardium. “ú–{“à‰ÈŠw‰ïŽGŽ. 2014; Feb 10; 103(2): 327-35.
    14. Žs“c•™Žq. æ“V«SŽŸŠ³Ž™‚̐ž__Œo”­’B. zŠÂŠí“à‰È. 2014; 75: 100-6.
    15. Žs“c•™Žq. æ“V«SŽŸŠ³Ž™‚̐ž__Œo”­’B.@“ú–{¬Ž™‰ÈŠw‰ïŽ. 2014; 118: 1181-9.
    16. Žs“c•™Žq. æ“V«SŽŸŠ³Ž™‚̍‚ŽŸ”]‹@”\áŠQ. “ú–{—Տ°–ƒŒŠw‰ïŽGŽ. 2014; 34: 674-83.
    17. Žs“c•™Žq. S‹Øãk–§‰»áŠQ. S‘Ÿà’c‹•ŒŒ«SŽŸŠ³ƒZƒ~ƒi[@S‘Ÿ. 2014; 46: 1177-84.
    18. Žs“c•™Žq. æ“V«SŽŸŠ³Ž™‚̐ž__Œo”­’B. “ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŽGŽ. 2014; 50: 1174-6.
    19. ‹àŒ“O˜a. dÇŠŽõÇ‚ɍR‹Û–òˆÈŠO‚É‚Ç‚ñ‚ÈŽ¡—Ö@‚ª‚ ‚é‚©H. ¬Ž™ŠŽõ–Ɖu 2014; 25(4): 456-7.
    20. ‹àŒ“O˜a. –Ɖu•s‘SÇ‚É‚š‚¯‚銎õÇ‚Ì—\–h. ¬Ž™‰È—Տ° 2014; 67(4): 695-700.
    21. ‹àŒ“O˜a. ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“•â[—Ö@?Ã’»Ü‚Ɣ牺’»Ü. ¬Ž™“à‰È 2014; 45(10): 1504.
    22. ‹àŒ“O˜a. R‘Ì•s‘S‚Æ’†•_ŒoŠŽõÇ. Neuroinfection 2014; 19(1): 103-7.
    23. ‹àŒ“O˜a.@‘¢ŒŒ•s‘S‚ð‡•¹‚·‚錎”­«–Ɖu•s‘SÇ.@“ú–{¬Ž™ŒŒ‰t‚ª‚ñŠw‰ïŽ@2014; 46(10): 1504.
    24. ‹àŒ“O˜a. ŒŽ”­«–Ɖu•s‘SÇ‚ɍ‡•¹‚·‚鎩ŒÈ‰ŠÇ«ŽŸŠ³@?‰ŠÇ«’°ŽŸŠ³ƒ‚ƒfƒ‹‚Æ‚µ‚Ä?@“ú–{¬Ž™‰ÈŠw‰ïŽ@2014;118(11): 1588-94.
    25. ‹àŒ“O˜a. ŒÌ ‹{˜e—˜’jæ¶‚ðŽÃ‚ñ‚Å. ¬Ž™ŠŽõ–Ɖu 2014;26(2):345-6.
    26. ”ÂàVŽõŽq. ¬Ž™‚ÌŽ¡—ÃŽwjuŠPšuEšb–vD¬Ž™‰Èf—à 2014; 77suppl: 10-3.
    27. ”ÂàVŽõŽq. ‹CŠÇŽxšb‘§D‚±‚Ç‚àƒPƒA 2014; 9: 16-20.
    28. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠŽõ‚É‚š‚¯‚鏬Ž™dÇ—á‚Ì“Á’¥‚Æ‚»‚̑΍ô. ¬Ž™‰È 2014; 55(7): 1017-25.
    29. ŽíŽsq’ˆ, ‹àŒ“O˜a. ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚ÌŽ¡—ÂƏW’cŠŽõ‚©‚çŠw‚Ô‚à‚Ì. ŠŽõÇ“à‰È 2014; 2(2): 195-202.
    30. ŽíŽsq’ˆ, ‘Ÿ“c–M—Y. ¬Ž™‚ÌŽ¡—ÃŽwj ‹~‹}ê–Ê‚É‚š‚¯‚鏉Šú‘Ήž “M…. ¬Ž™‰Èf—à 2014; 77(‘) 85-7.
    31. ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™‚ÌŽ¡—ÃŽwj ‹C“¹ˆÙ•šD¬Ž™‰Èf—à 2014; 77suppl: 427-9.
    32. Œ“c’Œ“¿, ‹àŒ“O˜a. –Ɖu•s‘SÇ‚ð‹^‚€‚Æ‚«‚̏‰ŠúŒŸž. ¬Ž™“à‰È 2014; 46(10): 1449-53.
    33. ”ª–ؐMˆê, –xìT“ñ˜Y, ŽíŽsq’ˆ. ¬Ž™‹~‹}ˆã—Â̎æ‚è‘g‚݂ɂ‚¢‚ā@?‘‡¬Ž™‰Èˆã‹³ˆç‚Ì‚È‚©‚Å?. •xŽRŽsˆãŽt‰ï‰ï•ñ@2014; 523(10): 15-6.

  • 2014”NŠw‰ï•ñ
    1. Itazawa T, Higuchi O, Ito Y, Okabe Y, Adachi SA, Adachi Y, Ito K, Ebisawa M. Risk of oral food challenges in children ?a prospective multicenter study-. 70th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2014 Feb.28-May. 4; San Diego, CA, USA.
    2. Ichida F: Insights into etiology and pathogenesis of childhood cardiomyopathy. The 5th Congress of the Asia Pacific Pediatric Cardiology Society; 2014 Mar. 7-9; New Delhi. (invited Lecture)
    3. Ichida F: Genetic Abnormalities in Myocardial Development&Ventricular Noncompaction. The Korean Cardiology-Related Societies Joint Scientific Congress ; 2014 April 18-19 ; Gwangju, Korea. (invited Lecture)
    4. Ichida F: Pulmonary Hypertension in Adult Congenital Heart Disease. The Korean Cardiology-Related Societies Joint Scientific Congress ; 2014 April 18-19; Gwangju, Korea. (invited Lecture)
    5. Kanegane H. Symposium XLP (X-Linked Lymphoproliferative Syndrome) and EB-Virus infection. PAS/ASPR Joint Meeting ; 2014 May 3-6; Vancouver, Canada. (invited Lecture)
    6. Yang X, Kunitsu T, Ikeda Y, Taga T, Wada T, Yachie A, Yasumi T, Heike T, Kaneganee H. Female patient with X-linked lymphoproliferative syndrome type 2 caused by extremely skewed inactivation of X-chromosome. PAS/ASPR Joint Meeting ; 2014 May 3-6; Vancouver, Canada.
    7. Hirono K, Nakaoka H, Ibuki K, Ozawa S, Ichida F. BMP10 involved in the induction of left ventricular noncompaction via BMP receptors . 10th International BMP Conference; 2014 Sep 16-20; Berlin.
    8. Nishida N, Yang X, Hoshino A, Kanegane H. Inflammatory bowel disease in Japanese patients with XIAP deficiency. The 16th Biennial Meeting of the European Society for Immunodeficiencies; 2014 Oct 29-Nov 1; Prague, Czech Republic.
    9. Kanegane H. Symposium First XLP Session. Whole exome sequencing reveals atypical phenotype of X-linked lymphoproliferative syndrome. A symposium for researchers and clinicians on XLP WAS. : 2014 Nov 3-4; London.
    10. Takasaki A, Hata Y, Hirono K, Nakaoka H, Ibuki K, Ozawa S, Yoshimura N, Nishida N, Ichida F. Sarcomere gene mutations in left ventricular noncompaction. The 87th Scientific sessions of AHA 2014; 2014 Nov 15-19; Chicago.
    11. Hashimoto I, Watanabe K, Ibuki K, Ichida F. Feasibility of single beat three-dimensional echocardiography for analysis of right ventricular systolic function in neonatal heart. The 87th Scientific sessions of AHA 2014; 2014 Nov 15-19; Chicago.
    12. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê. ‚—¬—ʂ̑̐Ö¬‘€•›ŒŒs˜H(ŠÌÃ–¬-‰E–[)‚ɑ΂µ‚Ästriker Target detachable coil‚ð—p‚¢‚œdouble catheter technique‚É‚æ‚éÇðp‚ðŽ{s‚µ‚œTCPCŒã’PSŽºÇ‚Ì1—á. ‘æ25‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï; 2014 Jan 22-24; Œ–{.
    13. —k@žF, Œ“c’Œ“¿, ‹àŒ“O˜a, ‡ˆä‹v”üŽq, _èŒ’m, ‹g“cŒ’ˆê, ¬ìœŽi, ‘哇Fˆê, ‘ºŒGé, ‰œ–ì—F‰î, ¬“‡š“ñ, ‹{–ì@Œå. X˜AœƒŠƒ“ƒp‘BÇŒóŒQƒ^ƒCƒv1‚Ì‚P‰ÆŒn‚É‚š‚¯‚郁ƒ‚ƒŠ[T×–E‚̑̍זE•ÏˆÙ. ‘æ7‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï; 2014 Jan 25; •Ÿ‰ª.
    14. “n•Ó—S‹I, –x]’åŽu, “c’†•ü”ü, ‹{@ˆêŽu, ‘«—§—Yˆê. SCN1Aˆâ“`ŽqŒŸž‚ªŽ¡—Õûj‚ÌŒˆ’è‚É—L—p‚Å‚ ‚Á‚œ“‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ65‰ñ¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï; 2014 Feb 2; ‹à‘ò.
    15. —k@žF. X-linked hypogammaglobulinemia associated with somatically reverted memory T cell in a family with X-linked lymphoproliferative syndrome type 1. ‘æ3‰ñ¬Ž™–Ɖu•s‘SƒZƒ~ƒi[; 2014 Feb 7; ‹à‘ò.
    16. ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. ‘Ù”Õ•«‡ŒŒŠÇƒŒ[ƒU[‹ÃŒÅpŒã‚ɉESŒn‡•¹Ç‚𗌎™‚É”F‚ß‚œ‘o‘ÙŠÔ—AŒŒÇŒóŒQ‚Ì‘o‘Ù—á. ‘æ20‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï; 2014 Feb 14-15; •lŒ.
    17. “c’†•ü”ü, ‹{@ˆêŽu, “n•Ó—S‹I, “c’‡çH, ‘«—§—Yˆê. ŒoŠÇ‰h—{Ž{s’†‚̏dÇSgáŠQŽ™iŽÒj‚É‚š‚¯‚錌’†ƒJƒ‹ƒjƒ`ƒ“”Z“x‚̐„ˆÚ‚ƗՏ°Çó‚Æ‚ÌŠÖ˜A‚ÉŠÖ‚·‚錟“¢. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    18. ‘ŠJË•œ, ¬‰Y@Ž, “c’†•ü”ü, ”óŒû@Žû, “c’‡çH, ‹{@ˆêŽu, ‘«—§—Yˆê. ž_‰^“®”­’B’x‰„‚ð‹^‚í‚ê‚œ‚ªA‹Ø¶ŒŸ‚æ‚èUllrichŒ^æ“V«‹ØƒWƒXƒgƒƒtƒB[‚Ɛf’f‚³‚ê‚œˆê—á. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    19. ¯–쌰G, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ’†’Ø‹v”T, ‘å’ØŒc•ã, ‹{˜e—˜’j. “–‰@‚É‚š‚¯‚錎”­«–Ɖu•s‘SÇ‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA¬Ñ. ‘æ310‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Mar 9; ‹à‘ò.
    20. ‹àŒ“O˜a. ƒŒƒNƒ`ƒƒ[uEBƒEƒCƒ‹ƒXŠÖ˜AƒŠƒ“ƒp‘BÇ‚̐V“WŠJv. ‘æ23‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï; 2014 March 16; “Œ‹ž.
    21. ‹àŒ“O˜a. ‹³ˆçu‰‰uŒŽ”­«–Ɖu•s‘SÇ‚ɍ‡•¹‚·‚鎩ŒÈ‰ŠÇv ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    22. ‹àŒ“O˜a. ‹³ˆçƒZƒ~ƒi[uŒŽ”­«–Ɖu•s‘SÇ‚ɑ΂·‚é”牺’—p–ƉuƒOƒƒuƒŠƒ“IgPro20(HizentraR)‚Ì—LŒø«‚ƈÀ‘S«‚ɂ‚¢‚āv ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    23. ”ÂàVŽõŽq, ’†—ÑŒºˆê, ”óŒû@Žû, •l“¹”ü‹I, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡_–Ÿ, ŠC˜VàVŒ³G, ‘«—§—Yˆê. H•šƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒû•‰‰×ŽŽŒ±‚Ì‘S‘’²ž.‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    24. “n•Ó—S‹I, •œŠâ–ŸŽq, –xìT“ñ˜Y, ”ÂàVŽõŽq, ‹{@ˆêŽu, ‹g“cär, ‰Á“¡ŒõL, ‘ºã—ÇŽq, ‘«—§—Yˆê. PIGAˆâ“`Žq•ÏˆÙ‚É‚æ‚é‘œ”­¬ŠïŒ`A“«‚Ä‚ñ‚©‚ñ‚ð‚«‚œ‚µ‚œ’jŽ™—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    25. •œŠâ–ŸŽq, ˜a“c‘ñ–ç, ’†’Ø‹v”T, ŽÂèŒ’‘Ÿ˜Y, ‹{˜e—˜’j, ‘«—§—Yˆê. ŠÈˆÕ…“¹‚ð‰î‚µ‚œYersinia enterocolitica O:8ŠŽõÇ‚̏W’c”­¶.‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    26. ‹{”ö¬–Ÿ, •œŠâ–ŸŽq, ˜a“c ‘ñ–ç, ‘q–{@’, ’†’Ø‹v”T, ŽÂèŒ’‘Ÿ˜Y, ‘«—§—Yˆê. äXŠÇ–ü‡•s‘S‚É‚æ‚é‹}«äX‰Š‚É’×ᇐ«‘å’°‰Š‚𕹔­‚µ‚œˆê—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    27. ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, ‘«—§—Yˆê, •œ–쏟‹v. Ã–¬ŠÇŠJ‘¶Ç‚ɑ΂µ‚ÄŠO‰È“IŽ¡—Âðs‚Á‚œ21trisomy‚Ì1—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    28. —k@žF, ‚–ؐ³–«, ‹e’r‰ëŽq, ‰¡“cr•œ, ¬’rŒ’ˆê, ‘ºŒGé, ¬“‡š“ñ, ‹àŒ“O˜a. NRAS‘̍זEƒ‚ƒUƒCƒN•ÏˆÙ‚É‚æ‚鎩ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ—lŽŸŠ³‚Ì‚P—á. ‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    29. ‹{è‚ ‚ä‚Ý, ¬ŒIˆºŽq, ’·’J“c—Sˆê, Žs“c•™Žq. ¬Ž™¶ŠˆKŠµ•aŒ’f‚É‚š‚¯‚énon-HDL ƒRƒŒƒXƒeƒ[ƒ‹‚Ì—L—p«D‘æ117‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2014 Apr 11-13; –ŒŒÃ‰®.
    30. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u“û—cŽ™šb‘§‚É‚š‚¯‚éICS‚̈ʒu•t‚¯‚̍člv”ŠO‘‚É‚š‚¯‚éi“û—cŽ™‚ɑ΂·‚éjICS‚̈ʒu•t‚¯. ‘æ26‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï; 2014 May 9-11; ‹ž“s.
    31. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹Ž@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ãŒŽ—R”üŽq, ˆÉ“¡_–Ÿ, ‹T“c@œ, Šì‘œ‘º“N˜N, “í–Ú˜a‘ã, Žè’ˏƒˆê˜Y. ŒoŒûH•š•‰‰×ŽŽŒ±‚É‚æ‚édÇ‚Ì—U”­Çó‚Æ“ÁˆÙ“IIgER‘̉¿‚ÌŠÖŒW. ‘æ26‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï; 2014 May 9-11; ‹ž“s.
    32. ‘«—§—Yˆê. “Á•Êu‰‰u‹z“üƒXƒeƒƒCƒh‚ð‚Ç‚€Žg‚€H¬Ž™šb‘§Ž¡—ÂÌStandard Care‚Ƃ́HvPediatric Expert Speakers Forum in Kobe; 2014 May 18: _ŒË.
    33. Žs“c•™Žq. “Á•Êu‰‰@æ“V«SŽŸŠ³pŒã‚Ì”­’BáŠQ‚ƐS—“I–â‘è. “Œ‹ž‚œ‚ܐS‘Ÿ•a‚ÌŽq‚Ç‚à‚ðŽç‚é‰ïŽs–¯ŒöŠJuÀ; 2014 May 18; ‰¡•l.
    34. ‘ŠJË•œ, “n•Ó—S‹I, ŽíŽsq’ˆ, “c’†•ü”ü, “c’‡çH, ‹{@ˆêŽu, X@Žõ, ‘«—§—Yˆê. ƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚Ì”œ•œ‚ª—LŒø‚Å‚ ‚Á‚œRNMDAŽó—e‘̍R‘Ì—z«•Ó‰Œn”]‰Š‚Ì11Î’jŽ™—á. ‘æ56‰ñ“ú–{¬Ž™_ŒoŠw‰ï; 2014 May 29-31; •lŒ.
    35. Žs“c•™Žq. ¬læ“V«SŽŸŠ³‚Ɛê–åˆã§“x. ‘æ10‰ñ¬læ“V«SŽŸŠ³ƒZƒ~ƒi[; 2014 May 31; “Œ‹ž.
    36. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™ƒAƒŒƒ‹ƒM[ŽŸŠ³ up to dateFšb‘§v. ‘æ9‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï; 2014 June 6-7; •lŒ.
    37. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Â–ؐ³Æ, “úŒG’qŒ›, –F‘º’ŒŽ÷, ‘«—§—Yˆê, Žs“c •™Žq. Ý‘îNIPPV‚ª—LŒø‚Ÿ‚Á‚œæ“V«SŽŸŠ³‚ɍ‡•¹‚µ‚œ‹CŠÇŽx‹·ó‚Ì3Ç—á. ‘æ32‰ñŒ“ú–{¬Ž™zŠÂŠíHOTŒ€‹†‰ï; 2014 June 7; ‘åã.
    38. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, Œ”ö’C˜N, “úŒG’qŒ›, –F‘º’ŒŽ÷. BASŒã‚àS–[ŠÔŒð’Ê‚ª–R‚µ‚­A¶Žº—¬“üáŠQ‚ª‹^‚í‚ꎡ—Õûj‚Ì‘I‘ð‚É“ïa‚·‚銮‘S‘匌ŠÇ“]ˆÊA’áo¶‘̏dŽ™‚̈ê—á. ‘æ23‰ñ¬Ž™zŠÂŠíƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2014 June 7; ‹ž“s.
    39. œA–ìŒbˆê, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ”š—R‹IŽq, Œ“c®Ž÷, ¬Š_Ž –L, •Ÿ›ž‹³ˆÌ. V¶Ž™Šú‚ɐS•s‘S‚É‚Ä”­Ç‚µƒTƒ‹ƒRƒƒAˆâ“`Žq‚Ì“ñd•ÏˆÙˆÙí‚ð”F‚ß‚œ¶ŽºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ311‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 June 8; •Ÿˆä.
    40. ”ª–ؐMˆê, ŒÜ\—’“o, ”šèŠì–F, ‰ª•”@Œh, ‘ºã”ü–çŽq, ‘ºãIŒ[, “ˆ”ö@’q, ‘«—§—Yˆê. •xŽRŽs‚É‚š‚¯‚鏬Ž™ˆã—ÓIƒPƒAEÝ‘îˆã—Öâ‘è‚Ö‚ÌŽæ‚è‘g‚݂ɂ‚¢‚Ä. ‘æ25‰ñ“ú–{¬Ž™‰Èˆã‰ï‘‰ï; 2014 June 14-15; ·‰ªD
    41. Žs“c•™Žq. “Á•Êu‰‰@S‹ØÇ‚̃gƒsƒbƒNƒX`SƒGƒR[‚©‚番ŽqƒŒƒxƒ‹‚ُ̈í‚ð’T‚é`. ‘æ40‰ñ’Ž‰¹”gŒŒ—¬Œ€‹†‰ï; 2014 June 28; “Œ‹ž.
    42. ‘«—§—YˆêDŽs–¯ŒöŠJuÀu¬Ž™‚º‚ñ‘§v‘æ31‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2014; June 28-29; –ŒŒÃ‰®.
    43. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹Ž@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ãŒŽ—R”üŽq, ˆÉ“¡_–Ÿ, ‹T“c@œ, Šì‘œ‘º“N˜Y, “í–Ú˜a‘ã, Žè’ˏƒˆê˜Y. ŒoŒûH•š•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚̏dÇ“x‚Æ•‰‰×ŽŽŒ±’†Ž~Žž‚Ì‘•‰‰×—Ê‚ÌŠÖŒW. ‘æ31‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2014; June 28-29; –ŒŒÃ‰®.
    44. œA–ìŒbˆê, –쑺‘׋v, ”š—R‹IŽq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “ˆäL, Œ“c®Ž÷, Žs“c•™Žq, ‘«—§—Yˆê. ‘ÙŽ™Šú‚ɐS•s‘S‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œMYH7ˆâ“`Žq•ÏˆÙ‚ð—L‚·‚鍶ŽºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    45. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Â–ؐ³Æ, “úŒG’qŒ›, Žs“c•™Žq, ‘«—§—Yˆê, –F‘º’ŒŽ÷. –³äBÇŒóŒQ‚̐ž_”­’B•]‰¿‚ðŠÜ‚ß‚œŽ¡—ЬÑ‚Æ—\Œã‚ÌŒŸ“¢. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    46. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, “n•Óˆê—m, Â–ؐ³Æ, “úŒG’qŒ›, –F‘º’ŒŽ÷, ‘«—§—Yˆê, Žs“c•™Žq. MYH7ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œ¶ŽºS‹Øãk–§‰»áŠQ‚š‚æ‚ѐSŽº’†ŠuŒ‡‘¹‚𔺂€EbsteinŠïŒ`‚ÌŽo’í—á. ‘æ50‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï; 2014 July 3-5; ‰ªŽR.
    47. ‰ª•”^Žq, “n•Óˆê—m, ‹à“c@®, ‹Ž–{ˆè•v, ŽR’J”ü˜a, ‹{@ˆêŽu. ‚Ä‚ñ‚©‚ñ‚ð‡•¹‚µ‚œ‹U«•›bó‘B‹@”\’ቺÇ(PHP)‡TŒ^‚̏—Ž™—á. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    48. —L‘ò@—I, ûüú±–ƒ”ü, “c’†•ü”ü, ŽíŽsq’ˆ, ¬àVˆ»‰À, Žs“c•™Žq, ‘«—§—Yˆê. ìè•a”N’·Ž™—á‚É‚š‚¯‚é—Տ°‘œ‚š‚æ‚ÑŽ¡—Ð헪. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    49. ’·‰ªvG, Œ“c’Œ“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê. ”牺’»Ü‚É‚æ‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚𓱓ü‚µ‚œR‘ÌŽY¶•s‘SÇ‚̈ê—á. ‘æ32‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2014 July 6; •xŽR.
    50. ‹{@ˆêŽu, ‘ŠJË•œ, ‘q–{@’, “c’†•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê. ƒCƒ“ƒtƒ‹ƒGƒ“ƒUœëŠ³Œã‚É”­ì‚ªÁŽž‚µ‚œ“‚Ä‚ñ‚©‚ñ‚Ì1—á. ‘æ8‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï“ŒŠC–k—€’n•û‰ï; 2014 July 12; Ã‰ª.
    51. Žs“c•™Žq. ‹³ˆçu‰‰@æ“V«SŽŸŠ³Ž™‚̐ž__Œo”­’B. ‘æ50‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï; 2014 July 13-15; ç—t.
    52. –xìT“ñ˜Y, ¬‰Y Ž, •Ÿ“cD, ìú±—TŽq, –q–{—D”ü, ‹g“cär, …“ckˆê. ”A×ŠÇŒ`¬•s‘S‚ð‡•¹‚µ‚œV¶Ž™ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚Ì’áo¶‘̏dŽ™—á. ‘æ50‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ïŠwpW‰ï; 2014 July 13-15; ç—t.
    53. ìè—TŽq, –q–{—D”ü, ¯–쌰G, à_“‡@ä, –쑺ŒbŽq, ‘ê“c‡Žq, ’†àV‰·Žq, ‹g“cär, ‹àŒ“O˜a. o¶Žž‚æ‚è”­Ç‚µ‚œRBM15-MKL1ƒLƒƒ‰ˆâ“`Žq—z«‹}«œ‘«”’ŒŒ•a. –k—€¬Ž™ŒŒ‰t§˜b‰ï; 2014 July 12; ‹à‘ò.
    54. ‘«—§—YˆêDƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uŠÂ‹«ˆöŽq‚ƃAƒŒƒ‹ƒM[”­ÇE‘ˆ«v‘æ24‰ñ‘Ûšb‘§Šw‰ï “ú–{E–kƒAƒWƒA•”‰ï; 2014; July 18-19; –ŒŒÃ‰®.
    55. ‘«—§—Yˆê. ¬Ž™ŒyÇšb‘§‚É‚š‚¯‚éICSŠÔŒ‡“Š—^‚̐¥”ñ Con‚Ì—§ê‚©‚ç. ‘æ34‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2014 July 26-27; ‹ž“s.
    56. Ž›‰ºV‘Ÿ˜Y, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, “¡“cC•œ, Žs“c•™Žq, ’†Œ•q—Y. WilliamsÇŒóŒQ‚É“Á’¥“I‚ȐSŒŒŠÇ•a•Ï‚Ì‚Ý‚ð—L‚µELNˆâ“`Žq‚Ì1‰–Šî•ÏˆÙ‚ð”F‚ß‚œ1—á. ‘æ50‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2014 Aug 10; Œ–{.
    57. ꎓ¡@—I, Œ“c’Œ“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê.@’°–ŒŠÔƒŠƒ“ƒpß‰Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚œè÷—±‹…“÷Žî‚Ì’jŽ™—á. ‘æ50‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï; 2014 Aug 10; Œ–{.
    58. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€Šó­_ŒoŠŽõÇu’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚É‚æ‚é‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Ð헪v. ‘æ19‰ñ“ú–{_ŒoŠŽõÇŠw‰ï‘‰ïŠwpW‰ï‘æ26‰ñ“ú–{_Œo–ƉuŠw‰ïŠwpW‰ï; 2014 Sep 4; ‹à‘ò.
    59. ˆÉŒ\“ñû¶, X‚±‚ž‚Š, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, Â–ؐ³Æ, “úŒG’qŒ›, –F‘º’ŒŽ÷. o¶’ŒŒã‚É‹@”\«”x“®–¬•Âœ‚ð’悵‚œS‹Øãk–§‰»áŠQ‚Ì‚P—á. ‘æ42‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï; 2014 Sep 13; ‹à‘ò.
    60. ‘«—§—Yˆê. u¬Ž™šb‘§ ÅV‚Ì’mŒ©vSymposium for Pediatrics 2014; 2014 Sep 21; “Œ‹ž.
    61. Œ“c’Œ“¿. ƒ[ƒNƒVƒ‡ƒbƒv@‰ŠÇ«’°ŽŸŠ³‚ð’æ‚·‚錎”­«–Ɖu•s‘SÇ. ‘æ42‰ñ“ú–{—Տ°–ƉuŠw‰ï; 2014 Sep 25-27; “Œ‹ž.
    62. ‘«—§—Yˆê. u¬Ž™‹CŠÇŽxšb‘§‚̉uŠw‚Æ‚»‚̐f’fv. Asthma Begins in Childhood; 2014 Sep 27-28; ‘å’Ã.
    63. ‹{@ˆêŽu, ‘ŠJË•œ, “n•Ó—S‹I, ‘q–{@’, “c’†•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘«—§—Yˆê. ŠŽõ‚ðŒ_‹@‚É”­ì‚ªÁŽž‚µ‚œ“‚Ä‚ñ‚©‚ñ‚Ì3—á. ‘æ48‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï; 2014 Oct 2-3; “Œ‹ž.
    64. ”ÂàVŽõŽq, ˜a“c‘ñ–ç, ŽÂèŒ’‘Ÿ˜Y, ‹à“c@®, X@‰ë—º, ‘«—§—Yˆê. ƒgƒVƒŠƒYƒ}ƒu’†Ž~Œã‚Ì‘œŠÖßŒ^Žá”N«“Á”­«ŠÖß‰Š‚̍ĔR‚ɑ΂µ‚ăgƒVƒŠƒYƒ}ƒu’PÜ‚É‚ÄŽ¡—ÍĊJ‚µ‚œˆê—á. ‘æ24‰ñ¬Ž™ƒŠƒEƒ}ƒ`Šw‰ï; 2014 Oct 3-5; å‘ä.
    65. ‘«—§—Yˆê. ‹³ˆçu‰‰u¬Ž™šb‘§‚Ì—\Œãv ‘æ32‰ñŒÄ‹zŠíE–ƉuƒVƒ“ƒ|ƒWƒEƒ€; 2014 Oct 4; “Œ‹ž.
    66. “c’†•ü”ü, •lè@Œi, éì”ü‰À, ˆÉ“¡ŽÀ, ‘«—§—Yˆê, ˆîŽ›G–M. ƒGƒRƒ`ƒ‹’²žiŽq‚Ç‚à‚ÌŒ’N‚Ɗ‹«‚ÉŠÖ‚·‚é‘S‘’²žj‚©‚ç‚Ý‚œ•xŽRŒ§‚É‚š‚¯‚éˆçŽ™‚ÌŒ»ó. ‘æ53‰ñ•xŽR¬Ž™•ÛŒ’Šw‰ï; 2014 Oct 5; •xŽR.
    67. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€`¬Ž™S‘ŸˆÚA‚ð‚¢‚©‚ɐ„i‚·‚é‚©`u6Î–¢–ž¬Ž™ƒhƒi[‚ÌŠÇ—‚ðŒoŒ±‚µ‚āv. ‘æ23‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2014 Oct 11; “Œ‹ž.
    68. œA–ìŒbˆê, ‚è–ƒ”ü, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq. ¶ŽºS‹Øãk–§‰»áŠQ‚É‚š‚¯‚éƒTƒ‹ƒRƒƒAˆâ“`Žq•ÏˆÙ‚̉ðÍ. ‘æ23‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2014 Oct 11; “Œ‹ž.
    69. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚É‚š‚¯‚é—Տ°Çó‚ƃoƒCƒ^ƒ‹ƒTƒCƒ“‚ÌŒŸ“¢. ‘æ46‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    70. Œ“c’Œ“¿, ¯–쌰G, ‘«—§—Yˆê, ‹àŒ“O˜a, “n•Ó—S‹I, ’†—ÑŒºˆê, r–Ø—ˆ‘Ÿ, Œ‘º—ǐ¬, ˜a“c‘׎O, ’J“à]ºG.@ŒŽˆö•s–Ÿ‚ÌIgAŒ‡‘¹Ç‚Æ‚µ‚ătƒHƒ[‚³‚ê‚œ activated PI3K-ƒÂ syndrome ‚̈ê—á. ‘æ46‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    71. “n•Ó—S‹I, –x]’åŽu, •œŠâ–ŸŽq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, Žs“c•™Žq, ‘«—§—Yˆê. Human metapneumovirusŠŽõ‚ðŒ_‹@‚É”­Ç‚µ‚œdÇmethicillin-resistant Staphylococcus aureus”x‰Š‚̈ê—á. ‘æ46‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2014 Oct 18-19; “Œ‹ž.
    72. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u“û—cŽ™šb‘§“û—cŽ™šb‘§‚Ì‚æ‚è—Ç‚¢f—Âð–ÚŽw‚µ‚āFƒtƒFƒmƒ^ƒCƒv•ª—Þ‚Æ‘Šú‰î“üv‘æ47‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2014 Oct 24-25; “Œ‹ž.
    73. —L‘ò@—I, ”ÂàVŽõŽq, “c’†•ü”ü, ‚è–ƒ”ü, ‹à“c@®, ’Ø“c‰ëm, Žç–{—ÏŽq, ‘«—§—Yˆê. ‹z‹C«šb–‚̌ŽˆöŒŸõ‚É‚æ‚é‰æ‘œf’f‚É‚ÄŒŒŠÇŽî‚ª‹^‚í‚ê‚œ‰ºˆô“ªŽîᇂÌ1—á. ‘æ47‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2014 Oct 24-25; “Œ‹ž.
    74. ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq. ”­Ç‘Šú‚©‚犥“®–¬Šg’£‚ð”F‚ß‹‘劥“®–¬áŽ‚ðŒ`¬‚µ‚œìè•a‚Ì2—á. ‘æ34‰ñ“ú–{ìè•aŠw‰ï; 2014 Oct 31-Nov 1; “Œ‹ž.
    75. ‰ª•”^Žq, –x]’åŽu,“n•Ó—S‹I,’‡‰ª‰pK,“c‘ºŒ«‘Ÿ˜Y,Œ“c’Œ“¿,ˆÉŒ\“ñ˜Y,¬àVˆ»‰À,ŽíŽsq’ˆ,œA–ìŒbˆê,‹àŒ“O˜a,Žs“c•™Žq,‘«—§—Yˆê. ìè•a‹}«Šú‚ÉŒ`Ž¿×–E‘‘œÇ‚ð”F‚ß‚œIVIGŽ¡—Õs‰ž‚Ì‚P—á. ‘æ34‰ñ“ú–{ìè•aŠw‰ï; 2014 Oct 31-Nov 1; “Œ‹ž.
    76. ŽíŽsq’ˆ, ûüú±–ƒ”ü, âV“¡@—I, “c’†•ü”ü, ‘«—§—Yˆê. ‰Æ‘°‚ÌŠó–]‚ɉˆ‚Á‚œ¬Ž™”]Ž€Š³ŽÒŠÇ—‚Ì‚ ‚è•û. ‘æ18‰ñ–k—€¬Ž™‹~‹}W’†Ž¡—ÃŒ€‹†‰ï; 2014 Nov 8; ‹à‘ò.
    77. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uŠÂ‹«‚ƃAƒŒƒ‹ƒM[F“ú–{‚É‚š‚¯‚鉩»‚ÌŒ’N‚ւ̉e‹¿v. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2014 Nov 8-9; Žl“úŽs.
    78. Adachi Y, Kanatani TK. Symposium gEnvironment and Allergy: Effects of Asian dust on respiratory health in Japanh ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2014 Nov 8-9; Žl“úŽs.
    79. ”ÂàVŽõŽq, ”óŒû@Žû, à_“¹”ü‹I, ’†—ÑŒºˆê, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š‚̏dÇ“x•]‰¿‚É‚š‚¯‚éVAS‚Ì—L—p«. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; Nov 2014 8-9; Žl“úŽs.
    80. Œ–쐳’mA‘«—§—YˆêAŒÜ\—’—²•vD¬Ž™šb‘§‚ÌŒo‰ß‚ƌċCˆêŽ_‰»’‚‘f‚È‚ç‚Ñ‚É‹C“¹‰ß•q«‚ÌŠÖ˜A«‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; Nov 2014 8-9; Žl“úŽs.
    81. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠŽõ‚É‚š‚¯‚éŠë‹@‘Ήž‚ÆIT‚ÌŠˆ—p. “ú–{—·sˆãŠw‰ï‘æ7‰ñ“Œ‹ž‘å‰ï; 2014 Nov 16. “Œ‹ž.
    82. ‘«—§—Yˆê. “Á•Êu‰‰u‹³ˆçŒ»ê‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[‚ւ̑Ήžv‘æ61‰ñ“ú–{ŠwZ•ÛŒ’Šw‰ï: 2014 Nov 15; ‹à‘ò.
    83. –쑺ŒbŽq, ¯–쌰G, ŽRè@“O, ‰ª“cˆÀO, âV“¡Ÿ•F, ×ì@•à, ‹àŒ“O˜a. ‘å’°‚ª‚ñ‚Ì11Î’jŽ™—á. ‘æ56‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2014 Nov 28-30; ‰ªŽR.
    84. ꎓ¡@—I, Œ“c’Œ“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‘«—§—Yˆê. • o“àƒŠƒ“ƒpßŽî’¯‚ð”F‚ß‚œœ‘“÷Žî‚ªæs‚µ‚œ‹}«œ‘«”’ŒŒ•a(AML M0)‚̈ê—á. ‘æ56‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2014 Nov 28-30; ‰ªŽR.
    85. ”ÂàVŽõŽq, •l“¹”ü‹I, ˜a“c‘ñ–ç, ’†—ÑŒºˆê, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê. ƒAƒŒƒ‹ƒM[«•@‰Š‡•¹‚Ì‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚é•@‰ŠÇó‚Æšb‘§ƒRƒ“ƒgƒ[ƒ‹ó‘Ô‚š‚æ‚ьċz‹@”\‚Æ‚ÌŠÖŒW. ‘æ41‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï; 2014 Dec 6; ‹à‘ò.
    86. Žs“c•™Žq. Žs–¯ŒöŠJuÀ S‘Ÿ“Ë‘RŽ€‚©‚çg‚ðŽç‚éF•s®–¬‚ð—‰ð‚µ‚æ‚€. Žq‹Ÿ‚̐S‘Ÿ“Ë‘RŽ€@Œú˜J¬‰ÈŒ€”ï•â•“«ŽŸŠ³Ž•žŒ€‹†Ž–‹Æu“Á”­«S‹ØÇ‚ÉŠÖ‚·‚é’²žŒ€‹†”ǁvŽåÃ“ú–{zŠÂŠíŠw‰ï–k—€Žx•”; 2014 Dec 7; •xŽR.
    87. ‘«—§—YˆêD ƒVƒ“ƒ|ƒWƒEƒ€uŽq‚Ç‚à‚Æ‘å‹CFŠÂ‹«‚ÆŽq‚Ç‚à‚̃AƒŒƒ‹ƒM[v ‘æ16‰ñ“ú–{Žq‚Ç‚àŒ’N‰ÈŠw‰ïŠwp‘å‰ï; 2014 Dec 13-14; ‹ž“s.
    88. ”ÂàVŽõŽq, ˜a“c‘ñ–ç, ‹à“c@®, ŽÂèŒ’‘Ÿ˜Y, –xìT“ñ˜Y, ‘«—§—Yˆê. ¶•šŠw“I»Ü‚𓱓ü‚µ‚œ‘œŠÖßŒ^Žá”N«“Á”­«ŠÖß‰Š‚ɑ΂µ‚ÄDrug free‚ðŽŽ‚Ý‚œ2Ç—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Dec 14; •xŽR.
    89. ‰ª•”^Žq, “n•Óˆê—m, ‹à“c@®, ‹Ž–{ˆè•v, ŽR’J”ü˜a, ‹{@ˆêŽu, ‹{X‰Á•áŽq, Ž…³Ž÷. ŒŸŒêáŠQ‚ÉTRH—Ö@‚ªŒø‰Ê“I‚Å‚ ‚Á‚œhuman metapneumovirus(hMPV)ŠŽõŠÖ˜A”]Ç‚̏—Ž™—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Dec 14; •xŽR.
    90. âV“¡@—I, “c’†•ü”ü, X‚±‚ž‚Š, •œŠâ–ŸŽq, ‚è–ƒ”ü, ‘q–{@’, ‹{@ˆêŽu, ‘«—§—Yˆê, Vˆä“c—v. ‘Šúf’f‚ÉŽŠ‚Á‚œ“ûŽ™dÇƒ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ312‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2014 Dec 14; •xŽR.

    2013”N

  • ’˜‘
    1. ‘«—§—Yˆê. ¬Ž™šb‘§‚Ì”­Ç‹@˜. “Œ“c—L’q‘Œ•Ò. “Œ‹ž: ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å; 2013. 32th˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX. šb‘§Ž¡—Â̎c‚³‚ê‚œ‰Û‘è; 3-6.
    2. Žs“c•™Žq. ¡“ú‚ÌŽ¡—ÃŽwj2013”Å. ŽRŒû@“O‘Œ•Ò. “Œ‹ž: ˆãŠw‘‰@; 2013. SŽŸŠ³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±; 1184-5.
    3. Žs“c•™Žq. ŽüŽYŠúˆãŠw@43(‘). “í“c@‘‘Œ•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2013. S‹ØÇ@ŽüŽYŠú‚̉摜f’f; 426-30.
    4. ”óŒû@Žû, ‘«—§—Yˆê. ‹C“¹ˆÙ•š‚É‚æ‚éŠP. ‘«—§@–ž‘Œ•Ò. “Œ‹ž: ‘‡ˆãŠwŽÐ; 2013. ’·ˆø‚­ŠP‚ÌŽ¡—ÃŽwj; 145-9 .
    5. Œ“c’Œ“¿, ‹àŒ“O˜a. ¬Ž™ŠŽõÇƒ}ƒjƒ…ƒAƒ‹. “ú–{¬Ž™ŠŽõÇŠw‰ï•Ò. “Œ‹ž: “Œ‹žˆãŠwŽÐ; 2012. ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒAƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“; 548-61.
  • ŒŽ’˜
    1. Itazawa T, Adachi Y, Ito Y, Higuchi O, Mochizuki H, Shimojo N, Inoue T. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol. Allergol Int. 2013 Mar;62(1):131-5.
    2. Higuchi O, Adachi Y, Adachi YS, Taneichi H, Ichimaru T, Kawasaki K. Mothers' knowledge about foreign body aspiration in young children. Int J Pediatr Otorhinolaryngol. 2013 Jan;77(1):41-4.
    3. Higuchi O, Adachi Y, Itazawa T, Ito Y, Yoshida K, Ohya Y, Odajima H, Akasawa A, Miyawaki T. Rhinitis has an association with asthma in school children. Am J Rhinol Allergy. 2013 Jan;27(1):e22-5.
    4. Ito Y, Adachi Y, Yoshida K, Akasawa A. No association between serum vitamin D status and the prevalence of allergic diseases in Japanese children. Int Arch Allergy Immunol. 2013;160(2):218-20.
    5. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, Tanaka H, Hama A, Muramatsu H, Hasegawa D, Nakamura K, Kanegane H, Tsukamoto K, Adachi S, Kawakami K, Kato K, Nishimura R, Izraeli S, Hayashi Y, Miyano S, Kojima S, Ito E, Ogawa S. Corrigendum: The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013 Nov 25;45(12): 1293-99.
    6. Marsh RA, Rao K, Satwani P, Lehmberg K, Muller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013 Feb 7;121(6):877-83.
    7. Ishida K, Fukao M, Watanabe H, Taguchi M, Miyawaki T, Matsukura H, Uemura O, Zhang Z, Unadkat JD, Hashimoto Y. Effect of salt intake on bioavailability of mizoribine in healthy Japanese males. Drug Metab Pharmacokinet 2013;28(1):75-80.
    8. Chang B, Gorbea C, Lezin G, Li L, Shan L, Sakai N, Kogaki S, Otomo T, Okinaga T, Hamaoka A, Yu X, Hata Y, Nishida N, Yost HJ, Bowles NE, Brunelli L, Ichida F. 14-3-3ƒÃ gene variants in a Japanese patient with left ventricular noncompaction and hypoplasia of the corpus callosum. Gene. 2013 Feb 15;515(1):173-80.
    9. Yoshida K, Adachi Y, Akashi M, Itazawa T, Murakami Y, Odajima H, Ohya Y, Akasawa A. Cedar and cypress pollen counts are associated with the prevalence of allergic diseases in Japanese schoolchildren. Allergy. 2013 Jun;68(6):757-63.
    10. Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Nishimura R, Wakita H, Kobayashi Y, Kanegane H, Tojo A, Imamura T, Imashuku S; Japan LCH Study Group. Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 2013 Jan;97(1):103-8.
    11. Shimizu M, Kanegane H, Wada T, Motoyoshi Y, Morio T, Candotti F, Yachie A. Aberrant glycosylation of IgA in Wiskott-Aldrich syndrome and X-linked thrombocytopenia. J Allergy Clin Immunol. 2013 Feb;131(2):587-90.e1-3.
    12. Katsunuma T, Fujisawa T, Nagao M, Akasawa A, Nomura I, Yamaoka A, Kondo H, Masuda K, Yamaguchi K, Terada A, Ikeda M, Nishioka K, Adachi Y, Kurihara K. Effects of transdermal tulobuterol in pediatric asthma patients on long-term leukotriene receptor antagonist therapy: results of a randomized, open-label, multicenter clinical trial in Japanese children aged 4-12 years. Allergol Int. 2013 Mar;62(1):37-43.
    13. Ohga S, Kang D, Kinjo T, Ochiai M, Doi T, Ishimura M, Kayamori Y, Urata M, Yamamoto J, Suenobu SI, Kanegane H, Ikenoue T, Shirahata A, Hara T. Paediatric presentation and outcome of congenital protein C deficiency in Japan. Haemophilia. 2013 May;19(3):378-84.
    14. Kamae C, Nakagawa N, Sato H, Honma K, Mitsuiki N, Ohara O, Kanegane H, Pasic S, Pan-Hammarstrom Q, van Zelm MC, Morio T, Imai K, Nonoyama S. Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin ƒÈ-deleting recombination excision circles. J Allergy Clin Immunol. 2013 May;131(5):1437-40.e5.
    15. Toki T, Kanezaki R, Kobayashi E, Kaneko H, Suzuki M, Wang R, Terui K, Kanegane H, Maeda M, Endo M, Mizuochi T, Adachi S, Hayashi Y, Yamamoto M, Shimizu R, Ito E. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome. Blood. 2013 Apr 18;121(16):3181-4.
    16. Wada T, Muraoka M, Yokoyama T, Toma T, Kanegane H, Yachie A. Cytokine profiles in children with primary Epstein-Barr virus infection. Pediatr Blood Cancer. 2013 Jul;60(7):E46-8.
    17. Sakazaki H, Niwa K, Nakazawa M, Saji T, Nakanishi T, Takamuro M, Ueno M, Kato H, Takatsuki S, Matsushima M, Kojima N, Ichida F, Kogaki S, Kido S, Arakaki Y, Waki K, Akagi T, Joo K, Muneuchi J, Suda K, Lee HJ, Shintaku H. Clinical features of adult patients with Eisenmenger's syndrome in Japan and Korea. Int J Cardiol. 2013 Jul 15;167(1):205-9.
    18. Torii Y, Kimura H, Ito Y, Hayakawa M, Tanaka T, Tajiri H, Yoto Y, Tanaka-Taya K, Kanegane H, Nariai A, Sakata H, Tsutsumi H, Oda M, Yokota S, Morishima T, Moriuchi H; Japanese Society for Pediatric Infectious Diseases. Clinicoepidemiologic status of mother-to-child infections: a nationwide survey in Japan. Pediatr Infect Dis J. 2013 Jun;32(6): 699-701.
    19. Nagai K, Ochi F, Terui K, Maeda M, Ohga S, Kanegane H, Kitoh T, Kogawa K, Suzuki N, Ohta S, Ishida Y, Okamura T, Wakiguchi H, Yasukawa M, Ishii E. Clinical characteristics and outcomes of chediak-Higashi syndrome: a nationwide survey of Japan. Pediatr Blood Cancer. 2013 Oct;60(10):1582-6.
    20. Matsuhisa H, Yoshimura N, Higuma T, Misaki T, Onuma Y, Ichida F, Oshima Y, Okita Y. Ventricular septal dysfunction after surgical closure of multiple ventricular septal defects. Ann Thorac Surg. 2013 Sep;96(3):891-7.
    21. Ito Y, Kimura H, Torii Y, Hayakawa M, Tanaka T, Tajiri H, Yoto Y, Tanaka-Taya K, Kanegane H, Nariai A, Sakata H, Tsutsumi H, Oda M, Yokota S, Morishima T, Moriuchi H; Japanese Society for Pediatric Infectious Diseases. Risk factors for poor outcome in congenital cytomegalovirus infection and neonatal herpes on the basis of a nationwide survey in Japan. Pediatr Int. 2013 Oct;55(5):566-71.
    22. Mori D, Ranawaka U, Yamada K, Rajindrajith S, Miya K, Perera HK, Matsumoto T, Dassanayake M, Mitui MT, Mori H, Nishizono A, Soderlund-Venermo M, Ahmed K. Human bocavirus in patients with encephalitis, Sri Lanka, 2009-2010. Emerg Infect Dis. 2013 Nov;19(11):1859-62.
    23. Kobayashi K, Miya K, Akiyama T, Endoh F, Oka M, Yoshinaga H, Ohtsuka Y. Cortical contribution to scalp EEG gamma rhythms associated with epileptic spasms. Brain Dev. 2013 Sep;35(8):762-70.
    24. Kanatani KT, Slingsby BT, Mukaida K, Kitano H, Adachi Y, Haefner D, Nakayama T. Translation and Linguistic Validation of the Allergy-CONTROL-ScoreTM for Use in Japan. Allergol Int. 2013 Sep; 62(3): 337-41.
    25. ŽíŽsq’ˆ, ¬Œ“¹—Y, ŒÜ\—’“o, ‹à“c@®, Œ‘q—TŠì, ¬‘qˆê«, •“c•¶l, ’J“à]ºG, ‹{˜e—˜’j. •xŽR‚𒆐S‚Æ‚µ‚œ’°ŠÇoŒŒ«‘å’°‹ÛO111W’cŠŽõ. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2013;117(9): 1409-15.
    26. ‘«—§—zŽq, ”óŒû@Žû, ŽíŽsq’ˆ, ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F, ìèˆê‹P. “û—cŽ™‚Ì‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚Ì‚œ‚ß‚Ì•ÛŒ’Žt‚É‚æ‚éŽw“±‚ÉŠÖ‚·‚é’²ž. “ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽ. 2013;23(2): 147-54.
    27. ¡‘º’Œl, —§Œ³ç”¿, ‘«—§—Yˆê, ‘ºãIŒ[, •£àV—³–ç, ‹gŒŽd”ü, ’†—ÑŒºˆê, ÔàV@W, ”öã—mˆê, ŸÀr—Y. ŒyÇ/’†“™ÇŽ‘±Œ^“û—cŽ™šb‘§‚ɑ΂·‚é’á—p—ʃuƒfƒ\ƒjƒh‹z“ü—pŒœ‘÷‰t‚Ì’·ŠúŠÇ—Œø‰Ê. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ. 2013;117(4): 732-9.
    28. ‘O“c@, ŒÃ’JŠìK, ˆîˆä@Œc, ¬ŒŠT“ñ, Š–ì_Ž÷, ã»Œõ—T, Œ— —Ts, Œ‰ª—Ú”üŽq, X@Ž•F, {“cŒ›Ž¡, ”Ñ“‡³‹I, ’rŒŽ@‘, ‘å–ØŠ°¶, ‹àŠÛ@_, “c“àé¶, ’†“‡O“¹, ŒŒŽ‰h‹N, à_‰ªŒšé, ‘ŸºNM, –x•ÄmŽu, “ˆäL, ˆÀ“cŒª“ñ, ‰¡àV³l, VŠ_‹`•v, Žs“c•™Žq, ¬–ìˆÀ¶, ¬ŽRk‘Ÿ˜Y, •]Œ“Ži, ¬—яrŽ÷, é”ö–M—², ”’Î@Œö, ’†ì‰ë¶, –쑺—Tˆê, ‘è’ŒŽ÷, ‘ºã’q–Ÿ, ˆÀ‰Í“àãà, ˆÀ“c“ŒŽn“N, ’†Œ•q—Y, ŽRŠÝŒhK, “ú–{¬Ž™zŠÂŠíŠw‰ïSŒŒŠÇŽŸŠ³‚̈â“`Žq‰uŠwˆÏˆõ‰ï. ƒ`ƒAƒm[ƒ[«æ“V«SŽŸŠ³‚É‚š‚¯‚é”]”^ᇂ̉uŠw@“ú–{¬Ž™zŠÂŠíŠw‰ïSŒŒŠÇŽŸŠ³‚̈â“`Žq‰uŠwˆÏˆõ‰ï@•œ¬20”N“x-22”N“xŒ€‹†‰Û‘è•ñ. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ. 2013;29(5): 236-42.
  • Ç—á•ñ
    1. Kanegane H, Taneichi H, Nomura K, Wada T, Yachie A, Imai K, Ariga T, Santisteban I, Hershfield MS, Miyawaki T. Successful bone marrow transplantation with reduced intensity conditioning in a patient with delayed-onset adenosine deaminase deficiency. Pediatr Transplant. 2013 Feb;17(1):E29-32.
    2. Nomura K, Hoshino A, Miyawaki T, Hama A, Kojima S, Kanegane H. Neutropenia and myeloid dysplasia in a patient with delayed-onset adenosine deaminase deficiency. Pediatr Blood Cancer. 2013 May;60(5):885-6.
    3. Adachi YS, Itazawa T, Okabe Y, Higuchi O, Ito Y, Adachi Y. A case of mite-ingestion-associated exercise- induced anaphylaxis mimicking wheat-dependent exercise-induced anaphylaxis. Int Arch Allergy Immunol. 2013;162(2):181-3.
    4. Otsubo K, Nomura K, Miyawaki T, Kanegane H. Nocturnal enuresis as a first manifestation of acute lymphoblastic leukemia. Pediatr Int. 2013 Feb;55(1):126-7.
    5. Otsubo K, Sakaki-Nakatsubo H, Taneichi H, Nomura K, Miyawaki T, Tokoro M, Kanegane H. Giardiasis in a patient undergoing chemotherapy for retinoblastoma and acute myelogenous leukemia. Pediatr Int 2013 Aug;55(4):524-7.
    6. Yang X, Miyawaki T, Kanegane H. Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment. Immunotherapy. 2013 Apr;5(4):415-25.
    7. Yang X, Kanegane H, Miyawaki T. Progress of diagnosis and treatment of X-linked inhibitor of apoptosis deficiency. Zhonghua Er Ke Za Zhi. 2012 Jun;50(6):428-30.
    8. Lee YW, Yang EA, Kang HJ, Yang X, Mitsuiki N, Ohara O, Miyawaki T, Kanegane H, Lee JH. Novel mutation of IL2RG gene in a Korean boy with X-linked severe combined immunodeficiency. J Investig Allergol Clin Immunol. 2013;23(1):65-7.
    9. Hisata S, Sakaguchi H, Kanegane H, Hidaka T, Ichinose M, Kojima S, Nukiwa T, Ebina M. A Novel Missense Mutation of DKC1 In Dyskeratosis Congenita With Pulmonary Fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25;30(3):221-5.
    10. ˆÉ“¡–õ“T, “c‘ºŒ«‘Ÿ˜Y, “n•Ó—S‹I, ‹{@ˆêŽu, ‹{˜e—˜’j. ’ZŠú‹L‰¯áŠQ‚Ì‚Ý‚ð’悵‚œRNMDAŽó—e‘̍R‘Ì—z«•Ó‰Œn”]Ç‚̏—Ž™—á. ¬Ž™‰È—Տ° 2013;66(3): 499-504.
    11. •œŠâ–ŸŽq, âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, ¬‰Y@Ž, “¡“cC•œ, “ñ’J@•, ”šèŠì–F. dÇ¶S•s‘S‚ɑ΂µAƒoƒ‹[ƒ“S–[’†Šu—ôŠJp‚ðŽ{s‚µ‹~–œ‚µ“Ÿ‚œV¶Ž™S‹Ø‰Š‚Ì1—á. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ. 2013;29(3): 149-55.
    12. ’‡‰ª²’qŽq, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j. Š°‰ð“±“ü—Ö@‘Šú‚É”dŽí«ŒŒŠÇ“à‹ÃŒÅ‚𔭏ǂµ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚̈ê—á. “ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ïŽGŽ. 2013;50(4): 615-8.
  • ‘à
    1. Obuchi M, Adachi Y, Takizawa T, Sata T. Influenza A(H1N1)pdm09 virus and asthma. Front Microbiol. 2013 14;4:307.
    2. ‘«—§—Yˆê. ¬Ž™‚̔얞‚Æšb‘§. ƒAƒŒƒ‹ƒM[E–Ɖu 2013;20(11):1601-07.
    3. ‘«—§—Yˆê. dÇšb‘§‚ÌŽ¡—Ã. ƒAƒŒƒ‹ƒM[E–Ɖu 2013;20(9): 1325-30.
    4. ‘«—§—Yˆê, â–{—Ž—Y, à_è—Y•œ. ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2012(‘æ10Í)@‹z“ü‹@Ší‚Æ‚»‚ÌŽg‚¢•û. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ. 2013;27(2): 196-9.
    5. ‘«—§—Yˆê, ”óŒû@Žû, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘Ÿ“c–M—Y, “ú–{¬Ž™ŒÄ‹zŠíŠw‰ï‹C“¹ˆÙ•š—\–hƒ[ƒLƒ“ƒOƒOƒ‹[ƒv. ¬Ž™‚É‚š‚¯‚é‹C“¹ˆÙ•šŽ–ŒÌ@Œ»ó‚Æ‚»‚Ì—\–h‚É‚Þ‚¯‚Ä. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 2013;117(9): 1396-402.
    6. ‘«—§—Yˆê. ‹C“¹‰ß•q«ŽŽŒ±. ¬Ž™“à‰È 2013;45(5): 967-9.
    7. ‘«—§—Yˆê. ê–åˆã‚Ì‚œ‚߂̃AƒŒƒ‹ƒM[ŠwuÀ: ‹CŠÇŽxšb‘§(¬Ž™)‚̃oƒCƒIƒ}[ƒJ[. ƒAƒŒƒ‹ƒM[ 2013;62(2): 124-30.
    8. ‘«—§—Yˆê. ‚æ‚èˆÀ‘S‚ȏ¬Ž™Ž•‰Èˆã—Ã‚ð‹‚ß‚Ä. ¬Ž™‰Èˆã‚Ì—§ê‚©‚ç?‚±‚Ç‚à‚Ì‹C“¹“àˆÙ•š‚ÉŠÖ‚·‚é—\–h‚ƑΉž–@?D¬Ž™Ž•‰È—Տ°. 2013;18: 32-8.
    9. ‘«—§—Yˆê. •@‰Š‡•¹¬Ž™šb‘§‚ÌŽ¡—Ã. —Տ°–ƉuEƒAƒŒƒ‹ƒM[‰È. 2013;60: 530-4.
    10. ‘«—§—Yˆê. “û—cŽ™šb‘§‚ÆVirus-induced wheeze. “ú–{¬Ž™ˆã‰ï•ñ. 2013;45: 28-30.
    11. ‘«—§—Yˆê. Œ€‹†‚ÌŽü•Ó‚©‚çul‚Ƃ̏o‰ï‚¢‚Ì’†‚ŁvŒÄ‹z 2013; 32: 671-2.
    12. Žs“c•™Žq. y‚í‚©‚éS“d}-•a‘Ô‚É”—‚é”»“ǂ̃Rƒcz S‹ØÇŽŸŠ³A‚»‚Ì‘Œ@S‹ØÇ. ¬Ž™‰Èf—Ã. 2013;76(11): 1732-8.
    13. Žs“c•™Žq. ƒnƒCƒŠƒXƒNŽ™‚Ö‚ÌRSƒEƒBƒ‹ƒXŠŽõ—\–h. “ú–{ˆãŽ–V•ñ 2013;4676:31-5.
    14. Žs“c•™Žq. ‘æ114‰ñˆãŠwuÀ ‘ål‚É‚È‚è‚ä‚­ŒN‚œ‚¿‚ց`æ“V«SŽŸŠ³‚Æ”­’BáŠQ@S‘Ÿ‚ð‚Ü‚à‚é. ‘S‘S‘Ÿ•a‚ÌŽq‹Ÿ‚ðŽç‚é‰ï‰ïŽ 2013; 594:14-7.
    15. ‹àŒ“O˜a, ‹{˜e—˜’j. y—‰ð‚µ‚ďo‚»‚€@¬Ž™‚ÌŒŸž-ƒI[ƒ_[EŽè‹ZE‰ðŽßz –ƉuEƒAƒŒƒ‹ƒM[EŠŽõÇ@–Ɖu’S“–×–E‹@”\ˆÙíŒŸž(ƒŠƒ“ƒp‹…). ¬Ž™‰Èf—à 2013;76(‘): 180-5.
    16. ‹àŒ“O˜a. ŒJ‚è•Ô‚·’†Žš‰Š‚©‚牜‚ðl‚Š‚Ü‚·‚©H ¬Ž™Žš•@ˆôA‰È. 2013;34(2): 283-8.
    17. ”ÂàVŽõŽq. ƒAƒŒƒ‹ƒM[ŽŸŠ³‚ÌŽ¡—Öòi10j@¬Ž™‰È—̈æ@’·ŽžŠÔì—p«ƒÀ2ŽhŒƒ–ò. ƒAƒŒƒ‹ƒM[E–Ɖu@2013G20i12j1875-1881.
    18. ŽíŽsq’ˆ:yŒŒð«”÷¬ŒŒŠÇÇ(TMA:TTP/HUS)‚̍ŐV’mŒ©zTMA‚Æ”]Ç‚Ì–â‘è. t‚Æ“§Í. 2013;74(6): 1063-8.
    19. ŽíŽsq’ˆ:yŒŒð«”÷¬ŒŒŠÇÇ(TMA:TTP/HUS)‚̍ŐV’mŒ©z‘“àŽ–—á. t‚Æ“§Í. 2013;74(6): 1087-90.
    20. ŽíŽsq’ˆ. ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇ‚ÉŠÖ˜A‚µ‚œ‹}«”]Ç‚Ì•a‘Ô‚ÆŽ¡—Á`‚Š‚Ñ‚·H’†“ÅŽ–Œ‚ÌŒoŒ±‚©‚ç`. ƒƒfƒBƒJƒ‹’©“ú; 2013 Aug 34-35.
    21. œA–ìŒbˆê, Žs“c•™Žq. yƒƒ“ƒ‰ƒ“ƒNã‚̏¬Ž™‚̗Տ°ŒŸž-•a‘Ԑ¶—‚ÉŠî‚­‘I‚Ñ•ûEl‚Š•û-zzŠÂAŒÄ‹zŠíŒnŽŸŠ³‚̗Տ°ŒŸž@S•s‘S. ¬Ž™‰ÈŠwƒŒƒNƒ`ƒƒ[. 2013;3(2): 397-402.
    22. ¯–쌰G, ‹àŒ“O˜a. y’m‚Á‚Ä‚š‚«‚œ‚¢ÅV‚̖Ɖu•s‘SÇ•ª—Þ-f’f‚©‚玡—Â܂Łz •a‘ԁ@–Ɖu’²ßáŠQ@Ž©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ, ‰Æ‘°«ŒŒ‹…æÐHƒŠƒ“ƒp‘gD‘‘œÇŒóŒQ‚È‚Ç. ¬Ž™‰Èf—Ã. 2013;76(3): 425-30.
    23. ¯–쌰G, ‹àŒ“O˜a: yŒŒ‹…æÐHÇŒóŒQ‚Ì•a‘ԂƐf—Â̐V“WŠJz X-linked lymphoproliferative syndrome(XLP)/ signaling-lymphocytic-activation-molecule-associated protein(SAP)‚Ì•a‘Ô. ŒŒ‰tƒtƒƒ“ƒeƒBƒA. 2013;23(1): 33-40.
    24. –{ŠÔŒ’ˆê, ¡ˆäk•ã, ‹àŒ“O˜a, –ìXŽRŒbÍ. MonoMACÇŒóŒQ (GATA2ˆÙíÇ). —Տ°–Ɖu?ƒAƒŒƒ‹ƒM[‰È 2013; 60(4): 439-46.
    25. “n糌’ˆê˜Y, X“ˆ’B–ç, ‹àŒ“O˜a. yŒŒ‰tÇŒóŒQ(‘æ2”Å)-‚»‚Ì‘Œ‚ÌŒŒ‰tŽŸŠ³‚ðŠÜ‚ß‚Ä-z ‘¢ŒŒŠ²×–EˆÙí@Ä¶•s—ǐ«•nŒŒ@æ“V«“Á”­«Ä¶•s—ǐ«•nŒŒ@Shwachman-DiamondÇŒóŒQ. “ú–{—Տ°. 2013; •ÊûŒŒ‰tÇŒóŒQ‘æ2”Å:24-7.
    26. ’†‘º—˜”ü, ‘«—§—Yˆê, ‘ºãIŒ[, ’J“à]ºG, ‘哈—E¬, áÁ‹|Œõ•¶, –k—€¬Ž™‹CŠÇŽxšb‘§Ž¡—ÃŒ€‹†‰ï. Pediatric Asthma Support System‚Ì“±“ü‚É‚æ‚éƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚œ¬Ž™‹CŠÇŽxšb‘§Ž¡—Â̐„i. ¬Ž™‰È—Տ°. 2013;66(6): 1079-90.

  • 2013”NŠw‰ï•ñ
    1. Adachi Y, Yoshida K, Itazawa T, Ohya Y, Odajima H, Akasawa H, Miyawaki T. Relationship between ARIA and ISAAC questionnaires regarding to the classification and severity of rhinitis in school children. 69th Annual Meeting of American Academy of Allergy, Asthma & Immunology; 2013 Feb 22-26; San Antonio, USA.
    2. Kanegane H. Epstein-Barr virus-associated lymphoproliferative disorders. ASPR-PSM 2013; 2013 May 9-12; Malaysia. (invited lecture)
    3. Kanegane H. Immunomodulatory therapy for lymphoproliferative disorders. ASPR-PSM 2013; 2013 May 9-12; Malaysia. (invited lecture)
    4. Itazawa T, Okabe Y, Ito Y, Higuchi O, Adachi SY, and Adachi Y. Impulse oscillometry is more sensitive to bronchodilator response than spirometry in children with asthma. 2013 Annual international congress co-sponsored by Korean Academy of Asthma, Allergy and Clinical Immunology and Korean Academy of Pediatric Allergy and Respiratory Disease; 2013 May 10-11; Seoul, Korea.
    5. Itazawa T, Adachi Y, Ito K, Ebisawa M. Severe reaction during oral food challenges in children in a prospective study. Asian Pacific Congress of Allergy, Asthma and Clinical Immunology; 2013 Nov 14-17; Taipei, Taiwan.
    6. œA–ìŒbˆê, ¬‰Y@Ž, â“c“ޏ, ”óŒû@Žû, âV“¡˜a—R, “n•Óˆê—m, Žs“c•™Žq. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚œìè•a‚Ì‚P—á. ‘æ5‰ñ–k—€ìè•aŒ€‹†‰ï; 2013 Jan 22; ‹à‘ò.
    7. ˆÉŒ\“ñ˜Y, Œ”ö‹vŽÀ‘ã, “¡‰ª‘א¶, ‰Á“¡‰·Žq, à_–{“Þ‰›, –F–{@A‹à@¬ŠC, –ž‰º‹IŒb, V‹³Šî, “c’†–õ•F, ¬–ìˆÀ¶. Œo”ç“I”x“®–¬Œ`¬p‚É‚š‚¯‚é’Ž‚ˆ³ƒoƒ‹[ƒ“‚ƍ‚ˆ³ƒoƒ‹[ƒ“‚Æ‚Ì”äŠr. ‘æ24‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ïŠwpW‰ï; 2013 Jan 24; ˆ€•Q.
    8. ¯–쌰G, ‹àŒ“O˜a, —k@žF, ‹{˜e—˜’j, ”º@‰pŽ÷, ‰E“c¹G, ‹Žˆä‰ÀŽq, Xˆä‰pˆê, Ž‰ÍMŒh. ƒŠƒ“ƒpŒnŽîá‡‚ð‡•¹‚µ‚œX˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì2—á. ‘æ6‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï; 2013 Jan 26; “Œ‹ž.
    9. ’‡‰ª‰pK, “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, ²“¡@Œ[, “¡“cC•œ, ”šèŠì–F. S–[’†ŠuŒ‡‘¹‚Æ•”•ª”xÃ–¬ˆÙí‡•¹‚Ì”x“®–¬«”x‚ŒŒˆ³‚ɑ΂µ‚āA”xŒŒŠÇŠg’£–ò‚Ì‘œÜ•¹—p—Ö@‚ª‘tŒ÷‚µ‚œ2Î—Ž™—á. ‘æ19‰ñ“ú–{¬Ž™”xzŠÂŒ€‹†‰ï; 2013 Feb 2; “Œ‹ž.
    10. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™ƒAƒŒƒ‹ƒM[«•@‰Š ¬Ž™‰È‚Ì—§ê‚©‚çv. ‘æ31‰ñ“ú–{Žš•@ˆôA‰È–ƉuƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Feb 7-9; ‘q•~.
    11. ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j. “¯Žíœ‘ˆÚAŒã‚É•”•ªŠ°‰ð‚Ì‚Ü‚Ü–³Ž¡—ÂŒ·Šú¶‘¶‚µ‚Ä‚¢‚é_Œo‰è×–EŽî‚̈ê—á. ‘æ35‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï; 2013 Mar 7-9; ‹à‘ò.
    12. –쑺ŒbŽq, ‹àŒ“O˜a, ŽíŽsq’ˆ, ‹{˜e—˜’j, ’@–LŽj, ˆÉ’B—mŽŠ. _Œo‰èŽî‚ÌŽ¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚ɑ΂·‚铯ŽíœˆÚAŒãA–«•ÂÇ«×‹CŠÇŽx‰Š‚ɑ΂µA—Œ‘€¶‘Ì”xˆÚA‚ðŽ{s‚µ‚œ¬Ž™—á. ‘æ35‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï; 2013 Mar 7-9; ‹à‘ò.
    13. ‘ŠJË•œ, ‹{@ˆêŽu, ‹{˜e—˜’j. •xŽR‘åŠw¬Ž™‰È‚ÅŒoŒ±‚µ‚œ‰ß‹Ž‚T”NŠÔ‚ÌWestÇŒóŒQ‚ɂ‚¢‚ẲuŠw“IŒŸ“¢. ‘æ307‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï; 2013 Mar 10; ‹à‘ò.
    14. ŽíŽsq’ˆ. •ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€2@¬Ž™‚Ì‹}«”]‰ŠE”]ÇuEHEC”]Çv. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    15. ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‹{˜e—˜’j. “–‰@‚É‚š‚¯‚éƒOƒŠ[ƒtƒPƒA‚Ì‘æˆê•à.`ƒOƒŠ[ƒtƒJ[ƒh‚Ì–ðŠ„‚É‚Â‚¢‚ā`. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    16. “n•Óˆê—m, Ö“¡˜a—R, Žs“c•™Žq, ‹{˜e—˜’j, Šâéûé”n, “úŒG’qŒ›, –F‘º’ŒŽ÷. TCPCp’ŒŒã‚©‚猌ðŒ`¬‚µASŠO“±ŠÇ•ÂÇ‚ð‚«‚œ‚µ‚œ3—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    17. ‘«—§—zŽq, ”óŒûŽû, ”ÂàVŽõŽq, ŽíŽsq’ˆ, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’q_, ìèˆê‹P. •ÛˆçŽ{Ý‚É‚š‚¯‚é‹C“¹Ž–ŒÌ—\–h‚Ì‚œ‚ß‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    18. –xìT“ñ˜Y, ‹{”ö¬–Ÿ, ìú±—TŽq, –q–{—D”ü, ‹g“cär, ‹{˜e—˜’j. ˜˜]Ò’ŏnjóŒQ‚̈ê—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    19. ‘ŠJË•œ, âV“¡˜a—R, “n•Óˆê—m, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq, ‹{˜e—˜’j, ”ª–ؐMˆê. LMNAˆâ“`Žq•ÏˆÙ‚𔺂€æ“V«‹ØƒWƒXƒgƒƒtƒB[‚̏—Ž™‚É‚š‚¯‚éS•s‘S‚ÌŒo‰ß. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    20. ’ށ@_”V, “c’†•ü”ü, ‰ª•”^Žq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‹{˜e—˜’j. ‹”MŠÂ‹«‰º‚É‚š‚¯‚é‰ß“x‚̉^“®‚É‚æ‚艡–ä‹Ø—Z‰ðÇ‚ð‚«‚œ‚µ‚œ‚P—á. ‘æ116‰ñ“ú–{¬Ž™‰ÈŠw‰ï; 2013 Apr 19-21; L“‡.
    21. ‘ŠJË•œ, –x]’åŽu, ¬‰Y@Ž, “n•Ó—S‹I, ”óŒû@Žû, ‹{@ˆêŽu, ŽíŽsq’ˆ. ¬Ž™‚É‚š‚¯‚é”ñƒwƒ‹ƒyƒX«‹}«•Ó‰Œn”]‰Š(RNMDAŽó—e‘̍R‘Ì—z«—á) ‚ɑ΂·‚鎡—Ð헪. ‘æ15‰ñ–k—€¬Ž™‹~‹}?W’†Ž¡—ÃŒ€‹†‰ï; 2013 May 11; ‹à‘ò.
    22. ‘«—§—Yˆê. ‘‡ƒAƒŒƒ‹ƒM[ˆãˆç¬ƒR[ƒXFšb‘§”­ì‚ւ̑Ήži¬Ž™j. ‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Տ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    23. ”ÂàVŽõŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹g“cKˆê, ŒÃì^‹|, ¬“c“ˆ”Ž, Ö“¡”Ž‹v, ÔàV@W. ƒEƒFƒu’²ž‚ð—p‚¢‚œŠw“¶‚É‚š‚¯‚éARIAiallergic rhinitis and its impact on asthmajŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錟“¢D‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Տ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    24. ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j. ¬”žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚ª‹^‚í‚ê‚œ‚šD‚ݏĂ«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—áD‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Տ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    25. ”óŒû@Žû, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, –q–ì‹P•F, Ž…’‰“¹. Žs”Ì‚Ì‘‡ŠŽ–`–ò‚Å‹}«”Ä”­«”­]Œ^”^ávÇ‚𔭏ǂµ‚œ—Ž™—áD‘æ25‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïtŠú—Տ°‘å‰ï; 2013 May 11-12; ‰¡•l.
    26. Žs“c•™Žq. “Á•Êu‰‰@‘ål‚É‚È‚è‚ä‚­ŒN‚œ‚¿‚ց`SŽŸŠ³Ž™‚Ì”­’BáŠQ‚ɂ‚¢‚ā`‘S‘S‘Ÿ•a‚ÌŽq‚Ç‚à‚ðŽç‚é‰ï@‹ž“sŽx•”u‰‰‰ï; 2013 May 12; ‹ž“s.
    27. ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a. ƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚ª‘tŒø‚µ‚œKasabach-MerrittÇŒóŒQ‚̈ê—á. ‘æ6‰ñ–k—€ƒwƒ‚ƒtƒBƒŠƒA§˜b‰ï; 2013 May 18; ‹à‘ò.
    28. Kanegane H, Yang X, Nishida N, Hoshino A, Miyawaki T. Clinical and genetic characterization of X-linked lymphoproliferative syndrome in Japan. The 4th JSH International symposium 2013; 2013 May 24-25; Ehime, Japan.
    29. Hoshino A, Kanegane H, Yang X, Ban H, Migita M, Kiyokawa N, Miyawaki T. B-precursor acute lymphoblastic leukemia in a patient with X-linked agammaglobulinemia. The 4th JSH International symposium 2013; 2013 May 24-25; Ehime, Japan.
    30. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê. ŒÄ‹z‹@”\‚ª—ǍD‚Å‚ ‚鏬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚̈Ӌ`. ‘æ30‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2013 June 8-9;ˆïéD
    31. ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê. •xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚鏜‹ŽH‘Ήž‚Ì5”NŠÔ‚̕ω». ‘æ30‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï; 2013 June 8-9;ˆïéD
    32. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€u’†Žš‰Š‚ɑ΂·‚é•Û‘¶—Ö@AŽèp—Ö@‚Ì‘I‘ðvŒJ‚è•Ô‚·’†Žš‰Š‚©‚牜‚ðl‚Š‚Ü‚·‚©H ‘æ8‰ñ“ú–{¬Ž™Žš•@ˆôA‰ÈŠw‰ï; 2013 June 20-21; ‘O‹Ž.
    33. ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê. ‹CŠÇŽxšb‘§¬Ž™‚̉‹t«ŽŽŒ±‚É‚š‚¯‚éImpulse Oscillometry System‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢. ‘æ107‰ñ —Տ°ŒÄ‹z¶—Œ€‹†‰ïŠwpW‰ï; 2013 June 22;“Œ‹ž.
    34. Œ‘q—TŠì, ‹{@ˆêŽu, ’·X–œ—¢Žq. ‘Ï“œ”\ˆÙíAt”X–EAõF‘ُ̈í‚𔺂€Dandy-Walker variant‚̏—Ž™—á. ‘æ48‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï; 2013 June 28-29; “¿“‡.
    35. Žs“c•™Žq. “Á•Êu‰‰@æ“V«SŽŸŠ³‚É‚š‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŒø‰Ê. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    36. œA–ìŒbˆê, âV“¡˜a—R, “n•Óˆê—m, ¬àVˆ»‰À, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, Žs“c•™Žq, –F‘º’ŒŽ÷, Dirk Foel. ƒtƒHƒ“ƒ^ƒ“Žèp“K‰žŠ³ŽÒ‚É‚š‚¯‚éƒGƒ“ƒhƒZƒŠƒ“‚Ì“®‘Ô. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    37. ’‡‰ª‰pK, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, ¬àVˆ»‰À, œA–ìŒbˆê, ‘«—§—Yˆê, Žs“c•™Žq. LMNAˆâ“`Žq•ÏˆÙ‚𔺂€æ“V«‹ØƒWƒXƒgƒƒtƒB[‚̏—Ž™‚É‚š‚¯‚éS•s‘S‚ÌŒo‰ß. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    38. ˆÉŒ\“ñ˜Y, Œ”ö‹v”ü‘ã, “¡‰ª‘א¶, ‰Á“¡‰·Žq, ²“¡Œc‰î, à_–{“Þ‰›, –F–{ , ‹à ¬ŠC, –ž‰º‹IŒb, V‹³Šî, ¬–ìˆÀ¶. Žá”NŠú‘å“®–¬•Ù‹t—¬‚ɑ΂·‚éŽèp“K‰ž•]‰¿‚̃pƒ‰ƒ_ƒCƒ€ƒVƒtƒg `Œo‹¹•ÇSƒGƒR[+SŒŒŠÇ‘¢‰e‚©‚çCS‘ŸMRI+ŒoH“¹SƒGƒR[ŒŸž‚ց`. ‘æ49‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï; 2013 July 11-13; “Œ‹ž.
    39. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq. ”xŒŒŠÇŠg’£Ü‚ÅŒo‰ßŠÏŽ@‚µ‚œASD-PAH‚̈ê—á.‘æ4‰ñPH-CHDƒNƒŠƒjƒJƒ‹ƒJƒ“ƒtƒ@ƒŒƒ“ƒX; 2013 July 20; ‘åã.
    40. ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F, ìèˆê‹P, ”ª–ؐMˆê. ¬Ž™‚É‚š‚¯‚é‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚É‚Þ‚¯‚Ä Ž–ŒÌ‚âŒ[”­Šˆ“®‚ÌŽÀ‘Ô. ‘æ23‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2013 Aug 31-Sep 1; •Ÿ‰ª.
    41. ‘«—§—Yˆê, ŽsŠÛ’q_, ¡ˆää‰p, ã“cN‹v, ‰€@N‰ë, ”óŒû¹F, ìèˆê‹P, ‘Ÿ“c–M—Y, ”ª–ؐMˆê. ¬Ž™‚É‚š‚¯‚é‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚É‚Þ‚¯‚Ä Œ[”­—pƒpƒ“ƒtƒŒƒbƒgì¬. ‘æ23‰ñ“ú–{ŠO—ˆ¬Ž™‰ÈŠw‰ï; 2013 Aug 31-Sep 1; •Ÿ‰ª.
    42. ‘«—§—Yˆê. u“û—cŽ™šb‘§‚É‚š‚¯‚éÅ‹ß‚̘b‘èv‘æ4‰ñPediatric Asthma Regional Seminar; 2013 Sep 7; å‘ä.
    43. ‘ºãIŒ[, ‚”ö@Š², ”öã—mˆê, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cär. ŠJ‹Æˆã‚ōs‚€H•šŒoŒû•‰‰×ŽŽŒ±‚ÌŒŸ“¢. ‘æ16‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï; 2013 Sep 14; •xŽR.
    44. ìè—TŽq, –q–{—D”ü, ¬‰Y@Ž, “c‘ºŒ«‘Ÿ˜Y, –xìT“ñ˜Y, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cär. “–‰@‚ÅŒoŒ±‚µ‚œV¶Ž™ƒ~ƒ‹ƒNƒAƒŒƒ‹ƒM[‚Ì3—á. ‘æ16‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï; 2013 Sep 14; •xŽR.
    45. ˆÉŒ\“ñ˜Y, ’‡‰ª‰pK, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, Â–ؐ³Æ, “úŒG’qŒ›, –F‘º’ŒŽ÷, –F–{@. S‘ŸÄ“¯Šú—Ö@ƒVƒ~ƒ…ƒŒ[ƒVƒ‡ƒ“‚ðs‚Á‚œ‚“xS•s‘S‚ð‡•¹‚µ‚œGlennŽèpŒãA‘å“®–¬kó•¡‡‚̈ê—á. ‘æ41‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï; 2013 Sep 14; ‹à‘ò.
    46. ¬‰Y@Ž, â“c“ޏ, ”óŒû@Žû, œA–ìŒbˆê, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚œ•s‘SŒ^ìè•a‚Ì9‚©ŒŽ—Ž™—á. ‘æ33‰ñ“ú–{ìè•aŠw‰ï; 2013 Sep 27-28, •xŽR.
    47. œA–ìŒbˆê, ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ¬Š_Ž –L, •Ÿ›ž‹³ˆÌ. ƒÀŽÕ’f–ò“Š—^‚É‚æ‚èS•s‘S‚ª‘ˆ«‚µ‚œ¶ŽºS‹Øãk–§‰»áŠQ‚̈ê—á. ‘æ22‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ï; 2013 Oct 5; ‘åã.
    48. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€uˆâ“`ŽqˆÙí‚Ɛ_ŒoŠŽõÇvR‘Ì•s‘SÇ‚Æ’†•_ŒoŠŽõÇ. ‘æ18‰ñ“ú–{_ŒoŠŽõÇŠw‰ï; 2013 Oct 10-12; ‹{è.
    49. Hoshino A, Nomura K, Noguchi K, Kotani T, Nakagawa N, Kanegane H. A case of relapsed APL without peripheral blood abnormalities and clinical symptoms detected by MRI. ‘æ75‰ñ“ú–{ŒŒ‰tŠw‰ï; 2013 Oct 10-13; ŽD–y.
    50. Žs“c•™Žq. ƒVƒ“ƒ|ƒWƒEƒ€f—Ñ̐§FŠw‰ï‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó@“ú–{zŠÂŠíŠw‰ï‚æ‚è@ŠwpˆÏˆõ‰ï@¬læ“V«SŽŸŠ³•”‰ï‚̐ݗ§. ‘æ9‰ñ¬læ“V«SŽŸŠ³ƒZƒ~ƒi[; 2013 Oct 19; ‘åã.
    51. ‘«—§—Yˆê. ƒXƒ|ƒ“ƒT[ƒhƒZƒ~ƒi[uHow to challenge and influence to the prognosis of childhood asthma: strategies and perspecitivev‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    52. ‘«—§—Yˆê. ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§Ž¡—à ƒXƒeƒbƒvƒ_ƒEƒ“‚ÆŽ¡—Ã’†Ž~‚Ì–ÚˆÀv‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.@
    53. ‘«—§—Yˆê. Pro ConuICS‚ÌŠÔŒ‡“Š—^FCon‚Ì—§ê‚©‚çv‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    54. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •l“¹”ü‹I, ”óŒû@Žû, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê. ƒ}ƒtƒBƒ“‚ð—p‚¢‚œ’Ž‰Á”M“û•‰‰×ŽŽŒ±‚Ì—L—p«‚ɂ‚¢‚Ä. ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    55. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹Ž@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ãŒŽ—R”üŽq, ˆÉ“¡_–Ÿ, ‹T“c@œ, Šì‘œ‘º“N˜N, “í–Ú˜a‘ã, Žè’ˏƒˆê˜Y. ‘S‘‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒûH•š•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÉŠÖ‚·‚é‘S‘’²ž. ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    56. ”ÂàVŽõŽq. ˆê”ʈãƒZƒ~ƒi[uf—ØAŒg‚̃^ƒCƒ~ƒ“ƒOF‹CŠÇŽxšb‘§v ‘æ50‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï; 2013 Oct 19-20; ‰¡•l.
    57. ‰ª•”^Žq, ’‡‰ª‰pK, ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, Žs“c•™Žq. “«ìè•a‚ɑ΂µ‚ÄIVIG‚š‚æ‚уVƒNƒƒXƒ|ƒŠƒ“•¹—p—Ö@‚ª—LŒø‚Å‚ ‚Á‚œ2—á. ‘æ13‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï; 2013 Oct 25; •xŽR.
    58. ‹àŒ“O˜a. ICDuK‰ïu–Ɖu•s‘SÇŠ³ŽÒ‚É‚š‚¯‚銎õ‘΍ôv ‘æ45‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    59. ŽíŽsq’ˆ. ƒVƒ“ƒ|ƒWƒEƒ€uEHEC O111W’cŠŽõŽ–—á‚É‚š‚¯‚éŒoŒ±‚©‚ç?EHEC”]Ç‚Ə¬Ž™‰Èˆã‚É‚æ‚éŠë‹@‘Ήž?v ‘æ45‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    60. “n•Ó—S‹I, –x]’åŽu, •œŠâ–ŸŽq, ŽíŽsq’ˆ, ”ÂàVŽõŽq, Žs“c•™Žq: human metapneumovirusŠŽõ‚ðŒ_‹@‚É”­Ç‚µ‚œdÇ methicillin-resistant Staphylococcus aureus ”x‰Š‚̈ê—á. ‘æ45‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    61. ¬‰Y@Ž, â“c“ޏ, ”óŒû@Žû, ‹àŒ“O˜a, ‹{˜e—˜’j. ”x–ì‚É‚Ñ‚Ü‚ñ«Œ‹ß•a•Ï‚ð”F‚ß‚œ•s‘SŒ^ìè•a‚Ì‚X‚©ŒŽ—Ž™—á. ‘æ45‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï; 2013 Oct 26-27; ŽD–y.
    62. Žs“c•™Žq. V¶Ž™ŠJSpŒã‚̍‚ŽŸ”]‹@”\áŠQ. “ú–{—Տ°–ƒŒŠw‰ï‘æ33‰ñ‘å‰ï; 2013 Nov 1-3; ‹à‘ò.iµ‘ҍu‰‰j
    63. ŽíŽsq’ˆ, œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, ¬‰Y@Ž, Žs“c•™Žq, ‘«—§—Yˆê. “–‰È‚É‚š‚¯‚édÇ¬Ž™Š³ŽÒ‚Ì’·‹——£”À‘—. ‘æ16‰ñ–k—€¬Ž™‹~‹}EW’†Ž¡—ÃŒ€‹†‰ï; 2013 Nov 2; ‹à‘ò.
    64. ‘«—§—Yˆê. “Á•Êu‰‰u¬Ž™‚É‚š‚¯‚éone airway, one diseasev“ú–{ƒAƒŒƒ‹ƒM[‹Š‰ï“Œ–kŽx•”Šwpu‰‰‰ï; 2013 Nov 2; å‘äD
    65. ‹àŒ“O˜a, –쑺ŒbŽq, ¯–쌰G. “–‰È‚É‚š‚¯‚é•a“˜AŒg‚É‚æ‚錌—F•af—Ã. ‘æ8‰ñ–k—€ƒwƒ‚ƒtƒBƒŠƒAƒZƒ~ƒi[; 2013 Nov 9; ‹à‘ò.
    66. ’†—ÑŒºˆê, Œ“c’Œ“¿, ’ށ@_”V, “n•Ó—S‹I, ˆÉ“¡–õ“T, ‘«—§—Yˆê, –쌎@~, ¬—я~“ñ. ‘æ27‰ñ“ú–{¬Ž™Ž‰Ž¿Œ€‹†‰ï; 2013 Nov 9-10; •Ÿˆä.
    67. ‘«—§—Yˆê. “Á•Ê•ñu‹C“¹ˆÙ•š`Ž–ŒÌ‚ðŒž‚ç‚·‚œ‚߂Ɂ`v‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    68. ›“c^–ç, ”ÂàVŽõŽq, •œŠâ–ŸŽq, “c’†•ü”ü, ‘«—§—Yˆê. •ÂÇ«‡–°Žž–³ŒÄ‹zÇŒóŒQ‚Æ”»’f‚³‚ê‚Ä‚¢‚œŠoÁáŠQ‚ƍl‚Š‚ç‚ê‚éƒ_ƒEƒ“Ç‚̈ê—á. ‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    69. Œ–쐳’m, ‘«—§—Yˆê, ŒÜ\—’—²•v. ¬Ž™šb‘§‚É‚š‚¯‚é—\–h“IŽ¡—Â̑Šú‰î“ü‚Ì—LŒø«‚ÉŠÖ‚·‚錟“¢ -ŽvtŠú‚É‚š‚¯‚é”­ìó‹µ‚â‹C“¹‰ß•q«‚̐„ˆÚ‚ւ̉e‹¿‚ɂ‚¢‚Ä-. ‘æ46‰ñ“ú–{¬Ž™ŒÄ‹zŠíŠw‰ï; 2013 Nov 22-23; ²‰ê.
    70. ‹àŒ“O˜a. ƒ[ƒNƒVƒ‡ƒbƒvu–Ɖu•s‘SÇv‘æ41‰ñ“ú–{—Տ°–ƉuŠw‰ï; 2013 Nov 27-29; ‰ºŠÖ.
    71. ‘«—§—Yˆê. ‹³ˆçu‰‰uŠÂ‹«ˆöŽq‚ƃAƒŒƒ‹ƒM[”­ÇE‘ˆ«v ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    72. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é––œ‹C“¹‚̏d—v«F––œ‹C“¹•a•Ï‚ð•W“I‚Æ‚µ‚œ‹z“ü—Ö@v‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    73. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[ŽŸŠ³ƒKƒCƒhƒ‰ƒCƒ“FTotal Allergist‚Æ‚µ‚Ă̏¬Ž™ƒAƒŒƒ‹ƒM[f—Áv‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    74. ‘«—§—Yˆê. ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[ƒ}[ƒ` up to date ¬Ž™‚©‚琬l‚܂ŁF¬Ž™‹CŠÇŽxšb‘§‚ƃAƒŒƒ‹ƒM[ƒ}[ƒ`v‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    75. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹Ž@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ãŒŽ—R”üŽq, ˆÉ“¡_–Ÿ, ‹T“c@œ, Šì‘œ‘º“N˜Y, “í–Ú˜a‘ã, Žè’ˏƒˆê˜Y. ‘S‘‚É‚š‚¯‚éŒoŒûH•š•‰‰×ŽŽŒ±‚É‚æ‚é—U”­Çó‚ÉŠÖ‚·‚é‘OŒü‚«’²ž. ‘æ63‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï; 2013 Nov 28-30; “Œ‹ž.
    76. ‹àŒ“O˜a. ƒVƒ“ƒ|ƒWƒEƒ€u‘¢ŒŒ•s‘S‚ð‡•¹‚·‚é–Ɖu•s‘SÇv‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    77. ‹àŒ“O˜a. Meet The Expartu–Ɖu•s‘S‚ð‡•¹‚·‚é–Ɖu•s‘SÇv ‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    78. –쑺ŒbŽq, ¯–쌰G, ‹àŒ“O˜a, ã–ì@–õ, ÎàV@L: —‘‘ƒ¬nŠïŒ`Žî‚É”­¶‚µ‚œŒŽŽn_ŒoŠOãó—t«Žîá‡(primitive neuroectodermal tumor: PNET)‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï; 2013 Nov 29-Dec 1; •Ÿ‰ª.
    79. ‘«—§—zŽq, à_“¹”ü‹I, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê. ‚šD‚ݏĂ«‚É‚æ‚鏬”žˆË‘¶«‰^“®—U”­ƒAƒiƒtƒBƒ‰ƒLƒV[‚ª‹^‚í‚ê‚œ1—á. ‘æ40‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï; 2013 Dec 7; ‹à‘òD
    80. ‹{@ˆêŽu, “n•Ó—S‹I, “c’†•ü”ü, “c’‡çH, ‘«—§—Yˆê, ìè‘‘å, ‰œ‘º’ql, ’†Œ@œ. •s“oZ‚ð”wŒi‚Æ‚µ‚Ä‚ÌŠwK•sU‚̏d—v«. ‘æ31‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï; 2013 Dec 8; •xŽR.
    81. ”ÂàVŽõŽq. ‚PŒ^“œ”A•aŠ³ŽÒ‚̉h—{ŠÇ—ƒXƒLƒ‹ƒAƒbƒv‚ð–ÚŽw‚µ‚Ä. “ú–{•a‘Ô‰h—{Šw‰ï•œ¬25”N“x“ŒŠCE–k—€’n‹æÇ—ጟ“¢‰ï; 2013 Dec 8;@•xŽR.

    2012”N

  • ’˜‘
    1. Žs“c•™ŽqF‚ŒŒˆ³Ç. u¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ15”Łv ‘åŠÖ••F‘Œ•Ò, ˆãŠw‘‰@, “Œ‹ž, 495-496, 2012.
    2. Žs“c•™ŽqF’m‚Á‚Ä‚š‚«‚œ‚¢“à‰ÈÇŒóŒQ. “à‰È@109Šª6†‘‘卆@BarthÇŒóŒQ, “ì]“°, “Œ‹ž, 1037-1038, 2012.
    3. Žs“c•™ŽqFVES‘Ÿ•af—Ãvƒ‰ƒNƒeƒCƒXƒVƒŠ[ƒY18.@¬l‚É‚È‚Á‚œæ“V«SŽŸŠ³. ŽÐ‰ï“I–â‘è.VŠ_‹`•vA[’J—²•Ò, •ªŒõ“°, “Œ‹ž, 152-156, 2012.
    4. ‘«—§—Yˆê: ×‹CŠÇŽx‰ŠDu¬Ž™‰Èf—ÁEŽ¡—ÃŽwjv‰““¡•¶•v•Ò, ’†ŽR‘“X, “Œ‹ž, 502-505, 2012.
    5. ‹àŒ“O˜a: ŒŽ”­«–Ɖu•s‘SÇ. u¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ15”Łv ‘åŠÖ••F‘Œ•Ò, ˆãŠw‘‰@, “Œ‹ž, 282-283, 2012.
    6. ‹àŒ“O˜a: -–Ɖu•s‘SÇ-@4.–Ɖu’²ßáŠQ.u¬Ž™‚Ì”­”MA to Z-f’fŽ¡—ÂÌTips‚ÆPitfalls-v ŒŽ@Žõ˜Y•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 174-177, 2012.
    7. ‹àŒ“O˜a: 4.X˜AœƒŠƒ“ƒp‘BÇŒóŒQ(XLP).uŽ©ŒÈ‰ŠÇ«ŽŸŠ³?Ž©‘R–Ɖu•s‘SÇ‚Æ‚»‚̋߉ŽŸŠ³v, ‹ß“¡’ŒŽÀA•œ‰Ær’j•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 163-165, 2012.
    8. ‹àŒ“O˜a: Case 15. X˜AœƒŠƒ“ƒp‘BÇŒóŒQ(XLP).uŽ©ŒÈ‰ŠÇ«ŽŸŠ³?Ž©‘R–Ɖu•s‘SÇ‚Æ‚»‚̋߉ŽŸŠ³v, ‹ß“¡’ŒŽÀA•œ‰Ær’j•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 230-232, 2012.
    9. ŽíŽsq’ˆ, ‹{˜e—˜’j: ŒŽ”­«–Ɖu•s‘SÇŒóŒQ.@1D‰t«–Ɖu•s‘S‚ðŽå‚Æ‚·‚鎟Š³DuƒJƒ‰[”Ł@“à‰ÈŠwv–å˜e@F, ‰iˆä—ÇŽO•Ò, Œ‘º‘“X, “Œ‹ž, 1321-1323, 2012.
    10. Œ“c’Œ“¿, ‹{˜e—˜’j: -–Ɖu•s‘SÇ-@2.Žå‚Æ‚µ‚čR‘Ì•s‘S‚ðŽŠ‚·ŽŸŠ³.u¬Ž™‚Ì”­”MA to Z-f’fŽ¡—ÂÌTips‚ÆPitfalls-v ŒŽ@Žõ˜Y•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 160-166, 2012.
    11. Œ“c’Œ“¿, ‹àŒ“O˜a: ƒRƒƒiƒEƒCƒ‹ƒX, ƒuƒjƒAƒEƒCƒ‹ƒX, JCƒEƒCƒ‹ƒX, ƒvƒŠƒIƒ“. u¬Ž™ŠŽõÇƒ}ƒjƒ…ƒAƒ‹v,@“ú–{¬Ž™ŠŽõÇŠw‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 548-561, 2012.
  • ŒŽ’˜
    1. Kanegane H., Yang X., Zhao M., Yamato K., Inoue M., Hamamoto K., Kobayashi C., Hosono A., Ito Y., Nakazawa Y., Terui K., Kogawa K., Ishii E., Sumazaki R., and Miyawaki T.: Clinical features and outcome of X-linked lymphoproliferative syndrome type1 (SAP deficiency) in Japan identified by the combination of flow cytometric assay and genetic analysis. Pediat Allergy Immunol 23: 488-493, 2012.
    2. Tanaka C, Matsui M, Uematsu A, Noguchi K, Miyawaki T. Developmental Trajectories of the Fronto-Temporal Lobes from Infancy to Early Adulthood in Healthy Individuals. Dev Neurosci. 2012;34(6):477-87.
    3. Miya K., Shimojima K., Sugawara M., Shimada S., Tsuri H., Harai-Tanaka T., Nakaoka S., Kanegane H., Miyawaki T., and Yamamoto T.: A de novo interstitial deletion of 8p11.2 including ANK1 identified in a patient with spherocytosis, psychomotor developmental delay, and distinctive facial features. Gene 506: 146-149, 2012.
    4. Harai T., Inoue R., Fujita Y., Tanaka A., Horio M., Hashimoto K., Hongou K., Miyawaki T., and Mori H.: Decreased susceptibility to seizures induced by pentylenetetrazole in serine racemase knockout mice. Epilepsy Res 102: 180-187, 2012.
    5. Higuchi O., Adachi Y., Itazawa T., Ito Y., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Relationship between rhinitis and nocturnal cough in school children. Pediatr Allergy Immunol 23: 562-566, 2012.
    6. Higuchi O., Okabe M., Yoshida T., Fathy M., Saito S., Miyawaki T, and Nikaido T.: Stemness of human wharton's jelly mesenchymal cells is maintained by floating cultivation. Cell Reprogram 14: 448-455,, 2012.
    7. Okabe Y., Adachi Y., Itazawa T., Yoshida K., Ohya Y., Akasawa A., and Miyawaki T.: Association between obesity and asthma in Japanese preschool children. Pediatr Allergy Immunol 23: 550-555, 2012.
    8. Otsubo K., Horie S., Nomura K., Miyawaki T., Abe A., and Kanegane H.: Acute promyelocytic leukemia following aleukemic leukemia cutis harboring NPM/RARA fusion gene. Pediatr Blood Cancer 59: 959-960, 2012.
    9. Ibuki K., Watanabe K., Yoshimura N., Kakimoto T., Matsui M., Yoshida T., Origasa H., and Ichida F.: The improvement of hypoxia correlates with neuroanatomic and developmental outcomes: Comparison of midterm outcomes in infants with transposition of the great arteries or single-ventricle physiology. J Thorac Cardiovasc Surg 143: 1077-1085, 2012.
    10. Yang X., Wada T., Imadome K., Nishida N., Mukai T., Fujiwara M., Kawashima H., Kato F., Fujiwara S., Yachie A., Zhao X., Miyawaki T., and Kanegane H.: Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. Herpesviridae 3: 1, 2012.
    11. Yang X., Kanegane H., Nishida N., Imamura T., Hanamoto K., Miyashita R., Imai K., Nonoyama S., Sanayama K., Yamaide A., Kato F., Nagai K., Ishii E., van Zelm MC., Latour S., Zhao XD., and Miyawaki T.: Clinical and Genetic Characteristics of XIAP Deficiency in Japan. J Clin Immunol 32: 411-420, 2012.
    12. Yang X., Kanegane H., Miyawaki T., and Zhao Z.: Progress of diagnosis and treatment of X-linked inhibitor of apoptosis deficiency. Chin J Pediatr 50: 428-430, 2012.
    13. Onouchi Y., Ozaki K., Burns JC., Shimizu C., Terai M., Hamada H., Honda T., Suzuki H., Suenaga T., Takeuchi T., Yoshikawa N., Suzuki Y., Yasukawa K., Ebata R., Higashi K., Saji T., Kemmotsu Y., Takatsuki S., Ouchi K., Kishi F., Yoshikawa T., Nagai T., Hamamoto K., Sato Y.,Honda A., Kobayashi H., Sato J., Shibuta S., Miyawaki M., Oishi K., Yamaga H., Aoyagi N., Iwahashi S., Miyashita R., Murata Y., Sasago K., Takahashi A., Kamatani N., Kubo M., Tsunoda T., Hata A., Nakamura Y., Tanaka T; Japan Kawasaki Disease Genome Consortium, Abe J., Kobayashi T., Arakawa H., Ichida F., Nomura Y., Miura M., Ikeda K., Hara T., Fukazawa R., Ogawa S., Hamaoka K. ; US Kawasaki Disease Genetics Consortium, Newburger JW., Baker AL., Rowley AH., Shulman ST., Melish ME., Mason WH., Takahashi M., Tremoulet AH.: A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 44: 517-521, 2012.
    14. Kobayashi T., Saji T., Otani T., Takeuchi K., Nakamura T., Arakawa H., Kato T., Hara T., Hamaoka K., Ogawa S., Miura M., Nomura Y., Fuse S., Ichida F., Seki M., Fukazawa R., Ogawa C., Furuno K., Tokunaga H., Takatsuki S., Gara S., Morikawa A; on behalf of the RAISE study group investigators.: Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. LANCET 379: 1613-1620, 2012.
    15. Honda F., Kano H., Kanegane H., Nonoyama S., Kim ES., Lee ES., Takagi M., Mizutani S., and Morio T.: The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 13: 369-378, 2012.
    16. Chida A., Shintani M., Yagi H., Fujiwara M., Kojima Y., Sato H., Imamura S., Yokozawa M., Onodera N., Horigome H., Kobayashi T., Hatai Y., Nakayama T., Fukushima H., Nishiyama M., Doi S., Ono Y., Yasukouchi S., Ichida F., Fujimoto K., Ohtsuki S., Teshima H., Kawano T., Nomura Y., Gu H., Ishiwata T., Furutani Y., Inai K., Saji T., Matsuoka R., Nonoyama S., and Nakanishi T.: Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol 110: 586-593, 2012.
    17. Uchiyama T., Yoshimura K., Kaneko K., Nemoto S., Ichida F., Hata Y., and Nishida N.: Surgical repair of left ventricular noncompaction in a patient with a novel mutation of the Myosin heavy chain 7 gene. Tohoku J Exp Med 228: 301-304, 2012.
    18. Yamanaka K., Higuma T., Watanabe K., Okada Y., Ichida F., and Yoshimura N. : Congenital sternal cleft. J Pediatr Surg 47: 2143-2145, 2012.
    19. Shimizu M., Kuroda M., Sakashita N., Konishi M., Kaneda H., Igarashi N., Yamahana J., Taneichi H., Kanegane H., Ito M., Saito S., Ohta K., Taniguchi T., Furuichi K., Wada T., Nakagawa M., Yokoyama H., and Yachie A.: Cytokine profiles of patients with enterohemorrhagic Escherichia coli O111-induced hemolytic-uremic syndrome. Cytokine 60: 694-700, 2012.
    20. Momoi N., Chang B., Takeda I., Aoyagi Y., Endo K., and Ichida F.: Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction. Eur J Pediatr 171: 515-520, 2012.
    21. Otsuka H., Arimura T., Abe T., Kawai H., Aizawa Y., Kubo T., Kitaoka H., Nakamura H., Nakamura K., Okamoto H., Ichida F., Ayusawa M., Nunoda S., Isobe M., Matsuzaki M., Yoshinori LD., Fukuda K., Sasaoka T., Izumi T., Ashizawa N., and Kimura A.: Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J 76: 453-461, 2012.
    22. Kawamura M., Kusano A., Furuya A., Hanai N., Tanigaki H., Tomita A., Horiguchi A., Nagata K., Itazawa T., Adachi Y., Okabe Y., Miyawaki T., and Kohno H.: New sandwich-type enzyme-linked immunosorbent assay for human MxA protein in a whole blood using monoclonal antibodies against GTP-binding domain for recognition of viral infection. J Clin Lab Anal 26: 174-183, 2012.
    23. Oshima K., Nagase T., Imai K., Nonoyama S., Obara M., Mizukami T., Nunoi H., Kanegane H., Kuribayashi F., Amemiya S., and Ohara O.: A dual reporter splicing assay using Halo Tag-containing proteins. Curr Chem Genomics 6: 27-37, 2012.
    24. Shimada S., Miya K., Oda N., Watanabe Y., Kumada T., Sugawara M., Shimojima K., and Yamamoto T.: An unmasked mutation of EIF2B2 due to submicroscopic deletion of 14q24.3 in a patient with vanishing white matter disease. Am J Med Genet A 158: 1771-1777, 2012.
    25. ˆÉ“¡–õ“T, ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§’·ŠúŠÇ—‚É‚š‚¯‚éƒXƒeƒbƒvƒ_ƒEƒ“Žž‚̌ċCˆêŽ_‰»’‚‘f‚É‚æ‚鑝ˆ«‚Ì—\‘ª‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 26: 258-265, 2012.
    26. ‹{@ˆêŽu, ‚è–ƒ”ü, âV“¡˜a—R, ”‘òŽõŽq, ãšŒhˆê˜Y, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: V¶Ž™?“ûŽ™‚ւ̃rƒ^ƒ~ƒ“K—\–h“Š—^‚ÉŠÖ‚·‚é•ÛŒìŽÒ‚̈ӎ¯’²ž. “ú–{¬Ž™‰ÈŠw‰ïŽ116F1554-1557, 2012.
  • Ç—á•ñ
    1. Matsukura H., Ibuki K., Nomura K., Higashiyama H., Takasaki A., Miyawaki T., Aikawa A., and Kanegane H.: Intracranial calcification in a uremic infant with Wilmsf tumor in a solitary kidney. CEN Case Rep 1: 86-89. 2012.
    2. Nakaoka H., Kanegane H., Taneichi H., Miya K., Yang X., Nomura K., Takezaki S., Yamada M., Ohara O., Kamae C., Imai K., Nonoyama S., Wada T., Yachie A., Hershfield MS., Ariga T., and Miyawaki T.: Delayed onset adenosine deaminase deficiency associated with acute disseminated encephalomyelitis. Int J Hematol 95: 692-696, 2012.
    3. Yamanaka K., Yoshimura N., Higuma T., and Ichida F.: Pseudoaneurysm following percutaneous balloon angioplasty for aortic arch recoarctation after the Norwood procedure. Gen Thorac Cardiovasc Surg 60: 305-307, 2012.
    4. Kanazawa Y., Asai M., Adachi Y., Yoshida T., Itazawa T., Shimao A., Inomata T., Abe H., and Watanabe Y.: Retropharyngeal abscess in a neonate: A case report and literature review. Int J Pediatr Otorhi 7: 115-118, 2012.
    5. Mohammadzadeh I., Yeganeh M., Aghamohammadi A., Parvaneh N., Behniafard N., Abolhassani H., Tabassomi F., Hemmat M., Kanegane H., Miyawaki T., Ohara O., and Rezaei N.: Severe primary antibody deficiency due to a novel mutation of micro heavy chain. J Investig Allergol Clin Immunol 22: 78-79, 2012.
    6. ”ÂàVŽõŽq, ’†’Ø‹v”T, ‹{@ˆêŽu, ŽíŽsq’ˆ, ‘«—§—Yˆê, a’JLŽq, ‹{˜e—˜’j: ”x‰Š‚ðŒ_‹@‚É‹}«ŒÄ‹z‹‡”—ÇŒóŒQ‚ÉŽŠ‚èAˆêŽ_‰»’‚‘f‹z“ü‚𓱓ü‚µ‚œ3—á. “ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽGŽ 23: 21-28, 2012.
    7. ¯–쌰G, ‹àŒ“O˜a, Œ“c’Œ“¿, –쑺ŒbŽq, ‘å‰ê³ˆê, ‹{˜e—˜’j: R‹Û–ò“Š—^‚É‚æ‚莡–ü‚µ“Ÿ‚œÄ”­«ŠÌ”^á‡‚ð‡•¹‚µ‚œ–«“÷‰èŽîÇ‚̈ê—á. ¬Ž™ŠŽõ–Ɖu 24: 175-179, 2012.
    8. “¹–ì~Žq, ’†oË‘ã, ²’|ˆÉ’ÃŽq, Œ–ìŽåáÁ, ˆÀ‘º@•q, –F‘º’ŒŽ÷, –쑺ŒbŽq, ‹àŒ“O˜a: dÇ•¡‡–Ɖu•s‘SÇ2—á‚É‚š‚¯‚铯Žíœ‘×–EˆÚAŒã‚̃LƒƒŠƒYƒ€‰ðÍ. “ú–{—AŒŒ×–EŽ¡—Êw‰ïŽ 58: 704-709, 2012.
  • ‘à
    1. Žs“c•™Žq: “ÁW@¬Ž™–«ŽŸŠ³‚̐¶ŠˆŽw“±?Å‹ß‚Ì’mŒ©‚©‚ç?@4. –«SŽŸŠ³ 3) S‹ØÇ. ¬Ž™‰È—Տ° 65: 709-717, 2012.
    2. Žs“c•™Žq: ¬læ“V«SŽŸŠ³‚Í’N‚ªf‚é‚Ì‚©`zŠÂŠí“à‰È‚Ə¬Ž™zŠÂŠí‰È‚̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“‚Ì•K—v«`. S‘Ÿ@4: 1-2, 2012.
    3. Žs“c•™Žq: ‘ål‚É‚È‚è‚ä‚­ŒN‚œ‚¿‚ց`æ“V«SŽŸŠ³‚̐_Œo”­’B—\Œã`. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ28: 293-294, 2012.
    4. Žs“c•™Žq: æ“V«SŽŸŠ³‚ÌŽüŽYŠúŠÇ—ƒAƒbƒvƒf[ƒg`æ“V«SŽŸŠ³‚ւ̃pƒŠƒrƒYƒ}ƒu“Š—^`. ŽüŽYŠúˆãŠw 10: 1349-1351, 2012.
    5. Žs“c•™Žq: Ž„‚̃‚ƒ`ƒx[ƒVƒ‡ƒ“ u‘f°‚炵‚¢’‡ŠÔ‚Æ‹€‚ÉŒ³‹C‚É‚È‚Á‚œŽq‚Ç‚à‚ª‚É‚Á‚±‚èÎ‚€uŠÔ‚ðŒ©‚é‚œ‚߂Ɂv@Fetal & Neonatal Medicine 4: 47-49, 2012.
    6. ‘«—§—Yˆê: ¬Ž™šb‘§Ž¡—Âɂš‚¯‚é‹z“üƒXƒeƒƒCƒh–òFV‚œ‚ÈŽg—p•û–@. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 26: 80-84, 2012.
    7. ‘«—§—Yˆê: ‹z“üƒXƒeƒƒCƒhÜ–òƒAƒhƒIƒ“‚̃|ƒCƒ“ƒg. ¬Ž™‰Èf—à 75: 1707-1712, 2012.
    8. ‘«—§—Yˆê: ‹z“üƒfƒoƒCƒXi‹z“üŠí?ƒXƒy[ƒT[j‚ÌŽí—Þ‚ÆŽg‚¢•û. šb‘§ 25: 153-157, 2012.
    9. ‘«—§—Yˆê, â–{—Ž—Y, à_è—Y•œ: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2012‚ɂ‚¢‚Ä -‹z“ü—Ö@FƒfƒoƒCƒX‚Æ‚»‚ÌŒø‰Ê“I‚ÈŽg‚¢•û-DƒAƒŒƒ‹ƒM[E–Ɖu 19: 730-737, 2012.
    10. ‘«—§—Yˆê, ‹Ž–{ŒõŽi: “Œ“ú–{‘åkÐ‚ƃAƒŒƒ‹ƒM[ŽŸŠ³FŽx‰‡Šˆ“®•ñ ”íÐŽ™‚Ö–hƒ_ƒj‚Ê‚¢‚®‚é‚Ý‚ð‘—‚éƒvƒƒWƒFƒNƒgDƒAƒŒƒ‹ƒM[E–Ɖu 19: 566-570, 2012.
    11. ‘«—§—Yˆê: ‰Æ’ë‚Ì’†‚ł̓Rƒ“ƒvƒ‰ƒCƒAƒ“ƒXH “ú–{¬Ž™“šb‘§?ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 10: 267-268, 2012.
    12. ‘«—§—Yˆê: ¬Ž™‚ðŽæ‚芪‚­”–â‘èFÐŠQŽž‚Ìšb‘§‚ð‚Í‚¶‚ß‚Æ‚·‚éƒAƒŒƒ‹ƒM[ŽŸŠ³‚ÌŽ¡—ÁEŠÇ—D AIR 11: 6-7, 2012.
    13. ‘«—§—Yˆê: ‰ïˆõ‚©‚çu‚ ‚܂肪‚ñ‚΂ç‚È‚¢‚Å‚­‚Ÿ‚³‚¢v. “ú–{¬Ž™‰Èˆã‰ï•ñ 57: 119-120, 2012.
    14. ‘«—§—Yˆê: •ÛˆçŠ‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[‘ΉžƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚Ä. ˆã•ñ‚Æ‚â‚Ü 1557: 10-11, 2012.
    15. ‹àŒ“O˜a: R‘ÌŽY¶•s‘SÇ‚É‚š‚¯‚é—Տ°ˆâ“`Šw. “ú–{ˆâ“`ƒJƒEƒ“ƒZƒŠƒ“ƒOŠw‰ïŽ 33: 55-61, 2012.
    16. ‹àŒ“O˜a: “ÁW@¬Ž™–«ŽŸŠ³‚̐¶ŠˆŽw“±?Å‹ß‚Ì’mŒ©‚©‚ç?@9. ŒŒ‰t?–ƉuŽŸŠ³ 3) ŒŽ”­«–Ɖu•s‘SÇ. ¬Ž™‰È—Տ° 65: 819-824, 2012.
    17. ‹àŒ“O˜a, ŽíŽsq’ˆ, ‹{˜e—˜’j: ’°ŠÇoŒŒ«‘å’°‹ÛO111‚̏W’c”­¶‚©‚çŠw‚ñ‚Ÿ‚±‚Æ. ¬Ž™ŠŽõ–Ɖu 24: 215-222, 2012.
    18. ‹àŒ“O˜a, –쑺ŒbŽq: ¬Ž™‚ª‚ñ‚̃g[ƒ^ƒ‹ƒPƒA‚ð‚ß‚Ž‚µ‚Ä. •xŽRŽsˆãŽt‰ï•ñ 490: 26-31, 2012.
    19. ”ÂàVŽõŽq: ƒAƒŒƒ‹ƒM[‘Š’kŽºQ&Au¬Ž™‰È@šb‘§‚ª‹^‚í‚ê‚œê‡A‘Šú‚ÉŽ¡—ÂðŠJŽn‚µ‚œ•û‚ªŽ©‘R—ð‚Í—Ç‚¢‚Å‚·‚©Hv@ƒAƒŒƒ‹ƒM[‚̗Տ° 32: 369, 2012.
    20. ŽíŽsq’ˆ: `ƒI[ƒo[ƒrƒ…[`•xŽREHEC/O111ƒAƒEƒgƒuƒŒƒCƒN‚©‚ç‚Ý‚œƒŠƒRƒ“ƒrƒiƒ“ƒgƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“»Ü‚É‚š‚¯‚é‰Â”\«. Thrombosis Medicine 2: 302-305, 2012.
    21. ”ª–ؐMˆê, ‹{@ˆêŽu: ŠO—ˆ¬Ž™‰È‚É‚š‚¯‚é”­’BáŠQ‚ւ̃Aƒvƒ[ƒ`. ŠO—ˆ¬Ž™‰È 15: 173-179, 2012.
    22. ¯–쌰G, ‹àŒ“O˜a: Ž©ŒÈ–ƉuƒŠƒ“ƒp‘BÇŒóŒQ. ¬Ž™“à‰È 44(‘): 236-237,@2012.
    23. Œè‘œç‘ã, ŒˆäŽOŽ}, Žs“c•™Žq: ACHD‚̐S—Šw“I“Á’¥‚ƐS—“IƒPƒA. Heart 12: 71-78, 2012.
    24. ‹ß“¡’ŒŽÀ, Ž›–{‹M‰p, Œˆä‰iŽq, ‰Á“¡‘Pˆê˜Y, Ôâ@“O, ÔàV@W, ˆÉ“¡_–Ÿ, ‘«—§—Yˆê, ¡ˆäF¬, ‘å–îKO, ŸÀr—Y, “ì•”Œõ•F, “¡àV—²•v, “ñ‘º¹Ž÷, Œˆä–Ò•F, ŽO‰YŽŽu, Xì‚Ý‚«: “Œ“ú–{‘åkÐFˆã—ÃŽx‰‡‚݂̍è•ûFƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž. “ú–{¬Ž™‰Èˆã‰ï•ñ 43: 57-62, 2012.
    25. ‹ß“¡’ŒŽÀ, Ž›–{‹M‰p, Œˆä‰iŽq, ‰Á“¡‘Pˆê˜Y, Ôâ@“O, ÔàV@W, ˆÉ“¡_–Ÿ, ‘«—§—Yˆê, ¡ˆäF¬, ‘å–îKO, ŸÀr—Y, “ì•”Œõ•F, “¡àV—²•v, “ñ‘º¹Ž÷, Œˆä–Ò•F, ŽO‰YŽŽu, Xì‚Ý‚«: “Œ“ú–{‘åkÐ‚ƃAƒŒƒ‹ƒM[ŽŸŠ³FŽx‰‡Šˆ“®•ñ “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï‚Æ‚µ‚Ä‚ÌŽæ‘g‚Ý. ƒAƒŒƒ‹ƒM[E–Ɖu 19: 572-576, 2012.
    26. ‹à’J‹v”üŽq, ‘«—§—Yˆê: ‰©»‚̏¬Ž™šb‘§‚É—^‚Š‚é‰e‹¿. ƒAƒŒƒ‹ƒM[‚̗Տ° 32: 996-1001, 2012.

  • 2012”NŠw‰ï•ñ
    1. Adachi Y.: Aproach to anaphylaxis and anaphylactic shock. Paediatric Asthma and Allergy Workshop in Myanmar. 2012, 1, 26-27, Yangon, Myanmar.
    2. Adachi Y.: Management of asthma: acute and long term. Paediatric Asthma and Allergy Workshop in Myanmar. 2012, 1, 26-27, Yangon, Myanmar.
    3. Adachi Y., Okabe Y., Itazawa T., Yoshida K., Ohya Y., Odajima H., Akasawa A., Miyawaki T.: Impact of rhinitis on asthma in Japanese children. American academy of Allergy Asthma & Immunology 2012 Annual meeting, 2012, 3, 2-6, Orlando, U.S.A.
    4. Kanegane H.: Lesson learned from Epstein-Barr virus. 2012 The Korean society of pediatrics infectious disease, 2012, 5, 20, Seoul. (Invited Lecture)
    5. Ichida F., Brunelli L., Bowles NE., Sakai N., Hamaoka A., and Yost HJ.: The scaffold adapter protein 14-3-3 is involved in human left ventricular noncompaction. 2012 Pediatric Academic Societies Annual Meeting, 2012, 4.28- 5.1, Boston, U.S.A.
    6. Miyawaki T., Kanegane H., Imai K., Yamada M., Takada H., Nonoyama S., Ariga T., Bexon M., Rojavin M., Kobayashi M., and Hara T.: Efficacy and safety of Hizentra, a subcutaneous immune globulin, in Japanese patients with primary immunodeficiency diseases. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    7. Kanegane H., Nomura K., Hoshino A.,and Miyawaki T.: Neutropenia and myeloid dysplasia in a patient with late-onset adenosine deaminase deficiency. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    8. Nishida N., Yang X., Kanegane H., Sanayama K., Goi K., Sugita K., Kato K., and Miyawaki T.: X-linked Dysgammaglobulinemia caused by hypomorphic XIAP mutation. The 15th Biennial Meeting of the European Society of Immunodeficiencies, 2012, 10, 3-6, Florence, Italy.
    9. Kanegane H.: X-linked dysgammaglobulin caused by hypomorphic XIAP mutation. A conference for medical research on X-linked lymphoproliferative disease 2012, 2012, 10, 8, London.
    10. Kanegane H., Yang X., Nishida N., Ishii E., and Miyawaki T.: Clinical features and outcome of X-linked lymphoproliferative syndrome type 1 (SAP deficiency) and type2 (XIAP deficiency) in Japan. 28th Annual meeting of the Histiocyte society, 2012, 10, 10-12, London.
    11. Yoshida T., Takasaki I., Kanegane H., Inomata S., Ito Y., Tamura K., Makimoto M., Saito S., and Miyawaki T.: Gene expression profiling in umbilical cord blood from small for gestational age neonates indicates prediction of adult diseases. The 3rd International Congress of Union of European Neonatal & Perinatal Societies, 2012, 11, 14-17, Porto, Portugal.
    12. Tamura K, Igarashi N., Futatani T., Yoshida T., and Miyawaki T.: Hypernatremia and body weight loss in exclusively breast-fed neonates. The 3rd International Congress of Union of European Neonatal & Perinatal Societies, 2012, 11, 14-17, Porto, Portugal.
    13. Ichida F., Chang B, Gorbea C., Lezin G., Sakai N., Kogaki S., Otomo T., Okinaga T., Hata Y., Nishida N., Yost J., Bowles NE., and Brunelli L.: 14-3-3ƒÃ gene variants in left ventricular noncompaction and hypoplasia of the corpus callosum. The 85th Scientific sessions of AHA 2012, 2012, 11, 16-20, Los Angels, U.S.A.
    14. Hashimoto I., Nakagawa H., Shibata K., Kaneda, H. Saito K., Watanabe K., Ozawa S. Ichida F., and Yoshimura N.: Complementary relationship of right ventricular contraction between longitudinal and radial directions. The 85th Scientific sessions of AHA 2012, 2012, 11, 16-20, Los Angels, U.S.A.
    15. —k@žF, ‹àŒ“O˜a, ‹{˜e—˜’j, Zhao X., Jiang L.: A boy with recurrent skin abcess and respiratory tract infection: a novel immunodeficiency? . ‘æ5‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï, 2012, 1, 21, “Œ‹ž.
    16. ¯–쌰G, ‹àŒ“O˜a, ‘å’ØŒc•ã, Œ‘q—TŠì, ‹{˜e—˜’j: œ‘ˆÚAŒã‚ɐt‘gD‚̉ü‘P‚ð”F‚ß‚œX˜Aœ«ŒŒ¬”ÂŒž­Ç‡IgAtÇ‚̈ê—á. ‘æ5‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï, 2012, 1, 21, “Œ‹ž.
    17. ¯–쌰G, “¡“cË‰›, –쑺ŒbŽq, ‹àŒ“O˜a, ‘å’ØŒc•ã, ‹{˜e—˜’j, ÎàV@L, ã–ì@–õ: —‘‘ƒŒŽ”­PNET‚Ì‚P—á. ‘æ35‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï, 2012, 2, 4, ‹à‘ò.
    18. ¯–쌰G, “n•Ó—S‹I, –xìT“ñ˜Y, ‹àŒ“O˜a, ‹{˜e—˜’j, X@‰ë—º: ƒŒƒCƒm[Œ»Û‚Ì‚Ý‚ª‘J‰„‚µ‚Ä‚¢‚鍬‡«Œ‹‡D•a‚Ì‚P—á. ‘æ35‰ñ–k—€¬Ž™ƒŠƒEƒ}ƒ`Œ€‹†‰ï, 2012, 2, 18, ‹à‘ò.
    19. ‹àŒ“O˜a, ˜`@˜a”ü, ˆäã‰ë”ü, •l–{˜aŽq, ¬—ѐçŒb, ×–숟Žq, ˆÉ“¡”\Ž, ’†‘ò—mŽO, ÆˆäŒN“T, Žqì˜aG, ÎˆäžÄˆê, ‹{˜e—˜’j: X˜AœƒŠƒ“ƒp‘BÇŒóŒQƒ^ƒCƒv1(SAPŒ‡‘¹Ç)‚ɑ΂·‚é‘¢ŒŒŠ²×–EˆÚA. ‘æ34‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2012, 2, 24-25, ‘åã.
    20. –쑺ŒbŽq, ŽíŽsq’ˆ, ‹àŒ“O˜a, —L‰ê@³, ‹{˜e—˜’j: œ‘”ñ”j‰ó“I‘Oˆ’u‚É‚ÄHLAˆê’v“¯–E‚æ‚蓯Žíœ‘ˆÚA‚ðs‚Á‚œ’x”­Œ^ADAŒ‡‘¹Ç‚Ì1—á. ‘æ34‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2012, 2, 24-25, ‘åã.
    21. ŽíŽsq’ˆ, ‹{˜e—˜’j: ’ጌ“œš‡Œã‚Ɉӎ¯áŠQA‹Ø—͒ቺ‚̍ĔR‚ð”F‚ß‚œÛHáŠQ‚Ì1—á. ‘æ39‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï, 2012, 2.28-3.1, ç—t.
    22. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹ÛO-111W’cŠŽõ‚̗Տ°‘œ. ‘æ51‰ñŠŽõ«’°‰ŠŒ€‹†‰ï, 2012, 3, 10, “Œ‹ž.
    23. —k@žF, Œ“c’Œ“¿, ‹{˜e—˜’j, ‹àŒ“O˜a, ˜a“c‘׎O, ’J“à]ºG, ¡—¯Œªˆê, “¡ŒŽ¬‰x: Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-assosiated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2. ‘æ21‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï, 2012, 3, 17, “Œ‹ž.
    24. ¯–쌰G, –x]’åŽu, ‘å’ØŒc•ã, ŽíŽsq’ˆ, ‹àŒ“O˜a, ‹{˜e—˜’j: ŠÌŽî‘åAŠÌ‹@”\áŠQ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œŠÌŒ^“œŒŽ•a‚Ì1—á. ‘æ304‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2012, 3, 11, ‹à‘ò.
    25. ŽíŽsq’ˆ, –x]’åŽu, –쑺ŒbŽq, ‹àŒ“O˜a, ¬Œ“¹—Y, ŽR“cŒbŽq, ‘Ÿ“c–M—Y, ’J“à]ºG, ˜ZŽÔ@’, ‹{˜e—˜’j:’°ŠÇoŒŒ«‘å’°‹ÛO-111W’cŠŽõ‚É‚š‚¯‚é‹}«”]Ç‚̃AƒEƒgƒuƒŒƒCƒN‘Ήž. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    26. ‘«—§—zŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’q_: “û—cŽ™‚Ì‹C“¹ˆÙ•šŽ–ŒÌ‚ð—\–h‚·‚é‚œ‚ß‚Ì•ÛŒ’Žt‚É‚æ‚éŽw“±‚ÉŠÖ‚·‚é’²ž. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    27. —k@žF, Œ“c’Œ“¿,‹àŒ“O˜a, ‹{˜e—˜’j: ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    28. ’‡‰ª²’qŽq, “c’†•ü”ü, ’‡‰ª‰pK, ”ÂàVŽõŽq, ŽÄ“c@K, ’ÔŠáÁˆê, ‹{˜e—˜’j: ‹}«ƒoƒ‹ƒvƒŽ_’†“łɑ΂µL-ƒJƒ‹ƒjƒ`ƒ““Š—^‚ðs‚Á‚œ‚PÎ’jŽ™—á. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    29. ‰ª•”^Žq, “c’†•ü”ü, –x]’åŽu, ‹{@ˆêŽu, ‹g“cär, “ñ’J@•, ‹{˜e—˜’j: “–‰@‚ÅŒoŒ±‚µ‚œƒVƒgƒŠƒ“Œ‡‘¹Ç‚Ì2—á. ‘æ115‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2012, 4, 20-22, •Ÿ‰ª.
    30. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚̗Տ°v. ‘æ48‰ñH“cŒ§zŠÂŠíŽŸŠ³Ž¡—ÃŒ€‹†‰ï, 2012, 5, 11, H“c.
    31. ”óŒû@Žû, ŽíŽsq’ˆ, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‹C“¹ˆÙ•š‚ɑ΂·‚é•ÛŒìŽÒ‚Ì”FŽ¯‚ÆŽ–ŒÌ—\–h‚Ì‚œ‚ß‚Ì•ÛŒ’Žw“±‚ÉŠÖ‚·‚é’²ž. ‘æ13‰ñ–k—€¬Ž™‹~‹}?W’†Ž¡—ÃŒ€‹†‰ï, 2012, 5, 12, ‹à‘ò.
    32. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‚É‚š‚¯‚éã‹C“¹E‰º‹C“¹‰ŠÇFŽ¡—Â̍l‚Š•ûv ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    33. ‘«—§—YˆêDƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“‚ÉŠî‚¢‚œŽ¡—ÁFƒKƒCƒhƒ‰ƒCƒ“‚Ì”äŠrv ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    34. ”ÂàVŽõŽq, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒoŒû•‰‰×ŽŽŒ±‚ŃAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð’悵‚œ—‘ƒAƒŒƒ‹ƒM[‚ɑ΂µ‚Ä‹}‘¬ŒoŒû–Ɖu—Ö@‚𓱓ü‚µ‚œˆê—á. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    35. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‹{˜e—˜’j: —cŽ™‚É‚š‚¯‚é”ì–ž‚Æšb‘§‚ÌŠÖŒW‚É‚š‚¯‚é‹@˜‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    36. ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”öã—mˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: Ž…‹›ìŽs‚É‚š‚¯‚é10”NŠÔ‚̏¬Ž™‹CŠÇŽxšb‘§“ü‰@Š³ŽÒ‚̐„ˆÚ?ƒNƒ‰ƒXƒ^[•ªÍ‚ð—p‚¢‚œƒvƒƒtƒ@ƒCƒ‹‰ðÍ‚ɂ‚¢‚Ä?. ‘æ24‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2012, 5, 12-13, ‘åã.
    37. ‹{@ˆêŽu, “c’†•ü”ü, X@Žõ, ‹{˜e—˜’j: ”­”M‚ðŒ_‹@‚ɍs“®ˆÙí‚ª‘ˆ«‚µARNMDAŽó—e‘̍R‘Ì‚ª—z«‚Å‚ ‚Á‚œL”Đ«”­’BáŠQ‚̈ê—á. ‘æ54‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2012, 5, 17-19, ŽD–y.
    38. “c’†•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j: ƒXƒeƒƒCƒh’ïR«‘SgŒ^dÇ‹Ø–³—͏ǂɑ΂µ‚ă^ƒNƒƒŠƒ€ƒX‚𓱓ü‚µ‚œ‚P—á. ‘æ54‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2012, 5, 17-19, ŽD–y.
    39. —k@žF, ‹àŒ“O˜a, Œ“c’Œ“¿, ‹{˜e—˜’j, ¯‰Á«Œá, ‰Á“¡•¶‘ã, ™ŒŽ–΍F, “àŠƒˆÀŽq: Ž©ŒÈ–Ɖu«—nŒŒ«•nŒŒ‚ð‡•¹‚µ‚œV¶Ž™”­Ç“œ”A•a‚Ì1 —á. ‘æ33‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2012, 5, 24, •xŽR.
    40. ‘«—§—Yˆê: JPGL2012 ‰ü’ù‚Ì—v“_F’·ŠúŠÇ—. ‘æ4‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[ŽŸŠ³ƒtƒH[ƒ‰ƒ€, 2012, 6, 2, ‹ž“s.
    41. “c’†•ü”ü, ‹{@ˆêŽu, ‘ŠJË•œ, â“c“ޏ, ”óŒû@Žû, ”ÂàVŽõŽq, ‹{˜e—˜’j: WestÇŒóŒQ”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œMenkes•a‚Ì1—á. ‘æ305‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2012, 6, 10, •Ÿˆä.
    42. ”ÂàVŽõŽq, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ì•aŒ^‚Æšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘ԁAŒÄ‹z‹@”\‚ÌŠÖŒW. ‘æ29‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2012, 6, 14-15, ‘åã.
    43. ’†—ÑŒºˆê, “c‘ºŒ«‘Ÿ˜Y, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: H•šƒAƒŒƒ‹ƒM[‚Æ‚µ‚Ä‘œ•i–ڂ̐H•š‚ð’·Šú‚ɏœ‹Ž‚³‚ê‚Ä‚¢‚œSˆö«šq“f‚̈ꏗŽ™—á. ‘æ29‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2012, 6, 14-15, ‘åã.
    44. ŽíŽsq’ˆ: ¬Ž™‚É‚š‚¯‚éEHEC O111W’cŠŽõ‘Ήž`‹Ù‹}ƒ[ƒŠƒ“ƒOƒŠƒXƒg‚ƍLˆæ”À‘—`. ‘æ20‰ñ“ú–{W’†Ž¡—ÈãŠw‰ï“ŒŠC–k—€’n•û‰ïƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“‡T, 2012, 6, 23, •xŽR.
    45. Œ‘q—TŠì, ‚è–ƒ”ü, ‹{˜e—˜•v, ‘Šì@Œú: ¶‘̐t‘ŸˆÚA‚W”NŒã‚É“Ë‘R‚Ì’`”’”A‚ð”F‚ß‚œˆê—á. ‘æ47‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ïŠwpW‰ï, 2012, 6, 29-30, “Œ‹ž.
    46. ‹{”ö¬–Ÿ, ¯–쌰G, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, Ž…³Ž÷: Chronic recurrent multifocal osteomyelitis (CRMO) ‚Ƃ̊ӕʐf’f‚ð—v‚µ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì’jŽ™—á. –k—€¬Ž™ŒŒ‰t§˜b‰ï, 2012, 6, 30, ‹à‘ò.
    47. ꎓ¡@—I, ¬‰Y@Ž, ”óŒû@Žû, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: “î•”‘gDˆ««ŽîᇂƂ̊ӕʂɋꗶ‚µ‚œ‹ØüˆÛŽîÇimyofibromatosisj‚Ì‚P—á. ‘æ28‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2012, 7, 1, •xŽR.
    48. “n•Óˆê—m, ’‡‰ª‰pK, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷: ƒtƒ@ƒ[Žl’¥ÇpŒãŠ³ŽÒ‚̍¶Žº‹@”\áŠQ ?QRSŽžŠÔ‰„’·‚ª‚µ‚ß‚·‚à‚Ì-. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    49. âV“¡˜a—R, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷, ˆÀ‘º@•q, Š£‚ ‚â‚Ì, “¡àV’m—Y: ƒtƒHƒ“ƒ^ƒ“pŒãŒo‰ß‚É”º‚€ŠÌ‘@ˆÛ‰»ƒ}[ƒJ[‚̕ω»‚ÆŽ¡—Ẩ”\«. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    50. ’‡‰ª‰pK, “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷: 64—ñMDCT‚ð—p‚¢‚œSŽº“à\‘¢•]‰¿. ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    51. Žs“c•™Žq: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u‚à‚€‚·‚®‘ål‚ɂȂ邱‚Ç‚à‚œ‚¿‚ցv ‘æ48‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2012, 7, 5-7, ‹ž“s.
    52. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u‹z“ü—Ö@‚̃sƒbƒgƒtƒH[ƒ‹‚ðl‚Š‚é ?¬Ž™-v. ‘æ35‰ñ‹z“ü—Ö@Œ€‹†‰ï, 2012, 7, 14, “Œ‹ž.
    53. ’†—ÑŒºˆê, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, •£àV—³–ç, ‰ª•””üŒb, ŽRŒ³ƒŽq, ˆÉ“Œ“¹•v, ”öã—mˆê, ‘«—§—zŽq, ‚”ö@Š², ‘ºãIŒ[, Œ–쐳’m, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚Ì‹z“ü—Ö@‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÆŽÀŽ{ó‹µ‚ÉŠÖ‚·‚é’²ž. ‘æ35‰ñ‹z“ü—Ö@Œ€‹†‰ï, 2012, 7, 14, “Œ‹ž.
    54. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€ušb‘§Ž¡—ÂɎc‚³‚ê‚œ‰Û‘èF¬Ž™šb‘§‚Ì”­Ç‹@˜v. ‘æ32‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX, 2012, 7, 28-29, ‹ž“s.
    55. ‘«—§—Yˆê: “Á•Êu‰‰u¬Ž™šb‘§‚É‚š‚¯‚éƒtƒFƒmƒ^ƒCƒvv. ‘æ40‰ñŒ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2012, 8, 19-20, •Ÿ‰ª.
    56. ’ށ@_”V, ‹{˜e—˜’j, –xìT“ñ˜Y, ‘å“Ž—R‹IŽq, “ˆ”öˆ»Žq, –q–{—D”ü, ‹g“cär: NO‹z“ü—Ö@‚ª’˜Œø‚µ‚œ’Ž’áo¶‘̏dŽ™‚Ì2—á. ‘æ48‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2012, 8, 26, •Ÿˆä.
    57. Žs“c•™Žq: “Á•Êu‰‰uV¶Ž™ŠJSpŒã‚̍‚ŽŸ”]‹@”\áŠQv “ú–{¬Ž™–ƒŒŠw‰ï‘æ18‰ñŠwpW‰ï, 2012, 9, 2, “È–Ø.
    58. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚̗Տ°v ‘æ6‰ñŽ­Ž™“‡¬Ž™zŠÂŠíŒ€‹†‰ï, 2012, 9, 8, Ž­Ž™“‡.
    59. ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‰uŠwŒ€‹†‚©‚ç‚Ý‚œOne Airway One disease‚ɂ‚¢‚Ä. ‘æ15‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2012, 9, 8, •xŽR.
    60. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ”óŒû@Žû, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚鏜‹ŽH‘Ήž‚ÌŽÀ‘Ô. ?•œ¬13”NA18”N“x’²ž‚Æ‚Ì”äŠr- ‘æ15‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2012, 9, 8, •xŽR.
    61. ’‡‰ª‰pK, ‘ŠJË•œ, âV“¡˜a—R, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j: Lamin A/C ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œ”ñ•ŸŽRŒ^ƒƒƒVƒ“—z«‹ØƒWƒXƒgƒƒtƒB[‚̈ê—á. ‘æ40‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï, 2012, 9, 8, ‹à‘ò.
    62. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€u‚È‚Å‚µ‚±ƒVƒ“ƒ|ƒWƒEƒ€ ?—«Œ€‹†ŽÒŽx‰‡‚ðl‚Š‚é?v. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    63. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢•]‰¿•û–@FŒÄ‹CNOAIOSA‹C“¹‰ß•q«‚ɂ‚¢‚Ä?v. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    64. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€ušb‘§ƒKƒCƒhƒ‰ƒCƒ“ world-wideF¬Ž™šb‘§ƒKƒCƒhƒ‰ƒCƒ“‚̍‘Û”äŠrv. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    65. ‘«—§—Yˆê, ˆäãšæ–Î, ‰ºð’ŒŽ÷, –]ŒŽ”Ž”V: “û—cŽ™šb‘§‚É‚š‚¯‚éƒuƒfƒ\ƒjƒh‹z“ü—pŒœ‘÷‰t“±“üŽž‚ɃvƒƒJƒeƒ[ƒ‹‰–Ž_‰–…˜a•š‹z“ü‰t‚Ƃ̍¬‡‰t‚ð‹z“ü‚·‚邱‚Æ‚Ì—L—p«‚ƈÀ‘S«‚ÌŒŸ“¢. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    66. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‚‹Ž@–L, ŽO‰YŽŽu, ŠC˜VàVŒ³G, ãŒŽ—R”üŽq, ˆÉ“¡_–Ÿ, ‹T“c@œ, Šì‘œ“c“N˜N, “í–Ú˜a‘ã, Žè’ˏƒˆê˜Y: ‘S‘‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[‚ɑ΂·‚éŒoŒûH•š•‰‰×ŽŽŒ±‚ÌŽÀ‘Ô’²ž. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    67. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ”óŒû@Žû, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚鏜‹ŽH‘Ήž‚ɂ‚¢‚Ä‚Ì’²ž. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    68. ’†—ÑŒºˆê, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, •£àV—³–ç, ŽRŒ³ƒŽq, ã–ì—zŽq, ˆÉ“¡“¹•v, ”öã—mˆê, ‚”ö@Š², ‘ºãIŒ[, Œ–쐳’m, ŒÜ\—’—²•v, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚È‚ç‚Ñ‚É‚»‚̉Ƒ°‚É‚š‚¯‚é‹z“üŽè‹Z‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²ž. ‘æ49‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï@2012, 9, 15-16, ‘åã.
    69. ¯–쌰G, ‹{”ö¬–Ÿ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ×ì@•à, ‰ª“cˆÀO, ŽRè@“O, âV“¡Ÿ•F: Žá”N«‘å’°‚ª‚ñ‚̈ê—á. ‘æ36‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï, 2012, 9, 15, ‹à‘ò.
    70. Žs“c•™Žq: ƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[uS‹Øãk–§‰»áŠQ‚̐f—Áv ‘æ60‰ñ“ú–{S‘Ÿ•aŠw‰ï,@2012, 9, 16, ‹à‘ò.
    71. ¯–쌰G, ‹àŒ“O˜a, ‘哈—E¬, ÎŠ_ŒiŽq, Š}ˆä³Žu, ¯ŽiNŠ°, ‹g“c@^, ‹à“c@áÁ, Ž›ˆä@Ÿ, ¡ˆäk•ã, X”ö—FG, ‹{˜e—˜’j: dÇ–Ɖu•s‘SÇ‚É‚š‚¯‚éƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚Æ‹C‹¹‚ɂ‚¢‚Ä. ‘æ3‰ñŠÖ“Œb‰z–Ɖu•s‘SÇŒ€‹†‰ï, 2012, 9, 22, “Œ‹ž.
    72. ”ÂàVŽõŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Žk, –F‘º’ŒŽ÷: ECMO‰º‚Å‚Ì‹C“¹ˆÙ•š“Eop‚É‚æ‚è‹~–œ‚µ“Ÿ‚œ‹CŠÇŽxˆÙ•š‚̈ꏗŽ™—á. ‘æ45‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2012, 9, 28-29, ˆ®ì.
    73. ‘«—§—zŽq, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: •xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚é‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚Ì‚œ‚ß‚ÌŽæ‚è‘g‚Ý‚ÌŒ»ó. ‘æ45‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2012, 9, 28-29, ˆ®ì.
    74. ”ÂàVŽõŽq, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ì•aŒ^•Ê‚̏dÇ“x‚Æšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘ԁAŒÄ‹z‹@”\‚ÌŠÖŒW. ‘æ20‰ñ—Տ°šb‘§Œ€‹†‰ï, 2012, 10, 6, ‹à‘ò.
    75. ŽíŽsq’ˆ:•xŽRŒ§‚É‚š‚¯‚éEHEC O111W’cŠŽõŽ–—á`—Տ°‚©‚ç‚ÌŽ‹“_`D‘æ95‰ñ“ú–{×‹ÛŠw‰ïŠÖ“ŒŽx•”‘‰ï, 2012, 10, 12, “Œ‹ž.
    76. Œ‘q—TŠì, –쑺ŒbŽq, ‹àŒ“O˜a: •ÐtŒŽ”­WilmsŽîᇑS“Eop‚É‚æ‚è‰i‘±“It’uŠ·—Ö@‚ð—v‚µA¬”]‚ɈُŠ«ÎŠD‰»‚ð”F‚ß‚œ—Ž™—á. ‘æ65‰ñÏ¶‰ïŠw‰ï, 2012, 10, 13-14, ‹ž“s.
    77. ‘«—§—Yˆê: “Á•Êu‰‰uÅV‚̏¬Ž™šb‘§‚Ì‚Ý‚©‚œ -•@Çó‚Æ‚ÌŠÖŒW‚ðŠÜ‚ß-v. ‘æ190‰ñ•ºŒÉŒ§Žš•@ˆôA‰Èˆã‰ï—Տ°§˜b‰ï, 2012, 10, 14, _ŒË.
    78. Nomura K., Hoshino A., Kanegane H., and Miyawaki T.: Neutropenia and myeloid dysplasia in a patient with late-onset adenosine deaminase deficiency. ‘æ74‰ñ“ú–{ŒŒ‰tŠw‰ïŠwpW‰ï, 2012, 10, 19-21, ‹ž“s.
    79. ‹{”ö¬–Ÿ, ’ށ@_”V, ‹{˜e—˜’j, –xìT“ñ˜Y, ìè—TŽq, “ˆ”öˆ»Žq, –q–{—D”ü, ‹g“cär: DŽ_‹…‘‘œÇ‚ð‡•¹‚µ‚œdÇTAM‚̈ê—á. ‘æ26‰ñ–k—€ŽüŽYŠú?V¶Ž™Œ€‹†‰ï, 2012, 10, 21, ‹à‘ò.
    80. ‹Ž–{ˆè•v, ŽÄ“c@K, ’†ì—TN, ã–ì—zŽq, ‹à“c@®, –쑺‰ÀO, œA–ìŒbˆê, Žs“c•™Žq: ˆÉ“¡”’”Á‚ɍ‡•¹‚µ‚œSŽº’†ŠuŒ‡‘¹Ç‚ªpŒãŠg’£Œ^S‹ØÇ‚ɐi“W‚µ‚œ’jŽ™—á. ‘æ21‰ñ“ú–{S‹ØÇŽŸŠ³Šw‰ïŠwpW‰ï, 2012, 10, 26, “Œ‹ž.
    81. Žs“c•™Žq: “Á•Êu‰‰uæ“V«SŽŸŠ³‚É‚š‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŒø‰Ê`ƒtƒHƒ“ƒ^ƒ“zŠÂ‚𒆐S‚Ɂ`v ‘åã¬Ž™‚o‚gƒtƒH[ƒ‰ƒ€, 2012, 11, 10, ‘åã.
    82. ‹àŒ“O˜a: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™ŒŒ‰t?Žîᇈã‚É’m‚Á‚Ä‚à‚ç‚¢‚œ‚¢–Ɖu•s‘SÇv ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 27, ‘O‹Ž.
    83. ‘«—§—Yˆê: ê–åˆã§“xŒöŠJ“¢˜_‰ïF–]‚Ü‚µ‚¢ê–åˆã‚ð–ÚŽw‚µ‚Ä ?¬Ž™‰ÈŒ€C‚ɂ‚¢‚Ä-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    84. ”ÂàVŽõŽq, ”óŒû@Žû, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚̃AƒŒƒ‹ƒM[«•@‰ŠÇó‚ƌċz‹@”\‚ÌŠÖŒW‚É‚š‚¯‚é’·ŠúŠÇ—–ò‚̉e‹¿-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    85. ”óŒû@Žû, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‹{˜e—˜’j: —cŽ™‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[«•@‰Š‚Ìšb‘§Çó‚ւ̉e‹¿-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    86. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‹g“cKˆê, ÔàV@W, ‹{˜e—˜’j: “ú–{‚̏¬Šw¶‚É‚š‚¯‚錌Žƒrƒ^ƒ~ƒ“D’l‚ƃAƒŒƒ‹ƒM[ŽŸŠ³—L•a—Š‚ÌŠÖ˜A«-. ‘æ62‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2012, 11.29-12.1, ‘åã.
    87. Žs“c•™Žq: “Á•Êu‰‰uƒtƒHƒ“ƒ^ƒ“zŠÂ‚É‚š‚¯‚é”xŒŒŠÇŠg’£–ò‚ÌŽ¡—ÃŒø‰Ê.v ‘æ6‰ñç—tæ“V«SŽŸŠ³PAHŒ€‹†‰ï, 2012, 11, 27, ç—t.
    88. ¯–쌰G, ‹àŒ“O˜a, Yang X., ’†”ö•ü•œ, ‰Á“¡Œ[•ã, “¡ŽR@‘, ‚‹ŽŠ°‹g, ¡‘ºr•F, ÎˆäžÄˆê, ‹{˜e—˜’j: ŽŸŽq‚Ì”­Ç‚ðŒ_‹@‚Ɉâ“`Žqf’f‚ÅŽ€ˆö‚ÌŠm’肵‚œ‰Æ‘°«ŒŒ‹…æÐH«ƒŠƒ“ƒp‘gD‹…Ç‚Ì2—á. ‘æ54‰ñ“ú–{¬Ž™ŒŒ‰tE‚ª‚ñŠw‰ï, 2012, 11.30-12.2, ‰¡•l.
    89. ¯–쌰G, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ŽR“c•ü”ü, ŽR˜H˜aF, –x@šæ¬, ’ßàV³m: Ä”­ALL‚ɑ΂·‚é”ñŒŒ‰ŽÒŠÔ“¯ŽíˆÚAŒã‚É‘å‘ڍœ’P“ƍĔ­‚ð‚«‚œ‚µ‚œˆê—á. ‘æ54‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2012, 11.30-12.2, ‰¡•l.
    90. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚š‚¯‚錌’†ƒrƒ^ƒ~ƒ“D”Z“x‚ƃAƒŒƒ‹ƒM[ŽŸŠ³—LÇ—Š‚ÌŠÖŒW. ‘æ39‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2012, 12, 15, ‹à‘ò.

    2011”N

  • ’˜‘
    1. Žs“c•™Žq: SŽŸŠ³‚ð‚à‚ÂŽ™“¶E¶“k‚ÌŠwZŠÇ—‰º‚ł̈µ‚¢•û@w¡“ú‚ÌŽ¡—ÃŽwjx2011@ŽRŒû@“O‘Œ•ÒAˆãŠw‘‰@, “Œ‹ž, 1174-1177, 2011.
    2. Žs“c•™Žq: ¬Ž™S•s‘S‚ƈâ“`ŽŸŠ³@wS‘ŸˆÚAxŒ“c@ôŠÄC, “ú–{S‘ŸˆÚAŒ€‹†‰ï•Ò, ƒVƒ…ƒvƒŠƒ“ƒK[EƒWƒƒƒpƒ“, “Œ‹ž, 393-397, 2011.
    3. ‘«—§—Yˆê: ‚¢‚šb‘§‚Ɛf’f‚·‚é‚Ì‚Å‚·‚©D¬Ž™“à‰È•Êûu¬Ž™‚̐f—Â̂µ‚©‚œvŒÜ\—’—²•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 495-497, 2011.
    4. ‘«—§—Yˆê: “û—cŽ™‚Ì‹z“üƒXƒeƒƒCƒhiICSj‚Ì“K³Žg—p‚ɂ‚¢‚Ä‹³‚Š‚ĉº‚³‚¢.u¬Ž™šb‘§‚Ì‚±‚±‚ª’m‚è‚œ‚¢ Q&AvŸÀr—Y•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 49-51, 2011.
    5. ‘«—§—Yˆê: šb‘§‚Ì”­ÇˆöŽq‚Æ‘ˆ«ˆöŽqDu30th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@2010”N‚É‚š‚¯‚é‹CŠÇŽxšb‘§‚Ì‘S‚āv‘«—§@–ž, XìºœA, HŽRˆê’j, ‘å“c@Œ’, “Œ“c—L’q•Ò, ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å, “Œ‹ž, 23-28, 2011.
    6. ‹àŒ“O˜a: ˆÕŠŽõA–Ɖu•s‘S. ¬Ž™‰È—Տ°ƒsƒNƒVƒXuÇó•ÊŒŸž‚Ì‘I‚Ñ•û?i‚ß•ûvŒÜ\—’—²‘•ÒW, ’†ŽR‘“X, “Œ‹ž, 112-115, 2011.
    7. ‹àŒ“O˜a: Shwachman-DiamondÇŒóŒQ. “ú–{—ÕକʍûuäX‘ŸÇŒóŒQ@‚»‚Ì‘Œ‚ÌäX‘ŸŽŸŠ³‚ðŠÜ‚߂āv”’’¹ŒhŽq•ÒW, “ú–{—Õà¬, ‘åã, 65-68, 2011.
    8. ‹àŒ“O˜a: æ“V«–Ɖu•s‘SÇ. uŒŒ‰tê–åˆãƒeƒLƒXƒgv“ú–{ŒŒ‰tŠw‰ï•ÒW, “ì]“°, “Œ‹ž, 340-343, 2011.
    9. ‹àŒ“O˜a, ‘å’ØŒc•ã, –쑺ŒbŽq: –Ɖu•s‘SŠÖ˜AƒŠƒ“ƒp‘B«ŽŸŠ³. u¬Ž™‚ª‚ñf—Ãnƒ“ƒhƒuƒbƒNv–x•”ŒhŽO•Ò, ˆã–òƒWƒƒ[ƒiƒ‹ŽÐ, ‘åã, 414-419,@2011.
    10. ”ÂàVŽõŽq: ‰Æ‘°‚⊳Ž™‚Ö‚ÌICS‚Ìà–Ÿ‚ɂ‚¢‚Ä‹³‚Š‚ĉº‚³‚¢Du¬Ž™šb‘§‚Ì‚±‚±‚ª’m‚è‚œ‚¢ Q&AvDŸÀr—Y•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 64-68, 2011.
    11. œA–ìŒbˆê, Žs“c•™Žq: EBM‚ÉŠî‚ž‚­“«ìè•a‚ÌŽ¡—Ð헪FƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—ÂƂ»‚̃ƒJƒjƒYƒ€wEBM¬Ž™ŽŸŠ³‚ÌŽ¡—ÁxŒÜ\—’—²ŠÄC, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 154-157, 2011.
    12. “n•Óˆê—m, Žs“c•™Žq: wƒi[ƒX‚̏¬Ž™‰ÈŠwx²’n@•×‘Œ•Ò, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 384-387, 2011.
    13. “n•Óˆê—m, Žs“c•™Žq: –[Žº’†ŠuŒ‡‘¹Ç@w‚±‚Ç‚àƒPƒA10.11ŒŽ†x“ú‘Œ€, –ŒŒÃ‰®, 34-37, 2011.
    14. ”óŒû@Žû, ‘«—§—Yˆê: ‹C“¹ˆÙ•šDu‚±‚Ç‚à‚ÌŠPšu f’fƒKƒCƒhƒuƒbƒNvƒjƒ…[ƒƒyƒvƒ^ƒCƒhŒ€‹†‰ï•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 83-85, 2011.
    15. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ŠPšuAšb–A”x‰¹‚ُ̈í. ¬Ž™‰È—Տ°ƒsƒNƒVƒX24uÇó•ÊŒŸž‚Ì‘I‚Ñ•û?i‚ß•ûvŒÜ\—’—²‘•ÒW, ’†ŽR‘“X, “Œ‹ž, 92-95, 2011.
    16. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ŒÄ‹zŠí‚ÉŠÖ‚·‚éfŽ@i–âfAŽ‹fA’®fj‚Å’ˆÓ‚·‚é“_‚Í‚È‚ñ‚Å‚·‚©. ¬Ž™“à‰È•Êûu¬Ž™‚̐f—Â̂µ‚©‚œvŒÜ\—’—²•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 129-131, 2011.
    17. ¬àVˆ»‰À, Žs“c•™Žq: zŠÂŠíŽŸŠ³@æ“V«SŽŸŠ³Aw¬Ž™—Տ°‰h—{ŠwxŽ™‹Ê_Žq‘Œ•Ò, f’f‚ÆŽ¡—ÃŽÐ, “Œ‹ž, 294-298, 2011.
  • ŒŽ’˜
    1. Nomura K., Kanegane H., Otsubo K., Wakiguchi H., Noda Y., Kasahara Y., and Miyawaki T.: Autoimmune lymphoproliferative syndrome mimicking chronic active Epstein-Barr virus infection. Int J Hematol 93: 760-764, 2011.
    2. Okabe Y., Itazawa T., Adachi Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of overweight with asthma symptoms in Japanese school children. Pediatr Int 53: 192-198, 2011.
    3. Ito Y., Adachi Y., Itazawa T., Okabe Y., Adachi YS., Higuchi O., Katsumuma T., and Miyawaki T.: Association between the results of the childhood asthma control test and objective parameters in asthmatic children. J Asthma 48: 1076-1080, 2011.
    4. Otsubo K., Kanegane H., Kamachi Y., Kobayashi I., Tsuge I., Imaizumi M., Sasahara Y., Hayakawa A., Nozu K., Iijima K., Ito S., Horikawa R., Nagai Y., Takatsu K., Mori H., Ochs H.D., and Miyawaki T.: Identification of FOXP3-negative regulatory T-like(CD4+CD25+CD127low) cells in patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Clin Immunol 141: 111-120, 2011.
    5. Zhao M., Kanegane H., Kobayashi C., Nakazawa Y., Ishii E., Kasai M., Terui K., Gocho Y., Imai K., Kiyasu J., Nonoyama S., and Miyawaki T.: Early and rapid detection of X-linked lymphoproliferative syndrome with SH2D1A mutations by flow cytometry. Cytometry Part B- Clin Cytom 80B: 8-13, 2011.
    6. Chang B., Nishizawa T., Furutani M., Fujiki A., Tani M., Kawaguchi M., Ibuki K., Hirono K., Taneichi H., Uese K., Onuma Y., Bowles N.E., Ichida F., Inoue H., Matsuoka R., and Miyawaki T.: Identification of novel TPM1 mutation in a family with left ventricular noncompaction and sudden death. Mol Genet Metab 102: 200-206, 2011.
    7. Booth C., Gilmour K.C., Veys P., Gennery A.R., Slatter M.A., Chapel H., Heath P.T., Steward C.G., Smith O., O'Meara A., Kerrigan H., Mahlaoui N., Cavazzana-Calvo M., Fischer A., Moshous D., Blanche S., Schmid J.P., Latour S., Saint-Basile G., Albert M., Notheis G., Rieber N., Stahm B., Ritterbusch H., Lankester A., Hatwig N.G., Meyts I., Plebani A., Soresina A., Finocchi A., Pignata C., Cirillo E., Bonanomi S., Peters C., Kalwak K., Pasic S., Sedlacek P/. Jazbec J., Kanegane H., Nichols K.E., Hanson I.C., Kapoor N., Haddad E., Cowan M., Choo S., Smart J., Arkwright P.D., and Gaspar H.B.: X-linked lymphoproliferative due to SAP/SH2D1A deficiency: amulticenter study on the manifestations, management and outcome of the disease. Blood 117: 53-62, 2011.
    8. Schmid J.P., Canioni D., Moshous D., Touzot F., Mahlaoui N., Hauck F., Kanegane H., Lopez-Granados E., Mejstrikova E., Pellier I., Galicier L., Galambrun C., Barlogis V., Bordigoni P., Fourmaintraux A., Hamidou M., Dabadie A., Deist F., Haerynck F., Ouachee-Chardin M., Rohrlich P., Stephan J-L., Lenoir C., Rigaud S., Lambert N., Milili M., Schiff C., Chapel H., Picard C., Basile G.S., Blanche S., Fischer A., and Latour S.: Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP dificiency) versus type 2(XLP-2/XIAP deficiency). Blood 117: 1522-1529, 2011.
    9. Imamura M., Kawai T., Okada S., Izawa K., Takachi T., Iwabuchi H., Yoshida S., Hosokai R., Kanegane H., Yamamoto T., Umezu H., Nishikomori R., Heike T., Uchiyama M., and Imai C.: Disseminated BCG infection mimicking metastatic nasopharyngeal carcinoma in immunodeficient child with a novel hypomorphic NEMO mutation. J Clin Immunol 31 : 802-810, 2011.
    10. Ishimura M., Takada H., Doi T., Imai K., Sasahara Y., Kanegane H., Nishikomori R., Morio T., Heike T., Kobayashi M., Ariga T., Tsuchiya S., Nonoyama S., Miyawaki T., and Hara T.: Nationwide survey of patients with primary immunodeficiency disease in Japan. J Clin Immunol 31 : 968-976, 2011.
    11. Futamura M., Ohya Y., Akashi M., Adachi Y., Odajima H., Akiyama K., and Akasawa A.: Age-related prevalence of allergic diseases in Tokyo schoolchildren. Allergol Int 60: 509-515, 2011.
    12. Taguchi M., Ichida F., Hirono K., Miyawaki T., Yoshimura N., Nakamura T., Akita C., Nakayama T., Saji T., Kato Y., Horiuchi I., and Hashimoto Y.: Pharmacokinetics of Bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension. Drug Metab Pharmacokinet 26: 280-287, 2011.
    13. Kato Y., Ichida F., Saito K., Watanabe K., Hirono K., Miyawaki T., Yoshimura N., Horiuchi I., Taguchi M., and Hashimoto Y.: Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug Metab Pharmacokinet 26: 295-299, 2011.
    14. Nakagawa N., Imai K., Kanegane H., Sato H., Yamada M., Kondoh K., Okada S., Kobayashi M., Agematsu K., Takada H., Mitsui N., Oshima K., Ohara O., Suri D., Rawat A., Singh S., Pan-Hammarstrome Q., Hammarstrome L., Reinhard S., Ariga T., Hara T., Miyawaki T., and Nonoyama S.: Quantification of k-deleting recombination excision circles in Guthrie cards for the identification of early B-cell maturation defects. J Allergy Clin Immunol 128: 223-225, 2011.
    15. Tadaki H., Saitsu H., Kanegane H., Miyake N., Imagawa T., Kikuchi M., Hara R., Kaneko U., Kishi T., Miyamae T., Nishimura A., Doi H., Tsurusaki Y., Sakai H., Yokota S., and Matsumoto N.: Exonic deletion of CASP10 in a patient presenting with systemic juvenile idiopathic arthritis, but not with autoimmune lymphoproliferative syndrome type IIa. Int J Immunogenet 38: 287-293, 2011.
    16. Arai T., Zhao M., Kanegane H., Zelm M.C. Futatani T., Yamada M., Ariga T., Ochs H.D., Miyawaki T., and Oh-ishi T.: Genetic analysis of contagious X-chromosome deletion syndrome encompassing the BTK and TIMM8A genes. J Hum Genet 56: 577-582, 2011.
    17. Morimoto A., Shioda Y., Imamura T., Kanegane H., Sato T., Kudo K., Nakagawa S., Nakadate H., Tauchi H., Hama A., Yasui M., Nagatoshi Y., Kinoshita A., Miyaji R., Anan T., Yabe M., and Kamizono J. for the LCH committee, the Japanese pediatric leukemia/lymphoma study group.: Nationwide survey of bisphosphonate therapy for children with reactivated langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 56:110-115, 2011.
    18. Taga T., Shimomura Y., Horikoshi Y., Ogawa A., Itoh M., Okada M., Ueyama J., Higa T., Watanabe A., Kanegane H., Iwai A., Saikawa Y., Kogawa K., Yamanaka J., and Tsurusawa M.: Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeroid leukemia: Report from the Japanese children's cancer and leukemia study group (CCLSG) AML 9805 down study. Pediatr Blood Cancer 57: 36-40, 2011.
    19. Yamaguchi M., Fujimura K., Kanegane H., Toga-Yamaguchi H., Chopra R., and Okamura N.: Mislocalization or low expression of mutated Shwachman-Bodian-Diamond syndrome protein. Int J Hematol 94: 54-62, 2011.
    20. Fujioka T., Kawashima H., Nishimata S., Ioi H., Takekuma K., Hoshika A., kanegane H., and Miyawaki T.: Atypical case of X-linked agammaglobulinemia diagnosed at 45 years of age. Pediatr Int 53: 611-612, 2011.
    21. Ohta H, Miyashita E, Hirata I, Matsumura R, Yoshida H, Hashii Y, Higashiura T, Yasumi T, Murata Y, Heike T, Yang X, Kanegane H, Ohara O, and Ozono K.: Hematopoietic stem cell transplantation with reduced intensity conditioning from a family haploidentical donor in an infant with familial hemophagocytic lymphohistiocytosis. Int J Hematol 94: 285-290, 2011.
    22. Kawakami C., Inoue A., Takitani K., Kanegane H., Miyawaki T., and Tamai H.: X-linked agammaglobulinemia complicated with endobronchial tuberculosis. Acta Paediatr 100: 466-468, 2011.
    23. Mori M., Kawashiri M., Hayashi T., Konnno T., Hayashi K., Ino H., Yoshimura T., Okeie K., Ichida F., Shigeyuki T., Watanabe G., and Yamagishi M.: Cardiac papillary fibroelastoma originated from atrial side of mitral valve leaflet. J Echocardiogr 9 : 156-157,2011.
    24. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™šb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiChildhood Asthma Control Test: C-ACTj‚Ì—L—p«‚Æ–â‘è“_. “ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 9: 30-35, 2011.
    25. âè®“¿A’O‰HŒöˆê˜Y, ã–ì—Ï•F, ‚ŽºŠîŽ÷, ’†Œ•q—Y, ‰Á“¡@‹Ï, Œ“‡³‹C, ¬“‡“Þ”üŽq, Žs“c•™Žq, ¬Š_Ž –L, éŒË²’mŽq, VŠ_‹`•v, Ô–Ø’õŽ¡, é”ö–M—², {“cŒ›Ž¡, ’†àV@œ, ²’n@•×: –{–M‚É‚š‚¯‚éEisenmengerÇŒóŒQ¬l—á‚ÌŒŸ“¢. ¬Ž™zŠÂŠíŠw‰ïŽGŽ 27: 121-131, 2011.
  • Ç—á•ñ
    1. Yang X., Wang J., Kanegane H., Miyawaki T., Zhao K.: Genetic and proteinic analysis of a Chinese boy with X-linked lymphoproliferative disease and his maternal relatives. Chinese J Pediatr 49: 416-420, 2011.
    2. Hamidah A., Renna M., Halim A.R.A., Ibrahim S., Eguchi M., Zarina A.L., Norazlin A.N., Iamal R., and Kanegane H.: Successful treatment of very large congenital infantile fibrosarcoma. Pediatr Int 53: 768-770, 2011.
    3. Ukeba-Terashita Y., Saita Y., Ito Y., Kanegane H., Kimura H., and Kobayashi I.: Chronological changes in Epstein-Barr virus genome and subsets of peripheral mononuclear cells in a case of HLH. Open J Pediatr 1: 30-33, 2011.
    4. Kawakami C., Inoue A., Kakitani K., Kanegane H., Miyawaki T., and Tamai H.: X-linked agammaglobulinemia complicated with endobronchial tuberculosis. Acta Paediatr 100: 466-468, 2011.
    5. –쑺ŒbŽq, ‹{’n@[, ‘å’ØŒc•ã, ‹àŒ“O˜a, “y‰®–M•F, ×ˆä@‘n, ‹{˜e—˜’j: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“Ÿ‚œ’†“ªŠWâ|ŒŽ”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ¬Ž™‚ª‚ñ@48: 310-314, 2011.
    6. ‚è–ƒ”ü, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒGƒLƒmƒRƒbƒNƒX‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œŠÌ•gŠŽõÇ‚Ì‚P—Ž™—á. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ@115: 1781-1785, 2011.
    7. ’|j—fm, ãp@—T“Ä, Vì¬“N, ÎàV@Œb, ‹{è—ÇŽ÷, Šâ“c“ÖŽq, –x@šæ¬, ’ßàV³m, ˆÀ“¡ˆèŽq, ‹àŒ“O˜a: —cŽ™Šú‚ÉŒ©“Š‚³‚ê‚Ä‚µ‚Ü‚Á‚œX˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. ¬Ž™‰È—Տ° 64: 61-65, 2011.
    8. –xìT“ñ˜Y, ŒÜ\—’“oF‹}«¬Ž™•Ð–ƒáƒ‚ð’悵‚œƒCƒ“ƒtƒ‹ƒGƒ“ƒU”]Ç‚Ì‚P—Ž™—áD¬Ž™‰È—Տ° 64: 255-260, 2011.
    9. –xìT“ñ˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚œ toxic shock syndrome ‚Ì‚P—á. ¬Ž™ŠŽõ–Ɖu 23: 141-147, 2011.
    10. ‚è–ƒ”ü, ‹g“cär, “¡–Ø–õŽq, ’––”’qŽÀ, ˆÉŒ\“ñ˜Y, “n糒qŽq, œAìTˆê˜Y, •l“cG—Y, •è–M˜a, ‹{˜e—˜’j: œãèpŒã‚É”]Žº“àoŒŒ‚𔭏ǂµ‚œ Late preterm ‚̈êãO–Ñ–Œ«‘o‘Ù—á. ¬Ž™‰È—Տ°@64: 2412-2416, 2011.
  • ‘à
    1. ‹{˜e—˜’j: ‚Æ‚à‚ ‚ê@‚ЂƂ@‚ЂƂÂ. ¬Ž™‰È—Տ° 64: 56-59, 2011.
    2. ‹{˜e—˜’j: Why we get sick?. ƒAƒŒƒ‹ƒM[?–Ɖu 18: 7, 2011.
    3. ‹{˜e—˜’j: æ“V«–Ɖu•s‘SÇ‚ɂ‚¢‚Ä. •êŽq•ÛŒ’‹Š‰ïŽu‚Ó‚œ‚΁v 75: 28-34, 2011.
    4. Žs“c•™Žq: zŠÂŠí•a—1 1.S‹ØŽŸŠ³ 2)¶ŽºS‹Øãk–§‰»áŠQ. •a—‚ƗՏ° 29: 149-153, 2011.
    5. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[ŽŸŠ³‚̐f’f‚ÆŽ¡—ẪsƒbƒgƒtƒH[ƒ‹ -¬Ž™šb‘§-. ƒAƒŒƒ‹ƒM[‚̗Տ°@31: 1048-1051, 2011.
    6. ‘«—§—Yˆê, ŸÀr—Y: ÐŠQŽž‚É‚š‚¯‚éšb‘§?ƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž‚Æ–â‘è“_. [“Œ“ú–{‘åkÐ‚Å‚Ì•ñ‚ƍ¡Œã‚Ö‚Ì’ñŒŸ[@5. ‘Ήžƒpƒ“ƒtƒŒƒbƒg(1)‚Í‚¶‚ß‚É. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 25: 739-741, 2011.
    7. ‘«—§—Yˆê, “¡àV—²•v: ÐŠQŽž‚É‚š‚¯‚éšb‘§?ƒAƒŒƒ‹ƒM[Š³Ž™‚ւ̑Ήž‚Æ–â‘è“_. [“Œ“ú–{‘åkÐ‚Å‚Ì•ñ‚ƍ¡Œã‚Ö‚Ì’ñŒŸ[@5. ‘Ήžƒpƒ“ƒtƒŒƒbƒg(2)šb‘§. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 25: 742-745, 2011.
    8. ‘«—§—Yˆê: •Ûˆç‚̏ê‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[ŽŸŠ³Ž™‚ւ̑Ήž.“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 9: 263-264, 2011.
    9. ‘«—§—Yˆê: ‹CŠÇŽxšb‘§‚̃tƒFƒmƒ^ƒCƒv. ¬Ž™‰È 52: 1807-181, 2011.
    10. ‹àŒ“O˜a, ‘å’ØŒc•ã, ‹{˜e—˜’j: §Œä«T×–E‚Ɉُí‚ð—L‚·‚錎”­«–Ɖu•s‘S. ‰ŠÇ‚ƖƉu 19: 210-216, 2011.
    11. ‹àŒ“O˜a: X˜AœƒŠƒ“ƒp‘BÇŒóŒQ-SAPŒ‡‘¹Ç‚ÆXIAPŒ‡‘¹Ç. ˆãŠw‚Ì‚ ‚ä‚Ý 238: 1058-1064, 2011.
    12. ”ÂàVŽõŽq: šb‘§f—Âɂš‚¯‚鏬Ž™‚̌ċz‹@”\ŒŸž. ¬Ž™‰È 52: 1013-1020, 2011.
    13. Hirono K, Ichida F: Possible new role of vascular endothelial growth factor-d during the acute phase of kawasaki disease. Circ J. 75:1324-1325, 2011.
    14. œA–ìŒbˆê, Žs“c•™Žq: ìè•aŒŒŠÇ‰Š‚Ì•a‘Ô. “ÁW/ìè•a‚̏”–â‘è. zŠÂŠí“à‰È 69: 399-406, 2011.
    15. ŽíŽsq’ˆ, ‹{˜e—˜’j: ‚—p—ʖƉuƒOƒƒuƒŠƒ“—Ö@. “ú–{—Տ° 69: 515-519, 2011.
    16. “n•Óˆê—m, Žs“c•™Žq: V¶Ž™ŠúS‘ŸŽèpŒã‚̐ž_‰^“®”­’B. ¬Ž™‰È 50: 219-223, 2011.
    17. “n•Óˆê—m, Žs“c•™Žq: S‹Ø‰ŠwÇŒóEŽŸŠ³ŒQ•Ê‚̗Տ°ŒŸž‚̐i‚ß•ûx¬Ž™‰Èf—Á@74(‘): 289-292, 2011.
    18. “n•Óˆê—m, Žs“c•™Žq: w¬Ž™‚̐f—Â̂µ‚©‚œ[‚ ‚È‚œ‚Ì‹^–â‚É“š‚Š‚Ü‚·xVIII.ŽŸŠ³•Ê‚̐f—Á@7.zŠÂŠíŽŸŠ³iV¶Ž™E“ûŽ™Šúj4)RSƒ‚ƒmƒNƒƒi[ƒ‹R‘Ì‚Ì“K‰ž‚ð‹³‚Š‚Ä‚­‚Ÿ‚³‚¢@¬Ž™“à‰È 43(‘): 610-611, 2011.
    19. ‰ª•””üŒb, ‘«—§—Yˆê: ¬Ž™šb‘§Ž¡—Âɂš‚¯‚é‹z“üŽw“±. ‹z“ü—Ö@ 3: 58-62, 2011.
    20. ‰ª•””üŒb: Q&A Žq‹Ÿ‚Å‚àA”ì–ž‚Æšb‘§‚ÍŠÖŒW‚ª‚ ‚è‚Ü‚·‚©. ƒAƒŒƒ‹ƒM[‚̗Տ°@31: 10, 2011.
    21. ¬àVˆ»‰À, Žs“c•™Žq: S‘ŸŒŸf‚̈Ӌ`‚ÆŽÀÛ. ¬Ž™‰È—Տ° 64: 1451-1462, 2011.
    22. ¬àVˆ»‰À, Žs“c•™Žq: æ“V«SŽŸŠ³‡•¹Ž™‚̃tƒHƒ[ƒAƒbƒv‚Å‚Ì’ˆÓ“_. ŽüŽYŠúˆãŠw 41: 1380-1382, 2011.
    23. ˆÉ“¡–õ“T, ‘«—§—zŽq, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒÄ‹z‚ÉŠÖ‚·‚éfŽ@i–âfAŽ‹fA’®fj‚Å’ˆÓ‚·‚é“_‚Í‚È‚ñ‚Å‚·‚©. ¬Ž™“à‰È 43(‘): 129-131, 2011.
    24. ‘å’ØŒc•ã, ‹àŒ“O˜a,‹{˜e—˜’j: ƒAƒŒƒ‹ƒM[ŽŸŠ³‚ƖƉu’²ß(Treg×–E) ¬Ž™‰È 52: 879-887, 2011.
    25. Œ“c’Œ“¿, ‹àŒ“O˜a: –Ɖu•s‘SÇŒóŒQiHIVŠŽõÇ‚ðŠÜ‚ށj. ¬Ž™‰È—Տ°@64: 2597-2602, 2011.
    26. Š`–{‘œç‘ã, Žs“c•™Žq: æ“V«SŽŸŠ³‡•¹Ž™‚̐ž__Œo”­’B—\Œã@“ÁW/How to Follow-up Q & A-ƒtƒHƒ[ƒAƒbƒv‚̃Rƒc‚·‚ׂċ³‚Š‚Ü‚·@ŽüŽYŠúˆãŠw@41: 1383-1385, 2011.

  • 2011”NŠw‰ï•ñ
    1. Adachi Y., Itazawa T., Adachi YS., Ito Y., Okabe Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of Obesity with Asthma in Japanese Preschool Children. 67th Annual Meeting of American Academy of Allergy, Asthma & Immunology, 2011, 3, 19-22, San Francisco, USA.
    2. Itazawa T., Adachi Y., YAdachi YS., Ito Y., Okabe Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Association of Body Composition with Asthma Control in Japanese Preschool Children. 67th Annual Meeting of American Academy of Allergy, Asthma & Immunology, 2011, 3, 19-22, San Francisco, USA.
    3. Hashimoto I., Saitou K., Ibuki K., Ozawa S., and Ichida F.: New index-pulmonary vascular index-for evaluation of pulmonary flow resistance in congenital heart disease. i2 summit, American College of Cardiology, 2011, 4, 4, New Orleans.
    4. Ichida F.: Genetic basis of noncompaction cardiomyopathy. 2011 Pediatric Academic Societies and Asian Society for Pediatric Research, 2011, 4, 30-5.1, Denver (U.S.A). (invited lecture)
    5. Kanegane H.: SAP and XIAP deficiency in hemophagocytic lymphohistiocytosis. 2011 Pediatric Academic Societies and Asian Society for Pediatric Research, 2011, 4, 30-5.1, Denver (U.S.A). (invited lecture)
    6. Saito K., Takasaki I., Hirono K., Ibuki K., Watanabe K., Bowles NE., Ichida F., and Miyawaki T.: MicroRNAs may control mRNA in circulating PBMCs during the acute phase of Kawasaki disease. The 45th Annual meeting for the association for European pediatric cardiology, 2011, 5, 20, Granada, Spain.
    7. Ichida F., Hata Y., Chang B., Ozawa S., Saito K., Ibuki K., Watanabe K., and Nishida N.: Genetic basis of left ventricular noncompaction. European Society of Cardiology Congress 2011, 2011, 8, 28, Paris.
    8. Yoshida T., Takasaki I, Kanegane H., Inomata S., Shimao A., Ito Y., Saito S., and Miyawaki T.: Identification of predictive makers for adult heart disease from gene expression profiling of cord blood. . 6th Recent advances in neonatal medicine an international symposium, 2011, 10, 2-4, Wurzburg, Germany.
    9. Inomata S., Yoshida T., Shimao A., Hatasaki K., Imamura H., and Miyawaki T.: The relationship between preterm birth and the risk factors for cardiovascular diseases in schoolchildren. 6th Recent advances in neonatal medicine an international symposium, 2011, 10, 2-4, Wurzburg, Germany.
    10. Ichida F., Hata Y., Chang B., Ozawa S., Saito K., Ibuki K., Watanabe K., Hirono K., Nishida N., Bowles NE., and Miyawaki T.: Genetic basis of left ventricular noncompaction. The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    11. Ibuki K., Watanabe K., Yoshimura N., Kakimoto T., Matsui M., Saito K., Ozawa S., Hirono K., Yoshida T., Noguchi K., and Ichida F.: The improvement of hypoxia correlates with neuroanatomical and developmental outcomes in infants with transposition of the great arteries or single ventricle physiology. The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    12. Saito K., Ozawa S., Inui A., Fujisawa T., Yasumura S., Sumi S., Ibuki K., Watanabe K., Ichida F., Yoshimura N., and Miyawaki T.: Type IV collagen 7S and hyaluronic acid predict the early stage of liver cirrhosis in patients after Fontan procedure The 84th Scientific sessions of AHA 2011, 2011, 11, 13-15, Orlando, U.S.A.
    13. “n•Óˆê—m, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, ŽR’†ŸO, “úŒG’qŒ›, –F‘º’ŒŽ÷: TRUFILL DCS ORBIT Detachable Coil‚ÌŽg—pŒoŒ±. ‘æ22‰ñ“ú–{Pediatric Interventional CardiologyŠw‰ï, 2011, 1, 20, ‰ªŽR.
    14. —k@žF, ‹àŒ“O˜a, ‹{˜e—˜’j, ¡‘ºr•F, •l–{˜aŽq, ‹{‰º—¥Žq: Clinical and genetic analysis of XIAP deficiency in Japan. ‘æ4‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï, 2011, 1, 22, •Ÿ‰ª.
    15. ’‡‰ª‰pK, ŽíŽsq’ˆ, ‹àŒ“O˜a, ‹{˜e—˜’j, ’|èrˆê˜Y, ŽR“c‰ë•¶, —L‰ê@³, M.S.Hershfield: –{–M‰‚Ì’x”­Œ^ADAŒ‡‘¹Ç‚Ì‚P—á. ‘æ4‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ï, 2011, 1, 22, •Ÿ‰ª.
    16. –쑺ŒbŽq, ‘å’ØŒc•ã,‹àŒ“O˜a, ‹{’n@[, “y‰®–M•F, ×ˆä@‘n, ÎàV@L, ‹{˜e—˜’j: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“Ÿ‚œ’†“ªŠWâ|ŒŽ”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ‘æ11‰ñ“ú–{‰¡–ä‹Ø“÷ŽîŒ€‹†ƒOƒ‹[ƒvŒ€‹†‰ï, 2011, 1, 29, “Œ‹ž.
    17. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ÎàV@L, ‹{’n@[, “y‰®–M•F, ×ˆä@‘n: ƒpƒ‰ƒtƒBƒ“•ï–„”÷¬ŒŸ‘Ì‚©‚çƒLƒƒ‰ˆâ“`Žq‚ðŒŸo‚µ“Ÿ‚œ’†“ªŠWâ|ŒŽ”­–E‘ƒŒ^‰¡–ä‹Ø“÷Žî‚̈ê—á. ‘æ33‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï, 2011, 2, 11, ‹à‘ò.
    18. ŽíŽsq’ˆ: ŒJ‚è•Ô‚·”xoŒŒ‚É‚æ‚è’·Šú’ÁÃ‚ð‹­‚¢‚ç‚ê‚œS‘©Œ^S‹ØÇ‚Ì7Î—Ž™—á. ‘æ38‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ï, 2011,2,24-26, ‰¡•l.
    19. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)W’cŠŽõ‚É‹Nˆö‚µ‚œ‹}«”]Ç‘œ”­—á‚ւ̑Ήž`˜g‘g‚Ý‚ð‰z‚Š‚œ˜AŒg‚̏d—v«`.‘æ11‰ñ–k—€¬Ž™‹~‹}?W’†Ž¡—ÃŒ€‹†‰ï, 2011, 5, 14, ‹à‘ò.
    20. ŽíŽsq’ˆ, ™ŽR–ŸŽq, ‹{˜e—˜’j: ¬Ž™‰Èˆã‚É‚š‚¯‚éÐŠQˆã—Â̂ ‚è•û‚Ƃ͉œ‚©. ‘æ11‰ñ–k—€¬Ž™‹~‹}?W’†Ž¡—ÃŒ€‹†‰ï, 2011, 5, 14, ‹à‘ò.
    21. –xìT“ñ˜Y, ŽíŽsq’ˆ: •xŽRŒ§‚ł̉ߋŽ10”N‚É‚š‚¯‚é“ûŽ™CPAÇ—á”À‘—‚ÌŒ»ó. ‘æ11‰ñ–k—€¬Ž™‹~‹}?W’†Ž¡—ÃŒ€‹†‰ï, 2011, 5, 14, ‹à‘ò.
    22. ‘«—§—Yˆê: ŒöŠJÀ’k‰ï Šî’²u‰‰u¬Ž™‰È‚©‚猩‚œ One Airway, One Diseasev. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2011, 5, 14-15, ç—t.
    23. ”ÂàVŽõŽq, ‘«—§—Yˆê, ˆÉ“¡’Œ, ‰ºð’ŒŽ÷, “¡àV—²•v, Šâ“c@—Í, ‹{˜e—˜’j: ŒoŒû•‰‰×ŽŽŒ±‚ŃAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð’悵‚œ—‘ƒAƒŒƒ‹ƒM[‚̈ꏗŽ™—á. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2011, 5, 14-15, ç—t.
    24. ˆÉ“¡–õ“TA‰ª•””üŒbA”ÂàVŽõŽqA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’j: ¬Ž™šb‘§‚É‚š‚¯‚é”x‹@”\ (FEV1,FEV1/FVC, FEF25-75) ‚ƃRƒ“ƒgƒ[ƒ‹ƒŒƒxƒ‹‚Æ‚ÌŠÖŒW.. ‘æ23‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2011, 5, 14-15, ç—t.
    25. ‹{@ˆêŽu, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‘q–{@’, –{‹œ˜a‹v, ‹{˜e—˜’j: Šá‰È“IˆÙí‚Å”­Œ©‚³‚ê‚œSepto-Optic Dysplasia‚Ì2“ûŽ™—á. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    26. ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j: V¶Ž™Šú‚ɗΓàá‚Å”­Ç‚µ‚œ_ŒoüˆÛŽîÇ1Œ^‚Ì1—á. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    27. –{‹œ˜a‹v, ‹{@ˆêŽu, ŒŽˆä•ü”ü, “¡–Ø–õŽq, “c’‡çH, ‘q–{@’, ‹{˜e—˜’j: ¬Ž™–Ɖu«’†•_ŒoŽŸŠ³‚̗Տ°@Å‹ß‚̐i•à —n˜A‹ÛŠŽõŠÖ˜A«ž__ŒoŽŸŠ³‚̗Տ°‘œ‚š‚æ‚уŠƒ\ƒKƒ“ƒOƒŠƒIƒVƒhR‘Ì‚Ì—z«—Š. ‘æ53‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2011, 5, 26-28, ‰¡•l.
    28. –쑺ŒbŽq, ‘å’ØŒc•ã, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒTƒCƒ‚ƒOƒƒuƒŠƒ““Š—^21‚©ŒŽŒã‚ÉŠ°‰ð‚ª“Ÿ‚ç‚ê‚œdÇŒ^AA (RCC) ‚Ì‚P—á. ‘æ18‰ñ¬Ž™Ä¶•s—ǐ«•nŒŒŽ¡—ÃŒ€‹†‰ï, 2011, 5, 28, –ŒŒÃ‰®.
    29. ŽíŽsq’ˆ:‚±‚Ç‚à‚Ì”­”M‚ ‚ꂱ‚ê`‰Šú‘Ήž‚𒆐S‚Ɂ`.Žs–¯ŒöŠJuÀ •a‹C‚̃VƒOƒiƒ‹, 2011, 5, 28, •xŽR.
    30. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒXƒpƒCƒƒƒgƒŠ[‚ɂČċz‹@”\—ǍD‚Æ”»’f‚³‚ê‚œšb‘§¬Ž™‚É‚š‚¯‚éimpulse oscillation systemiIOSj‚ð—p‚¢‚œ‹C“¹‰Â‹t«‚ÌŒŸ“¢. ‘æ28‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2011, 6, 4-5, ‰¡•l.
    31. ŽíŽsq’ˆ, ˜a“c‘ñ–ç, ‹{˜e—˜’j: ’ጌ“œš‡‚É‚Ä‹~‹}”À‘—‚³‚ê‚œBMI 7.8‚̏dÇÛHáŠQ—Ž™‚É‚š‚¯‚éŠÇ—ŒoŒ±. ‘æ25‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï, 2011,6,10-11, “Œ‹ž.
    32. ™ŽR–ŸŽq, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j, ¬‰Y@Ž, “¡“cC•œ, “ñ’J@•: ‘m–X•Ù‹t—¬‚É‚æ‚é”xÃ–¬‚€‚ÁŒŒ‚ɑ΂µ‚ăoƒ‹[ƒ“S–[—ôŠJp‚ðŽ{s‚µA‹~–œ‚µ“Ÿ‚œV¶Ž™S‹Ø‰Š‚Ì‚P—á. ‘æ302‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2011, 6, 12, •Ÿˆä.
    33. ’‡‰ª²’qŽq, ŒŽˆä•ü”ü, ’‡‰ª‰pK, ”ÂàVŽõŽq, ‹{˜e—˜’j: ƒoƒ‹ƒuƒŽ_’†“Å‚É‚æ‚éis«ˆÓŽ¯áŠQ‚ð”F‚ß‚œ‚PÎ’jŽ™—á. ‘æ302‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2011, 6, 12, •Ÿˆä.
    34. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚Ì‹CŠÇŽxšb‘§‚É‚š‚¯‚éIOSiimpulse oscillation systemj‚Ì—L—p«‚ɂ‚¢‚āD‘æ14‰ñ–k—€¬Ž™šb‘§Œ€‹†‰ï, 2011, 6, 18, ‹à‘ò.
    35. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ‰Á“¡—I–ç, “cŒû‰ë“o, –x“àˆÐ²’j, ‹Ž–{ª–ç, –F‘º’ŒŽ÷: “ú–{læ“V«SŽŸŠ³Š³Ž™‚É‚š‚¯‚郏[ƒtƒ@ƒŠƒ“•K—v“Š—^—Ê‚ÉŠÖ‚·‚éVKORC1‚̈â“`Žq‘œŒ^‚̉e‹¿‚ɂ‚¢‚Ä. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    36. âV“¡˜a—R, ¬àVˆ»‰À, Š£‚ ‚â‚Ì, “¡‘ò’m—Y, ˆÀ‘º@•q, Šp@dŠì, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, –F‘º’ŒŽ÷, ‹{˜e—˜’j: @ƒtƒHƒ“ƒ^ƒ“pŒã‚̊̐üˆÛ‰»‚ÉŠÖ‚µ‚Ä4Œ^ƒRƒ‰[ƒQƒ“7S‚š‚æ‚уqƒAƒ‹ƒƒ“Ž_‚Ì‘Šú”­Œ©ƒ}[ƒJ[‚Æ‚µ‚Ä‚Ì—L—p«. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    37. ¬àVˆ»‰À, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j: ¬Ž™æ“V«SŽŸŠ³‚É”º‚€”x‚ŒŒˆ³‚ւ̃^ƒ_ƒ‰ƒtƒBƒ‹‚ÌŽg—pŒoŒ±. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    38. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, Š`–{‘œç‘ã, ¬àVˆ»‰À, “n•Óˆê—m, ‹g“cär, Žs“c•™Žq, ‹{˜e—˜’j, “úŒG’qŒ›, –F‘º’ŒŽ÷, ŒˆäŽOŽ}: æ“V«SŽŸŠ³Ž™‚É‚š‚¢‚Ä’áŽ_‘fŒŒÇ‚̉ü‘P‚Í”]‚̐¬’·‚Æ”­’B—\Œã‚ð‰ü‘P‚·‚é`Š®‘S‘匌ŠÇ“]ˆÊÇ‚Æ’PSŽºÇ‚Ì’†Šú—\Œã‚Ì”äŠr`. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    39. ‹{è‚ ‚ä‚Ý, ¬ŒIˆºŽq, ’·’J“c—Sˆê, Žs“c•™Žq: ¬Ž™‚̐HŒã‚É‚š‚¯‚éƒgƒŠƒOƒŠƒZƒŠƒh’l‚š‚æ‚ÑLDLƒRƒŒƒXƒeƒ[ƒ‹ŒvŽZ’l‚Ì•]‰¿. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    40. ‹Ž–{ˆè•v, ¬àVˆ»‰À, Žs“c•™Žq: ŠwZS‘Ÿ•aŒŸf‚ÅŒ©‚‚©‚éPVCÇ—á‚̐SƒGƒR[‚É‚æ‚éŒ`‘Ô“I“Á’¥. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    41. ™ŽR–ŸŽq, “n•Óˆê—m, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, Žs“c•™Žq, “¡“cC•œ, “ñ’J@•: ‘m–X•Ù‹t—¬‚É‚æ‚é”xÃ–¬‚€‚ÁŒŒ‚É‚œ‚¢‚µ‚ăoƒ‹[ƒ“S–[—ôŠJp‚ðŽ{s‚µA‹~–œ‚µ“Ÿ‚œV¶Ž™S‹Ø‰Š‚Ì‚P—á. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    42. ’‡‰ª‰pK, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, Žs“c•™Žq, ‹{˜e—˜’j, ŽR’†ŸO, ‘卂TŒá, “úŒG’qŒ›, –F‘º’ŒŽ÷: ’á—p—ʃAƒ~ƒIƒ_ƒƒ“‚ª—LŒø‚Å‚ ‚Á‚œ¬Ž™“«•s®–¬3—á‚ÌŒoŒ±. ‘æ47‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2011, 7, 6-8, •Ÿ‰ª.
    43. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)ŠŽõ‚É‚æ‚é‹}«‰óŽ€«”]Ç‚̉摜ŠŒ©. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    44. ”ª–ؐMˆê, ‹{ˆêŽu, ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹ÛO-111 ƒEƒCƒ‹ƒXŠŽõ‚É”F‚ß‚ç‚ê‚œ‹}«‰óŽ€«”]Ç‚̉摜ŠŒ©‚̐„ˆÚ‚ɂ‚¢‚ā@•œ¬23”N•xŽRŒ§‚Å”F‚ß‚ç‚ê‚œO-111ŠÖ˜A”]Ç‚Ì“ÁˆÙ‚ȉ摜ŠŒ©‚ðf’f‚·‚é‚œ‚ß‚É. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    45. –쑺ŒbŽq, –x]’åŽu, ŽíŽsq’ˆ, ‹{˜e—˜’j, Œ‘q—TŠì: ’°ŠÇoŒŒ«‘å’°‹ÛO-111 ƒXƒeƒƒCƒhƒpƒ‹ƒX—Ö@‚ðs‚Á‚œHUS‚Ì1—á. ‘æ26‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2011,7,10, •xŽR.
    46. ’––”’qŽÀ, ‹g“cär, ”šèŠì–F, ¡‘º”Ž–Ÿ, ‹{˜e—˜’j: Šw“¶Œ’f‚ð—p‚¢‚œ‘ŽYŽ™‚Ɛ¶ŠˆKŠµ•aƒŠƒXƒNˆöŽq‚ÉŠÖ‚·‚錟“¢. ‘æ47‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï, 2011, 7, 10-12, ŽD–y.
    47. Š`–{‘œç‘ã, ‹g“cär, ‹{˜e—˜’j: ‘ŽYŽ™‚Ì”­’BŽx‰‡‚É‚š‚¯‚éƒxƒCƒŠ[“û—cŽ™”­’BŒŸž(‘æ3”Å)‚Ì—L—p«‚ÌŒŸØ. ‘æ47‰ñ“ú–{ŽüŽYŠúEV¶Ž™ˆãŠw‰ï, 2011, 7, 10-12, ŽD–y.
    48. ŽíŽsq’ˆ: ’°ŠÇoŒŒ«‘å’°‹Û(EHEC)W’cŠŽõ‚É‹Nˆö‚µ‚œ‹}«”]Ç‘œ”­—á‚ւ̑Ήž`˜g‘g‚Ý‚ð‰z‚Š‚œ˜AŒg‚̏d—v«`.‘æ15‰ñ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõÇŒ€‹†‰ï,2011,7,15-16, ‘åã.(µ‘ҍu‰‰)
    49. âV“¡˜a—R, ‚èˆê˜N, œA–ìŒbˆê, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j:‹}«Šúìè•a‚Ì—¬ŒŒ’†––œŒŒ’PŠj‹…×–E‚É‚š‚¯‚éƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«. ‘æ75‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï, 2011, 8, 3-4, ‰¡•l.
    50. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é‹}«”­ìŠÇ—. ‘æ5‰ñ‘Š–ÍŒŽ—Տ°ƒAƒŒƒ‹ƒM[ƒZƒ~ƒi[, 2011, 8, 5-7, ‰¡•l.
    51. âV“¡˜a—R, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j:“«ìè•a‚ɑ΂·‚éƒVƒNƒƒXƒ|ƒŠƒ“A‚ÌŒø‰Ê‚š‚æ‚эì—p‹@˜‚ÌŒŸ“¢. ‘æ15‰ñìè•aŽ¡—ͧ˜b‰ï, 2011, 8, 14, “Œ‹ž.
    52. ‘«—§—Yˆê: ‹³ˆçƒZƒ~ƒi[u“û—cŽ™šb‘§‚̐f’f‚ÆŽ¡—Áv‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    53. ŽíŽsq’ˆ, ŒŽˆä•ü”ü, ‹{˜e—˜’j: ŠŽõŒ¹‚Æ‚µ‚ÄŽº“àŽ”ˆç‚̃PƒdƒƒŠƒNƒKƒ‚ª‹^‚í‚ê‚œSalmonella poonaŠŽõÇ‚Ì“ûŽ™—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    54. âV“¡˜a—R, ‚èˆê˜N, “n•Óˆê—m, ¬àVˆ»‰À, Žs“c•™Žq, ‹{˜e—˜’j: ‹}«Šúìè•a‚Ì—¬ŒŒ’†––œŒŒ’PŠj‹…×–E‚É‚š‚¯‚éƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«`miR-93‚É‚æ‚éVEGFA‚̐§Œä`. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    55. ™ŽR–ŸŽq, “n•Ó—S‹I, ‘å’ØŒc•ã, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‹CŠÇˆ³”r‚ð‚«‚œ‚µ‚œ“ûŽ™_Œo‰èŽî‚Ì2—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011, 8, 12-14, “Œ‹ž.
    56. ’‡‰ª‰pK, ŽíŽsq’ˆ, ‹àŒ“O˜a, ’|èrˆê˜Y, ŽR“c‰ë•¶, —L‰ê@³, ‹{˜e—˜’j: –{–M‰‚Ì’x”­Œ^ADAŒ‡‘¹Ç‚̈ê—á. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011,8,12-14, “Œ‹ž.
    57. ’‡‰ª²’qŽq, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ŽsŠÛ’qG, aŒû’BO, ¡ˆää‰p, ã“cN‹v, ”óŒû¹F, ìú±ˆê‹P: •xŽRŒ§‚É‚š‚¯‚é2Î–¢–žŽ™‚Ì•êe‚É‚š‚¯‚鏬Ž™‚Ì‹C“¹ˆÙ•š‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²ž. ‘æ114‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï, 2011,8,12-14, “Œ‹ž.
    58. ’ށ@_”V, ‹{@ˆêŽu, ŒŽˆä•ü”ü, ’‡‰ª²’qŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ‰º“‡Œ\Žq, ŽR–{rŽŠ: ƒAƒŒƒCCGH‚É‚æ‚萳Šm‚ÉŒ‡Žž•”ˆÊ‚𓯒肵‚œ‚W”ԐõF‘Ì•”•ªŒ‡Žž‚̈ê—á. ‘æ47‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2011, 8, 21, –ŒŒÃ‰®.
    59. “ˆ”öˆ»Žq, ’––”’qŽÀ, ”óŒû@Žû, ‹g“cär, ‹{˜e—˜’j: ’°ŠÇoŒŒ«‘å’°‹ÛŠŽõ‚É”º‚€HUS”­Ç•ê‘Ì‚æ‚è‹Ù‹}’鉀ØŠJ‚ŏo¶‚µ‚œ‘ŽYŽ™. ‘æ47‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2011, 8, 21, –ŒŒÃ‰®.
    60. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: “–‰È‚É‚š‚¯‚é—‘ƒAƒŒƒ‹ƒM[‚ɑ΂·‚é‹}‘¬ŒoŒû–Ɖu—Ö@‚ÌŒoŒ±. ‘æ14‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2011, 9, 3, •xŽR.
    61. “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷: 64—ñMDCT‚ð—p‚¢‚œSŽº“à\‘¢•]‰¿. ‘æ39‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï, 2011, 9, 10, •Ÿˆä.
    62. ¬àVˆ»‰À, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷: ¬Ž™æ“V«SŽŸŠ³‚É”º‚€”x‚ŒŒˆ³Ç‚ւ̃AƒhƒVƒ‹ƒJ‚ÌŽg—pŒoŒ±. ‘æ1‰ñ–k—€¬Ž™PAHŒ€‹†‰ï, 2011, 9, 16, ‹à‘ò.
    63. ‹àŒ“O˜a: ƒ~ƒjƒŒƒNƒ`ƒƒ[u–Ɖu•s‘SÇ‚̃XƒNƒŠ[ƒjƒ“ƒOŒŸž‚ƐV‚œ‚ɉÁ‚í‚Á‚œŽŸŠ³‚ɂ‚¢‚āv, ‘æ2‰ñŠÖ“Œb‰z–Ɖu•s‘SÇŒ€‹†‰ï, 2011, 9, 18, “Œ‹ž.
    64. Î‘º–šŽq, ‹àŒ“O˜a, ŽR“c‘œŽq: Š³Ž™?‰Æ‘°‚̖ڐü‚ðl‚Š‚œƒvƒŒƒCƒ‹[ƒ€‚­‚è. ‘æ11‰ñ’†•”¬Ž™‚ª‚ñƒg[ƒ^ƒ‹ƒPƒAŒ€‹†‰ï, 2011, 10, 1, –ŒŒÃ‰®.
    65. ŽíŽsq’ˆ: •xŽR‘åŠw•t‘®•a‰@‚É‚š‚¯‚é‹s‘Ò—\–h‚Ö‚ÌŽæ‚è‘g‚Ý. ‘æ50‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2011,10,2, •xŽR.
    66. ‹{@ˆêŽu, ‘«—§—zŽq, ‘«—§—Yˆê, ’·”ü’q‘ã, ‹{˜e—˜’j: V¶Ž™E“ûŽ™‚É‚š‚¯‚éƒrƒ^ƒ~ƒ“K2ƒVƒƒbƒv—\–h“Š—^‚ɑ΂·‚é•ÛŒìŽÒ‚̈ӎ¯’²ž. ‘æ50‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2011, 10, 2, •xŽR.
    67. ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‘q–{@’, “¡–Ø–õŽq, “c’‡çH, ‹{˜e—˜’j, –{‹œ˜a‹v: ƒoƒ‹ƒvƒŽ_ƒiƒgƒŠƒEƒ€“Š—^’†‚ÉFanconiÇŒóŒQ‚š‚æ‚уJƒ‹ƒjƒ`ƒ“Œ‡–RÇ‚ð‚«‚œ‚µ‚œ‚R—á. ‘æ45‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2011, 10, 6-7, VŠƒ.
    68. ‹{@ˆêŽu, ŒŽˆä•ü”ü,‘q–{@’, –{‹œ˜a‹v, ”ª–ؐMˆê, ‹{˜e—˜’j: “‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚élevetiracetam‚ÌŽ¡—ÃŒø‰Ê‚ÌŒŸ“¢. ‘æ45‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2011, 10, 6-7, VŠƒ.
    69. ‚è–ƒ”ü, –쑺ŒbŽq, –x]’åŽu, ‹àŒ“O˜a, ‹{˜e—˜’j, ŒÃŽs@Œb, æ™@—, Ž…’‰“¹, –쓇F”V: ”畆ŒŽ”­ Ewing/PET‚̈ê—á. ‘æ34‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï, 2011, 10, 8, ‹à‘ò.
    70. ‘«—§—Yˆê: ‹³ˆçƒZƒ~ƒi[u¬Ž™ŒÄ‹zŠíŽŸŠ³‚Ì‹~‹}f—à -‹C“¹ˆÙ•š-v ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    71. ‘«—§—zŽq, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ‹C“¹ˆÙ•šŽ–ŒÌ—\–h‚Ì‚œ‚ß‚Ì•ÛŒìŽÒ‚ɑ΂·‚é•ÛŒ’Žw“±‚ÉŠÖ‚·‚é’²ž. ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    72. ‚è–ƒ”ü, ”ÂàVŽõŽq, “ˆ”öˆ»Žq, ’––”’qŽÀ, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Œp: ¶ŒãŠÔ‚à‚È‚­‚æ‚è‹z‹C«šb–‚ð”F‚ß‚œˆôŒã”^ᇂ̐V¶Ž™—á. ‘æ44‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2011, 10, 15-16, ‰F“s‹{.
    73. ’––”’qŽÀ,“ˆ”öˆ»Žq, ‹g“cär, ‹{˜e—˜’j, •ÄàV—‰Â, ˆî“cvŽOŽq, âV“¡@Ž , ŽR“c’O: ‘ÙŽ™Šú‚æ‚è‘œ”­‚·‚鍜Ü‚ð”F‚߁A“ûŽ™Šú‘Šú‚æ‚èƒrƒXƒtƒHƒXƒtƒHƒl[ƒgŽ¡—ÂðŠJŽn‚µ‚œœŒ`¬•s‘S‚̈ê—á. ‘æ25‰ñ–k—€ŽüŽYŠú?V¶Ž™Œ€‹†‰ï, 2011, 10, 16, ‹à‘ò.
    74. Nomura K., Kanegane H., Horie S., Otsubo K., Abe A., and Miyawaki T.: Acute promyelocytic leukemia originating from leukemia cutis associated with cutaneous mastocytosis. ‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï, 2011, 10, 14-16, –ŒŒÃ‰®.
    75. Yoshida K., Toki T., Park MJ., Nagata Y., Wang R., Shiraishi Y., Sanada M., Nagasaki M., Miyano S., Kanegane H., Kawakami K., Koji K., Kojima S., Hayashi Y., Ito E., and Ogawa S.: Ehole exome analysis of transient abnormal myelopoiesis(TAM) and AMKL with Down syndrome. ‘æ73‰ñ“ú–{ŒŒ‰tŠw‰ï, 2011, 10, 14-16, –ŒŒÃ‰®.
    76. ŽíŽsq’ˆ,Žá™‰ë_,‰œŽ›@Œh,‘Ÿ“c–M—Y,˜ZŽÔ@’,Z“c@—º:ƒ†ƒbƒPÛH‚É‚æ‚é’°ŠÇoŒŒ«‘å’°‹ÛW’cŠŽõ‚É‹Nˆö‚µ‚œ‹}«”]Ç‘œ”­—á‚ւ̑Ήž. ‘æ39‰ñ“ú–{‹~‹}ˆãŠw‰ï, 2011,10,18-20, “Œ‹ž.
    77. “n•Óˆê—m, âV“¡˜a—R, ¬àVˆ»‰À, Žs“c•™Žq, ’†ˆäG˜a, “úŒG’qŒ›, –F‘º’ŒŽ÷: BTƒVƒƒƒ“ƒgŒo—R‚Å”x“®–¬ƒoƒ‹[ƒ“Šg’£p‚ðŽ{s‚µ‚œ5—á‚Ì‚Ü‚Æ‚ß. ‘æ11‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï, 2011, 10, 28, •xŽR.
    78. Okabe Y., Higuchi O., Itazawa T., Adachi Y., Ito Y., Yoshida K., Ohya Y., Odajima H., Akasawa A., and Miyawaki T.: Rhinitis is a risk factor for asthma in Japanese school children. Joint Congress of Asia Pacific Association of Pediatric Allergy, Respirology & Immunology and 48th Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology, 2011, 10, 28-30, Fukuoka.
    79. Adachi Y.: Symposium gBronchial Asthma Long-term ManagementhInhaled corticosteroid in the management of childhood asthma. Joint Congress of Asia Pacific Association of Pediatric Allergy, Respirology & Immunology and 48th Annual Meeting of Japanese Society of Pediatric Allergy and Clinical Immunology, 2011, 10, 28-30, Fukuoka.
    80. ”ÂàVŽõŽq: ƒVƒ“ƒ|ƒWƒEƒ€uV‚µ‚¢ƒoƒCƒIƒ}[ƒJ[ŒÄ‹CNOF‰Â”\«‚ÆŒÀŠE‚ðl‚Š‚é -ŒÄ‹CNO‘ª’è‚É‚æ‚éšb‘§Ž¡—ƒjƒ^ƒŠƒ“ƒO-v ‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘Ÿ•œ—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    81. ‘«—§—Yˆê, ŽO‰YŽŽu, Xì‚Ý‚«, Ôâ@“O, ŽRŒûiŽq, —é–؏‡‘¢, ‹Ž–{ŒõŽi, ŸÀr—Y, Ž›–{‹M‰p, ‹ß“¡’ŒŽÀ: “Œ“ú–{‘åkÐ‚Å”íÐ‚µ‚œ‚±‚Ç‚à‚ւ́u–hƒ_ƒj‚Ê‚¢‚®‚é‚݁v‚ð‘—‚éƒvƒƒWƒFƒNƒg‚ÌŒŸØD‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘Ÿ•œ—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    82. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô•]‰¿‚É‚š‚¯‚éÅ‘åŒÄ‹C’†ŠÔ—¬—ʁiFEF25-75j‚̗Տ°“IˆÓ‹`. ‘æ48‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA‘æ16‰ñƒAƒWƒA‘Ÿ•œ—m¬Ž™ƒAƒŒƒ‹ƒM[ŒÄ‹zŠí–ƉuŠw‰ï‡“¯Šwp‘å‰ï, 2011, 10, 28-30, •Ÿ‰ª.
    83. ‹àŒ“O˜a: ‹³ˆçu‰‰@’°ŠÇoŒŒ«‘å’°‹ÛO111‚̏W’c”­¶‚©‚çŠw‚ñ‚Ÿ‚±‚Æ. ‘æ43‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï, 2011, 10, 29-30, ‰ªŽR.
    84. ”óŒû@Žû, ‰ª•””üŒb, ‘«—§—zŽq, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚É‚š‚¯‚é•@Çó‚Æšb‘§ƒRƒ“ƒgƒ[ƒ‹ó‘ԁA”x‹@”\AŒÄ‹CˆêŽ_‰»’‚‘f‚Æ‚ÌŠÖŒW. ‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ï, 2011, 11, 10-12, “Œ‹ž.
    85. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§ƒRƒ“ƒgƒ[ƒ‹‚ª—ǍD‚ÈŽ™‚É‚š‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘f‚Æ”x‹@”\‚̕ω». ‘æ61‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ï, 2011, 11, 10-12, “Œ‹ž.
    86. ‹g“cär, “ˆ”öˆ»Žq, ’––”’qŽÀ, ‹{˜e—˜’j, •Ä“c@“N: w‚ ‚©‚¿‚á‚ñ‹äŠy•”x‚É‚æ‚éˆãŠw¶‚Ö‚ÌEarly Exposure. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    87. ‹g“cär, ’––”’qŽÀ, “ˆ”öˆ»Žq,‹{˜e—˜’j: ä`‘ÑŒŒˆâ“`Žq”­Œ»‚©‚ç‚Ý‚œ¶ŠˆKŠµ•a”­Ç—\’mƒ}[ƒJ[‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    88. “ˆ”öˆ»Žq, ’––”’qŽÀ, ‹g“cär, ‹{˜e—˜’j: ¶Œã‚Ü‚à‚È‚­‚æ‚èšb–‚ð”F‚ß‚œˆôŒã”^ᇂÌ1—á. ‘æ56‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2011, 11, 13-15, “Œ‹ž.
    89. ”ÂàVŽõŽq, ‰ª•””üŒb, ”óŒû@Žû, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§¬Ž™‚É‚š‚¯‚éImpulse Oscillometry System (IOS)‚ð—p‚¢‚œ‹C“¹‰Â‹t«‚ÌŒŸ“¢. ‘æ19‰ñ—Տ°šb‘§Œ€‹†‰ï, 2011, 11, 19, ‘åã.
    90. Žs“c•™Žq, ²’n@•×, Š–ì_Ž÷, ¬ìrˆê, ’†Œ•q—Y: ‰ä‚ª‘‚̏¬Ž™ŠúS‹ØŽŸŠ³‚Ì•p“x`‰ß‹Ž‚U”NŠÔ‚̊󏭎ŸŠ³’²ž‚©‚ç`. ‘æ20‰ñ“ú–{¬Ž™S‹ØŽŸŠ³Šw‰ïŠwpW‰ï, 2011, 11, 19, “Œ‹ž.
    91. ‹àŒ“O˜a: uƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[v¬Ž™ŒŒ‰t?Žîᇈã‚É’m‚Á‚Ä‚à‚ç‚¢‚œ‚¢–Ɖu•s‘SÇ. ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 27, ‘O‹Ž.
    92. Î‘º–šŽq,‹àŒ“O˜a, ŽR“c‘œŽq: Š³Ž™?‰Æ‘°‚̖ڐü‚ðl‚Š‚œƒvƒŒƒCƒ‹[ƒ€‚­‚è. ‘æ53‰ñ“ú–{¬Ž™ŒŒ‰t?‚ª‚ñŠw‰ï, 2011, 11, 25-27, ‘O‹Ž.
    93. ‰ª•””üŒb, ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚É‚š‚¯‚é•@‰Š‚ªšb‘§‚É‹y‚Ú‚·‰e‹¿. ‘æ38‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2011, 12, 3, ‹à‘ò.
    94. ¯–쌰G, “¡“cË‰›, Œ“c’Œ“¿, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ‘å“퐎•¶: PCR–@‚É‚Ä”^`‚©‚ç×‹ÛDNA‚ðŒŸo‚µ‚Š‚œŠÌ”^ᇍ‡•¹–«“÷‰èŽîÇ‚̈ê—á. ‘æ19‰ñH×–E‹@”\ˆÙíÇŒ€‹†‰ï, 2011, 12, 3, “Œ‹ž.

    2010”N

  • ’˜‘
    1. Žs“c•™ŽqF”ì‘åŒ^S‹ØÇDu¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–ŸCŸÀr—YCŠÖŒûiˆê˜YC‚‹Ž®l•ÒCf’f‚ÆŽ¡—ÎЁC“Œ‹žC349-350, 2010D
    2. Žs“c•™ŽqFŠg’£Œ^S‹ØÇDu¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–ŸCŸÀr—YCŠÖŒûiˆê˜YC‚‹Ž®l•ÒCf’f‚ÆŽ¡—ÎЁC“Œ‹žC351-352, 2010.
    3. Žs“c•™ŽqFS‹Ø‰Š.u¬Ž™‚ÌŽ¡—ÃŽwjv‰ª@–ŸCŸÀr—YCŠÖŒûiˆê˜YC‚‹Ž®l•ÒCf’f‚ÆŽ¡—ÎЁC“Œ‹žC353-354, 2010D
    4. “n•Óˆê—mCŽs“c•™ŽqF¬læ“V«SŽŸŠ³CSŽº’†ŠuŒ‡‘¹DuzŠÂŠíŒ€Cƒm[ƒgv‰iˆä—ÇŽO•ÒCf’f‚ÆŽ¡—ÎЁC“Œ‹žC632-634, 2010D
    5. ‘«—§—YˆêF¬Ž™‚Ì”x‰ŠDu¡“ú‚ÌŽ¡—ÃŽwj2010”N”Ł|Ž„‚Í‚±‚€Ž¡—µ‚Ä‚¢‚évŽRŒû@“OC–kŒŽŒõ•vC•ŸˆäŽŸ–î•ÒCˆãŠw‘‰@C“Œ‹žC1097-1098, 2010D
    6. ‘«—§—YˆêF“û—cŽ™šb‘§‚̊ӕʐf’fDu29th ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX@šb‘§‚̐f’f‚ÆŽ¡—Âɂš‚¯‚é–â‘è“_v‘«—§@–žCXìºœACHŽRˆê’jC‘å“c@Œ’C“Œ“c—L’q•ÒCƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”ŁC“Œ‹žC108-115, 2010D
  • ŒŽ’˜
    1. Hirono K., Yoshimura N., Taguchi M., Watanabe K., Nakamura T., Ichida F., and Miyawaki T.: Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery. J Thorac Cardiov Surg, 140: 346-351, 2010.
    2. Otsubo K. , Kanegane H., Eguchi M., Eguchi I.M., Tamura K., Nomura K., Abe A., Ishii E., and Miywaki T.: ETV6-ARNT fusion in a patient with childhood T lymphoblastic leukemia. Cancer Genet Cytogen, 202: 22-26, 2010.
    3. Chang B., Momoi N., Shan L., Mitomo M., Aoyagi Y., Endo K., Takada I., Chen R., Xing Y., Yu X., Watanabe A., Yoshida T., Kanegane H., Tsubata S., Bowles N.E., Ichida F., Miyawaki T., Noncompaction study collaborators: Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction. Mol Genet Metab, 100: 198-203, 2010.
    4. Matsuzaki T., Matsui M., Ichida F., Nakazawa J., Hattori A., Yoshikosi K., Miyazaki M., Fujii M., Hagino I., Kagisaki K., and Yagihara T.: Neurodevelopment in 1-year-old Japanese infants after congenital heart surgery. Pediatr Int, 52: 420-427, 2010.
    5. Ito Y., Adachi Y., Itazawa T., Okabe Y., Adachi S.Y., Katsunuma T., and Miyawaki T.: Comparison of exhalation time methods (6 sec vs. 10 sec) of a hand-held exhaled nitric oxide analyzer. Pediatr Pulmonol, 45: 1005-1008, 2010.
    6. Kuramoto T., Daikoku T., Yoshida Y., Takemoto M., Oshima K., Eizuru Y., Kanda Y., Miyawaki T., and Shiraki K.: Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther 333: 816-821, 2010.
    7. Matsuhisa H., Yoshimura N., Niimi H., and Ichida F.: Open-heart surgery in an infant with heterozygous factor VII deficiency. Interact Cardiovasc Thorac Surg, 10: 1037-1038, 2010.
    8. Makino T., Horikawa S., Hongo K., Ichida F., Furuichi M., Ueda C., Miyawaki T., and Shimizu T.: Livedo racemosa presenting with congenital fibromuscular dysplasia. Br J Dermatol, 163: 1362-1364, 2010.
    9. Kanezaki R., Toki T., Terui K., Xu G., Wang R., Shimada A., Hama A., Kanegane H., Kawkami K., Endo M., Hasegawa D., Kogawa K., Adachi S., Ikeda Y., Iwamoto S., Taga T., Kosaka Y., Kojima S., Hayashi Y., and Ito E.: Down syndrome and GATA1 mutations in trasient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood, 116: 4631-4638, 2010.
    10. Imamura T., Sato T., Shiota Y., Kanegane H., Kudo K., Nakagawa S., Nakadate H., Tauchi H., Kamizono J., and Morimoto A.: Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol, 91: 646-651, 2010.
    11. Yoshinaga M., Takahashi H., Shinomiya M., Miyazaki A., Kuribayashi N., and Ichida F.: Impact of having one cardiovascular risk factor on other cardiovascular risk factor levels in adolescents. J Atheroscler Thromb, 17: 1167-1175, 2010.
    12. Tsurusawa M., Shimomura Y., Asami K., Kikuta A., Watanabe A., Horikoshi Y., Matsushita T., Kanegane H., Ohta S., Iwai A., Mugishima H., and Koizumi S.: Long-term results of the Japanese childhood cancer and leukemia study group studies 811, 841, 874 and 911 on chilohood acute lymphoblastic leukemia. Leukemia, 24: 335-344, 2010.
    13. Toga A., Wada T., Sakakibara Y., Mase S., Araki R., Tone Y., Toma T., Kurokawa T., Yanagisawa R., Tamura K., Nishida N., Taneichi H., Kanegane H., and Yachie A.: Clinical significance of cloned expansion and CD5 down-regulation in Epstein-barr virus (EBV)-infected CD8+ T lymphocytes in EBV-associated hemophagocytic lymphohistiocytosis. J Infect Dis, 201: 1923-1932, 2010.
    14. Sekine T., Konno M., Sasaki S., Moritani S., Miura T., Wong WS., Nishio H., Nishiguchi T., Ohuchi MY., Tsuchiya S., Matsuyama T., Kanegane H., Ida K., Miura K., Harita Y., Hattori M., Horita S., Igarashi T., Saito H., and Kunishima S.: Patients eith Epstein-Fechtner syndromes owing to MYH9 R702 mutation develop progressive proteinuric renal disease. Kidney Int, 78: 207-214, 2010.
    15. Kondo N., Nishimura T., Nishima S., Morikawa A., Aihara Y., Akasaka T., Akasawa A., Adachi Y., Arakawa H., Ikarashi T., Ikebe T., Inoue T., Iwata T., Urisu A., Ebisawa M., Ohya Y., Okada K., Odajima H., Katsunuma T., Kameda M., Kurihara K., Kohno Y., Sakamoto T., Shimojo N., Suehiro Y., Tokuyama K., nambu M., hamasaki Y., Fujisawa T., Matsui T., Matsubara T., Mayumi M., Mukoyama T., Mochizuki H., Yamaguchi K., and Yoshihara S.: Japanease pediatric guidelines for the treatment and management of bronchial asthma 2008. Pediatr Int, 52: 319-326, 2010.
    16. Kanatani K., Isao I., Al-Delaimy W., Adachi Y., Mathews W., Ramsdell J., Toyama Asian Desert-Dust and Asthma Study Team.: Desert-dust exposure is associated with increased risk of asthma hospitalization in children. Am J Respir Crit Care Med, 182: 1475-1481, 2010.
    17. Taga T., Shimomura Y., Hori T., Horikoshi Y., Ogawa A., Itoh M., Watanabe A., Saikawa Y., Ueyama J., Hyakuna N., Chin M., Iizuka S., Miyake M., Iwai A., Kamitamari A., Kanegane H., Sato N., and Tsurusawa M.: A morphology-based approach for the treatment of children with acute myeloid leukemia: A report from the Japanease Children's Cancer and Leukemia Study Group AML 9805 study. Jpn J Pediatr Hematol, 24: 283-291, 2010.
    18. Yamaji K., Okamoto T., Yokota S., Watanabe A., Horikoshi Y., Asami K., Kikuta A., Hyakuna N., Saikawa Y., Ueyama J., Watanabe T., Okada M., Taga T., Kanegane H., Kogawa K., Chin M., Iwai A., Matsushita T., Shimomura Y., Hori T., Tsurusawa M., and Japanease Children's Cancer and Leukemia Study Group: Minimal residual disease-based augmented therapy in chilohood acute lymphoblastic leukemia: a report from the Japanease Childhood Cancer and Leukemia Study Group. Pediatr Blood Cancer 55: 1287-1295, 2010.
    19. Tamhankar P.M., Zhao M., Kanegane H., and Phadke S.R.:Identification of DKC1 gene mutation in an Indian patients. Indian J Pediatr 77: 310-312, 2010.
    20. Kawashima H., Kanegane H., Mori M., imanaka K., Shinjo M., Murata T., Kasahara Y., Taniguchi Y., Sugita K., and Miyawaki T.: Hyper IgD and periodic fever syndrome in Japan. “Œ‹žˆã‰È‘åŠwŽGŽC68: 235-238, 2010D
    21. ‰ª•””üŒb, ‘«—§—Yˆê, ”ÂàVŽõŽq, ’†—ÑŒºˆê, •£àV—³–ç, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ‘«—§—zŽq, ‹{˜e—˜’j, ‘å–îKO, ¬“c“‡”Ž, ÔàV@W: “û—cŽ™šb‘§‚̉uŠw’²ž‚Ì‚œ‚ß‚ÌŽ¿–â•\‚̑Ó–«‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@24: 705-712, 2010.
  • Ç—á•ñ
    1. Harai T. , Kanegane H., Ito Y., Saito M., Hongo K., and Miyawaki T.: Case of acute cerebellar ataxia associated with primary Epstein-Barr virus infection. Pediatr Int, 52: e178-e180, 2010.
    2. Zhao M. , Kanegane H., Ouchi K., Imamura T., latour S., and Miyawaki T.: A novel XIAP mutation in a Japanese boy with recurrent pancytopenia and splenomegaly. Haematologica, 95: 688-689, 2010.
    3. ‘å’ØŒc•ãC‹àŒ“O˜aC–쑺ŒbŽqC•l“cG—YCŒI–{¹‹IC“¹‹ïL_C“c’†k‘Ÿ˜YC‹{˜e—˜’jFŒ‰Ê‘Ìyolk sac tumor‚ÌŽ¡—ÃŒo‰ß’†‚Ƀp[ƒLƒ“ƒ\ƒ“ÇŒóŒQ‚𔭏ǂµ‚œ’jŽ™—áD“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽC24: 150-154, 2010D
    4. –xìT“ñ˜YC“c‘ºŒ«‘Ÿ˜YC‰eŽR—²ŽiC“n•Óˆê—mC–{‹œ˜a‹vCŽs“c•™ŽqC‹{˜e—˜’jF‘¢‰eCT‚É‚æ‚é3ŽŸŒ³Ä\’zŒŒŠÇ‰æ‘œ‚É‚æ‚èf’f‚µ‚œüˆÛ‹ØŒ`¬•s‘S‚Ì1“ûŽ™—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1588-1591, 2010D
    5. –xìT“ñ˜YC”ÂàVŽõŽqC–Ø‘]ŒŽŒåC‹àŒ“O˜aC‹{˜e—˜’jFäX•ª”含ƒgƒŠƒvƒVƒ“ƒCƒ“ƒqƒrƒ^[ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œ‰Æ‘°«äX‰Š‚Ì1—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1603-1607, 2010D å@‹v”TCˆÉŒ\“ñ˜YC’†—ÑŒºˆêCŽÂèŒ’‘Ÿ˜YC‹àŒ“O˜aC‹{˜e—˜’jFŽš«…“ªÇ‚Ì1—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1723-1728, 2010D
    6. âV“¡˜a—RC’ÔŠáÁˆêC‘ºãIŒ[C–{ŠÔˆê³F—ˆ‰@ŽžS”x’âŽ~6—á‚ÌŒŸ“¢‚š‚æ‚ÑŽ€–SŽž‰æ‘œf’f‚ÌŒoŒ±D¬Ž™‰È—Տ°C63: 515-520, 2010D
    7. “c‘ºŒ«‘Ÿ˜YC‹g“cärC–xìT“ñ˜YC“ŒŽROKCà_“‡@äCÎàV@LCˆÉ“¡ŽÀC“‡@—FŽqC•Ä“c@“NC‰–è—LGCâV“¡@Ž C‹{˜e—˜’jF‘Ù”Õ“àãO–ÑŠà‚É‚æ‚è‘ÙŽ™•ê‘ÌŠÔ—AŒŒÇŒóŒQ‚𔭏ǂµ‚œ“ñãO–Ñ–Œ“ñ—r–Œ«‘o‘Ù‚Ì1—áDŽüŽYŠúˆãŠwC40: 273-276, 2010D
  • ‘à
    1. Žs“c•™ŽqFS‹Øãk–§‰»áŠQD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 1819-1828, 2010D
    2. Žs“c•™ŽqFS‹Ø‰Š,S–ŒŽŸŠ³‚Ìup to date ¶ŽºS‹Øãk–§‰»áŠQD¬Ž™“à‰ÈC42: 730-732, 2010D
    3. Žs“c•™ŽqFS‹Ø‰Š,S–Œ‰Š ƒtƒ[ƒ`ƒƒ[ƒg‚ł݂鎄‚̏ˆ•ûD¬Ž™‰È—Տ°C63: 623-628, 2010D
    4. Žs“c•™ŽqF‚±‚±‚Ü‚Å‚í‚©‚Á‚Ä‚¢‚鎩ŒÈR‘Ì‚ÆŽ©ŒÈ–ƉuŽŸŠ³@Šg’£Œ^S‹ØÇD¬Ž™‰Èf—ÁC73i‘j: 2201-2203, 2010D
    5. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Æ‚»‚̑ΉžD“ú–{¬Ž™‰ÈŠw‰ïŽGŽC114: 23-30, 2010D
    6. ‘«—§—YˆêF¬Ž™šb‘§‚É‚š‚¯‚é‹z“üƒÀŽhŒƒ–ò‚ÌŽg‚¢•ûD¬Ž™‰ÈC51: 1273-1278, 2010D
    7. ‘«—§—YˆêF‹CŠÇŽxšb‘§@f—ÃKƒCƒhƒ‰ƒCƒ“‚̉ðàD¬Ž™‰È—Տ°C63: 2539-2543, 2010D
    8. ‘«—§—YˆêF¬Ž™dÇšb‘§‚̗Տ°D—Տ°–ƉuEƒAƒŒƒ‹ƒM[‰ÈC53: 179-183, 2010D
    9. ‘«—§—YˆêF“û—cŽ™šb‘§DŒÄ‹zC29: 1194-1198, 2010D
    10. ‹àŒ“O˜aC˜a“c‘׎OC–Ø‘º@GFEBƒEƒCƒ‹ƒXŠŽõÇD¬Ž™‰ÈC51: 554-555, 2010D
    11. ‹àŒ“O˜aCVˆä^—“ށC’J“à]ºGF–«Šˆ“®«EBƒEƒCƒ‹ƒXŠŽõÇDƒ‚ƒ_ƒ“ƒƒfƒBƒAC56: 93-99, 2010D
    12. ‹{˜e—˜’jC‹àŒ“O˜aFŒŽ”­«–Ɖu•s‘SÇ-–³‚Ü‚œ‚Í’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ-@f’f‚ÆŽ¡—Â̐V‚µ‚¢ƒgƒŒƒ“ƒhD“ú–{—ÕଁC68: 1197-1203, 2010D
    13. ‹àŒ“O˜aC‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇ‚É‚š‚¯‚é’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇDŒŒ‰tƒtƒƒ“ƒeƒBƒAC20: 1983-1989, 2010D
    14. ‹àŒ“O˜a: ‚Ç‚Ì‚æ‚€‚È‚Æ‚«‚ɖƉu•s‘SÇ‚ð‹^‚€‚©H ¬Ž™ŠŽõ–Ɖu 22: 417-419, 2010.
    15. –{‹œ˜a‹vC‹{@ˆêŽuF¬Ž™“«‚Ä‚ñ‚©‚ñ‚ÌŽ©ŒÈ–Ɖu“I”wŒiD¬Ž™‰ÈC51:1749-1753, 2010D
    16. ”ÂàVŽõŽqF’á”N—‚É‚š‚¯‚éŒÄ‹z‹@”\ŒŸž‚ÌŽÀŒ»‚ð–ÚŽw‚µ‚āD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 389-396, 2010D
    17. ”ÂàVŽõŽqC‘«—§—YˆêFƒAƒŒƒ‹ƒM[ŽŸŠ³‚Ɗ‹«ˆöŽq‚̉uŠwD—Տ°–ƉuEƒAƒŒƒ‹ƒM[‰ÈC53: 36-41, 2010D
    18. ”ÂàVŽõŽqC‘«—§—YˆêF¬Ž™šb‘§‚Ì‹}«‘ˆ«‚ɑ΂·‚鏉Šú‘ΉžDƒAƒŒƒ‹ƒM[‚̗Տ°C30: 902-906, 2010D
    19. ”ÂàVŽõŽqFImpulse oscillometry system (IOS) ‚É‚æ‚é”x‹@”\‚Ì•]‰¿•û–@D“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽGŽC21: 33-37, 2010D
    20. “n•Óˆê—mCŽs“c•™ŽqFV¶Ž™Šú‰ñfpŒã‚Ì”]‚ŽŸ‹@”\áŠQDFetal & Neonatal Medicine, 2: 40-44, 2010D
    21. ‘«—§—zŽqF‚Í‚¶‚Ü‚è‚̓`ƒŠ‚Ì’†D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 401-408, 2010D
    22. ‘å’ØŒc•ãC‹àŒ“O˜aC¬—шê˜YC‹{˜e—˜’jFIPEXÇŒóŒQ‚ƃqƒgTreg×–EDJpn J Clin Immunol, 33: 196-206, 2010D
    23. ”óŒû@ŽûC‘«—§—YˆêF‚±‚ê‚Ÿ‚¯‚Í’m‚Á‚Ä‚š‚«‚œ‚¢‹C“¹ŽŸŠ³‚̍ŐVf’fŒŸž–@@IV. š\ႥŒŒ‰tŒŸž@ŒŒ‰t¥¶‰»ŠwŒŸžD¬Ž™‰Èf—ÁC73: 1763-1765, 2010D
    24. “c‘ºŒ«‘Ÿ˜YC‹àŒ“O˜aC‹{˜e—˜’jFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQD¬Ž™‰Èf—ÁC73: 2210-2214, 2010D
    25. à_è—Y•œCáÁ‹|Œõ•¶C‘«—§—YˆêF¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‰ðà@ƒKƒCƒhƒ‰ƒCƒ“‚ð‚Ç‚€“Ç‚Þ‚©g‘æ10Í@¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é‹z“ü‹@Ší‚Æ‚»‚ÌŽg‚¢•û"D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽC24: 241-246, 2010D

  • 2010”NŠw‰ï•ñ
    1. Miyawaki T., and Kanegane H.: Early recognition of primary immunodeficiency diseases by flow cytometry. 13th Asian Pacific Congress of Pediatrics, 2009, 10, 10-14, China. (Invited lecture)
    2. Kanegane H.: Flow cytometric diagnosis of XLP1 and 2. The world's first conference on X-linked lymphoproliferative disease, 2010, 2, 15, London.
    3. Adachi Y., Itazawa T., Matsuno M., Adachi YS., Ito Y., Okabe Y., Akasawa A., and Miyawaki T.: Association of obesity with lung function of symptom-free asthmatic children. 66th Annual Meeting of American Asthma Allergy & Immunology, 2010, 2, 26-3, 2, New Orleans, LA, USA.
    4. Itazawa T., Adachi Y., Matsuno M., Adachi YS., Ito Y., Okabe Y., Akasawa A., and Miyawaki T.: Association of obesity with asthma control in childhood asthma. 66th Annual Meeting of American Asthma Allergy & Immunology, 2010, 2, 26-3, 2, New Orleans, LA, USA.
    5. Ichida F.: Left ventricular noncompaction, Genetic clinical features and genetic background. 6th Krea-Japan-China Forum, 2010, 3, 27, Soeul. (Invited lecture)
    6. Kanegane H., Koura U., Sakaki H., Otsubo K., Nomura K., Morio T., Wada T., Yachie A., Oshima K., Ohara O., and Miyawaki T.: T-B+NK+ severe combined immunodeficiency caused by a common gamma chain deficiency. 2010 First American Primary Immune Deficiency National Conference, 2010, 5, 20-23, Philadelphia, USA.
    7. Ichida F: Left ventricular noncompaction, Genetic clinical features and genetic background. The 44th Annual Meeting of AEPC, 2010, 5, 28, Innsbruck. (Invited lecture)
    8. Ichida F. : Genetics and manifestations of Noncompaction. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    9. Saito K., Hirono K., Ibuki K., Watanabe K., Ozawa S., Ichida F., Miyawaki T., and Yoshimura N.: NT-pro-BNP is sensitive to latent chronic heart failure in congenital heart disease. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    10. Saito K., Hirono K., Ibuki K., Kanegane H., Ichida F., Miyawaki T., and Kemmotsu Y.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    11. Ibuki K., Saito K., Hirono K., Yoshimura N., Taguchi M., Watanabe K., Nakamura T., Ichida F., and Miyawaki T.: Bosentan induces clinical and hemodynamic improvement in candidates for right heart bypass surgery. APPCS Panel Discussion, 2010, 7, 7, Chiba.
    12. Kanegane H., Otsubo K., Yang X., Kamachi Y., Kobayashi I., and Miyawaki T.: Identification of FOXP3-negative regulatory T-like (CD127dimCD25+CD4+) cells in patients with IPEX. 14th Meeting of the European Society for Immunodeficiencies, 2010, 10, 6-9, Turkey .
    13. Ichida F., Chang B., TNishizawa T., Furutani M., Fujiki A., Tani M., KawaguchiM., Ibuki K., Hirono K., Bowles N.E., and Matsuoka R.: Identification of a novel TPM1 mutation in a family with left ventricular noncompaction and sudden death. The 83th Scientific Sessions of AHA 2010, 2010, 11, 13-17, Chicago.
    14. Saito K., Takasaki I., Hirono K., Ibuki K., Watanabe K., Bowles N.E., Ichida F., and Miyawaki T.: MicroRNAs may control MRNA networks in circulating PBMCs during the acute phase of Kawasaki disease. The 83th Scientific Sessions of AHA 2010, 2010, 11, 13-17, Chicago.
    15. “n•Óˆê—mCˆÉŒ\“ñ˜YCâV“¡˜a—RCœA–ìŒbˆêCŽs“c•™ŽqC–F‘º’ŒŽ÷F‚“x‹·ó•a•Ï‚ɑ΂·‚é’Ž‚‘ψ³ƒoƒ‹[ƒ“CONQUEST‚Ì—LŒø«D‘æ21‰ñ“ú–{Pediatric Interventional Cardiology (JPIC) Šw‰ïŠwpW‰ïC2010, 1, 21-23, Ã‰ªD
    16. ˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêCŽs“c•™ŽqCŽR’†ŸOC‘卂TŒáC“úŒG’qŒ›C–F‘º’ŒŽ÷C•x“c@‰pFTCPCpŒã‚Ì”x“®–¬ƒXƒeƒ“ƒg“àŒŒð«•ÂÇ‚ɑ΂µCƒJƒe[ƒeƒ‹‚É‚æ‚錌ð‹zˆøœ‹Ž‚ðs‚Á‚œ2Ç—áD‘æ21‰ñ“ú–{Pediatric Interventional Cardiology (JPIC) Šw‰ïŠwpW‰ïC2010, 1, 21-23, Ã‰ªD
    17. ¬‰Y@ŽCå@‹v”TC‘å’ØŒb•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC•õŠÝŽu’ÃŽqCX”ö—FGC˜a“c‘׎OC’J“à]ºGC‘哈GˆêC¬ŒŽ@ŽûF“¯Žíœ‘ˆÚA‚É‚Ä‹~–œ‚µ‚Š‚œdÇƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‡•¹dÇ•¡‡–Ɖu•s‘SÇ‚Ì1—áD‘æ3‰ñ“ú–{–Ɖu•s‘SÇŒ€‹†‰ïC2010, 1, 30, “Œ‹žD
    18. ‘å’ØŒc•ãC‹àŒ“O˜aF‰Eèò•”ŒðŠŽ_ŒoßŒŽ”­ALK—z«_Œo‰èŽî‚Ì3‚©ŒŽ—Ž™—áD‘æ5‰ñJNBSG‘‰ïC2010, 1, 31, “Œ‹žD
    19. ‘«—§—YˆêFJPGL2008‚ÆŽÀ’n—Տ°‚Æ‚ÌGAP‚ðŒŸØ‚·‚é|f’fEŠÇ—‚Ì‚œ‚ß‚ÌŒŸž‚ÉŠÖ‚·‚éGAP|D‘æ18‰ñ¬Ž™—Տ°–ò—EƒAƒŒƒ‹ƒM[E–ƉuŒ€‹†‰ïC2010, 1, 30-31, ŽOdD
    20. œA–ìŒbˆêCˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jCŽR’†ŸOC‘卂TŒáC“úŒG’qŒ›C–F‘º’ŒŽ÷F”x‚ŒŒˆ³‚ð—L‚·‚é‰ESƒoƒCƒpƒXŽèp“K‰ž¢“ï—á‚ɑ΂·‚éƒ{ƒZƒ“ƒ^ƒ“‚Ì—L—p«D‘æ16‰ñ“ú–{¬Ž™”xzŠÂŒ€‹†‰ïC2010, 2, 6, “Œ‹žD
    21. å@‹v”TC¬‰Y@ŽC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFlHŒÄ‹zŠÇ—‰º‚Å“¯Žíœ‘ˆÚA‚ðs‚Á‚œ‘SgƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‡•¹dÇ•¡‡–Ɖu•s‘SÇ‚Ì1—áD‘æ32‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïC2010, 2, 19-20, •lŒD
    22. ‘å’ØŒc•ãCå@‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF”ñŠ°‰ðó‘Ô‚ÅHLA”Œ‡’vŒŒ‰ƒhƒi[‚©‚ç––œŒŒŠ²×–EˆÚA‚ðs‚Á‚œAMLC—Œ‘€–Ô–Œ‰èŽî‚̏d•¡‚ª‚ñ‚̏—Ž™—áD‘æ32‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ïC2010, 2, 19-20, •lŒD
    23. “n•Ó—S‹IC‹{@ˆêŽuC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC‰ª“cˆÀOCŽRè@“OCŽO‰Y³‹`Cã–ì—zŽqC’B@GŽ÷CŽÄ“c“NŽuC‘ŽRG–ŸCŒKŒŽ@‹­C‚‹Ž’å‰ÀC•Ÿ–{‘׋KC‰Í–ì”üKCˆÉìœA“¹C–؉º‰p—ŽqC–©@GC–쓇F”VC‰ª“c’ŒŽ÷C–xàV@“OCÒì@‘ŸF•af˜AŒgCWŠw“IŽ¡—Âɂæ‚芰‰ð‚ÉŽŠ‚Á‚œ• o“à”j—ô‚µ‚œŠÌ‰èŽî‚̈ê—áD‘æ31‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ïC2010, 2, 27, ‹à‘òD
    24. Hirono K., Saito K., Ibuki K., Watanabe K., Ichida F., and Miyawaki T.: Cyclosporin improves coronary artery lesions and inflammation via down regulation of calcineurin-NFAT signaling in refractory Kawasaki disease. ‘æ74‰ñ“ú–{zŠÂŠíŠw‰ïEŠwpW‰ïC2010, 3, 5-7, ‹ž“sD
    25. ‘åÀ–FŽqCŒ‹vO“TC–F‘º’ŒŽ÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jF³í¬Ž™¶Žº‹ÇŠ•Ç‰^“®“Á«FƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚œ•]‰¿D‘æ74‰ñ“ú–{zŠÂŠíŠw‰ïEŠwpW‰ïC2010, 3, 5-7, ‹ž“sD
    26. ‹àŒ“O˜aC‹{˜e—˜’jFX-linked lymphoproliferative disease: An update. ‘æ20‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ïC2010, 3, 6, “Œ‹žD ‘å“àˆêFC¡‘ºr•FC”[’J^—R”üC‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jC×ˆä@‘nFXIAPŒ‡‘¹ÇiX˜AœƒŠƒ“ƒp‘B2Œ^j‚Ì1—áD‘æ6‰ñŒŒ‹…æÐHÇŒóŒQŒ€‹†‰ïC2010, 3, 6, “Œ‹žD
    27. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ÆVirus-induced wheezev@‘æ9‰ñ‹ãBŠO—ˆ¬Ž™‰ÈŒ€‹†‰ïC2010, 3, 14, ‹{èDiµ‘ҍu‰‰j
    28. Œè‘œç‘ãFƒVƒ“ƒ|ƒWƒEƒ€uæ“V«SŽŸŠ³‚Ì”­’B‚ɐS—Šw‚͉œ‚ª‚Å‚«‚é‚Ì‚©|“ûŽ™Šú”­’B‚Ì—lŽqv@‘æ21‰ñ“ú–{”­’BS—Šw‰ïŠwpW‰ïC2010, 3, 26, _ŒËD
    29. “n•Ó—S‹IC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF‹z‹C«šb–‚𔺂€ŒÄ‹z¢“ï‚𗈂œ‚µ‚œcŠuŽîᎂ̓ûŽ™—áD‘æ5‰ñ•xŽRERƒtƒH[ƒ‰ƒ€C2010, 4, 9, •xŽRD
    30. Žs“c•™ŽqF•ª–ì•ÊƒVƒ“ƒ|ƒWƒEƒ€@–ƉuƒOƒƒuƒŠƒ“•s‰ž—á‚ɑ΂·‚éRƒTƒCƒgƒJƒCƒ“—Ö@D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    31. ‹àŒ“O˜aCŠ—’r‹g˜NC‹{˜e—˜’jF‚킪‘‚ÌIPEXÇŒóŒQ‚̗Տ°“I¥–ƉuŠw“I“Á’¥D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    32. ”~ìŒåŽiC“n•Óˆê—mCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jCd“cFMCã–{–õ‰îC•Ÿ“cW–çCŠ}ŒŽŒQ¶Fƒ`ƒAƒm[ƒ[‚ðŒ_‹@‚ɐæ“V«–å–¬Œ‡‘¹ÇEŠÌ”xÇŒóŒQ‚Ɛf’f‚µ¶‘̊̈ڐA‚ðŽ{s‚µ‚œ1—áD‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    33. ”ÂàVŽõŽqCŒ–쐳’mCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêCÔàV@WC‹{˜e—˜’jF”ì–ž‚ª¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚â”x‹@”\‚É‹y‚Ú‚·‰e‹¿D‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    34. Œè‘œç‘ãCŽs“c•™ŽqCŒˆäŽOŽ}FpŒãæ“V«SŽŸŠ³Ž™‚̐_Œo”­’B“I’·Šú—\ŒãD‘æ113‰ñ“ú–{¬Ž™‰ÈŠw‰ïC2010, 4, 23-25, ·‰ªD
    35. ‘«—§—YˆêFƒe[ƒ}ŠÙ@Šw‰ïƒAƒ[ušb‘§Ž¡—Âɂš‚¯‚éRLT–ò‚Ì–ðŠ„v@‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    36. ‘«—§—YˆêFƒ~ƒjƒVƒ“ƒ|ƒWƒEƒ€u“ûŽ™šb‘§‚ÆŠŽõ|“û—cŽ™šb‘§‚̐f’f@ƒRƒc‚ƃsƒbƒgƒtƒH[ƒ‹|v@‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    37. ‘ºã—mŽqC¬“c“ˆ”ŽC‘«—§—YˆêC‹g“cKˆêC‘å–îKOCÔàV@WF¬Ž™‚É‚š‚¯‚é‰^“®—U”­šb‘§‚ÌŽÀ‘ԁD‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    38. ”ÂàVŽõŽqC‘«—§—YˆêC‹g“cKˆêC‘å–îKOC¬“c“ˆ”ŽCÔàV@WC‹{˜e—˜’jF—cŽ™‚É‚š‚¯‚é‘ÌŠi‚ƃAƒŒƒ‹ƒM[ŽŸŠ³‚ÌŠÖŒWD‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    39. ˆÉ“¡–õ“TC”ÂàVŽõŽqC‰ª•””üŒbC”óŒû@ŽûC’†—ÑŒºˆêC•£àV—³–çC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒg‚Å‹qŠÏ“I‚ȃRƒ“ƒgƒ[ƒ‹ó‘Ô‚ð‚Ç‚±‚Ü‚Å•]‰¿‚Å‚«‚é‚©D‘æ22‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2010, 5, 8-9, ‹ž“sD
    40. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC‘«—§—YˆêC‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚É‚š‚¯‚镉‰×ŽŽŒ±Œã‚̏œ‹ŽH‰ðœ‚ÌŒ»óD‘æ31‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2010, 5, 13, •xŽRD
    41. ‘åÀ–FŽqCŒ‹vO“TC–F‘º’ŒŽ÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jF2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚émultiple VSDpŒã‚Ì‚Ë‚¶‚ê‚Æ‚Ù‚Ç‚¯‚Ì•]‰¿D‘æ21‰ñ“ú–{SƒGƒR[}Šw‰ïC2010, 5, 13-15, ŽD–yD
    42. Žs“c•™ŽqFæ“V«SŽŸŠ³‚É‚š‚¯‚é”x‚ŒŒˆ³‚ÌŽ¡—ÁD“ޗǏ¬Ž™æ“V«SŽŸŠ³ƒZƒ~ƒi[C2010, 5, 15, “ޗǁDiµ‘ҍu‰‰j
    43. ŽíŽsq’ˆCœA–ìŒbˆêCˆÉŒ\“ñ˜YC¬‰Y@ŽC–x‰ªzŽqCVŽðŠì”ü‘ãCŽs“c•™ŽqC‹{˜e—˜’jF¬Ž™ŠCŠO”À‘—‚É‚š‚¯‚é–â‘è“_‚̍lŽ@D‘æ10‰ñ–k—€¬Ž™‹~‹}EW’†Ž¡—ÃŒ€‹†‰ïC2010, 5, 15, ‹à‘òD
    44. ‹{@ˆêŽuC–{‹œ˜a‹vC‹{˜e—˜’jF“ªŠW“àãó×–EŽîᇂ̒†•_Œo‡•¹Ç‚ÉŠÖ‚·‚錟“¢D‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ïC2010, 5, 20-22, •Ÿ‰ªD
    45. –{‹œ˜a‹vC“¡–Ø–õŽqCŒŽˆä•ü”üC“c’‡çHC‹{@ˆêŽuC‹{˜e—˜’jF“Á”­«‚Ä‚ñ‚©‚ñ‚Ì”F’m‹@”\D‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ïC2010, 5, 20-22, •Ÿ‰ªD
    46. ŽíŽsq’ˆFƒCƒ“ƒtƒ‹ƒGƒ“ƒUAiH1N1j2009ŠŽõ‚É‚š‚¯‚鑁Šúf’fƒ}[ƒJ[‚Æ‚µ‚Ä‚ÌMxA’`”’‘ª’è‚̈Ӌ`D‘æ24‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ïC2010, 5, 28-29, ‹ž“sD
    47. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC‘«—§—YˆêC‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚É‚š‚¯‚镉‰×ŽŽŒ±Œã‚̏œ‹ŽH‰ðœ‚ÌŒ»óD‘æ27‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïC2010, 5, 29-30, “Œ‹žD
    48. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ƃA[ƒŠ[ƒCƒ“ƒ^[ƒxƒ“ƒVƒ‡ƒ“v@‘æ27‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïC2010, 5, 29-30, “Œ‹žD
    49. ‘åÀ–FŽqCŒ‹vO“TC–F‘º’ŒŽ÷C“n•Óˆê—mC¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jFƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚É‚æ‚émultiple VSDp‘OŒã‚̏¬Ž™‹ÇŠ•Ç‰^“®‚Ì”äŠrD“ú–{’Ž‰¹”gˆãŠw‰ï‘æ83‰ñŠwpW‰ïC2010, 5, 29-31, ‹ž“sD
    50. ŒŽˆä•ü”üC‘q–{@’C“¡–Ø–õŽqC‹{@ˆêŽuCŠÛŽRŒ³ËCóˆä³ŽkC–{‹œ˜a‹vF“–‰@‚ÅŽ{s‚µ‚œˆô“ª‹CŠÇ•ª—£p‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ299‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2010, 6, 13, •ŸˆäD
    51. ‹{@ˆêŽuCÔ‰H@’C“¡–Ø–õŽq,‘«—§—zŽqC‹{˜e—˜’jF‚¯‚¢‚ê‚ñ‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œƒrƒ^ƒ~ƒ“DŒ‡–R«’áƒJƒ‹ƒVƒEƒ€ŒŒÇ‚Ì1Î’jŽ™—áD‘æ299‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2010, 6, 13, •ŸˆäD
    52. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚̗Տ°i“Á•Êu‰‰jD‘æ71‰ñ–k—¢zŠÂŠí§˜b‰ïC2010, 6, 24, _“ސìDiµ‘ҍu‰‰j
    53. “n•Óˆ»‰ÀCÖ“¡˜a—RCˆÉŒ\“ñ˜YC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jF¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢|“û—cŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá|iYIAŽóÜjD‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    54. Žs“c•™ŽqFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[uRSV infection in Congenital heart diseasevæ“V«SŽŸŠ³‚ÆRSVŠŽõÇD‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    55. “n•Óˆê—mCˆÉŒ\“ñ˜YCâV“¡˜a—RCŽs“c•™ŽqC‹{˜e—˜’jCŽR’†ŸOC“úŒG’qŒ›C–F‘º’ŒŽ÷C¬àVˆ»‰ÀF“à‘ŸöˆÊÇŒóŒQ‚ɍ‡•¹‚·‚é‹CŠÇŒ`‘Ԉُí‚̉e‹¿|MDCT‚ð—p‚¢‚œ‹CŠÇ‚ÌŒ`‘Ô•]‰¿|D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    56. ˆÉŒ\“ñ˜YCœA–ìŒbˆêC‘åÀ–FŽqC¬‰Y@ŽCâV“¡˜a—RC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jFdÇS•s‘SŠ³ŽÒ‚É‚š‚¯‚éŠCŠOq‹ó”À‘—Žž‚̐S‹@”\‚̕ω»D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    57. ‹Ž–{ˆè•vCã–ì—zŽqCŒ‰Y‰ÂjC‹à“c@®CˆÉŒ\“ñ˜YCâV“¡˜a—RC‘åÀ–FŽqCŽs“c•™ŽqC‹{˜e—˜’jFDeformed Ventricle‚ð—L‚·æ“V«SŽŸŠ³‚ɑ΂·‚éS‹@”\•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    58. Œè‘œç‘ãCŽs“c•™ŽqCŒˆäŽOŽ}C–F‘º’ŒŽ÷F“ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ê‚œæ“V«SŽŸŠ³Ž™‚̏AŠwŽž”F’m‹@”\D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—t.
    59. Œè‘œç‘ãCŒˆäŽOŽ}CŽs“c•™ŽqC–F‘º’ŒŽ÷CŽsì@”£C”ª–ØŒŽrŽFV¶Ž™E“ûŽ™ŠJSpŒã‚̐ž_E‰^“®”­’B‚ÌŒpŽž“I•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    60. ‘åÀ–FŽqCŒ‹vO“TC–F‘º’ŒŽ÷CâV“¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jFmultiple VSD‚š‚æ‚ÑVSD2Œ^pŒã‚̍¶Žº‹ÇŠ•Ç‰^“®‚Ì”äŠr@2DƒXƒyƒbƒNƒ‹ƒgƒ‰ƒbƒLƒ“ƒO–@‚ð—p‚¢‚œ•]‰¿D‘æ46‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ïC2010, 7, 7-9, ç—tD
    61. âV“¡˜a—RF“«ìè•a‚ɑ΂·‚éƒVƒNƒƒXƒ|ƒŠƒ“A‚ÌŒø‰Ê‚š‚æ‚эì—p‹@˜‚ÌŒŸ“¢D‘æ14‰ñìè•aŽ¡—ͧ˜b‰ïC2010, 7, 9, ç—tD
    62. ŽíŽsq’ˆC‹{@ˆêŽuC”ÂàVŽõŽqC–{‹œ˜a‹vC‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚œdÇƒCƒ“ƒtƒ‹ƒGƒ“ƒUAiH1N1j2009ŠŽõÇ‚Æ•xŽRŒ§‚É‚š‚¯‚é‘΍ô‚ðU‚è•Ô‚Á‚āD‘æ25‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ïC2010, 7, 11, ‚‰ªD
    63. ™ŽR–ŸŽqC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC•l“cG—YCŒI–{¹‹IFNeoadjuvant chemotherapy ‚ðs‚Á‚œ AT/RT‚̈ê—áD‘æ9‰ñ¬Ž™”]Žîᇎ¡—ÃŒ€‹†‰ïC2010, 7, 17, ‘åãD
    64. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g2010”N‚É‚š‚¯‚é‹CŠÇŽxšb‘§‚Ì‚·‚ׂÄ"ušb‘§‚Ì”­ÇˆöŽq‚Æ‘ˆ«ˆöŽqi‰q¶‰Œà‚ðŠÜ‚ށjv@‘æ30‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒXC2010, 7, 31-8, 1, ‹ž“sDiµ‘ҍu‰‰j
    65. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Ì‹}«”­ì‚ÌŽ¡—ÁD‘æ4‰ñ‘Š–ÍŒŽƒAƒŒƒ‹ƒM[ƒZƒ~ƒi[C2010, 8, 8, ‰¡•lD
    66. ŽíŽsq’ˆC–x]’åŽuC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC’@–LŽjCˆÉ’B—mŽŠF‘¢ŒŒŠ²×–EˆÚAŒã‚ɍ‡•¹‚µ‚œ•ÂÇ«×‹CŠÇŽx‰Š‚ɑ΂µ‚Ä—Œ‘€¶‘Ì”xˆÚA‚ðŽ{s‚µ‚œ15Î’jŽ™—áD‘æ46‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ïC2010, 8, 22, ‹à‘òD
    67. ’‡‰ª‰pKC“n•Óˆê—mCâV“¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀCœA–ìŒbˆêCŽíŽsq’ˆC‹{@ˆêŽuCŽs“c•™ŽqC‹{˜e—˜’jC‚è–ƒ”üCãšŒhˆê˜YFS”x’âŽ~‚©‚ç‘h¶‚µ“Ÿ‚œS‘©Œ^S‹ØÇ‚̈ê—áD‘æ46‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ïC2010, 8, 22, ‹à‘òD
    68. Œè‘œç‘ãCˆÉŒ\“ñ˜YCâV“¡˜a—RC¬àVˆ»‰ÀC“n•Óˆê—mCŽs“c•™ŽqC–F‘º’ŒŽ÷Fæ“V«SŽŸŠ³Ž™‚̐ž_‰^“®”­’BD‘æ38‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ïC2010, 8, 28, ‹à‘òD
    69. ”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF–{–M¬Ž™‚É‚š‚¯‚éšb‘§‚Ɣ얞‚ÌŠÖŒWD‘æ13‰ñ•xŽR¬Ž™ƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2010, 9, 4, •xŽRD
    70. ™ŽR–ŸŽqC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCÎàV@LC‘ê“c‡ŽqF‰Eèò•”ŒðŠŽ_ŒoßŒŽ”­ALK—z«_Œo‰èŽîstageE‚Ì“ûŽ™—áD‘æ32‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ïC2010, 9, 11, ‹à‘òD
    71. Kanegane H., Zhao M., and Miyawaki T: Clinical and genetic characteristics of X-linked lyomphoproliferative diagnosed in Japan. ‘æ72‰ñ“ú–{ŒŒ‰tŠw‰ïC2010, 9, 24-26, ‰¡•lD
    72. Otsubo K., Kanegane H., Eguchi M., Ishimae M., Nomura K., Abe A., Ishii Eiichi and Miyawaki T.: A TEL-ARNT fusion in a boy with T lymphoblastic leukemia. ‘æ72‰ñ“ú–{ŒŒ‰tŠw‰ïC2010, 9, 24-26, ‰¡•lD
    73. Žs“c•™ŽqF¬Ž™Šú‚̐S‹ØÇ|Å‹ß‚̘b‘è|D‘æ6‰ñ_“ސ쏬Ž™zŠÂŠíŒ€‹†‰ïC2010, 9, 25, _“ސìDiµ‘ҍu‰‰j
    74. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°D“Œ–M‘åŠw’nˆæ˜AŒgŠwpW‰ïMeet the ExpertsC2010, 10, 1, “Œ‹žDiµ‘ҍu‰‰j
    75. å@‹v”TC”~ìŒåŽiCˆÉ“¡–õ“TCŽÂèŒ’‘Ÿ˜YC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFÝ‘îƒ^[ƒ~ƒiƒ‹ƒPƒA‚ðŽ{s‚µ‚œ15Î‘‰èŽî‚̏—Ž™—áD‘æ10‰ñ’†•”‚ª‚ñƒg[ƒ^ƒ‹ƒPƒAŒ€‹†‰ïC2010, 10, 2, –ŒŒÃ‰®D
    76. Œè‘œç‘ãC‹g“cärC“ñ’J•CŒˆäŽOŽ}CˆÉŒ\“ñ˜YC“n•Óˆê—mCŽs“c•™ŽqFBayley“û—cŽ™”­’BŒŸž‚É‚æ‚é”­’B•]‰¿‚Æ‚»‚Ì—LŒø«F‘æ49‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ïC2010, 10, 3, •xŽRD
    77. ˆÉŒ\“ñ˜YC‘åÀ–FŽqCâV“¡˜a—RC¬àVˆ»‰ÀC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jFdÇS•s‘SŠ³Ž™‚É‚š‚¯‚éŠCŠOq‹ó”À‘—Žž‚̐S‹@”\‚̕ω»D‘æ29‰ñ“ú–{S‘ŸˆÚAŒ€‹†‰ïŠwpW‰ïC2010, 10, 9, “Œ‹žD
    78. ŽíŽsq’ˆCŽá™‰ë_CHœA‹I“lŽiC—L“ˆ‘ñ˜YC‰œŽ›@ŒhF¬Ž™ŠCŠO”À‘—‚ÌŽÀÛ‚Æ–â‘è“_‚̍lŽ@D‘æ38‰ñ“ú–{‹~‹}ˆãŠw‰ïC2010, 10, 9-11, “Œ‹žD
    79. Žs“c•™ŽqF“Á•Ê”­ŒŸuIVNG•s‰ž—á‚ɑ΂·‚鎡—ÃvƒƒgƒR[ƒ‹`ƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@‚Ì–â‘è“_‚Æ“K³Žg—p`v@‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    80. ꎓ¡˜a—RC‚èˆê˜NCˆÉŒ\ŽŸ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêCƒj[ƒ‹ƒ{[ƒŒƒXCŽs“c•™ŽqC‹{˜e—˜’jFìè•a‹}«Šú‚Ì’PŠj‹…×–E‚É‚š‚¯‚éCƒ}ƒCƒNƒRNA‚É‚æ‚émRNA‚Ì”­Œ»§Œä‚̉”\«‚ɂ‚¢‚āD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    81. ’‡‰ª²’qŽqCꎓ¡˜a—RCˆÉŒ\“ñ˜YC¬àVˆ»‰ÀC“n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jC“úŒG’qŒ›C[ŒŽˆêWC–F‘º’ŒŽ÷Fìè•aŒã‹}«S‹Ø[Ç‚É‚æ‚èŒ`¬‚³‚ê‚œ¶ŽºáŽ‚ɑ΂µCŠ¥“®–¬ƒoƒCƒpƒXp‚ƍ¶ŽºŒ`¬p‚ðŽ{s‚µ‚œ5Î’jŽ™—áD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    82. –x]’åŽuCꎓ¡˜a—RCˆÉŒ\“ñ˜YC“n•Óˆê—mCŽíŽsq’ˆCŽs“c•™ŽqC‹{˜e—˜’jC“úŒG’qŒ›C–F‘º’ŒŽ÷FFontanpŒã‘Šú‚ɐìè•a‚𔭏ǂµ‚œˆê—áD‘æ30‰ñ“ú–{ìè•aŠw‰ïEŠwpW‰ïC2010, 10, 10-11, ‹ž“sD
    83. ‹{@ˆêŽuC‚è–ƒ”üC–x]’åŽuC“n•Ó—T‹IC‘q–{@’CŒŽˆä•ü”üC“¡–Ø–õŽqC–{‹œ˜a‹vC‹{˜e—˜’jFTopiramate‚Ì“Š—^‚ðŒ_‹@‚É“Ë”­«‚Ì‹»•±ó‘Ô‚ªoŒ»‚·‚é‚æ‚€‚É‚È‚Á‚œŠOŒã‚Ä‚ñ‚©‚ñ‚̈ê—áD‘æ44‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ïC2010, 10, 14-15, ‰ªŽRD
    84. ˆÉ“¡–õ“TC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒgiC-ACTj‚É‚æ‚Á‚Ä‹qŠÏ“I‚ȃRƒ“ƒgƒ[ƒ‹ó‘Ô‚Í•]‰¿‰Â”\‚©H@‘æ18‰ñ—Տ°šb‘§Œ€‹†‰ïC2010, 10, 16, “Œ‹žD
    85. ‹g“cärC’––”’qŽÀC“ˆ”öˆ»ŽqCˆîâ@~CâV“¡@Ž C‹{˜e—˜’jFSGAŽ™ä`‘ÑŒŒ‚É‚š‚¯‚éˆâ“`Žq”­Œ»‚Ì–Ô—…“I‰ðÍ‚ɂ‚¢‚āD‘æ24‰ñ–k—€ŽüŽYŠú¥V¶Ž™Œ€‹†‰ïC2010, 10, 17, ‹à‘òD
    86. Adachi Y.: Clinical aspects of severe asthma in children. The 3rd Asthma Meeting in Tokyo, 2010, 10, 23, Tokyo.
    87. ”ÂàVŽõŽqC‚è–ƒ”üC‹{@ˆêŽuC‘«—§—YˆêC‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒUƒEƒCƒ‹ƒXAiH1N1jŠŽõ‚̉ñ•œŠú‚É”­Œ©‚³‚ê‚œPlastic Bronchitis‚̈ê—áD‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    88. –x]’åŽuCŽíŽsq’ˆC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC“n•Ó—S‹IF‹CŠÇ“à‘}ŠÇ‚É‚Ä‹~–œ‚µ“Ÿ‚œdÇƒNƒ‹[ƒvÇŒóŒQ‚Ì1—áD‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    89. ‘«—§—zŽqC”óŒû@ŽûC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jCaŒû’BOCŽsŠÛ’q_C¡ˆää‰pCã“cN‹vC”óŒû¹FCìèˆê‹PF•xŽRŒ§‚É‚š‚¯‚é2Î–¢–žŽ™‚Ì•ÛŒìŽÒ‚É‚š‚¯‚é‹C“¹ˆÙ•š‚ÌŽ–ŒÌ—\–h‚ɂ‚¢‚Ä‚Ì’mŽ¯‚ÉŠÖ‚·‚é’²žD‘æ43‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïC2010, 10, 29-30, •Ÿ‰ªD
    90. ”ÂàVŽõŽqCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚É‚š‚¯‚éšb‘§ƒRƒ“ƒgƒ[ƒ‹‚ÉŠÖ‚·‚é–âf•[iC-ACT, JPACj‚ÌŒ‹‰Ê‚Æ‹qŠÏ“IŽw•W‚ÌŠÖŒWD‘æ37‰ñ–k—€šb‘§Œ€‹†‰ïC2010, 11, 20, ‹à‘òD
    91. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‹g“cKˆêC¬“c“ˆ”ŽC‘å–îKOCÔàV@WC‹{˜e—˜’jF4-5ÎŽ™‚É‚š‚¯‚é”ì–ž‚Æšb‘§‚ÌŠÖŒWD‘æ60‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ïC2010, 11, 25-27, “Œ‹žD
    92. ”ÂàVŽõŽqCˆÉ“¡–õ“TC‰ª•””üŒbC”óŒû@ŽûC’†—ÑŒºˆêC•£àV—³–çC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jFŽ¿–â•[‚Ōċz‹@”\‚ðŠÜ‚ß‚œ¬Ž™šb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚Í•]‰¿‰Â”\‚©D‘æ60‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ïC2010, 11, 25-27, “Œ‹žD
    93. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u–Ÿ‚ç‚©‚É‚È‚è‚‚‚ ‚é“‰»ˆöŽqC‚È‚º“‰»‚·‚é‚Ì‚©H|”ì–ž|v@ƒAƒXƒsƒŠƒ“•s‘ϏǁE“«šb‘§Œ€‹†‰ï2010C2010, 11.27, “Œ‹žD
    94. ‚è–ƒ”üC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jFƒGƒLƒmƒRƒbƒNƒX‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œŠÌ•gŠŽõÇ‚̈ꏗŽ™—áD‘æ42‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ïC2010, 11, 27-28, å‘äD
    95. ”ÂàVŽõŽqC’†—ÑŒºˆêC‰ª•””üŒbC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚Ì”­”M«ŽŸŠ³‚É‚š‚¯‚錌’†ƒvƒƒJƒ‹ƒVƒgƒjƒ“‚ÆMxA’`”’‚Ì‘ª’è‚̈Ӌ`D‘æ42‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ïC2010, 11, 27-28, å‘äD
    96. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™‹CŠÇŽxšb‘§‚ÌŠÇ—‚̃Rƒc|Šw“¶ŠúŽ¡—Â𒆐S‚Ɂ|v@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    97. ‘«—§—zŽqCˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqCŽRŒ³ƒŽqC’†—ÑŒºˆêC•£àV—³–çC‘«—§—YˆêC‹{˜e—˜’jFŒÄ‹CˆêŽ_‰»’‚‘f”Z“x‘ª’èŠíCNIOX MINO‚Í6•bƒ‚[ƒh‚Å‚à’P‰ñ‘ª’è‚Å—Ç‚¢‚Ì‚©H@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    98. ”ÂàVŽõŽqC‰ª•””üŒbC”óŒû@ŽûC‘«—§—YˆêC‹g“cKˆêC‘å–îKOC¬“c“ˆ”ŽCÔàV@WC‹{˜e—˜’jFšb‘§—cŽ™i4-5Îj‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ô‚Æ‘ÌŠi‚ÌŠÖŒWD‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    99. ˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF‹CŠÇŽxšb‘§ŠÇ—‚É‚š‚¯‚éƒXƒeƒbƒvƒ_ƒEƒ“‚ÅFeNO‚Í‘ˆ«‚ð—\‘ª‚Å‚«‚é‚©H@‘æ47‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2010, 12, 4-5, ‰¡•lD
    100. Žs“c•™ŽqF“Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚̗Տ°D‘æ7‰ñ‚’m¬Ž™zŠÂŠíEìè•aŒ€‹†‰ïC2010, 12, 9, ‚’mDiµ‘ҍu‰‰j
    101. Žs“c•™ŽqF“Á•Êu‰‰@S‹Øãk–§‰»áŠQ‚̗Տ°D‘æ4‰ñˆ€•Q”­’BS‘Ÿ•aŒ€‹†‰ïC2010, 12, 11, ŒŽRDiµ‘ҍu‰‰j
    102. Œ“c’Œ“¿C‹àŒ“O˜aC‹{˜e—˜’jF’·ŠúŠÔR‹Û–ò“Š—^‚É‚æ‚Á‚ÄŽ¡–ü‚µ‚Š‚œŠÌ”^ᇍ‡•¹–«“÷‰èŽîÇ‚̈ê—áD‘æ18‰ñH×–E‹@”\ˆÙíÇŒ€‹†‰ïC2010, 12, 11, “Œ‹žD
    103. ”ÂàVŽõŽqCŒŽˆä•ü”üC˜a“c‘ñ–çC’‡‰ªGKCˆÉ“¡–õ“TC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jF‹}‘¬ŒoŒû–Ɖu—Ö@‚𓱓ü‚µ‚œ—‘ƒAƒŒƒ‹ƒM[‚Ì2Ç—áD‘æ300‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2010, 12, 12, ‹à‘òD
    104. Š`–{‘œç‘ãC‹g“cärC“ñ’J@•CŒˆäŽOŽ}CˆÉŒ\“ñ˜YCâV“¡˜a—RC“n•Óˆê—mC¬àVˆ»‰ÀCŽs“c•™ŽqFBayley“û—cŽ™”­’BŒŸž‚É‚æ‚é”­’B•]‰¿D‘æ300‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2010, 12, 12, ‹à‘òD
    105. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‹{’n@[C“y‰®–M•FC×ˆä@‘nC‹{˜e—˜’jF^ŽìŽî«’†Žš‰Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚œ’†“ªŠWâ|ŒŽ”­‰¡–ä‹Ø“÷Žîi–E‘ƒŒ^j‚̈ê—áD‘æ52‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2010, 12, 17-19, ‘åãD
    106. ™ŽR–ŸŽq,‘å’ØŒc•ãC–쑺ŒbŽqC ‹àŒ“O˜aCÎàV@LC‘ê“c‡ŽqC‹{˜e—˜’jF‰Eèò•”ŒðŠŽ_ŒoßŒŽ”­‚Ì ALK—z«_Œo‰èŽî‚Ì“ûŽ™‚Ì1Ç—áD‘æ52‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2010, 12, 17-19, ‘åãD

    2009”N

  • ’˜‘
    1. ‹{˜e—˜’j: –Ɖu•s‘S.uV—Տ°“à‰ÈŠwv,ŠÑ˜a•q”Ž‘Œ•Ò, ˆãŠw‘‰@, “Œ‹ž, 1514-1519, 2009.
    2. ‹{˜e—˜’j: 16Í. ŒŽ”­«–Ɖu•s‘S. u–ƉuŠwƒCƒ‰ƒXƒgƒŒƒCƒeƒbƒh‘æ7”Łv, ‚’йŽu‘ŒŠÄ–ó, “ì]“°, “Œ‹ž, 299-310, 2009.
    3. Žs“c•™Žq: SŽŸŠ³‚ð‚à‚“û—cŽ™‚Ì“úí¶Šˆ‚ÌŠÇ—‚ÆŽw“±. ŽRŒû@“O‘Œ•ÒAw¡“ú‚ÌŽ¡—ÃŽwj@2009”N”Łx, ˆãŠw‘‰@, 1003-100 , 2009.
    4. Žs“c•™Žq: SŽG‰¹. V¶Ž™E“ûŽ™•Ò.ŽüŽYŠú‘Š’k318, ŽüŽYŠúˆãŠw‘Š§† 39F512-514, 2009.
    5. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[‚̊‹«ˆöŽq. u–Ɖu‹@\§Œä‚Ì—‰ð‚ƃAƒŒƒ‹ƒM[”­Ç‚̃ƒJƒjƒYƒ€v@’†ŒŒ›Ži‘Œ•Ò, —r“yŽÐ, “Œ‹ž, 170-175, 2009.
    6. ‘«—§—Yˆê, ˆÉ“¡–õ“T, ‹{˜e—˜’j: ‹CŠÇŽxšb‘§. ‰ŠÇEÄ¶ˆãŠwŽ–“TDŒ“‡jŽ¡‘Œ•Ò,’©‘q‘“X, “Œ‹ž, 256-259, 2009.
    7. ‹àŒ“O˜a: ‚SÍ@–ƉuEƒAƒŒƒ‹ƒM[EäPŒŽ•a. u}‰ð¬Ž™‰Èv, ‹v•Û“cŒ’•v‘Œ•Ò, ‹à–F“°, ‹ž“s, 95-134, 2009.
    8. œA–ìŒbˆêAŽs“c•™ŽqFƒCƒ“ƒtƒŠƒLƒVƒ}ƒu—Ö@. uìè•a‚Ì‚·‚ׂāv, Îˆä³_‘Œ•Ò, ƒAƒNƒ`ƒ…ƒAƒ‹¬Ž™‰È, ’†ŽR‘“X, “Œ‹ž, 112-115, 2009.
    9. ”ÂàVŽõŽq, ‘«—§—Yˆê: “ûŽ™šb‘§‚Ì’·ŠúŠÇ—. ¬Ž™‰È—Տ°ƒsƒNƒVƒXEu”N‘ã•Ê¬Ž™ƒAƒŒƒ‹ƒM[«ŽŸŠ³‚ւ̑ΉžvDŒÜ\—’@—²•Ò, ’†ŽR‘“X, “Œ‹ž, 110-113, 2009.
    10. “n•Óˆê—m, Žs“c•™Žq:æ“V«SŽŸŠ³pŒã‚̐ž_‰^“®”­’B. Annual Review zŠÂŠí, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 278-283,2009.
  • ŒŽ’˜
    1. Watanabe K., Uese K., Higuchi O., Futatani T., Yoshimura N., Nakamura T., and Ichida F.: Three-dimensional computed tomographic findings of bilateral tracheal bronchus. Pediatr Cardiol 30: 87-88, 2009.
    2. Watanabe K., Matsui M., Matsuzawa J., Tanaka C.11, Noguchi K., Yoshimura N., Hongo K., Ishiguro M., Wanatabe S., Hirono K., Uese K., Ichida F., Origasa H., Nakazawa J., Oshima Y., Miyawaki T., Matsuzaki T., Yagihara T, Bilker W., and Gur RC.: Impaired neuroanatomic development in infants with congenital heart disease. J Thorac Cardiov Surg 137: 146-153, 2009.
    3. Hirono K., Konishi T., Origasa H., Ichida F., and Miyawaki T.: Echocardiographic and electrocardiographic analyses of patients with severe motor and intellectual disabilities. Heart Vessels 24: 46-53, 2009.
    4. Hirono K., Kemmotsu Y., Wittkowski H., Foell D., Saito K., Ibuki K., Watanabe K., Watanabe S., Uese K., Kanegane H., Origasa H., Ichida F., Roth J., Miyawaki T., and Saji T.: Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 65: 696-701, 2009.
    5. Hirono K., Miura M., Kanegane H., Miyamoto M., Okada Y., Yamazaki T., Yoshimura N., Ichida F., Ito E., and Miyawaki T.: Hepatocyte growth factor in transient myeloproliferative disorder of Down syndrome. Pediatr Int 51: 754-755, 2009.
    6. Saito K., Ibuki K., Yoshimura N., Hirono K., Watanabe S., Watanabe K., Uese K., Yasukouchi S., Ichida F., and Miyawaki T.: Cardiac resynchronization therapy in a 3-year-old girl with isolated noncompaction of the left ventricle and narrow QRS complex. Circ J 73: 2173-2177, 2009.
    7. Watanabe S., Hashimoto I., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Saito S., Miyawaki T., Niemabb P., and Sahn D.J.: Characterization of ventricular myocardial performance in the fetus by tissue doppler imaging. Circ J 73: 943-947,2009.
    8. Higuchi O., Adachi Y., Ichimaru T., Asai M., and Kawasaki K.: Foreign body aspiraion in children: A nationwide survey in Japan. Int J Pedia Otorhinolaryngol 73: 659-661, 2009.
    9. Ito Y., Adachi Y., Makino T., Higashiyama H., Fuchizawa T., Shimizu T., and Miyawaki T.: Expansion of FOXP3-positive CD4+CD25+ T cells associated with disease activity in atopic dermatitis. Ann Allerg Asthma Immun 103: 160-165, 2009.
    10. Morinishi Y., Imai K., Nakagawa Noriko., Sato H., Horiuchi K., Ohtsuka Y., Kaneda Yumi., Taga T., Hisakawa H., Miyaji R., Endo M., Oh-ishi T., Kamachi Y., Akahane K., Kobayashi C., Tsuchida M., Morio T., Sasahara Y., Kumaki S., Ishigaki K., Yoshida M., Urabe T., Kobayashi N., Okimoto Y., Reichenbach J., Hashii Y., Tsuji Y., Kogawa K., Yamaguchi S., Kanegane H., Miyawaki T., Yamada M., Ariga T., and Nonoyama S.: Identification of severe combined immunodeficiency by T-cell receptor excision circles quantification using neonatal guthrie cards. J Pediatr 155: 829-833, 2009.
    11. Nanki T., Takada K., Komano Y., Morio T., Kanegane H., Nakajima A., Lipsky P.E., and Miyasaka N.: Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 11: R149, 2009.
    12. Neil E. B., Hirono K., Yu X., and Ichida F.: Parvoviral Genomes are not present in endothelial cells of Kawasaki disease patients who develop coronary artery lesions. Pediatr Infect Dis J 28: 345, 2009.
    13. Horiuchi I., Mori Y., Taguchi M., Ichida F., Miyawaki T., and Hashimoto Y.: Mechanisms responsible for the altered pharmacokinetics of bosentan: Analysis utilizing rats with bile duct ligation-induced liver dysfunction. Biopharm Drug Dispos 30: 326-333, 2009.
    14. Yoshimura N., Matsuhisa H., Otaka S., Kitahara J., Murakami H., Uese K., Ichida F., and Misaki T.: Surgical management of multiple ventricular septal defects: the role of the felt sandwich technique. J Thorac Cardiovasc Surg 137: 924-928, 2009.
    15. Dougu N., Joho S., Shan L., Shida T., Matsuki A., Uese K., Hirono K., Ichida F., Tanaka K., Nishino I., and Inoue H.: Novel LAMP-2 mutation in a family with Danon disease presenting with hypertrophic cardiomyopathy. Circ J 73: 376-380, 2009.
    16. Keerthikumar S., Raju R., Kandasamy K., Hijikata A., Ramabadran S., Balakrishnan L., Ahmed M., Rani S., Selvan LD., Somanathan DS., Ray S., Bhattacharjee M., Gollapudi S., Ramachandra YL., Bhadra S., Bhattacharyya C., Imai K., Nonoyama S., Kanegane H., Miyawaki T., Pandey A., Ohara O., and Mohan S.: RAPID: Resource of Asian primary immunodeficiency diseases. Nucleic Acids Res. 37: D863-D867, 2009.
    17. Aghamohammadi A., Cheraghi T., Rezaei N., Kanegane H., Abdollahzede S., Talaei-KhoeiM., Heidari G., Zandieh F., Moin M., and Miyawaki T.: Neutropenia associated with x-linked agammaglobulinemia in an Iranian referral center. Iran J Allergy Asthma Immunol 8: 43-47,2009.
    18. Wang Y., Kanegane H., Wang X., Han X., Zhang Q., Zhao S., Yu Y., Wang J., and Miyawaki T.: Mutation of the BTK Gene and clinical feature of X-linked agammaglobulinemia in Mainland China. J Clin Immunol 29 : 352-356, 2009.
    19. Kojima N., Ohya Y., Futamura M., Akashi M., Odajima H., Adachi Y., and Akasawa A.: Exercise-induced asthma is associated with impaired quality of life among children with asthma in Japan. Allergol Int 58:187-192, 2009.
    20. Fujiwara M., Miyamoto S., Iguchi K., Matsunaka T., Sakashita H., Tsuruyama T., Kanegane H., Marusawa H., Nakase H., and Chiba T.: Acute Epstein-Barr virus infection presenting as severe gastroenteritis without infectious mononucleosis-like manifestations. Clin J Gastroenterol, 2: 398-403, 2009.
    21. “n•Óˆ»‰À, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: ¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢|“û—cŽ™”­Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá|.“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@25: 16-22, 2009.
    22. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, [“‡‹u–ç, •œ“c–rŽq, Œ‘º˜aŽq, Žs“c•™Žq, ‚‹ŽGl: ‚Z¶‚̐¶ŠˆKŠµ•a—\–hŒŸf. “ú–{¬Ž™‰ÈŠw‰ïŽGŽ 113: 1687-1694, 2009.
    23. ”ª–ؐMˆêC‹{@ˆêŽuC–{‹œ˜a‹vCŒÜ\—’“oF¬Ž™‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒUŠŽõ‚É”º‚€‚¹‚ñ–Ï‚š‚æ‚Ñ“ÁˆÙ‚Ȑ_ŒoÇó‚ɂ‚¢‚ā|‚”M‚¹‚ñ–Ï‚š‚æ‚шӎ¯•Ï—e‚𗈂œ‚·•a‘Ԃɂ‚¢‚ā|D’¹Žæ—Տ°‰ÈŠwC2: 63-71, 2009D
    24. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, “c’†—TŽ¡, ŒI—ѐLˆê, ˆÉ“¡‘P–ç, Žs“c•™Žq, ‚‹ŽGl: ‚Z¶‚ð‘ΏۂƂµ‚œƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€—\–hŒ’f-Ž­Ž™“‡Œ§Eç—tŒ§E•xŽRŒ§‚É‚š‚¯‚錟fŒ‹‰Ê‚Ì”äŠr- ”ì–žŒ€‹†15: 217-221, 2009.
    25. ’J“à]ºG, áÁ‹|Œõ•¶, ‘«—§—Yˆê, ’†‘º—˜”ü:•ÛŒìŽÒƒAƒ“ƒP[ƒg‚É‚æ‚é–k—€’n‹æ‚É‚š‚¯‚鏬Ž™‹CŠÇŽxšb‘§f—Â̎À‘Ô’²ž.“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 23: 103-112, 2009.
    26. ’ßàV³m, ‘œ‰ê@’, –x‰z‘×—Y, ¬ì@~, ‹e“c@“Ö, ‹àŒ“O˜a, ‰ª“c‰ë•F, •S–ŒL”V, ’@Šî–Ÿ, Šâˆä’©K, “n•Ó@V, “n•Ó@—Í, ‰º‘º•Ûl, ‘哇Fˆê, ¬Ž™Šà”’ŒŒ•aŒ€‹†ƒOƒ‹[ƒv: —\–h“I“ªŠWÆŽË‚ðÈ‚¢‚œ ALLŒ^Ž¡—ÂðŽó‚¯‚œ59—á‚̏¬Ž™ƒŠƒ“ƒp‰è‹…«ƒŠƒ“ƒpŽî‚Ì—\Œã-CCLSG-NHL960—Տ°ŽŽŒ±‚Ì•ñ-. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 23: 244-250, 2009.
    27. ‹Ž‘º—T–ç, –ì’Ê°‘å, _“cˆÇŽq, ‘ì@», ’|“‡‘׍O, ‹àŒ“O˜a, ‹{˜e—˜’j, ”Ñ“‡ˆêœ, Œ”ö‰ë•¶: IPEX ÇŒóŒQ‚ƐtŽŸŠ³. “ú–{¬Ž™t‘ŸŠw‰ïŽ 22: 131-135, 2009.
  • Ç—á•ñ
    1. Kanegane H., Nomura K., Abe A., Makino T., Ishizawa S., Shimizu T., Naoe T., and Miyawaki T.: Spontaneous regression of aleukemic cutis harboring a NPM/RARA fusion gene in an infant with cutaneous mastosytosis. Int J Hematol 89: 86-90, 2009.
    2. Kanegane H., Nakano T., Shimono Y., Zhao M., and Miyawaki T.: Pneumocytis jiroveci pneumonia as a an atypical presentation of X-linked agammaglobulinemia. Int J Hematol 89: 716-717, 2009.
    3. Sakaki H., Kanegane H., Nomura K., Goi K., Sugita K., Miura M., Ishii E., and Miyawaki T: Early lineage switch in an infant acute lymphoblastic leukemia. Int J Hematol 90: 653-655, 2009.
    4. Saito K., Ibuki K., Yoshimura N., Hirono K., Watanabe S., Watanabe K., Uese K., Yasukouchi S., Ichida F., and Miyawa T. : Successful cardiac resynchronization therapy in a 3-year-old girl eith isolated left ventricular non-compaction and narrow QRS complex -A case report - . Circ J 73: 2173-2177,2009.
    5. Matsuhisa H., Yoshimura N., Kitahara J., Otaka S., Ichida F., Funada H., and Misaki T.: An infected pseudoaneurysm following a modified Blalock-Taussig shunt. Interact Cardiovasc Thorac Surg. 8: 108-110, 2009.
    6. Imashuku S., Azuma N., Kanegane H., and Kasahara Y.: M-protein-positive chronic Epstein-barr virus infection: features mimicking HIV-1 infection. Int J Hematol 90: 235-238, 2009.
    7. Kawakami C., Inoue A., Koh M., Takitani K., Kanegane H., Miyawaki T., and Tamai H.: Three brothers of X-kinked agammaglobulinemia; the relation between phenotype and neutropenia. Int J Hematol 90: 117-119 2009.
    8. “c‘ºŒ«‘Ÿ˜Y, ‹àŒ“O˜a, Œ“c’Œ_, å@‹v”T, –쑺ŒbŽq, –ö‘ò@—Ž, ˜a“c‘׎O, ’J“à]ºG, ‹{˜e—˜’j: Epstein-BarrƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÐH«ƒŠƒ“ƒp‘gD‹…Ç‚Q—á‚É‚š‚¯‚é–ƉuŠw“I¥ƒEƒCƒ‹ƒXŠw“I‰ðÍ. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 23: 360-365, 2009.
    9. Œ‰ª@—CãŒŽ@—²C‹{@ˆêŽuC–쑺ŒbŽqC‹àŒ“O˜aCŠp“c‰ë•FC—é–Ø“¹—YFŒ‰Ê‘Ì•”germinoma‚ÌŽ¡—Ã’†‚É‹}«ö—ó‘Ô‚ðŒJ‚è•Ô‚µ‚œˆê—áDž_‰ÈC15: 482-487, 2009D
    10. ‹àŒ“çt, ‘«—§—Yˆê, Žs“c•™Žq: QT‰„’·ÇŒóŒQ‚ð‡•¹‚µ‚œ‹CŠÇŽxšb‘§2Ç—á‚É‚š‚¯‚éFluticasone propionate - salmeterol combination‚Ì—L—p«. Progress in Medicine 29: 1815-1821, 2009.
    11. ŒŒG‰pŽ¡, ŽRŠÝ“ÄŽŠ, ‰PˆäVŽ¡, ŽR“cŒj‘Ÿ˜Y, ŽR–{’—T, ‹g“cär, ‹àŒ“O˜a: 3D-CT‚ª³Šm‚ȍœ•a•Ï‚Ì”cˆ¬‚É—L—p‚Å‚ ‚Á‚œœœ“ªŠWˆÙŒ`¬Ç‚Ì‚P—á. ¬Ž™‰È—Տ°@62: 511-515, 2009.
  • ‘à
    1. Ichida F.: Left ventricular noncompaction.@Circ J. 73 : 19-26, 2009.
    2. Žs“c•™Žq: NoncompactionS‹Øãk–§‰»áŠQ. ‰Á–Θ_•¶‚ɑ΂·‚éEditorial Comment S‘Ÿ 41: 166-167, 2009.
    3. Žs“c•™Žq: Danon•a‚É‚š‚¯‚éS‹ØÇ@™]˜_•¶‚ɑ΂·‚éEditorial Comment S‘Ÿ 41: 419-21, 2009.
    4. Žs“c•™ŽqFNoncompactionS‹Øãk–§‰»áŠQ@S‘ŸHEART's Selection 3
    5. ‘«—§—Yˆê: ƒGƒfƒBƒgƒŠƒAƒ‹uð“ú‚܂ł̏펯‚́A¡“ú‚Ì”ñíŽ¯Hv@“ú–{¬Ž™“šb‘§ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 7: 189-190, 2009.
    6. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‚̉ü’ù“_ -‹}«”­ì‘Ήž-D“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 7: 238-241, 2009.
    7. ‘«—§—Yˆê: ƒXƒeƒƒCƒh{’·ŽžŠÔì—p«ƒÀ2ŽhŒƒ–ò‡ÜŽg—p‚Ì“K‰ž. ¬Ž™“à‰È 41: 1457-1461, 2009.
    8. ‘«—§—Yˆê: ‚º‚ñ‚»‚­‚̉uŠw‚Æ—\Œã. ƒ`ƒƒƒCƒ‹ƒhƒwƒ‹ƒX 12: 398-401, 2009.
    9. ‘«—§—Yˆê: ƒƒCƒRƒgƒŠƒGƒ“hR–ò‚Ì’PÜ—Ö@‚Æ•¹—p—Ö@DƒAƒŒƒ‹ƒM[E–Ɖu 16: 812-818, 2009.
    10. ‘«—§—Yˆê: “ûŽ™šb‘§‚Ì‹}«”­ì‚Æ’·ŠúŠÇ—‚ւ̑ΉžD¬Ž™‰È 50: 551-557, 2009.
    11. ‘«—§—Yˆê: V‚µ‚¢ƒKƒCƒhƒ‰ƒCƒ“‚ª‘E‚ß‚é“û—cŽ™šb‘§‚ÌŽ¡—Ð헪. Pediatric Allergy for Clinicians 13: 64-68, 2009.
    12. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‰ü’ù‚É‚š‚¯‚钍ˆÓ“_ -‹}«”­ì‚ւ̑Ήž‚ɂ‚¢‚Ä-DPediatric Allergy for Clinicians 13: 18-22, 2009.
    13. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[‚Ɗ‹«ˆöŽq. ŽÀŒ±ˆãŠw 27: 3366-3371, 2009.
    14. ‹àŒ“O˜a: V¶Ž™‚É‚š‚¯‚é–Ɖu‹@”\‚Æ‚»‚Ì”­’B. “ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ïŽ 18: 155-164, 2009.
    15. ‹àŒ“O˜a, ‹{˜e—˜’j: Duncan•a(X˜AœƒŠƒ“ƒp‘BÇŒóŒQ). ¬Ž™‰Èf—à 72(‘): 256, 2009.
    16. ‹àŒ“O˜a, ‹{˜e—˜’j: autoimmune lymphoproliferativeÇŒóŒQ. ¬Ž™‰Èf—à 72(‘): 400, 2009.
    17. ‹àŒ“O˜a: bare lymphocyteÇŒóŒQ. ¬Ž™‰Èf—à 72(‘): 401, 2009.
    18. ‹àŒ“O˜a, æâ@”ü“ß, ‹{˜e—˜’j: –³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ¬Ž™‰È50: 1134-1139, 2009.
    19. ‹àŒ“O˜a, äç‰êŽq, ‹{˜e—˜’j: –Ɖu•s‘SÇ‚Ì FACS ‚É‚æ‚éŠÈˆÕf’f–@. —Տ°ŒŸž@53: 541-546, 2009.
    20. –{‹œ˜a‹v: ’†SE‘€“ª•”‚Éž™”g‚ðŽ‚Â—Ç«¬Ž™‚Ä‚ñ‚©‚ñ. ¬Ž™“à‰È 41: 435-43, 2009.
    21. ”ÂàVŽõŽq, ‘«—§—Yˆê: JPGL2008‚̉ü’ù‚ÉŠÖ‚µ‚Ä -‰¢•Ä‚̃KƒCƒhƒ‰ƒCƒ“‚Æ”ä‚ׂœ“Á’¥-.šb‘§ 22: 17-22, 2009.
    22. ”ÂàVŽõŽq: šb‘§‚Ì•a‘Ô•]‰¿F‹C—¬§ŒÀ. “ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽ@20: 38-42, 2009.
    23. “n•Óˆê—m, Žs“c•™Žq: V¶Ž™ŠúS‘ŸŽèpŒã‚̐ž_‰^“®”­’B.¬Ž™‰È 50: 219-223, 2009.
    24. ˆÉ“¡–õ“T, ‘«—§—Yˆê: ‹CŠÇŽxšb‘§‚̐f’f@f’f‚É‚š‚¯‚é–âf‚ƐfŽ@–@‚ÌŠî–{D¬Ž™“à‰È 41:1388|1392, 2009.
    25. ²’n@•×, —é–ØŒ[”V, Žs“c•™Žq, ¬—с@“O: ìè•a‹}«ŠúŽ¡—Â̍őOü. Pharma Medica 27: 167-175, 2009.
    26. ŽsŠÛ’q_, ‘«—§—Yˆê: ‘S‘’²ž‚©‚ç‚Ý‚œ¬Ž™‚Ì‹CŠÇE‹CŠÇŽxˆÙ•š‚̐f’f‚ÆŽ¡—Ã. ¬Ž™‰È 50: 2073-2077, 2009.

  • 2009”NŠw‰ï•ñ
    1. Ichida F.: Left ventricular noncompaction. Recent advances in the cardiovascular treatment. Chungam National University-Toyama University Joint International Symposium, 2009, 2, 6, Daejeon, Korea.
    2. Adachi Y., Okabe Y., Itazawa T., Adachi Y.S., Miyawaki T., Odajima H., Ohya Y., and Akazawa A.: Validity of a questionnaire for diagnosis of asthma in younger children. 65th Annual Meeting of American Academy of Allergy & Immunology, 2009, 3, 13-17, Washington, DC, USA.
    3. Ichida F., Xing Y., Shan L., Chen R., Watanabe S., Tsubata S., Neil E.B., and Jeffrey A.T.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    4. Watanabe S., Saito K., Ibuki K., Watanabe K., Hirono K., Uese K., Ichida F., and Miyawaki T.: Clinical features of left ventricular noncompaction in infants and children. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    5. Watanabe K., Matsui M., Yoshimura N., Hirono K., Ichida F., Ohshima Y., Matsuzaki T., and Yagihara T.: Impaired neuroanatomic development in infants with congenital heart disease. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    6. Ibuki K., Hirono K., Saito K., Watanabe K., Watanabe S., Ichida F., and Miyawaki T.: Combination therapy of bosentan, beraprost and HOT improve pulmonary artery hypertension related to congenital heart disease in contraindications for right heart bypass surgery. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    7. Saito K., Hirono K., Ibuki K., Kanegane H., Ichida F., and Miyawaki T.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    8. Hirono K., Ibuki K., Saito K., Watanabe K., Watanabe S., Ichida F., and Miyawaki T.: NT-pro-BNP is sensitive to latent chronic heart failure in the patients with single ventricle physiology and Tetralogy of Fallot. 5th World Congress of Pediatric Cardiology and Cardiac Surgery. 2009, 6, 22, Cairns, Australia.
    9. Hirono K., Kemmotsu Y., Toho, Saito K., Ibuki K., Kanegane H., Ichida F., Saji T., and Miyawaki T.: S100 proteins could not be suppressed by infliximab treatment in refractory Kawasaki disease. American Heart Association, Basic Cardiovascular Sciences Conference 2009, 2009, 7, 20, Las Vegas. USA.
    10. Adachi Y.: Japanese Pediatric Asthma Guideline 2008. The 2nd asthma meeting in Tokyo, 2009, 10, 3, Tokyo.
    11. Miyawaki T.: early recognition of primary immunodeficiency disease by flow cytometry. 13th Asian pacific congress of pediatrics, 2009. 10, 14-18, Shanghai, China.
    12. œA–ìŒbˆê, “n•Óˆê—m, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n粈»‰À, ãšŒhˆê˜Y, –F‘º’ŒŽ÷, Žs“c•™Žq, ‹{˜e—˜’j: ¶S’áŒ`¬ÇŒóŒQ‚̍¶”x“®–¬‹·ó‚ɑ΂µ‚āAƒtƒHƒ“ƒ^ƒ“ŽüpŠú‚ɃXƒeƒ“ƒg—¯’up‚ðs‚Á‚œ3—á. ‘æ20‰ñ“ú–{Pediatric Interventional CardiologyŒ€‹†‰ï, 2009, 1, 16, “Œ‹ž.
    13. ‹àŒ“O˜a, ‘q–{@’, –쑺ŒbŽq, ‹{˜e—˜’j, ‹g–ì“Ä”Í, Œ‘q—TŠì: t‰Š‚ð‡•¹‚µ‚œX˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚Q—á. ‘æ‚Q‰ñ“ú–{–Ɖu•s‘SŒ€‹†‰ï, 2009, 1, 31, “Œ‹ž.
    14. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[ŽŸŠ³‘‡f—Âð–ÚŽw‚µ‚Ä -ƒsƒbƒgƒtƒH[ƒ‹‚̉ñ”ð-A¬Ž™‰È‚Ì—§ê‚©‚çv@‘æ17‰ñ“ú–{¬Ž™—Տ°–ò—EƒAƒŒƒ‹ƒM[–ƉuŒ€‹†‰ï, 2009, 1.31-2.1, ‰F“s‹{.
    15. å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‘å’ØŒc•ã, ˜a“c‘׎O, ‹{˜e—˜’j: ‘œÊ‚ȍ‡•¹Ç‚𔺂Á‚œX˜AœŒŒ¬”ÂŒž­ÇŠ³ŽÒ‚ɑ΂·‚é”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA. ‘æ31‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2009, 2, 5-6, ŽD–y.
    16. –{‹œ˜a‹v, ‘q–{@’, ‰eŽR—²Ži, ‹{˜e—˜’j: Pallister-KillianÇŒóŒQ‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï, 2009, 2, 8,‹à‘ò.
    17. ‘q–{@’, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ”ª–ؐMˆê, ‹{˜e—˜’j: ƒyƒjƒVƒŠƒ“G“Š—^Œãž_Çó‚ÌŒy‰õ‚ª‚Ý‚ç‚ê‚œPANDAS‚̈ê—á. ‘æ55‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï, 2009, 2, 8,‹à‘ò.
    18. Œè‘œç‘ã, Žs“c•™Žq, “n•Óˆê—m, –F‘º’ŒŽ÷, ŒˆäŽOŽ}: “û—cŽ™‚̏”­’B. ‘æ‚U‰ñCREST—̈æ“àŒ€‹†•ñ‰ï@2009, 3, 20, ‘åã.
    19. ‹àŒ“O˜a, ‘ºã@ƒ, “›ˆä”ü, íŽRKˆê, ÎàV@L, –쑺ŒbŽq, ‹{˜e—˜’j: ¬lƒ‰ƒ“ƒQƒ‹ƒnƒ“ƒX×–E‘gD‹…Ç‚Ì‚Q—á. ‘æ28‰ñLCHŒ€‹†‰ï 2009, 3, 28, ‘åã.
    20. Žs“c•™Žq: Šî’²u‰‰uæ“V«SŽŸŠ³pŒã‚̐ž__Œo”­’BvD‘æ39‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï, 2009, 4, 22, •xŽR.
    21. Œè‘œç‘ã, Žs“c•™Žq, –F‘º’ŒŽ÷, ŽOè‘ñ˜Y, ŒˆäŽOŽ}, ”ª–ØŒŽrŽ: V¶Ž™E“ûŽ™ŠúŠJSpŒãŠ³Ž™‚̏AŠwŽž”F’m‹@”\D‘æ39‰ñ“ú–{S‘ŸŒŒŠÇŠO‰ÈŠw‰ïŠwp‘‰ï, 2009, 4, 22, •xŽR.
    22. ‘«—§—Yˆê: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u“û—cŽ™šb‘§‚ÌŽ¡—Ð헪`ƒKƒCƒhƒ‰ƒCƒ“‚Í‚Ç‚€•Ï‚í‚Á‚œ‚©Hv@‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    23. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€u–Ɖu•s‘SÇ‚Æ—\–hÚŽív‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    24. ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: ŒÄ‹CNO”Z“x‚©‚ç‚Ý‚œšb‘§¬Ž™‚É‚š‚¯‚éMS-IOS‚̗Տ°“IˆÓ‹`. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    25. œA–ìŒbˆê, “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, ‘卂TŒá, –kŒŽ~ˆê˜Y, Œ‹vO“T, –F‘º’ŒŽ÷, Žs“c•™Žq, ‹{˜e—˜’j: æ“V«SŽŸŠ³‚É‚š‚¯‚éNT-pro BNP‚Ì—L—p«. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    26. Œè‘œç‘ã, Žs“c•™Žq, ŒˆäŽOŽ}, “n•Óˆê—m, ”‹–쐶’j, ”ª–ØŒŽrŽ: Bayley“û—cŽ™”­’BŒŸži‘æ‚Q”Łj‚ð—p‚¢‚œæ“V«SŽŸŠ³Ž™‚̐_Œo”­’B•]‰¿. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    27. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, “c’†—TŽ¡, ŒI—ѐLˆê, Žs“c•™Žq, ‚‹ŽGl: Ž­Ž™“‡Œ§Eç—tŒ§E•xŽRŒ§‚̍‚Z¶‚É‚š‚¯‚鐶ŠˆKŠµ•b—\–hŒŸfŒ‹‰Ê‚Ì’nˆæ·. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    28. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, [“‡‹u–ç, Žs“c•™Žq, ‚‹ŽGl: •xŽRŒ§‚ÌT‚Z¶‚É‚š‚¯‚鐶ŠˆKŠµ•a—\–hŒŸfŒ‹‰Ê‚̐«·‚š‚æ‚ѐ¶ŠˆKŠµ‚Æ‚ÌŠÖ˜A. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    29. ‘q–{@’, ‹àŒ“O˜a, –쑺ŒbŽq, Œ‘q—TŠì, ‹{˜e—˜’j: X˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ɍ‡•¹‚µ‚œŽ‘±«’á•â‘ÌŒŒÇ«t‰Š. ‘æ112‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2009, 4, 17-19, “Þ—Ç.
    30. –{‹œ˜a‹v, ‘q–{@’, “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, ‹{˜e—˜’j: —n˜A‹ÛŠŽõ‚É”º‚€ƒgƒEƒŒƒbƒgáŠQ‚ɂ‚¢‚Ä. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    31. “¡–Ø–õŽq, ‘q–{@’, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ‹{˜e—˜’j: AD/HD‚Ö‚ÌCPT(‚à‚®‚ç[‚ž)‚É‚æ‚é•]‰¿. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    32. ŒŽˆä•ü”ü, ‘q–{@’, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ‹{˜e—˜’j: ”ñ“ÁˆÙ“I‚ÈŒo‰ß‚ð‚œ‚Ç‚Á‚œPANDAS‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    33. ‰eŽR—²Ži, ‘q–{@’, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, –{‹œ˜a‹v, ‹{˜e—˜’j: ‰ß‹Ž5”NŠÔ‚ÉŒoŒ±‚µ‚œHHV-6”]‰Š‚Ì5—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    34. ‘q–{@’, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ‹{˜e—˜’j: Ý‘îŒÄ‹zŠÇ—‚ÉŠÖ‚·‚éˆêlˆÄ. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    35. “n•Ó—S‹I, ‰eŽR—²Ži, ‘q–{@’, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, –{‹œ˜a‹v, ‹{˜e—˜’j: ‘œÊ‚È•sˆÓ‰^“®‚ð’悵‚œ”ñƒwƒ‹ƒyƒX”]‰Š‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2009, 5, 28-30, ’¹Žæ.
    36. ¬‰Y@Ž, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œX˜AœdÇ•¡‡–Ɖu•s‘SÇ‚Ì“ûŽ™—á. ‘æ30‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2009, 5, 28, •xŽR.
    37. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008‚̉ü’ù—v“_ -‹}«”­ì‘Ήž-v@‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    38. ‘«—§—Yˆê, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—zŽq, ‹{˜e—˜’j: dÇšb‘§Ž™‚É‚š‚¯‚éƒtƒ‹ƒ`ƒJƒ]ƒ“{ƒZƒŒƒxƒ“ƒg‡Ü‚ÌŽg—pŒoŒ±. ‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    39. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é”ì–ž‚ƏdÇ“x‚ÉŠÖ‚·‚錟“¢D‘æ26‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2009, 5, 30-31, •Ÿ‰ª.
    40. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€udÇšb‘§‚Ì•a‘Ô‚ÆŠ³ŽÒ‚É—D‚µ‚¢Ž¡—ÂƂ»‚ÌŠJ”­ -¬Ž™“«šb‘§‚̗Տ°-v ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    41. ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ”‘òŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘f’l‚ɉe‹¿‚ð‹y‚Ú‚·ˆöŽq‚ÌŒŸ“¢. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    42. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‹g“cKˆê, ‘å–îKO, ¬“c“ˆ”Ž, ÔàV@W, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚é”ì–ž‚ƌċz‹@”\‚ÉŠÖ‚·‚錟“¢. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    43. ‰ª•””üŒb, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚̃Rƒ“ƒgƒ[ƒ‹ó‘Ԃɑ΂·‚é•@‰ŠÇó‚̉e‹¿. ‘æ21‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2009, 6, 4-6, Šò•Œ.
    44. Žs“c•™Žq: ‹³ˆçu‰‰u”x‚ŒŒˆ³:Å‹ß‚ÌŽ¡—ƒ·ŠúŒø‰Êv. ‘æ3‰ñ¬læ“V«SŽŸŠ³ƒZƒ~ƒi[, 2009, 6, 6, “Œ‹ž.
    45. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, ãšŒhˆê˜Y, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j: “«ìè•a‚ɑ΂µ‚ăVƒNƒƒXƒ|ƒŠƒ“A‚ª‘tŒø‚µ‚œ3Ç—á. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    46. ¬‰Y@Ž, “c‘ºŒ«‘Ÿ˜Y, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‘œ”­‚·‚铪ŠW“àoŒŒ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œ‹}«‘Oœ‘«”’ŒŒ•aiAPLj‚Ì1—á. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    47. ‹{è‚ ‚ä‚Ý, ‹g‰i³•v, ŽÂ‹{³Ž÷, ‚‹ŽGl, •œ“c–rŽq, Žs“c•™Žq: ‚‰ª‚Z¶ŠˆKŠµ•a—\–hŒŸfŒ‹‰ÊE‘æŽl•ñ Ž­Ž™“‡Œ§¥ç—tŒ§‚Z¶‚Æ‚Ì”äŠr. ‘æ23‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï, 2009, 6, 28, •xŽR.
    48. ‹{@ˆêŽu, “n•Ó—S‹I, –{‹œ˜a‹v, ‹{˜e—˜’j: Œo‰ß’†‚ɍ¶‰E·‚Ì‚ ‚é‹­’Œ”­ì‚ð”F‚ß‚œŽž—§ƒ~ƒIƒNƒƒj[‚Ä‚ñ‚©‚ñ‚̈ê—á. ‘æ2‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï’†•”E–k—€’n•û‰ï, 2009, 7, 11, –ŒŒÃ‰®.
    49. –쑺ŒbŽq, ¬‰Y@Ž, ‘å’ØŒc•ã, å@‹v”T, ‹àŒ“O˜a: ”ñŠ°‰ðó‘Ô‚ÅHLA•s“K‡ŒŒ‰ƒhƒi[‚©‚ç––œŒŒŠ²×–EˆÚA‚ðs‚Á‚œAML M4,—Œ‘€–Ô–Œ‰è×–EŽîd•¡‚ª‚ñ‚̏—Ž™—á. ‘æ5‰ñCCLSG‰Ä‹GƒZƒ~ƒi[, 2009, 7, 5, ” ª.
    50. ‹àŒ“O˜a, ¬‰Y@Ž, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹{˜e—˜’j: lHŒÄ‹zŠÇ—‰º‚Å“¯Žíœ‘ˆÚA‚ðs‚Á‚œ‘SgƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‡•¹dÇ•¡‡–Ɖu•s‘SÇ‚̈ê—á. ‘æ5‰ñCCLSG‰Ä‹GƒZƒ~ƒi[, 2009, 7, 5, ” ª.
    51. –xìT“ñ˜Y, ‰eŽR—²Ži, –쑺ŒbŽq, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚œ toxic shock syndrome‚̈ê—á. ‘æ12‰ñ•xŽR¬Ž™ŠŽõ–ƉuŒ€‹†‰ï, 2009, 7, 11, •xŽR.
    52. œA–ìŒbˆê, —с@Žj˜N, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, –k“‡@ŒM, ˆäã@”Ž, Žs“c•™Žq, ‹{˜e—˜’j: ¬Ž™‚É‚š‚¯‚éƒzƒ‹ƒ^[S“d}ŒŸž‚É‚æ‚éQTŽžŠÔ‚ÌŒŸ“¢. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    53. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, Œè‘œç‘ã, ‹{˜e—˜’j, ‘卂TŒá, –kŒŽ~ˆê˜Y, –F‘º’ŒŽ÷, ŒˆäŽOŽ}: “ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ê‚œæ“V«SŽŸŠ³Ž™‚Ì”]—e—ʁApŒã”­’B‚̉“ŠuŠú•]‰¿D‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    54. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, ‘卂TŒá, –kŒŽ~ˆê˜Y, Œ‹vO“T, –F‘º’ŒŽ÷: “à‘ŸöˆÊÇŒóŒQ‚É”º‚€‹CŠÇ•a•Ï‚̏p‘O•]‰¿‚ɑ΂·‚éMDCT‚Ì—LŒø«. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    55. “n•Óˆ»‰À, Ö“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, ˆÀ‘º@•q: ƒtƒHƒ“ƒ^ƒ“pŒãÇ—á‚É‚š‚¯‚éŠÌ‘@ˆÛƒ}[ƒJ[‚Ì—LŒø«. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    56. Œè‘œç‘ã, ”‹–쐶’j, Œ®èNŽ¡, ”ª–ØŒŽrŽ: V¶Ž™E“ûŽ™ŠúŠJSpŒã‚̉^“®”­’B‚ɉe‹¿‚ð‹y‚Ú‚·”ˆöŽq. ‘æ45‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïEŠwpW‰ï, 2009, 7, 15, _ŒË.
    57. ¬‰Y@Ž, ‘å’ØŒc•ã, ‹{@ˆêŽu, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, óˆä³Žk: ‹}‘¬‚ÈŒo‰ß‚Ōċz•s‘S‚ÉŽŠ‚Á‚œplastic bronchitis‚Ì1—á. ‘æ45‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2009, 8, 23, –ŒŒÃ‰®.
    58. ˆÉ“¡–õ“T, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘fiFeNOj‚Ì‘ª’è‚Ɖe‹¿‚ð‹y‚Ú‚·ˆöŽq‚ɂ‚¢‚Ä. ‘æ12‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2009, 9, 12, •xŽR.
    59. “n•Óˆê—m, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, œA–ìŒbˆê, Žs“c•™Žq, Â–ؐ³–ç, ŽR’†ŸO, ‘卂TŒá, “úŒG’qŒ›, –F‘º’ŒŽ÷: TCPCŽ{sŽž‚ɃXƒeƒ“ƒg‚ð—¯’u‚µ‚œ‚ªA•ÂÇ‚ÉŽŠ‚Á‚œ¶”x“®–¬‚ɑ΂µ‚ÄŒŒðœ‹Ž—Ö@‚ðŽ{s‚µÄŠJ’Ê‚ð“Ÿ‚œŽOë•Ù•Âœ(EB)‚Ì‚P—á. ‘æ37‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï, 2009, 9, 19, ‹à‘ò.
    60. –{‹œ˜a‹v, “¡–Ø–õŽq, ŒŽˆä•ü”ü, “c’‡çH, ‹{ˆêŽu, ‹{˜e—˜’j: “Á”­«‚Ä‚ñ‚©‚ñ‚Ì”F’m‹@”\‚ÌŒŸ“¢. ‘æ43‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2009, 10, 22-23, O‘O.
    61. Žs“c•™Žq: “Á•Êu‰‰ (S‹Øãk–§‰»áŠQ‚̗Տ°( ‘æ18‰ñŠÖ“Œ¬Ž™S‹ØŽŸŠ³Œ€‹†‰ï, 2009, 10, 3, “Œ‹ž.
    62. Ö“¡˜a—R, œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: ƒVƒNƒƒXƒ|ƒŠƒ“A‚ð“Š—^‚µ‚œ“«ìè•a3Ç—á‚É‚š‚¯‚éƒTƒCƒgƒJƒCƒ“‚ÌŒŸ“¢. ‘æ29‰ñ“ú–{ìè•aŠw‰ï, 2009, 10, 17,–ŒŒÃ‰®.
    63. ”ÂàVŽõŽq: ƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™‚Ì”x‹@”\‚̃Xƒ^ƒ“ƒ_[ƒh -IOS‚É‚æ‚é”x‹@”\‚Ì•]‰¿•û–@-v. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2009, 10, 17-18, ‚è.
    64. ”ÂàVŽõŽq, ‹{@ˆêŽu, å@‹v”T, ŽíŽsq’ˆ, ‘«—§—Yˆê, ‹{˜e—˜’j: ”x‰Š‚ðŒ_‹@‚ɏdÇ‹}«ŒÄ‹z•s‘S‚ÉŽŠ‚Á‚œŽ™‚ɑ΂·‚éˆêŽ_‰»’‚‘f‹z“ü—Ö@‚Ì“±“ü. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2009, 10, 17-18, ‚è.
    65. ’†—ÑŒºˆê, ˆÉ“¡–õ“T, ”óŒû@Žû, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—Yˆê, –F‘º’ŒŽ÷, ‹{˜e—˜’j: “–‰È‚É‚š‚¯‚éæ“V«‹CŠÇ‹·óÇ—á‚ÌŒŸ“¢. ‘æ42‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2009, 10, 17-18, ‚è.
    66. Kanegane H., Zelm M.C.V., Agematsu K., Sekiguchi T., Arai T., Oishi T., and Miyawaki T.: Clinical and immunological characteristics of CD19 deficiency. ‘æ71‰ñ“ú–{ŒŒ‰tŠw‰ï, 2009, 10, 23-25, ‹ž“s.
    67. Nomura K., Kanegane H., Tamura K., Nishida M., Kuramoto T., Sakaki H., yanagisawa R., Wada T., Yachie A., and Miyawaki T.: Immunological and viological analysis of EB virus-associated hemophagocytic lymphohistiocytosis. ‘æ71‰ñ“ú–{ŒŒ‰tŠw‰ï, 2009, 10, 23-25, ‹ž“s.
    68. “n•Ó—S‹I, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, ¬àVˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, –F‘º’ŒŽ÷, ‹{˜e—˜’j: CRT‚ðŽ{s‚µ‚œ“ûŽ™Šú”­ÇS‹Øãk–§‰»áŠQ‚Ì1—á`SˆÚA‚ÉŒü‚¯‚ā`. ‘æ9‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï, 2009, 10, 23, •xŽR.
    69. ”ÂàVŽõŽq, Œ–쐳’m, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ÔàV@W, ‹{˜e—˜’j: ¬Ž™‚Ìšb‘§‚É‚š‚¢‚Ĕ얞‚Å‚ ‚邱‚Æ‚ªƒRƒ“ƒgƒ[ƒ‹ó‘Ԃɉe‹¿‚·‚é. ‘æ59‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2009, 10, 29-31, H“c.
    70. Œ–쐳’m, ŒÜ\—’—²•v, ”ÂàVŽõŽq, ‘«—§—Yˆê, ÔàV@W, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™šb‘§‚É‚š‚¢‚Ĕ얞‚Å‚ ‚邱‚Æ‚ª‹C“¹‰ß•q«‚â”x‹@”\‚ɉe‹¿‚·‚é. ‘æ59‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2009, 10, 29-31, H“c.
    71. –xìT“ñ˜Y, ‰eŽR—²Ži, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‰Â‹t«”]—À–c‘å•”•a•Ï‚𔺂Á‚œ Toxic shock syndrome‚̈ê—á. ‘æ41‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï, 2009, 11, 14-15, •Ÿˆä.
    72. ‹àŒ“O˜a, ’†–ì‹MŽi, ‰º–ì‹gŽ÷, æâ@”ü›P, ‹{˜e—˜’j: ƒjƒ…[ƒ‚ƒVƒXƒ`ƒX”x‰Š‚ð‡•¹‚µ‚œX˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̈ê—á. ‘æ41‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï, 2009, 11, 14-15, •Ÿˆä.
    73. ‘å’ØŒc•ã, ]Œû^—Žq, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: t(1;12)(q21;p13)‚𔺂Á‚œT×–E«‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚É‚š‚¯‚éƒLƒƒ‰ˆâ“`Žq‰ðÍ. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    74. ¬‰Y@Ž,‘å’ØŒc•ã,–쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ‘œ”­‚·‚铪ŠW“àoŒŒ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œ‹}«‘Oœ‘«”’ŒŒ•a(APL)‚̈ê—á. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    75. ˆÀ“c²’qŽq, ŽíŽsq’ˆ, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: Š°‰ð“±“ü—Ö@‘Šú‚ÉDIC‚ð‡•¹‚µ‚œALL‚̈ê’jŽ™—á. ‘æ51‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2009, 11, 27-29, ç—t.
    76. Žs“c•™Žq: “Á•Êu‰‰uS‹Øãk–§‰»áŠQ‚̗Տ°v. ‘æ48‰ñVŠƒS•s‘SŒ€‹†‰ï, 2009, 11, 26, VŠƒ.
    77. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: •‰‰×ŽŽŒ±Œã‚ɏœ‹Ž‰ðœ‚ðs‚Á‚œH•šƒAƒŒƒ‹ƒM[Ç—á‚ÌŒo‰ß. ‘æ36‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2009, 11, 28,‹à‘ò.
    78. ‘«—§—Yˆê: ƒKƒCƒhƒ‰ƒCƒ“ŒöŠJ“¢˜_‰ïušb‘§Ž¡—ẪOƒŒ[ƒ][ƒ“‚ðŒŸØ‚·‚é -“û—cŽ™šb‘§‚Ì“K³f—Ã-v. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    79. ‘«—§—Yˆê: ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u¬Ž™šb‘§Ž¡—Âɂš‚¯‚é‹z“üƒÀŽhŒƒ–ò‚̈ʒu‚¯v. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    80. ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éŒÄ‹C’†ˆêŽ_‰»’‚‘fieNOj‘ª’è‚Æ‹C“¹‰Â‹t«‚ÌŠÖŒW. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    81. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •£àV—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜’j: H•šƒAƒŒƒ‹ƒM[Ž™‚É‚š‚¢‚Ä•‰‰×ŽŽŒ±Œã‚ɏœ‹Ž‰ðœ‚ðs‚Á‚œÇ—á‚ÌŒo‰ß‚ɂ‚¢‚Ä. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    82. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹g“cKˆê, ¬“c“ˆ”Ž, ‘å–îKO, ÔàV@W, ‹{˜e—˜’j: ‰ä‚ª‘‚̏¬Ž™‚É‚š‚¯‚é‘ÌŠi‚Æšb‘§‚Æ‚ÌŠÖŒW. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    83. ˆÉ“¡–õ“T, ”ÂàVŽõŽq, ‰ª•””üŒb, ‘«—§—Yˆê, ŽRŒ³ƒŽq, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éŒÄ‹CˆêŽ_‰»’‚‘f‚Ì‘ª’莞ŠÔ‚ÉŠÖ‚·‚錟“¢. ‘æ46‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2009, 12, 5-6, •Ÿ‰ª.
    84. ‹{@ˆêŽu, ˆÉŒ\“ñ˜Y, ‹{˜e—˜’j: Ž…‹›ì‘‡•a‰@‚É‚š‚¯‚é10”NŠÔ‚̏¬Ž™“ü‰@Š³ŽÒ”‚̐„ˆÚD‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2009, 12, 13,•xŽR.
    85. å@‹v”T, ”~ìŒåŽi, ˆÉ“¡–õ“T, ŽÂèŒ’‘Ÿ˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ŒI–{¹‹I: Ý‘îƒ^[ƒ~ƒiƒ‹ƒPƒA‚ðŽ{s‚µ‚œŒoŒ±‚ð’Ê‚µ‚Ä. ‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2009, 12, 13,•xŽR.
    86. ‚è–ƒ”ü, ‹{@ˆêŽu, ²“¡Š²“Þ, âV“¡˜a—R, ”‘òŽõŽq, ‹{˜e—˜’j: ƒrƒ^ƒ~ƒ“KŒ‡–R‚É‚æ‚铪ŠW“àoŒŒ‚ð‚«‚œ‚µ‚œ“ûŽ™—áD‘æ24‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2009, 12, 13,•xŽR.

    2008”N

  • ’˜‘
    1. Aghamohammadi A., Lougaris V., Plebani A., Miyawaki T. Anne Durandy., and Hammarstrom L.: Chapter 3 Predominantly antibody deficiencies. uPrimary immunodeficiency diseasesv, Rezaei N., Aghamohammadi A., Notarangelo L.D. eds., Springer, Berlin Heidelberg, 97-130, 2008.
    2. Žs“c•™Žq: S‹Ø‰Š.w¬Ž™‰ÈŠwx ‘æ3”Å, ˆãŠw‘‰@,“Œ‹ž, 1110-1112, 2008.
    3. Žs“c•™Žq: ¬lŠú‚É‚È‚é‚Æ‹N‚±‚邱‚Ɓ\‚»‚Ì“Á’¥C•p“x\ˆâ“`D¬l‚̐æ“V«SŽŸŠ³ƒKƒCƒhƒuƒbƒN, ’O‰HŒöˆê˜Y‘Œ•Ò, ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, “Œ‹ž, 138-142, 2008.
    4. Žs“c•™Žq: zŠÂŠíÇŒóŒQ@IIIi‘æ‚Q”Łj.V—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.6 VIII. S‹ØŽŸŠ³C¬Ž™ŠúS‹ØÇ, –îè‹`—Y‘Œ•Ò, “ú–{—Տ°2008”N•Êû, “ú–{—Տ°ŽÐ, “Œ‹ž, 141-148,2008.
    5. Žs“c•™Žq: ”ì‘åŒ^S‹ØÇ, III zŠÂŠíŽŸŠ³, u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—1v, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 420-424, 2008.
    6. ‘«—§—Yˆê: DŽ_‹…«”x‰Š. u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv, ¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò,“Œ‹žˆãŠwŽÐ, “Œ ‹ž, 114-117, 2008.
    7. ‹àŒ“O˜a, æâ@”ü“ß, ‹{˜e—˜’j: BTKŒ‡‘¹Ç. ¬Ž™“à‰È‘Š§u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv, ¬Ž™“à‰ÈE¬Ž™ ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 1266-1270, 2008.
    8. ‘å’ØŒc•ã, ‹àŒ“O˜a, ‹{˜e—˜’j: X˜AœƒŠƒ“ƒp‘B«ŽŸŠ³. ¬Ž™“à‰È‘Š§u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv, ¬ Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, “Œ‹ž, 1322-1326, 2008.
    9. ãšŒhˆê˜Y, Žs“c•™ŽqFæ“V«SŽŸŠ³@3.‘”xÃ–¬ŠÒ—¬ˆÙí,•”•ª”xÃ–¬ŠÒ—¬ˆÙí, ScimitarÇŒóŒQ. uu‹`˜^@¬Ž™‰Èv ƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 454-455 ,2008.
    10. ãšŒhˆê˜Y, Žs“c•™Žq: æ“V«SŽŸŠ³@10DS–[’†ŠuŒ‡‘¹. uu‹`˜^@¬Ž™‰ÈvƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 472-473, 2008.
    11. ãšŒhˆê˜Y, Žs“c•™Žq: Œã“V«SŽŸŠ³@3DS‹Ø‰Š,S–Œ‰Š. 4DS‹ØÇ.uu‹`˜^@¬Ž™‰ÈvƒƒWƒJƒ‹ƒrƒ…[ŽÐ, 500-505, 2008.
  • ŒŽ’˜
    1. Miya K., Inoue R., Takata Y., Abe M., Natsume R., Sakimura K., Hongou K., Miyawaki T., and Mori H.: Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 510: 641-654,2008.
    2. Taneichi H., Kanegane H., Sira M.M., Futatani T., Agematsu K., Sako M., Kaneko H., Kondo N., Kaisho T., and Miyawaki T.: Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. Clin Immunol 126: 148-154, 2008.
    3. Futatani T., Nii E., Obata M., Ichida F., Okabe Y., Kanegane H., and Miyawaki T.: Molecular characterization of two novel VEGFR3 mutations in Japanese families with Milroy's disease. Pediatr Int 50: 116-118, 2008.
    4. Shan L., Makita N., Xing Y., Watanabe S., Futatani T., Ye F., Saito K., Ibuki K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Origasa H., Bowles N.E., and Towbin J.A.: SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. Mol Genet Metab. 93: 468-474, 2008.
    5. Shan L., Dougu, N., Joho S., Shida T., Matsuki A., Uese K., Ichida F., Miyawaki T., Tanaka K., Inoue H: A novel LAMP-2 mutation in a family with hypertrophic cardiomyopathy: O-072. Pediatr Int 50:740, 2008.
    6. Tsurusawa M., Taga T., Horikoshi Y., Ogawa A., Kikuta A., Kanegane H., Matsushita T., Hyakuna N., Shimomura Y., Ohshima K; Lymphoma committee of Japanese childhood cancer and leukemia.: Favourable outcomes in children with diffuse large B-cell lymphoma treated by a short-term ALL-like regimen: a report on the NHL960 study from the Japanese childhood cancer and leukemia study group. Leuk Lymphoma 49: 734-739, 2008.
    7. Sato T., Toki T., Kanezaki R., Xu G., Terui K., Kanegane H., Miura M., Adachi S., Migita M., Morinaga S., Nakano T., Endo M., Kojima S., Kiyoi H., Mano H., and Ito E.: Functional analysis of JAK3 mutation in transient myeloproliferative disoder and acute megakaryoblastic leukaemia accompanying Down syndrome. Brit J Haematol 141: 681-688,2008.
    8. Shin D-M., Jo E-K., Kanegane H., Futatani T., Zhao M., Song C-H., Yamagishi A., and Miyawaki T.: Transcriptional regulatory defects in the first intron of Bruton's throsine kinase. Pediatr Int 50: 801-805, 2008.
    9. Shimada A., Kato M., Tamura K., Hirato J., Kanegane H., Takeuchi Y., Park MJ., Sotomatsu M., Hatakeyama S., Hayashi Y.: Hemophagocytis lymphohistiocytosis associated with uncontrolled inflammatory cytokinemia and chemokinemia was caused by systemic anaplastic large cell lymphoma: A case report and review of the literature. J Pediatr Hematol Oncol 30: 785-787, 2008.
    10. ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’J“à]ºG, ‘哈—E¬, áÁ‹|Œõ•¶: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚ƃ`ƒFƒbƒN•\‚𓱓ü‚·‚é ‚±‚Æ‚É‚æ‚鏬Ž™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚œŽ¡—Єi‚ÌŒø‰Ê. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 22: 369-378, 2008.
    11. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ‹{˜e—˜’j:ƒCƒ\ƒvƒƒeƒm[ƒ‹Ž‘±‹z“ü—Ö@’†‚̏™–¬ ”­Œ»‚ÉŠÖ‚·‚錟“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@22: 349-356, 2008.
    12. ”óŒû@Žû, ‘«—§—Yˆê, óˆä³Žk: ƒs[ƒiƒbƒc‚É‚æ‚é‹CŠÇE‹CŠÇŽxˆÙ•š. ¬Ž™ŠO‰È 40: 1230-1234, 2008.
    13. ŽsŠÛ’q_C”óŒû@ŽûC‘«—§—YˆêCóˆä³ŽkCìèˆê‹P: ¬Ž™‚É‚š‚¯‚é‹CŠÇE‹CŠÇŽxˆÙ•š‚Ì‘S‘’²ž?—\–hô‚̐„i‚É ‚Þ‚¯‚Ä?. “ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽGŽ@19: 85-89,2008.
    14. Œè‘œç‘ã, ŒˆäŽOŽ}, ’†àV@, Žs“c•™Žq, ”ª–ØŒŽrŽ: æ“V«SŽŸŠ³Ž™‚̍‚ŽŸ”]‹@”\•]‰¿‚Æ‚µ‚ẴxƒCƒŠ[“û—c Ž™”­’BŽÚ“x“±“ü‚ÌŽŽ‚Ý. ”]‚Æ”­’B40: 308-312, 2008.
    15. Œìr˜Y, ²’n@•×, “‚àVŒ«—S, Ž›ˆä@Ÿ, Žs“c•™Žq, ’Ë–ì^–ç, ¬Š_Ž –L: ¬Ž™Šú”ì‘åŒ^S‹ØÇ‘S‘’²žŒ‹‰Ê@“ú –{¬Ž™zŠÂŠíŠw‰ïŽGŽ 24: 572-574, 2008.
    16. —é–ØŒb”üŽq, ‘哈‹`”Ž, “y”ì‘P˜Y, ‘卂TŒá, ‹Ž–{ˆè•v, Žs“c•™Žq, ‹{˜e—˜’j, ŽOè‘ñ˜Y 13ƒgƒŠƒ\ƒ~[‚Ü‚œ‚Í18ƒgƒŠƒ\ƒ~[‚ɑ΂·‚éŠJSp‚ÌŒoŒ±. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 24: 546-554, 2008.
  • Ç—á•ñ
    1. Kanegane H., Itazawa T., Saito M., Nishikomori R., Makino T., Shimizu T., Adachi Y., Nakahata T., and Miyawaki T.: A CIAS1 mutation in a Japanese girl with familial cold autoinflammatory syndrome. Eur J Pediatr 167: 245-247, 2008.
    2. Otubo K., Kanegane H., Nomura K., and Miyawaki T.: Atypical lymphoproliferative disorder in a patient with X-linked thrombocytopenia. Pediatr Bllod Cancer 51: 443-444,2008.
    3. Matsukura H., Fuchizawa T., Higuchi O., and Miyawaki T. : Gross hematuria as an unusual manifestation in minimal change nephrotic syndrome. Clin Nephrol 69 : 142-144, 2008.
    4. Fukushima K., Ueno Y., Kanegane H., Yamagiwa Y., Inoue J., Kido O., Nagasaki F., Kogure T., Kakazu E., Nakagome Y., Matsuda Y., Obara N., Kimura O., and Shimosegawa T.: A case of severe recurrent hepatitis with common variable immunodeficiency. A case of severe recurrent hepatitis with common variable immunodeficiency. Hepatol Res 38: 415-420, 2008.
    5. Tsuji Y., Kogawa K., Imai K., Kanegane H., Fujimoto J., and Nonoyama S.: Evans syndrome in a patient with Langerhans cell histiocytosis: possible pathogenesis of autoimmunity in LCH. Int J Hematol 87: 75-77, 2008.
    6. Hamidah A., Rashid R.A., Jamal R., Zhao M., and Kanegane H.: X-linked dyskeratosis congenital in Malaysia. Pediatr Blood Cancer 50: 432, 2008.
    7. Hamada H., Kurimoto M., Hayashi N., Nagai S., Kurosaki K., Nomoto K., Kanegene H., Nomura K., and Endo S.: Pilomyxoid astrocytoma in a patient presenting with fatal hemorrhage. J Neurosurg Pediatr 1: 244-246, 2008.
    8. ”ÂàVŽõŽq, ‹àŒ“O˜a, ‘«—§—Yˆê, ‹{˜e—˜’j, –q–ì‹P•F, Ž…’‰“¹, Ä“¡@, Œ¬X—²‘Ÿ: ‰Æ‘°«ŠŠ—⎩ŒÈ‰ŠÇÇŒóŒQ ‚̈ê—á. ƒAƒŒƒ‹ƒM[‚̗Տ° 28: 221-225, 2008.
    9. ŒŽˆä•ü”ü, ŽíŽsq’ˆ, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ’˜–Ÿ‚ȏ—«‰»“û–[‚ð’悵‚œcŠu×–EŽîᇍ‡•¹ Klinefelter ÇŒóŒQ‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ 22: 42-46, 2008.
    10. ˆÉ“¡G˜a, •£àV—³–ç, ’†“ˆˆ€Žq, ‹{˜e—˜’j: ”w•”’É‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œŠÌŒÀ‹Ç«Œ‹ß«‰ßŒ`¬‚Ì10Î—Ž™—á. ¬Ž™‰È f—Á@71: 165-168, 2008.
    11. —é–ØŒb”üŽq, ‘哈‹`”Ž, “y”ì‘P˜Y, ‘卂TŒá, ‹Ž–{ˆè•v, Žs“c•™Žq, ‹{˜e—˜’j, ŽOè‘ñ˜Y: 13ƒgƒŠƒ\ƒ~[‚Ü‚œ‚Í18ƒgƒŠ ƒ\ƒ~[‚ɑ΂·‚éŠJSp‚ÌŒoŒ±.“ú–{¬Ž™zŠÂŠíŠw‰ïŽ 24: 38-46. 2008.
  • ‘à
    1. ‘«—§—Yˆê: MxA’`”’‚ðŽw•W‚Æ‚µ‚œ¬Ž™ƒEƒCƒ‹ƒXŠŽõ‚̐f’f. —Տ°‚ƃEƒCƒ‹ƒX 36: 257-262, 2008.
    2. ‘«—§—Yˆê, ˆÉ“¡–õ“T, ‹{˜e—˜’j: ƒAƒŒƒ‹ƒM[ŽŸŠ³‚̐§ŒäƒVƒXƒeƒ€.¬Ž™‰È 49: 1223-1228, 2008.
    3. ‘«—§—Yˆê, ‹{˜e—˜’j, ŽR“c‘œŽq: ¬Ž™‚Ì‹CŠÇŽx‰ŠC”x‰Š. ‚±‚Ç‚àƒPƒA 3: 82-86,2008.
    4. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[f—Â̗Ž‚Æ‚µŒŠ(pit fall)@ƒKƒCƒhƒ‰ƒCƒ“‚Ì“K«Žg—p. ¬Ž™‰Èf—à 71:1209-1214,2008.
    5. ‘«—§—Yˆê: ‰ŠÇ«ƒTƒCƒgƒJƒCƒ“‚È‚Ç‚ð—p‚¢‚œŠŽõÇ‚̐f’f–@. ¬Ž™‰Èf—à 71: 37-42, 2008.
    6. ‘«—§—Yˆê: ŒoŒû‚̍RƒAƒŒƒ‹ƒM[–ò‚Í‘œ‚­‚ÌŽí—Þ‚ª‚ ‚è‚Ü‚·‚ªC‚Ç‚Ì‚æ‚€‚ÉŽg‚¢•ª‚¯‚é‚Ì‚Å‚·‚©u–ò‚ÉŠÖ‚·‚é‘f–p‚È ‹^–âv¬Ž™“à‰È 40: 335-337, 2008.
    7. ‹àŒ“O˜a: ŠŽõÇ‚©‚çæ“V«–Ɖu•s‘SÇ‚ðl‚Š‚éD¬Ž™ŠŽõ–Ɖu 20: 175-182,2008.
    8. ‹àŒ“O˜a, ‹{˜e—˜’j:ŒŽ”­«–Ɖu•s‘SÇ‚É‚š‚¯‚é—Տ°Çó.¬Ž™‰È—Տ° 61: 1743-1749, 2008.
    9. ‹àŒ“O˜a, æâ@”ü“ß,‹{˜e—˜’j: ”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ.ƒAƒŒƒ‹ƒM[E–Ɖu 15: 1322-1328, 2008.
    10. ‹àŒ“O˜a, ‹{˜e—˜’j: –ƉuŽŸŠ³f—Â̐i•à‚Æ“W–]. ¬Ž™‰Èf—à 71: 1973-1978, 2008.
    11. ‘å’ØŒc•ã, ‹àŒ“O˜a,‹{˜e—˜’j: æ“V«–Ɖu•s‘SÇ‚ÆEBV ŠŽõÇ. ŒŒ‰tEŽîá‡‰È 56: 272-280,2008.
    12. ÔàV@W, ¬“c“ˆ”Ž, ‘«—§—Yˆê, ‘å–îKO, –ŸÎ^K, ¬“ˆ‚È‚ÝŽq: ¬Ž™‹CŠÇŽxšb‘§‚̉uŠw. šb‘§ 21: 26-34, 2008.

  • 2008”NŠw‰ï•ñ
    1. Adachi Y., Okabe Y., Itazawa T., Adachi YS., Miyawaki T., Odajima H., Ohya Y., and Akazawa A.: Prevalence of, and risk factors for allergic diseases in 3-year-old children in Japan. 64th Annual Meeting of American Academy of Allergy & Immunology, 3, 14-18, 2008, Philadelphia, USA.
    2. Hirono K., Wittkowski H., Vogl T., Ibuki K., Saito K., Uese K., Ichida F., and Miyawaki T.: Reverse kinetics of circulating soluble receptor for advanced glycation end products (sRAGE) and its ligand S100A12 in acute Kawasaki disease. The 57th American College of Cardiology 08, 2008, 3, 31, Chicago.
    3. Miyawaki T.: Variable EBV infection situation in children. International workshop on Pediatric immunology, 2008, 10, 21-23, Chong-chin, China. (Invited Lecture)
    4. Hirono K., Saito K., Watanbe S., Higuchi O., Ibuki K., Uese K., Ichida F., Kanegane H., Miyawaki T., Kennmotsu Y., and Saji T.: The efficacy of infliximab treatment and dynamic changes of inflammatory cytokines in patients with refractory Kawasaki disease. The 4th International Kawasaki Disease Symposium, 2008, 4, 11, Taipei.
    5. Adachi Y.: gRole of beta2-agonists in the management of childhood asthmah, 16th Annual Meeting of Philippine Academy of Pediatric Pulmonologists and 8th National Meeting on Childhood Asthma, 2008, 5, 2, Baguio City, Philippines. (Invited Lecture)
    6. Ichida F.: Efficacy of Bosentan therapy in candidates for right heart bypass surgery. Panel discussion Challenges in the management of CHD-PAH@ 5th Scientific Symposium: Strategic Perception for PAH Management, 2008, 6, 8, Tokyo.
    7. Kanegene H., Yamada M., Zhao M., Futatani T., Oh-ishi T., Sakiyama Y., Ariga T., and Miyawaki T.: A Japanese patients with X-linked agammaglobulinemia and deafness caused by contiguous X-chromosome deletion including the BTK, TIMM8A, TAF7L, and DRP2 genes. The 13th meeting of the European Society for Immunodeficiencies, 2008, 10, 16-19, Netherlands.
    8. Hirono K, Ibuki K., Saito K., Watanabe K., Watanabe S., Ichida F., Miyawaki T., Yoshimura N., Akita C., and Nakamura T.: . Bosentan induces clinical and hemodynamic improvement in candidates for right heart bypass surgery. The 81th Scientific sessions 2008 American 2008, 11, 10, U.S.A.
    9. Kanegane H.: Flow cytometric diagnosis of primary immunodeficiency diseases. Symposium for PID in Asia, 2008, 12, 11-12, Yokohama.
    10. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: EBV”ñŠÖ˜AƒŠƒ“ƒpŽî‚𔭏ǂµ‚œX˜AœŒŒ¬”ÂŒž­Ç‚Ì‚P’jŽ™—á. ‘æ1‰ñ “ú–{–Ɖu•s‘SŒ€‹†‰ï, 2008, 1, 19,“Œ‹ž.
    11. œA–ìŒbˆê, ˆÉŒ\“ñ˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, ãšŒhˆê˜Y, ‘卂TŒá, Œ‹v‹v“T, –kŒŽ~ˆê˜Y, –F‘º’ŒŽ÷, Žs“c•™Žq, ‹{˜e—˜’j: ‰ESƒoƒCƒpƒXŽèp“K‰ž¢“ï—á‚ɑ΂·‚éCƒ{ƒZƒ“ƒ^ƒ“Cƒxƒ‰ƒvƒƒXƒgCÝ‘îŽ_‘f•¹—p—Ö@‚Ì—L—p «. ‘æ14‰ñ“ú–{¬Ž™”xzŠÂŒ€‹†‰ï, 2008, 2, 2, “Œ‹ž.
    12. ‘«—§—Yˆê: ‹z“üƒXƒeƒƒCƒhŒœ‘÷‰t‚Ì•¬–¶“Á« -ƒlƒuƒ‰ƒCƒU[‚É‚æ‚鍷ˆá-. ‘æ17‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒX, 2008, 2, 2-3, VŠƒ.
    13. ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: 9q34ÇŒóŒQ‚̈ê—á. ‘æ53‰ñ“ú–{¬Ž™_ Œo–k—€’n•û‰ï, 2008, 2, 10, ‹à‘ò.
    14. ŒŽˆä•ü”ü, ‹àŒ“O˜a, ˆÉ“¡–õ“T, ”ÂàVŽõŽq, –{‹œ˜a‹v, ‹{˜e—˜’j, âV“¡–œ—¢Žq, ˆÉ“¡‰Ã‹K: EBƒEƒCƒ‹ƒXŠŽõ‚É”º‚€‹} «¬”]‰Š‚ƍl‚Š‚ç‚ê‚œ‚P—á. ‘æ18‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï, 2008, 3, 8, “Œ‹ž.
    15. Œ“c’Œ“¿, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ’J“à]ºG, –ö‘ò@—Ž: VƒÀ3+CD8+T×–E‚̃Nƒ[ƒ“«‘B‚ð ”F‚ß‚œEBƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÐHƒŠƒ“ƒp‘gD‹…Ç‚̈ê—á. ‘æ18‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï, 2008, 3, 8, “Œ‹ž.
    16. ‘«—§—Yˆê: V‚œ‚ÈŽ¡—Öò‚ð‚Ç‚Ì‚æ‚€‚ÉŽg‚€‚Ì‚© -ƒuƒfƒ\ƒjƒh{ƒÀ2ŽhŒƒ–ò-. ‘æ18‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 4, 13, •Ÿ‰ª.
    17. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u‚q‚rƒEƒCƒ‹ƒXŠŽõ‚̐f’f‚Æ—\–hŽ¡—Â̌ø‰Ê‚ðl‚Š‚év.æ“V«SŽŸŠ³‚ւ̃pƒŠƒrƒYƒ}ƒu‚ÌŒø‰Ê‚Æ–â ‘è“_. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    18. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€uŽ©ŒÈ–ƉuŽŸŠ³‚̈â“`ŽqˆÙív. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    19. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éImpulse Oscillometry System‚Ì—L—p«‚ÌŒŸ“¢. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    20. ‘«—§—zŽq, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j, ¬“c“ˆ”Ž, ‘å–îKO, ÔàV@W: •xŽRŒ§‚É‚š‚¯‚é‚RÎŽ™‚̃AƒŒ ƒ‹ƒM[ŽŸŠ³‚Ì”­Ç‚Ɗ‹«ˆöŽq‚ÌŠÖŒW‚ÉŠÖ‚·‚錀‹†. ‘æ111‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 4, 25-27, “Œ‹ž.
    21. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€uIVIG•s‰ž—á‚ɑ΂·‚éV‚œ‚Ȃ鎡—Ð헪v.‚h‚u‚h‚f•s‰ž—á‚ɑ΂·‚éRƒTƒCƒgƒJƒCƒ“—Ö@. ‘æ12‰ñìè •aŽ¡—ͧ˜b‰ï, 2008, 4, 27, “Œ‹ž.
    22. –{‹œ˜a‹v, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ”ª–ؐMˆê, ‹{˜e—˜’j: _Œož_Çó‚ð’悵‚œŠ³ŽÒ‚É ‚š‚¯‚錌’†R”]R‘́@‘æ50‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2008, 5, 31, “Œ‹ž.
    23. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, •£‘ò—³–ç, ’†—ÑŒºˆê, ŽRŒ³ƒŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜ ’j: ”x‹@”\‘ª’肪‹êŽè‚ÈŽq‚Ç‚à‚É‚š‚¯‚é‚æ‚萳Šm‚È‘ª’è‚ÌŽŽ‚Ý. ‘æ25‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2008, 5.31-6.1, “Þ—Ç.
    24. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€uã‰º‹C“¹ŽŸŠ³‚̍Ž•ž‚ÉŒü‚¯‚Ä -¬Ž™‹CŠÇŽxšb‘§‚̓‰»—vˆö‚Æ‚»‚̉ñ”ð-v ‘æ 20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    25. ‘«—§—Yˆê, ”ÂàVŽõŽq, ‘«—§—zŽq, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ’†—ÑŒºˆê, •£‘ò—³–ç, ‹{˜e—˜’j, ÔàV@ W: “û—cŽ™šb‘§‰uŠw’²ž—pŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錀‹†. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    26. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒÀ2ŽhŒƒ–ò‹z“ü‚Ö‚Ì”œ‰ž«‚©‚ç‚Ý‚œšb‘§ ¬Ž™‚É‚š‚¯‚éMS-IOS‚̗Տ°“IˆÓ‹`. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    27. ‘«—§—zŽqCˆÉ“¡–õ“TC”óŒû@ŽûC‰ª•””üŒbC”ÂàVŽõŽqCŽRŒ³ƒŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jDƒAƒjƒ[ƒVƒ‡ ƒ“‚ð—p‚¢‚œŒÄ‹C“®ì—U“±‚É‚æ‚é”x‹@”\‘ª’è‚Ì—L—p« ‘æ2•ñ@EasyOne‚ð—p‚¢‚Ä. ‘æ20‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Õ °‘å‰ï, 2008, 6, 12-14, “Œ‹ž.
    28. ”ÂàVŽõŽq: ‹CŠÇŽxšb‘§Š³Ž™‚Ì•ÛŒìŽÒ‚ɑ΂·‚éˆÓŽ¯’²ž‚ÌŒ‹‰Ê. –k—€¬Ž™šb‘§Ž¡—ÃŒ€‹†‰ï, 2008, 6, 21, ‹à‘ò.
    29. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§f—ÃKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚œŽ¡—Â̂·‚·‚ß. –k—€¬Ž™šb‘§Ž¡—ÃŒ€‹†‰ï, 2008, 6, 21, ‹à‘ò.
    30. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€uV¶Ž™‚̖Ɖu‹@”\‚Æ‚»‚Ì”­’B v‘æ18‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2008, 6, 27, ”Ž ‘œ.(µ‘ҍu‰‰)
    31. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u¶ŠUæ“V«SŽŸŠ³@”DPEoŽY‚̈ãŠwS—ŽÐ‰ï“I–â‘è@æ“V«SŽŸŠ³‚ÍŒJ‚è•Ô‚·‚©? æ“V«S ŽŸŠ³‚̉uŠwv.@‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    32. Ichida F., Saji T., Nakazawa M., Oyama K., Harada K.: Efficacy and safety of anti-RS virus monoclonal antibody palivizumab for pediatric patients with congenital heart diseases.‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    33. “n•Óˆê—m, Î•^—R”ü, ŒˆäŽOŽ}, œA–ìŒbˆê, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, ”ª–ØŒŽrŽ, Œè‘œç‘ã: Bayley scale ‚ð—p‚¢‚œ“ûŽ™‘Šú‚ÉŠJSp‚ðŽ{s‚³‚ê‚œŽ™‚Ì”­’B•]‰¿. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    34. âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆê—m, “n•Óˆ»‰À, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, ˆÀ‰Í“àãà: S ‘ŸÄ“¯Šú—Ö@(CRT)‚ðŽ{s‚µ‚œnarrow QRS complex‚̍¶ŽºS‹Øãk–§‰»áŠQ(LVNC)3Î—Ž™—áC–ñ2”NŠÔ‚ÌŒo‰ß.‘æ44 ‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    35. ˆÉŒ\“ñ˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‘卂TŒá, Œ‹vO“T, –kŒŽ~ˆê˜Y, ‹g‘º’ŒŽ÷, Œ”ö‰Äl, ‹v•Û@ŽÀ: HOT‚ƃ{ƒZƒ“ƒ^ƒ““à•ž‚ŃtƒHƒ“ƒ^ƒ“Žèp‚É“ž’B‚µ‚œ–³äBÇŒóŒQ‚Ì1—á. ‘æ44‰ñ“ú–{ ¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    36. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: “ú—î35‚É”­Ç‚µƒVƒNƒ ƒXƒ|ƒŠƒ“‚ª—LŒø‚Å‚ ‚Á‚œ“«ìè•a‚Ì1—á. ‘æ44‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 2008, 7, 2-4, •Ÿ“‡.
    37. ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: —n˜A‹ÛŠŽõ‚É”º‚¢‘œÊ‚Ȑž__ŒoÇó ‚ð’悵‚œ—Ž™—á. ‘æ21‰ñ“ú–{¬Ž™‰ÈŠw‰È•xŽR’n•û‰ï, 2008, 7, 6, •xŽR.
    38. ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: 9q34ÇŒóŒQ‚̈ê—á. ‘æ1‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw ‰ï’†•”E–k—€’n•û‰ï, 2008, 7, 21, –ŒŒÃ‰®.
    39. ‰ª•””üŒb, ‘«—§—zŽq, ”ÂàVŽõŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ˆê”ʂ̐H•i‚ð—p‚¢‚œH•šƒAƒŒ ƒ‹ƒM[Ž™‚ɑ΂·‚éŠO—ˆ‚ł̐H•š•‰‰×ŽŽŒ±‚Ì—L—p«. ‘æ11‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[ŽŸŠ³Œ€‹†‰ï, 2008, 9, 13, •xŽR.
    40. ‘«—§—Yˆê: ƒAƒŒƒ‹ƒM[ŽŸŠ³‚É‚š‚¯‚鐧ŒäƒVƒXƒeƒ€. ‘æ26‰ñƒtƒH[ƒ‰ƒ€‘n–ò, 2008, 9, 26, •xŽR.
    41. “c‘ºŒ«‘Ÿ˜Y, ”ÂàVŽõŽq, ‘«—§—Yˆê, •“c•¶l, ŽO‰Y³‹`, ‹{˜e—˜’j: ‚Ñ–Ÿ«”x–EoŒŒÇŒóŒQ‚Ì1Î—Ž™—á. ‘æ41‰ñ“ú –{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    42. ”óŒû@Žû, ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‹{˜e—˜’j: 2007”N“x“~‹G‚É“ü‰@‰Á—Âð—v‚µ‚œ‹}«×‹CŠÇŽx‰Š10—á‚ÌŒŸ “¢. ‘æ41‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    43. ”ÂàVŽõŽq: ƒ[ƒNƒVƒ‡ƒbƒvušb‘§‚Ì•a‘Ô•]‰¿ -‹CŠÇŽxšb‘§¬Ž™‚É‚š‚¯‚é‹C—¬§ŒÀ-v. ‘æ41‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw ‰ï, 2008, 10, 3-4, ”ŸŠÙ.
    44. –{‹œ˜a‹v: ƒVƒ“ƒ|ƒWƒEƒ€u”­’B«“ǂݏ‘‚«áŠQ‚Ì•a‘ԂƑΉžv. ‘æ47‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï, 2008, 10, 5, •xŽR.
    45. –{‹œ˜a‹v: ƒVƒ“ƒ|ƒWƒEƒ€u“–‰È‚É‚š‚¯‚éAD/HD‚ւ̑Ήžv. ‘æ1‰ñ•xŽRŒ§”­’BáŠQŒ€‹†‰ï, 2008, 10, 5, •xŽR.
    46. ‘å’ØŒc•ã, å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, Š@³Ž¡: –Ô–Œ‰èŽîC‹}«”’ŒŒ•a•¹”­Š³Ž™‚ɑ΂·‚鉻Šw—Ö@ ’†‚É”­Ç‚µ‚œƒAƒ‹ƒWƒAŠŽõÇ‚Ì‚P—á. ‘æ70‰ñ“ú–{ŒŒ‰tŠw‰ï, 2008, 10, 10-12, ‹ž“s.
    47. “n•Óˆ»‰À, ‹{ˆêŽu, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, ŽOè‘ñ˜Y, ÎàV@L, Œìr˜Y, Vatta Matteo.: S‹Ø“àÎŠD‰»‚𔺂Á‚œŒŽ”­«S“à–ŒüˆÛ’e«ÇiEFEj‚Ì1—á. ‘æ17‰ñŠÖ“Œ¬Ž™S‹ØŽŸŠ³Œ€‹†‰ï, 2008, 10, 11, “Œ‹ž.
    48. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, –k—€¬Ž™šb‘§Ž¡—ÃŒ€‹†‰ï: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚ƃ`ƒFƒbƒN•\‚𓱓ü‚·‚邱‚Æ‚É‚æ ‚é¬Ž™‹CŠÇŽxšb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ɉˆ‚Á‚œŽ¡—Єi‚ÌŒø‰Ê. ‘æ16‰ñ—Տ°šb‘§Œ€‹†‰ï, 2008, 10, 18, “Œ‹ž.
    49. œA–ìŒbˆê, ŠÄ•š@–õ, ˆÉŒ\“ñ˜Y, Ö“¡˜a—R, “n•Óˆê—m, “n•Óˆ»‰À, ãšŒhˆê˜Y, ‹àŒ“O˜a, Žs“c•™Žq, ‹{˜e—˜’j, ² ’n@•×: ƒCƒ“ƒtƒŠƒLƒVƒ}ƒuŽ¡—Âðs‚Á‚œ“«ìè•a‚É‚š‚¯‚éƒTƒCƒgƒJƒCƒ“‚Ì“®‘Ô. ‘æ28‰ñ“ú–{ìè•aŒ€‹†‰ï, @ 2008, 10, 17-18, ŽD–y.
    50. –{‹œ˜a‹v, ŒŽˆä•ü”ü, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ”ª–ؐMˆê, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñŠ³ŽÒ‚É‚š‚¯‚é LysogangliosideR‘Ì‚Ì•Û—L—Š. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    51. ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: WestÇŒóŒQ‚ð‡•¹‚µ‚œ9q34Œ‡ŽžÇŒóŒQ ‚̈ê—á. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    52. ‰eŽR—²Ži, ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, “c’‡çH, ‹{˜e—˜’j: ”­ì«‰^“®—U”­«•‘“¥ƒAƒeƒg[ƒ[‚Ì5 —á. ‘æ42‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2008, 10, 18-19, “Œ‹ž.
    53. Œ‘q—TŠì, ‘q–{@’, ‹àŒ“O˜a, –쑺ŒbŽq, ‹{˜e—˜’j: X˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ(XLA)‚ɍ‡•¹‚µCŽ‘±«’á•â‘Ì ŒŒÇ‚ð’悵‚œƒƒTƒ“ƒMƒEƒ€‘B«t‰Š‚̈ê—á. ‘æ16‰ñ–k—€tŽŸŠ³EŒŒ‰tò‰»—Ö@Œ€‹†‰ï,2008, 10, 25, ‹à‘ò.
    54. “c‘ºŒ«‘Ÿ˜Y, Œ“c’Œ“¿, å@‹v”T, ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, –ö‘ò@—Ž, ’J“à]ºG, ‹{˜e—˜’j: EBƒEƒCƒ‹ƒXŠÖ ˜AŒŒ‹…æÐH«ƒŠƒ“ƒp‘gD‹…Ç‚Ì‚Q—á. ‘æ50‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2008, 11, 14-16, ç—t.
    55. ‘«—§—Yˆê: “Á•Êu‰‰u¬Ž™‚Ì‹C“¹ˆÙ•š ?f’f‚ÆŽ¡—ÁC‚»‚µ‚Ä—\–h-v ‘æ33‰ñ“Œ“ú–{¬Ž™‰ÈŠw‰ï, 2008, 11, 23, _“ސì.
    56. ‘«—§—Yˆê: ƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€u‹CŠÇŽxšb‘§‚̐V‚œ‚ÈŽ¡—Ð헪 -¬Ž™‚É‚š‚¯‚é‚æ‚è—Ç‚¢šb‘§Ž¡—Â̎À‘H-v ‘æ58 ‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    57. ‘«—§—Yˆê: “Á•ÊƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[ŽŸŠ³‚Ɗ‹«ˆöŽq‚̉uŠw ?Šˆàu‰q¶‰Œàv‚ÌŒoˆÜ‚ÆŒ»óŒŸØ?v ‘æ58‰ñ “ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    58. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ’†—ÑŒºˆê, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§¬Ž™‚É‚š‚¯‚éŒÄ‹CNO”Z“x‚ƌċz‹@ ”\‚Æ‚ÌŠÖŒW. ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    59. ‘ºãIŒ[, ”óŒû@Žû, •£àV—³–ç, ”ÂàVŽõŽq, ‘«—§—Yˆê, ¬“c“ˆ”Ž: ¬Ž™šb‘§‚̉ƒë‚Å‚Ì”­ìŽž‚É‚š‚¯‚éƒÀ2ŽhŒƒ–ò‚ÌŽg —p‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²ž. ‘æ58‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2008, 11, 27-29, “Œ‹ž.
    60. Žs“c•™Žq: ƒVƒ“ƒ|ƒWƒEƒ€u¶ŽºS‹Øãk–§‰»áŠQLeft ventricular noncompactionv. ‘æ30‰ñS‹Ø¶ŒŸŒ€‹†‰ï, 2008, 11, 28, ŽOd.
    61. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: šb‘§Ž™‚Ì‹C—¬§ŒÀ‘ª’è‚É‚š‚¯‚éƒgƒsƒbƒNƒXD‘æ35 ‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2008, 12, 6, ‹à‘ò.
    62. “c‘ºŒ«‘Ÿ˜Y, ‹g–{’q”ü, ”ÂàVŽõŽq, ‹{˜e—˜’j: ŒJ‚è•Ô‚·‹¹˜ˆ³”—œÜ‚Å”­Ç‚µ‚œœŒ`¬•s‘SÇ‚Ì“ûŽ™—á. ‘æ26‰ñ¬Ž™ ‘ãŽÓ«œŽŸŠ³Œ€‹†‰ï, 2008, 12, 6, ‘åã.
    63. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2008 ‰ðà -‘ŠúŽ¡—Éî“ü‚ÌŒø‰Ê-v. ‘æ45‰ñ“ú –{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    64. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’|ƒm“à—TŽÀ, ’Óc‰p•v, ‘哈—E¬, ’J“à]ºG, áÁ‹|Œõ•¶, ‹{˜e—˜’j: ‹C ŠÇŽxšb‘§Š³Ž™•ÛŒìŽÒ‚É‚š‚¯‚é•a‘Ô‚Ì—‰ð“x‚ÆŽ¡—ÖڕW‚ÉŠÖ‚·‚é’²ž. ‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    65. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ”óŒû@Žû, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘ºãIŒ[, ‘«—§—Yˆê, ‹{˜e—˜ ’j: •ÛˆçŽ{Ý‚ł̐H•šƒAƒŒƒ‹ƒM[œ‹ŽH’ñ‹Ÿ‚É‚š‚¯‚鉀Ž™‚Ö‚Ì”z—¶. ‘æ45‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.
    66. ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—zŽq, ŒÜ\—’—²•v, ‘ºãIŒ[, ”öã—mˆê, ‚”ö@Š², ’†—ÑŒºˆê, •£àV—³–ç, ‘«—§—Yˆê, ‹{˜e —˜’j, ÔàV@W: “û—cŽ™šb‘§‰uŠw’²ž—pŽ¿–â•[‚̑Ó–«‚ÉŠÖ‚·‚錀‹†@‘æ2•ñ@’·ŠúŠÇ—–ò‚ÌŽg—p‚ɂ‚¢‚āD‘æ45 ‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2008, 12, 13-14, ‰¡•l.

    2007”N

  • ’˜‘
    1. Shan L., Xing Y., Futatani T., Tsubata S., Watanabe S., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E., and Towbin J.A.: SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia. future aspects of medical sciences and education gChallenge of integrated medical sciencesh Edited by Nadal-Ginard B and Takakura K. IREIIMS, Tokyo, 148-149, 2007.
    2. Žs“c•™Žq: S‹Ø‚̍\‘¢‚ƐS‹ØÇ‚Ì•ªŽqˆãŠw.@u—Տ°S‘Ÿ”­¶Šwv,ŽRŠÝŒhK,”’ÎŒö•Ò,ƒƒWƒJƒ‹ƒrƒ…[ŽÐ,“Œ‹ž,195-202, 2007.
    3. Žs“c•™Žq: “ñŽŸ«S‹ØÇ‚ðŒ©‚Ì‚ª‚³‚È‚¢. ¶ŽºS‹Øãk–§‰»áŠQuVES‘Ÿ•af—Ãvƒ‰ƒNƒeƒBƒX 10@S‹ØÇ‚ðŽ¯‚éE f‚éEŽ¡‚·v. ˆé•”ŒõÍ‘Œ•Ò, •¶Œõ“°, “Œ‹ž, 342-347, 2007.
    4. Žs“c•™Žq: æ“V«SŽŸŠ³Du‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ3”Łvˆä‘º—T•v‘Œ•Ò, •ªŒõ“°, “Œ‹ž, 150-162, 2007.
    5. ‘«—§—Yˆê: ‹z“üƒfƒBƒoƒCƒX‚Ì‘I‘ð MDI‚©DPI‚©…—n‰t‚©,uTHE 26th ROKKO CONFERENCED‹CŠÇŽxšb‘§‚Ì‚æ‚è‚æ‚¢Ž¡ —Â̂œ‚߂Ɂv, ¬—ѐߗY‘Œ•Ò, 49-55, ƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”Å, “Œ‹ž, 2007.
    6. ‹àŒ“O˜a, ‹{˜e—˜’j, ¡ˆäk•ã: æ“V«–Ɖu•s‘SÇ‚̐f’f‚̐i•à‚ÆEBM‚ÉŠî‚­Ž¡—Ö@‚ÌŽÀÛ‚́H,uEBM¬Ž™ŽŸŠ³ ‚ÌŽ¡—ÁvŒÜ\—’—²‘Œ•Ò, 351-353, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2007.
    7. ‹àŒ“O˜a: œœ“ªŠWˆÙŒ`¬Ç,uœŒn“ŽŸŠ³ƒ}ƒjƒ…ƒAƒ‹v“ú–{®Œ`ŠO‰ÈŠw‰ï,¬Ž™®Œ`ŠO‰ÈˆÏˆõ‰ï•Ò,144-145,“ì]“°, “Œ‹ž,2007.
    8. ãšŒhˆê˜Y, Žs“c•™Žq: ¶S•ÂÇ«ŽŸŠ³DuŽüŽYŠú‚̏njóEf’fEŽ¡—Ãiƒr@ŽüŽYŠúˆãŠw‘æ37Šª‘Š§v, ŽüŽYŠúˆãŠw •ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, 583-585, 2007.
    9. ãšŒhˆê˜Y, Žs“c•™Žq: ƒ`ƒAƒm[ƒ[«SŽŸŠ³.uŽüŽYŠú‚̏njóEf’fEŽ¡—Ãiƒr@ŽüŽYŠúˆãŠw‘æ37Šª‘Š§v, ŽüŽYŠú ˆãŠw•ÒWˆÏˆõ‰ï•Ò, “Œ‹žˆãŠwŽÐ, 597-582, 2007.
    10. ÔàV@W, ‘«—§—Yˆê, Šâ“c@—Í, ŒIŒŽ˜aK, Œ–Ž“c•q”V, –]ŒŽ”Ž”V: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒnƒ“ƒhƒuƒbƒN2007, X ìºœA, ŒŠÔŽOŠ]ŠÄC, ‹Š˜aŠé‰æ, “Œ‹ž, 2007.
  • ŒŽ’˜
    1. Kanegane H., Agematsu K., Futatani T., Sira M.M., Suga K., Sekiguchi T., Zelm M.C., and Miyawaki T.: Novel mutation in a Japanese patient with CD19 deficiency. Genes Immun 8: 663-670, 2007.
    2. Fuchizawa T., Adachi Y., Ito Y., Higashiyama H., Kanegane H., Futatani T., Kobayashi I., Kamachi Y., Sakamoto T., Tsuge I., Tanaka H., Banham A.H., Ochs H.D., and Miyawaki T.: Developmental changes of FOXP3-expressing CD4+CD25+ regulatory T cells and their impairment in patients with FOXP3 gene mutations. Clin Immunol 125: 237-246, 2007.
    3. Matsukura H., Miya K., Arai M., Miyawaki T., and Inaba S.: Minimal change variants with mesangial IgA deposits. Clin Nephrol 68: 337-338, 2007.
    4. Matsukura H., Kida K., Miya K., Kanegane H., Arai M., and Miyawaki T.: Gross hematuria as a manifestation of membranous nephropathy. Clin Nephrol 68: 339-340, 2007.
    5. Hashimoto I., Uese K., Watanabe S., Watanabe K., Hirono K., Ichida F., and Miyawaki T.: Assessment of variables affecting velocity of left ventricle in healthy children. Pediatr Int 49: 305-309, 2007.
    6. Chen X., Origasa H., Kamibeppu K., Ichida F., and Varni J.A.: Reliability and validity of the pediatric quality of life inventory (PedsQL) short form-15 (SF15) generic core scales in Japan. Quality Life Res 16: 1239-1249, 2007.
    7. Imai K., Kanegane H., Kumaki S., Ariga T., Tsuchiya S., Morio T., Tsuji Y., Agematsu K., Takada H., Nonoyama S., and Miyawaki T.: Retrospective analysis of stem cell transplantations for severe combined immunodeficiency in Japan. Bone Marrow Transpl 39: S75-76, 2007.
    8. Arai A., Kitano A., Kanegane H., Miyawaki T., and Miura O.: Relapsing campylobacter coli bacteremia with reactive arthritis in a patient with X-linked agammaglobulinemia. Int Med 46: 605-609, 2007.
    9. Yoshihara T., Kobayashi M., Kikuta A., Kato K., Adachi N., Kikuchi A., Ishida H., Hirota Y., kuroda H., Nagatoshi Y., Inukai T., Koike K., Kigasawa H., Yagasaki H., Tokuda K., Kishimoto T., Nakano T., Fujita N., Goto H., Nakazawa Y., Kanegane H., Matsuzaki A., Osugi Y., Hasegawa D., Uoshima N., Nakamura K., Tsuchida M., Tanaka R., Eatanabe A., and Yabe H.: Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Int J Hematology 85: 246-255, 2007.
    10. Hirose Y., Ichida F., Oshima Y., and Yoshimura N.: Developmental status of young infants with congenital heart disease. Pediatr Int 49: 468-471, 2007.
    11. Amoras ALB., da Silva MTN., Zollner RL., Kanegane H., Miyawaki T., and Viela MMS.: Expression of Fc gamma and complement receptors in monocytes of X-linked agammaglobulinaemia and common variable immunodeficiency patients. Clin Exp Immunol 150: 422-428, 2007.
    12. Atarod L., Aghamohammadi A., Moin M., Kanegane H., Rezaei N., Rezaei K.K., Amirzagar A.A., Futatani T., and Miyawaki T.: Successful management of neutropenia in a patient with CD40 ligand deficiency bu immunoglobulin replacement therapy. Iran J Allergy Asthma Immunol 6: 37-40, 2007.
    13. Grebe S., Ichida F., Grabitz R., B?ltmann B., Heidemann S., and Kaisenberg C.S.V.: Reversed pulmonary artery flow in isolated noncompaction of the ventricular myocardium. Fetal Diagn Ther 22: 29-32, 2007.
    14. Wittkowski H., Hirono K., Ichida F., Vogl T., Ye F., Yanlin X., Saito K., Uese K., Miyawaki T., Viemann D., Roth J., and Foell D.: Acute Kawasaki disease is associated with reverse regulation of soluble receptor for advance glycation end products and its proinflammatory ligand S100A12. Arthritis Rheum 56: 4174-4181, 2007.
    15. ‘«—§—Yˆê, ˆäãšæ–Î, ‹Ž–{ŒõŽi, ‹ß“¡’ŒŽÀ, áÁ‹|Œõ•¶, XìºœA, ŒŠÔŽOŠ]: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ 2005‚ª“ûŽ™šb‘§‚ÌŽ¡—ÃŒ»ê‚É—^‚Š‚œ‚à‚Ì?‘æ15‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï‚ł̃Aƒ“ƒP[ƒg’²žŒ‹‰Ê‚æ‚è?. “ú–{ ¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@21: 116|123, 2007.
    16. ‘«—§—zŽq, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‚”ö@Š², ŽRŒ³ƒŽq, ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜ ’j: •ÛˆçŽ{Ý‚ł̐H•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‘Ήž‚É‚š‚¯‚é•Ï‰» ?•xŽRŒ§‚É‚š‚¯‚é•œ¬13”N“x‚Æ18”N“x’² ž‚Ì”äŠr-. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ21: 305|310, 2007.
    17. ŽíŽsq’ˆ, ŒŽˆä•ü”ü, ‹{˜e—˜’j: ŠC…ƒpƒ“ƒc‚̃Cƒ“ƒi[ƒƒbƒVƒ…‚É‚æ‚鏬Ž™‰AŒs•””畆‘¹‚Ì‚Q—á. ¬Ž™“à‰È@39: 527|530, 2007.
    18. óˆä³Žk, ‘«—§—Yˆê, ’†ì@”£, –Ø‘º@Š°, ”ÂàVŽõŽq, ˜a“c—Ï”V•, ˆÀ•”‰pŽ÷, •š–؍G², Ô”‹Ÿˆê, ˆÀ‘º²“s‹I, ›’ Ï“úo•v, “n•Ós—Y: ¬Ž™‚Ì‹CŠÇE‹CŠÇŽxˆÙ•šÇ—á‚ÌŒŸ“¢. “ú‹CH‰ï•ñ58: 64|70, 2007.
    19. –ö“à¹, ˆÉ“¡Šó”ü, ‰F‰Á]@i, ‹àŒ“O˜a, ‹{˜e—˜’j: D’†‹…Œž­‚𔺂Á‚œX˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. —Õ ଏ¬Ž™ˆãŠw@55: 37|40, 2007.
    20. œA£K”ü, ‹{–{çŽj, Žs“c•™Žq, –F‘º’ŒŽ÷, ‘哈‹`”Ž: “ûŽ™Šú‚ÉŽèp‚ð—v‚·‚鎙‚Ì”­’B‚ÉŠÖ‚·‚錀‹†\‚PÎ”Œ‚É‚š‚¯ ‚é”­’B‚Æ‚»‚ÌŠÖ˜A—vˆö\@¬Ž™•ÛŒ’Œ€‹†@66: 75|82, 2007.
  • Ç—á•ñ
    1. Kanegane H., Watanabe S., Nomura K., Xu G., Ito E., and Miyawaki T.: Distinct clones are associated with the development of @ transient myeloproliferative disorder and acute megakaryocytic leukemia in a patient with Down syndrome. Int J Hematol 86: 250-252, 2007.
    2. ˆÉ“¡G˜a, ŽíŽsq’ˆ, Œ‘q—TŠì, ‹{˜e—˜’j: ”x‰Š‡•¹‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œ—n˜A‹ÛŠŽõŒã‹}«Ž…‹…‘̐t‰Š‚Ì‚QÇ—á. ¬ Ž™‰È—Տ°@60: 323|330, 2007.
  • ‘à
    1. ‹{˜e—˜’j: ’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@17: 31|37, 2007.
    2. Žs“c•™Žq: ˆâ“`ŽqˆÙí‚É‚æ‚é•s®–¬‚ƐS‹ØŽŸŠ³|‚»‚Ì•a‘ÔŒ`¬‚Ì‹@˜‚ÆŽ¡—Ð헪\•ªŽqSŒŒŠÇ•a@8: 136|142, 2007.
    3. Žs“c•™Žq: æ“V«SŽŸŠ³‚Æ‚q‚rƒEƒBƒ‹ƒXŠŽõÇ. “~‚̃EƒBƒ‹ƒXŠŽõÇ. ¬Ž™‰Èf—Á@70: 2249|2253, 2007.
    4. Žs“c•™Žq: ”ñŽèp‚̃`ƒAƒm[ƒ[ŽŸŠ³‚̃PƒA,S‘ŸˆÈŠO‚ÌŽèp,–ƒŒ,Ž•‰ÈŽ¡—Ã,’m. ¬læ“V«SŽŸŠ³f—ÃKƒCƒhƒ‰ƒC ƒ“(2006”N‰ü’ù”Å). Circulation J 71: SupplementVI, 2007.
    5. Žs“c•™ŽqFƒ`ƒAƒm[ƒ[,ÔŒŒ‹…‘‘œÇ‚̍‡•¹Ç. ¬læ“V«SŽŸŠ³f—ÃKƒCƒhƒ‰ƒCƒ“(2006”N‰ü’ù”Å). Circulation J 71: SupplementVI, 2007.
    6. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚ÌŠ°‰ð‚ÆŽ¡—Ã. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@21: 271|280, 2007.
    7. ‘«—§—Yˆê: ’·ŠúŠÇ—‚̕ύX‚ƏI—¹‚ð‚Ç‚€‚·‚é‚© uƒfƒBƒx[ƒg “ûŽ™šb‘§vDƒAƒŒƒ‹ƒM[E–Ɖu 14: 1346|1352, 2007.
    8. ‘«—§—Yˆê: “ûŽ™‚Ìšb–f—à uŠO—ˆƒAƒŒƒ‹ƒM[f—ÃABCv ¬Ž™‰Èf—Á@70: 1247|1252, 2007.
    9. ‹àŒ“O˜a: ŠŽõÇ‚Æ—\–hÚŽí. ¬Ž™ŠŽõ–Ɖu 19: 427|431, 2007.
    10. ‹àŒ“O˜a, å@‹v”T, –쑺ŒbŽq, ‹{˜e—˜’j, M“c@‹v: –Ɖu•s‘SÇ‚É‚Ý‚é^‹ÛŠŽõÇ‚Æ‚»‚̑΍ô?R^‹Û–ò‚ÌŽž‘ã? ‰»Šw—Ö@‚̗̈æ@23: 411|415, 2007.
    11. ‹àŒ“O˜a, ãŒˆê‰i, ‹{˜e—˜’j: Ž©ŒÈ‰ŠÇ«ÇŒóŒQ (autoinflammatory syndrome) ‚ƈâ“`ŽqˆÙí. ƒŠƒEƒ}ƒ`‰È 38: 370 |379, 2007.
    12. ”ÂàVŽõŽq, ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§‚Ì‹}«”­ì‚ւ̑Ήž uƒvƒ‰ƒCƒ}ƒŠEƒPƒAˆã‚Ì‚œ‚߂̏¬Ž™ƒAƒŒƒ‹ƒM[‚̐f‚©‚œ ? ê–åˆãEŠwZˆãE‰Æ’ëˆã‚̘AŒg-v Ž¡—Á@89: 1798|1804, 2007.
    13. •lè—Y•œ, ˆäãšæ–Î, ‘«—§—Yˆê: ƒKƒCƒhƒ‰ƒCƒ“‚ð‚Ç‚€“Ç‚Þ‚©u‘æ10Í ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é‹z“üŠí‹@‚Æ‚»‚ÌŽg‚¢ •ûv“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 21: 235|239, 2007.

  • 2007”NŠw‰ï•ñ
    1. ItoY., Adachi Y., Itazawa T., Saito K., Uese K., Ichida F., and Miyawaki T.: Comorbidity of life-threatening arrhythmia in children with asthma. 63nd Annual Meeting of American Academy of Allergy & Immunology, 2007, 2, 23-27, San Diego,USA.
    2. Adachi Y.: Procaterol as Reliever and Controller in Pediatric Asthma, Pediatrics KOL symposium, 2007, 3, 4, Bali, Indonesia.(Invited Lecture)
    3. Watanabe S., Hashimoto I., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Sakai M., Saito S., Miyawaki T., Nieman P., and Sahn D.J.: Characterization of ventricular myocardial performance in fetus by tissue doppler imaging. The 56th scientific sessions of American college of cardiology, 2007, 3, 24-27, New Orleans, U.S.A.
    4. Shan L., Xing Y., Watanabe S., Futatani T., Tsubata S., Ye F., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E. and Towbin J.A. : SCN5A mutations in Japanese patients with left ventricular noncompaction and arrhythmia. The 56th scientific sessions of American college of cardiology, 2007, 3, 24-27, New Orleans, U.S.A.
    5. Adachi Y.: Role of beta2-agonists in the management of childhood asthma. The 4th Meeting of Taiwanese Society of Pediatric Pulmonology, 2007, 4, 15, Taipei, Taiwan. (Invited Lecture)
    6. Adachi Y.: Immunological Aspects in Childhood Asthma. 2007 Spring academic meeting of Taiwanese Society of Pediatric Allergy Asthma and Immunology , 2007, 4, 15, Kaohsiung, Taiwan. (Invited Lecture)
    7. Kanegane H.: X-linked lymphoproliferative syndrome in Japan. 3rd Hemophagocytic syndrome research meeting, 2007, 4, 1, Tokyo.
    8. Watanabe K., Matsui M., Ishiguro M., Matsuzaki T., Watanabe S., Hirono K., Uese K., Yoshimura N., Ichida F., and Miyawaki T.: Neuroanatomical development of infants undergoing heart surgery evaluated by quantitative three-dimentional magnetic resonance imaging. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    9. Saito K., Ichida F., Ibuki K., Hirono K., Watanabe S., Uese K., Miyawaki T., Ohtaka S., Yoshimura N., and Yasukouchi S.: Cardiac resynchronization therapy in a 3-year-old girl with isolated left ventricular noncompaction and narrow QRS complex. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    10. Ibuki K., Hirono K., Uese K., Saito K., Watanabe S., Watanabe K., Ichida F., Miyawaki T., Ohtaka S., Kitahara J., Murakami H., and Yoshimura N.: Efficacy of combination therapy of bosentan, beraprost and HOT in candidates for right heart bypass surgery. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    11. Hirono K., Wittkowski H., Vogl T., Ibuki K., Saito K., Uese K., Ichida F., and Miyawaki T.: Reverse kinetics of circulating soluble receptor for advanced glycation end products (sRAGE) and its ligand S100A12 in acute Kawasaki disease. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    12. Shan L., Dougu N., Joho S., Shida T., Matsuki A., Uese K., Ichida F., Miyawaki T., Tanaka K., and Inoue H.: A novel LAMP-2 mutation in a family with hypertrophic cardiomyopathy. The 3rd Congress of Asian Society for Pediatric Research, 2007, 10, 6-8, Tokyo.
    13. Itazawa T., Adachi Y., Mochizuki H., Shimojo N., Inoue T., Nishimuta T., Morikawa A., and Nishima S.: Aerosol characteristics of admixture of budesonide inhalation solution with beta2-agonist, procaterol. XX World Allergy Congress 2007, 2007, 12, 2-6, Bangkok, Thailand.
    14. ãšŒhˆê˜Y, Ä“¡˜a—R, “n•Óˆ»‰À, “n•Óˆê—m, œA–ìŒbˆê, Žs“c•™Žq, ‘ºã”Ž‹v, –F‘º’ŒŽ÷: ƒNƒŠƒbƒvœ‹Žp‚Ń`ƒAƒm[ ƒ[‚ª‰ü‘P‚¹‚žRV-PAƒVƒƒƒ“ƒg‚ɑ΂µ‚ăoƒ‹[ƒ“Ž¡—Âðs‚È‚Á‚œNorwoodpŒã‚Ì‚P—á. ‘æ18‰ñ“ú–{Pediatric Interventional CardiologyŒ€‹†‰ïŠwpW‰ï, 2007, 1, 19|20, •Ÿ‰ª.
    15. ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ‰ª•””üŒb, ”ÂàVŽõŽq, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜ ’j: •ÛˆçŽ{Ý‚É‚š‚¯‚éH•šœ‹ŽŽwŽŠ‘‚ÍŠ®‘Sœ‹Ž‚©ŒÂ•Ê‘Ήž‚©@?•xŽRŒ§‚É‚š‚¯‚éƒAƒ“ƒP[ƒg’²žŒ‹‰Ê‚æ‚è?. ‘æ7 ‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2007, 1, 27, “Œ‹ž.
    16. –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ˆÀ‘º²“s‹I: ¶Žš‰º‘B•”‰¡–ä‹Ø“÷Žî,‚»‚ÌŒã‚ÌŒo‰ß?Ž¡—ÏI—¹‚RƒJŒŽŒã,¶è󕔃Šƒ“ ƒpßÄ”­. ‘æ26‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï, 2007, 2, 3, ‹à‘ò.
    17. Ä“¡˜a—R, “n•Óˆ»‰À, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘卂TŒá, –kŒŽ~ˆê˜Y, ‘ºã”Ž‹v, –F‘º’ŒŽ÷, ‹v•Û@ŽÀ: ƒ{ ƒZƒ“ƒ^ƒ“, ƒxƒ‰ƒvƒƒXƒg, HOT‚𕹗p‚µGlennŽèp‰Â”\‚Æ‚È‚Á‚œ’PSŽº‚Ì‚WÎ’jŽ™—á. ‘æ13‰ñ“ú–{¬Ž™”xzŠÂŒ€‹† ‰ï, 2007, 2, 3, “Œ‹ž.
    18. ‹{@ˆêŽu, “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‰eŽR—²Ži, “c’‡çH, –{‹œ˜a‹v, ‹{˜e—˜’j: —ǐ«“ûŽ™áz¹‚ÌŠù‰‚ð—L‚·‚éPKC‚Ìˆê —á. ‘æ51‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï, 2007, 2, 4, ‹à‘ò.
    19. ‘å’ØŒc•ã, å@‹v”T, ”óŒû@Žû, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ŠÛ’J‰xŽq, ²Ž¡”Ž•v: HLA3À•sˆê’v‚Ì•ƒ•ê‚©‚瓯 Ží‘¢ŒŒŠ²×–EˆÚA‚ðs‚Á‚œmonosomy7‚̈ꏬŽ™—á. ‘æ29‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï, 2007, 2, 16|17, •Ÿ‰ª.
    20. Ä“¡˜a—R, “n•Óˆ»‰À, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘卂TŒá, –kŒŽ~ˆê˜Y, ‘ºã”Ž‹v, –F‘º’ŒŽ÷, ˆÀ‰Í“à‘: ¶ ŽºS‹Øãk–§‰»áŠQ‚Ì‚RÎ—Ž™‚ɑ΂µ‚ĐS‘ŸÄ“¯Šú—Ö@iCRTj‚ðŽ{s‚µ‚œŒoŒ±. ‘æ33‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï, 2007, 2, 25, ‹à‘ò.
    21. å@‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: “¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚œ Diamond-Blackfan•nŒŒ‚̈ê—á. ‘æ289‰ñ“ú–{¬ Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2007, 3, 11, ‹à‘ò.
    22. Shan L., Xing Y., Watanabe S., Futatani T., Tsubata S., Ye F., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Bowles N.E., and Towbin J.A. : SCN5A mutations in Japanese patients with left ventricular noncompaction and arrhythmia. The 71 th@annual scientific meeting of the Japanese circulation society, 2007, 3, 15-17, Kobe.
    23. “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñ‚ÌWISC-‡V. ‘æ31‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï, 2007, 3, 10, ‹à‘ò.
    24. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ƒAƒjƒ[ƒVƒ‡ƒ“‚É‚æ‚éŒÄ‹C“®ì—U“±‘• ’u•t‚«”x‹@”\‘ª’è‹@Ší‚Ì—L—p«. ‘æ10‰ñ–k—€šb‘§Œ€‹†‰ï, 2007, 3, 24, ‹à‘ò.
    25. ‹àŒ“O˜a, ãŒˆê‰i, “ñ’J@•, M. M. Sira,, {‰êŒ’ˆê, ŠÖŒû—²“T, ‹{˜e—˜’j: CD19Œ‡‘¹‚É‚æ‚é’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒ Ç‚Ì‚P—á. ‘æ30‰ñ“ú–{¬Ž™ˆâ“`Šw‰ï, 2007, 4, 19, ‹ž“s.
    26. ‹àŒ“O˜a: ƒ[ƒNƒVƒ‡ƒbƒvuŠŽõ‚ƍR‘ÌŽY§•s‘Sv‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    27. ‹àŒ“O˜a, ”ÂàVŽõŽq, Ä“¡@, Œ¬X—²‘Ÿ, ‹{˜e—˜’j: ‰Æ‘°«ŠŠ—⎩ŒÈ‰ŠÇÇŒóŒQ‚Ì‚P—á. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw ‰ï, 2007, 4, 20|22, ‹ž“s.
    28. –쑺ŒbŽq, “n•Óˆ»‰À, ‹àŒ“O˜a, ˆÉ“¡‰x˜N, ‹{˜e—˜’j: TAM ‚ÆAMKL‚Ì”­Ç‚ɈقȂéGATA-1ˆâ“`Žq•ÏˆÙƒNƒ[ƒ“‚ª ŠÖ—^‚µ‚œDownÇŒóŒQ‚Ì‚P—á. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    29. œA–ìŒbˆê, âV“¡˜a—R, “n•Óˆ»‰À, ”óŒû@Žû, ãšŒhˆê˜Y, Žs“c•™Žq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“•s‰žìè •a‚ɑ΂·‚éInfliximab‚Ì—LŒø«‚ƃTƒCƒgƒJƒCƒ“‚Ì“®‘Ô. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    30. ‘«—§—zŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: •ÛˆçŽ{ Ý‚ł̐H•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‚ÌŽÀ‘Ô?•œ¬13”N“x’²ž‚Æ‚Ì”äŠr?. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20 |22, ‹ž“s.
    31. ‰ª•””üŒb, ŒE“c”Ž“¹, ‘ºãIŒ[, ŽO‰Y³‹`, ”öã—mˆê, ˆÉ“¡–õ“T, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: Žs’†”x ‰Š‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ‚Ì•p“x?––œŒŒMxA’`”’”­Œ»‚ðŽw•W‚Æ‚µ‚Ä?. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž “s.
    32. Shan L., Dougu N., Joho S., Uese K., Hirono K., Watanabe S., Watanabe K., Saito Y., Ichida F., and Miyawaki T.: A novel LAMP-2 mutation in a family with hypertrophic cadiomyopathy. ‘æ110‰ñ“ú–{¬Ž™‰ÈŠw‰ï, 2007, 4, 20|22, ‹ž“s.
    33. ”ÂàVŽõŽq, ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, •£àV—³–ç, ‰ª•””üŒb, ŽRŒ³ƒŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜ ’j: ¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é•s®–¬‚ÌŒŸ“¢. ‘æ24‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï, 2007, 5, 26-27, “Œ‹ž.
    34. ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹àŒ“O˜a, ‹{˜e—˜’j, –q–ì‹P•F: ŠŠ—âå@–ƒ]‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚œ‰Æ‘°«ŠŠ—⎩ŒÈ‰ŠÇÇŒóŒQ ifamilial cold autoinflammatory syndromej‚̈ê—á. ‘æ28‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2007, 5, 31, •xŽR.
    35. ‹àŒ“O˜a: ƒVƒ“ƒ|ƒWƒEƒ€u’á‚Ü‚œ‚Í–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ɑ΂·‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@v ‘æ55‰ñ“ú–{—AŒŒ ×–EŽ¡—Êw‰ï, 2007, 5, 31|6, 2, –ŒŒÃ‰®.
    36. ‹{˜e—˜’j: EBƒEƒCƒ‹ƒXŠŽõ‚ƈâ“`«ƒŠƒ“ƒp‘BŽŸŠ³. ‘æ48‰ñ“ú–{—Տ°ƒEƒBƒ‹ƒXŠw‰ï, 2007, 6, 2|3, •xŽR.(µ‘ҍu‰‰)
    37. ‘«—§—Yˆê, ’†—ÑŒºˆê, ‹{˜e—˜’j: ƒVƒ“ƒ|ƒWƒEƒ€uƒEƒCƒ‹ƒXŠŽõÇ‚̍ŋ߂̘b‘èvMxA’`”’‚ðŽw•W‚Æ‚µ‚œ¬Ž™ƒEƒCƒ‹ƒX ŠŽõÇ‚̐f’f. ‘æ48‰ñ“ú–{—Տ°ƒEƒBƒ‹ƒXŠw‰ï, 2007, 6, 2|3, •xŽR.
    38. ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ŠŠ—âå@–ƒ]‚Æ‚ÌŠÓ•Ê‚ð—v‚µ‚œ‰Æ‘°«ŠŠ—⎩ŒÈ‰ŠÇÇŒóŒQifamilial cold autoinflammatory syndromej‚̈ê—á. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2007, 6, 10|12, ‰¡•l.
    39. ‘«—§—zŽq, ˆÉ“¡–õ“T, •£‘ò—³–ç, ‰ª•””üŒb, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: “w—͐«ŒÄo‚ª•s\•ª‚Èšb‘§Ž™ ‚É‚š‚¯‚éƒAƒjƒ[ƒVƒ‡ƒ“‚ð—p‚¢‚œŒÄ‹C“®ì—U“±‚É‚æ‚é”x‹@”\‘ª’è‚Ì—L—p«. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å ‰ï, 2007, 6, 10|12, ‰¡•l.
    40. ˆÉ“¡–õ“T, ”óŒû@Žû, ’†—ÑŒºˆê, ‰ª•””üŒb, ”ÂàVŽõŽq, ŽRŒ³ƒŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: MS-IOS‚É‚æ‚é”x ‹@”\•]‰¿‚É‹y‚Ú‚·ŒÄ‹zƒpƒ^[ƒ“‚̉e‹¿. ‘æ19‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï, 2007, 6, 10|12, ‰¡•l.
    41. –쑺ŒbŽq, ‹àŒ“O˜a, “n•Óˆ»‰À, ¬ìŽŸ˜Y, “ñ’J@•, L–ìŒbˆê, ŽO‰Y³‹`, ˆÉ“¡‰x˜Y, ‹{˜e—˜’j: Å‹ßŒoŒ±‚µ‚œ transient abnormal myelopoiesis ‚Ì‚T—á. ‘æ17‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2007, 6, 29-30, •xŽR.
    42. ‘å’ØŒc•ã, ¬ìŽŸ˜Y, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, ®“c‰žŽq, ŽRŠÝ“ÄŽŠ, ‘“‡LŽ¡: ‹‘匌¬”‚Æè÷—±‹…••“ü‘Ì ‚ð”F‚ß‚œ MYH9 ˆÙíÇ‚̈ê’jŽ™—á. ‘æ17‰ñ“ú–{ŽY•wl‰ÈEV¶Ž™ŒŒ‰tŠw‰ï, 2007, 6, 29-30, •xŽR.
    43. ãšŒhˆê˜Y, âV“¡˜a—R, ˆÉŒ\“ñ˜Y, “n•Óˆ»‰À,@“n•Óˆê—m,@”óŒû@Žû,@œA–ìŒbˆê,@Žs“c•™Žq,@‹àŒ“O˜a,@‹{˜e—˜ ’j: “«ìè•a‚ɑ΂·‚éInfliximab‚Ì—LŒø«‚ÌŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï, 2007, 7, 4|6, “Œ‹ž.
    44. Œè‘œç‘ã, Œ®èNŽ¡, ”‹–쐶’j, ”’ÎCˆê, ‰zŒã–ΔV, ”ª–ØŒŽrŽ, ’†àV@, ŒˆäŽOŽ}, Žs“c•™Žq: ƒxƒCƒŠ[“û—c Ž™”­’BŒŸž‚ð—p‚¢‚œV¶Ž™ŠúE“ûŽ™ŠúŠJSppŒã”­’B•]‰¿. ‘æ43‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï, 2007, 7, 4|6, “Œ ‹ž.
    45. “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, –{‹œ˜a‹v, ‹{˜e—˜’j: ‚Ä‚ñ‚©‚ñ‚̍‚ŽŸ”]‹@”\‚̉ðÍ. ‘æ49‰ñ“ú–{¬Ž™_ ŒoŠw‰ï, 2007, 7, 5|7, ‘åã.
    46. –{‹œ˜a‹v, “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: Ž©•ÂÇŠ³ŽÒ‚š‚æ‚Ñ•êe‚ÌŒŒ’†R”]R‘Ì ‚̉ðÍ. ‘æ49‰ñ“ú–{¬Ž™_ŒoŠw‰ï, 2007, 7, 5|7, ‘åã.
    47. âV“¡–œ—¢Žq, ‹{˜e—˜’j: ‘S’E–т̐žž‚Å”­Œ©‚³‚ê‚œBasedow•a‚̏—Ž™—á. ‘æ43‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï, 2007, 9, 2, –Œ ŒÃ‰®.
    48. ˆÉŒ\“ñ˜Y, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, –F‘º’ŒŽ÷, M“c@‹v, “n•Óˆê—m: BTƒVƒƒƒ“ƒgpŒãFallot Žl’¥Ç‚ɍ‡•¹‚µ‚œŠŽõ«‹U«“®–¬áŽ‚̈ê—á. ‘æ34‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï, 2007, 9, 8, ‹à‘ò.
    49. Œè‘œç‘ã, ŒˆäŽOŽ}, ’†àV@, Žs“c•™Žq, ”ª–ØŒŽrŽ: S‘ŸŽèp‚ðŽó‚¯‚œ‚PÎŽ™‚Ì”F’m‰^“®”­’B‚Æ“ü‰@‚É‚æ‚é•ê Žq•ª—£‘ÌŒ±‚ÌŠÖ˜A\ƒxƒCƒŠ[“û—cŽ™”­’BŽÚ“x\‘æ‚Q”Å‚ð—p‚¢‚ā[ ‘æ71‰ñ“ú–{S—Šw‰ï, 2007, 9, 18|20, “Œ‹ž.
    50. ŒŽˆä•ü”ü, –{‹œ˜a‹v, “¡–Ø–õŽq, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ’ÔŠTˆê, ”ª–ؐMˆê, Žs“c•™Žq, ‹{˜e—˜’j: 9q34Ç ŒóŒQ‚̈ê—á. ‘æ52‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï, 2007, 9, 23, ‹à‘ò.
    51. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€hƒAƒŒƒ‹ƒM[«ŽŸŠ³‚̍ŐV‚ÌŒ€‹†‚©‚犳ŽÒ‹³ˆç‚܂Łh uŽ¡—Â̎Š“K‰»,V‚µ‚¢Expert Panel‚© ‚çv. ‘æ17‰ñ‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2007, 10, 7, “Œ‹ž.
    52. ‹{˜e—˜’j: æ“V«–Ɖu•s‘SÇ‚Æ’†•_ŒoŠŽõ. ‘æ12‰ñ“ú–{_ŒoŠŽõÇŠw‰ï, 2007, 10, 12|13, •Ÿ‰ª.(µ‘ҍu‰‰)
    53. ”ÂàVŽõŽq, ‹àŒ“O˜a, ‘«—§—Yˆê, ‹{˜e—˜’j, âV“¡@, Œ¬X—²‘Ÿ, ’†”š—Žr: Žá”N«“Á”­«ŠÖß‰Š‚Æ‚ÌŠÓ•Ê‚ð—v‚µ ‚œ‰Æ‘°«ŠŠ—⎩ŒÈ‰ŠÇÇŒóŒQ‚̈ê—á. ‘æ35‰ñ“ú–{—Տ°–ƉuŠw‰ï, 2007, 10, 19|20, ‘åã.
    54. ˆÉŒ\ˆê˜Y, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j: V¶Ž™“Á”­«SŽº•p”‚Ì1—á. ‘æ7‰ñ•xŽR¬Ž™zŠÂŠíŒ€ ‹†‰ï, 2007, 10, 19,•xŽR.
    55. ˆÉ“¡G˜a, ˆÉ“ÞŽu”¿”ü, ‹g“cär, “ŒŽROK, “ñ’J@•, ‹{˜e—˜’j: —\’è’鉀ØŠJ‚ɂďo¶‚µ‚œ‚É‚à‚©‚©‚í‚ç‚ž”­Ç ‚µ‚œ‘SgŒ^V¶Ž™ƒwƒ‹ƒyƒX‚Ì1—á. ‘æ21‰ñ–k—€ŽüŽYŠúEV¶Ž™Œ€‹†‰ï, 2007, 10, 21,‹à‘ò.
    56. Ä“¡˜a—R, ˆÉŒ\ˆê˜Y, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‹{˜e—˜’j, ‘卂TŒá, –kŒŽ~ˆê˜Y, –F‘º’ŒŽ÷, ˆÀ‰Í“à‘: S‘ŸÄ“¯Šú—Ö@iCRTj‚ª—LŒø‚Å‚ ‚Á‚œ narrowQRS‚̍¶ŽºS‹Øãk–§‰»áŠQ‚É”º‚€dÇS•s‘S‚Ì3Î—Ž™iCRTŒã1 ”N‚ÌŒo‰ßj. ‘æ16‰ñŠÖ“Œ¬Ž™S‹ØŽŸŠ³Œ€‹†‰ï, 2007, 10, 27, “Œ‹ž.
    57. –{‹œ˜a‹v, “¡–Ø–õŽq, ŒŽˆä•ü”ü, ‹{@ˆêŽu, ‰eŽR—²Ži, “c’‡çH, ‹{˜e—˜’j: —\–hÚŽí‚É”º‚€’†•_Œo‡•¹Ç. ‘æ41 ‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï, 2007, 11, 1|2, •Ÿ‰ª.
    58. ‘«—§—Yˆê: ƒVƒ“ƒ|ƒWƒEƒ€gšb‘§Ž€ƒ[ƒ‚͉”\‚©H -Ž¡—Â̐i•à‚ÆŒ»ó-h u“û—cŽ™‚Ìšb‘§v. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[ Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3, ‰¡•l.
    59. ‘«—§—Yˆê, ”ÂàVŽõŽq, –]ŒŽ”Ž”V, ‰ºð’ŒŽ÷, ˆäãšæ–Î, Œ–Ž“c•q”V, XìœAº, ŒŠÔŽOŠ]: ƒuƒfƒ\ƒjƒh‹z“üŒœ‘÷‰t‚ƃv ƒƒJƒeƒ[ƒ‹‹z“ü‰t‚̍¬‡‚É‚æ‚镬–¶“Á«‚ւ̉e‹¿@‘æ‚P•ñƒWƒFƒbƒgŽ®ƒlƒuƒ‰ƒCƒU[. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï H‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    60. ”ÂàVŽõŽq, ‘«—§—zŽq, ˆÉ“¡–õ“T, ‰ª•””üŒb, ”óŒû@Žû, ‘«—§—Yˆê, ‹{˜e—˜’j, ‘ºãIŒ[: ¬Ž™šb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒg iChildhood Asthma Control TestFC-ACTj‚Ì—L—p«‚ÌŒŸ“¢. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1| 3,‰¡•l.
    61. ˆÉ“¡–õ“T, –q–ì‹P•F, ‘«—§—Yˆê, “ŒŽROK, •£àV—³–ç, Ž…’‰“¹, ‹{˜e—˜’j: ƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚š‚¢‚Ä––œ« FOXP3—z«§Œä«T×–E‚͏dÇ“x‚É‘ŠŠÖ‚µ‘‰Á‚·‚é. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    62. ŒÜ\—’—²•v, ˆÉ“Œ“¹•v, Œ–쐳’m, ‘ºãIŒ[, ‘«—§—Yˆê, ‘«—§—zŽq: “dŽqƒJƒ‹ƒe‚É‚æ‚é‹CŠÇŽxšb‘§’·ŠúŠÇ—‚ÌŽŽ‚Ý. ‘æ57‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwp‘å‰ï, 2007, 11, 1|3,‰¡•l.
    63. ‰ª•””üŒb, ŒE“c”Ž“¹, ”öã—mˆê, ’†—ÑŒºˆê, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ¬Ž™‚ÌŽs’†”x‰Š‚ɑ΂·‚鎡—ÕûjŒˆ’è ‚É––œŒŒMxA’`”’‘ª’è‚Í—L—p‚©. ‘æ39‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï, 2007, 11, 9|11, ‰¡•l.
    64. ”ÂàVŽõŽq, ‘«—§—zŽq, ‰ª•””üŒb, ˆÉ“¡–õ“T, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: ¬Ž™—pšb‘§ƒRƒ“ƒgƒ[ƒ‹ƒeƒXƒg‚©‚ç‚Ý ‚œImpulse Oscillometry System‚Ì—L—p«. ‘æ40‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2007, 11, 17|18, ‘åã.
    65. ”óŒû@Žû, ”ÂàVŽõŽq, ‘«—§—zŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒWƒFƒbƒgŽ®‚È‚ç‚тɃƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[‚É‚š‚¯‚éƒvƒ ƒJƒeƒ[ƒ‹‹z“ü‰t‚Ì•¬–¶“Á«‚̈Ⴂ. ‘æ40‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï, 2007, 11, 17|18,‘åã.
    66. ˆÉ“¡G˜a, ˆÉ“ÞŽu”¿”ü, “ŒŽROK, ‹g“cär, “ñ’J@•, ‹{˜e—˜’j, ŽíŽsq’ˆ: ‘Ù“àŠŽõ‚ªŽŠŽ‚³‚ê‚œ—\’è’鉀ØŠJ ‚ŏo¶‚̐V¶Ž™‘SgŒ^’Pƒƒwƒ‹ƒyƒXŠŽõÇ‚̈ê—á. ‘æ52‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2007, 11, 24|26, ‚Œ.
    67. ‹g“cärC“ñ’J@•C¬ìŽŸ˜Y, “ŒŽROK, ˆÉ“ÞŽu”¿”ü, ˆÉ“¡G˜a, ‹{˜e—˜’j: ‰“û’†‚̐V‹K–Ɖu’²ßƒ^ƒ“ƒpƒN Syntenin-1‚Íä`‘ÑŒŒƒiƒC[ƒu‚a×–E‚ðIgAŽY¶×–E‚Ö‚Æ•ª‰»‚³‚¹‚é. ‘æ52‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï, 2007, 11, 24|26, ‚Œ.
    68. ˆÉ“¡–õ“T, ‘«—§—Yˆê, ”ÂàVŽõŽq, “ŒŽROK, ‹{˜e—˜’j, –q–ì‹P•F, Ž…’‰“¹: ƒAƒgƒs[£”畆‰Š‚É‚š‚¯‚鐧Œä«T× –E‚ÌŒŸ“¢. ‘æ34‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï, 2007, 12, 1, ‹à‘ò.
    69. ˆÉŒ\“ñ˜Y, âV“¡˜a—R, “n粈»‰À, “n•Óˆê—m, œA–ìŒbˆê, ãšŒhˆê˜Y, Žs“c•™Žq, ‘卂TŒá, Œ‹vO“T, –kŒŽ~ˆê˜Y, –F‘º’ŒŽ÷, Œ”ö‰Äl, ‹v•Û@ŽÀ: HOT‚ƃ{ƒZƒ“ƒ^ƒ““à•ž‚ŃtƒHƒ“ƒ^ƒ“Žèp‚É“ž’B‚µ‚œ–³äBÇŒóŒQ‚Ì1—á. ‘æ25‰ñŒ“ú –{¬Ž™zŠÂŠíHOTŒ€‹†‰ï, 2007, 12, 8, ‘åã.
    70. ‘«—§—Yˆê: ¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“ ?“û—cŽ™šb‘§‚Ì’·ŠúŠÇ—‚𒆐S‚É-. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[ Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®. (µ‘ҍu‰‰)
    71. ‘«—§—Yˆê, ”ÂàVŽõŽq, ”óŒû@Žû, –]ŒŽ”Ž”V, ‰ºð’ŒŽ÷, ˆäãšæ–Î, Œ–Ž“c•q”V, XìœAº, ŒŠÔŽOŠ]: ƒuƒfƒ\ƒjƒh‹z“ü Œœ‘÷‰t‚ƃvƒƒJƒeƒ[ƒ‹‹z“ü‰t‚̍¬‡‚É‚æ‚镬–¶“Á«‚ւ̉e‹¿@‘æ2•ñƒƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[‚É‚š‚¯‚錟“¢. ‘æ 44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®.
    72. ‘«—§—Yˆê, ‘ºãIŒ[, ’†‘º—˜”ü, ’J“à]ºG, ‘哈—E¬ ,áÁ‹|Œõ•¶: ŠO—ˆ‚Å‚ÌŠÈ’P‚È–âf•[‚𓱓ü‚·‚邱‚Æ‚É‚æ‚éšb ‘§ƒKƒCƒhƒ‰ƒCƒ“‚É‘¥‚µ‚œŽ¡—Єi‚ÌŒø‰Ê. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®.
    73. ‘«—§—zŽq, ”ÂàVŽõŽq, ‰ª•””üŒb, •£‘ò—³–ç, ŽRŒ³ƒŽq, ‚”ö@Š², ”öã—mˆê, ‘«—§—Yˆê, ‘ºãIŒ[, ‹{˜e—˜’j: H•šƒA ƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éˆê”ʂ̐H•i‚ð—p‚¢‚œH•š•‰‰×ŽŽŒ±‚Ì—L—p«. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®.
    74. ’†—ÑŒºˆê, –xìT“ñ˜Y, ‰eŽR—²Ži, ŽÂèŒ’‘Ÿ˜Y, ”ÂàVŽõŽq, ‘«—§—Yˆê, ‹{˜e—˜’j: ƒ`ƒIƒyƒ“ƒ^[ƒ‹Ã’Œã‚ɃAƒiƒtƒB ƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð‚«‚œ‚µ‚œ1’jŽq—á. ‘æ44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®.
    75. ŒÜ\—’—²•v, ˆÉ“Œ“¹•v, Œ–쐳’m, ‘ºãIŒ[, ‘«—§—Yˆê, ‘«—§—zŽq: “dŽqƒJƒ‹ƒe‚É‚æ‚é‹CŠÇŽxšb‘§Ž™‚Ì’·ŠúŠÇ—. ‘æ 44‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï, 2007, 12, 8|9, –ŒŒÃ‰®.
    76. Œ“c’Œ“¿, ˆÉ“¡G˜a, “ŒŽROK, ‹{˜e—˜’j, ˆÉ“ÞŽu”¿”ü, ‹g“cär, “ñ’J@•, ‰ºàVLs: ‘ÙŽ™Šú‚æ‚è”]ŽºŠg‘å‚ðŽw“E ‚³‚ê‚Ä‚¢‚œZellwegerÇŒóŒQ‚Ì‚P—á. ‘æ291‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï, 2007, 12, 9, •xŽR.
    77. ‹{˜e—˜’j: R‘ÌŽY¶•s‘S‚É‚š‚¯‚é–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚Ì‚ ‚ç‚œ‚È“WŠJ. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14 |15, å‘ä. (µ‘ҍu‰‰)
    78. –쑺ŒbŽq, ‹àŒ“O˜a, –q–ì‹P•F, Ž…’‰“¹, ÎàV@L, ˆÀ•”–ŸO, ’Œ]’mŽ÷, ‹{˜e—˜’j: NPM/RARA‚ªŠÖ—^‚µ‚œ aleukemic leukemia cutis ‚̈ê—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.
    79. ‘å’ØŒc•ã, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j, –ö‘òGˆê˜Y, ŽíŽsq’ˆ: —ŒŠá«–Ô–Œ‰è×–EŽî‚É‹}«œ‘«”’ŒŒ•a‚𕹔­ ‚µ‚œ“ñdŠà‚̏—Ž™—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.
    80. å@‹v”T, ŒŽˆä•ü”ü, ”ÂàVŽõŽq, –쑺ŒbŽq, ‹àŒ“O˜a, ‹{˜e—˜’j: ƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚ª’˜Œø‚µ‚œ Kasabach-Merritt ÇŒóŒQ‚Ì‚P—á. ‘æ49‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï, 2007, 12, 14|15, å‘ä.

    2006”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒŒ—F•a“™ŒŒ‰t–ƉuŽŸŠ³Cu¬Ž™–«ŽŸŠ³ƒ}ƒjƒ…ƒAƒ‹v‰Á“¡’‰–ŸŠÄCC484-488Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    2. ‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇDu¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ14”Łv‘åŠÖ••F‘Œ•ÒC225CˆãŠw‘‰@C“Œ‹žC2006.
    3. ‹{˜e—˜’jC‹àŒ“O˜aF’á‚Ü‚œ‚Í–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ. uÃ’—p–ƉuƒOƒƒuƒŠƒ“»Üƒnƒ“ƒhƒuƒbƒNvC³‰ª@“OŠÄCC 30-37CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC‘åãC2006.
    4. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQDu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Ê‘æ‚R”Łvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹€•ÒC528-529C “Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    5. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQDu¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ14”Łv‘åŠÖ••F‘Œ•ÒC387-388CˆãŠw‘‰@C“Œ‹žC2006.
    6. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQDu—Տ°S‘Ÿ•aŠwvŒè‰v“¿•ÎC402-403C•¶Œõ“°C“Œ‹žC2006.
    7. Žs“c•™ŽqFS‹ØÇDw¬Ž™‚ÌŽ¡—ÃŽwjx¬Ž™‰Èf—ѝŠ§†D‰q“¡‹`Ÿ‘Œ•ÒC 379-381Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    8. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQ‚Ì”­¶‚Ɛf’fDwS‘Ÿ•af—Ãvƒ‰ƒNƒeƒBƒXxŒI—эK•v•ÒC182-185C•¶Œõ“°C“Œ‹žC 2006.
    9. ‘«—§—YˆêFƒNƒ‹[ƒvÇŒóŒQDu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Ê‘æ‚R”Łvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹€•ÒC444-445C “Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    10. ‘«—§—YˆêF‹}«‘ˆ«ŽžŽ¡—ÖòFƒeƒIƒtƒBƒŠƒ“EƒAƒ~ƒmƒtƒBƒŠƒ“Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC 62-65Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    11. ‘«—§—YˆêFƒRƒ‰ƒ€FƒeƒIƒtƒBƒŠƒ“ˆ•ûŽž‚É•K—v‚Ȑe‚Ö‚Ìà–Ÿ‚Ì‚µ‚©‚œCu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr —Y•ÒC65Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    12. ‘«—§—YˆêFŽ„‚̏ˆ•ûⳁF‚VÎ ’·ŠúŠÇ—–ò‚𑝗ʂµ‚Ä‚àÇó‚ª‚æ‚­‚È‚ç‚È‚¢Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvC ŸÀr—Y•ÒC104-105Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    13. ‘«—§—YˆêFŽ„‚̏ˆ•ûⳁF‚XÎ –«‚ÌŠPšu‚Æ•@•Â‚ð‘i‚Š‚Ä—ˆ‰@Cu¬Ž™ƒAƒŒƒ‹ƒM[ƒVƒŠ[ƒYwšb‘§xvCŸÀr—Y•ÒC 133Cf’f‚ÆŽ¡—ÎЁC“Œ‹žC2006.
    14. ‘«—§—YˆêFušb‘§—\–hEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2006vC“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï ŠÄCC‹Š˜aŠé‰æC“Œ‹žC2006.
    15. ‘«—§—YˆêF•@•›•@o‰Š‚̍‡•¹CuTHE 25th ROKKO CONFERENCEDšb‘§‚Ì•a‘Ô‚ÆŽ¡—©‚ç‚Ý‚œ¢‘ã“Ii”N—î“Ij“Á ’¥vC¬—ѐߗY‘Œ•ÒC51-56Cƒ‰ƒCƒtƒTƒCƒGƒ“ƒXo”ŁC“Œ‹žC2006.
    16. ‘«—§—YˆêF¬Ž™‚Ì”x‰ŠCu¡“ú‚ÌŽ¡—ÃŽwj 2006”N”Ł|Ž„‚Í‚±‚€Ž¡—µ‚Ä‚¢‚év48”ŁCŽRŒû@“O‘Œ•ÒC964-966Cˆã Šw‘‰@C“Œ‹žC2006.
    17. ‹àŒ“O˜aC‹{˜e—˜’jFƒEƒCƒ‹ƒXŠŽõÇ. uƒlƒ‹ƒ\ƒ“¬Ž™‰ÈŠw‘æ17”ŁvC‰q“¡‹`ŸŠÄCC1051-1091CƒGƒ‹ƒ[ƒrƒAEƒW ƒƒƒpƒ“C“Œ‹žC2005.
    18. ‹àŒ“O˜aC‹{˜e—˜’jF–ƉuŒn.u‚±‚ê‚Ÿ‚¯‚Í’m‚Á‚Ä‚š‚«‚œ‚¢.¬Ž™ˆã—Â̒mŽ¯vC•ÊŠ•¶—Y•ÒC21-25CU‹»ˆãŠwo”ŎЁC “Œ‹žC2006.
    19. ‹àŒ“O˜aCã“cˆç‘ãCÎˆäžÄˆêFHemophagocytic lymphohistiocytosis ‚É‚š‚¯‚éƒp[ƒtƒHƒŠƒ“ˆâ“`ŽqˆÙí.uAnnual Review ŒŒ‰t 2006vC‚‹vŽj–›‘Œ•ÒC178-187C’†ŠOˆãŠwŽÐC“Œ‹žC2006.
    20. ‹àŒ“O˜aFŒŒ—F•a“™ŒŒ‰t–ƉuŽŸŠ³Cu¬Ž™–«ŽŸŠ³ƒ}ƒjƒ…ƒAƒ‹v‰Á“¡’‰–ŸŠÄCC 488-492C495-496f’f‚ÆŽ¡—ÎЁC “Œ‹žC2006.
    21. ‹àŒ“O˜aCæâ”ü›PF‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQDu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Ê‘æ‚R”Łvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ ‰ï‹€•ÒC238C“Œ‹žˆãŠwŽÐC“Œ‹žC2006.
    22. ‹àŒ“O˜aF“`õ«’PŠjÇC–«Šˆ“®«EBƒEƒCƒ‹ƒXŠŽõÇDu¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ14”Łv‘åŠÖ••F‘Œ•ÒC252-253C ˆãŠw‘‰@C“Œ‹žC2006.
    23. ‹àŒ“O˜aC‹{˜e—˜’jFEBV ‚ɑ΂·‚é–Ɖu‰ž“š. uƒwƒ‹ƒyƒXƒEƒCƒ‹ƒXŠwv“ú–{—Õ଑Š§C564-567C“ú–{—Õ଎ЁC‘åãC 2006.
    24. –{‹œ˜a‹vFŽüŠú«ŽlŽˆ–ƒáƒDu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Ê‘æ‚R”Łvu¬Ž™“à‰Èvu¬Ž™ŠO‰Èv•ÒWˆÏˆõ‰ï‹€•ÒC784-785C “Œ‹žˆãŠwŽÐC“Œ‹žC2006.
  • ŒŽ’˜
    1. Adachi Y.S., Itazawa T., Nakabayashi M., Fuchizawa T., Okabe Y., Ito Y., Adachi Y., Murakami G., and Miyawaki T. : Safety and usefulness of a novel eMotion electric mesh nebulizer in children with asthma. Allergology Int 55: 167-171, 2006.
    2. Adachi Y.S., Adachi Y., Itazawa T., Yamamoto J., Murakami G., and Miyawaki T.: Ability of preschool children to use dry powder inhalers as evaluated by In-Check meter. Pediatr Int 48: 62-65, 2006.
    3. Itazawa T., Adachi Y., Nakabayashi M., Fuchizawa T., Murakami G., and Miyawaki T. : Theophylline metabolism in acute asthma with MxA-indicated viral infection. Pediatr Int 48: 54-57, 2006.
    4. Taneichi H., Kanegane H., Futatani T., Otsubo K., Nomura K., Sato Y., Hama A., Kojima S., Kohdera U., Nakano T., Hori H., Kawashima H., Inoh Y., Kamizono J., Adachi N., Osugi Y., Mizuno H., Hotta N., Yoneyama H., Nakashima E., Ikegawa S., and Miyawaki T. : Clinical and genetic analyses of presumed Shwachman-Diamond syndrome in Japan. Int J Hematol 84: 60-62, 2006.
    5. Hirono K., Foell D., Xing Y., Miyagawa T. S., Ye F., Ahlmann M., Vogl T., Futatani T., Chen R., Yu X., Watanabe K., Watanabe S., Tsubata S., Uese K., Hashimoto I., Ichida F., Nakazawa M., Roth J., and Miyawaki T. : Expression of myeloid-related protein-8 and -14 in patients with acute Kawasaki disease. J Am Coll cardiol 48: 1257-1264, 2006.
    6. Nakabayashi M., Adachi Y., Itazawa T., Okabe Y., Kanegane H., Kawamura M., Tomita A., and Miyawaki T.: MxA-Based recognition of viral illness in febrile children by a whole blood assay. Pediatr Res 60: 770-774, 2006.
    7. Xing Y., Ichida F., Matsuoka T., Isobe T., Ikemoto Y., Higaki T., Tsuji T., Haneda N., Kuwabara A., Chen R., Futatani T., Tsubata S., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Bowles K.R., Bowles N.E., and Towbin J.A. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Mol Genet Metab 88 : 71-77, 2006.
    8. Aghamohammadi A., Fiorini M., Moin M., Parvaneh., Teimourian S., Yeganeh M., Goffi F., Kanegane H., Amirzargar A. A., Pourpak Z., Rezaei N., Salavati A., Pouladi N., Abdollahzade S., Notarangelo L.D., Miyawaki T., and Plebani A. : Ckinical, immunological and molecular characteristics of 37 Iranian patients with X-linked agammaglobulinemia. Int Arch Allegy Immunol. 141 : 408-414, 2006.
    9. Kanemoto N., Horigome H., Nakayama J., Ichida F., Xing Y., Buonadonna A. L., kanemoto K., and Gentile M.: Interstitial 1q43-q43 deletion with left ventricular noncompaction myocardium. Eur J Med Genet 49 : 247-253, 2006.
    10. Nakazawa M., Saji T., Ichida F., Oyama K., Harada K., and Kusuda S. : Guidelines for the use of palivizumab in infants and young children with congenital heart disease. Pediatr Int . 48 : 190-193, 2006.
    11. Kobayashi R., Ariga T., Nonoyama S., Kanegane H., Tsuchiya S., Morio T., Yabe H., Nagatoshi Y., Kawa K., Tabuchi K., Tsuchida M., Miyawaki T., and Kato S. : Outcome in patients with Wiskott-Aldrich syndrome following stem cell transplantation: an analysis of 57 patients in Japan. Brit J Haematol 135 : 362-366, 2006.
    12. Minegishi Y., Saito M., Morio T., Watanabe K., Agematsu K., Tsuchiya S., Takada H., Hara T., Kawamura N., Ariga T., Kaneko H., Kondo N., Tsuga I., Yachie A., Sakiyama Y., Iwata T., Bessho F., Ohishi T., Joh K., Imai K., Kogawa K., Shinohara M., Fujieda M., Wakiguchi H., Pasic S., Abinun M., Ochs H.D., Renner E.D., Jansson A., Belohradsky B.H., Metin A., Shimizu N., Mizutani S., Miyawaki T., Nonoyama S., and Karasuyama H.: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25 : 745-755 , 2006.
    13. Grebe S., Ichida F., Grabitz R., B?ltmann B., Heidemann S., von Kaisenberg CS. : Reversed pulmonary artery flow in isolated noncompaction of the ventricular myocardium. Fetal Diagnosis and Therapy. 22: 29-32, 2006.
    14. Murakami H., Yoshimura N., Kitahara J., Otaka S., Ichida F., and Misaki T. : Collision of the caval flows caused early failure of the Fontan circulation. J Thorac Cardiovasc Surg. 132: 1235-1236, 2006.
    15. ˆÉ“¡–õ“TC‘«—§—zŽqC•£àV—³–çC”ÂàVŽõŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒNƒŠƒbƒN‚Öƒ‰ [iƒhƒ‰ƒCƒpƒEƒ_[Ž®‹z“üŠíj‚ð—p‚¢‚œÛ‚Ì‹z‹C—¬‘¬‚ÌŒŸ“¢. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@20F160-165C2006.
    16. “y”ì‘P˜YC‘哈‹`”ŽC“‡’ÐeŽuCŽOè‘ñ˜YC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“ñ’J@•FŽèpŽž‘̏d2C500g–¢–ž ‚̐æ“V«SŽŸŠ³Š³ŽÒ‚ɑ΂·‚éŠO‰ÈŽ¡—Â̑I‘ð. “ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@22: 75-79C2006.
    17. –Ø‘º@G, ‰Í@Œh¢, ‘åÎ@•×, ‘O“c–Ÿ•F, ‰ª‘º—²s, ‘å‰ê³ˆê, ‹àŒ“O˜a, X@‰ë—º, X–{@“N, X”ö—FG, ¡ˆäÍ ‰î, ‰ª–ì‘f•F, ’J“à]ºG, “y‰®@Ž , ˜eŒû@G: –«Šˆ“®«EBƒEƒCƒ‹ƒXŠŽõÇ‚Ì’·Šú—\Œã‚ɂ‚¢‚Ä. “ú–{¬Ž™‰ÈŠw ‰ïŽ@110: 1578|1580, 2006.
  • Ç—á•ñ
    1. Matsukura H., Itoh Y., Kanegane H., Arai M., Miyawaki T., and Murakami G.: Acute tubulointerstitial nephritis : possible association with cytomegalovirus infection. Pediatr Nephrol 21 : 442-443, 2006.
    2. Honma T., Kanegane H., Shima T., Otsubo K., Nomura K., and Miyawaki T.: Neuroblastoma in an XYY male. Cancer Genet Cytogen 168 : 83-84, 2006.
    3. Otsubo K., Kanegene H., Nomura K., Ogawa J., and Miyawaki T.: Identification of a novel MYH9 mutation in a patient with May-Hegglin anomaly. Pediatr Blood Cancer. 47 : 968-969, 2006.
    4. Mitsui T., Tsukamoto N., Kanegane H., Agematsu K.,Sekigami T., Irisawa H., Saitoh T., Uchiumi H., Handa H., Matsushima T., Karasawa M., Murakami H., Miyawaki T., and Nojima Y. : X-linked agammaglobulinemia diagnosed in adulthhood: A case report. Int J Hematol 84 : 154-157, 2006.
    5. Yoshino A., Honda M., Kanegane H., Obata K., Matsukura H., Sakazume S., Katada Y., Miyawaki T., Ueda Y., and Nagai T.: Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia. Pediatr Nephrol 21 : 36-38,2006.
    6. Yoshimura N., Murakami H., Otaka S., Watanabe K., Watanabe S., Uese K., Nomura K., Hashimoto I., Kanegane H., Ichida F., and Misaki T.: Open heart operration in a child with congential heart disease and hereditary spherocytosis. Circ J 70: 1655-1657 , 2006.
    7. Kawashima H., Ushio M., Aritaki K., Kashiwagi Y., Watanabe C., Nishimata S., Takekuma K., Hoshika A., Taneichi H., and Kanegane H.: Discordant endocrinopathy in a sibling with shwachman-diamond syndrome. J Trop Pediatr 52 : 445-447, 2006.
    8. Alangari A., Abobaker A., Kanegane H., and Miyawaki T.: X-linked lymphoproliferative disease associated with hypogammaglobulinemia and growth-hormone deficiency. Eur J Pediatr 165 : 165-167, 2006.
    9. ˆÉ“¡–õ“TC‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFƒVƒ…ƒEŽ_ƒJƒ‹ƒVƒEƒ€Œ‹ÎÇ‚ð‡•¹‚µ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a ‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽ@20F30-33C 2006.
    10. Œ‰i‹M”VCŽR–{ŽŽqC‹{–{Œ’ŽuC’‡“‡‘å•ãC’؈䗎¶C”‹àV@iC•Ÿ“‡Œ[‘Ÿ˜YC•àVGŒõC™“cŒ›ˆêC‹àŒ“O˜aC ]ŒûŒõ‹»F—Δ^‹Û”sŒŒÇ‚Å”­Ç‚µ‚œD’†‹…Œž­Ç‚𔺂€‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—á. “ú–{¬Ž™ŒŒ‰tŠw‰ïŽ@ 20F101-104C2006.
    11. ŠÖªŠîŽ÷C‚‹Ž³hC•l–싐GC‘åãŒ€“ñC”Ñ“c­OC–î•”‚Ý‚Í‚éC‘åã–ƒ—R—¢C‹àŒ“O˜aC‹{˜e—˜’jF”œ•œ«’† Žš‰Š‚ɑ΂·‚ép‘OŒŸž‚©‚ç”­Œ©‚³‚ê‚œ‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ—á. Žš•@—Տ°@99F95-100C 2006.
    12. ¬Œ”ŽŽjC”§š’m‰ëC‚—œ–œ”üC–؍è‘P˜YC‹g“cärC‹àŒ“O˜aFœœ“ªŠWœˆÙŒ`¬Ç‚Ì‚P—á?’ág’·‚ɑ΂·‚é‚f‚g •â[—Ö@‚ÌŒø‰Ê‚àŠÜ‚ß‚Ä?@¬Ž™‰È—Տ°@59F1175-1179C 2006.
    13. ¬’r“¹–ŸC‰Ÿ–¡˜a•vCãŒˆê‰iC“ñ’J@•F¬Ž™Šú‚æ‚芎õ‚ðŒJ‚è•Ô‚µ28Î‚ŏ‰‚߂Đf’f‚³‚ê‚œ‚PŒ^‚IgMÇŒó ŒQ. —Տ°ŒŒ‰t 47F1377-1380C 2006.
  • ‘à
    1. ‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇ‚̍ŋ߂̘b‘è. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@16F529-531C 2006.
    2. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬D‘æ8‰ñ—Տ°S‘Ÿ•aƒtƒH[ƒ‰ƒ€ “ú–{S“d}Šw‰ïŽ@6:5-16C 2006.
    3. Žs“c•™ŽqFNoncompactionS‹Øãk–§‰»áŠQ@wS‘ŸxHEARTfs Selection 38 : 1020-1023C 2006.
    4. ‘«—§—YˆêF¬Ž™ƒAƒŒƒ‹ƒM[Šw‚̐V‚µ‚¢“WŠJ@‚PÍ3. 3)¬Ž™‹CŠÇŽxšb‘§‚Ì‹}«”­ì. ¬Ž™‰È—Տ°@59(‘)F1283-1290C 2006.
    5. ‘«—§—YˆêF¬Ž™šb‘§‚Ì”­ìŽž‚̃Aƒ~ƒmƒtƒBƒŠƒ“‚ÌŽg‚¢•û‚́H@‚p•‚`‚Å‚í‚©‚éƒAƒŒƒ‹ƒM[ŽŸŠ³@2: 463-465C 2006.
    6. ‘«—§—YˆêF¬Ž™šb‘§‚̐f’f‚ÆŽ¡—ÁC¬Ž™šb‘§‚Ì‘Šúf’f‚Æ‚»‚̉ۑè. —Տ°–ƉuEƒAƒŒƒ‹ƒM[‰È 46: 483-487C 2006.
    7. ‘«—§—YˆêF“û—cŽ™‚Ìšb‘§Ž¡—Âɑ΂·‚éV‚œ‚È“WŠJCƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚œ‹z“üƒXƒeƒƒCƒh—Ö@. Pharma Medica 24: suppl 15-20C 2006.
    8. ‘«—§—YˆêFƒAƒŒƒ‹ƒM[Ž™CŽÐ‰ï‚ÅŽx‚Š‚é‚»‚Ì–¢—ˆ. “ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïŽ 4: 144-149C 2006.
    9. ‘«—§—YˆêF¬Ž™‚Ì‘J‰„«ŠPšu‚ɑ΂·‚é’ÁŠPE‹Žá‚–ò‚ÌŽg‚¢•û. ¬Ž™‰Èf—à 69: 1503-1507C 2006.
    10. ‘«—§—YˆêFH•šƒAƒŒƒ‹ƒM[ Ž¡—Â̋³ˆçEŽw“±‚ɂ‚¢‚Ä. Topics in Atopy 5: 33-38C 2006D
    11. ‘«—§—YˆêF“ûŽ™šb‘§‚ÌŽÀ‘ԁCf’fCŽ¡—Ã. “ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ 19 : 27-32C 2006.
    12. ‘«—§—Yˆê: ¬Ž™šb‘§‚Ì‘Šúf’f‚Æ‚»‚̉ۑè. —Տ°–ƉuEƒAƒŒƒ‹ƒM[‰È46: 483|487, 2006.
    13. ‘«—§—Yˆê: ƒNƒ‹[ƒvÇŒóŒQ. ¬Ž™“à‰È38(‘): 444|445, 2006.
    14. ‹àŒ“O˜aC“ñ’J@•C‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇ‚Å“¯’肳‚ê‚Ä‚¢‚錎ˆöˆâ“`Žq.¬Ž™‰È@47F25-38C 2006.
    15. ‹àŒ“O˜aC‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇ\ˆâ“`ŽqŽ¡—ÈȊO‚ÌŽ¡—Á\. ¬Ž™‰Èf—Á@69F251-253C 2006.
    16. ‹àŒ“O˜aC‹{˜e—˜’jF–ƉuƒOƒƒuƒŠƒ“•â[—Ö@‚̐V‚œ‚È“WŠJ. ŒŒ‰tƒtƒƒ“ƒeƒBƒA@16F601-607C 2006.
    17. ‹àŒ“O˜aF‚Ç‚Ì‚æ‚€‚ÈŽž‚ɖƉu•s‘SÇ‚ð‹^‚€‚©H@¬Ž™ŠŽõ–Ɖu 18F41-46C 2006.
    18. ‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚É‚š‚¯‚é Th1/Th2 ƒTƒCƒgƒJƒCƒ“ƒoƒ‰ƒ“ƒX. —Տ°–Ɖu@45F 468-471C 2006.
    19. ‹àŒ“O˜aC‘å’ØŒc•ãC‹{˜e—˜’jF–Ɖu•só‘Ԃł̍R‹Û–ò—Ö@?æ“V«–Ɖu•s‘SÇ.¬Ž™“à‰È@38F1203-1206C 2006.
    20. ‹àŒ“O˜aCæâ@”ü›PC‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘B«ŽŸŠ³. —Տ°‚ƃEƒCƒ‹ƒX@34F133-140C 2006.
    21. ‹àŒ“O˜a, æâ@”ü“ß: ‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQD¬Ž™“à‰È38(‘): 238, 2006.
    22. –{‹œ˜a‹vF•KŒgI‚¯‚¢‚ê‚ñˆÓŽ¯áŠQy‚»‚ÌŽž‚Ç‚€‚·‚éz‚¯‚¢‚ê‚ñ‚ÌŽ¡—ÂƊǗC‚¯‚¢‚ê‚ñ‚ÉŠÖ‚·‚é’mŽ¯C‚¯‚¢‚ê‚ñ ‚ƊԈႊ‚â‚·‚¢¶—“I‰^“®CˆÙí‰^“®. ¬Ž™“à‰È 38F207-210C 2006.

  • 2006”NŠw‰ï•ñ
    1. Adachi Y.: Guest Lecture gA new Japanese guideline for asthma in childhoodh Early Intervention Meeting 2006, 2006,2, London.
    2. Adachi Y., Okabe Y., Itazawa T., Adachi YS., Nakabayashi M., Fuchizawa T., Miyawaki T., Odajima H.: Quality of life of children with allergic diseases. 62nd Annual Meeting of American Academy of Allergy, Asthma & Immunology,2006,3,Miami Beach,USA.
    3. Itazawa T., Adachi Y., Okabe Y., Adachi YS., Nakabayashi M., Harai T., Miya K., Uese K., and Miyawaki T. :. A child case of anaphylaxis to polyvinylpyrrolidone containing medicines. 62nd Annual Meeting of American Academy of Allergy, Asthma & Immunology,2006,3,Miami Beach,USA.
    4. Hirono K., Foell D., Xing Y., Miyagawa-Tomita S., Ye F., Watanabe K., Watanabe S., Uese K., Nakazawa M., Ichida F., Roth J., and Miyawaki T.: Dynamic changes of Myeloid-Related Protein (MRP)8/MRP14 positive circulating endothelial cells in patients with acute Kawasaki disease. The 70th Annual scientific meeting of the Japanese circulation society,3,2006,Nagoya.
    5. Shan L., Xing Y., Ye bF., Chen R., Tsuji T., Haneda N., Matsuoka T., Yu X., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese,K. Hamamichi Y., Hashimoto I., Ichida F., Miyawaki T., and Towin JA.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 70th Annual scientific meeting of the Japanese circulation society,2006,3,Nagoya.
    6. Adachi Y.FGuest Lecture gNew Concept of Beta2-agonists. Focus on Intrinsic Efficacyh, Scientific Meeting gNew Concept of Beta2-agonistsh ,2006,5,Jakarta & Surabaya,Indonesia.
    7. Kanegane H., Agematsu K., Futatani T., Suga K., Sekiguchi T., and Miyawaki T. : A novel CD19 deficiency in a Japanease patient with hypogammmagloblinemia. 2006 Primary Immunodeficiency diseases consortium conference,2006,6,San Francisco,U.S.A.
    8. Shan L., Ichida F., Xing Y., Chen R., Futatani T., Tsubata S., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Bowles KR,. Bowles NE., and Towbin JA.., etc. Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Pediatric Heart Forum 2006, 2006,9,Shanghai,China.
    9. Kanegane H., Agematsu K., Futatani T., Suga K., Sekiguchi T., and Miyawaki T.: A novel CD19 deficiency in a Japanese patients with hypogammaglobulinemia. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    10. Taneichi H., Kanegane H., Futatani T., and Miyawaki T. : Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    11. Aghamohammadi A., Kanegane H., Amizargar A.A., Pourpak Z., Rezaei N., Salavati A., Abdollahzade S., Notarangelo L.D., and Miyawaki T. : Molecular analysis in Iranian patients with antibody deficiency. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    12. Zhao M., Kanegane H., Futatani T., and Miyawaki T. : Enhanced expression of SAP in CD45RO+CD8+ T cells and NK cells and its deficiency in X-linked lymphoproliferative disease. 12th meeting of the European society for immunodeficiencies,2006,10,Budapest,Hungary.
    13. Hirono K., Foell D., Xing Y., Miyagawa-Tomita S., Ye F., Watanabe K., Watanabe S., Uese K., Nakazawa M., Ichida F., Roth J., and Miyawaki T.: Dynamic change and pivotal role of Myeloid-Related Protein (MRP) 8 and MRP14 in acute Kawasaki disease. The 79th Scientific Sessions of American Heart Association,2006,11,Chicago.
    14. Ichida F., Watanabe K., Matsui M., Noguchi K., Yoshimura N., Oshima Y., Murakami H., Watanabe S., Hirono K., UeseK., Origsa H., Nakazawa J., Yagihara T., Bilker WB., and Gur RC. Neuroanatomical development of infants undergoing heart surgery evaluated bu quantitative three-dimensional magnetic resonance imaging. The 79th Scientific Sessions of American Heart Association,2006,11,Chicago.
    15. Shan L., Xing Y., Futatani T., Tsubata S., Watanabe S., Saito K., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T.C Bowles NE., and Towbin JA. : SCN5A variant in Japanese patients with left ventricular noncompaction and arrhythmia. The 2nd IREIIMS Open Symposium,2006,12,Tokyo.
    16. Shan L., Xing Y., Watanabe S., Futatani T., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T.C Bowles NE., and Towbin JA. : SCN5A variant in Japanese patients with left ventricular noncompaction and arrhythmia. The 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.(Young Investigatorfs Award 2006)
    17. Hirono K., Kobayashi Y., Mitani Y., Kaneda H., Okabe T., Miura M., Kameda K., Konishi T., Ichida F., and Miyawaki T.: C The 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.
    18. Watanabe S., Hashimoto I., Saito K., Watanabe K., Uese K., Hirono K., Ichida F., Saito S., and Miyawaki T. : Characterization of ventricular myocardial performance in the fetus by tissue Doppler imaging. The 2nd Congress of the Asian Society for Pediatric Research. 2006,12,Yokohama.
    19. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚Ì‹}«ŠúŽ¡—ƒ·ŠúŠÇ—v. Airway Forum 2006 in •ŸˆäC2006C1C•Ÿˆä.
    20. ‘«—§—zŽqC”ÂàVŽõŽqC‰ª•””üŒbCŽRŒ³ƒŽqC‚”ö@Š²C”öã—mˆêC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚š ‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹ŽŽwŽŠ‘‚Ì—L—p«. ‘æ6‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2006C1C“Œ‹ž.
    21. ‘«—§—YˆêF“Á•Êu‰‰uJPGL2005‚ÌŽå‚ȕύX“_‚ƍ¡Œã‚ÌŽ¡—ÓW–]v. ‹ž“s¬Ž™‰Èˆã‰ïŠwpu‰‰‰ïC2006C2C‹ž“s.
    22. ‘«—§—YˆêD“Á•Êu‰‰u“û—cŽ™šb‘§‚Ì‹}«ŠúŽ¡—ƒ·ŠúŠÇ—v. ¬Ž™šb‘§ƒtƒH[ƒ‰ƒ€ in SAPPOROC2006C2CŽD–yD
    23. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‹{˜e—˜’jCÎàV@LC•Ÿ‰ª‡–çCŽO‰Y³‹`F¶Žš‰º‘B•”‰¡–ä‹ØŽî‚̈ê—á. ‘æ24‰ñ –k—€¬Ž™ŠàÇ—ጟ“¢‰ïC2006C2.‹à‘ò.
    24. “n•Óˆ»‰ÀC‹Ž–{ˆè•vCÄ“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqCÄ“¡Ž C‹{˜e—˜’jF‘gDƒhƒvƒ‰–@ ‚ð—p‚¢‚œ‘ÙŽ™S‹@”\‚Ì•]‰¿. ‘æ12‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹†‰ïŠwpW‰ïC2006C2CŒyˆä‘ò.
    25. ãšŒhˆê˜YC“n•Óˆê—mC“n•Óˆ»‰ÀCŽs“c•™ŽqFæ“V«SŽŸŠ³‚É‚š‚¯‚é3DCT‚Ì—L—p«‚ÌŒŸ“¢. ‘æ31‰ñ–k—€¬Ž™zŠÂ ŠíŒ€‹†‰ïC2006C2C‹à‘ò.
    26. œA–ìŒbˆêCŽO’J—S‰îC‹à“c®C‰ª•”ŒhCŽO‰Y³‹`CX‰i‹šŽqCŽs“c•™ŽqFAccelerated idioventricular rhythm‚ð”F‚œ‚ß V¶Ž™‚Ì‚P—á. ‘æ31‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ïC2006C2C‹à‘ò.
    27. –{‹œ˜a‹vC‹{ˆêŽuC‰eŽR—²ŽiC“c’‡çHC‹{˜e—˜’jFR”]R‘Ì‚ª—z«‚Ÿ‚Á‚œ•sˆÓ‰^“®‚Ì4—á. ‘æ49‰ñ“ú–{¬Ž™_ ŒoŠw‰ï–k—€’n•û‰ïC2006C2C‹à‘ò.
    28. ¬ìŽŸ˜YCÎŽRº•FC“ŒŽROKCœAìTˆê˜YCŽðˆä³—˜C“ñ’J@•C‘同N°CâV“¡@Ž C‹{˜e—˜’jF’Ž’áo¶‘Ì dŽ™‚Ì’°úE‚ɑ΂·‚éŠO‰È“IŽ¡—Ö@‚Ì‘I‘ð‚ɂ‚¢‚Ä. ‘æ9‰ñ•xŽRŒ§•êŽqˆã—ÃŒ€‹†‰ïC2006C2C•xŽR.
    29. ‘«—§—YˆêFPro/Con uƒAƒŒƒ‹ƒM[«•@‰Š‚ÌŽ¡—ÂŚb‘§‚̃Rƒ“ƒgƒ[ƒ‹‚͉ü‘P‚·‚é‚©Hv@‘æ3‰ñŽOd‹C“¹ƒAƒŒƒ‹ƒM [Œ€‹†‰ïC2006C3C’ÁD
    30. –{‹œ˜a‹vC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHC‹{˜e—˜’jFHHV6”]‰Š‰ñ•œŠúˆÈ~‚Éáz¹‚ðŒJ‚è•Ô‚µ‚œ2—á. ‘æ30‰ñ–k —€‚Ä‚ñ‚©‚ñ§˜b‰ïC2006C3C‹à‘ò.
    31. ‰eŽR—²ŽiC‹{@ˆêŽuC–{‹œ˜a‹vC‹{˜e—˜’jC‹T“cˆê”ŽC¬Œ@“OFdÇSgáŠQŽ™iŽÒj‚ɑ΂·‚é”x“àƒp[ƒJƒbƒV ƒ‡ƒ“ƒxƒ“ƒ`ƒŒ[ƒ^[‚Ì’ZŠúŽg—p—á.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2006C3C‹à‘ò.
    32. ‘å’ØŒc•ãCŒŽˆä•ü”üC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCŒI–{¹‹IC‰““¡r˜YFÅ‹ß‚P”NŠÔ‚Å“–‰È‚ªŒoŒ±‚µ‚œ”]Žîᇠ‚S—á.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2006C3C‹à‘ò.
    33. ‘q–{@’CŒÜ\—’“oC’·‰«—DŽqC’†ŽR—SŽqC”öã—mˆêC”šèŠì–FF‚a‚b‚fV–@iuŒ‹Šj—\–h–@v‰ü³j‚̉e‹¿‚Æ“–‰È ‚Å‚ÌŽæ‚è‘g‚Ý.‘æ286‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ïC2006C3C‹à‘ò.
    34. ‹àŒ“O˜aC“ñ’J@•C{‰êŒ’ˆêCŠÖŒû—²Œ›CãŒˆê‰iC‹{˜e—˜’jFCD19Œ‡‘¹‚É‚æ‚é–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ. ‘æ109 “ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    35. –쑺ŒbŽqC‘å’ØŒc•ãC‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jFˆŸ‹}«‰óŽ€«ƒŠƒ“ƒpß‰Š‚É‚š‚¯‚é MxA ’`”’‚ÌŒŸ“¢. ‘æ109 “ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    36. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jC¬“c“ˆ@”ŽCÔàV@WF•xŽRŒ§‚É‚š ‚¯‚éISAACŽ¿–â•[‚ð—p‚¢‚œƒAƒŒƒ‹ƒM[ŽŸŠ³’²ž”üŒb@‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    37. “n•Óˆê—mCŽs“c•™ŽqC‹{˜e—˜’jCŒˆäŽOŽ}CÎ•^—R”üC–F‘º’ŒŽ÷C‘哈‹`”ŽC’†‘òCŒè‘œç‘ãC”ª–ØŒŽrŽF V¶Ž™ŠúC“ûŽ™‘ŠúŽèp‚ðŽ{s‚³‚ê‚œæ“V«SŽŸŠ³Ž™‚̐ž_‰^“®”­ç—\Œã. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    38. “n•Óˆ»‰ÀC‹Ž–{ˆè•vC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jCÖ“¡Ž F‘gDƒhƒvƒ‰–@‚ð—p‚¢‚œ‘Ù Ž™S‹@”\‚Ì•]‰¿. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    39. ‘å’ØŒc•ãC–쑺ŒbŽqC¬ìŽŸ˜YC‹àŒ“O˜aC‹{˜e—˜’jC®“c‰žŽqCŽRŠÝ“ÄŽŠF‹‘匌¬”‚Æè÷—±‹…••“ü‘Ì‚ð”F‚ß‚œ MYH9 ˆÙíÇ‚̈ê’jŽ™—á. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C‹à‘ò.
    40. –{‹œ˜a‹vC‹{ˆêŽuC‰eŽR—²ŽiC“c’‡çHCL–ìŒbˆêC‹{˜e—˜’j. ŒŒ’†R”]R‘Ì‚ª—z«‚ðŽŠ‚µ‚œ“ÁˆÙ‚È”]‰ŠE”]ÇŒã ‚Ä‚ñ‚©‚ñ‚Ì2—á. ‘æ109“ú–{¬Ž™‰ÈŠw‰ïC2006C4C ‹à‘ò.
    41. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u’vŽ€« EB ƒEƒCƒ‹ƒXŠÖ˜AŽŸŠ³‚̐f’f‚ÆŽ¡—Ã?‚w˜AœƒŠƒ“ƒp‘B«ŽŸŠ³v‘æ80“ú–{ŠŽõ ÇŠw‰ïC2006C4C “Œ‹ž.
    42. ‘«—§—YˆêF“Á•Êu‰‰uŽq‚Ç‚à‚̐H•šƒAƒŒƒ‹ƒM[v. •œ¬18”N“x•xŽR‰h—{Žm‰ï‘‰ïC2006C5C•xŽR.
    43. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚̐f’f‚Ə¬Ž™šb‘§ƒKƒCƒhƒ‰ƒCƒ“‚ÌŽæ‚舵‚¢‚ɂ‚¢‚āv. ‘æ‚U‰ñ¬Ž™‰Èˆã‚Ì‚œ‚ß‚Ì šb‘§ƒtƒH[ƒ‰ƒ€C2006C5C‘åã.
    44. ‘«—§—zŽqC”óŒû@ŽûCˆÉ“¡–õ“TC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™‚É‚š‚¯‚é‹CŠÇŽxšb‘§‚Æ•@‰Š‚ÌŠÖ ˜A‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ27‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2006C5C•xŽR.
    45. ‘«—§—zŽqC”óŒû@ŽûCˆÉ“¡–õ“TC”ÂàVŽõŽqCŽRŒ³ƒŽqC”öã—mˆêC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™ ‚É‚š‚¯‚é•@•›•@o‰Š‚È‚ç‚тɃAƒŒƒ‹ƒM[«•@‰Š‚̍‡•¹—Š. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2006C5C“Œ ‹ž.
    46. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jC¬“c“ˆ@”ŽCÔàV@WF•xŽRŒ§‚É‚š ‚¯‚éISAACŽ¿–â•[‚ð—p‚¢‚œƒAƒŒƒ‹ƒM[ŽŸŠ³’²ž. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2006C5C“Œ‹ž.
    47. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—zŽqC‘«—§—YˆêF“–‰@ƒAƒŒƒ‹ƒM[ŠO—ˆ‚É‚š‚¯‚é‹CŠÇŽxšb‘§Ž™‚Ì ”N—î‘w•ÊƒvƒŠƒbƒNƒeƒXƒg—z«—Š‚ɂ‚¢‚Ä. ‘æ18‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ïC2006C5C“Œ‹ž.
    48. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‹CŠÇŽxšb‘§Ž¡—Âɂš‚¯‚éÅ‹ß‚̘b‘èv. ÎìŒ§¬Ž™‰Èˆã‰ïC2006C6C‹à‘ò.
    49. ‘«—§—YˆêF“Á•Êu‰‰uV‚µ‚¢¬Ž™‹CŠÇŽxšb‘§f—ẪRƒc‚Æ—Ž‚Æ‚µŒŠv. ‘æ4‰ñ¬Ž™šb‘§ƒtƒH[ƒ‰ƒ€in‘œ–€C2006C6C “Œ‹ž.
    50. –{‹œ˜a‹vCŒŽˆä•ü”üC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHC”ª–ؐMˆêC‚‹ŽK—˜C‹{˜e—˜’jF‚Ä‚ñ‚©‚ñ‚̖Ɖu“I”wŒi‚É ŠÖ‚·‚錟“¢. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    51. ‹{@ˆêŽuC–{‹œ˜a‹vC‰eŽR—²ŽiCŒŽˆä•ü”üC”ª–ؐMˆêC‚‹ŽK—˜C‹{˜e—˜’jF“ÁˆÙ‚È”]‰ŠE”]ÇŒã‚Ä‚ñ‚©‚ñ‚̈êŒQ ‚É‚š‚¯‚éR”]R‘Ì‚ÌŒŸ“¢. ‘æ48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    52. ‰eŽR—²ŽiC‹{@ˆêŽuC ŒŽˆä•ü”üC–{‹œ˜a‹vC”ª–ؐMˆêC‹{˜e—˜’jF—\–hÚŽíŒã‚É‚¯‚¢‚ê‚ñ‚ð’悵‚œ2—á. ‘æ48‰ñ “ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    53. ŒŽˆä•ü”üC–{‹œ˜a‹vC‹{@ˆêŽuC ‰eŽR—²ŽiC•£‘ò—³–çC‹{˜e—˜’jFRamsay-Hunt ÇŒóŒQ‚É”][Ç‚𔭏ǂµ‚œˆê—á. ‘æ 48‰ñ“ú–{¬Ž™_ŒoŠw‰ï2006C6C“Œ‹ž.
    54. ‘«—§—YˆêF‰ï’·u‰‰uƒAƒŒƒ‹ƒM[Ž™CŽÐ‰ï‚ÅŽx‚Š‚é‚»‚Ì–¢—ˆv‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï2006C 6C •xŽR.
    55. ‰ª•””üŒbC”ÂàVŽõŽqC”óŒû@ŽûCˆÉ“¡–õ“TC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF‰ßŠ·‹CÇŒóŒQ‡•¹‚̏dÇ šb‘§Ž™‚Æ‚µ‚ďЉ‚ê‚œ2—á. ‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï2006C6C •xŽR.
    56. Œ–쐳’mCˆÉ“Œ“¹•vC‹gZ@ºC‘«—§—YˆêCŒÜ\—’—²•vFŽ{Ý“ü‰@—Ö@‚ðs‚Á‚œšb‘§Ž™‚Ì‹C“¹‰ß•q«‚̐„ˆÚ‚Æ—\Œã ‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ23‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï2006C6C•xŽR.
    57. –{‹œ˜a‹vF¬Ž™_ŒoŽŸŠ³‚̖Ɖu“I”wŒi. ‘æ235‰ñŒàŒ¬Ž™‰ÈW’k‰ïC2006C6C•xŽR.
    58. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚É‚š‚¯‚銎õ‚Ì–ðŠ„v ‘æ45‰ñ‹žŽ —Տ°ƒAƒŒƒ‹ƒM[§’k‰ïC2006C7.29C‹ž“s.
    59. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™šb‘§‚̐f’f‚ÆŽ¡—ÂƏ¬Ž™ƒKƒCƒhƒ‰ƒCƒ“‚ɂ‚¢‚āv “úˆã¶ŠU‹³ˆç‹Š—͍uÀC2006C7C˜a ‰ÌŽR.
    60. œA–ìŒbˆêC¬Œ“OCŽs“c•™ŽqFdÇSgáŠQŽ™‚É‚š‚¯‚éS“dŠw“I“Á’¥. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C 7C–ŒŒÃ‰®.
    61. “n•Óˆê—mCŒˆäŽOŽ}CÎ•^‹|C–F‘º’ŒŽ÷C‘ºã”Ž‹vC“n•Óˆ»‰ÀCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽC ”ª–ØŒŽrŽFŠJSp‚ðŽ{s‚³‚ê‚œæ“V«SŽŸŠ³Ž™‚Ì”­ç—\Œã\Bayley scale‚š‚æ‚Ñ3D-MRI‚ð—p‚¢‚œ”]—e—Ê‚Ì•]‰¿|. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–ŒŒÃ‰®.
    62. “n•Óˆ»‰ÀC‹Ž–{ˆè•vCÖ“¡˜a—RC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqCÖ“¡Ž C‹{˜e—˜’jF‘gDƒhƒvƒ‰–@ ‚ð—p‚¢‚œ‘ÙŽ™SŸk”\‚Ì•]‰¿. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–ŒŒÃ‰®.
    63. ’P —í’ŸC‚µ‚ñ‰—ԁC“ñ’J•C’ÔŠáÁˆêC“n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jFSCN5A mutations in Japanese patients with left ventricular noncompaction. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC2006C7C–ŒŒÃ ‰®.
    64. Œè‘œç‘ãC’†àV@CŒˆäŽOŽ}CŽs“c•™ŽqCÎ•^‹|CŠp@GHCâ–{ŠìŽO˜YC²–ìr“ñCà_˜e³DC‘O“c³MC ”ª–ØŒŽrŽF¬Ž™ŠJSpŒã‚É‚š‚¯‚é”­’B•]‰¿‚Æ‚µ‚Ä‚ÌBayley scale‚Ì“±“ü. ‘æ42‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ïC 2006C7C–ŒŒÃ‰®.
    65. Shan L.: Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. ‘æ‚V‰ñ¬ Ž™SŒŒŠÇ•ªŽqˆãŠwŒ€‹†‰ïC2006C7C–ŒŒÃ‰®.
    66. å ‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðs‚Á‚œŽá”N«œ‘’P‹…«”’ŒŒ•a‚Ì‚P—á. ‘æ11‰ñ•xŽR‘¢ŒŒ Š²×–EˆÚA§˜b‰ïC2006C7C•xŽR.
    67. ‹àŒ“O˜aC‘«—§—YˆêC‹{˜e—˜’jFƒNƒ‰ƒ~ƒWƒAEƒjƒ…[ƒ‚ƒjƒGŠŽõÇ‚̗Տ°‘œ.‘æ‚X‰ñ•xŽR¬Ž™ŠŽõ–ƉuŒ€‹†‰ïC2006C 7C •xŽR.
    68. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g‹CŠÇŽxšb‘§‚Ì‚æ‚è‚æ‚¢Ž¡—Â̂œ‚߂Ɂh u‹z“üƒfƒBƒoƒCƒX‚Ì‘I‘ðCMDI‚©DPI‚©ƒlƒuƒCƒU[ ‚©v ‘æ27‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒXC2006C8C‹ž“s.
    69. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™šb‘§Ž¡—Âɂš‚¯‚éƒÀ2ŽhŒƒ–ò‚̈ʒu‚¯v ‘æ13‰ñAllergy Forum in GunmaC2006C9C‘O ‹Ž.
    70. –{‹œ˜a‹vFƒ[ƒNƒVƒ‡ƒbƒvu¬Ž™“«‚Ä‚ñ‚©‚ñ‚ÌŽ©ŒÈ–Ɖu“I”wŒiv. ‘æ40‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï‘‰ïC2006C9C@@.
    71. Ö“¡˜a—RC“n•Óˆ»‰ÀCãšŒhˆê˜YCŽs“c•™ŽqC”‘òŽõŽqC‘«—§—Y\C‹{˜e—˜’jCÎŒŽr“ñCFèŒ’F‹CŠÇŽxšb‘§Ž¡ —Ã’†?ŽhŒƒ–ò‹z“ü‚É‚æ‚èQT‰„’·ÇŒóŒQ‚ª”­Œ©‚³‚ê‚œ[—á. ‘æ32‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ïC2006C9C‹à‘ò.
    72. “n•Óˆê—mCÄ“¡˜a—RC“n•Óˆ»‰ÀCãšŒhˆê˜YCŽs“c•™ŽqFæ“V«SŽŸŠ³Ž™‚ɑ΂·‚éƒpƒŠƒrƒYƒ}ƒu“Š—^\ƒtƒ@[ƒXƒg ƒV[ƒYƒ“‚ðU‚è•Ô‚Á‚Ä. ‘æ32‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ïC2006C9C‹à‘ò.
    73. L–ìŒbˆêFExpression of myeloid-related protein (MRP) 8 and MRP14 in patients with acute Kawasaki disease. ‘æ54‰ñ“ú–{ S‘Ÿ•aŠw‰ïC2006C9CŽ­Ž™“‡(2006”N“xYIA—DGÜ).
    74. ‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çC‘«—§—YˆêC‹{˜e—˜’jF•xŽRŒ§‚É‚š‚¯‚鏬Ž™ƒAƒŒƒ‹ƒM[ŽŸŠ³ ’²ž. ‘æ9‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2006C9C•xŽR.
    75. –쑺ŒbŽqCâV“¡˜a—RC‹àŒ“O˜aC‹{˜e—˜’jCŽO’J—S‰îC‹à“c@®CŽO‰Y³‹`F• •”ŽîᎂðŒ_‹@‚ÉŒ©‚‚©‚Á‚œ_Œo‰è ×–EŽî stage IVA ‚Ì1—á. ‘æ25‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ïC2006C9C‹à‘ò.
    76. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€uJPGL2005‚̉ü’ù‚ª“ûŽ™šb‘§‚ÌŽ¡—ÃŒ»ê‚É—^‚Š‚œ‚à‚́CƒAƒ~ƒmƒtƒBƒŠƒ“’v ‘æ15‰ñ¬Ž™ ‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2006C10C_ŒË.
    77. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éƒÀ2ŽhŒƒ–ò‚Ì“K³Žg—pv “ŒŽO‰Í¬Ž™‰Èˆã‰ïŠwpu‰‰‰ïC2006C10C –L‹Ž.
    78. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§‚É‚š‚¯‚éÅ‹ß‚̘b‘èv ‹ž“s•{•a‰@–òÜŽt‰ï•œ¬18”N“xŠwpˆÏˆõ‰ïŠwpu‰‰‰ïC 2006C10C‹ž“s.
    79. “n•Óˆ»‰ÀCÄ“¡˜a—RCãšŒhˆê˜YC‹àŒ“O˜aCŽs“c•™ŽqC‹{˜e—˜’jFŠeŽíŽ¡—ÂɒïR«‚̐ìè•a‚ɃVƒNƒƒXƒ|ƒŠƒ“ A‚ª—LŒø‚Å‚ ‚Á‚œˆê—á. @‘æ26‰ñ“ú–{ìè•aŒ€‹†‰ï. 2006C10C‘åã.
    80. Ä“¡˜a—RC“n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jFƒÁƒOƒƒuƒŠƒ“‰ß•qÇ‚̐ìè•aŽ™‚É‘Î ‚µ‚ÄInfliximabiRTNF|ƒ¿R‘́j‚ðŽg—p‚µ‚œŒoŒ±. ‘æ26‰ñ“ú–{ìè•aŒ€‹†‰ïC2006C10C‘åã.
    81. “n•Óˆ»‰ÀCÄ“¡˜a—RCãšŒhˆê˜YCŽs“c•™ŽqC‘卂TŒáC–F‘º’ŒŽ÷C‘ºã”Ž‹vC–kŒŽ~ˆê˜YCŽOè‘ñ˜YFŽŠ“KAV delay ‚̐ݒè‚É‚æ‚èCS•s‘S‚̉ü‘P‚ð”F‚ß‚œ¶S’áŒ`¬ÇŒóŒQCƒy[ƒXƒ[ƒJ[‘}“üŒã‚̈ê—á. •xŽR¬Ž™zŠÂŠíŠw‰ïC2006C 10C•xŽR.
    82. ‘«—§—YˆêF“Á•Êu‰‰u“û—cŽ™šb‘§Ž¡—Âɂš‚¯‚éV‚µ‚¢“W–]v •œ¬18”N“x•ŸˆäŒ§¬Ž™‰Èˆã‰ïŠwpW‰ïC2006C11C •Ÿˆä.
    83. ‘«—§—YˆêF“Á•Êu‰‰uƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ƁC‚»‚̑Ήž‚ɂ‚¢‚āv •œ¬18”N“x•xŽRŒ§—{Œì‹³—@Šˆ“®Œ€C‰ïC 2006C11C•xŽR.
    84. ‘«—§—YˆêF“Á•Êu‰‰uŠwZ‚É‚š‚¯‚éƒAƒŒƒ‹ƒM[ŽŸŠ³‚ւ̑Ήžv Vì’n‹æ‚“™ŠwZ•ÛŒ’˜A—‹Š‹c‰ïC2006C11C‹›’Ã.
    85. ‘«—§—YˆêF“Á•Êu‰‰u¬Ž™‚É‚š‚¯‚éOne airway, One disease‚̍l‚Š•ûv ‘æ2‰ñŒQ”n‹C“¹ŽŸŠ³Œ€‹†‰ïC2006C11CŒQ ”n.
    86. ‘«—§—YˆêF“Á•Êu‰‰u“ûŽ™šb‘§‚̐f’f‚ÆŽ¡—Ã?Å‹ß‚̘b‘è?v ˆ€’m¬Ž™ƒAƒŒƒ‹ƒM[u‰‰‰ïC2006C11C–ŒŒÃ‰®.
    87. ‘«—§—YˆêFƒCƒuƒjƒ“ƒOƒVƒ“ƒ|ƒWƒEƒ€gŒÄ‹zŠíŽŸŠ³‚ɑ΂·‚éV‚œ‚Ȑf’f‚ւ̃Aƒvƒ[ƒ`hu“û—cŽ™šb‘§‚Ì‘Šúf’f‚É‚š ‚¯‚é‰Û‘èv. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    88. ˆÉ“¡–õ“TC”óŒû@ŽûC”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—zŽqC‘«—§—YˆêCŽRŒ³ƒŽqC‘ºãIŒ[C‹{˜e—˜’jF’vŽ€“I•s®–¬ ‚ð‡•¹‚·‚é‹CŠÇŽxšb‘§Ž™‚ÌŠÇ—. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    89. ‘«—§—zŽqC’†—ÑŒºˆêC•£àV—³–çC”ÂàVŽõŽqC‚”ö@Š²C”öã—mˆêCŠžŒŽ¹ŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•Û ˆçŽ{Ý‚É‚š‚¯‚éH•šœ‹ŽŽwŽŠ‘‚Ì‚ ‚è•û?Š®‘Sœ‹Ž‚©ŒÂ•Ê‘Ήž‚©[. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC 2006C11C“Œ‹ž.
    90. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘«—§—YˆêC‘«—§—zŽqC‘ºãIŒ[F“û—cŽ™‚É‚š‚¯‚éˆê‰ß«šb–C”ñƒAƒgƒs[Œ^šb ‘§CƒAƒgƒs[Œ^šb‘§‚Ì‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ56‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹GŠwpW‰ïC2006C11C“Œ‹ž.
    91. ”óŒû@ŽûC‘«—§—YˆêCŽsŠÛ’q_Cóˆä³ŽkCìèˆê‹PFh‘è•ñu¬Ž™‚É‚š‚¯‚é‹CŠÇE‹CŠÇŽxˆÙ•š‚ÉŠÖ‚·‚é’²žŒ‹ ‰Êv. ‘æ39‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïC2006C11C“Œ‹ž.
    92. ‘ºãIŒ[CˆÉ“¡–õ“TC’ÔŠáÁˆêC–{ŠÔ@mC”ÂàVŽõŽqCãšŒhˆê˜YC‘«—§—YˆêF2005/2006‚É‚š‚¯‚éRSƒEƒCƒ‹ƒXŠŽ õ‚Å‚Ì“ü‰@—á‚̗Տ°“IŒŸ“¢. ‘æ39‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïC2006C11C“Œ‹ž.
    93. ‘«—§—YˆêF‹³ˆçƒZƒ~ƒi[u¬Ž™ŒÄ‹zŠíŽŸŠ³‚É‚š‚¯‚郍ƒCƒRƒgƒŠƒGƒ“Žó—e‘̝hR–ò‚̍ŐV’mŒ©v. ‘æ43‰ñ“ú–{¬Ž™ƒA ƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    94. ”ÂàVŽõŽqC‰ª•””üŒbCˆÉ“¡–õ“TC”óŒû@ŽûC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jC‘ºãIŒ[CŒ–쐳’mFƒCƒ\ƒvƒƒŒƒe ƒm[ƒ‹Ž‘±‹z“ü—Ö@’†‚̏™–¬”­Œ»‚ɂ‚¢‚Ä. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    95. ‘«—§—zŽqC’†—ÑŒºˆêC•£àV—³–çC‰ª•””üŒbC”ÂàVŽõŽqC‚”ö@Š²CŽRŒ³ƒŽqC”öã—mˆêC‘ºãIŒ[C‘«—§—YˆêC‹{ ˜e—˜’jF•xŽRŒ§‚Ì•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‚ÌŽÀ‘Ô’²ž|•œ¬13”N“x‚Æ‚Ì”äŠr|. ‘æ43 ‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    96. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘«—§—YˆêC‘«—§—zŽqC‘ºãIŒ[F“û—cŽ™‚É‚š‚¯‚éˆê‰ß«šb–C”ñƒAƒgƒs[Œ^šb ‘§CƒAƒgƒs[Œ^šb‘§‚̗Տ°Œo‰ß‚Æ‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    97. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[FŽŒ]•a•Ï‚ªæs‚µ‚œšb‘§‚Ɛæs‚µ‚È‚©‚Á‚œšb ‘§‚̗Տ°Œo‰ß‚È‚ç‚Ñ‚É‹C“¹‰ß•q«‚Ì”äŠrŒŸ“¢. ‘æ43‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïC2006C11Cç—t.
    98. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uŠî‘bŽŸŠ³‚ðŽ‚ÂŠ³Ž™‚ɑ΂·‚é—\–hÚŽí?ŠŽõÇ‚Æ—\–hÚŽív.‘æ38‰ñ“ú–{¬Ž™ŠŽõÇŠw ‰ïC2006C11C‚’m.
    99. å@‹v”TC‹àŒ“O˜aC‹{˜e—˜’jCˆÉŒ\“ñ˜YC’†—ÑŒºˆêCŽÂèŒ’‘Ÿ˜YFŽš«…“ªÇ‚̈ê—á.‘æ38‰ñ“ú–{¬Ž™ŠŽõÇ Šw‰ïC2006C11C‚’m.
    100. ‹àŒ“O˜aF‹³ˆçu‰‰uæ“V«–Ɖu•s‘SÇ‚ÉŠÖ‚·‚éV‚µ‚¢˜b‘èv.‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    101. ‘å’ØŒc•ãC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFŒ‰Ê‘Ìãó×–EŽîᇂ̎¡—ÃŒo‰ß’†‚Ƀp[ƒLƒ“ƒ\ƒ“ÇŒóŒQ‚𔭏ǂµ‚œˆê’j Ž™—á. ‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    102. å@‹v”TC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC’†‘ò—mŽOC¬’rŒ’ˆêCŒ“c˜a”VFÔ‰è‹…Œn×–E‚Ì‘‰Á‚ð”F‚ß‚œŽá”N« œ‘’P‹…«”’ŒŒ•a‚̈ê—á. ‘æ48‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ïC2006C11C‘åã.
    103. “ñ’J@•C ¬ìŽŸ˜YC ˆÉ“ÞŽu”¿”üC “ŒŽROKC ‹{˜e—˜’jFCDKN1C(p57kip2)ˆâ“`Žq•ÏˆÙ‚É‚æ‚éBeckwith-Wiedemann ÇŒóŒQ‚Ì‹É’áo¶‘̏dŽ™—á. ‘æ51‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ïC2006C11C‘å‹{.
    104. Œè‘œç‘ãC’†àV@CŒˆäŽOŽ}CŽs“c•™ŽqC”ª–ØŒŽrŽFBayley“û—cŽ™”­’BŽÚ“x‚É‚æ‚é”­’Bž’èi‚QjS‘ŸŽŸŠ³ Ž™‚Ö‚Ì“K—p. ‘æ70‰ñ“ú–{S—Šw‰ïC2006C11C•Ÿ‰ª.
    105. ‘«—§—YˆêF‹³ˆçu‰‰u¬Ž™‚Ìšb‘§‚É‚š‚¯‚é‹z“üƒfƒoƒCƒX‚ɂ‚¢‚āv ‘æ6‰ñ•xŽRšb‘§Œ€‹†‰ïC2006C12C•xŽR.
    106. Kanegane H., Agematsu K., Futatani T., Sira M., and Miyawaki T. : A novel CD19 deficiency in a Japanese patients with hypogammaglobulinemia. ‘æ36‰ñ“ú–{–ƉuŠw‰ï,2006,12,‘åã.
    107. ˆÉ“¡–õ“TC•£àV—³–çC“ŒŽROKC‘«—§—YˆêC‹àŒ“O˜aC‹{˜e—˜’jC¬—шê˜YC“c’†@Š®CŠ—’r‹g˜NFFOXP3—z« CD25+CD4+T×–E‚̐¬’·‚É”º‚€•Ï‰»‚Æ FOXP3 ˆâ“`Žq•ÏˆÙ—á‚É‚š‚¯‚éˆÙí. ‘æ36‰ñ“ú–{–ƉuŠw‰ïC2006C12C‘åã.
    108. ‹àŒ“O˜aC–쑺ŒbŽqC‹{˜e—˜’jF–«“÷‰èŽîÇ‚ɑ΂·‚éƒ{ƒŠƒRƒiƒ][ƒ‹‚ÌŽg—pŒoŒ±.‘æ18‰ñH×–E‹@”\ˆÙíÇŒ€‹† ‰ï. 2006C12C“Œ‹ž.
    109. ˆÉ“¡–õ“TC”óŒû@ŽûC”ÂàVŽõŽqC‰ª•””üŒbC‘«—§—YˆêF’vŽ€«•s®–¬‚ð‡•¹‚µ‚œ¬Ž™‚É‚š‚¯‚éšb‘§ŠÇ—. ‘æ14‰ñ—Õ °šb‘§Œ€‹†‰ïC2006C12C‹à‘ò.
    110. ‘«—§—zŽqCˆÉ“¡–õ“TC”óŒû@ŽûC‰ª•””üŒbC”ÂàVŽõŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF•ÛˆçŽ{Ý‚ł̐H•šƒAƒŒƒ‹ ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‚ÌŽÀ‘ԁ|•œ¬13”N“x’²ž‚Æ‚Ì”äŠr|. ‘æ33‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ïC2006C12C‹à‘ò.

    2005”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇŒóŒQ.w¡“ú‚ÌŽ¡—ÃŽwj2005x@ŽRŒû“O‘Œ•Ò,959,ˆãŠw‘‰@,“Œ‹ž,2005.
    2. Ichida F. : Novel gene mutations in patients with left ventricular noncompaction and evidence for genetic heterogeneity. Cardiovascular Development and Congenital Malformations. Edited by Artman M, Blackwell Futura,277-278, Oxford, UK,2005.
    3. Žs“c•™ŽqFS‘ŸŠO‰ÈKnack & Pitfalls.ŽY‰È,V¶Ž™‰È,¬Ž™‰È,ŠO‰È‚Ƃ̃Rƒ‰ƒ{ƒŒ[ƒVƒ‡ƒ“.‚–{áÁˆê•Ò,29-31,•¶Œõ“°,“Œ ‹ž,2005.
    4. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQ.w¡“ú‚̏¬Ž™Ž¡—ÃŽwjx@‘æ14”Å,726,ˆãŠw‘‰@,“Œ‹ž,2005.
    5. Žs“c•™ŽqFVu–Ú‚ÅŒ©‚ézŠÂŠí•aƒVƒŠ[ƒYvwæ“V«SŽŸŠ³x@Šg’£Œ^S‹ØÇ,”ì‘åŒ^S‹ØÇ,ãk–§‰»áŠQ,359-367,ƒ ƒWƒJƒ‹ƒrƒ…[ŽÐ,“Œ‹ž,2005.
    6. ƒ^ƒ‰EƒEƒH[ƒJ[iŠÄC@‹{˜e—˜’jjFŽq‹Ÿ‚ÌŠŽõÇƒPƒA‹³–{.ŽY’²o”Å,“Œ‹ž,2005.
    7. ‹àŒ“O˜a,Œ‘q—TŠì,–쑺ŒbŽq,‹{˜e—˜’jFƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg,‚m‚jŠˆ«,ŒŒŽ–ƉuƒOƒƒuƒŠƒ“.u”’l‚©‚猩‚鏬Ž™‚̐¬ ’·‚Æ”­’B.vÂ–ØŒp–«‘Œ•Ò,47-55,‹àŒŽo”Å,“Œ‹ž,2005.
  • ŒŽ’˜
    1. Kanegane H., Kasahara Y., Okamura J., Hongo T., Tanaka R., Nomura K., Kojima S., and Miyawaki T.: Identification of DKC1 gene mutations in Japanese patients with X-linked dyskeratosis congenita. Brit J Haematol. 78: 130-133,2005.
    2. Kanegane H., Taneichi H., Nomura K., Futatani T., and Miyawaki T. : Severe neutropenia in Japanease patients with X-linked agammaglobulinemia. J Clin Immunol 25: 491-495,2005.
    3. Tabata Y., Villanueva J., Lee S.M., Zhang K., Kanegane H., Miyawaki T., Sumegi J., and Filipovich A.H. : Rapid detection of intracellular SH2D1A protein in cytoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. Blood 105: 3066-3071,2005.
    4. Conley M.E., Broides A., Hemandez-Trujillo V., Howard V., Kanegane H., Miyawaki T., and Shurtleff S.A. : Genetic analysis of patients with defects in early B-cell development. Immunol Rev 78 : 130-133,2005.
    5. Viemann D., Strey A., Janning A., Jurk K., Klimmek K., Vogl T., Hirono K., Ichida F., Foell D., Kehrel B., Gerke V., Sorg C., and Roth J. : Myeloid-related protein 8 and 14 induce a specific inflammatory response in human microvascular endothelial cells. Blood. 105: 2955-2962,2005.
    6. Yumura-Yagi K., Inoue M., Sakata N., Okamura T., Yasui M., Sawada A., Sato E., Chayama K., Endo C., Sasabe M., Miyamura T., Park Y.D., Nakano T., Inagaki J., Kishimoto T., Nomura K., Saito I., Hamada S., Nakano T., Hashii Y., and Kawa K.: Unrelated donor bone marrow transplantation for 100 pediatric patients : a single institutefs experience. Bone Marrow Transplant 36 : 307-313, 2005.
    7. Oshima Y., Doi Y., Misaki T., Ichida F. : Surgical repair of coronary sinus orifice atresia. Eur J Cardiothorac Surg. 27:351-352,2005.
    8. Wang XC., Wang Y., Kanegane H., Miyawaki T., and Yu YH. : Gene diagnosis of X-linked agammaglobulinemia. Zhonghua Er Ke Za Zhi 43: 449-452,2005.
    9. Okano M., Kawa K., Kimura H., Yachie A., Wakiguchi H., Maeda A., Imai S., Ohga S., Kanegane H., Tsuchiya S., Morio T., Mori M., Yokota S., and Imashuku S.: Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80: 64-69,2005.
    10. Tanaka-Kitajima N., Sugaya N., Futatani T., Kanegane H., Suzuki C., Oshiro M., Hayakawa M., Futamura M., Morishima T., and Kimura H. : Ganciclovir therapy for congenital cytomegalovirus infection in six infants. Pediatr Infect Dis J 24: 782-785,2005.
    11. Taniuchi S., Masuda M., Fujii Y., Izawa K., Kanegene H., and Kobayashi Y. : The role of a mutation of the CXCR4 gene in WHIM syndrome. Haematologica 90: 1271-1272,2005.
    12. Taguchi M., Hongou K., Yagi S., Miyawaki T., Takizawa M., Aiba T., and Hashimoto Y. : Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab. Pharmacokinet 20: 107-112,2005.
    13. ‹àŒ“O˜a,ŽíŽsq’ˆ,“ñ’J@•,‹{˜e—˜’jFIgGƒTƒuƒNƒ‰ƒX‘ª’è‚̗Տ°“I•K—v«‚ÌŒŸ“¢.“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@109F 16-21,2005.
    14. ŽíŽsq’ˆ,‹{–{—TŽq,–kì³M,’†—ÑŒºˆê,‹{˜e—˜’jFdÇSgáŠQŽ™iŽÒj‚É‚š‚¯‚é”­”M‚̊ӕʐf’f`MxA’`”’‚ðŽw•W ‚Æ‚µ‚ā`.“ú–{dÇSgáŠQŠw‰ïŽ@30F93-997,2005.
    15. ’†àV@œ,²’n@•×,Žs“c•™Žq,¬ŽRk‘Ÿ˜Y,“í“c@‘,ŒŽ“cŒ’‰îFæ“V«SŽŸŠ³Ž™‚É‚š‚¯‚éƒpƒŠƒrƒYƒ}ƒu‚ÌŽg—p‚ÉŠÖ‚·‚é ƒKƒCƒhƒ‰ƒCƒ“.“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@21F60-62,2005.
    16. œA£K”üCŽs“c•™ŽqC‘哈‹`”ŽF“ûŽ™Šú‚ɐS‘ŸŽèp‚ð—v‚·‚鎙‚Ì”­’B‚ÉŠÖ‚·‚錀‹†|“ûŽ™Šú‘O”Œ‚É‚š‚¯‚é”­’B‚Æ‚» ‚ÌŠÖ˜A—vˆö|¬Ž™•ÛŒ’Œ€‹†@64F669- 675,2005.
  • Ç—á•ñ
    1. Kanegane H., Ito Y., Ohshima K., Shichijo T., Tomimasu K., Nomura K., Futatani T., Sumazaki R., and Miyawaki T. : X-linked lymphoproliferative syndrome presenting with systemic lymphocytic vasculitis. Am J Hematol 78: 130-133,2005.
    2. Yoshida T., Kanegane H., Otsubo K., Nomura K., Hirokawa S., Tsuneyama K., Egawa H., and Miyawaki T. : Acute lymphoblastic leukemia after living donor liver transplantation. Pediatr Int 47: 579-582,2005.
    3. Igarashi N., Mugishima H., Sukegawa K., Kanegane H., and Yachie A. : 4 year follow-up of growth in a patient with Hunter disease who received unrelated bone marrow transplantation. Clin Pediatr Endocrinol 14: 19-24,2005.
    4. Satoh N., Koike T., Takato H., Fujiwara M., Emura I., and Kanegane H. : Fatal primary Epstein-Barr virus infection due to clonal CD8+ T-lymphocyte proliferation in an immunocompetent adult. Int J Hematol 82: 169-170,2005.
    5. Hoshino T., Kanegane H., Doki N., Irisawa H., Sakura T., Nojima Y., Miyawaki S., and Miyawaki T. : X-linked lymphoproliferative disease in an adult. Int J Hematol 82: 55-58,2005.
    6. ‘å’ØŒc•ãCŒÜ\—’“oC”šèŠì–FFƒpƒ‹ƒ{B19ƒEƒCƒ‹ƒXŠŽõ‚ÉŠÖ˜A‚µ‚œ‘œÊ‚ȗՏ°‘œ‚ð’悵‚œ3—á. ¬Ž™‰È—Տ°@58F 225-228C2005.
    7. –{ŠÔ@m,å@‹v”T,”ÂàVŽõŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—zŽq,‘«—§—Yˆê,óˆä³Žk,‹{˜e—˜’jF‚È‚º‹C“¹ˆÙ•š‚ªf’f‚³‚ê‚é ‚Ü‚Å‚É’·ŽžŠÔ‚ð—v‚µ‚œ‚Ì‚©|ƒs[ƒiƒbƒc‹zˆø‚Ì‚R¬Ž™—á‚ÌŒŸ“¢.“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ïŽGŽ 16: 21-26,2005.
  • ‘à
    1. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬.‘æ8‰ñ—Տ°S‘Ÿ•aƒtƒH[ƒ‰ƒ€,“ú–{S“d}Šw‰ïŽF26,2005.
    2. Žs“c•™ŽqFŒÇ—§«¶ŽºS‹Øãk–§‰»áŠQ‚Ƃ͉œ‚Å‚·‚©H¬Ž™zŠÂŠíŽŸŠ³-‚»‚±‚ª’m‚è‚œ‚¢Q&A.¬Ž™“à‰È37F 1730-1732,2005.
    3. ‘«—§—Yˆê,ŒÜ\—’—²•vF¬Ž™‚̃AƒXƒsƒŠƒ“šb‘§. Topicws in Atopy 4:20-23,2005.
    4. ‹àŒ“O˜a,‹{˜e—˜’jFEBƒEƒCƒ‹ƒX‚Í‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ(XLP)”­Ç‚É‚¢‚©‚ÉŠÖ‚í‚Á‚Ä‚¢‚é‚©.ŒŒ‰tƒtƒƒ“ ƒeƒBƒA@15F85-92,2005.
    5. ‹àŒ“O˜a,‹{˜e—˜’jF”’l‚©‚猩‚鏬Ž™‚̐¬’·‚Æ”­’B.ƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg.¬Ž™‰È@46F47-48,2005.
    6. ‹àŒ“O˜a,–쑺ŒbŽq,‹{˜e—˜’jF”’l‚©‚猩‚鏬Ž™‚̐¬’·‚Æ”­’B.NKŠˆ«.¬Ž™‰È@46F49,2005.
    7. ‹àŒ“O˜a,‹{˜e—˜’jF”’l‚©‚猩‚鏬Ž™‚̐¬’·‚Æ”­’B.ŒŒŽ–ƉuƒOƒƒuƒŠƒ“.¬Ž™‰È@46F50,2005.
    8. –{‹œ˜a‹v,“c’‡çH,”ª–ؐMˆê,íŽRKˆê,‹{˜e—˜’jF—n˜A‹ÛŠŽõÇ‚Ə¬Ž™Ž©ŒÈ–ƉuŠÖ˜A«ž__ŒoŽŸŠ³.@¬Ž™‰È@46 : 563-569,2005.
    9. “ñ’J@•,‹àŒ“O˜a,‹{˜e—˜’jFæ“V«–Ɖu•s‘SÇŒóŒQ.“ú–{—Տ°@63(‘)F559-564,2005.
    10. ”ÂàVŽõŽq,‘«—§—YˆêF‹êí‚·‚éšb‘§‚Æ‚»‚̑΍ôu“û—cŽ™Šú‚Ìšb‘§v. šb‘§ 18 : 42-47,2005.
    11. ‹g“cär,‹àŒ“O˜aFRuntŠÖ˜A“]ŽÊˆöŽq‚Q(RUNX2).¶‘̂̉Ȋw@56F368-369,2005.
    12. ‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹ŽŽwŽŠ‘ì¬‚ÌŽŽ‚Ý.ƒAƒŒƒ‹ƒM[‰È@19F 348-354,2005.
    13. ‘«—§—zŽq,’†—ÑŒºˆê,•£àV—³–ç,”ÂàVŽõŽq,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•xŽRŒ§“à¬Ž™‰Èˆã‚É‚š‚¯‚éšb‘§’·ŠúŠÇ—‚ɑ΂· ‚éˆÓŽ¯’²ž|ƒAƒ“ƒP[ƒg’²ž‚É‚æ‚é‚T”NŠÔ‚̕ω»|¬Ž™‰È—Տ°@58F993-998,2005.
    14. ŽíŽsq’ˆ,‹àŒ“O˜aFæ“V«ŒŒ‹…Œž­Ç‚Ì•a‘Ô‚ÆŽ¡—Ã.7.ShwachmanÇŒóŒQ.ŒŒ‰tƒtƒƒ“ƒeƒBƒA15F429-435,2005.
    15. “n•Óˆê—m,Žs“c•™ŽqFæ“V«SŽŸŠ³‚É‚š‚¯‚édÇRSƒEƒBƒ‹ƒXŠŽõÇ‚ÌŒoŒ±. RSV Actual Information 7 : 1-4, 2005.

  • 2005”NŠw‰ï•ñ
    1. Miyawaki T.: Primary immunodeficiencies inducing EBV-associated severe illnesses. The First International Congress of Immunodeficiency Disorders,2005,2,Teheran,Iran. (Invited Lecture)
    2. Adachi Y., Adachi YS., Nakabayashi M., Fuchizawa T., Itazawa T., Murakami G.,, and Miyawaki T.: Food allergic reactions in kindergartens in Japan. 61st Annual Meeting of American Academy of Allergy, Asthma & Immunology,2005,3,San Antonio, USA.
    3. Miyawaki T.FClinical and molecular features of congenital agammaglobulinemia. 2005 Shanghai International Pediatric Forum. 2005,6,Shanghai,China. (Invited Lecture)
    4. Ichida F., Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Miyawaki T., Karla R. Bowles., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 78th Scientific Sessions of American Heart Association,2005,11,Dallas,U.S.A.
    5. Nakabayashi M., Okabe Y., Fuchizawa T., Itazawa T., Adachi Y., Murakami G., and Miyawaki T. : A whole blood assay of MxA for diagnosis of viral infection in febrile children. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    6. Hirono K., Xing Y., Miyagawa-Tomita S., Futatani T., Watanabe K., Watanabe S., Tsubata S., Uese K., Hashimoto I., Ichida F., and Miyawaki T.: Profound expression of myeloid-related protein (MRP) 8 and MRP14 in Kawasaki disease. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    7. Mostafa S., Futatani T., OgawaJ., Kanegane H., and Miyawaki T. : Breast milk contains a novel factor promoting maturation of naive B cells into IgA-secreting cells. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    8. Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Ichida F., Miyawaki T., Karla R. Bowles., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. 1st Congress of Asian Society for Pediatric Research,2005,11,Tokyo.
    9. ‘«—§—zŽq,’†—ÑŒºˆê,•£‘ò—³–ç,”ÂàVŽõŽq,‚”ö@Š²,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™ ‚ɑ΂·‚éH•šœ‹ŽŽwŽŠ‘ì¬‚ÌŽŽ‚Ý.‘æ‚T‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2005,1,“Œ‹ž.
    10. ‹{˜e—˜’jF(“Á•Êu‰‰)æ“V«–Ɖu•s‘SÇ‚̊ȈՐf’f‚ƗՏ°“I‘œ—l«,‘æ8‰ñŠò•Œ¬Ž™ŠŽõÇ§˜b‰ï,2005,‚P,Šò•Œ.
    11. ‹àŒ“O˜aF“Á•Êu‰‰uæ“V«–Ɖu•s‘SÇ‚̐f‚©‚œv‘æ31‰ñ–k‹ãB¬Ž™ŒŒ‰tEŽîᇍ§˜b‰ï,2005,1,–k‹ãB.
    12. ”óŒû@Žû,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jFŒŒ‹…æÐHƒŠƒ“ƒp‘gD‹…Ç‚Ì“ûŽ™—á.‘æ9‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹† ‰ï,2005,1,‹à‘ò.
    13. ˆÉ“¡–õ“T,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹I,‚‹Ž”Ž”V,íŽRKˆêF¶â¿œ“ŽŒŽ”­‰¡–ä‹ØŽî stage 4 ‚Ì‚P—á.‘æ22 ‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2005,2,‹à‘ò.
    14. –{‹œ˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jF–ƉuCü—Ö@‚ªáz¹dÏ/ŒQ”­‚É‘tŒ÷‚µ‚œÇŒó«‹ÇÝŠÖ˜A‚Ä‚ñ‚©‚ñ‚Ì ‚R—á. ‘æ47‰ñ–k—€¬Ž™_ŒoŠw‰ï,2005,2,‹à‘ò.
    15. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚Æ•s®–¬.ƒtƒ@ƒCƒA[ƒTƒCƒhƒZƒ~ƒi[.The 69th Annual Scientific Meeting of the Japanese Circulation Society,2005,3,Yokohama.
    16. Xing Y., Ye F., Chen R., Tsuji T., Haneda N., Matsuoka T.,Yu X., Tsubata S., Futatani T., Watanabe S., Watanabe K., Hirono K., Uese K., Hamamichi Y., Hashimoto I., Ichida F., Miyawaki T., and Towin J.A. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 69th Annual Scientific Meeting of the Japanese Circulation Society,2005,3,Yokohama.
    17. –{‹œ˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,,“c’‡çH,‹{˜e—˜’jFƒ~ƒIƒNƒƒj|”­ì‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œDeVivo•ai‹^‚¢j‚̈ê—á. ‘æ 29‰ñ–k—€‚Ä‚ñ‚©‚ñŠw‰ï,2005,3,‹à‘ò.
    18. ‹àŒ“O˜a,‹{˜e—˜’j,‘Oì@Žü,Œ’rˆê•F,ì–{@–LFƒJƒ“ƒWƒ_”sŒŒÇ‚ðŒJ‚è•Ô‚µ‚œˆê—Ž™—á.‘æ16‰ñ•xŽR“«ŽŸŠ³ŠŽ õÇŒ€‹†‰ï,2005,3,•xŽR.
    19. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,‹{˜e—˜’jFŠO—ˆ‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•š•‰‰×ŽŽŒ±‚Ì ŽÀÛ@|“ñd–ÓŒŸ–@‚𒆐S‚Ɂ|.‘æ26‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2005,3.17,•xŽR.
    20. –쑺ŒbŽq,“¡–Ø–õŽq,ŒŽˆä•ü”ü,å@‹v”T,ˆÉ“¡–õ“T,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹IF•›•@oŒŽ”­ˆ««Žîᇂ̂R—á.‘æ283 ‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2005,3,‹à‘ò.
    21. –{‹œ˜a‹v,‹{@ˆêŽu,‰eŽR—²Ži,“c’‡çH,ŽR’J”ü˜a,”ª–ؐMˆê,X@Žõ,íŽRKˆê,‹{˜e—˜’jFR”]R‘Ì‚ð—L‚·‚鏬Ž™‚Ä‚ñ‚© ‚ñ‚̗Տ°‘œ.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    22. ‹àŒ“O˜a,“ñ’J@•,‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚È‚ç‚тɈâ“`Žq‰ðÍ‚É‚æ‚é‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̐f ’f.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    23. ”ÂàVŽõŽq,‘«—§—zŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—Yˆê,‚”ö@Š²,”öã—mˆê,‘ºãIŒ[,ŠC˜VàVŒ³G,‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[ ‚ɑ΂·‚éŠO—ˆ‚ł̐H•š•‰‰×ŽŽŒ±‚̈À‘S«.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    24. ’†—ÑŒºˆê,”ÂàVŽõŽq,•£àV—³–ç,ŽRŒ³ƒŽq,‘«—§—zŽq,‘«—§—Yˆê,ùŒŽ²Žq,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jF¬Ž™ƒEƒCƒ‹ƒXŠŽõ Ç‚É‚š‚¯‚é‘SŒŒ ELISA –@‚É‚æ‚é MxA ’`”’‘ª’è‚Ì—L—p«.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    25. L–ìŒbˆê,“n•Óˆê—m,—t@”ò,ƒfƒCƒ‹ƒNƒtƒHƒGƒ‹,“n•Óˆ»‰À,ãšŒhˆê˜Y,‹Ž–{ˆè•v,’ÔŠ áÁˆê,Žs“c•™Žq,‹{˜e—˜’jFTNF-ƒ¿ ‚ÌŽhŒƒ‚É‚æ‚éMRP 8/MRP 14‚Ì“®‘Ô.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    26. ˆÉ“¡–õ“T,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jF”A˜HŒ‹Î‚ð‡•¹‚µ‚œ‹}«ƒŠƒ“ƒp‹}«”’ŒŒ•a‚Ì‚P—á.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw ‰ï,2005,4,“Œ‹ž.
    27. Xing Y., Chen R., Tsuji T., Haneda N., Matsuoka T., Isobe T., Kuwabara A., Higaki T., Ikemoto Y., Tsubata S., Futatani T., Watanabe S., Hirono K., Ichida F., Miyawaki T., and Neil E. Bowels. : Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity.‘æ108‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2005,4,“Œ‹ž.
    28. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,‚”ö@Š²,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒ ƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹ŽŽwŽŠ‘‚̍쐬‚É“–‚œ‚Á‚Ä‚Ì–â‘è“_.‘æ22‰ñ“ú–{“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï,2005,5,‘å ã.
    29. ”‘òŽõŽq,‘«—§—zŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‰ª•””üŒb,‘«—§—Yˆê,ŽRŒ³ƒŽq,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jFƒƒbƒVƒ…Ž®ƒlƒuƒ‰ ƒCƒU[iƒGƒ‚[ƒVƒ‡ƒ“j‚ƃRƒ“ƒvƒŒƒbƒT[Ž®ƒlƒuƒ‰ƒCƒU[iƒ^[ƒ{ƒWƒ…ƒjƒAj‚Ì”äŠrŒŸ“¢.‘æ22‰ñ“ú–{“šb‘§E ƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï,2005,5,‘åã.
    30. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚̗Տ°.‘æ19‰ñ—Տ°’Ž‰¹”gƒZƒ~ƒi[,2005,6,“Œ‹ž.
    31. Žs“c•™ŽqFæ“V«SŽŸŠ³‚ÆRSƒEƒBƒ‹ƒXŠŽõÇ\ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žƒKƒCƒhƒ‰ƒCƒ“.‘æ88‰ñ“ŒŠC¬Ž™zŠÂŠí’k˜b ‰ï,2005,6,–ŒŒÃ‰®.
    32. ‘«—§—zŽq,”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‘«—§—Yˆê,”öã—mˆê,‘ºãIŒ[,‹{˜e—˜’jFƒƒbƒVƒ…Ž®ƒlƒuƒ‰ƒCƒU[,e-Motion‚ð —p‚¢‚œƒÀ2ŽhŒƒ–ò‹z“ü‚É‚æ‚éS””‚ւ̉e‹¿.‘æ17‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2005,6,‰ªŽR.
    33. ”‘òŽõŽq,’†—ÑŒºˆê,•£‘ò—³–ç,‰ª•””üŒb,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jF“\•tŒ^ƒÀ2ŽhŒƒ–ò‚ÌŒëŽg—p‚É‚æ‚Á‚Ä’†“Å‚ÉŽŠ‚Á ‚œ‚P“ûŽ™—á.‘æ17‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2005,6,‰ªŽR.
    34. –쑺ŒbŽq,“¡–Ø–õŽq,ŒŽˆä•ü”ü,å@‹v”T,ˆÉ“¡–õ“T,‹àŒ“O˜a,‹{˜e—˜’j,ˆÀ‘º²“s‹IF•›•@oŒŽ”­ˆ««Žîᇂ̂R—á.‘æ18‰ñ •xŽRŠàŽ¡—ͧ˜b‰ï,2005,6,•xŽR.
    35. –{‹œ˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jF‘œÊ‚È”­ìÇó‚ð’悵‚œGLUT-1 deficiency syndrome‚̈ê—á.‘æ284 ‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2005,6,•Ÿˆä.
    36. ‘«—§—YˆêFƒZƒ~ƒi[g˜aŠ¿–ò‚ƏÁ‰»ŠÇhu¬Ž™‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[‚ÌŒ»ó‚Ɖۑèv@‘æ26‰ñ˜aŠ¿–òŒ€‹†Š“Á•Ê ƒZƒ~ƒi[,2005,7,•xŽR.
    37. ”óŒû@Žû,”ÂàVŽõŽq,“¡–Ø–õŽq,‘«—§—Yˆê,‹{˜e—˜’jF•p‰ñ‚É–³ŒÄ‹z”­ì‚ðŒJ‚è•Ô‚µ‚œ•S“úŠP‚̈ê—á.‘æ‚W‰ñ•xŽR¬Ž™ŠŽõ –ƉuŒ€‹†‰ï,2005,7,•xŽR.
    38. “ñ’J@•,‘«—§—Yˆê,‹{˜e—˜’j,˜a“c’ŒŽ÷FV¶Ž™ƒ}ƒXƒXƒNƒŠ[ƒjƒ“ƒOŒŸž‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œƒVƒgƒŠƒ“Œ‡‘¹Ç‚̐V¶ Ž™—á.‘æ15‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2005,7,•xŽR.
    39. ŒŽˆä•ü”ü,ãšŒhˆê˜Y,“n•Óˆ»‰À,“n•Óˆê—m,ŽíŽsq’ˆ,“¡–Ø–Ÿ,Žs“c•™ŽqFPseudo VT‚ð”F‚ß,‚Žü”gƒJƒe[ƒeƒ‹ƒAƒuƒŒ[ƒV ƒ‡ƒ“Ž¡—Âðs‚Á‚œWPWÇŒóŒQ‚̈ê—á.‘æ15‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2005,7,•xŽR.
    40. ‹Ž–{ˆè•v,“n•Óˆ»‰À,ãšŒhˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jF³í‘ÙŽ™S‚É‚š‚¯‚鍶‰ES‹@”\. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠw pW‰ï,2005,7,“Œ‹ž.
    41. L–ìŒbˆê,“ñ’J@•,’C‰h—Ñ,“n•Óˆê—m,“n•Óˆ»‰À,’ÔŠáÁˆê,‹Ž–{ˆè•v,ãšŒhˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFìè•a‹}«Šú‚É‚š‚¯ ‚é”’ŒŒ‹…’†myeloid-related-protein(MRP)8‚š‚æ‚ÑMRP14‚̈â“`Žq”­Œ»‚ÌŒŸ“¢“®‘Ô. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwp W‰ï,2005,7,“Œ‹ž.
    42. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,ãšŒhˆê˜Y,‹Ž–{ˆè•v,Žs“c•™Žq,‹{˜e—˜’jF¶ŽºS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢|“ûŽ™”­ Ç—á‚ÆŽá”N”­Ç—á‚Ì‘Šˆá\. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    43. “n•Óˆê—m,Œè‘œç‘ã,“n•Óˆ»‰À,Žs“c•™Žq,‘哈‹`”Ž,L£K”ü,ŒˆäŽOŽ},’†ì,‹{˜e—˜’j,”ª–ØŒŽrŽFæ“V«SŽŸŠ³Ž™ ‚É‚š‚¯‚鐞_‰^“®”­’B‚Ì•]‰¿|BayleyŽ®“û—cŽ™”­’BŒŸž“±“ü‚ÌŽŽ‚݁|. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7, “Œ‹ž.
    44. Ä“¡˜a—R,ˆÉ“¡G˜a,“n•Óˆ»‰À,¬ìŽŸ˜Y,“ñ’J•,‹Ž–{ˆè•v,“y”ì‘P˜Y,‘哈‹`”Ž,Žs“c•™Žq,‹{˜e—˜’jF¶S’áŒ`¬ÇŒóŒQ iHLHSj‚ð‡•¹‚µ‚œ46XX, der(9)t(5;9)(q33.3;p22)‚Ì‘o‘Ù—á. ‘æ41‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ïŠwpW‰ï,2005,7,“Œ‹ž.
    45. ‹àŒ“O˜aFƒpƒlƒ‹ƒfƒBƒXƒJƒbƒVƒ‡ƒ“uEBƒEƒCƒ‹ƒXŠÖ˜A T/NK ×–EƒŠƒ“ƒp‘B«ŽŸŠ³.v‘æ12‰ñƒwƒ‹ƒyƒXŠŽõÇƒtƒH [ƒ‰ƒ€,2005,8,¬’M.
    46. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€gšb‘§‚Ì•a‘Ô‚ÆŽ¡—©‚ç‚Ý‚œ¢‘ã“Ii”N—î“Ij“Á’¥huŠw“¶Šú@•›•@o‰Š‚Ƃ̍‡•¹v@‘æ 26‰ñ˜ZbƒJƒ“ƒtƒ@ƒŒƒ“ƒX,2005,8,‹ž“s.
    47. ‘å’ØŒc•ã,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jFŒÒŠÖß’É‚ðŽåÇó‚Æ‚µ,DIC‚È‚ç‚Ñ‚ÉäX‰Š‚ð‡•¹‚µ‚œ‹}«’P‹…«”’ŒŒ•a‚Ì‚P —á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–ŒŒÃ‰®.
    48. ‰eŽR—²Ži,‹{@ˆêŽu,–{‹œ˜a‹v,Œ‘òƒŽq,ŽR’J”ü˜a,‹{˜e—˜’j,¬Œ@“O,”ª–ؐMˆêFäX‰Š‚É”º‚€‚¯‚¢‚ê‚ñ‚ɑ΂µƒJƒ‹ƒoƒ} ƒ[ƒsƒ“‚ð“Š—^‚µ‚œÛ”­],–³è÷—±‹…Ç‚ð’悵‚œ‚P—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–ŒŒÃ‰®.
    49. ‹{@ˆêŽu,ˆÉ“¡–õ“T,–{‹œ˜a‹v,“ñ’J@•,‰eŽR—²Ži,‹{˜e—˜’jF‘œÊ‚È”­ìÇó‚ð’悵‚œ GLUT-1 deficiency syndrome ‚Ì ‚P—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–ŒŒÃ‰®.
    50. –{‹œ˜a‹v,‹{@ˆêŽu,‰eŽR—²Ži,X@Žõ,‹{˜e—˜’jF”­Ç‚ɖƉu“I‹@˜‚ÌŠÖ—^‚ª„Ž@‚³‚ê‚éŠC”n•a•Ï‚ð—L‚·‚鏬Ž™‚Ä‚ñ‚© ‚ñ‚Ì‚Q—á.‘æ41‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2005,8,–ŒŒÃ‰®.
    51. Žs“c•™ŽqFæ“V«SŽŸŠ³‚ÆRSƒEƒBƒ‹ƒXŠŽõÇ\ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žƒKƒCƒhƒ‰ƒCƒ“.‘æ30‰ñ–k—€¬Ž™zŠÂŠíŒ€‹† ‰ï,2005,9,‹à‘ò.
    52. ”ÂàVŽõŽq,’†—ÑŒºˆê,‹{@ˆêŽu,ŒŽˆä•ü”ü,ãšŒhˆê˜Y,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’jFƒAƒXƒxƒŠƒ“ƒhƒ‰ƒCƒVƒƒbƒv‚ÉŠÜ‚Ü ‚ê‚éƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á.‘æ8‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2005,9,•x ŽR.
    53. Žs“c•™ŽqF¬Ž™‚̐S‘Ÿ«“Ë‘RŽ€. ‘æ22‰ñ“ú–{S“dŠw‰ïŠwpW‰ïŽs–¯ŒöŠJuÀ,2005,10,•xŽR.
    54. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g¬Ž™šb‘§‚̐f’f‚ÆŽ¡—Áh u‘Šúf’f‚Æ‚»‚̉ۑè _“ûŽ™šb‘§‚𒆐S‚É-v.‘æ55‰ñ“ú–{ƒAƒŒ ƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    55. ”ÂàVŽõŽq,‘«—§—zŽq,‰ª•””üŒb,•£àV—³–ç,’†—ÑŒºˆê,‘«—§—Yˆê,‘ºãIŒ[,ŒÜ\—’—²•v,‹{˜e—˜’jFƒC[ƒW[ƒAƒYƒ}ƒvƒƒOƒ‰ ƒ€—pƒAƒ“ƒP[ƒg‚Æ”x‹@”\‚Æ‚ÌŠÖŒW‚ÉŠÖ‚·‚錟“¢.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    56. ‘«—§—zŽq,‚”ö@Š²,ŽRŒ³ƒŽq,”öã—mˆê,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF•ÛˆçŽ{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH •šœ‹ŽŽwŽŠ‘‚Ì—L—p«.‘æ55‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    57. ŒÜ\—’—²•v,Œ–쐳’m,ˆÉ“Œ“¹•v,‘«—§—Yˆê,‘«—§—zŽq,‘ºãIŒ[FSpO2‚Í‹C“¹‰ß•q«ŽŽŒ±‚ÌŽw•W‚Æ‚È‚è‚Š‚é‚©.‘æ55‰ñ“ú –{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2005,10,·‰ª.
    58. –{‹œ˜a‹v,‹{ˆêŽu,‰eŽR—²Ži,“c’‡çH,‹{˜e—˜’jFƒOƒ‹ƒR[ƒX—A‘—’S‘ÌŒ‡‘¹Ç‚Ì”]”gŠŒ©iÇ—á•ñj.‘æ39‰ñ“ú–{‚Ä ‚ñ‚©‚ñŠw‰ï,2005,10, .
    59. “n•Óˆê—m,ãšŒhˆê˜Y,Ä“¡˜a—R,“n•Óˆ»‰À,œA–ìŒbˆê,Žs“c•™Žq,‹{˜e—˜’jF“®–¬áŽÁ‘ÞŒã,‰“ŠuŠú‚ɐΊD‰»‚É‚æ‚é—Œœœ ‰º“®–¬Š®‘S•ÂÇ‚ð‚«‚œ‚µ‚œ1—á. ‘æ25‰ñ“ú–{ìè•aŒ€‹†‰ï,2005,10,“Œ‹ž.
    60. Ä“¡˜a—R,‘å’ØŒc•ã,œA–ìŒbˆê,“n•Óˆê—m,“n•Óˆ»‰À,ãšŒhˆê˜Y,‹Ž–{ˆè•v,Žs“c•™Žq,‹{˜e—˜’j,’ÔŠáÁˆê,‘ºãIŒ[F‘€•›ŒŒ s‚Ì”­’B‘£i‚ðŠú‘Ò‚µ,ƒwƒpƒŠƒ“—Ö@‚ðŽŽ‚Ý‚œìè•aŒãS‹Ø[Ç‚Ì“ûŽ™—á. ‘æ25‰ñ“ú–{ìè•aŒ€‹†‰ï,2005,10,“Œ‹ž.
    61. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,ãšŒhˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFŒÇ—§«S‹Øãk–§‰»áŠQ‚Æ•s®–¬. ‘æ14‰ñŠÖ“ŒS‹ØŽŸŠ³ Œ€‹†‰ï,2005,10,“Œ‹ž.
    62. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€g¬Ž™‹CŠÇŽxšb‘§Ž¡—ÁEŠÇ—ƒKƒCƒhƒ‰ƒCƒ“2005h u“ûŽ™šb‘§‚ÌŽÀ‘ԁEf’fEŽ¡—Áv@‘æ 42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    63. ˆÉ“¡–õ“T,‘«—§—zŽq,•£‘ò—³–ç,”ÂàVŽõŽq,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’jF‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éV‚µ‚¢ƒhƒ‰ƒCƒpƒEƒ_[‹z “üŠí‹ïƒNƒŠƒbƒNƒwƒ‰[‚ð—p‚¢‚œÛ‚Ì‹z‹C—¬‘¬‚Ì‘ª’è.‘æ42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    64. ”ÂàVŽõŽq,’†—ÑŒºˆê,”óŒû@Žû,‰ª•””üŒb,ŽRŒ³ƒŽq,”öã—mˆê,‘«—§—Yˆê,‹{˜e—˜’jFƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ‚é ƒAƒiƒtƒBƒ‰ƒLƒV[‚̈ê—á.‘æ42‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2005,11,•Ÿˆä.
    65. “n•Óˆ»‰À,“n•Óˆê—m,œA–ìŒbˆê,ãšŒhˆê˜Y,Žs“c•™Žq,‹{˜e—˜’jFŒÇ—§«S‹Øãk–§‰»áŠQ‚Æ•s®–¬. “ú–{¬Ž™S“dŠwŒ€‹† ‰ï,2005,11,VŠƒ.
    66. ”óŒû Žû,”ÂàVŽõŽq,’†—ÑŒºˆê,•£àV—³–ç,‘«—§—Yˆê,‹{˜e—˜’j,óˆä³Žk,‹v•ÛŽ›ŒPŽq,‰““¡@[,ŽRŠÝ“ÄŽŠFŠPšu‚Æšb–‚ðŒJ ‚è•Ô‚µ,Congenital Lobar OverinflationiCLOj‚ƍl‚Š‚ç‚ê‚œˆê—á.‘æ38‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2005,11,VŠƒ.
    67. ‹àŒ“O˜aFƒ~[ƒgƒUƒGƒLƒXƒp[ƒgu‚Ç‚Ì‚æ‚€‚ÈŽž‚ɖƉu•s‘SÇ‚ð‹^‚€‚©Hv‘æ37‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2005,11,’Ã.
    68. –쑺ŒbŽq,‘å’ØŒc•ã,‹àŒ“O˜a,‹{˜e—˜’jF•›•@oŒŽ”­ˆ««Žîᇂ̂R—á.‘æ21‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2005,‰F“s‹{.
    69. ‘å’ØŒc•ã,Š}ŒŽ‘Pm,˜eŒû@G,–ì“cKO,–쑺ŒbŽq,‹àŒ“O˜a,‹{˜e—˜’jŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQ type1a‚Æ–«Šˆ“® « EB ƒEƒCƒ‹ƒXŠŽõÇ.‘æ47‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2005,11,‰F“s‹{.
    70. ŒŽˆä•ü”ü,‹àŒ“O˜a,‘«—§—Yˆê,‹{˜e—˜’j.ƒNƒ‰ƒ~ƒWƒAEƒjƒ…[ƒ‚ƒjƒGIgMR‘Ì—z«—á‚̗Տ°“IŒŸ“¢.‘æ16‰ñ“ú–{¬Ž™‰È Šw‰ï•xŽR’n•û‰ï,2005,12,•xŽR.
    71. ”ÂàVŽõŽq,’†—ÑŒºˆê,‹{@ˆêŽu,ŒŽˆä•ü”ü,ãšŒhˆê˜Y,‘«—§—zŽq,‘«—§—Yˆê,‹{˜e—˜’j.ƒ|ƒŠƒrƒjƒ‹ƒsƒƒŠƒhƒ“iPVPj‚É‚æ ‚éƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì1—á.‘æ32‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2005,12,‹à‘ò.
    72. ”óŒû@Žû,”ÂàVŽõŽq,‘«—§—zŽq,‰ª•””üŒb,‘«—§—Yˆê,‘ºãIŒ[,‹{˜e—˜’j.¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éƒC[ƒW[ƒAƒYƒ}ƒv ƒƒOƒ‰ƒ€—pƒAƒ“ƒP[ƒgŒ‹‰Ê‚Æ”x‹@”\‚ÌŠÖŒW.‘æ13‰ñ—Տ°šb‘§Œ€‹†‰ï,2005,12,•Ÿ‰ª.

    2004”N

  • ’˜‘
    1. ‹{˜e—˜’jA“ñ’J@•F–Ɖu•s‘SÇŒóŒQ‚ÌŽŸŠ³•ª—ށB“à‰Èf—Âp•‚`‘æ39†A186-187A˜Z–@o”ŎЁA“Œ‹žA 2004.
    2. Žs“c•™ŽqF¬Ž™‚É‚Ý‚ç‚ê‚éS–Œ‰Š‚ɂ‚¢‚āB¬Ž™‰Èf—ÃQ & AB1551-1552A˜Z–@o”ŎЁA“Œ‹žA2004.
    3. Žs“c•™ŽqFŠŽõ«S“à–Œ‰Š‚ɂ‚¢‚āB¬Ž™‰Èf—ÃQ & AB1552-1553A˜Z–@o”ŎЁA“Œ‹žA2004.
    4. ‹g“cär,ŠpŽŠˆê˜Y,‹àŒ“O˜aFDysplasia with predominant membranous bone involvement –Œ«œ‚ðN‚·œˆÙŒ`¬Ç|ŠT à.u–Ú‚ÅŒ©‚鍜Œn“ŽŸŠ³2004vˆÉ“¡•¶”V‘Œ•Ò,182-184,“Œ‹žˆãŠwŽÐ,“Œ‹ž,2004.
    5. X@–ΘYA‹àŒ“O˜aAŠâŒŽŒ[ŽA‰Ÿ–¡˜a•vF‚»‚Ì‘Œ‚Ì EBV ŠÖ˜A T/NK ƒŠƒ“ƒp‘B«ŽŸŠ³BuÅVEˆ««ƒŠƒ“ ƒpŽîƒAƒgƒ‰ƒXv‹e’r¹O‘Œ•ÒA276-280A•¶Œõ“°A“Œ‹žA2004.
  • ŒŽ’˜
    1. Miyawaki T.: Primary immunodeficiencies inducing EBV-associated severe illness. Iranian J Allergy Asthma Immunol. 3: 51-57,2004.
    2. Hashimoto I., Hejmadi A., Li X., Jones M., Davis C. H., Swanson J.C., Schindera S. T., and Sahn D. J.: Tissue doppler-derived myocardial acceleration for evaluation of left ventricular diastolic function. J Am Coll Cardiol. 44 : 1459-1466,2004.
    3. Ogawa J., Sasahara A., Yoshida T., Sira M. M., Futatani T., Kanegane H., and Miyawaki T. : Role of transforming growth factor-ƒÀ in breast milk for initiation of IgA production in newborn infants. Early Hum Dev 77 : 67-75,2004.
    4. Ye F., Foell D., Hirono K., Vogl T., Futatani T., Rui C., Yu X., Watanabe S., Watanabe K., Uese K., Hashimoto I., Roth J., Ichida F., Miyawaki T. : Nautrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 94 : 840-844,2004.
    5. Yu X., Hirono K., Ichida F., Uese K., Rui C., Watanabe S., Watanabe K., Hashimoto I., Kumada T., Okada E., Terai M., Suzuki A., and Miyawaki T.: Enhanced iNOS expression in leukocytes and circulating endothelial cells is associated with the progression of coronary artery lesion in acute Kawasaki disease. Pediatr Res: 688- 694,2004.
    6. Asghar A.., Parvaneh N., Kanegana H., Moin M., Amirzargar A.A., Farhoudi A., Pourpak Z., Movahedi M., Gharagozlou M., Rezaei N., Futatani T., and Miyawaki T.: Screening of the Bruton tyrosine kinase (BTK) gene mutations in 13 Iranian patients with presumed X-linked agammaglobulinemia. Iranian J Allergy, Asthma and Immunology. 3 : 175-179,2004.
    7. Takada H., Kanegane H., Nomura A., Yamamoto K., Ihara K., Takahashi Y., Tsukada S., Miyawaki T., and Hara T.: Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactiva-tion. Blood 103 : 185-187,2004.
    8. Harada S., Kamata Y., Ishii Y., Eda H., Kitamura R., Obayashi M., Ito S., Ban F., Kuranari J., Nakajima H., Kuze T., Hayashi M., Okabe N., Senpuku H., Miyasaka N., Nakamura Y., Kanegane H., and Yanagi K. : Maintenance of serum immunoglobulin G antibodies to Epstein-Barr virus (EBV) nuclear antigen 2 in healthy individuals from different age groups in a Japanease population with a high childhood incidence of asymptomatic primary EBV infection. Clin Diagn Lab Immun. 11 : 123-130,2004.
    9. Tsurusawa M., ChinM., Iwai A., Nomura K., Maeba H., Taga T., Higa T., Kuno T., Hori T., Muto A., and Yamagata M.: L-asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leckemia under asparaginase treatment. Cancer Chemoth Pharm 53 : 204-208,2004.
    10. Kenton AB., Sanchez X., Coveler KJ., Makar KA., Jimenez S., Ichida F., Murphy RT., Elliott PM., McKenna W., Bowles NE., Towbin JA., and Bowles KR.: Isolated left ventricular noncom-paction is rarely caused by mutations in G4.5, ƒ¿-dystrobrevin and FK binding protein-12. Mol Genet Metab. 82 : 162-166,2004.
    11. Li X., Jones M., Irvine T., Rusk RA., Mori Y., Hashimoto I., Von Ramm OT., Li J., Zetts A., Pemberton J., and Sahn DJ.: Real-time 3-dimensional echocardiography for quantification of the difference in left ventricular versus right ventricular stroke volume in a chronic animal model study: Improved results using C-scans for quantifying aortic regurgitation. J Am Soc Echocardiogr. 17 : 870-875,2004.
    12. Watanabe N., Kanegane H., Kinuya S., Shuke N., Yokoyama K., Kato H., Tomizawa G., Shimizu M., Funada H., and Seto H.: The radiotoxity of 131I therapy of thyroid cancer: Assessment by micronucleus assay of B lymphocytes. J Nucl Med : 608-611,2004.
    13. Yoshida R., Hasegawa T., Hasegawa Y., Nagai T., Kinoshita E., Tanaka Y., Kanegane H., Ohyama K., Onishi T., Hanew K., Okuyama T., Horikawa R., Tanaka T., and Ogata T.: Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocr Metab. 89: 3359-3364,2004.
    14. Watanabe D., Ezoe S., Fujimoto M., Kimura A., Saito Y., Nagai H., Tachibana I., Matsumura I., Tanaka T., Kanegane H., Miyawaki T., Emi M., Kanakura Y., Kawase I., Naka T., and Kishimoto T.: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Brit J Haematol. 426 : 726-735,2004.
    15. Jo E.K., Kook H., Uchiyama T., Hakozaki I., Kim Y.O., Song C.H., Park J.K., Kanegane H., Tsuchiya S., and Kumaki S.: Characterization of a novel nonsense mutation in the Interleukin-7 receptor ƒ¿ gene in a Korean patient with severe combined immunodeficiency. Int J Hematol . 80: 332-335,2004.
    16. Oshima Y., Koto K., Shimazu C., Misaki T., Ichida F., and Hashimoto I.: Cusp extension technique for bicuspid aortic valve in Turner-like stigmata. Asian Cardiovasc Thorac Ann.12 : 266-269,2004.
    17. Prakash K ., Li X., Hejmadi A., Hashimoto I., and Sahn DJ. : Determination of asymmetric cavity volumes using real-time three-dimensional echocardiography: an in vitro balloon model study. Echocardiography. 21:257-263,2004.
    18. ‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAà_“¹”ü‹IA‰ª•””üŒbA”‘òŽõŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF•Ûˆç Ž{Ý‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•šœ‹Ž‚ÌŽÀ‘ԁ[•xŽRŒ§‚É‚š‚¯‚é’²žŒ‹‰Ê[B“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï Ž@18F100-107,2004.
    19. ”ÂàVŽõŽqA‘«—§—YˆêAˆÉ“Œ“¹•vAŒ–쐳’mAŽRŒ³ƒŽqA‘ºãIŒ[AŒÜ\—’—²•vA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb ‘§‚É‚š‚¯‚éDSCG+Procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@18F571- 577,2004.
    20. ŽO‰Y³‹`AãšŒhˆê˜YA‘ºãIŒ[AûŠˆä³tAZ“c@—ºA‘«—§—YˆêA‹{˜e—˜’jF•xŽRŒ§‚É‚š‚¯‚鏬Ž™‹~‹} ˆã—Â̌»ó‚Æ–â‘è“_B“ú–{¬Ž™‰ÈŠw‰ïŽ@108F1234-1240,2004.
    21. ’†ì@”£A—с@—²ˆêA‹{˜e—˜’jAŽ›àV·”NFƒNƒŠƒjƒJƒ‹EƒNƒ‰[ƒNƒVƒbƒv‚É‚š‚¯‚éˆã—Ïî•ñ‹³ˆç‚ÌŒoŒ±` ƒRƒ“ƒsƒ…[ƒ^ƒŠƒeƒ‰ƒV[‚©‚çî•ñƒŠƒeƒ‰ƒV[‚ւ̃Vƒtƒg`ˆãŠw‹³ˆç@35F337-342,2004.
    22. ’†àV@œA’O‰HŒöˆê˜YA‹g‰i³•vAŽ›ˆä@ŸA‰zŒã–ΔVA“¡ŒŽ@‘ìA‘ºã’q–ŸAŽs“c•™ŽqAé”ö–M—²A‰H ª“c‹IKAžwŠ_‚ŽjA—é–؁@_Aã‘ºGŽ÷AÎ˜a“c–«•FA—§–ì@Ž A‹v•Û“cˆêŒ©A•Ÿ“‡—T”VA’Ë–ì^–çAX@‘P Ž÷Fæ“V«SŽŸŠ³‚É‚š‚¯‚銎õ«S“à–Œ‰Š‚Ì—\–hAŽ¡—ÂɊւ·‚é‘S‘’²ž\‘æ2•ñ\@“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@ 20F668-673,2004.
    23. ’†àV@œA²’n@•×AŽs“c•™ŽqA¬ŽRk‘Ÿ˜YA“í“c@‘AŒŽ“cŒ’‰îFæ“V«SŽŸŠ³Ž™‚É‚š‚¯‚éƒpƒŠƒrƒYƒ} ƒu‚ÌŽg—p‚ÉŠÖ‚·‚éƒKƒCƒhƒ‰ƒCƒ“B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@108F1548-1551,2004.
    24. ŽíŽsq’ˆA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚킪‘‚É‚š‚¯‚é‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚̗Տ°f’f‚ÉŠÖ‚· ‚錟“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@108F1118-1122,2004.
  • Ç—á•ñ
    1. Matsukura H., Kanegane H., Miya K., Ohtsubo K., Higuchi A., Tanizawa T., and Miyawaki T.: IgA nephropathy associated with X-linked thrombocytopenia. Am J Kidney Dis 43 : E7-E11,2004.
    2. Jo E.K., Kumaki S., Wei D., Tsuchiya S., Kanegane H., Song C.H., Noh H.A., Kim Y.O., Kim S.Y., Chung H.Y., Kim H.Y., and Kook H. : X-linked severe combined immunodeficiency syndrome : The first Korean case with ƒÁc chain gene mutation and subsequent genetic counseling. J Korean Med Sci 19 : 123-126,2004.
    3. Mikami T., Hayasaka S., Nagai Y., Yanagisawa S., Futatani T., and Takano Y. : Congenital corneal staphyloma associated with aphakia. J. Pediat. Ophth Strab 41 : 180-182,2004.
    4. ŽíŽsq’ˆAV’J®‹vA“¡“cC•œA“n•Ó@KAŒÜ\—’@“oA”šèŠì–FF—A‰tŒž—Ê‚É”º‚Á‚Ēጌ“œš‡‚ð‚«‚œ‚µ ‚œ_Œo«HŽv•sUÇ‚Ì‚P—áB¬Ž™‰È45F123-127,2004.
  • ‘à
    1. ‹{˜e—˜’jFƒAƒŒƒ‹ƒM[‘Š’kŽº‚p•‚`BƒAƒŒƒ‹ƒM[‚̗Տ°@24F406,2004.
    2. Žs“c•™ŽqFŒ€Cˆã‚Ì‚œ‚ß‚Ì‚æ‚­Œ©‚鎟Š³ABCuìè•av¬Ž™‰Èf—ÓÁW†,801-804,2004.
    3. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQu“ñŽŸ«S‹ØÇ\ŠÓ•Êf’f‚É•K—v‚È’mŽ¯\vHeart ViewA528-532,2004.
    4. ‘«—§—YˆêFšb‘§—li«j‹CŠÇŽx‰Š‚Æ‚ÍŽŸŠ³’PˆÊ‚©B¬Ž™“à‰È@36F545-548,2004.
    5. ‹àŒ“O˜a,‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇ‚É‚š‚¯‚é–ƉuˆÙí 1) X-linked lymphoproliferative disease.@ƒAƒŒƒ‹ƒM[E–Ɖu@ 11F1570-1575,2004.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF”º«ƒŠƒ“ƒp‘B«ŽŸŠ³iDuncanÇŒóŒQjBŒŒ‰tEŽîᇉȁ@48F357-365,2004.
    7. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚d‚aƒEƒCƒ‹ƒXŠŽõÇB¬Ž™‰È@45F451-456,2004.
    8. ‹àŒ“O˜aA‹{˜e—˜’jFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQB¬Ž™“à‰È@36F1600-1603,2004.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFX-linked lymphopro-liferative disease. ƒAƒŒƒ‹ƒM[E–Ɖu@11F1570- 1575,2004.
    10. ‹àŒ“O˜aA‹{˜e—˜’jFEBƒEƒCƒ‹ƒX‚Í‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ(XLP)”­Ç‚É‚¢‚©‚ÉŠÖ‚í‚Á‚Ä‚¢‚é‚©BŒŒ‰tƒtƒ ƒ“ƒeƒBƒA@15F85-92,2004.
    11. “ñ’J@•A‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇB—Տ°ŠÅŒì@30F985-988,2004.
    12. “ñ’J@•AŽíŽsq’ˆA‹{˜e—˜’jFƒ}ƒNƒƒtƒ@[ƒW‚Ì‹@”\‚ÆBtkB—Տ°–Ɖu@41F583-586,2004.
    13. “ñ’J@•,‹àŒ“O˜a,‹{˜e—˜’jF–Ɖu•s‘SÇ‚ð‹^‚€‚Ì‚Í‚Ç‚Ì‚æ‚€‚È‚Æ‚«‚©.¬Ž™“à‰È@36F1702-1706,2004.
    14. ŽíŽsq’ˆA‹àŒ“O˜aA‹{˜e—˜’jF”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇiBTK Œ‡‘¹ÇjB¬Ž™“à‰È@36F1736- 1739,2004.
    15. ‚“c‰pr,‹àŒ“O˜a,–쑺–Ÿ•F,‹{˜e—˜’j,ŒŽ@Žõ˜YFNon-random X inactivation ‚É‚æ‚菗Ž™‚É”­¶‚µ‚œBTKŒ‡‘¹–³ƒKƒ“ ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ.—Տ°–Ɖu@42F36-42,2004.

  • 2004”NŠw‰ï•ñ
    1. Adachi Y., Adachi YS., Itazawa T., Yamamoto J., Murakami G., and Miyawaki T.: Measurement of peak inspiratory flow rates with an in-check meter to identify preschool children's ability to use dry powder inhalers; diskus and turbuhaler. 61th anniversary meeting of American academy of allergy, asthma and immunology annual meeting,2004,3,San Francisco, USA.
    2. Hashimoto I., Barber J.B, Jones M., Li X., and Sahn DJ.: Regional spectrum of tissue doppler dereived myocardial acceleration during isovolumic relaxation and its relationship to peak filling. The 53th annual scientific session American college of cardiology,2004,3,New Orleans, U.S.A.
    3. Hashimoto I., Crispin HD., Lee J-S., Ichida F., Miyawaki T., and Sahn DJ.: Accuracy of RF field strain rate (elasticity) imaging : Studies using a calibrated physiologic contracting myocardial phantom. The 53th annual scientific session American college of cardiology,2004,3,New Orleans, U.S.A.
    4. Adachi Y.: Guideline asthma management and experience in Japan. The 20th national congress of allergy and immunology in ThailandA2004,4,Bangkok,Thailand.(Invited Lecture)
    5. Kanegane H., Futatani T., Wang Y., and Miyawaki T.: Nation-wide survey of X-linked agammaglobulinemia by flow cytometric and genetic analyses in Japan. 11th meeting for the European society for Immunodeficiencies,2004,10,Paris .
    6. Aghamohammadi A., Kanegane H., Mostafa M., Lida A., Ali-Akbar A., Kiara R-K., Futatani T., Nima R., and Miyawaki T. : Recurrent and persistant neutropenia in patient with X-linked hyper IgM syndrome. 11th meeting for the European society for Immunodeficiencies,2004,10,Paris .
    7. Ichida F., Ye F., Foell D., Vogl T., Hirono K., Watanabe S., Watanabe K., Uese K., Miyawaki T., and Roth J. : Neutrophil derived S100A12 is profoundly upregulated in early stage of acute Kawasaki disease. The 77th scientific sessions of American heart association,2004,11, New Orleans,U.S.A.
    8. Hirono K., Ye F., Foell D., Watanabe S., Watanabe K., Uese K., Ichida F., Miyawaki T., and Roth J.: Possible role of myeloid related protein(MRP)8 and MRP14 in progression of coronary artery lesions in acute Kawasaki disease. The 77th scientific sessions of American heart association,2004,11, New Orleans,U.S.A.
    9. “n•Óˆê—mA“n粈»‰ÀAL–ìŒbˆêAãšŒhˆê˜YA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA‘å’ØŒc•ãA“ñ’J•A“y”ì‘P ˜YA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFpŒã‘Šú‚ÉŒJ‚è•Ô‚µŒo”ç“I‘å“®–¬•ÙŒ`¬p‚ðŽ{s‚µ‚œ‘å“®–¬‹|—£’f‚Ì“ûŽ™ —áB‘æ15‰ñ“ú–{Pedia-tric Interventional CardiologyŒ€‹†‰ï,2004,1,“Œ‹ž.
    10. ‘«—§—zŽqA”ÂàVŽõŽqA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[A‹{˜e—˜’jF•xŽRŒ§‚É‚š‚¯‚éˆãŽt‚É‚æ‚éH•šƒAƒŒƒ‹ƒM [Ž™‚ɑ΂·‚éH•šœ‹ŽŽw“±‚ÌŽÀ‘ԁB‘æ4‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2004,1,“Œ‹ž.
    11. ˆÉŒ\“ñ˜YA‘q–{@’A“ŒŽROKA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YA“yŠò‘P‹IAˆê–؍Ž”VAÎ àV@LFÅ‹ß“–‰È‚É‚ÄŒoŒ±‚µ‚œ‹»–¡‚ ‚é_Œo‰è×–EŽî‚Ì‚Q—á|Ž©‘R‘ޏk‚µ‚œ IVS ‚Ì‚P—á‚Æ Horner ’¥Œó‚ð‡•¹‚µ‚œ ‚P—á|B‘æ20‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2004,2,‹à‘ò.
    12. ‹Ž–{ˆè•vF‘ÙŽ™•s®–¬‚Ì‘gDƒhƒvƒ‰[‚ƃXƒgƒŒƒCƒ“ƒŒƒCƒg‚É‚æ‚é•]‰¿B‘æ10‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹† ‰ï,2004,2,“Þ—Ç.
    13. ŽRŒ³ƒŽqA’ÔŠáÁˆêA‘ºãIŒ[A–{ŠÔˆê³A–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆÉ“¡‰x˜NA¬’rŒ’ˆêFGATA- 1 ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œ Down ÇŒóŒQ‡•¹ transient myeloproliferative disorder ‚̈ê—áB‘æ8‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒg ƒJƒCƒ“Œ€‹†‰ï,2004,2,‹à‘ò.
    14. “n粈»‰ÀA‹Ž–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA‘哈‹`”ŽF‘gDƒhƒvƒ‰[–@ ‚ð—p‚¢‚œ‘ÙŽ™¶ŽºŽûk”\‚Ì•]‰¿B‘æ10‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹†‰ï,2004,2,“Þ—Ç.
    15. Ä“¡˜a—RA‘哈‹`”ŽA“y”ì‘P˜YA“‡’ÐeŽuA‘卂TŒáAŽOè‘ñ˜YA“n•Óˆê—mA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜ ’jA‹g“cärA“ñ’J@•FIAA(type B) pŒã‚ÌASR‚ɑ΂µ‚āARossŽèp‚ðŽ{s‚µ‚œ CHARGEÇŒóŒQ‚Ì1—áB‘æ27‰ñ –k—€¬Ž™zŠÂŠíŒ€‹†‰ï,2004,2,‹à‘ò.
    16. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAŽRŒ³ƒŽqA‘«—§—YˆêA‹{˜e—˜’jFšb‘§¬Ž™‚É‚š‚¯‚é‹z‹C—¬‘¬ ‘ª’è|DPI“±“ü‚Ì‚œ‚ß‚ÌŠî‘b“IŒŸ“¢|B‘æ25‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2004,2,•xŽR.
    17. Ye F., Ichida F., Hirono K., Watanabe S., Watanabe K., Uese K., Hashimoto I., Miyawaki T., Foell D., Vogl T., and Roth J. : Profound S100A12 expression in neutrophils in early stage of acute Kawasaki disease. The 68th annual scientific meeting of the Japanese circulation society,2004,3,Tokyo.
    18. Watanabe S., Hashimoto I., Watanabe K., Hirono K., Keiichiro K., Ichida F., Miyawaki T., and Sahn DJ. : Validation of myocardial accelera-tion during Isovolumic contraction as a non-invasive index of left ventricular contractility. The 68th annual scientific meeting of the Japanese circulation society,2004,3,Tokyo.
    19. ‘«—§—YˆêF¬Ž™šb‘§Ž¡—ÂɊւ·‚éƒAƒ“ƒP[ƒgB‘æ‚V‰ñ–k—€šb‘§Œ€‹†‰ï,2004,3,‹à‘ò.
    20. –{‹œ˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHAŒ‘òƒŽqAŠžŒŽ¹ŽqA”ª–ؐMˆêA‹{˜e—˜’jF—n˜A‹ÛŠŽõÇ‚ª ”­Ç‚ÉŠÖ—^‚µ‚œ‚ÆŽv‚í‚ê‚鏬Ž™_Œož_ŽŸŠ³B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2004,4,‰ªŽR.
    21. ‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jFIgG ƒTƒuƒNƒ‰ƒX‘ª’è‚̗Տ°“Iƒj[ƒhFƒAƒ“ƒP[ƒg’²ž‚É‚æ‚錟“¢B‘æ107 ‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2004,4,‰ªŽR.
    22. ‹Ž–{ˆè•vA“n粈»‰ÀA“n•Óˆê—mAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jFƒŠƒAƒ‹ƒ^ƒCƒ€‚RŽŸŒ³SƒGƒR[–@‚ð—p ‚¢‚œ¬Ž™æ“V«SŽŸŠ³‚ÌŒ`‘Ԑf’fB‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    23. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[A‹{˜e—˜’jFƒxƒNƒƒƒTƒ]ƒ“ ‚Å‚ÌŽ¡—ÃŒø‰Ê‚ª\•ª‚Å‚È‚©‚Á‚œšb‘§¬Ž™‚ɑ΂·‚éƒtƒ‹ƒ`ƒJƒ]ƒ“‚Ì—LŒø«B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW ‰ï,2004,4,‰ªŽR.
    24. ”ª–ؐMˆêA”ª–ØŽO˜YAŽíŽsq’ˆA–{‹œ˜a‹vA‹{˜e—˜’jAŒ‘q—TŠìA“¡àV—TŽqFƒAƒ“ƒP[ƒg’²ž‚©‚ç‚̃Cƒ“ ƒtƒ‹ƒGƒ“ƒU‚ÉŠÖ‚·‚é‹~‹}ŠO—ˆf—Âɂ‚¢‚Ă̍lŽ@B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    25. “c’‡çHAŒ‘òƒŽqA‹{@ˆêŽuA‰eŽR—²ŽiA–{‹œ˜a‹vA”ª–ؐMˆêAŒˆäŽOŽ}A‹{˜e—˜’jF“û—cŽ™Šú‚©‚çŽv tŠú‚É‚š‚¯‚錒í”­’B”]‚Ì MRI ‚É‚æ‚錟“¢B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    26. “n粈»‰ÀA‹Ž–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnF‘gDƒhƒvƒ‰ [–@‚ð—p‚¢‚œ“™—eŽûkŠúS‹Ø‰Á‘¬“x‚͍¶ŽºŽûk”\‚Ì”ñNP“IŽw•W‚Æ‚µ‚Ä—L—p‚©B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW ‰ï,2004,4,‰ªŽR.
    27. “n•Óˆê—mA‹Ž–{ˆè•vA“n•Ó ˆ»‰ÀAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jB‰EŽºŽûk•]‰¿‚É‚š‚¯‚éS ‹Ø‰Á‘¬“x‘gDƒhƒvƒ‰[–@‚Ì—L—p«B‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    28. ˆÉŒ\“ñ˜YA“ŒŽROKA“¡–Ø–õŽqA‰eŽR—²ŽiArˆä”ü˜aŽqA–쑺ŒbŽqA‹àŒ“O˜aAŒ‘q—TŠìA‹{˜e—˜’jF •Ðt–³Œ`¬‚É”­Ç‚µ‚œ Wilms Žîᇂ̈ê—áB‘æ107‰ñ“ú–{¬Ž™‰ÈŠw‰ïŠwpW‰ï,2004,4,‰ªŽR.
    29. å@‹v”TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆÀ‘º²“s‹IAÎàV@LF•úŽËü—Ö@‹y‚Ñ DeVIC —à –@‚ª—LŒø‚Å‚ ‚Á‚œ nasel NK/T cell lymphoma ‚Ì‚P—Ž™—áB‘æ14‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï,2004,5,“Œ‹ž.
    30. ‹àŒ“O˜aA‹{˜e—˜’jA{–è@—ºF‚킪‘‚Ì‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚̗Տ°“IˆÓ‹`B‘æ14‰ñEBƒEƒCƒ‹ƒXŠŽ õÇŒ€‹†‰ï,2004,5,“Œ‹ž.
    31. ‘«—§—zŽqA”ÂàVŽõŽqAà_“¹”ü‹IA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚é H•šœ‹ŽŽwŽŠ‘ì¬‚ÌŽŽ‚݁|•xŽRŒ§“à‚̈ãŽt‚ւ̃Aƒ“ƒP[ƒgŒ‹‰Ê|B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å ‰ï,2004,5,‘O‹Ž.
    32. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çAŽRŒ³ƒŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF¬Ž™‚É‚š‚¯‚éšb ‘§”­ìŽž‚Æ”ñ”­ìŽž‚Ì‹z‹C—¬‘¬‚ÌŒŸ“¢|DPI‚ÌŽg—p‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢|B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ° ‘å‰ï,2004,5,‘O‹Ž.
    33. ŒÜ\—’—²•vAŒ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêA‘ºãIŒ[Fƒ‚ƒ“ƒeƒ‹ƒJƒXƒg“Š—^‘OŒã ‚É‚š‚¯‚é‹C“¹‰ß•q«‚Ì•Ï“®‚ÉŠÖ‚·‚錟“¢B‘æ16‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2004,5,‘O‹Ž.
    34. •£‘ò—³–çA”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêAŽRŒ³ƒŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFšb‘§Ž™‚ɑ΂·‚é ƒhƒ‰ƒCƒpƒEƒ_[‹z“üŠíiDPIjŽg—p‚ÉŠÖ‚·‚éŠî‘b“IŒŸ“¢|”ñ”­ìŽž‚È‚ç‚Ñ‚É”­ìŽž‚Ì‹z‹C—¬‘¬|B‘æ21‰ñ“ú–{¬ Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï,2004,6,‰F“s‹{.
    35. ‘«—§—YˆêF—Šw—Ö@‚É‚š‚¯‚鍡Œã‚̉ۑèBƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚闝Šw—Ö@‚̃Rƒc‚Æ—Ž‚Æ ‚µŒŠvB‘æ21‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï,2004,6,‰F“s‹{.
    36. “ñ’J@•AŽs“c•™ŽqA‹{˜e—˜’jFVEGFR3 ƒLƒi[ƒ[ƒhƒƒCƒ““à‚̃~ƒXƒZƒ“ƒX•ÏˆÙ‚É‚æ‚éˆâ“`«ƒŠƒ“ƒp•‚Žî (Milroy•a)‚̈ê‰ÆŒnB‘æ28‰ñ“ú–{ƒŠƒ“ƒpŠw‰ï‘‰ï,2004,6,•xŽR.
    37. “n粈»‰ÀA‹Ž–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚œ ‘ÙŽ™S‹@”\‚̉ðÍB‘æ11‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,2004,6,‹à‘ò.
    38. ˆÉ“¡–õ“TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA’J“à]ºGA‰¡“cr•œA‹{˜e—˜’jFƒŒƒCƒm[Œ»Û ‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œ¬Ž™”畆‹Ø‰Š‚̈ê—áB‘æ41‰ñ–k—€—Տ°–ƉuEÇ—ጟ“¢Œ€‹†‰ï,2004,7,‹à‘ò.
    39. ‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnFŽOŽŸŒ³‘gDƒhƒvƒ‰[–@‚ð—p‚¢‚œS‹Ø‘gD«ó‚Ì”»’èB‘æ40 ‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    40. L–ìŒbˆêA—t@”òA“n•Óˆê—mA“n粈»‰ÀAãšŒhˆê˜YA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADirk Foell, Jahammes RothFìè•a‹}«Šú‚É‚š‚¯‚éMRP 8/MRP 14‚Ì“®‘ԁB‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW ‰ï,2004,7,“Œ‹ž.
    41. “n粈»‰ÀA‹Ž–{ˆè•vA“n•Óˆê—mAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jADavid SahnF‘gDƒhƒvƒ‰ [–@‚ð—p‚¢‚œ“™—eŽûkŠúS‹Ø‰Á‘¬“x‚͍¶ŽºŽûk”\‚Ì”ñNP“IŽw•W‚Æ‚µ‚Ä—L—p‚©B‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ï ŠwpW‰ï,2004,7,“Œ‹ž.
    42. “n•Óˆê—mA‹Ž–{ˆè•vA“n•Ó ˆ»‰ÀAœA–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‰EŽºŽûk•]‰¿‚É‚š‚¯‚éS ‹Ø‰Á‘¬“x‘gDƒhƒvƒ‰[–@‚Ì—L—p«B‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ‹ž.
    43. Ä“¡˜a—RA‘哈‹`”ŽA“y”ì‘P˜YA–Œ‘q—¢DAŽOè‘ñ˜YA‹Ž–{ˆè•vAŽs“c•™ŽqA‹g“cärA“ñ’J•A‹{˜e—˜ ’jF¶S’áŒ`¬ÇŒóŒQ‚ɑ΂µA“ñSŽºC•œ‚ðŽŽ‚Ý‚œ‚P—áB‘æ40‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2004,7,“Œ ‹ž.
    44. ˆÉ“¡–õ“TA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA‹{˜e—˜’jFƒŒƒCƒm[Œ»Û‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œ¬Ž™ ”畆‹Ø‰Š‚̈ê—áB‘æ40‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2004,8,Šò•Œ.
    45. å@‹v”TA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFŒŒ¬”‘‘œ‚𔺂Á‚œ monosomy 7‚̈ê—áB‘æ40‰ñ’†•”“ú–{¬ Ž™‰ÈŠw‰ï,2004,8,Šò•Œ.
    46. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF¬lŠú‚ɐf’f‚³‚ê‚œ‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB‘æ66‰ñ “ú–{ŒŒ‰tŠw‰ï‘‰ïE‘æ46‰ñ—Տ°ŒŒ‰tŠw‰ï‘‰ï,2004,9,‹ž“s.
    47. –쑺ŒbŽqA‹àŒ“O˜aAÎàV@LA‹{˜e—˜’jFNasal NK/T cell lymphoma ‚Ì‚Q—Ž™—áB‘æ66‰ñ“ú–{ŒŒ‰tŠw‰ï ‘‰ïE‘æ46‰ñ—Տ°ŒŒ‰tŠw‰ï‘‰ï,2004,9,‹ž“s.
    48. ‘«—§—zŽqA”‘òŽõŽqA‘«—§—YˆêA‰Ÿ“cŠì”ŽA‹{˜e—˜’jFŒûoƒAƒŒƒ‹ƒM[ÇŒóŒQ‚Ì‚P’jŽ™—áB‘æ7‰ñ•xŽR¬Ž™ šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2004,9,•xŽR.
    49. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‹{˜e—˜’jFdÇšb‘§“û—cŽ™2—á‚É‚š‚¯‚éHFA-BDP ‚ÌŽg—pŒoŒ±B‘æ‚P‰ñ•xŽRšb‘§–ò•šŽ¡—ÃŒ€‹†‰ï,2004,9,•xŽR.
    50. ‹Ž–{ˆè•vA“n•Óˆê—mA“n粈»‰ÀAL–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒbƒvƒ‰[–@‚ð—p‚¢ ‚œdÇS‹ØÇ‚̐S‹@”\”»’èB‘æ21‰ñ“ú–{’Ž‰¹”gˆãŠw‰ï’†•”’n•û‰ï,2004,10,•xŽR.
    51. “n粈»‰ÀA‹Ž–{ˆè•vA“n•Óˆê—mAL–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jF‘gDƒhƒbƒvƒ‰[–@‚ð—p‚¢ ‚œ¬Ž™‚É‚š‚¯‚é“™—eŽûkŠúS‹Ø‰Á‘¬“x‰ðÍB‘æ21‰ñ“ú–{’Ž‰¹”gˆãŠw‰ï’†•”’n•û‰ï,2004,10,•xŽR.
    52. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‹{˜e—˜’jFdÇŽ‘±Œ^‚Ìšb‘§“û—cŽ™‚Q—á‚Ö‚ÌHFA- BDP“±“üŒoŒ±B‘æ12‰ñ—Տ°šb‘§Œ€‹†‰ï,2004,10,L“‡.
    53. ‹àŒ“O˜aA“ñ’J@•A–쑺ŒbŽqA‹vŠÔ–ØŒåA“y‰®@Ž A–ìXŽRŒbÍA‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇŒóŒQ‚Ì ˆâ“`Žqf’f‚É‚š‚¯‚鍑Û‹Š—́B‘æ36‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2004,11,“Œ‹ž.
    54. –쑺ŒbŽqA‹àŒ“O˜aA“ñ’J@•A‹àŽq‰p—YA‹ß“¡’ŒŽÀA‹{˜e—˜’jFIgGƒTƒuƒNƒ‰ƒX‘ª’è‚̗Տ°“Iƒj[ƒh‚ÆIgG ƒTƒuƒNƒ‰ƒXŒ‡‘¹Ç‚ÌŽÀ‘ԁB‘æ36‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2004,11,“Œ‹ž.
    55. âV“¡˜a—RA“ŒŽROKA–쑺ŒbŽqA‹àŒ“O˜aA‘«—§—YˆêA‹{˜e—˜’jF‘lŒa•”Œ‹Šj«ƒŠƒ“ƒpß‰Š‚Ì—cŽ™—áB‘æ 36‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2004,11,“Œ‹ž.
    56. ‘å’ØŒc•ãA‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFhistiocytosis ‚𔺂Á‚œcŠuŒŽ”­ Germ cell tumor ‚̈ê’jŽ™—áB‘æ20‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2004,11,‹ž“s.
    57. ”óŒû@ŽûAˆÉŒ\ŽŸ˜YA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF—‘‰©”XŠà‚ð‡•¹‚µ‚œ Aicardi ÇŒóŒQ‚̈ê—áB‘æ 20‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2004,11,‹ž“s.
    58. ‹àŒ“O˜aFƒ‚[ƒjƒ“ƒOƒŒƒNƒ`ƒƒ[u–Ɖu•s‘SÇvB‘æ46‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2004,11,‹ž“s.
    59. å@‹v”TA–쑺ŒbŽqA‹àŒ“O˜aA^•”@~‹{˜e—˜’jFŒŒ¬”‘‘œ‚𔺂Á‚œ monosomy 7 ‚̈ê—áB‘æ46‰ñ“ú –{¬Ž™ŒŒ‰tŠw‰ï,2004,11,‹ž“s.
    60. ‘«—§—YˆêF˜_‰ðuƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚̓AƒXƒv[ƒ‹‚©ƒvƒƒ^ƒm[ƒ‹‚©vB‘æ41‰ñ“ú–{¬Ž™ƒA ƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    61. ”ÂàVŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFdÇšb‘§‚Ì“û—cŽ™‚É‚š‚¯‚é HFA-BDP‚ÌŒø‰Ê|2—á‚ÌŽg—pŒoŒ±‚©‚çB‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    62. ‘«—§—zŽqAà_“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêAŠC˜VàVŒ³GA‹{˜e—˜’jFŠO—ˆ‚É‚š‚¯‚é H•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éH•š•‰‰×ŽŽŒ±B‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    63. Œ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é—\–h“IŽ¡—Â̑Šú“±“ü‚Ì—L—p«‚É ‚‚¢‚Ä‚ÌŒŸ“¢B‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    64. ŒÜ\—’—²•vAŒ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêA‘ºãIŒ[FŽó“®‹i‰Œ‚ª¬Ž™šb‘§‚ÌŒÄ ‹C’†CO”Z“xAŒÄ‹z‹@”\A‹C“¹‰ß•q«‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚āB‘æ41‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2004,11,“Œ‹ž.
    65. –{ŠÔ@mAå@‹v”TA”ÂàVŽõŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—zŽqA‘«—§—YˆêAóˆä³ŽkA‹{˜e—˜’jFf’f ‚³‚ê‚é‚Ü‚Å’·ŠúŠÔ‚ð—v‚µ‚œƒs[ƒiƒc‚É‚æ‚é‹C“¹ˆÙ•š‚Ì‚R—áD‘æ37‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2004,11,“Œ‹ž.
    66. ”ÂàVŽõŽqAÄ“¡˜a—RA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF”w•”’É‚Å”­Œ©‚³‚êA‚`ŒQ—n ˜A‹ÛŠŽõ‚É‚æ‚é‚ƍl‚Š‚ç‚ê‚œ‘œ”­«‰~Œ`”x‰Š‚̈ê—áB‘æ37‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2004,11,“Œ‹ž.
    67. ŒÜ\—’—²•vAŒ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‘«—§—zŽqA”öã—mˆêAŠžŒŽ¹ŽqA‘ºãIŒ[FŠÔÚ‹i‰Œ‚ª¬ Ž™šb‘§‚̌ċz‹@”\‚Æ‹C“¹‰ß•q«‚É‹y‚Ú‚·‰e‹¿‚ɂ‚¢‚āB‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2004,11,‰¡•l.
    68. ”‘òŽõŽqA‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêAŽRŒ³ƒŽqA‘ºãIŒ[A‹{˜e—˜’jF•xŽRŒ§“à¬Ž™‰È ˆã‚É‚š‚¯‚éšb‘§Ž¡—Âɑ΂·‚él‚Š•û‚Ì‚T”NŠÔ‚ł̕ω»B‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2004,11,‰¡•l.
    69. ‘«—§—zŽqA”ÂàVŽõŽqAà_“¹”ü‹IA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚é H•šœ‹ŽŽwŽŠ‘ì¬‚ÌŽŽ‚݁|•xŽRŒ§“à‚Ì•ÛˆçŽ{Ý‚ւ̃Aƒ“ƒP[ƒgŒ‹‰Ê|B‘æ54‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘ ‰ï,2004,11,‰¡•l.
    70. ŽíŽsq’ˆA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ—R—ˆŽ÷ó×–E‚É‚š‚¯‚é Toll- like receptor ligands ‚ɑ΂·‚鉞“š«B‘æ34‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2004,12,ŽD–y.
    71. Mostafa S., Yoshida T., Futatani T., Kanegane H., and Miyawaki T. : Human breast milk can promote class switching of neonatal naive B-cells into IgA-secreting cells. ‘æ34‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2004,12,ŽD–y.
    72. ‘«—§—zŽqA”ÂàVŽõŽqA’†—ÑŒºˆêA•£‘ò—³–çA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF“–‰ÈŠO—ˆ‚ł̐H•šƒAƒŒƒ‹ƒM [Ž™‚ɑ΂·‚éH•š•‰‰×ŽŽŒ±‚ÌŽÀÛB‘æ31‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2004,12,‹à‘ò.

    2003”N

  • ’˜‘
    1. ‹{˜e—˜’jC”ª–ؐMˆêFˆã—Õ¶‘ì¬ã‚Ì’ˆÓ“_‚RDf’f‘uƒRƒAEƒ[ƒeƒCƒVƒ‡ƒ“¬Ž™‰Èv^‹|Œõ•¶‘Œ•ÒC8-9C‹à–F“°C“Œ‹žC2003.
    2. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQBu¡“ú‚̏¬Ž™‚ÌŽ¡—ÃŽwjv‘æ13”ŁC‘åŠÖ••F‘Œ•ÒC364-365CˆãŠw‘‰@C“Œ‹žC2003.
    3. Žs“c•™ŽqF¬Ž™‚Ì•s®–¬Bu¡“ú‚ÌŽ¡—ÃŽwj 2003”N”ŁvCŽRŒû@“O‘Œ•ÒC903-904CˆãŠw‘‰@C“Œ‹žC2003.
    4. Žs“c•™ŽqFŠî–{fŽ@–@B‹¹• •”uƒRƒAEƒ[ƒeƒCƒVƒ‡ƒ“¬Ž™‰ÈváÁ‹|Œõ•¶‘Œ•ÒC52-55C‹à–F“°C“Œ‹žC2003.
    5. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQBuAnnual ReviewzŠÂŠí@2003v™‰º–õ˜Y‘Œ•ÒC83-88C’†ŠOˆãŠwŽÐC“Œ‹žC2003.
    6. ‘«—§—YˆêF‹C“¹•W“I×–E‚É‹y‚Ú‚·‰ŠÇ‰ž“š‚Ì“Á’¥Bu}àF¬Ž™šb‘§‚Ì“Á’¥-•a‘Ô‚Æ–ò•š—Ö@‚𒆐S‚É-vCŒŠÔŽOŠ]‘Œ•ÒC42-54CƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐC“Œ‹žC2003.
    7. ‘«—§—YˆêF¬Ž™‚É‚Ý‚ç‚ê‚é‹CŠÇŽxŠg’£Ç‚ɂ‚¢‚āBu¬Ž™‰Èf—Âp•‚`v’ǘ^‘æ37†CÔ’ˏ‡ˆê‘Œ•ÒC1420-1421C˜Z–@o”ŎЁC“Œ‹žC2003D
    8. ‘«—§—YˆêFÌŒŒBuƒRƒAEƒ[ƒe[ƒVƒ‡ƒ“@¬Ž™‰ÈvCáÁ‹|Œõ•¶‘Œ•ÒC66-67C‹à–F“°C‹ž“sC2003D
    9. ‘«—§—YˆêF‹z“ü—Ö@BuƒRƒAEƒ[ƒe[ƒVƒ‡ƒ“@¬Ž™‰ÈvCáÁ‹|Œõ•¶‘Œ•ÒC170-171C‹à–F“°C‹ž“sC2003D
    10. ‘«—§—YˆêF‹}«×‹CŠÇŽx‰ŠBu¡“ú‚̏¬Ž™Ž¡—ÃŽwjv13”ŁC‘åŠÖ••F‘Œ•ÒC270-271CˆãŠw‘‰@C“Œ‹žC2003.
    11. ‘«—§—YˆêFdÇ‹CŠÇŽxšb‘§”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚ɂ‚¢‚āBu¬Ž™‰ÈŠO—ˆf—ẪRƒc‚Æ—Ž‚Æ‚µŒŠ‚P@¬Ž™šb‘§f—ÁvCXìºœA•ÒC132-133C’†ŽR‘“XC“Œ‹žC2003.
    12. ‘«—§—YˆêFŠO—ˆ‚ÅŠÈ’P‚É‚Å‚«‚é”x‹@”\ŒŸž|ƒÀ2ŽhŒƒ–ò‚ɑ΂·‚锜‰ž«ŒŸž|Bu¬Ž™‰ÈŠO—ˆf—ẪRƒc‚Æ—Ž‚Æ‚µŒŠ‚P@¬Ž™šb‘§f—ÁvCXìºœA•ÒC41-41C’†ŽR‘“XC“Œ‹žC2003D
    13. ‹àŒ“O˜aC‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇŒóŒQBu“à‰ÈŠw‘攪”Łv™–{P–Ÿ‘Œ•ÒC1322-1327C’©‘q‘“XC“Œ‹žC2003.
    14. “ñ’J@•C‹{˜e—˜’jFV¶Ž™E¬Ž™•ÛŒ’‚W‘Ù“àŠŽõBuƒ_ƒCƒiƒ~ƒbƒN@ƒƒfƒBƒVƒ“‚Vv‰ºð•¶•‘Œ•ÒC28¥23-28¥26CŒ‘º‘“XCVŠƒC2003.
  • ŒŽ’˜
    1. Hashimoto I., Li X., Bhat A.H., Jones M., Zetts A. D., and Sahn D.J. : Myocardial strain rate is a superior method for evaluation of left ventricular subendocardial function compared with tissue doppler imaging. J Am Coll Cardiol 42 : 1574-1583,2003.
    2. Yoshida T., Kanegane H., Osato M., Yanagida M., Miyawaki T., Ito Y., and Shigesada K.: Functional analysis of RUNX2 mutations in cleidocranial dysplasia : novel insights into genotype-phenotype correlations. Blood Cell Mol Dis. 30: 184-193,2003.
    3. Itazawa T., Adachi Y., Okabe Y., Hamamichi M., Adachi Y. S., Toyoda M., Morohashi M., and Miyawaki T.: Developmental changes in interleukin-12-producing ability by monocytes and their relevance to allergic diseases. Clin Exp Allergy 33 : 525-530,2003.
    4. Foell D., Ichida F., Vogl T., Yu X., Chen R., Miyawaki T., Sorg C., and Roth J.: S100A12 (EN-RAGE) in monitoring Kawasaki disease. LANCET 361 : 1270-1272,2003.
    5. Yagi H., Furutani Y., Hamada H., Sasaki T., Asakawa S., Minoshima S., Ichida F., Joo K., Kimura M., Imamura S., Kamatani N., Momma K., Takao A., Nakazawa M., Shimizu N., and Matsuoka R.: Role of TBX1 in human del22q11.2 syndrome. LANCET 362 : 1366-1373,2003.
    6. Oyoshi MK., Nagata H., Kimura N., Zhang Y., Demachi A., Hara T., Kanegane H., Matsuo Y., Yamaguchi T., Morio T., Hirano A., Shimizu N., and Yamamoto K. : Preferential expansion of VƒÁ9-JƒÁP/VƒÂ2-JƒÂ3 ƒÁ-ƒÂ T cells in Nasal T-cell lymphoma and chronic active Epstein-Barr virus infection. Am J Pathol 162: 1629-1638,2003.
    7. Amoras AL., Kanegane H., Miyawaki T., and Vilela MM.: Defective Fc-, CR1- and CR3-mediated monocyte phagocytosis and chemotaxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. J Investig Allergol Clin Immunol 13:181-188,2003.
    8. Kimura H., Morishima T., Kanegane H.,Ohga S., Hoshino Y., Maeda A., Imai S., Okano M., Morio T., Yokota S., Tsuchiya S., Yachie A., Imashuku S., Kawa K., Wakiguchi H., and Members of the Japanese association for research on Epstein-Barr virus and related diseases.: Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis 187 : 527-533,2003.
    9. Gagliardi M.C., Finocchi A., Orlandi P., Cursi L., Cancrini C., Moschese V., Miyawaki T., and Rossi P. : Bruton's tyrosine kinase defect in dendritic cells from X-linked agammaglobulinae-mia patients does not influence their differenti-ation, maturation and antigen-presenting cell function. Clin Exp Immunol 133 : 115-122,2003.
    10. Jo EK., Wang Y., Kanegane H., Futatani T., Song CH., Park JK., Kim JS, Kim DS, Ahn KM., Lee SI., Park HJ., Hahn YS., Lee JH., and Miyawaki T.: Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients. J Hum Genet 48: 322-326,2003.
    11. Carnevali S., Mio T., Adachi Y., Spurzem J.R., StrizI., Romberger D.J., Illig M.,and Rennard. S.I.: Gamma radiation inhibits fibroblast-mediated collagen gel retraction. Tissue Cell 35: 459-69;2003.
    12. Li X., Jones M., Wang HF., Davies CH., Swanson JC., Hashimoto I., Rusk RA., Schindera ST., Barber BJ., and Sahn DJ. : Strain rate acceleration yields a better index for evaluating left ventricular contractile function as compared with tissue velocity acceleration during isovolumic contraction time: an in vivo study. J Am Soc Echocardiogr 16:1211-1216,2003.
    13. Miyazaki S., Tsuda H., Sakai M., Hori S., Sasaki Y., Futatani T., Miyawaki T., and Saito S.: Predominance of Th2-promoting dendritic cells in early human pregnancy decidua. J Leukocyte Biol 74: 514-522,2003.
    14. Œ–쐳’mCˆÉ“Œ“¹•vC‹gZ@ºC‘«—§—YˆêCŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§dÇ”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@@[dl‘Ì‚Æl‘Ì‚Ì”äŠrŒŸ“¢[B“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@17F115-121,2003.
    15. L£K”üCˆê–Ø”ü’qŽqCŽs“c•™ŽqC‘哈‹`”ŽFæ“V«SŽŸŠ³Ž™—Èçƒj[ƒY‚ÉŠÖ‚·‚錀‹†[‘æ1•ñFV‚µ‚¢ŽÚ“x‚ÌŠJ”­[“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F14-19,2003.
    16. L£K”üCˆê–Ø”ü’qŽqCŽs“c•™ŽqC‘哈‹`”ŽFæ“V«SŽŸŠ³Ž™—Èçƒj[ƒY‚ÉŠÖ‚·‚錀‹†[‘æ2•ñFê–å‰Æ‚Æ•êe‚ª”cˆ¬‚·‚é—Èçƒj[ƒY‚Ì”äŠrŒŸ“¢[“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F20-27, 2003 .
    17. ’†àV@œC’O‰HŒöˆê˜YC‹g‰i³•vCŽ›ˆä@ŸC‰zŒã–ΔVC“¡ŒŽ@‘ìC‘ºã’q–ŸCŽs“c•™ŽqCé”ö–M—²C‰Hª“c‹IKCžwŠ_‚ŽjC—é–؁@_Cã‘ºGŽ÷CÎ˜a“c–«•FC—§–ì@Ž C‹v•Û“cˆêŒ©Fæ“V«SŽŸŠ³‚É‚š‚¯‚銎õ«S“à–Œ‰Š‚Ì”­¶•p“xC—\–hCŽ¡—ÂɊւ·‚é‘S‘’²žÑ‘æ1•ñѓú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F117-122, 2003.
    18. Œ‰ª—Ú”üŽqC“ì‘ò@‹CHŒ³@Š]CŽs“c•™ŽqC‘Ÿ“c”ªç—YC¬ìrˆêC¬–ìˆÀ¶C¬ŽRk‘Ÿ˜YC•]Œ“ŽiC¬â˜a‹PC—¢Œ©Œ³‹`Cé”ö–M—²C£Œû³ŽjC‚‹Ž‰x˜YC’†ì‰ë¶C‰Hª“c‹IKC”nê@ŽC•Ÿd~ˆê˜YC‘O“c@C‘ºˆäFˆÀCX@ˆê”ŽCX@Ž•FC‹g‰i³•vCˆÀ“¡³•FF‰Æ‘°“à”­ÇSŒŒŠÇŽŸŠ³iSŽº’†ŠuŒ‡‘¹CS–[’†ŠuŒ‡‘¹Cƒtƒ@ƒ[Žl’¥ÇC“®–¬ŠÇŠJ‘¶j‚ÉŠÖ‚·‚é‰uŠw’²ž•ñ[1999”N8ŒŽ`2002”N7ŒŽ[@¬Ž™zŠÂŠíŠw‰ïŽGŽ@19F622-628, 2003.
    19. áÁ‹|Œõ•¶C‘哈—E¬C‹{˜e—˜’jC‚‹ŽOºC¬ò»ˆêF•a‰@¬Ž™‰È‹Î–±ˆã‚̋Ζ±ó‹µ‚Æ‚»‚̉ü‘P‚ɂ‚¢‚āB“ú–{¬Ž™‰ÈŠw‰ïŽ@107F85-92,2003.
  • Ç—á•ñ
    1. Kanegane H., Vielela MMS., Wang Y., Futatani T., Matsukura H., and Miyawaki T.: Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis. Pediatr Nephrol 18: 454-456,2003.
    2. Hashimoto I., Ichida F., and Miyawaki T.: A case of large VSD with right sided diaphragmatic hernia. Cardiol Young 13:109-110,2003.
    3. Onoue Y., Adachi Y., Ichida F., and Miyawaki T.: Effctive use of corticosteroid in a child with life-threatening plastic bronchitis after Fontan operation. Pediatr Int 45: 107-109,2003.
    4. Aghamohammadi A., Kanegane H., Moein M., Farhoudi A., Pourpak Z., Movahedi M., Gharagozlou., Zarger AAA., and Miyawaki T.: Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodificiency. Int J Hematol 78 : 45-47,2003.
    5. Jo EK., Futatani T., Kanegane H., Kubota T., Lee YH.,Jung JA., Song CH., Park JK., Nonoyama S., and Miyawaki T.: Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome. Int J Hematol 78 : 40-44,2003.
    6. Chujo T., Yachie A., Kanegane H., Kimura H., Shiobara S., and Nakao S. : Epstein-Barr virus(EBV)-associated post-transplantation lympho-proliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation. Am J Hematol 72 : 255-258,2003.
    7. Hirokawa S., Uotani H., Okami H., Tsukada K., Futatani T., and Hashimoto I.: A case of congenital middle cervical cleft with congenital heart disease. J Pediatric Surg 38: 1099-1101, 2003 .
    8. Nii M., Mori K., Yuasa Y., and Ichida F.: Isolated noncompaction of myocardium associated with calcification in the Interventricular Septum. Pediatr Cardiol. Epub,Sep.4,2003.
    9. Oshima Y., Koto K., Shimazu C., Misaki T., Ichida F., and Hashimoto I.: Transannular patching for tetralogy of Fallot with an anomalous right coronary artery. Jpn J Thorac Cardiovasc Surg. 51:73-76,2003.
    10. Oshima Y., Hashimoto I., Shimazu C., and Ichida F.: Atypical infantile form of scimitar syndrome with bronchomalacia. Interactive Cardiovascular and Thoracic Surg 2: 298-300,2003.
    11. Irga N., Wierzba J., Brozek J., Ochman K., Kanegane H., Miyawaki T., and Neuman-Laniec M.: X-linked agammaglobulinemia(XLA) associated to agranulocytosis. Wiad Lek 56: 378-380,2003.
    12. ŽíŽsq’ˆC‰ÆéˆŸ‹IŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jC‘â@ŽFƒrƒ“ƒNƒŠƒXƒ`ƒ““Š—^‚É‚æ‚茰«‰»‚µ‚œCharcot-Marie-Tooth•a1AŒ^‚Ì‚P—áB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽ 17F34-37,2003.
    13. ”öã—mˆêC‘«—§—YˆêC”ÂàVŽõŽqC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC’C–€‹M”üŽqC¬–ìˆÀ¶C”ª–ØŒŽrŽFFontan pŒã‚T”N‚Å”­Ç‚µ‚œ plastic bronchitis ‚Ì‚P’jŽ™—áB“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ19F51-55,2003.
    14. ˆÉ“¡–õ“TC’†—ÑŒºˆêC–쑺ŒbŽqC‹àŒ“O˜aC‰ª•””üŒbC‹{˜e—˜’jFŒŒ‹…æÐHÇŒóŒQ‚ð‡•¹‚µ‚œ Anaplastic large cell lymphoma ‚̈ê—áB“ú–{¬Ž™‰ÈŠw‰ïŽ@107F85-92,2003.
    15. ‘“c²˜aŽqC’†–ì‹MŽiC_’J@âVC‹àŒ“O˜aC‹{˜e—˜’jFƒyƒjƒVƒŠƒ“‘ϐ«”x‰Š‹…‹Û‚É‚æ‚é‹}«’†Žš‰Š‚Å”­Œ©‚³‚ê‚œ‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—áBŽš•@ˆôA‰ÈE“ªèò•”ŠO‰È@75F365-369,2003.
    16. Š¥–Ø’q”VC‰Í‡—˜®C‹à@Œc²Cé@G•ãC‘å‹Ž”Ž•¶CŒÃ¯’mŒÈC’J“à]ºGC‹àŒ“O˜aC‹{˜e—˜’jC‘åÎ@•×Fp47- phox Œ‡‘¹Œ^–«“÷‰èŽîÇ‚𔺂€ Williams ÇŒóŒQ‚Ì‚P—áB—Տ°–ƉuŠw‰ïŽGŽ 26F299-303,2003.
    17. Žu…–ƒŽÀŽqCŒ—с@³C–Ø‘º@GC¯–ì@—mC‹àŒ“O˜aC‹{˜e—˜’jFEBƒEƒCƒ‹ƒXŠÖ˜AŒŒ‹…æÐHÇŒóŒQ‚É‚ÄŽ€–S‚µ‚œ‚w˜AœƒŠƒ“ƒp‘B«ÇŒóŒQ‚̌ǔ­—áB¬Ž™ŠŽõ–Ɖu 15F3-7,2003.
    18. ˆîˆäˆèŽqC‹àŒ“O˜aCX–{@ŽC^•”@~C‹{˜e—˜’jC×’J—º‘ŸF“ûŽ™Šú‘Šú‚É—nŒŒ«•nŒŒ‚ÆŒŒ¬”ÂŒž­‚Å”­Ç‚µ‚œ Autoimmune Lympho-proliferative Syndrome ‚Ì‚P—áB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ@17F492-496,2003.
  • ‘à
    1. Yachie A., Kanegane H., and Kasahara T.: Epstein-Barr virus-associated T-/natural killer cell lymphoproliferative disease. Semin Hematol 40 : 124-132,2003.
    2. Žs“c•™ŽqF¬l‚Æ‚È‚Á‚œ¬Ž™SŽŸŠ³Buæ“V«SŽŸŠ³CS‹ØÇC•s®–¬‚̈â“`‚ƈâ“`‘Š’kv¬Ž™‰Èf—ÓÁW†B1105-1110,2003.
    3. ‘«—§—YˆêF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚é‹C“¹ƒŠƒ‚ƒfƒŠƒ“ƒO‚Ì•a‘ԁBƒAƒŒƒ‹ƒM[‚̗Տ°@23F759-763,2003.
    4. ‹àŒ“O˜aFEBƒEƒCƒ‹ƒXŠÖ˜AŽŸŠ³‚ÌŽ¡—Â̐i•àB‰»Šw—Ö@‚̗̈æ@19F1591-1595,2003.
    5. ‹àŒ“O˜aC‹{˜e—˜’jFXLP‚È‚ç‚Ñ‚É‚»‚ÌŽü•ÓŽŸŠ³‚̃Qƒmƒ€ˆãŠwBƒQƒmƒ€ˆãŠw@‚RF317-322,2003.
    6. ‹àŒ“O˜aCãŒˆê‰iC‹{˜e—˜’jFICOS‚̈â“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SÇB—Տ°–Ɖu@40F499-506,2003.
    7. ‹àŒ“O˜aC‹{˜e—˜’jFƒŠƒ“ƒp‘B«ŽŸŠ³‚Ɛæ“V“Iˆâ“`ŽqˆÙíB“ú–{—Տ°–ƉuŠw‰ï‰ïŽ@26F311-322,2003.
    8. ‹àŒ“O˜aCŽÂèŒ’‘Ÿ˜YC“ñ’J@•C‹{˜e—˜’jFEBƒEƒCƒ‹ƒXŠŽõ‚ƈâ“`«ƒŠƒ“ƒp‘BŽŸŠ³B¬Ž™ŠŽõ–Ɖu 15F25-30,2003.
    9. ŠÇ@®_C‚“c‰prC‘å‰ê³ˆêC‹àŒ“O˜aC‹{˜e—˜’jCŒŽ@Žõ˜YFƒŠƒ“ƒp‹…‚ÌŠˆ«‰»§Œä‚ƃp[ƒtƒHƒŠƒ“`‰Æ‘°«ŒŒ‹…æÐHƒŠƒ“ƒp‘gD‹…Ç‚̐¬ˆö`B—Տ°–Ɖu@40F110-116,2003.

  • 2003”NŠw‰ï•ñ
    1. “n•Óˆê—mCãšŒhˆê˜YC“n•Óˆ»‰ÀCL–ìŒbˆêCà_“¹—T“ñC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“‡’ÐeŽuC‘哈‹`”ŽCŽOè‘ñ˜YC¬—яrŽ÷Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚̍¶”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ăXƒeƒ“ƒg—¯’u‚ðs‚¢CpŒã7”N‚ɍĊg’£‚ðs‚Á‚œ1—áB‘æ14‰ñ“ú–{Pediatric Interventional Cardio-logy Œ€‹†‰ï,2003,1,‘åã.
    2. à_“¹—T“ñCL–ìŒbˆêC“n•Óˆê—mC“n•Óˆ»‰ÀCãšŒhˆê˜YC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“‡’ÐeŽuC‘哈‹`”ŽCŽOè‘ñ˜YFMAPCA‚ɑ΂µƒRƒCƒ‹Çðp‚ª—LŒø‚Å‚ ‚Á‚œVSD, PA‚Ì1—áB‘æ14‰ñ“ú–{Pediatric Interventional Cardiology Œ€‹†‰ï,2003,1,‘åã.
    3. “ñ’J@•C”ª–ؐMˆêCÄ“¡@Ž C“‡@—FŽqC²X–ׁؑC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽF“–‰@NICU‚É‚š‚¯‚éæ“V«SŽŸŠ³”À‘——á‚ÌŒŸ“¢`“KØ‚È”À‘—‚ª‚È‚³‚ê‚Ä‚¢‚é‚©`‘æ6‰ñ•xŽRŒ§•êŽqˆã—ÃŒ€‹†‰ï,2003,1,•xŽR.
    4. “n粈»‰ÀC“n•Óˆê—mCà_“¹—S“ñCŽs“c•™ŽqC‹{˜e—˜’jC“¡–Ø–õŽqCƒj’J@•CŠp’JŽûŽqCŒŽR—æ“ށC“à@®ŽqC•Ä“c@“NC²X–ׁؑCŽðˆä³—˜CâV“¡@Ž C“»@³‹`C“‡’ÐeŽuC‘哈‹`”ŽCŽOè‘ñ˜YF‘ÙŽ™Šú‚æ‚èŒo‰ßŠÏŽ@‚µ‚œ‘“®–¬Š²ˆâŽc‚̈ê—áB‘æ9‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹†‰ï,2003,2,•ºŒÉ.
    5. “¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFƒpƒ‹ƒ{ƒEƒCƒ‹ƒXB19ŠŽõ‚É‚æ‚茌¬”ÂŒž­‚È‚ç‚тɍD’†‹…Œž­‚𗈂µ‚œ‚P’jŽ™—áB‘æ‚V‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,2003,2,‹à‘ò.
    6. ŒŽˆä•ü”üC“¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCˆÀ‘º²“s‹IC‰–“cࠎqCŒF’J¹–ŸCPŒ—R‹LŽqF•›•@oŒŽ”­‚Ì Ewing/PNET Žîᇂ̂P—áB‘æ18‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2003,2,‹à‘ò.
    7. ”‘òŽõŽqC’†—ÑŒºˆêC•£‘ò—³–çCà_“¹”ü‹IC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚É‚š‚¯‚é’P‹…IL-12ŽY¶”\‚ɂ‚¢‚āB‘æ3‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2003,2,“Œ‹ž.
    8. ‘«—§—zŽqC”‘òŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC”öã—mˆêC‘ºãIŒ[F•xŽRŒ§‚Ì—c’t‰€E•Ûˆç‰€‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–Žw“±‚ÌŽÀ‘ԁB‘æ3‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2003,2,“Œ‹ž.
    9. Itazawa T., Adachi Y., Adachi YS., Yamamoto J., Hamamichi M., Murakami G., and Miyawaki T.: Virus infection reduces theophylline metabolism in acute asthma: Increased lymphoid MxA protein as a marker for viral infection. 60th annivers-ary meeting of American academy of allergy, asthma and Immunology,2003,3,Denver,USA.
    10. ”ÂàVŽõŽqCà_“¹”ü‹ICŽíŽsq’ˆCŽRŒ³ƒŽqC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jC‘ºãIŒ[Fšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠŽõ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚ā|B‘æ24‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2003,3,•xŽR.
    11. –쑺ŒbŽqC‘å’ØŒc•ãC‹{@ˆêŽuC‹àŒ“O˜aC‹{˜e—˜’jFHLA1À•sˆê’v‚Ì•êe‚æ‚蓯Žíœ‘ˆÚA‚ðs‚Á‚œŽ¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚Ì‚P—áB‘æ277‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2003,3,‹à‘ò.
    12. “ñ’J@•C”ª–ؐMˆêCÖ“¡@Ž C‹g“cärCà_“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jCˆÉ“¡–õ“TC”šèŠì–FF•xŽRŒ§‚É‚š‚¯‚éæ“V«SŽŸŠ³”À‘——á‚ÌŒŸ“¢B‘æ277‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2003,3,‹à‘ò.
    13. –{‹œ˜a‹vC‹{@ˆêŽuC‰eŽR—²ŽiC“c’‡çHCŒ‘òƒŽqCŽR’J”ü˜aC”ª–ؐMˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚œESESÇŒóŒQ‚Ì‚R—áB‘æ27‰ñ–k—€‚Ä‚ñ‚©‚ñŒ€‹†‰ï,2003,3,‹à‘ò.
    14. Hashimoto I., Barber B.J., Coffman J.E., Li X., and Sahn D.J. : Myocardial strain rate is a superior method for evaluation of left ventri-cular subendocardial function compared to TDI. The 52nd annual scientific session of American college of cardiology,2003,4,Chicago.
    15. Hashimoto I., Hejmadi A., Li X., Barber B.J., Jones M., and D. J. Sahn.: Quantitative assess-ment of regional peak myocardial acceleration during Isovolumic contraction and relaxation time by tissue doppler imaging. The 52nd annual scientific session of American college of cardiology,2003,4,Chicago.
    16. Kanegane H., and Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndro-mes of genetic origin. The international sympo-sium on infection and immunity in childhood,2003,4,Fukuoka.
    17. –{‹œ˜a‹vC‹{@ˆêŽuC“c’‡çHCŒ‘òƒŽqC‰eŽR—²ŽiCŽR’J”ü˜aC”ª–ؐMˆêC‹{˜e—˜’jFƒsƒŠƒhƒLƒVƒ“ˆË‘¶«áz¹‚Ì”]”gŠŒ©B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    18. ”ÂàVŽõŽqCà_“¹”ü‹ICŽíŽsq’ˆC‘«—§—zŽqC‘«—§—YˆêC‹{˜e—˜’jCŽRŒ³ƒŽqC‘ºãIŒ[Fšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠŽõ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚ā|B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    19. “n•Óˆ»‰ÀC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFSŠïŒ`‚ð‡•¹‚µ‚œS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    20. •l“¹—T“ñC‹Ž–{ˆè•vC–ìŒû@‹žC“n•Óˆ»‰ÀC“n•Óˆê—mCL–ìŒbˆêCãšŒhˆê˜YCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFƒtƒ@ƒ[Žl’¥ÇpŒã‰“ŠuŠú‚É‚š‚¯‚é”x“®–¬•Ù‹t—¬’è—ʉ»‚ÌŽŽ‚݁B‘æ106‰ñ“ú–{¬Ž™‰ÈŠw‰ï‘‰ï,2003,4,•Ÿ‰ª.
    21. ‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jCD. J SahnF‘gDƒhƒbƒvƒ‰[‰Á‘¬“x‰ðÍ‚ð—p‚¢‚œ¶ŽºS‹@”\‚̉ðÍB‘æ14‰ñ“ú–{SƒGƒR[}Šw‰ïŠwpW‰ï,2003,4,_ŒË.
    22. ‹{@ˆêŽuC‘å’ØŒc•ãC•£‘ò—³–çCFè@Œ’C‰eŽR—²ŽiC“c’‡çHC–{‹œ˜a‹vC”ª–ؐMˆêC‹{˜e—˜’jF”]‰ŠŒã‚Ì‘J‰„«ˆÓŽ¯áŠQ‚ɑ΂µ‚ÄTRH—Ö@‚ªŒø‰Ê‚ð”F‚ß‚œˆê—áB‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    23. ‰eŽR—²ŽiC‹{@ˆêŽuC“c’‡çHCŒ‘òƒŽqC–{‹œ˜a‹vCŽR’J”ü˜aC”ª–ؐMˆêC‹{˜e—˜’jFHHV-6”]‰Š‚̗Տ°Šw“I“Á’¥‚ÉŠÖ‚·‚錟“¢B‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    24. –{‹œ˜a‹vC‹{@ˆêŽuC“c’‡çHCŒ‘òƒŽqC‰eŽR—²ŽiCŽR’J”ü˜aC”ª–ؐMˆêC‹{˜e—˜’jF–ƉuƒOƒƒuƒŠƒ“—Ö@‚ª‘tŒ÷‚µ‚œ”]‰ŠŒã‚Ä‚ñ‚©‚ñ‚̈ê—áB‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    25. “c’‡çHC‹{@ˆêŽuC‰eŽR—²ŽiCŒIŒŽ^‹IŽqCŒ‘òƒŽqC–{‹œ˜a‹vCŽR’J”ü˜aC”ª–ؐMˆêCŒˆäŽOŽ}C¬Œ@“OC‹{˜e—˜’jF“û—cŽ™Šú‚©‚çŽvtŠú‚É‚š‚¯‚錒í”­’B”]‚Ì‚l‚q‚h‚É‚æ‚錟“¢B‘æ45‰ñ“ú–{¬Ž™_ŒoŠw‰ï‘‰ï,2003,5,•Ÿ‰ª.
    26. ’†“c@–FC–L“c‰ë•FC”‹Ž³ºC‘«—§—YˆêF“«‰~Œ`’E–яǂ̎o–…—áD‘æ27‰ñ“ú–{¬Ž™”畆‰ÈŠw‰ï,2003,6,“Œ‹ž.
    27. ŽRŒ³ƒŽqCà_“¹”ü‹IC‘«—§—zŽqC‘«—§—YˆêC‘ºãIŒ[C‹{˜e—˜’jF—cŽ™‚É‚š‚¯‚éƒhƒ‰ƒCƒpƒEƒ_[‹z“ü”\—Í‚ÌŒŸ“¢|‹z“ü—¬‘¬‚Ì‘ª’è‚ð—p‚¢‚ā|B‘æ20‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ïC2003,6,’Ã.
    28. ‘«—§—zŽqC”ÂàVŽõŽqC‘«—§—YˆêC‹{˜e—˜’jC”öã—mˆêC‘ºãIŒ[F—cŽ™‚É‚š‚¯‚é‹z“ü—¬‘¬‚Ì‘ª’è|ƒhƒ‰ƒCƒpƒEƒ_[‚Ì‹z“ü‰Â”\”N—î‚ÌŒŸ“¢|B‘æ15‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2003,5,‰¡•l.
    29. ŽRŒ³ƒŽqC’ÔŠáÁˆêC‘ºãIŒ[C–{ŠÔˆê³CFè@Œ’C‘«—§—YˆêFƒCƒl‰È‰Ô•²šb‘§‚ª‹^‚í‚ê‚œ‚P—áB‘æ15‰ñ‰Ô•²ÇŒ€‹†‰ï,2003,5,•xŽR.
    30. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‚ª‚ñ‚̈â“`“I”wŒiv‚킪‘‚É‚š‚¯‚é‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚̗Տ°‚ƈâ“`ŽqŒ€‹†‰ðÍB‘æ‚X‰ñ‰Æ‘°«Žîᇌ€‹†‰ï,2003,6,“Œ‹ž.
    31. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̐f’f‚ÆŽ¡—ÁBv‘æ22‰ñŽ ‰êŒŒ‰tŽŸŠ³Œ€‹†‰ï,2003,6,Ž ‰ê.
    32. ‹Ž–{ˆè•vCãšŒhˆê˜YC“n•Óˆ»‰ÀC“n•Óˆê—mCL–ìŒbˆêCŽs“c•™ŽqC‹{˜e—˜’jCD.J. SahnFƒXƒgƒŒƒCƒ“ƒŒ[ƒgƒCƒ[ƒWƒ“ƒO–@‚ð—p‚¢‚œ¶ŽºS“à–Œ‰ºS‹Ø‘w‚Ì‹@”\•]‰¿B‘æ10‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,2003,6,‹à‘ò.
    33. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̐f’f‚ÆŽ¡—Áv‘æ61‰ñ—Տ°¬Ž™Œ€‹†‰ï,2003,7,é‹Ê.
    34. ‹àŒ“O˜aF“Á•Êu‰‰u–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̐f’f‚ÆŽ¡—Áv‘æ64‰ñé‹Ê¬Ž™ŒŒ‰t“¯D‰ï,2003,7,é‹Ê.
    35. ‹Ž–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnF‘ÙŽ™•s®–¬f’f‚É‚š‚¯‚éƒXƒgƒŒƒCƒ“ƒŒ[ƒg–@‚Ì—L—p«B‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    36. —t@”òC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêCãšŒhˆê˜YC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jCFoell D.CRoth J.Fìè•a‹}«Šú‚É‚š‚¯‚錌Ž’†S100A12‚Ì“®‘ԁB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    37. “n•Óˆ»‰ÀC‹Ž–{ˆè•vC“n•Óˆê—mCL–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFŒ’í¬Ž™‚É‚š‚¯‚鍶ŽºS‹Ød—Ê‚Ì‘‰Á‚ª¶Žº“àŒŒ—¬“`”À‘¬“xflow propagation velocity‚É—^‚Š‚é‰e‹¿‚ɂ‚¢‚āB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    38. ‹Ž–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnF‘gDƒhƒvƒ‰‰Á‘¬“x‰ðÍ‚ð—p‚¢‚œ¶ŽºS‹@”\‚̉ðÍB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    39. ‹Ž–{ˆè•vC“n•Óˆê—mC“n•Óˆ»‰ÀCL–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽCD.J. SahnFƒXƒgƒŒƒCƒ“ƒŒ[ƒg–@‚ð—p‚¢‚œ¶ŽºS“à–Œ‰ºS‹Ø‚Ì‹@”\‰ðÍB‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    40. “n•Óˆê—mCŒŽˆä•ü”üC“n•Óˆ»‰ÀCL–ìŒbˆêCãšŒhˆê˜YC•l“¹—T“ñC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC‘哈‹`”ŽFæ“V«SŽŸŠ³‚ɍ‡•¹‚µ‚œdÇRSƒEƒBƒ‹ƒXŠŽõ‚Ì2—á`ƒpƒŠƒrƒYƒ}ƒu‚Ì“K‰žŠg‘å‚ÉŒü‚¯‚ā`B‘æ39‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2003,7,_ŒË.
    41. ˆÉ“¡G˜aC‘«—§—YˆêC‹{˜e—˜’jC‹g“cärC“ñ’J@•FV¶Ž™‘Šú‚æ‚è”­Ç‚µ‚œƒ~ƒ‹ƒNƒAƒŒƒ‹ƒM[‚̈ê—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,Œ–{.
    42. âV“¡˜a—RC‹g“cärCóˆä³ŽkC’ÔŠáÁˆêC”öã—mˆêC‘«—§—YˆêC‹{˜e—˜’jF“–‰È‚ÅŒoŒ±‚µ‚œPlastic Bronchitis‚Ì2—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,Œ–{.
    43. –{ŠÔ@mC‘«—§—zŽqC“¡–Ø–õŽqC“n•Óˆ»‰ÀC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YF“–‰È‚ÅŒoŒ±‚µ‚œMalignant rhabdoid tumor of the kidney(MRTK)‚Ì2—áB‘æ39‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2003,8,Œ–{.
    44. ‹àŒ“O˜aCˆÉ“¡”\ŽC‘哇FˆêC–쑺ŒbŽqC‹{˜e—˜’jF‚킪‘‚Ì‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚É‚š‚¯‚é—Տ°•a—Šw“I“Á’¥B‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï,2003,8,‘åã.
    45. –쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jFŒ‹ß«g”Á‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œŽá”N«–«œ‘«”’ŒŒ•a‚Ì‚Q—áB‘æ65‰ñ“ú–{ŒŒ‰tŠw‰ï‘‰ï,2003,8,‘åã.
    46. ŽRŒ³ƒŽqC’ÔŠáÁˆêC‘ºãIŒ[C–{ŠÔˆê³CFè@Œ’C‘«—§—YˆêFƒCƒl‰È‰Ô•²šb‘§‚Ì‚P—áB‘æ‚U‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2003,9,•xŽR.
    47. ˆÉŒ\“ñ˜YC“ŒŽROKC“¡–Ø–õŽqC‰eŽR—²ŽiCrˆä”ü˜aŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YCŒ‘q—TŠìF“§Í‚ð•K—v‚Æ‚µ‚œ•ÐtŒŽ”­‚ÌWilmsŽîᇂ̈ê—á,‘æ19‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2003,9,‹à‘ò.
    48. ˆÉŒ\“ñ˜YC“ŒŽROKC“¡–Ø–õŽqC‰eŽR—²ŽiCrˆä”ü˜aŽqC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YCŒ‘q—TŠìF“§Í‚ð•K—v‚Æ‚µ‚œ•ÐtŒŽ”­‚ÌWilmsŽîᇂ̈ê—áB‘æ33‰ñ•xŽRŒ§tŽŸŠ³ElH“§ÍŒ€‹†‰ï,2003,9,•xŽR.
    49. ˆÉ“¡G˜aCâV“¡˜a—RC”ÂàVŽõŽqC–쑺ŒbŽqC‹àŒ“O˜aC–{‹œ˜a‹vC‹{˜e—˜’jF‰Eã‰ºŽˆ‚Ì•sˆÓ‰^“®‚ÆŽvtŠú‘”­Ç‚ðŒ_‹@‚ɐf’f‚³‚ê‚œ‚g‚b‚fŽY¶”]ŽîᇂÌ1—áB‘æ27‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,2003,9,‹à‘ò.
    50. ‘«—§—zŽqC”ÂàVŽõŽqC‘«—§—YˆêCŽRŒ³ƒŽqC”öã—mˆêC‘ºãIŒ[C‹{˜e—˜’jFH•šƒAƒŒƒ‹ƒM[Ž™‚̐H•š§ŒÀ‚ɂ‚¢‚Ă̈ãŽt‚̑Ήž‚ÉŠÖ‚·‚éƒAƒ“ƒP[ƒg’²žŒ‹‰ÊB‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    51. ”ÂàVŽõŽqC‘«—§—zŽqC’†—ÑŒºˆêC•£‘ò—³–çCà_“¹”ü‹IC‘«—§—YˆêC‹{˜e—˜’jF¬Ž™šb‘§‚É‚š‚¯‚éƒtƒ‹ƒ`ƒJƒ]ƒ“‚Ì—LŒø«|ƒxƒNƒƒƒTƒ]ƒ“‚©‚ç‚̈ڍs—á‚É‚š‚¯‚éŒo‰ß|B‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    52. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêFDSCG‹z“ü—Ö@‚â‹z“üƒXƒeƒƒCƒh—Ö@‚Íšb‘§Ž™‚̃Cƒ“ƒtƒ‹ƒGƒ“ƒUœëŠ³—Š‚ɉe‹¿‚ð‹y‚Ú‚·‚©B‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    53. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚̃qƒXƒ^ƒ~ƒ“‹z“ü臒l‚Ə”ˆöŽq‚Æ‚ÌŠÖ˜A‚ɂ‚¢‚āB‘æ53‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    54. –{ŠÔ@mC‘«—§—zŽqCà_“¹”ü‹IC’†—ÑŒºˆêC•£‘ò—³–çC“yŠò‘P‹IC‘«—§—YˆêC‹{˜e—˜’jFdÇšb‘§”­ì‚É”^‹¹‚𕹔­‚µ‚œ‚P’jŽ™—áB‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    55. ŒÜ\—’—²•vCŒ–쐳’mCˆÉ“Œ“¹•vC‘ºãIŒ[C‘«—§—YˆêC‘«—§—zŽqC”öã—mˆêF‹CŠÇŽxšb‘§Š³ŽÒ‚Ì•@”S–Œ×–Ef‚Í‹C“¹‰ŠÇ‚ÌŽw•W‚Æ‚È‚è‚€‚é‚©B‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    56. ”ÂàVŽõŽqC‘«—§—YˆêCˆÉ“Œ“¹•vCŒ–쐳’mCŽRŒ³ƒŽqC‘ºãIŒ[CŒÜ\—’—²•vC‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éDSCG + procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB‘æ40‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2003,10,Šò•Œ.
    57. ‹àŒ“O˜aFŽw’艉‘èuNonanÇŒóŒQ‚ÆŽá”N«œ‘’P‹…«”’ŒŒ•aBv‘æ26‰ñ“ú–{¬Ž™ˆâ“`Šw‰ïŒ“‘æ‚R‰ñ—Տ°ˆâ“`Œ€‹†‰ï,2003,10,’·è.
    58. –Œ‘q—¢DC‘卂TŒáC“y”ì‹`˜YC‘哈‹`”ŽCŽOè‘ñ˜YCÄ“¡˜a—RC²X–ׁؑC‹g“cärC“ñ’J@•C‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jFTwo ventricular repair‚ðŽ{s‚µ‚œ¶S’áŒ`¬ÇŒóŒQ(COA, SAS, MS, ASD)‚̈ê—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï,2003,10,•xŽR.
    59. “n•Óˆê—mC“n•Óˆ»‰ÀC‘å’ØŒc•ãCœA–ìŒbˆêCãšŒhˆê˜YC“ñ’J@•C‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“y”ì‹`˜YC“‡’ÐeŽuC‘哈‹`”ŽCŽOè‘ñ˜YF“ûŽ™‘Šú‚ÉŒJ‚è•Ô‚µŒa”ç“I‘å“®–¬•ÙŒ`¬p‚ðŽ{s‚µ‚œ‘å“®–¬‹|—£’f‚Ì1—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï,2003,10,•xŽR.
    60. “n•Óˆ»‰ÀCŒŽˆä•ü”üC“n•Óˆê—mCœA–ìŒbˆêCãšŒhˆê˜YC‹Ž–{ˆè•vCŽs“c•™ŽqC‹{˜e—˜’jC“y”ì‹`˜YC“‡’ÐeŽuC‘哈‹`”ŽCŽOè‘ñ˜YC•x“c‰pF—Œ‘€”x“®–¬‹·ó‚ɑ΂µƒXƒeƒ“ƒg—¯’u‚ðŽ{s‚µ‚œ‘“®–¬Š²ˆâŽc‚Ì1—áB‘æ3‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï,2003,10,•xŽR.
    61. ‹àŒ“O˜aC–쑺ŒbŽqC˜`@˜a”üC•l–{˜aŽqC“¿ŽR”üC¬’r˜arC‹{‘º”\ŽqC‰Í@Œh¢C‰ª–{”ü•äC•Ÿ“‡@ŒhC‹{˜e—˜’jFX˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚̐f’f‚Æ‘¢ŒŒŠ²×–EˆÚAB‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    62. –쑺ŒbŽqC”\“o‹M‹vC‹àŒ“O˜aC‹{˜e—˜’jFSƒ^ƒ“ƒ|ƒi[ƒf‚Å”­Ç‚µ‚œˆ««ƒŠƒ“ƒpŽî‚̈ê—áB‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    63. ŽíŽsq’ˆC‹àŒ“O˜aC–쑺ŒbŽqC²“¡—Y–çC¬“‡š“ñC‰Íè—T‰pC–x@_Ž÷C‰Í“‡®ŽuC’rìŽu˜YC‹{˜e—˜’jF‚킪‘‚Ì Shwachman-Diamond ÇŒóŒQ‚É‚š‚¯‚é—Տ°“IEˆâ“`Šw“IŒŸ“¢B‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    64. ‘å’ØŒc•ãC‹g“cärC–쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jF¶‘̊̈ڐAŒã‚É”­Ç‚µ‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚̈ê—á‘æ45‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2003,10,‹à‘ò.
    65. Ichida F., Foell D., Vogl T., Ye F., Hirono K., Watanabe S., Watanabe K., Uese K., Miyawaki T., and Roth J.: S100A12 (EN-RAGE): A novel serum marker in the monitering of Kawasaki disease. The 76th scientific sessions of American heart association, 2003,11,Orlando.
    66. Hashimoto I., and Ashraf M.: Tissue Doppler derived myocardial acceleration for evaluation of left ventricular diastolic function. The 76th scientific sessions of American heart association,2003,11,Orlando.
    67. Hashimoto I., Coffman J.E., Davis. C.H.: Does color M-mode derived flow propagation velocity reflect actual flow propagation? The 76th scientific sessions of American heart association, 2003,11,Orlando.
    68. ŽíŽsq’ˆA‹àŒ“O˜aA‰€@‰xA“ñ’J@•A‹{˜e—˜’jFX˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚̗Տ°f’f‚ÉŠÖ‚·‚錟“¢B‘æ35‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2003,11,•xŽR.
    69. Š¥–Ø’q”VC‰Í‡—˜®C‹à@Œc²Cé@G•ãC‹àŒ“O˜aC‘åÎ@•×FBCGÚŽíŒã‚Ìãü‰ºƒŠƒ“ƒpßŽî‘å‚ðŒ_‹@‚ɏíõF‘Ì—ò«Œ^–«“÷‰èŽîÇ‚Ɛf’f‚³‚ê‚œ‚Q—áB‘æ35‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2003,11,•xŽR.
    70. ”ÂàVŽõŽqC‘«—§—YˆêC”öã—mˆêCŽRŒ³ƒŽqC‘ºãIŒ[C‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‚É‚š‚¯‚éDSCG+procaterol‚ÆDSCG’P“Æ‚Ì’èŠú‹z“ü—Ö@‚Ì’·ŠúŒø‰ÊB‘æ30‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2003,12,‹à‘ò.
    71. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹CŠÇŽxšb‘§‚ÌŠO—ˆŠÇ—v‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2003,11,“¿“‡.
    72. ’†—ÑŒºˆêC‰eŽR—²ŽiC–쑺ŒbŽqC‘«—§—YˆêC‹{˜e—˜’jFŠÔŽ¿«”x‰Š‚ð‡•¹‚µ‚œ”畆‹Ø‰Š‚ƍl‚Š‚ç‚ê‚éˆê—Ž™—áB‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2003,11,“¿“‡.
    73. å@‹v”TC”‘òŽõŽqC–{ŠÔ@mCŒŽˆä•ü”üC“n•Óˆ»‰ÀC“yŠò‘P‹IC‘«—§—YˆêC‹{˜e—˜’jF1”NŠÔ‚ÅŒoŒ±‚µ‚œ”x‰»”^Ç‚Ì3—áB‘æ36 ‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2003,11,“¿“‡.
    74. Wang Y., Kanegane H., Futatani T., Tsukada S., and Miyawaki T.: Nation-wide survey of X-linked agammaglobulinemia by flow cytometric and mutational analysis. ‘æ33‰ñ“ú–{–ƉuŠw‰ï‘‰ï,2003,12,•Ÿ‰ª.
    75. ŽíŽsq’ˆC‹àŒ“O˜aC‹{˜e—˜’jF‰ä‚ª‘‚ÌSchwachman-Diamond ÇŒóŒQ‚̗Տ°“IEˆâ“`“IŒ€‹†B‘æ11‰ñH×–E‹@”\ˆÙíŒ€‹†‰ï,2003,12,“Œ‹ž.
    76. ˆÉ“¡G˜aC”ÂàVŽõŽqC–쑺ŒbŽqC‹àŒ“O˜aC–{‹œ˜a‹vC‹{˜e—˜’jF‰Eã‰ºŽˆ‚Ì•sˆÓ‰^“®CŽvtŠú‘”­Ç‚Å”­Ç‚µ‚œ¶Šî’êŠjgerminoma‚̈ê—áB‘æ279‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2003,12,•xŽR.

    2002”N

  • ’˜‘
    1. Kanegane H., Futatani T., Nomura K., and Miyawaki T.FGenetic analysis of X-linked agammaglobulinaemia identified by flow cytometric analysis in unrelated 65 Japanese families. uLeucocyte typing VIIvMason D. ed.,129-131, Oxford university press,New York,2002.
    2. Nomura K., Kanegane H., Karasuyama H., and Miyawaki T.: Genetic defect in human X-linked agammaglobulinaemia impedes the maturational evolution of pro-B cells into later stage of pre-B cells in the B-cell differentiation pathway. uLeucocyte typing VIIvMason D. ed.,129-131, Oxford university press,New York,2002.
    3. ‹{˜e—˜’jA‹àŒ“O˜aFæ“V«–Ɖu•s‘SÇ‚̈â“`ŽqˆÙíBu–ƉuŽŸŠ³-state of arts Ver.2v¡Œ“ñ˜Y‘Œ•ÒA477-482AˆãŽ•–òo”ŁA“Œ‹žA2002.
    4. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQB¬Ž™“à‰È‘Š§u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA330-334A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
    5. Žs“c•™ŽqFS‹ØÇBu¬Ž™‚ÌŽ¡—ÃŽwjvŒ”öé•‘Œ•ÒA281-283Af’f‚ÆŽ¡—ÎЁA“Œ‹žA2002.
    6. Žs“c•™ŽqFŒÇ—§«S‹Øãk–§‰»áŠQBu¡“ú‚̏¬Ž™Ž¡—ÃŽwjv‘æ13”Å‘åŠÖ••F‘Œ•ÒAˆãŠw‘‰@A“Œ‹žA2002.
    7. Žs“c•™ŽqF¬Ž™‚Ì•s®–¬Bu¡“ú‚ÌŽ¡—ÃŽwj@2003”N”ŁvŽRŒû“O‘Œ•ÒA903-904AˆãŠw‘‰@A“Œ‹žA2002.
    8. ‹àŒ“O˜aA‹{˜e—˜’jFR‘ÌŽY¶•s‘S‚ðŽå‚Æ‚·‚é–Ɖu•s‘SÇBu¬Ž™‰ÈŠw‘æ‚Q”ŁvˆÉ“¡ŽŒÈ‘Œ•ÒA@717-721AˆãŠw‘‰@A“Œ‹žA2002.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFBTKˆÙí‚𔺂í‚È‚¢B×–EŒ‡‘¹Œ^–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB¬Ž™“à‰È‘Š§u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA1126-1130A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
    10. ‹àŒ“O˜aFŽ©ŒÈ–Ɖu«ƒŠƒ“ƒp‘BÇŒóŒQB¬Ž™“à‰È‘Š§u¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—‚Pv¬Ž™“à‰ÈE¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï•ÒA1195-1199A“Œ‹žˆãŠwŽÐA“Œ‹žA2002.
  • ŒŽ’˜
    1. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Shimizu M., Seto H., and Miyawaki T., Low-dose dobutamine stress radionuclide ventriculography reveals silent myocardial dysfunction in Kawasaki disease. Jpn Circ J 66:63-69,2002.
    2. Hashimoto I., Mori Y., Rusk RA., Davies CH., Li X., Mack GK., and Sahn DJ.: Strain rate imaging: an in vitro "Validation" study using a physiologic balloon model mimicking the left ventricle. Echocardiography. 8:669-77,2002.
    3. Yoshida T., Kanegane H., Osato M., Yanagida M., Miyawaki T., Ito Y., and Shigesada K.: Functional analysis of RUNX2 mutations in Japanese patients with cleidocranial dysplasia demonstrates novel genotype-phenotype correlations. Am. J. Hum. Genet. 71: 724-738,2002.
    4. Shinozaki K., Kanegane H., Matsukura H., Sumazaki R., Tsuchida M., Makita M., Kimoto Y., Kanai R., Tsumura K., Kondoh T., Moriuchi H., and Miyawaki T.: Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 14: 1215-1223,2002.
    5. Wang Y., Kanegane H., Sanal O., Tezcan I., Ersoy F., Futatani T., and Miyawaki T.: Novel Igƒ¿(CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia. Am J Med Genet 108: 333-336,2002.
    6. Chen R., Tsuji T., Ichida F., Bowles KR., Watanabe S., Hirono K., Tsubata S., Hamamichi Y., Bowels NE., Miyawaki T., and Towbin JA.: Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. Mol Genet Metab 77: 319-325,2002.
    7. Tani S. M., Wang Y., Kanegane H., Futatani T., Pinto J., Viela M. M.S., and Miyawaki T.: Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammagulobulinemia. Hum Mutat 531 : 195-205,2002.
    8. Otto F., Kanegane H., and Mundlos S.: Mutations in the RUNX2 gene in patients with cleidocranial dysplasia. Hum Mutat 19: 209-216,2002.
    9. Kawai S., Minegishi M., Ohashi Y., Sasahara Y., Kumaki S., Konno T., Miki H., Derry J., Nonoyama S., Miyawaki T., Horibe K., Tachibana N., Kudoh E., Yoshimura Y., Izumikawa Y., Sako M., and Tsuchiya S.: Flow cytometric determination of intracyto-plasmic Wiskott-Aldrich syndrome protein in peripheral blood lymphocyte subpopulations. J Immunol Method 260: 195-205,2002.
    10. Inaba K., Miyawaki T., Longnecker R., Matsukura H., Tsukada S., and Kurosaki T.: Bruton's tyrosine kinase regulates B cell antigen receptor-mediated JNK1 response through Rac1 and phospholipase C-ƒÁ2 activation. FEBS Lett 13 : 260-262,2002.
    11. Morikawa K., Morikawa S., Nakamura M., and Miyawaki T.: Characterization of granulocyte colony-stimulating factor receptor expressed on human lymphocytes. Brit J Haematol 118 : 296-304,2002.
    12. Agematsu K., Futatani T., Hokibara S., Kobayashi N., Takamoto M., Tsukada S., Suzuki H., Koyasu S., Miyawaki T., Sugane K., Komiyama A., and Ochs HD.: Absence of memory B cells in patients with common variable immunodeficiency. Clin Immunol. 103: 34-42,2002.
    13. Li J., Li X., Mori Y., Rusk RA., Lee JS., Davies CH., Hashimoto I., El-Sedfy GO., Li XN., and Sahn DJ.: Quantification of flow volume with a new digital three-dimensional color Doppler flow approach: an in vitro study. J Ultrasound Med. 12:1303-11,2001.
    14. Li X., Wanitkun S., Li XN., Hashimoto I., Mori Y., Rusk RA., Hicks SE., and Sahn DJ.: Quantification of instantaneous flow rate and dynamically changing effective orifice area using a geometry independent three-dimensional digital color Doppler method: An in vitro study mimicking mitral regurgitation. J Am Soc Echocardiogr. 10:1189-96,2002.
    15. Rein AJ., O'Donnell C., Geva T., Nir A., Perles Z., Hashimoto I., Li XK., and Sahn DJ.: Use of tissue velocity imaging in the diagnosis of fetal cardiac arrhythmias. Circulation.14:1827-33,2002.
    16. ‹àŒ“O˜aF¬Ž™–«ŽŸŠ³‚Ì’·ŠúŒo‰ß‚ƃPƒAF¬ˆçˆã—Â̎‹“_‚©‚çB–ƉuŽŸŠ³B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@106F1589-1593,2002.
    17. ‹àŒ“O˜aFX-linked lymphoproliferative syndrome. “ú–{—Տ°–ƉuŠw‰ï‰ïŽ 25F129-134,2002.
    18. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF‚w˜Aœ–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éƒÁ-ƒOƒƒuƒŠƒ“’uŠ·—Ö@B“ú–{—Տ°–ƉuŠw‰ï‰ïŽ 25F337-343,2002.
    19. ‹àŒ“O˜aA–쑺ŒbŽqAŠ}ŒŽ‘PmA‰ª‘º@ƒA–{‹œ‹P–ŸA–î•”‚Ý‚Í‚éA¬“‡š“ñA‹S“ª•qKA‹{˜e—˜’jFDyskeratosis congenita‚É‚š‚¯‚éDKC1ˆâ“`Žq‰ðÍB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽGŽ@16F78-83,2002.
    20. ‹g“cärA‹àŒ“O˜aAŽª“c–F’jAˆÉ“¡‘P–çA‰iˆä•q˜YA–î–ìŒöˆêA“c’†—tŽqAŒŠª@Ž AŽRì”ŽŽqAŽ›–{’mŽjA‹ÊˆäLÆA•Sˆä@‹œA‘å‹Ž”Ž•¶AŒ@”ü˜aAâV“¡–œ—¢ŽqA‹{˜e—˜’jF‚킪‘‚É‚š‚¯‚鍜œ“ªŠWˆÙŒ`¬Ç‚̗Տ°“IEˆâ“`Šw“IŒŸ“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@105F442-447,2001. i2002”N“xƒtƒFƒ[ƒVƒbƒvƒAƒ[ƒhŽóÜj
  • Ç—á•ñ
    1. Matsukura H., Shinozaki K., Kageyama R., Yagi S., and Miyawaki T.: Acute poststreptococcal glomerulonephritis in a child Bardet-Biedl syndrome. Pediatr Nephrol 17: 70,2002.
    2. Kageyama R., Matsuzawa J., Hongo K., Yamatani M., Yagai S., Miyawaki T., and Konishi T.: Rashes, agranulocytosis, and hypogamma-globulinemia after carbamazepine therapy. Epilepsia 43 67,2002.
    3. Hirata D., Nara H., Inaba T., Muroi R., Kanegane H., Miyawaki T., Okazaki H., and Minota S.: von Recklinghausen disease in a patients with X-linked agammaglobulinemia. Internal Med. 41: 1039-1043,2002.
    4. Katamura K., Hattori H., Kunishima T., Kanegane H., Miyawaki T., and Nakahata T.: Non-progressive viral myelitis in X-linked agammaglobulinemia. Brain Dev-JPN 24 : 109-111,2002.
    5. –î–ìŒöˆêA‹g“cärA‹àŒ“O˜aA‰ª–{”N’jA‘哇”ü•ÛA²X–؏²A™–{¹–çA•Ð–ìr‰pA‘ë–{¹rFCore binding factor ƒ¿1 (CBFA1) ˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚œœœ“ªŠWˆÙŒ`¬Ç (Cleidocranial dysplasia) ‚Ì•êŽq—áBƒzƒ‹ƒ‚ƒ“‚ƗՏ° 49F145-148,2001.
  • ‘à
    1. Kanegane H., Nomura K., Miyawaki T., and Tosato G.: Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit Rev Oncol Hematol. 44: 239-249,2002.
    2. ‹{˜e—˜’jFautoimmune-lymphoproliferativeÇŒóŒQ(ALPS)Bu¬Ž™‚̏njóŒQv¬Ž™‰Èf—Ã(‘)64F319,2001.
    3. Žs“c•™ŽqFŒÇ—§«S‹ØS‹Øãk–§‰»áŠQBS‘Ÿ@34: 139-141, 2002.
    4. Žs“c•™ŽqFæ“V«SŽŸŠ³‚̐f’f‚ÆŽ¡—Á`‘ÙŽ™f’f‚©‚çV¶Ž™‘ŠúŽ¡—ÂɌü‚¯‚ā`@“ú–{ŽY•wl‰ÈŠw‰ï•xŽR’n•û•”‰ïŽGŽA70-74,2002.
    5. ‹àŒ“O˜aFŽ©ŒÈ–Ɖu‚ƃAƒ|ƒg[ƒVƒXB¬Ž™“à‰È34F1795-1798,2002.
    6. ”ÂàVŽõŽqA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚ƃEƒCƒ‹ƒXŠŽõÇ‚ÌŠÖŒWBƒAƒŒƒ‹ƒM[‰È@13F322-328,2002.

  • 2002”NŠw‰ï•ñ
    1. à_“¹—T“ñAãšŒhˆê˜YAL–ìŒbˆêA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’j, “ñ’J@•A“ŒŽROKA”ª–ؐMˆêA²X–ׁؑA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFƒRƒCƒ‹Çðp‚ðŽ{s‚µ‚œScimitarÇŒóŒQ‚̐V¶Ž™—áB‘æ13‰ñ“ú–{Pediatric Interventional Cardiology Œ€‹†‰ï,2002,1,“¿“‡.
    2. ‘«—§—YˆêF‘åŠwŒ€‹†ŽºƒŒƒ|[ƒguƒAƒŒƒ‹ƒM[ŽŸŠ³‚É‚š‚¯‚éTh1/Th2ƒoƒ‰ƒ“ƒXvD‘æ12‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒXšb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2002,2,VŠƒ.
    3. ˆÉ“¡–õ“TA’†—ÑŒºˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA‰ª•””üŒbFŒŒ‰tæÐHÇŒóŒQ‚ð‡•¹‚µ‚œanaplastic large cell lymphoma ‚̈ê—áB‘æ‚U‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,2002,2,‹à‘ò.
    4. ‹Ž–{ˆè•vAL–ìŒbˆêAãšŒhˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFColor M-mode Doppler Echo‚ð—p‚¢‚œ”xŒŒ—¬‚Ì•]‰¿B‘æ8‰ñ¬Ž™”xzŠÂŒ€‹†‰ï,2002,2,“Œ‹ž.
    5. ‹Ž–{ˆè•vAL–ìŒbˆêAãšŒhˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jADavid J SahnF‘ÙŽ™•s®–¬f’f‚É‚š‚¯‚éTissue Doppler Echo–@‚Ì—L—p«‚ɂ‚¢‚āB‘æ8‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹†‰ï,2002,2,H“c.
    6. ãšŒhˆê˜YAL–ìŒbˆêAà_“¹—T“ñA“n•Óˆ»‰ÀA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YA¬—яrŽ÷Fƒtƒ@ƒ[Žl’¥ÇªŽ¡pŒã‚̍¶”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ăXƒeƒ“ƒg—¯’u‚ðs‚¢ApŒã7”N–ڂɃXƒeƒ“ƒgÄŠg’£‚ðs‚Á‚œ1—áB‘æ23‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,2002,2,‹à‘ò.
    7. L–ìŒbˆêAãšŒhˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YAÄ“¡„ŽA‹v•Û@ŽÀAŠÖ@‰ë”ŽFJatenepŒã10”N–ڂɍ¶”x“®–¬•ªŠò•”‹·ó‚ɑ΂µ‚ÄŒo”ç“I”x“®–¬Œ`¬p‚ðs‚Á‚œŠ®‘S‘匌ŠÇ“]ˆÊÇ‚Ì1—áB‘æ23‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,2002,2,‹à‘ò.
    8. Hashimoto I., Julia C. Swanson-Birchill, Ichida F., Miyawaki T., Crispin H. Davies, David J. Sahn. : The relationship between strain rate values in orthogonal directions. 51th American college of cardiology,2002,3, Anaheim, USA.
    9. ItazawaT., Adachi Y., Onoue Y., Okabe Y., Hamamichi M., Adachi YS., and Miyawaki T.: Developmental change in IL-12 production by monocytes. 58th Annual Meeting of American Academy of Allergy, Asthma and Immunology,2002,3,New York, USA.
    10. Hongou K., Tanaka C., Matsuzawa J., Yamatani M., Yaga S., and Miyawaki T.: Various encephalopathies due to human Herpesvirus-6 infectioni‚Scase reportsj. 5Th Annual Meeting of the Infantile Seizure Society,2002,3,Tokyo.
    11. ‘«—§—zŽqA’†—ÑŒºˆêA•£àV—³–çA”ÂàVŽõŽqA‰¡“cF”VA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F—c’t‰€E•Ûˆç‰€‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–§ŒÀ‚ÌŽÀ‘ԁ`•xŽRŒ§‚Å‚Ì’²žŒ‹‰ÊB‘æ14‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2002,3,ç—t.
    12. ”ÂàVŽõŽqA•l“¹”ü‹IA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[ŽŸŠ³Š³ŽÒ––œŒŒ’P‹…‚ÌIL-12ŽY¶”\`”N—î‚É‚æ‚鍷ˆÙ‚ɂ‚¢‚āB‘æ14‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2002,3,ç—t.
    13. –{‹œ˜a‹vA“c’‡çHAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF‘œÊ‚È”­ìÇó‚ð”F‚ß‚œ‘O“ª—t‚Ä‚ñ‚©‚ñ‚Ì‚P—áB‘æ26‰ñ–k—€‚Ä‚ñ‚©‚ñŒ€‹†‰ï,2002,3,‹à‘ò.
    14. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™–«ŽŸŠ³‚Ì’·ŠúŒo‰ß‚ƃPƒAF¬ˆçˆã—Â̎‹“_‚©‚çv–ƉuŽŸŠ³B‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–ŒŒÃ‰®.
    15. Hashimoto I., Hirono K., Watanabe S., Hamamichi Y., Uese K., Ichida F., and Miyawaki T.: Color M-mode propagation velocity of transmitral flow is useful for the assessment of left ventricular diastolic function in children with cardiomyopathy. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    16. Watanabe S., Ichida F., Hamamichi Y., Rui C., Hirono K., Uese K., Hashimoto I., Miyawaki T., and Jeffrey A. Towbin. : Clinical features of isolated left ventricular noncompaction ~infantile type and juvenile type. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    17. Rui C., Tsuji T., Ichida F., Karla R. Bowles, Watanabe S., Hirono K., Tsubata S., Hamamichi Y., Miyawaki T., and Jeffrey A. Towbin. : Novel gene mutation in isolated left ventricular noncompaction. ‘æ66‰ñ“ú–{zŠÂŠí•aŠw‰ïŠwpW‰ï,2002,4,ŽD–y.
    18. ‰€@‰xA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jFMutation analysis of BTK gene in Brazilian patients with presumed XLA. ‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–ŒŒÃ‰®.
    19. ŒÜ\—’“oA”ž“‡G—YA’@Šî–ŸA—Sì˜aŽqA‹àŒ“O˜aA’J“à]@ºFƒnƒ“ƒ^[•a(MPSII)’†ŠÔŒ^‚É‚š‚¯‚é”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA(UR-BMT)Œã‚Q”NŠÔ‚ÌŒo‰ßB‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–ŒŒÃ‰®.
    20. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA•l“¹”ü‹IA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FV¶Ž™‚É‚š‚¯‚éIL-10AIL-12AIL-18ŽY¶”\‚ÌŒŸ“¢D‘æ105‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2002,4,–ŒŒÃ‰®.
    21. ’†—ÑŒºˆêA‹àŒ“O˜aA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jF‘‰t’†EBƒEƒCƒ‹ƒXDNA‚ð“I‚ÉŒoŽž“I‚ÉŠÏŽ@‚µ‚Š‚œEBƒEƒCƒ‹ƒX‰ŠŽõ‚É‚æ‚é––œ_Œo‰Š‚Ì‚P—áB‘æ12‰ñEBƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï,2002,5,“Œ‹ž.
    22. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u‹CŠÇŽxšb‘§‚É‚š‚¯‚闝Šw—Ö@@¬Ž™‰È‚Ì—§ê‚©‚çvB‘æ19‰ñ“ú–{¬Ž™“šb‘§EƒAƒŒƒ‹ƒM[ŽŸŠ³Šw‰ï,2002,5,‘åãD
    23. ŒIŒŽ^‹IŽqA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”玿Œ`¬ˆÙíÇ‚ɍ‡•¹‚µ‚œ‚Ä‚ñ‚©‚ñ‚̗Տ°“Á’¥‚ɂ‚¢‚āB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2002,6,å‘ä .
    24. •l“¹—T“ñA“n•Óˆ»‰ÀAL–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽF¬Ž™S‘ŸŽèp‚É‚š‚¯‚ép’†ŒoH“¹SƒGƒR[‚ÌŒoŒ±B‘æ9‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,2002,6,‹à‘ò.
    25. ‘«—§—YˆêFTh2ƒ}[ƒJ[‚Æ‚µ‚ẴPƒ‚ƒJƒCƒ“Žó—e‘́B‘æ1‰ñƒPƒ‚ƒJƒCƒ“R‘̗Ö@Œ€‹†‰ï,2002,6,“Œ‹ž.
    26. ”‘òŽõŽqAà_“¹”ü‹IA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F¬Ž™‹CŠÇŽxšb‘§”­ìŽž‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ|MxA’`”’‚ðŽw•W‚Æ‚µ‚ā|D‘æ23‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2002,6,•xŽR.
    27. ŽíŽsq’ˆA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jF“Ë”­«”­]Ç‚ɍ‡•¹‚µ‚œ’vŽ€«”]‰Š‚̈ê—áB‘æ16‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï,2002,6,_ŒË.
    28. ”ª–ؐMˆêAŽíŽsq’ˆA–{‹œ˜a‹vA‹{˜e—˜’jAŽO‰Y@—mF×‹Û«‘–Œ‰Š‚É‚š‚¯‚éd–Œ‰º•a•Ï‚ÌŽ¡—Õûj‚ɂ‚¢‚āB‘æ16‰ñ“ú–{¬Ž™‹~‹}ˆãŠw‰ï,2002,6,_ŒË.
    29. –쑺ŒbŽqC‹àŒ“O˜aC‹{˜e—˜’jCœAìTˆê˜YF_Œo‰èŽîƒ}ƒXƒXƒNƒŠ[ƒjƒ“ƒO‚ÉŠÖ‚·‚éˆêlŽ@B‘æ275‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2002,6,•Ÿˆä.
    30. Chen R, Tsuji T., Watanabe S.,Tsubata S., Hamamichi Y., Ota J., and Imai Y. : Novel G4.5 gene mutation in the isolated left ventricular noncompaction. ‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    31. ‹Ž–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêAãšŒhˆê˜YA•l“¹—T“ñA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽFColor M-mode–@‚É‚æ‚鍶Žº“àŒŒ—¬“`”À‘¬“x‚ð—p‚¢‚œ¶ŽºŠg’£”\‚Ì•]‰¿B‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    32. ãšŒhˆê˜YA‹Ž–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêA•l“¹—T“ñA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽFColor M-mode–@‚É‚æ‚é”x“®–¬“àŒŒ—¬“`”À‘¬“x‚ð—p‚¢‚œ”x¬ŒŒŠÇ’ïR‚̐„’èB‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    33. •l“¹—T“ñA‹Ž–{ˆè•vA“n•Óˆ»‰ÀAL–ìŒbˆêAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽA–ìŒû@‹žFƒtƒ@ƒ[Žl’¥ÇpŒã‰“ŠuŠú‚É‚š‚¯‚é”x“®–¬•Ù‹t—¬’è—ʉ»‚ÌŽŽ‚݁B‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    34. œA–ìŒbˆêAChen RuiAãšŒhˆê˜YA•l“¹—T“ñA“n•Óˆ»‰ÀA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAFoell Dirk, Roth JohannesFìè•a‹}«Šú‚É‚š‚¯‚錌Ž’†MRP 8/MRP 14‚Ì“®‘ԁB‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    35. “n•Óˆ»‰ÀA•l“¹—T“ñAœA–ìŒbˆêAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢B`‘æ2•ñ`B‘æ38‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï‘‰ïŠwpW‰ï,2002,7,“Œ‹ž.
    36. ŽRŒ³ƒŽqA’ÔŠáÁˆêA‘ºãIŒ[A–{ŠÔˆê³Aà_“¹”ü‹IA‘«—§—YˆêFŒŒŽKL-6‚ÌŒoŽž“I•Ï‰»‚ð‚Ý‚œ–ƒ]”x‰Š‚̈ê—áB‘æ‚X‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2002,7,‚‰ª.
    37. Kanegane H., Shinozaki K., Matsukura H., and Miyawaki T.: Establishment of monoclonal anti-body against SLAM-associated protein and its clinical application to diagnosis of X-linked lymphoproliferative disease. The 29th World congress of the International society of Hematology,2002,8,Seoul.
    38. Adachi Y., Itazawa T., Adachi YS., Yamamoto J., Murakami G., and Miyawaki T.: Viral infection and asthma exacerbation -Increased lymphoid MxA expression as a marker for viral infection-. 4th APAPARI/9thTPAIS/11thPSCAI Joint Meeting,2002,9,Tokyo.
    39. –{‹œ˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFd•¡áŠQ‚ÌŠÇ—-‹CŠÇØŠJ‚ÌŠÇ—-B‘æ42‰ñ–k—€¬Ž™_Œo,2002,9,‹à‘ò.
    40. –{‹œ˜a‹vA‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFRáz¹Ü‚É‚æ‚è”ñáz¹«”­ìdÏó‘Ô‚ª—U”­‚³‚ê‚œ‚ƍl‚Š‚ç‚ê‚œ3—áB‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò.
    41. ‰eŽR—²ŽiA‹{@ˆêŽuA“c’‡çHAŒ‘òƒŽqA–{‹œ˜a‹v@ŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFAicardi ÇŒóŒQ‚̈ê—áB‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò .
    42. ‹{@ˆêŽuA‰eŽR—²ŽiA“c’‡çHAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFCYP2CƒTƒuƒtƒ@ƒ~ƒŠ[‚̈â“`Žqf’fî•ñ‚ÉŠî‚­ƒtƒFƒjƒgƒCƒ“ŒÂ•Ê“Š—^ÝŒv–@‚Ì•]‰¿B‘æ36‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2002,9,Œyˆä‘ò.
    43. •l“¹—T“ñA“n•Ó ˆ»‰ÀAœA–ìŒbˆêAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éleft ventricular noncompaction‚̗Տ°‘œ‚ÌŒŸ“¢B‘æ50‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï,2002,9,–ŒŒÃ‰®.
    44. •l“¹—T“ñAœA“cŒåŽuAãšŒhˆê˜YAš¢Šp•¶GAŒŽ•õ“ñAŽs“c•™ŽqFLeft ventricular non-compaction‚̉Ƒ°—ái–UŒŸ—ájB‘æ50‰ñ“ú–{S‘Ÿ•aŠw‰ïŠwpW‰ï,2002,9,–ŒŒÃ‰®.
    45. “n•Óˆ»‰ÀAœA–ìŒbˆêAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“»@³‹`A“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFŠwZS‘ŸŒŸf‚Å”­Œ©‚³‚ê‚œBWGÇŒóŒQ‚Ì1—áB‘æ24‰ñ–k—€¬Ž™zŠÂŠíŒ€‹†‰ï,2002,9,‹à‘ò.
    46. ‹àŒ“O˜aA˜eŒû@GA–쑺ŒbŽqA‹{˜e—˜’jF–«Šˆ“®«EBƒEƒCƒ‹ƒXŠŽõÇ—lŽŸŠ³‚É‚š‚¯‚éFas ˆâ“`Žq•ÏˆÙB‘æ64‰ñ“ú–{ŒŒ‰tŠw‰ï,2002,9,‰¡•l.
    47. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFŒo‰ß’†‚É Histiocytic sarcoma ‚ð‡•¹‚µ‚œ T-ALL ‚̈ê’jŽ™—áB‘æ44‰ñ“ú–{—Տ°ŒŒ‰tŠw‰ï,2002,9,‰¡•l.
    48. ‘å’ØŒc•ãA‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆê–؍Ž”VA“yŠò‘P‹IA‚‹Ž”Ž”VA‚–ìN—YFHistiocytosis ‚ð‡•¹‚µ‚œcŠuŒŽ”­ germ cell tumor ‚Ì‚P’jŽ™—áB‘æ17‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2002,9,‹à‘ò.
    49. Amoras. A.L.B , Kanegane H., Miyawaki T., and Vilela M.M.S. : Defective Fc, CR1 and CR3-mediated monocyte phagocytosis and chemataxis in common variable immunodeficiency and X-linked agammaglobulinemia patients. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    50. Tani S.M., Wang Y., Kanegane H., Futatani T., Pinto J.A., Vilela M.M.S. and Miyawaki T.: Identification of mutations in the Bruton's tyrosine kinase gene of Brazilian patients with X-linked agammaglobulinemia. 10th Meeting of Eur Soc forImmunodeficiencies,2002,10,Weimer,Germany.
    51. Kanegane H., Shinozaki K., Matsukura H., and Miyawaki T.: Establishment of a monoclonal antibody against SLAM-associated protein and its clinical application to the diagnosis of X-linked lymphoproliferative disease. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    52. Kanegane H., Vilela., Matsukura H., Wang Y., Taneichi H., Futatani T., and Miyawaki T.: Glomerulonephritis in autoimmune lympho-proliferative syndrome. 10th Meeting of Eur Soc for Immunodeficiencies,2002,10,Weimer,Germany.
    53. Miyawaki T.: Clinical and molecular diagnosis of hereditary agammaglobulinemia. 2002 International Workshop of Pediatric Infection and @Immunity. 2002,10, Chongqing, China.
    54. Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndrome of genetic origins. 2002 International Workshop of Pediatric Infection and Immunity. ,2002,10, Chongqing, China.
    55. Miyawaki T.: Epstein-Barr virus infection and lymphoproliferative syndrome of genetic origins. 2002. National Congress of Pediatric Immunology,2002,10,Haikou, China.
    56. Hashimoto I., Li X., Jones M., Sahn DJ. : Myocardial strain rate is a superior method for evaluation of leftventricular subendocardial function compared to TDI. Cardiac Ultrasound summit,2002,10,Miami,USA.
    57. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u‹C“¹ƒAƒŒƒ‹ƒM[‚ÌŽ¡—ÁEŠ³ŽÒ‹³ˆçEƒp[ƒgƒi[ƒVƒbƒv‚̍\’zv‘æ‚X‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2002,10,“ß”eD
    58. –쑺ŒbŽqA‹àŒ“O˜aA‰Á“¡ƒŽqAˆäŽèŒû@—TA‹{˜e—˜’jFƒfƒXƒtƒFƒ‰[ƒ‹‚Ì–éŠÔŽ‘±”牺’‚ðs‚Á‚Ä‚¢‚éƒÀ-thalassemia‚̃pƒLƒXƒ^ƒ“—Ž™—áB‘æ44‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2002,10,“Œ‹ž.
    59. ‘å’ØŒc•ãA‹{@ˆêŽuAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA’|’J@Œ’A—с@‘׏GA‹{˜e—˜’jFMLL tandem duplication ‚ð”F‚ß‚œŽ¡—Ê֘Aœ‘ˆÙŒ`¬ÇŒóŒQ‚̈ê—áB‘æ44‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2002,10,“Œ‹ž.
    60. IchidaF., Chen R., Tsuji T., Karla R. Bowles, Watanabe S., Tsubata S., Hamamichi Y., Miyawaki T., Neil E Bowles and Jeffrey A. Towbin. : Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. The 75th Scientific Sessions of American Heart Association,2002,11,Chicago.
    61. “n粈»‰ÀA“n•Óˆê—mAà_“¹—S“ñAŽs“c•™ŽqA‹{˜e—˜’jA“¡–Ø–õŽqA“ñ’J@•AŠp’JŽûŽqAŒŽR—æ“ށA“à@®ŽqA•Ä“c@“NA²X–ׁؑAŽðˆä³—˜AâV“¡@Ž A“»@³‹`A“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YF‘ÙŽ™Šú‚æ‚èŒo‰ßŠÏŽ@‚µ‚œ‘“®–¬Š²ˆâŽc‚̈ê—áB‘æ2‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï,2002,11,•xŽR.
    62. ãšŒhˆê˜YAV‹@—²A“n粈»‰ÀA“n•Óˆê—mAà_“¹—S“ñAŽs“c•™ŽqA“à@®ŽqAŒŽR—æ“ށAŽðˆä³—˜AâV“¡@Ž F‘ÙŽ™–[ŽºƒuƒƒbƒN‚Ì1—áB‘æ2‰ñ•xŽR¬Ž™zŠÂŠíŒ€‹†‰ï,2002,11,•xŽR.
    63. ”‘òŽõŽqAà_“¹”ü‹IA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jAŽRŒ³ƒŽqA‘ºãIŒ[F“û—cŽ™‚É‚š‚¯‚éšb‘§”­ìŽž‚̃EƒCƒ‹ƒXŠŽõ‚ªƒeƒIƒtƒBƒŠƒ“‘ãŽÓ‚É‹y‚Ú‚·‰e‹¿|MxA’`”’‚ðŽw•W‚Æ‚µ‚ā|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    64. ‘«—§—zŽqA’†—ÑŒºˆêA•£‘ò—³–çA‰ª•””üŒbA‚”ö@Š²A‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêF—c’t‰€E•Ûˆç‰€‚É‚š‚¯‚éH•šƒAƒŒƒ‹ƒM[Ž™‚ɑ΂·‚éHŽ–§ŒÀ‚ÌŽÀ‘ԁ|•xŽRŒ§‚É‚š‚¯‚é’²žŒ‹‰Ê‚»‚Ì‚Q|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    65. Œ–쐳’mAˆÉ“Œ“¹—YA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éDSCG‹z“ü—Ö@‚̗Տ°“IŒŸ“¢|‘Šú“±“ü‚Ì—LŒø«‚ɂ‚¢‚ā|B‘æ52‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2002,11,‰¡•l.
    66. ’†—ÑŒºˆêA‘«—§—YˆêA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAœAìTˆê˜YAŒ–{^KA–{“c‹`MF”x‹CŽî‚̐is‚ð‘jŽ~‚Å‚«‚È‚©‚Á‚œV¶Ž™ƒ}ƒ‹ƒtƒ@ƒ“ÇŒóŒQ‚Ì‚P—áD‘æ35‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2002,11,ç—t.
    67. ‘å’ØŒc•ãA‹{@ˆêŽuA’†—ÑŒºˆêAˆÉ“¡–õ“TA•£‘ò—³–çA”‘òŽõŽqA–{‹œ˜a‹vA‘«—§—YˆêA‹{˜e—˜’jFŒJ‚è•Ô‚·ŒÄ‹zŠíŠŽõ—\–h‚Ì‚œ‚ß–éŠÔ‚Ì”ñNPlHŠ·‹C‚𓱓ü‚µ‚œ2Î—Ž™—áD‘æ35‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2002,11,ç—t.
    68. Œ–쐳’mA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚É‚š‚¯‚鎡—Ã’†Ž~‘OŒã‚Ì‹C“¹‰ß•q«‚Æ—\Œã‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ10‰ñ—Տ°šb‘§Œ€‹†‰ï,2002,11,“Œ‹ž.
    69. ŒÜ\—’—²•vAŒ–쐳’mAˆÉ“Œ“¹•vA‘ºãIŒ[A‘«—§—YˆêF’Ž‰¹”gƒlƒuƒ‰ƒCƒU[iƒEƒ‹ƒgƒ‰ƒXƒ|[ƒc4000WBj‚̗Տ°“IŒŸ“¢B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    70. ‘ºãIŒ[AŽRŒ³ƒŽqAŒÜ\—’—²•vA‘«—§—YˆêA‘«—§—zŽqAŒ–쐳’mAˆÉ“Œ“¹•vF‹}«šb‘§”­ì‚É‚š‚¯‚é’Ž‰¹”gƒlƒuƒ‰ƒCƒU[iƒEƒ‹ƒgƒ‰ƒXƒ|[ƒc400WB)‚Ì—L—p«‚ÌŒŸ“¢|3Ží—ނ̃lƒuƒ‰ƒCƒU[ŠÔ‚Ì”äŠr|B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    71. Œ–쐳’mAˆÉ“Œ“¹•vA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éDSCG‹z“ü—Ö@‚̗Տ°“IŒŸ“¢]­—ʂ̃À2ŽhŒƒ–ò•¹—p‚ª‹C“¹‰ß•q«‚ɉe‹¿‚ð—^‚Š‚é‚©]B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    72. •£‘ò—³–çA‘«—§—zŽqA”‘òŽõŽqA’†—ÑŒºˆêAà_“¹—T“ñA‹Ž–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jF‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ɖ^“®—U”­«šb‘§‚Æ‚ÌŠÓ•Ê‚ª“‚¢1—áB‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    73. à_“¹”ü‹IA‘«—§—zŽqA”‘òŽõŽqA‰ª•””üŒbA‚”ö@Š²A‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêF‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢|QOL’²ž•[Œ‹‰Ê‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ā|B‘æ39‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2002,11,·‰ª.
    74. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uEBƒEƒCƒ‹ƒXŠŽõ‚ƈâ“`«ƒŠƒ“ƒp‘BŽŸŠ³Bv‘æ34‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2002,11,ŽD–y.
    75. –쑺ŒbŽqA‹àŒ“O˜aA‹gì“NŽjA‹{˜e—˜’jF’°dÏ‚ðŒJ‚è•Ô‚µ‚œ“Ë”­«”­]Ç‚̈ê—áB‘æ34‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2002,11,ŽD–y.
    76. “n•Óˆ»‰ÀA“¡–Ø–õŽqA–쑺ŒbŽqA‹àŒ“O˜aAÒì@‘ŸA‘Ÿ“c@–΁A@—é–؁@FAŒF’J¹–ŸAPŒ—R‹LŽqA’|’J@Œ’A—с@‘׏GA‹{˜e—˜’jF•›•@oŒŽ”­‚ÌEwing/PNETŽîᇌQ‚Ì‚P—áB‘æ18‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2002,11,•Ÿ‰ª.
    77. “¡–Ø–õŽqA“n•Óˆ»‰ÀA–쑺ŒbŽqA‹àŒ“O˜aA‹›’J‰p”VAœAìTˆê˜YA”ó“nŒõ‹PA—с@‘׏GA`‡ˆêA‹{˜e—˜’jFMalignant rhabdoid tumor of the kidney (MRTK) ‚Ì‚P—áB‘æ18‰ñ“ú–{¬Ž™‚ª‚ñŠw‰ï,2002,11,•Ÿ‰ª.
    78. IchidaF., Chen R., Tsuji T., Haneda N., Bowles KR., Tsubata S., Use K., Hirono K., Watanabe S., Hamamichi Y., Hashimoto I., Miyawaki T., Bowles NE., and Towbin. JA. : Novel gene mutations in patients with left ventricular noncompaction and evidence for genetic heterogeneity. The 1st International symposium on Etiology and Morphogenesis of Congenital Cardiovascular Disease in the Post-Genomic Era.,2002,12,Tokyo.
    79. ”óŒû@ŽûA”‘òŽõŽqA¬Œ“¹—YA¡‘º”Ž–ŸAŒE“c”Ž“¹AûŠˆä³tAŒŽˆä•ü”üA“ñ’J@•A‘«—§—YˆêA‹{˜e—˜’jA…’JW•ãAˆê–؍Ž”VA“yŠò‘P‹IA’ÓcŠî°F”x‰Š‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œæ“V«”X–E«‘BŽî—lŠïŒ`iCCAMj‚̈ê—áB‘æ10‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2002,12,•xŽR.
    80. à_“¹”ü‹IA‘«—§—zŽqA”‘òŽõŽqA‘«—§—YˆêA‹{˜e—˜’jA”öã—mˆêA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锜‰ž«‘ª’è‚̗Տ°“I—L—p«B‘æ29‰ñ–k—€ƒAƒŒƒ‹ƒM[§˜b‰ï,2002,12,‹à‘ò.
    81. •£‘ò—³–çA‘«—§—zŽqA”‘òŽõŽqA’†—ÑŒºˆêAà_“¹—S“ñA‹Ž–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jFEIA or EIA? i‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ɖ^“®—U”­«šb‘§‚Æ‚ÌŠÓ•Ê‚ª“‚¢1—ájB‘æ2‰ñ•xŽRšb‘§Œ€‹†‰ï,2002,12,•xŽR.
    82. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jF‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éD’†‹…Œž­B‘æ10‰ñH×–E‹@”\ˆÙíÇŒ€‹†‰ï,2002,12,“Œ‹ž.

    2001”N

  • ’˜‘
    1. ‹{˜e—˜’jFŒŽ”­«–ƉuÇŒóŒQBu¡“ú‚ÌŽ¡—ÃŽwj2001v‘œ‰ê{K’j‘Œ•ÒA837-838AˆãŠw‘‰@A“Œ‹žA2001.
    2. Žs“c•™ŽqF¶ŽºS‹Øãk–§‰»áŠQBu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Êv¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹€•ÒA518-519A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
    3. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚̏zŠÂŠíŽŸŠ³Ž¡—ÃŽwjA‘æ2”Łv×“cºˆê‘Œ•ÒA493-494AˆãŠw‘‰@A“Œ‹žA2001.
    4. Žs“c•™ŽqFæ“V«SŽŸŠ³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ2”Łvˆä‘º—T•v‘Œ•ÒA•ªŒõ“°A“Œ‹žA2001.
    5. ‹àŒ“O˜aFautoimmune lymphoproliferative syndrome(ALPS)Bu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Êv¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹€•ÒA246-247A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
    6. “ñ’J@•A‹{˜e—˜’jFR‘ÌŒ‡–R‚ðŽå‚Æ‚·‚é–Ɖu•s‘SBu¬Ž™ŽŸŠ³‚̐f’fŽ¡—Êv¬Ž™“à‰È¬Ž™ŠO‰È•ÒWˆÏˆõ‰ï‹€•ÒA236-237A“Œ‹žˆãŠwŽÐA“Œ‹žA2001.
  • ŒŽ’˜
    1. Ichida F., Tsubata S., Bowles K.R., Haneda N., Uese K., Miyawaki T., Dreyer W.J., Messina J., Li H., Bowles N.E., and Towbin J.A. : Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103 : 1256-1263,2001.
    2. Matsukura H., Inaba S., Shinozaki K., Yanagihara T., Hara M., Higuchi A., Takada T., Tanizawa T., and Miyawaki T.: Influence of prolonged corticosteroid therapy on the outcome of steroid-responsive nephrotic syndrome. Am J Nephrol. 21 : 362-367,2001.
    3. Kanegene H., Futatani T., Wang Y., Nomura K., Shinozaki K., Matsukura H., Kubota T., Tsukada S., and Miyawaki T.: Clinical and mutational characteristics of X-linked agammagloburinemia and its carrier identified by flow cytometric assesment combined with genetic analysis. J Allergy Clin Immunol 108 : 1012-1020,2001.
    4. Hongou K. , Konishi T., Matsuzawa J., Yagi S., and Miyawaki T.: A case of migrating partial seizures in an infant with severe eczema, conjunctivitis, and loss of hair. Epilepsia 42 : 72-73,2001.
    5. Futatani T., Watanabe C., Baba Y., Tsukada S., and Ochs HD.: Bruton's tyrosine kinase is present in normal platelets and its absence identifiespatients with X-linked agammaglobulinaemia and carrier females. Brit J Haematol. 114: 141-149,2001.
    6. Ziegner UH., Ochs HD., Schanen C., Feig SA., Seyama K., Futatani T., Gross T., Wakim M., Roberts RL., Rawlings DJ., Dovat S., Fraser JK., and Stiehm ER. : Unrelated umbilical cord stem cell transplantation for X-linked immuno-deficiencies. J Pediatr. 138 : 570-573,2001.
    7. Matsuzawa J., Matsui M., Konishi T., Noguchi K., Gur RC., Bilker W., and Miyawaki T.: Age-related volumetric changes of brain gray and white matter in healthy infants and children. Cerebral Cortex. 11 : 335-342,2001.
    8. Hamamichi Y., Ichida F., YU X., Hirono K., Uese K., Hashimoto I., Tsubata S., Yoshida T., Futatani T., Kanegane H., and Miyawaki T.: Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: Its possible role in progression of coronary artery lesions. Pediatr Res 49: 74-80,2001.
    9. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Miyawaki T., Ono Y., and Kamiya T.: Isolated noncompaction of the ventricular myocardium -UFCT and magnetic resonance imaging - Int J Cardiac Imag 17 : 305-314,2001.
    10. Itazawa T,. Adachi Y., Imamura H., Okabe Y., Yamamoto J., Onoue Y., Adachi Y. S., Miyawaki T., and Murakami G. : Increased lymphoid MxA expression in acute asthma exacerbation in children. Allergy 56 : 895-898,2001.
    11. Wang Y., Kanegane H. , Sanal O.,Ersoy F., Tezcan I., Futatani T., Tsukada S., and Miyawaki T.: Bruton's tyrosine kinase gene mutations in Turkish patients with presumed X-linked agammaglobulinernia. Hum Mutat 18 : 356,2001.
    12. Yu X., Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole stress ultrasonic myocardial tissue characterization in patients with history of Kawasaki disease. J Am Soc Echocardiogr 14 : 682-90,2001.
    13. Konishi T., Matsuzawa J., Hongou K., Murakami M., Yamatani M., and Yagi S.: Candidate selection for surgical treatment in children with intractable epilepsies. Epilepsia 42 : 56,2001.
    14. Xianyi Yu., Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole stress ultrasonic myocardial tissue characterization in patients with history of Kawasaki disease. J Am Soc. Echocardio. 14:682-690, 2001.
    15. Mio T., Liu X., Toews M.L., Adachi Y. , D.J. Romberger D.J., Spurzem J.R., and Rennard S.I. : Bradykinin augments fibroblast-mediated contraction of released collagen gels. Am J Physiol Lung Cell Mol Physiol 281:L164-71,2001.
    16. Sakamoto M., Kanegane H., Fujii H., Tsukada S., Miyawaki T. , and Shinomiya N.FMaternal germinal mosaicism of X-linked agamma-globulinemia. Am J Med Genet 99 : 234-237,2001.
    17. Usui K., Sasahara Y., Tazawa R., Hagiwara K., Tsukada S., Miyawaki T., Tsuchiya S., and Nukiwa T. : Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults. Respir. Res. 2:188-192,2001.
    18. Kimura H., Hoshino Y., Kanegane H., Tsuge I., Okamura T., Kawa K., and Morishima T. : Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood 98 : 280-286,2001.
    19. Sumazaki R., Kanegane H., Osaki M., Fukushima T., Tsuchida M., Matsukura H., Shinozaki K., Kimura H., Matsui A., and Miyawaki T.: SH2D1A mutations in Japanese males with severe Epstein-Barr virus-associated illnesses. Blood. 98 : 1268-1270,2001.
    20. Jo E.K., Kanegane H., Nonoyama S., Tsukada S., Lee J.H., Lim K., Shong M., Song C.H., Kim H.J, Park J.K., and Miyawaki T.: Characterization of mutations, including a novel regulatory defect in the first intron, in Bruton's tyrosine kinase gene from seven Korean X-linked agammaglobulinemia families. J Immunol 167 : 4038-4045,2001.
    21. Nakamura A., Tsurusawa M., Kato A., Taga T., Hatae Y., Miyake M., Mimaya J., Onodera N., Watanabe A., Watanabe T., Kanegane H., Matsushita T., Iwai A., Hyakuna N., Gushi K., Kawakami T., Sekine I., Izichi O., Asami K., Kikuta A., Tanaka A., and Fujimoto T.(Children's Cancer and Leukemia Study Group (CCLSG)) : Prognostic impact of CD45 antigen expression in high-risk, childhood B-cell precursor acute lymphoblastic leukemia. Leukemia Lymphoma 42 : 393-398,2001.
    22. Agematsu K., Nagumo H., Hokibara S., Mori T., Wada T., Yachie H., Kanegane H., Miyawaki T., Sugita K., Karasuyama H., and Komiyama A. : Complete arrest from pro- to pre-B cells in a case of B cell-negative severe combined immunodeficiency (SCID) without recombinase activating gene (RAG) mutations. Clin Exp Immunol 124 : 461-464,2001.
    23. Ikeda N., Hayasaka S., Yano H., Kadoi C., Matsumoto M., Imamura H., and Miyawaki T.: Retinopathy of prematurity in Toyama area of Japan. Ann Ophthalmol 33 : 303-308,2001.
    24. Li J., Li X., Mori Y., Rusk RA., Lee JS., Davies CH., Hashimoto I. , El-sedfy GO., Li XN., and Sahn Dj. : Quantification of flow volume with a new digital three-dimensional color Doppler flow approach : an in vitro study. J Ultrasound Med 20 : 1303-1311,2001.
    25. Moro H., Iwai K., Mori N.,Watanabe M., Fukushi M., Oie M., Arai M., Tanaka Y., Miyawaki T., Gejyo F., Arakawa M., and Fujii M. : Interleukin-2-dependent but not independent T-cell lines infected with human T-cell leukemia virus type I selectively express CD45RO, a marker for persistent infeotion in vivo. Virus Genes 28 : 263-271,2001.
    26. ‰¡“cF”VA‘«—§—YˆêA”öã—mˆêA•l“¹”ü‹IA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF–òÜŽt‚É‚æ‚é‹CŠÇŽxšb‘§Š³ŽÒ‚ɑ΂·‚é‹z“üŽw“±‚ÌŽÀ‘Ô’²ž@-•xŽRŒ§“à‚Ì•a‰@–ò‹Ç‚È‚ç‚тɉ@ŠO’²Ü–ò‹Ç‚É‚š‚¯‚鍷ˆÙ‚ɂ‚¢‚Ä -D“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@15F208-214,2001.
    27. ‹g“cärA‹àŒ“O˜aAŽª“c–F’jAˆÉ“¡‘P–çA‰iˆä•q˜YA–î–ìŒöˆêA“c’†—tŽqAŒŠª@Ž AŽRì”ŽŽqAŽ›–{’mŽjA‹ÊˆäLÆA•Sˆä@‹œA‘å‹Ž”Ž•¶AŒ@”ü˜aAâV“¡–œ—¢ŽqA‹{˜e—˜’jF‚킪‘‚É‚š‚¯‚鍜œ“ªŠWˆÙŒ`¬Ç‚̗Տ°“IEˆâ“`Šw“IŒŸ“¢B“ú–{¬Ž™‰ÈŠw‰ïŽGŽ@105F442-447,2001.
  • Ç—á•ñ
    1. Itazawa T., Noguchi K., Ichida F., and Miyawaki T.: Magnetic resonance imaging for early detection of Takayasu arteritis. Pediatr. Cardiol. 22:163-164,2001.
    2. Adachi Y., Onoue Y., Matsuzawa J., Ieki A., Yagi S., and Miyawaki T.: External chest compression for the treatment of a mechanically ventilated child with status asthmaticus. Acta Pediatr 90 : 826-827,2001.
    3. ”ª–ؐMˆêAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jA¬Œ@“OFEyelid myoclonia with absences Eyelid myoclonia withabsences‚ÌŒZ’í—áB”]‚Æ”­’B@33F517-522,2001.
    4. Itazawa T., Noguchi K., Ichida F., and Miyawaki T.: Magnetic resonance imaging for early detection of Takayasu arteritis. Pediatr. Cardiol 22 : 163-164,2001.
    5. “n•Óˆ»‰ÀAŒIŒŽ^‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jFGM1ƒKƒ“ƒOƒŠƒIƒVƒh[ƒVƒX‚Ì––œŒŒ‰t‘œB¬Ž™‰È@42F137-138,2001.
    6. Uotani H., Hirosawa S., Saito F., Tauchi K., Shimoda M., Ishizawa S., Kawaguchi M., Nomura K., Kanegane H., and Tsukada K. : Non-Hodgkin's lymphoma of the ascending colon in a patient with Becker muscular dystrophy : Report of a case. Surg Today 31 : 1016-1019,2001.
  • ‘à
    1. ‹{˜e—˜’jFautoimmune-lymphoproliferativeÇŒóŒQ(ALPS)Bu¬Ž™‚̏njóŒQv¬Ž™‰Èf—Ã(‘)64F319,2001.
    2. Žs“c•™ŽqFS‹Øãk–§‰»áŠQ‚ÌŒ»‹µBuæ“V«SŽŸŠ³‚̃g[ƒ^ƒ‹ƒPƒA[v¬Ž™“à‰È@33F720-722,2001.
    3. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[ŽŸŠ³‚ƃPƒ‚ƒJƒCƒ“D•ªŽq×–EŽ¡—Á@2F603-608,2001.
    4. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒgƒs[«ŽŸŠ³‚ƃPƒ‚ƒJƒCƒ“BMolecular Medicine 38F160-166,2001.
    5. ‹àŒ“O˜aFŒŽ”­«–Ɖu•s‘SÇŒóŒQBu¬Ž™‚̏njóŒQv¬Ž™‰Èf—Ã(‘)@64F363,2001.
    6. ‹àŒ“O˜aFæ“V«ŒŒ‰t–ƉuˆÙíÇ‚̐f’f‚̐i•àB“ú–{¬Ž™ŒŒ‰tŠw‰ïŽ,89-94,2001.
    7. ŽÂèŒ’‘Ÿ˜YA‹àŒ“O˜aA‹{˜e—˜’jFSAP(SLAM-associated protein)‚ُ̈í‚ÆEBƒEƒCƒ‹ƒXŠŽõB–Ɖu@11F109-113,2001.

  • 2001”NŠw‰ï•ñ
    1. ‘匎“N•vA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFEBƒEƒBƒ‹ƒX‰ŠŽõ‚É‚æ‚錌‹…æÐHƒŠƒ“ƒp‘gD‹…‘BÇ‚̈ê—áB‘æ‚T‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,2001,1,‹à‘ò.
    2. “ŒŽROKAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YAÎàV@LF• ’É‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œƒo[ƒLƒbƒgƒŠƒ“ƒpŽî‚̈ê—áB‘æ14‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,2001,2,‹à‘ò.
    3. ‹Ž–{ˆè•vAãšŒhˆê˜YAà_“¹—T“ñA“ŒŽROKA“ñ’J@•AL–ìŒbˆêA“n•Óˆ»‰ÀAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA“y”ì‹`˜YA‘哈‹`”ŽAŽOè‘ñ˜YA²X–ׁؑAœAìTˆê˜YA‘š“cŒõ‹`FCoil embolization‚ðŽ{s‚µ‚œA‰E‰¡Šu–Œƒwƒ‹ƒjƒAA”x•ª‰æÇAScimitarÇŒóŒQAS–[’†ŠuŒ‡‘¹A‘å“®–¬kó‚̐V¶Ž™—áB‘æ21‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,2001,2,‹à‘ò.
    4. Adachi Y., Okabe Y., Onoue Y., Yamamoto J., Adachi YS., Toyoda M., Morohashi M., Matsushima K., and Miyawaki T.: Cutaneous lymphocyte antigen expression on circulating Th1- and Th2-type cells in patients with atopic dermatitis. 57th Annual Meeting of American Academy of Allergy, Asthma and Immunology,2001,3,New Orleans,USA.
    5. ‘匎“N•vAŽíŽsq’ˆA“ŒŽROKA‹Ž–{ˆè•vA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YA“n•Óˆ»‰ÀA“c’‡çHA•l“¹—T“ñA’|’J“¿—YFRSƒEƒCƒ‹ƒX‚É‚æ‚é‹}«×‹CŠÇŽx‰Š”­Ç‚ðŒ_‹@‚É”­Œ©‚³‚ê‚œŒŒŠÇ—Ö‚Ì1“ûŽ™—áB‘æ271‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2001,3,‹à‘ò.
    6. –쑺ŒbŽqA‘匎“N•vA‰eŽR—²ŽiA‹àŒ“O˜aA‹{˜e—˜’jFLeukapheresis‚ðs‚Á‚œ‹}«ƒŠƒ“ƒp«”’ŒŒ•a‚Ì1’jŽ™—áB‘æ271‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2001,3,‹à‘ò.
    7. ‰ª•””üŒbA‘«—§—YˆêA”ÂàVŽõŽqAŽRŒ³ƒŽqA”öã—mˆêA‹{˜e—˜’jF––œŒŒ‚s×–E‚É‚š‚¯‚éCCR7”­Œ»‚Ì”N—î“I„ˆÚ‚Æ‚»‚Ì‹@”\‚ɂ‚¢‚āB‘æ22‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2001,3,•xŽR.
    8. Ichida F., Haneda N., Bowles K. R., Tsubata S.,Uese K., Hamamichi Y., Hashimoto I., Miyawaki T., and Towbin J.A. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    9. Hamamichi Y., Ichida F., Chen R., Uese K., Hirono K.,Tsubata S., Miyawaki T., Seto H.,and Sahn D. J. : Dipyridamole stress ultrasonic myocardial tissue characterization in patients with Kawasaki disease. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    10. Hashimoto I., Ichida F., Miyawaki T., and Sahn D. J. : Angle dependency of tissue Doppler left ventricular regional wall velocities: In Vitro studies using a novel balloon phantom.‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s .
    11. Hashimoto I., Ichida F., Miyawaki T., and Sahn D. J. : .Detection of modeled old myocardial infarction using tissue Doppler versus strain rate imaging: In Vitro Studies Using a "Calibrated" Myocardial Phantom. ‘æ65‰ñ“ú–{zŠÂŠíŠw‰ï,2001,3,‹ž“s.
    12. Hashimoto I., Rusk R. A., Li X., Mori Y., Mack G., Lee J. S., Wanikun S., Sahn D. J. : Improved accuracy for determination of endocardial borders and cavity volumes with second harmonic echo in real-time 3D echocardiography: In-Vitro studies. 50th American College of Cardiology,2001,3,Orland,USA.
    13. Hashimoto I., Davies C. H., Li X., Lee J. S., Ichida F., Miyawaki T., and Sahn D. J. : The angle dependency of strain rate imaging compared to B-mode strain measurements: studies in a physiologic myocardial model. 50th American College of Cardiology,2001,3,Orland,USA.
    14. ‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid J. SahnFƒoƒ‹[ƒ“ƒ‚ƒfƒ‹‚ð—p‚¢‚œ‚RŽŸŒ³SƒGƒR[‚̍¶Žº‹@”\•]‰¿‚É‚š‚¯‚鐞“x‚ÌŒŸ“¢B‘æ12‰ñ“ú–{SƒGƒR[}Šw‰ïA2001,4,“Œ‹ž.
    15. ‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jADavid J. SahnFƒoƒ‹[ƒ“ƒ‚ƒfƒ‹‚ð—p‚¢‚œStrain Rate Imaging‚̍¶Žº‘€•Ç‚ł̉ðÍB‘æ12‰ñ“ú–{SƒGƒR[}Šw‰ïA2001,4,“Œ‹ž.
    16. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[‚Ì”­Ç—vˆö‚Æearly intervention@ŠÂ‹«—vˆö‚Æ‚»‚̑΍ô@ƒAƒŒƒ‹ƒQƒ“i‹z“üEH•šjvB‘æ‚S‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ïA2001,4,–ŒŒÃ‰®.
    17. Hashimoto I., Ichida,F., Miyawaki T., Stetten G., von Ramm O., Jones M., Panza J.A., Sachdev V., and Sahn D.J. : Accuracy of real-time three-dimensional echocardiography for determining left ventricular volumes and ejection fractions: a physiologic balloon model and experimental animal model with sonomicrometry measurements of LV volumes.The 3rd world congress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    18. Hirono K., Yu X., Ichida F., Chen R., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Terai M., and Miyawaki T.: Nitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    19. Hirose Y., Ichida F.: A study of how pro-fessionals and mothers recognize the needs of children with congenital heart disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    20. Watanabe S., Yu X., Hashimoto I., Ichida F., Chen R., Hirono K., Hamamichi Y., Uese K., Tsubata S., Miyawaki T. , Seto H., and Sahn D.J. : Dipyridamole stress ultrasonic myocardial tissue characterization in patients with Kawasaki disease. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    21. Ichida F. , Haneda N., Bowles K.R., Tsubata S., Uese K., Hirono K., Hamamichi Y., Hashimoto I., Miyawaki T., and Towbin, J.A. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. The 3rd world cogress of pediatric cardiology and cardiac surgery,2001,5,Toronto,Canada.
    22. ‰¡“cF”VA‘«—§—zŽqA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒÀŽhŒƒÜ‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢`Ž¡—ÂȂç‚Ñ‚É‹C“¹‰ß•q«‚Æ‚ÌŠÖŒW‚ɂ‚¢‚ā`‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2001,5,‰¡•l.
    23. ”ÂàVŽõŽqA‰ª•””üŒbA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF‰h—{•â•H•iŠJŽnŒã‚É”­Ç‚µ‚œH•šˆË‘¶«‰^“®—U”­«ƒAƒiƒtƒBƒ‰ƒLƒV[‚Ì‚P—áB‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2001,5,‰¡•l.
    24. •l“¹”ü‹IAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jAFè@Œ’AŒIŒŽ^‹IŽqFƒvƒƒ^ƒm[ƒ‹Ž‘±‹z“ü’†‚ÉBurugadaÇŒóŒQ—l‚̐S“d}ˆÙí‚𗈂µ‚œ‹CŠÇŽxšb‘§‚̈ê—áB‘æ13‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2001,5,‰¡•l.
    25. Žs“c•™ŽqA‰Hª“c‹IKA’ÔŠáÁˆêAœA–ìŒbˆêA“n•Óˆ»‰ÀAãšŒhˆê˜YA•l“¹—T“ñA‹Ž–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[ƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚É‚š‚¯‚éV‚µ‚¢ƒ¿-Dystrobrevin ˆâ“`ŽqˆÙíB‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    26. Wang Y., Kanegane H., Miyawaki T., and Ozden S.FA novel Igƒ¿ gene mutation in a Turkish patient with B cell-deficient agammaglobuli-nemia. ‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    27. Chen R., Yu X., Ichida F., Hirono K., Uese K., Hamamichi Y., Hashimoto I., Terai M., and Miyawaki T.FNitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. ‘æ104‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2001,5,˜a‰ÌŽR.
    28. –{‹œ˜a‹vA‰eŽR—²ŽiA“c’‡çHAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA“à“¡‰x—YFƒWƒNƒƒ|Ž_‚š‚æ‚Ñvit.B1“Š—^Œã‚ɗՏ°Çó‚š‚æ‚щ摜ŠŒ©‚̉ü‘P‚ª‚Ý‚ç‚ê‚œLeigh”]Ç‚̈ê—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    29. ‰eŽR—²ŽiA“c’‡çHAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF—L”MŽžáz¹dÏ‚Å”­Ç‚µ‚œ2”]‰Š‚̈ê—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    30. ”ª–ؐMˆêA“c’‡çHAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jA¬Œ@“OFHallervorden-Spatz syndrome‚ÌŽoA’í—áB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2001,6,‰ªŽR.
    31. “ñ’J@•A”ª–ؐMˆêAŽíŽsq’ˆA‹{˜e—˜’jA•Ä“c@“NA²X–ׁؑAÄ“¡@Ž A‹v•Û“¹–çAŒKŽR’Œ–çA•l“cG•vA‰““¡r˜YA’†—ÑŒºˆêAZ“c@—ºA“ˆ@‘å“ñ˜YFƒRƒCƒ‹Çðp‚É‚æ‚èS•s‘S‚̉ü‘P‚ª“Ÿ‚ç‚ê‚œæ“V«“ªŠW“à“®Ã–¬á‘‚̐V¶Ž™—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    32. “ñ’J@•A“ŒŽROKA²X–؁@‘ׁA‰¡ŽR—TŽiA”ª–ؐMˆêA¡‘º”Ž–ŸAâV“¡@Ž A‹{˜e—˜’jF17”ԐõF‘̘rŠÔ‹tˆÊ‚É‚æ‚éMiller-DiekerÇŒóŒQ‚̉Ƒ°“à”­¶—áB‘æ37‰ñ“ú–{V¶Ž™Šw‰ï,2001,7,‰¡•l.
    33. Kanegane H. , Sumazaki R., Shinozaki K., Matsukura H., Kimura H., and Miyawaki T.FClinical and mutational characterization of X-linked lymphoproliferative syndrome in Japan. The 21th International Symposium of the Sapporo cancer seminar foundation Epistein-Barr virus and human cancer,2001,7,Sapporo.
    34. Œ‘q—TŠìA‘匎“N•vA•£‘ò—³–çA‹{˜e—˜’jFqí«‹›—Øᝏǂð‚Æ‚à‚È‚Á‚œƒXƒeƒƒCƒh’ïR«ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áB‘æ45‰ñ’†•”“ú–{Ž…‹…‘̐t‰Š’k˜b‰ï,2001,7,–ŒŒÃ‰®.
    35. Žs“c•™ŽqA‰Hª“c‹IKA’ÔŠ^ˆêAL–ìŒbˆêAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[ ƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚É‚š‚¯‚éV‚µ‚¢ƒ¿-Dystrobrevinˆâ“`Žq•ÏˆÙB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,Ã‰ª.
    36. Žs“c•™ŽqA‰Hª“c‹IKA ’ÔŠ^ˆêAL–ìŒbˆêA“n•Óˆ»‰ÀAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vA‹{˜e—˜’jAƒWƒFƒtƒŠ[Eƒ^ƒEƒrƒ“FS‹Øãk–§‰»áŠQ‚̈â“`ŽqŒŸõB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,Ã‰ª.
    37. ‹Ž–{ˆè•vA•l“¹—T“ñAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽAŽOè‘ñ˜YFS–[’†ŠuŒ‡‘¹Ç‚É‚š‚¯‚é”x‘ÌŒŒ—¬”ä‚̐SƒGƒR[‚É‚æ‚鐄’èS–[’†ŠuŒ‡‘¹EƒTƒCƒY‚Æ‘m–X•Ù—ÖƒTƒCƒY‚É‚æ‚錟“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, Ã‰ª.
    38. ”öã—mˆêA‘«—§—YˆêA”ÂàVŽõŽqA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA’C–€‹M”üŽqA‘å“àG—YA¬–ìˆÀ¶A”ª–ØŒŽrŽFFontanpŒã5”N‚Å”­Ç‚µ‚œ plastic bronchitis‚Ì1’jŽ™—áB‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, Ã‰ª.
    39. L–ìŒbˆêAChen RuiAãšŒhˆê˜YAà_“¹—T“ñA“n•Óˆ»‰ÀA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jAŽ›ˆäŸFìè•a‹}«Šú‚É‚š‚¯‚é—¬ŒŒ’†ŒŒŠÇ“à”ç×–E‚Å‚ÌiNOS”­Œ»‚̈Ӌ`B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, Ã‰ª.
    40. •l“¹—T“ñA“n•Óˆ»‰ÀAœA–ìŒbˆêAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF”­ÇŽžŠú‚É‚æ‚éS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, Ã‰ª.
    41. “n•Óˆ»‰ÀA‰Hª“c‹IKAœA–ìŒbˆêAãšŒhˆê˜YA•l“¹—T“ñA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFSŠïŒ`‚ɍ‡•¹‚µ‚œS‹Øãk–§‰»áŠQ‚̗Տ°‘œ‚ÌŒŸ“¢B‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7,Ã‰ª.
    42. Chen R., Hirono K., Yu X., Ichida F., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Terai M., and Miyawaki T.FNitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. ‘æ37‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2001,7, Ã‰ª.
    43. ”óŒû@ŽûA•£àV—³–çA‘«—§—YˆêA‹{˜e—˜’jA‹{ŒŽ²–íAŒŽ@—SˆèAŽOè‘ñ˜YA“n•Óˆ»‰ÀAŽÂèŒ’‘Ÿ˜YFŒJ‚è•Ô‚·”x‰Š‚ðŒ_‹@‚ɐf’f‚³‚ê‚œ”x•ª‰æÇ‚̈ê—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    44. “ŒŽROKAŒE“c”Ž“¹A¬Œ“¹—YA¡‘º”Ž–ŸAûŠˆä³tA–ìàV@Š°A–kìŽGAŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜NA‹g“c—çŽqF• ’É‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œBurkittƒŠƒ“ƒpŽî‚̈ê—áB‘æ‚V‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2001,7,‚‰ª.
    45. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAˆäã—S–õA–î•”‚Ý‚Í‚éF”ñŒŒ‰ŽÒŠÔ“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚œFanconi•nŒŒ‚̈ê—áB‘æ ‰ñ‘¢ŒŒŠ²×–EˆÚA§˜b‰ï,2001,7, .
    46. •£àV—³–çA”óŒû@ŽûA–{‹œ˜a‹vA‘«—§—YˆêA‹{˜e—˜’jAXK—Iˆê˜YF•@ƒ}ƒXƒN‚É‚æ‚éNIPPV‚Ő‡–°Žž–³ŒÄ‹z‚ªƒRƒ“ƒgƒ[ƒ‹‰Â”\‚Æ‚È‚Á‚œ”ñ•ŸŽRŒ^‹ØƒWƒXƒgƒƒtƒB[‚̈ê—áB‘æ37‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2001,8,‹à‘ò.
    47. ŽíŽsq’ˆAˆÉ“¡–õ“TA’†—ÑŒºˆêA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jFV¶Ž™Šú‚©‚ç•”•ª”­ì‚ª•p”­‚µ‚œ“«‚Ä‚ñ‚©‚ñ‚̈ê—á‘æ37‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2001,8,‹à‘ò.
    48. ‹àŒ“O˜aA–쑺ŒbŽqAŠ}ŒŽ‘PmA‰ª‘º@ƒA–{‹œ‹P–ŸA–î•”‚Ý‚Í‚éA¬“‡š“ñA‹{˜e—˜’jFDyskeratosis congenita‚É‚š‚¯‚éDKC1ˆâ“`Žq‰ðÍB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    49. –쑺ŒbŽqA‹àŒ“O˜aA‹{@ˆêŽuA‹g“c@‹ªA–èŽjŽ¡A‹{˜e—˜’jFDŽ_‹…‘‘œ‚𔺂Á‚œf(5;12)(q31;p12)‚̐õF‘ُ̈í‚ðŽ‚ÂAMLM2Ä”­—áB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    50. ŽíŽsq’ˆA‰ÆéˆŸ‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAÀ‘qŽü•FA‘â@ŽFALL‚ɑ΂·‚évincristine“Š—^‚É‚æ‚茰«‰»‚µ‚œCharcot-Marie-Tooth•a(1AŒ^)‚̈ê—áB‘æ43‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2001,9,–k‹ãB.
    51. Žs“c•™ŽqFæ“V«SŽŸŠ³‚̐f’f‚ÆŽ¡—Á`‘ÙŽ™f’f‚©‚çV¶Ž™‘ŠúŽ¡—ÂɌü‚¯‚ā`B•œ¬13”N“x“ú–{ŽY‰È•wl‰ÈŠw‰ï•xŽR’n•û‰ïƒVƒ“ƒ|ƒWƒEƒ€,2001,9,•xŽR.
    52. ‘ºãIŒ[A•l“¹”ü‹IA’ÔŠáÁˆêA–{ŠÔˆê³A•l“¹—T“ñA‘«—§—YˆêA‹ž’JªŽOFŽ¡—Ã’†’f‚É‚æ‚è‘å”­ì‚ð‚š‚±‚µ‚œŽvtŠúšb‘§‚Ì‘oŽq—áD‘æ‚S‰ñ•xŽR¬Ž™šb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2001,9,•xŽR.
    53. ŽíŽsq’ˆA”‘òŽõŽqAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‘«—§—YˆêA‹{˜e—˜’jA”ª–ؐMˆêAò@‹IŽqA•Ä“c@“NA¬ìŽŸ˜YA“ñ’J@•FƒKƒ“ƒVƒNƒƒrƒ‹‚ª—LŒø‚Å‚ ‚Á‚œÇŒó«æ“V«ƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒXŠŽõÇ‚̈ê—áB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,2001,9,‹à‘ò.
    54. Œ‘q—TŠìA•£‘ò—³–çA‘匎“N•vA‹{˜e—˜’jF‰ºŽˆ‚ÌŽ‡”Á‚ð‚Æ‚à‚È‚Á‚œ—n˜A‹ÛŠŽõÇŒã‹}«Ž…‹…‘̐t‰ŠB‘æ‚X‰ñ’†•”“ú–{¬Ž™t‘Ÿ•aŒ€‹†‰ï,2001,9,•xŽR.
    55. Yu X., Ichida F., Hirono K., Chen R., Uese K., Hamamichi Y., Hashimoto I., Tsubata S. , Terai M., and Miyawaki T.: Nitric oxide contributes to the progression of coronary artery lesions in acute Kawasaki disease. The 23rd International Congress of Pediatrics,2001,9,Beijing,China.
    56. ‹àŒ“O˜aA‹{˜e—˜’jFƒŠƒ“ƒp‘BÇŒóŒQB•œ¬13”N“x‘æ1‰ñŒŽ”­«–Ɖu•s‘SÇŒóŒQ’²žŒ€‹†”ǔljï‹c,2001,9,Œ–{.
    57. Œ–쐳’mAˆÉ“Œ“¹•vA‹gZ@ºA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚̗Տ°ŒŸ“¢-Ž¡—Ã’†Ž~Œã‚ÌŒo‰ß‚Æ‹C“¹‰ß•q«‚̐„ˆÚ‚ɂ‚¢‚Ä‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    58. ‰ª•””üŒbA•l“¹”ü‹IA”‘òŽõŽqAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF––œŒŒ‚s×–E‚É‚š‚¯‚éCCR7”­Œ»‚Ì”N—î“I„ˆÚ‚Æ‚»‚Ì‹@”\‚ÉŠÖ‚·‚錟“¢B‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    59. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA‰¡“cF”VA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F––œŒŒ’P‹…‚É‚š‚¯‚éIL-12ŽY¶”\‚ÆIL-10ŽY¶”\‚Æ‚ÌŠÖŒWB‘æ51‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,•Ÿ‰ª.
    60. ŽíŽsq’ˆA‘匎“N•vA“ŒŽROKA”ÂàVŽõŽqA“‡’ÐeŽuA‘哈‹`”ŽA‘«—§—YˆêA‹{˜e—˜’jF“–‰RSƒEƒCƒ‹ƒX‚É‚æ‚é×‹CŠÇŽx‰Š‚ƍl‚Š‚ç‚ê‚œŒŒŠÇ—Ö‚Ì‚Q‚©ŒŽ—Ž™—áB‘æ34‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2001,10,•Ÿ“‡.
    61. •£àV—³–çA‰eŽR—²ŽiA–쑺ŒbŽqA‹àŒ“O˜aA‹{ŒŽ²–íAŒŽ@—SˆèA‘«—§—YˆêA‹{˜e—˜’jFp‘O‚É”x”^ᇂƐf’f‚³‚ê‚Ä‚¢‚œinflammatory myo-fibroblastic tumor‚Ì‚P’jŽ™—áB‘æ34‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2001,10,•Ÿ“‡.
    62. ‘«—§—zŽqA‰¡“cF”VA•l“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢@-ŒoŽž“I‘ª’è‚É‚æ‚銳ŽÒŽw“±‚ւ̉ž—p‚ɂ‚¢‚Ä-B‘æ38‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,¬‘q.
    63. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jAˆäãŽõ–΁Fƒtƒ‹ƒ`ƒJƒ]ƒ“‹z“üŠJŽnŒã‚ÉŒ°Ý‰»‚µ‚œChurg-Strauss ÇŒóŒQ‚ƍl‚Š‚ç‚ê‚é1’jŽ™—áD‘æ38‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2001,10,¬‘q.
    64. “ñ’J@•A”ª–ؐMˆêA‰ÆéˆŸ‹IŽqAŽs“c•™ŽqA‹{˜e—˜’jA“‡’ÐeŽuA‘哈‹`”ŽA’Ðì@—́A“¿ŽR•ŽqA•Ä“c@“NAÄ“¡@Ž F‹CŠÇ“àƒXƒeƒ“ƒg—¯’u‚É‚æ‚èŒÄ‹zó‘Ԃ̉ü‘P‚ª“Ÿ‚ç‚ê‚œ¶Žå‹CŠÇ‹·óÇ‚̈ê—áB‘æ15‰ñ–k—€–¢nŽ™V¶Ž™Œ€‹†‰ï,2001,10,‹à‘ò.
    65. “ñ’J@•A”ª–ؐMˆêA‹{˜e—˜’jA²X–؁@‘ׁAÄ“¡@Ž F‚wõF‘Ì’·˜r•”•ª‰ßè‚𔺂Á‚œ‚U”ԐõF‘Ì’Z˜r•”•ªŒ‡Žž‚Ì’jŽ™—áB‘æ22‰ñ–k—€æ“VˆÙíŒ€‹†‰ï,2001,11,•xŽR .
    66. –쑺ŒbŽqA‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@BIVIGƒgƒ„ƒ}ƒtƒH[ƒ‰ƒ€,2001,11,•xŽR.
    67. Hashimoto I., Davies C. H., Lee J.S., Ichida F., Miyawaki T., and Sahn D. J. : Improved detection of modeled old myocardial infarction using strain rate imaging in comparison to tissue doppler: In vitro studies using a "calibrated" myocardial phantom which mimics tethering. The 74rd scientific sessions of american heart association, 2001,11,Anaheim,USA.
    68. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@B‘æ33‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2001,11,‰F•”.
    69. ‹àŒ“O˜aA‰€@‰xA–쑺ŒbŽqA‹{˜e—˜’jA–ìXŽRŒbÍFƒuƒ‰ƒWƒ‹‚É‚š‚¯‚éæ“V«–Ɖu•s‘SÇ‚̐f’fB‘æ33‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2001,11,‰F•”.
    70. ‹àŒ“O˜aFƒVƒ“ƒ|ƒWƒEƒ€uX-linked lympho-proliferative syndromev‘æ29‰ñ“ú–{—Տ°–ƉuŠw‰ï,2001,12,‘åã.
    71. Wang Y., Nomura K., Futatani T., Kanegane H., and Miyawaki T. : A novel Igƒ¿(CD79a) gene mutation in a Turkish patient with B cell deficient agammaglobulinemia. ‘æ29‰ñ“ú–{—Տ°–ƉuŠw‰ï,2001,12,‘åã.
    72. –쑺ŒbŽqA“ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éƒÁƒOƒƒuƒŠƒ“’uŠ·—Ö@B‘æ29‰ñ“ú–{—Տ°–ƉuŠw‰ï,2001,12,‘åã.
    73. “ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jA“n•Óç»AOchs HansA”nê‹`—TA’Ë“c@‘FŒŒ¬”‚ɂš‚¯‚éƒuƒ‹ƒgƒ“Œ^ƒ`ƒƒVƒ“ƒLƒi[ƒ[‚Ì”­Œ»‚Æ‚»‚ÌŠ³ŽÒE•ÛˆöŽÒf’f‚ւ̉ž—pB‘æ31‰ñ“ú–{–ƉuŠw‰ï,2001,12,‘åã.
    74. “ñ’J@•A”ª–ؐMˆêA¬ìŽŸ˜YAŽíŽsq’ˆA‹{˜e—˜’jA•Ä“c@“NA²X–ׁؑAÄ“¡@Ž FƒRƒCƒ‹Çðp‚É‚æ‚è‹~–œ‚µ“Ÿ‚œæ“V«“ªŠW“à“®Ã–¬á‘‚̈ê—áB‘æ46‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï,2001,12,‰¡•l.
    75. ŽíŽsq’ˆA¬ìŽŸ˜YA•Ä“c@“NA“ñ’J@•A”ª–ؐMˆêAÄ“¡@Ž A”‘òŽõŽqA‹{˜e—˜’jFæ“V«ƒTƒCƒgƒƒKƒŠŽõÇ‚É‚š‚¯‚éMxA’`”’”­Œ»‚ÌŒoŽž“I‘ª’è‚Æ‚»‚̈Ӌ`B‘æ46‰ñ“ú–{–¢nŽ™V¶Ž™Šw‰ï,2001,12,‰¡•l.
    76. ‘«—§—zŽqA•l“¹”ü‹IA‰ª•””üŒbA”ÂàVŽõŽqA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§Ž™‚É‚š‚¯‚éƒÀŽhŒƒ–ò‹z“ü‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢@-ŒoŽž“I‘ª’è‚É‚æ‚銳ŽÒŽw“±‚ւ̉ž—p‚ɂ‚¢‚Ä-B•xŽRšb‘§Œ€‹†‰ï,2001,12,•xŽR.
    77. ”ÂàVŽõŽqA’†—ÑŒºˆêA•£àV—³–çA•l“¹”ü‹IA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jA‘ºãIŒ[FV¶Ž™‚É‚š‚¯‚éIL-12ŽY¶”\’ቺ‚ÆIL-10‚È‚ç‚Ñ‚ÉIL-18ŽY¶”\‚Æ‚ÌŠÖŒWD‘æ28‰ñ–k—€ƒAƒŒƒ‹ƒM[§˜b‰ï,2001,12,‹à‘ò.

    2000”N

  • ’˜‘
    1. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚̏zŠÂŠíŽŸŠ³Ž¡—ÃŽwjA‘æ2”Łv×“cºˆê‘Œ•ÒAˆãŠw‘‰@,2000.
    2. Žs“c•™ŽqFæ“V«SŽŸŠ³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠw‰ü’ù‘æ2”Łvˆä‘º—T•v‘Œ•Ò,•ªŒõ“°,“Œ‹ž,2000.
  • ŒŽ’˜
    1. Uese K., Hagiwara N., Miyawaki T., and Kasanuki H. : Properties of the transient outward current in sino-atrial node cells. J Mol Cell Cardiol 31 : 1975-1984,1999.
    2. Kanegane H., Nomura K., Miyawaki T., Sasahara Y., Kawai S., Tsuchiya S., Murakami G., Futatani T., and Ochs HD. : X-linked thrombocytopenia identified by flow cytometric demonstration of defective Wiskott-Aldrich syndrome protein in lymphocytes. Blood 95 : 1110-1111,2000.
    3. Kanegane H., Tsukada S., Iwata T., Futatani T., Nomura K., Yamamoto J., Yoshida T., Agematsu K., Komiyama A., and Miyawaki T.: Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin. Exp. Immunol.120 : 512-517 ,2000.
    4. Nomura K., Kanegane H., Karasuyama H., Tsukada S., Agematsu K., Murakami G., Sakazume S., Sako M., Tanaka R., Kuniya Y., Komeno T., Ishihara S., Hayashi K., Kishimoto T., and Miyawaki T.: The genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into later stage of pre-B cells in B cell differentiation pathway. Blood 96 : 610-617,2000.
    5. Tsubata S., Bowles KR., Vatta M., Zintz C., Titus J., Muhonen L., Bowles NE., and Towbin JA. : Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardio-myopathy. J Clin Invest. 106 : 655-662,2000.
    6. Yamamoto J., Adachi Y., Onoue Y., Kanegane H., Miyawaki T., Toyoda M., Seki T., and Morohashi M. : CD30 expression on circulating memory CD4+ T cells as a Th2-dominated situation in patients with atopic dermatitis. Allergy 55 : 1011-1018,2000.
    7. Yamamoto J., Adachi Y., Onoue Y., Adachi Y.S., Okabe Y., Itazawa T., Toyoda M., Seki T., Morohashi M,. Matsushima K., and Miyawaki T.: Differential expression of the chemokine receptors by the Thl - and Th2-type effector populations within circulating CD4+ T cells . J Leuk. Biol. 68 : 568-574,2000.
    8. Striz I., Mio T., Adachi Y., Robbins R. A., Romberger D. J., Rennard S. I.: IL-4 and IL-13 stimulate human bronchial epithelial cells to release IL-8. Inflammation 23 : 545-555,1999.
    9. Striz I., Mio T., Adachi Y., Romberger D. J., Rennard S. I.: Th2-type cytokines modulate IL-6 release by human bronchial epithelial cells. Immunol. Letters 70:83-88;1999.
    10. Yamaguchi T., Murakami A., Fukahara K., Ueda T., Ichida F., Miyawaki T., and Misaki T. : Changes in T-cell receptor subsets after cardiac surgery in children.@Surg Today. 30 : 875-878,2000.
    11. Tsunoda S., Kawano M., Koni I., Kasahara Y., Yachie A., Miyawaki T., and Seki H. : Diminished expression of CD59 on activated CD8+ T Cells undergoing apoptosis in systemic lupus erythematosus and Sjgren's syndrome. Scand. J. Immunol. 51 : 293 -299,2000.
    12. Honda K., Kanegane H., Eguchi M., Kimura H., Morishima T., Masaki K., Tosato G., Miyawaki T., and Ishii E. : Large deletion of the X-linked lymphoproliferative disease gene detected by fluorescence in situ hybridization. Am. J. Hematol. 64: 128-132, 2000.
    13. Uozaki Y., Murakami A., Yanagi K., Ichida F., Hashimoto I., and Misaki T. : Total anomalous pulmonary venous connection with bronchogenic cyst in neonatal period. Jpn J Thorac Cardiovasc Surg. 48 : 583-585,2000.
    14. Bowles KR., Abraham SE., Brugada R., Zintz C., Comeaux J., Sorajja D., Tsubata S., Li H., Brandon L., Gibbs RA., Scherer SE., Bowles NE., and Towbin JA. : Construction of a highresolution physical map of the chromosome 10q22-q23 dilated cardiomyopathy locus and analysis of candidate genes. Genomics. 67 : 109-27,2000.
    15. Striz I., Mio T., Adachi Y., Carnevali S., Romberger D. J., Rennard S. I.: Effects of interferons alpha and gamma on cytokine production and phenotypic pattern of human bronchial epithelial cells. Int. J. Immuno-pharmaco. 22:573-587;2000.
    16. Miura M., Yachie A., Hashimoto I., Okabe T., Murata N., Fukuda A., and Koizumi S. : Coexistence of lymphoblastic and monoblastic populations with identical mixed lineage leukemia gene rearrangements and shared immunoglobulin heavy chain rearrangements in leukemia developed in utero. J. Pediatr. Hematol Oncol. 22 : 81-85,2000.
    17. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éD’†‹…Œž­B“ú–{¬Ž™ŠŽõ–Ɖu@12F107-111, 2000.
    18. ŽR’J”ü˜aA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA”ª–ؐMˆêF‚Ä‚ñ‚©‚ñŽ¡—Ã’†Ž~—á‚É‚š‚¯‚éÄ”­“Á’¥[”N—îˆöŽq‚ÌŠÖ—^‚ɂ‚¢‚ā[B”]‚Æ”­’B@32F15-20,2000.
    19. ‰¡“cF”VA‘«—§—YˆêA‘ºãIŒ[AŒ–쐳’mAŒÜ\—’—²•vA”öã—mˆêA‘«—§—zŽqAŽRŒ³ƒŽqA‰ª•””üŒbA”ÂàVŽõŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§Š³ŽÒ‰Æ’ë‚É‚š‚¯‚é“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚œ”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽÀ‘Ô’²žD“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïŽ@14:212-218;2000.
  • Ç—á•ñ
    1. Hamamichi Y., Okada E., and Ichida F.: Anomalous origin of the left main coronary artery from non-facing sinus of valsalva associated with sudden death in a young athlete. Cardiol Young 10 : 147-149,2000.
    2. Shinomiya N., Kanegane H., Watanabe A., Yamaguchi Y., Fuitatani T., and Miyawaki T.: Point mutation in intron 11 of Brutons's tyrosine kinase in atypical X-linked agamma-globulinemia. Pediatr Int. 42 : 689-692,2000.
    3. Ichida F.: Anomalous origin of the left main coronary artery from non-facing sinus of valsalva associated with sudden death in a young athlete. Cardiol. Young. 10 : 669,2000.
    4. ‹g“cärA‹àŒ“O˜aA‘«—§—zŽqA‹{˜e—˜’jF‘åò–åŠJ‘å‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œœœ“ªŠWˆÙŒ`¬ÇB¬Ž™‰È@41F2061-2062,2000.
    5. ŒÃ‰®FŽqA–x“c’qåA›À@—²A•œ–؉ë‹vAèŽRK—YA‹àŒ“O˜aA‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚Ì‚P—áB—Տ°¬Ž™ˆãŠw@47F175-178,1999.
  • ‘à
    1. ‹{˜e—˜’jA‹àŒ“O˜aA“ñ’J@•F‚a×–E‰Šú•ª‰»áŠQ‚Æ‚µ‚Ä‚Ì–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Տ°–ƉuŠw‰ïŽ@23F435-444,2000.
    2. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jF––œŒŒ‚s×–EƒTƒuƒZƒbƒg‚É‚š‚¯‚é×–E“àƒTƒCƒgƒJƒCƒ“‘ª’è‚̗Տ°“IˆÓ‹`BCYTOMETRY RESEARCH 10F9-16,2000.
    3. ‘«—§—YˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒqƒg––œŒŒƒwƒ‹ƒp[‚s×–Eã‚̃Pƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»B—Տ°–Ɖu@34F302-308, 2000.
    4. ‘«—§—YˆêFŽvtŠúšb‘§‚ƃÀ2ŽhŒƒÜMDIBƒAƒŒƒ‹ƒM[‚̗Տ°@20F934-934,2000.
    5. ”ª–ؐMˆêA–{‹œ˜a‹vA¬Œ@“OA‹{˜e—˜’jF¬Ž™‚̏W’†Ž¡—Á[‚¯‚¢‚ê‚ñdÏB@¬Ž™“à‰È@32F161-168,2000.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘Œ‚̖ƉuŽŸŠ³‚ðŠÜ‚߂ā`‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Տ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 59-62,2000.
    7. ‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘Œ‚̖ƉuŽŸŠ³‚ðŠÜ‚߂ā`íõF‘̐«—ò«Œ^–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Տ°@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 63-65,2000.
    8. âV“¡–œ—¢ŽqA‹àŒ“O˜aA‹{˜e—˜’jF–ƉuÇŒóŒQ`‚»‚Ì‘Œ‚̖ƉuŽŸŠ³‚ðŠÜ‚߂ā`¬’·ƒzƒ‹ƒ‚ƒ“Œ‡‘¹‚𔺂€”º«Œ^’áƒÁƒOƒƒuƒŠƒ“ŒŒÇB“ú–{—Տ°@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.32 69-71,2000.
    9. ‹àŒ“O˜aAŽÂèŒ’‘Ÿ˜YA‹{˜e—˜’jA{–è@—ºF‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚Ì•aˆöE•a‘Ô‚ÆŽ¡—ÁB¬Ž™“à‰È@32F2024-2026 ,2000.
    10. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF_ŒoÇŒóŒQ`‚»‚Ì‘Œ‚̐_ŒoŽŸŠ³‚ðŠÜ‚߂ā`Langerhans×–E‘gD‹…ÇB“ú–{—Տ°•Êû@—̈æ•ÊÇŒóŒQƒVƒŠ[ƒY 30 : 369-373,2000.
    11. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF”º«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•aˆöE•a‘Ô‚ÆŽ¡—ÁB¬Ž™“à‰È32F1992-1995 ,2000.
    12. ‘«—§—zŽqA‘«—§—YˆêFƒAƒgƒs[«”畆‰Š“û—cŽ™‚É‚š‚¯‚é‹CŠÇŽxšb‘§”­Ç‚Ì—\–hBšb‘§ 13F43-48 ,2000.
    13. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñƒvƒ‰ƒX‚ð‚à‚‘S”Ê‚Ä‚ñ‚©‚ñ‰ÆŒn‚ɂ‚¢‚āB¬Ž™‰È—Տ°@53F23- 27,2000.
    14. âV“¡@Ž A‹{˜e—˜’jFä`‘ÑŒŒ‚Ì•ªŽq¶•šŠwE–Ɖu’S“–×–EBŒŒ‰tE–ƉuEŽîᇠ5 : 257-263,2000.
    15. {–è@—ºA¬—ѐçŒbAˆÉ–{‰ÄŽ÷AŒˆä@—zA‹àŒ“O˜aA‹{˜e—˜’jFXLPFEBƒEƒCƒ‹ƒX‚É“ÁˆÙ“I‚ȖƉu•s‘SÇB‘gD”|—{HŠw 26F239-242,2000.

  • 2000”NŠw‰ï•ñ
    1. ŽíŽsq’ˆA‹g“c@‹ªA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚œKi-1 lymphomaÄ”­—áB‘æ‚S‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,2000,1,‹à‘ò.
    2. Adachi Y., Onoue Y., Yamamoto J., Adachi Y.S., Seki D., Toyoda M., Morohashi M., Matsushima K., and Miyawaki T.: Selective Expression of CD30 and CCR4, but not CCR3 on Circulating CD4+ Cells as a Marker for Th2-type. AAAI,2000,2,
    3. ãšŒhˆê˜YAŒIŒŽ^‹IŽqA’ÔŠáÁˆêA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA ‰F‰—è‘׍OF‹CŠÇŽx“Ç‚ð‡•¹‚µ’˜–Ÿ‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚œSŽº’†ŠuŒ‡‘¹‚̈ê—áB‘æ19‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,2000,2,‹à‘ò.
    4. à_“¹—T“ñAŒ“c–€A‰ª•”@ŒhAŽO‰Y³‹`A–ìè‹IŽqAç’¹“N–çAŽs“c•™ŽqF‘ÙŽ™Šú‚æ‚èãŽº«•p”‚ð’悵Ž¡—Âɓïa‚µ‚œˆê—áB‘æ‚U‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŒ€‹†‰ï,2000,2,_“ސì.
    5. ŒIŒŽ^‹IŽqA“n•Óˆ»‰ÀAãšŒhˆê˜YA’ÔŠáÁˆêA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jA‰F‰—è‘׍OF‹CŠÇŽx“Ç‚ð‡•¹‚µ’˜–Ÿ‚È”x‚ŒŒˆ³‚ð‡•¹‚µ‚œSŽº’†ŠuŒ‡‘¹‚̈ê—áB‘æ6‰ñ¬Ž™”xzŠÂŒ€‹†‰ï,2000,2,“Œ‹ž.
    6. ŽRŒ³ƒŽqA‘«—§—YˆêA”öã—mˆêA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºA‹{˜e—˜’jFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––œŒŒT×–E‚É‚š‚¯‚éƒPƒ‚ƒJƒCƒ“EƒŒƒZƒvƒ^[”­Œ»‚ɂ‚¢‚āB‘æ21‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,2,•xŽRD
    7. ”ª–ؐMˆêA¬Œ@“OA“n•Óˆ»‰ÀAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jAŽRŒ³ƒŽqAFè@Œ’F‘ÙŽ™…Žî‚ð’悵‚œƒŠƒ\ƒ\-ƒ€•a‚Ì’jŽ™—áB‘æ37‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,2000,2,‹à‘ò.
    8. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêA‘ºãIŒ[F¬Ž™‚É‚š‚¯‚éƒlƒRƒAƒŒƒ‹ƒM[‚̗Տ°B‘æ10‰ñ“’“cãƒJƒ“ƒtƒ@ƒŒƒ“ƒXšb‘§ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,2,VŠƒD
    9. Hashimoto I., Mori Y., Xiaokui L., Suthep W., Rosemary A R., and D. J. Sahn. : Strain rate imaging : An in vitro validation study using a physiologic balloon model mimicking the Left ventricle. American College of Cardiology 49th Annual Scientific Session,2000,3,California.
    10. “n•Óˆ»‰ÀA‹g“cärA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jA“c’†’ŒŽqA–Ø‘º@GFƒKƒ“ƒVƒNƒƒrƒ‹“Š—^‚ðs‚Á‚œæ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ‚̈ê—áB‘æ268‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2000,3,‹à‘ò.
    11. Œ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF’·ŠúŠÔ–³”­ì‚ÅŒo‰ß‚µ‚Ä‚¢‚é‹CŠÇŽxšb‘§Ž™‚Ì‹C“¹‰ß•q«‚š‚æ‚ьċz‹@”\‚̐„ˆÚ‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ36‰ñ‹C“¹‰ß•q«Œ€‹†‰ï,2000,3,“Œ‹žD
    12. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF“M…Œã‚É“_“ª‚Ä‚ñ‚©‚ñ‚𔭏ǂµ‚œˆê—áB‘æ24‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,2000,3,‹à‘ò.
    13. –{‹œ˜a‹vA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFÇŒó«‘S”Ê‚Ä‚ñ‚©‚ñB‘æ24‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,2000,3,‹à‘ò.
    14. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‹{˜e—˜’jFƒAƒgƒs[«”畆‰Š––œŒŒƒTƒuƒZƒbƒg‚ł̃Pƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚̗Տ°“IˆÓ‹`B‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    15. ‹àŒ“O˜aA{–è—ºAŽÂèŒ’‘Ÿ˜YAŒ‘q—TŠìAŒˆä@—zA˜`@˜a”üA]Œû^—ŽqA–{“cŒiŽqAÎˆäžÄˆêA‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘BŽŸŠ³‚É‚š‚¯‚é‚r‚`‚oˆâ“`ŽqˆÙíB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    16. –쑺ŒbŽqA‹àŒ“O˜aAãŒˆê‰iA¬‹{ŽR~A‹{˜e—˜’jF‚w˜Aœ–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚鍜‘‚a‘O‹ì×–E‚̉ðÍB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    17. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–쏺GFœœE“ªŠWˆÙŒ`¬Ç‚É‚š‚¯‚éCBFA1•ÏˆÙB‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    18. ˜°@Œ›ˆêA‹Ž–{ˆè•vAŽs“c•™ŽqAãšŒhˆê˜YAà_“¹—T“ñA’ÔŠáÁˆêA‹{˜e—˜’jFƒWƒsƒŠƒ_ƒ‚[ƒ‹•‰‰×Integrated Backscatter‚É‚æ‚éìè•aŒãS‹Ø‹•ŒŒ‚̐f’fB@‘æ103‰ñ“ú–{¬Ž™‰ÈŠw‰ï,2000,4,˜a‰ÌŽR.
    19. ‘«—§—YˆêAŽRŒ³ƒŽqA‰ª•””üŒbA”öã—mˆêAŒ“‡jŽ¡A‹{˜e—˜’jF––œŒŒ‚s×–E‚É‚š‚¯‚éTh2ƒ}[ƒJ[‚Æ‚µ‚ẴPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[- CCR3‚ÆCCR4‚ɂ‚¢‚Ä -B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2000,4,•Ÿ‰ª.
    20. Œ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêA‹gZ@ºFƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚̗Տ°“IŒŸ“¢@- dl ‘Ì‚Æ l ‘Ì‚Ì”äŠrŒŸ“¢ -B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2000,4,•Ÿ‰ª.
    21. ”ÂàVŽõŽqA‘ºãIŒ[A‰¡“cF”VA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ‚ÌŠÖ—^‚Ì‹Gß“I•Ï“®@-MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä-B‘æ12‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,2000,4,•Ÿ‰ª.
    22. ‘«—§—zŽqA‰ª•””üŒbA”‘òŽõŽqA‘«—§—YˆêA‹{˜e—˜’jFƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚ւ̈ڍs‚ƃlƒR‚È‚ç‚тɐH•šƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ37‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,2000,4,•xŽRD
    23. ŽÂèŒ’‘Ÿ˜YA‹àŒ“O˜aAŒ‘q—TŠìA‹{˜e—˜’jA{–è—ºF‚w˜AœƒŠƒ“ƒp‘BŽŸŠ³‚̊ȈՐf’f–@‚ÌŠJ”­B‘æ10‰ñEBƒEƒBƒ‹ƒXŒ€‹†‰ï,2000,5,“Œ‹ž.
    24. –쑺ŒbŽqA‹àŒ“O˜aA‹{@ˆêŽuA‹{˜e—˜’jA¯–ì@—mA–Ø‘º@GA–Ø‘º’šGA‘哇FˆêF“¯Ží––œŒŒŠ²×–EˆÚA‚ðs‚Á‚œEBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-T×–EƒŠƒ“ƒpŽî‚̈ê—áB‘æ10‰ñEBƒEƒBƒ‹ƒXŒ€‹†‰ï,2000,5,“Œ‹ž.
    25. Kanegane H., Futatani T., Nomura K., and Miyawaki T. : Genetic analysis of X-linked agammaglobulinemia identified by flow cytometricanalysis in unrelated 65 Japanese families. The 7th international workshop and conference on human leucocyte differentation antigens.,2000,6,Harrogate,U.K.
    26. Nomura K., Kanegane H., Karasuyama H., and Miyawaki T.: Genetic defect in human X-linked agammaglobulinemia impedes the maturational evolution of pro-B cells into later stage of pre-B cells in the B cell differentiation pathway. The 7th international workshop and conference on human leucocyte differentation antigens.,2000,6,Harrogate,U.K.
    27. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA“n•Óˆ»‰ÀA’†—ÑŒºˆêA‘ºãIŒ[A–{ŠÔˆê³A–î•”‚Ý‚Í‚éFŒŒ¬”ÂŒž­‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œFanconi•nŒŒ‚̈ê—áB‘æ269‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,2000,6,‹à‘ò.
    28. Œ‘q—TŠìA”öã—mˆêA‹{˜e—˜’jFƒVƒNƒƒtƒHƒXƒAƒ~ƒhEƒpƒ‹ƒX—Ö@‚ª—LŒø‚Å‚ ‚Á‚œƒ‹[ƒvƒXt‰Š‚̈ê—áB‘æ35‰ñ“ú–{¬Ž™‰ÈŠw‰ït‘Ÿ•aŠw‰ï,2000,6,•Ÿ‰ª.
    29. –{‹œ˜a‹vAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA¬Œ@“OF”­ì«‰^“®—U”­«•‘“¥ƒAƒeƒg-ƒ[‚ɐ_Œo’²ß«Žž_‚ð‡•¹‚µ‚œ1—áB‘æ42‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2000,6,‘åã.
    30. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêFŒ’íŽ™”]‚Ì‚É‚š‚¯‚éŠD”’Ž¿‚š‚æ‚Ñ”’Ž¿‘̐ς̔N—î“I•Ï‰»B‘æ42‰ñ“ú–{¬Ž™_ŒoŠw‰ï,2000,6,‘åã.
    31. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA‹{@ˆêŽuF“¯Ží––œŒŒŠ²×–EˆÚA‚ðs‚Á‚œEBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-T×–EƒŠƒ“ƒpŽî‚̈ê—áB‘æ‚T‰ñ•xŽR‘¢ŒŒŠ²×–EˆÚA§˜b‰ï,2000,6,•xŽR.
    32. ‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’j, D.J. Sahn.FTissue Doppler ƒGƒR[–@‚ÌDoppler AngleˆË‘¶«‚ÌŒŸ“¢B‘æ7‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,2000,6,‹à‘ò.
    33. ˜°@Œ›ˆêA‹Ž–{ˆè•vAŽs“c•™ŽqAà_“¹—T“ñAãšŒhˆê˜YA’ÔŠáÁˆêA‹{˜e—˜’jAD. J. SahnA£ŒË@ŒõFTissue Doppler ƒGƒR[–@‚ÌDoppler AngleˆË‘¶«‚ÌŒŸ“¢B‘æ7‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,2000,6,‹à‘ò.
    34. Kanegane H., Yoshida T.,and Miyawaki T.: Clinical and genetic analysis of cleidocranial dysplasia in Japan. International workshop on the runt-domain transcription factors,2000,7,Kyoto.
    35. ŒIŒŽ^‹IŽqAFè@Œ’Aà_“¹”ü‹IA‘«—§—YˆêF“Á”­«”xƒwƒ‚ƒWƒfƒ[ƒVƒX‚Ì‚P’jŽ™—áD‘æ‚T‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,2000,7,•xŽR.
    36. ˜°@Œ›ˆêAL–ìŒbˆêAà_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFìè•a‹}«Šú‚É‚š‚¯‚é’P‹…‚Å‚ÌVEGF‚ÆiNOS”­Œ»‚̈Ӌ`B‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    37. à_“¹—T“ñAL–ìŒbˆêAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF–{–M‚É‚š‚¯‚éIsolated noncompaction of ventricular myo-cardium‚̒ǐՒ²žB‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    38. Žs“c•™ŽqA’ÔŠáÁˆêAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vA‹{˜e—˜’jAJ A. TowbinFS‹Øãk–§‰»áŠQ‚̈â“`Žq‰ðÍB‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    39. ãšŒhˆê˜YAŒIŒŽ^‹IŽqA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–؁@–ŸF‰^“®Žž‚ÌŽž_”­ì‚É‚Ä”­Ç‚µ‚œŠî‘bŽŸŠ³‚Ì‚È‚¢S–[‘e“®‚̈ê—áB‘æ36‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,2000,7,Ž­Ž™“‡.
    40. Kanegane H., Shinozaki K., Sumazaki R., Matsukura H., and Miyawaki T. : Genetic analysis of X-linked lymphoproliferative disease in Japan. 28th World congress of the international socity of hematology,2000,8,Toronto,Canada.
    41. ¬ìŽŸ˜YAà_“¹”ü‹IA‹g“cärA‹{˜e—˜’jA²X–؁@‘ׁAœA–ìŒbˆêA”öã—mˆêFKasabach-MerrittÇŒóŒQ‚̈êV¶Ž™—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–ŒŒÃ‰®.
    42. ‰eŽR—²ŽiA’ÔŠáÁˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹Ž–{ˆè•vAŽs“c•™ŽqAŒE“c”Ž“¹A‹{˜e—˜’jF_Œoß‰èŽîŠ°‰ðŒã‰“ŠuŠú‚É‘ˆ«‚µ‚œ”ÓŠúS‹@”\áŠQ‚̈ê—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–ŒŒÃ‰®.
    43. “ŒŽROKAŽíŽsq’ˆA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jFRGM1bR‘Ì—z«‚̃Mƒ‰ƒ“ƒoƒŒ[ÇŒóŒQ‚̈ê—áB‘æ36‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,2000,8,–ŒŒÃ‰®.
    44. ‹àŒ“O˜aFƒCƒuƒjƒ“ƒOƒZƒ~ƒi[u–ƉuŠÄŽ‹‹@\‚Ì”jù‚Æ‚»‚̑΍ô`æ“V«ŒŒ‰t–ƉuˆÙíÇ‚̐f’f‚̐i•àvB‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    45. –쑺ŒbŽqAŽíŽsq’ˆA‹àŒ“O˜aA‹{˜e—˜’jFR‘ã‘ÖŒyœ’PƒNƒ[ƒ“R‘Ì‚ð—p‚¢‚œ‚a×–E«ƒŠƒ“ƒp«”’ŒŒ•a‚̍וª—Þ‚ÌŽŽ‚݁B‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    46. ŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“¯Žíœ‘ˆÚA‚ðŽ{s‚µ‚œKi-1 lymphomaÄ”­—áB‘æ42‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,2000,9,‘åã.
    47. –{‹œ˜a‹vAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA¬Œ@“OA‹{˜e—˜’jF”M«áz¹Œã‚ɁAŒã“ª•”ž™™”g‚ðŽŠ‚·—ǐ«‚Ä‚ñ‚©‚ñ‚𔭏ǂµ‚œÇ—á‚̗Տ°“IŒŸ“¢B‘æ34‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2000,9,‘åã.
    48. ‰eŽR—²ŽiAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA¬Œ@“OFƒJƒ‹ƒoƒ}ƒ[ƒsƒ“‚É‚æ‚è”­]A–³è÷—±‹…ÇA’áƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚𗈂µ‚œ4Î—Ž™—áB‘æ34‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,2000,9,‘åã.
    49. –{‹œ˜a‹vAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jAŒE“c”Ž“¹FLeigh”]Ç‚̈ê—áB‘æ38‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,2000,9,‹à‘ò.
    50. Œ‘q—TŠìA”öã—mˆêA‹{˜e—˜’jF‹}«Ž…‹…‘̐t‰Š—l‚Ì”­Ç‚ð‚µ‚œ–Œ«‘B«t‰Š‚̈ê—áB‘æ‚W‰ñ’†•”¬Ž™t‘Ÿ•aŒ€‹†‰ï,2000,9,Šò•Œ.
    51. ’ÔŠáÁˆêAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“y”ì‘P˜YA‰F‰—è‘׍OF—‘‰~E‚̕œ‚Ì‚œ‚ߌŒŠÇ‘¢‰e‚É‚æ‚éVSD‚̈ʒu‚ÌŠm”F‚É“ïa‚µ‚œTGA(III)B‘æ20‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,2000,9,‹à‘ò.
    52. –{‹œ˜a‹vAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA¬Œ@“OF‚Ä‚ñ‚©‚ñ‚ÌŒo‰ß’†‚ÉŒŸŒêáŠQ‚ð‚«‚œ‚µ‚œ—Ž™—áB‘æ‚W‰ñ•xŽRŒ§¬Ž™—Տ°_ŒoŠwŒ€‹†‰ï,2000,9,•xŽR .
    53. ”ª–ؐMˆêAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’j@¬Œ@“OFƒ`ƒbƒN‚ÆŠÓ•Ê‚ð—v‚µ‚œ‚Ä‚ñ‚©‚ñ‚ÌŒZ’í—áB‘æ‚W‰ñ•xŽRŒ§¬Ž™—Տ°_ŒoŠwŒ€‹†‰ï,2000,9,•xŽR.
    54. ‰¡“cF”VA‘«—§—zŽqA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFŠO—ˆ‚Å‚Ì‹CŠÇŽxšb‘§Ž™‚ɑ΂·‚éŒÄ‹z‹@”\‘ª’è‚Ì—L—p«-ƒÀ2ŽhŒƒÜ‹z“ü‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢-B‘æ‚R‰ñ•xŽR¬Ž™šb‘§EƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,9,•xŽRD
    55. ‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[«ŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@šb‘§‚É‚š‚¯‚é‹C“¹ã”ç -‹C“¹ã”ç‚ƃTƒCƒgƒJƒCƒ“-vB‘æ‚R‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,10,“Œ‹ž.
    56. Œ–쐳’mA‘«—§—YˆêAŒÜ\—’—²•vFƒVƒ“ƒ|ƒWƒEƒ€uƒAƒŒƒ‹ƒM[«ŽŸŠ³‚Ì•a‘Ô‚ÆŽ¡—Á@šb‘§Ž™‚ÌŽ¡—ÂƊǗ -‹C“¹‰ß•q«‚Æ‚»‚̉ü‘P- vB‘æ‚R‰ñ¬Ž™‹C“¹ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,10,“Œ‹ž.
    57. “ñ’J@•A¬ìŽŸ˜YA‰eŽR—²ŽiAâV“¡–œ—¢ŽqA‹{˜e—˜’jA²X–؁@‘ׁF–òÜ‚É‚æ‚é“ñŽŸ«’áƒAƒ‹ƒhƒXƒeƒƒ“Ç‚ƍl‚Š‚ç‚ê‚œV¶Ž™—áB‘æ14‰ñ–k—€–¢nŽ™§˜b‰ï,2000,10,‹à‘ò.
    58. Ichida F., Haneda N., Karla R.B., Tsubata S., Miyawaki T., Hua Li, Neil E. B., and J.A. Towbin. : ƒ¿-Dystrobrevin mutations in nonisolated left ventricular noncompaction and evidence for genetic heterogeneity. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    59. Hashimoto I., Gordon Mack, and D.J Sahn. : Strain rate imaging: an in vitro "Validation" study using a balloon model mimicking the left ventricle. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    60. Xianyi Yu, Hashimoto I., Ichida F., Uese K., Hamamichi Y., Tsubata S., and Miyawaki T.: Dipyridamole Stress Ultrasonic Myocardial Tissue Characterization in Patients with History of Kawasaki Disease. The 73rd scientific sessions of American heart association,2000,11,New Orleans.
    61. ‰ÆéˆŸ‹IŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAŽðˆä³—˜AâV“¡@Ž AˆäoŒû@—TFƒÀ-thalassemia‚ɑ΂·‚éo¶‘Of’fB‘æ21‰ñ–k—€æ“VˆÙíŒ€‹†‰ï,2000,11,•Ÿˆä.
    62. ‹àŒ“O˜aA“ñ’J@•A–쑺ŒbŽqA’Ë“c@‘A‹{˜e—˜’jF’áƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éBtkˆâ“`Žq•ÏˆÙFŠÈˆÕf’f‚ƈâ“`Žq‰ðÍB‘æ30‰ñ“ú–{–ƉuŠw‰ï,2000,11,å‘ä.
    63. ŽÂèŒ’‘Ÿ˜YA‹àŒ“O˜aAŒ‘q—TŠìA{–è@—ºA‹{˜e—˜’jFRSAP’PƒNƒ[ƒ“R‘̂̍쐬‚Æ‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚̊ȈՐf’fB‘æ30‰ñ“ú–{–ƉuŠw‰ï,2000,11,å‘ä.
    64. ‘«—§—YˆêA”ÂàVŽõŽqA‰ª•””üŒbA”öã—mˆêA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF‰@“àE‰@ŠO–ò‹Ç‚É‚š‚¯‚éšb‘§Š³ŽÒ‚ɑ΂·‚é‹z“üŽw“±‚ÌŽÀ‘Ô’²žB‘æ33‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,2000,11,Ž­Ž™“‡.
    65. ‘«—§—YˆêFƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[u‹z“ü—Ö@‚ÌŽÀÛ -ƒÀŽhŒƒÜ‚ɂ‚¢‚Ä-vB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹Ž.
    66. ”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jF––œŒŒ’P‹…‚©‚ç‚ÌIL-12ŽY¶”\@-”N—î‚É‚æ‚鍷ˆÙ‚ɂ‚¢‚Ä-B‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹Ž.
    67. •l“¹—T“ñAŒ“c–€A‰ª•”@ŒhAŽO‰Y³‹`A‘«—§—YˆêA‹{˜e—˜’jF‘Šú‚̃Cƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚É‚æ‚è‹~–œ‚µ“Ÿ‚œˆÓŽ¯áŠQ‚𔺂€šb‘§‘å”­ìiƒjƒAƒ~ƒXj‚Ì‚P—áB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹Ž.
    68. ‰¡“cF”VA‘«—§—zŽqA‰ª•””üŒbA”ÂàVŽõŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF‹CŠÇŽxšb‘§¬Ž™‚É‚š‚¯‚éƒÀŽhŒƒÜ‹z“ü‚ɑ΂·‚锜‰ž«‚ÌŒŸ“¢@-Ž¡—ÂƂ̊֌W‚ɂ‚¢‚Ä-B‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹Ž.
    69. ‘«—§—zŽqA•l“¹”ü‹IA”öã—mˆêAŠâ’J‰ëŽqAŠžŒŽ¹ŽqA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«ŽŸŠ³Š³Ž™‚É‚š‚¯‚éƒlƒRRŒŽœ‹ŽŽw“±‚ÌŒø‰Ê‚ɂ‚¢‚āB‘æ37‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,2000,11,‘O‹Ž.
    70. ‹àŒ“O˜aA‰€@‰xAŽÂèŒ’‘Ÿ˜YA‹{˜e—˜’jA¯–ì@—mA–Ø‘º@GF–«Šˆ“®«EBƒEƒBƒ‹ƒXŠŽõÇ‚É‚š‚¯‚éSAP/SH2D1Aˆâ“`Žq‰ðÍB‘æ32‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2000,11,“Œ‹ž.
    71. ‘匎“N•vA–쑺ŒbŽqA‰€@‰xA‹àŒ“O˜aA‹{˜e—˜’jAŒIŒŽ^‹IŽqAFè@Œ’A¯–ì@—mA–Ø‘ºGFEBƒEƒBƒ‹ƒX‰ŠŽõ‚É‚æ‚錌‹…æÐHƒŠƒ“ƒp‘gD‹…‘BÇ‚Ì‚P—áB‘æ32‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2000,11,“Œ‹ž.
    72. –쑺ŒbŽqA“n•Óˆ»‰ÀA‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA“c’†’ŒŽqA–Ø‘º@GFƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒX-DNAƒRƒs[”‚ðŒoŽž“I‚ÉŠÏŽ@‚µ‚Š‚œæ“V«ƒTƒCƒgƒƒKƒƒEƒBƒ‹ƒXŠŽõÇ‚Ì‚P—áB‘æ32‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,2000,11,“Œ‹ž.
    73. “n•Óˆ»‰ÀA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒUŠŽõ‚É”º‚¢BickerstaffŒ^”]Š²”]‰Š‘œ‚ð’悵‚œ‹}«ŽUÝ«”]Ò‘‰Š‚̏—Ž™—áB‘æ32‰ñ“ú–{¬Ž™ŠŽõ–ƉuŠw‰ï,2000,11,“Œ‹ž.
    74. ‰ª•””üŒbA‘«—§—YˆêAŽRŒ³ƒŽqA”ÂàVŽõŽqA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºAŒ“‡jŽ¡FƒAƒgƒs[«”畆‰Š––œŒŒ‚s×–E‚É‚š‚¯‚éCLA‚ƃPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚ÌŠÖŒWB‘æ50‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2000,11,‰¡•l.
    75. ‘«—§—YˆêA‰¡“cF”VA”ÂàVŽõŽqA‰ª•””üŒbAŽRŒ³ƒŽqA”öã—mˆêA‘«—§—zŽqA‘ºãIŒ[A‹{˜e—˜’jF–òÜŽt‚É‚æ‚éšb‘§Š³ŽÒ‹z“üŽw“±‚ÌŽÀ‘Ô’²žB‘æ50‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,2000,11,‰¡•l.
    76. ‘«—§—zŽqA”öã—mˆêA‘«—§—YˆêA‘ºãIŒ[A‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«ŽŸŠ³Š³Ž™‚É‚š‚¯‚éƒlƒRRŒŽ‚ÌŠÖ—^‚Æ‚»‚̑΍ôB‘æ27‰ñ–k—€ƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,11,‹à‘ò.
    77. ”ÂàVŽõŽqA‘ºãIŒ[A‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‚Ìšb‘§”­ì‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ‚ÌŠÖ—^-––œŒŒƒŠƒ“ƒp‹…“à‚ÌMxA’`”’”­Œ»‚ðŽw•W‚Æ‚µ‚Ä-B‘æ9‰ñ—Տ°–ò—EƒAƒŒƒ‹ƒM[E–ƉuŒ€‹†‰ï‚È‚ç‚Ñ‚É‘æ‚P‰ñH•šƒAƒŒƒ‹ƒM[Œ€‹†‰ï,2000,11,“Œ‹žD
    78. ‹g“cärA‹àŒ“O˜aAâV“¡–œ—¢ŽqAd’菟ÆAˆÉ“¡‰Ã–ŸAˆÀˆä‰Ä¶A‹{˜e—˜’jF‚킪‘‚É‚š‚¯‚鍜œ“ªŠWˆÙŒ`¬Ç‚̗Տ°“IEˆâ“`Šw“IŒŸ“¢B‘æ12‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïœŒn“ŽŸŠ³Œ€‹†‰ï,2000,11,ç—t.
    79. Œ‘q—TŠìAŽíŽsq’ˆA‹{˜e—˜’jAV’J®‹vFƒPƒCƒLƒTƒŒ[ƒgˆ—ƒ~ƒ‹ƒN‚É‚æ‚荂‚jŒŒÇ‚ðƒRƒ“ƒgƒ[ƒ‹o—ˆ‚œ“ûŽ™–«t•s‘S‚̈ê—áB‘æ14‰ñ–k—€CAPD—Տ°§˜b‰ï,2000,12,‹à‘ò.
    80. ŽíŽsq’ˆA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFä`‘ÑŒŒŠ²×–EˆÚA‚ðs‚È‚Á‚œgp91-phoxŒ‡‘¹–«“÷‰èŽîÇB‘æ‚W‰ñH×–E‹@”\Œ€‹†‰ï,2000,12,“Œ‹ž.

    1999”N

  • ’˜‘
    1. Žs“c•™ŽqFŒŽ”­«”x‚ŒŒˆ³ÇBu¬Ž™‚ÌŽ¡—ÃŽwjv‘OìŠì•œ‘Œ•Ò,261-263,f’f‚ÆŽ¡—ÃŽÐ,“Œ‹ž,1999.
    2. Žs“c•™ŽqF”ì‘åŒ^S‹ØÇBu¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ12”Łv–î“cƒˆê‘Œ•Ò,111,ˆãŠw‘‰@,1999.
    3. Žs“c•™ŽqFS“à–ŒüˆÛ’e«ÇBu¡“ú‚̏zŠÂŠíŽŸŠ³Ž¡—ÃŽwj‘æ‚Q”Łv×“cºˆê‘Œ•Ò,ˆãŠw‘‰@,1999.
    4. ¡‘º”Ž–ŸA‹{˜e—˜’jF–ƉuŠw“IŒŸžBu¬Ž™‰ÈŒ€Cˆãƒm[ƒgvŽR’†—ŽG‘Œ•Ò,387-390,f’f‚ÆŽ¡—ÃŽÐ,“Œ‹ž,1999.
    5. ‹àŒ“O˜aA‹{˜e—˜’jA{–è@—ºF‚w˜AœƒŠƒ“ƒp‘BŽŸŠ³iDuncan•aj‚ÆSAPˆâ“`ŽqˆÙíBuAnnual Review –Ɖu2000v–î“cƒˆê‘Œ•Ò,335-341,’†ŠOˆãŠwŽÐ,“Œ‹ž,1999.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF—Տ°‚ɖ𗧂f’f“I–ƉuŠw‚Ö‚Ì—U‚¢BuJAMA–ƉuEƒAƒŒƒ‹ƒM[“ÁWvŠÝ–{’‰ŽOŠÄC,33-46,–ˆ“úV•·ŽÐ,“Œ‹ž,1999.
    7. ”öã—mˆêFƒSƒLƒuƒŠ‚Æšb‘§Bu‹CŠÇŽx‚º‚ñ‘§‚ÉŠÖ‚í‚é‰Æ’ë“à‹z“üƒAƒŒƒ‹ƒQƒ“@Œ»Ý‚Ì’mŒ©‚Æ‚»‚̑΍ôv,¬‰®“ñ˜Z,‰i‘qr˜a•Ò,ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ,“Œ‹ž,203-212,1999.
    8. ”öã—mˆêFƒ`ƒƒƒ^ƒeƒ€ƒV‚Æšb‘§Bu‹CŠÇŽx‚º‚ñ‘§‚ÉŠÖ‚í‚é‰Æ’ë“à‹z“üƒAƒŒƒ‹ƒQƒ“@Œ»Ý‚Ì’mŒ©‚Æ‚»‚̑΍ôv¬‰®“ñ˜Z,‰i‘qr˜a•Ò,ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ,“Œ‹ž,219-226,1999.
  • ŒŽ’˜
    1. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., Fukahara K., Murakami A., Nakajima A., Futatsuya R., and Miyawaki T. : Evaluation of pulmonary blood supply by multiplanar cine magnetic resonance imaging in patients with pulmonary atresia and severe pulmonary stenosis. Int. J. of Cardiac Imaging 15:306-312,1999.
    2. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Murakami A., and Miyawaki T.: Novel technique using biplane cine magnetic resonance imaging for evaluation of left ventricular volume in children. Int. J. of Cardiac Imaging. 15:412-416,1999.
    3. Ichida F., Hamamichi Y., Miyawaki T., Ono Y., Kamiya T., Akagi T.,Hamada H., MD, Hirose O., Isobe T., Yamada K., Kurotobi S., Mito H.,Miyake T., Murakami Y., Nishi T., Shinohara M., Seguchi M., Tashiro S., and Tomimatsu H. : Clinical features of isolated noncompaction of the ventricular myocardium. Long-term clinical course, hemodynamic properties, and genetic background. J. Am. Coll. Cardiol. 34 : 233-240,1999.
    4. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., Miyawaki T., and Tosato G.FIncreased cell-free viral DNA in fatal cases of chronic active Epstein-Barr virus infection. Clin. Infect. Dis. 28:906-909,1999.
    5. Hashimoto I., Ichida F., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., and Miyawaki T.: A novel method for indexing echocardiographic left ventricular mass in infants, children and adolescents: Evaluation of obesity-induced left ventricular hypertrophy. Pediatr. Int. : 41,126-131,1999.
    6. Hashimoto I., Ichida F., Miura M., Okabe T., Kanegane H., Uese K., Hamamichi Y., Misaki T., Koizumi S., and Miyawaki T.: Automatic border detection identifies asymptomatic anthracycline cardiotoxicity in children with malignancy. Circulation 99:2367-2370,1999.
    7. Tsurusawa M., Katano N., Yamamoto Y., Hirota T., Koizumi S., Watanabe A., Takeda T., Hatae Y., Yatabe M., Mimaya J., Gushiken T., Nishi K., Anami K., Kikuta A., Kanegane H., Asami K., Nishikawa K., Sekine I., Kawano Y., Iwai A., Furuyama T., Ijichi O., Miyake M., Mugishima H., Ota S., and Fujimoto T.FImprovement in CNS protective treatment in Non-High-Risk childhood acute lymphoblastic leukemia: Report from the Japanese children's cancer and leukemia study group. Med. Pediatr. Oncol. 32: 259-266,1999.
    8. Hashimoto S., Miyawaki T., Futatani T., Kanegane H., Usui K., Nukiwa T., Namiuchi S., Matsushita M., Yamadori T., Suemura M., Kishimoto T., and Tsukada S. : Atypical X-Iinked agammaglobulinemia diagnosed in three adults.Intern. Medi. 38 : 722-725,1999.
    9. Striz I., Mio T., Adachi Y., Heires P., Robbins R. I., Spurzem J. R., Illig M. J., Romberger D. J., and Rennard S.I. : IL-4 induces ICAM-1 expression in human bronchial epithelial cells and potentiates TNF-ƒ¿. Am. J. Physiol. 277 : L58-L64, 1999.
    10. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêF•”•ª”­ìÇó‚ð”F‚ß‚œŒ‡_‚Ä‚ñ‚©‚ñÇ—á‚̗Տ°”]”g“Á’¥B”]‚Æ”­’B 31 : 395-401,1999.
    11. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñ‚Ì—\–h“Š—^‚ƍĔ­|AED˜A‘±“Š—^‚ÆDZPŠÔŒ‡“Š—^–@‚Ì”äŠrˆêB¬Ž™‰È—Տ° 52F21-26,1999.
  • Ç—á•ñ
    1. Kanegane H., Nomura K., Miyawaki T., Sasahara Y., Kawai S., Tsuchiya S., Murakami G., Futatani T., and Ochs MD.FX-linked thrombocytopenia identified by flow cytometric demonstration of detective Wiskott-Aldrich protein in lymphocytes. Blood. 95: 1110-1111, 1999.
  • ‘à
    1. Kanegane H., Miyawaki T., Yachie A., Oh-ishi T., Bahtia K., and Tosato G. : Development of EBV-positive T-cell lymphoma following infection of peripheral blood Tcells with EBV. Leuk. Lym. 34 : 603-607,1999.
    2. ‘«—§—YˆêF‹CŠÇŽxšb‘§‚Ì‹C“¹‰ß•q«B¬Ž™‰È—Տ°@52F1665-1669,1999.
    3. ”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™‚Ì”MŽË•aE”M’†ÇB@“ú–{çΎ–V•ñ@3926 : 28-32,1999.
    4. –{‹œ˜a‹vA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF‚¯‚¢‚ê‚ñB¬Ž™“à‰È@31(‘)F278-284,1999.
    5. –{‹œ˜a‹vA¬Œ@“OA‘ŽqDAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF‚¯‚¢‚ê‚ñ«ŽŸŠ³‚̐f’fAŽ¡—ÂƗ\–h—ǐ«“ûŽ™‚¯‚¢‚ê‚ñB¬Ž™“à‰È@31F551-555,1999.
    6. ‹àŒ“O˜aA‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇB—Տ°ŒŸž 43F425-428,1999.
    7. ‹àŒ“O˜aA{–è@—ºA‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘B«ÇŒóŒQ‚̐¬ˆö‚Æ‚µ‚Ä‚Ì‚r‚`‚oˆâ“`ŽqˆÙíB—Տ°–Ɖu@32F631-636,1999.
    8. ‹àŒ“O˜aA‹{˜e—˜’jF–Ÿ‚ç‚©‚É‚³‚ê‚œ‚w˜AœƒŠƒ“ƒp‘B«ÇŒóŒQ‚ÌŒŽˆöˆâ“`ŽqBˆãŠw‚Ì‚ ‚ä‚Ý 189F898-899,1999.
    9. ‹àŒ“O˜aA‹{˜e—˜’jFŒŽ”­«–ƉuÇŒóŒQiŽå‚Æ‚µ‚čR‘ÌŽY¶•s‘S‚ðŽŠ‚·‚à‚́jB¬Ž™‰Èf—à 62(‘)F118-119,1999.
    10. ‹àŒ“O˜aA˜eŒû@GFEBƒEƒBƒ‹ƒXŠŽõÇ‚É‚š‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10B¬Ž™ŠŽõ–Ɖu11F151-156 ,1999.

  • 1999”NŠw‰ï•ñ
    1. ”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFATGAƒVƒNƒƒXƒ|ƒŠƒ“‚`AG-CSF“Š—^‚É‚æ‚芰‰ð‚ð“Ÿ‚œ“Á”­«Ä¶•s—ǐ«•nŒŒ‚̏—Ž™—áB‘æ‚R‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,1999,1,‹à‘ò.
    2. ‘«—§—YˆêAŽRŒ³ƒŽqA”öã—mˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––œŒŒ‚s×–Eã‚É”­Œ»‚·‚éCD30‚̈Ӌ`- Th2ƒ^ƒCƒv—DˆÊ‚ÌŽw•W‚Æ‚µ‚Ä-A‘æ20‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,1999,1,•xŽR.
    3. ŽR’J”ü˜aA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqA”ª–ؐMˆêA‹{˜e—˜’jFParoxysmal kinesigenic choreoathetosis ‚Ì‚P‰ÆŒnB‘æ35‰ñ¬Ž™_Œo–k—€’n•û‰ï,1999,2,•xŽR.
    4. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™_ŒoŽŸŠ³‚É‚š‚¯‚éƒvƒƒgƒ“MRS‚̗Տ°‰ž—p.‘æ35‰ñ¬Ž™_ŒoŠw‰ï–k—€’n‰ï,1999,2,‹à‘ò.
    5. Hamamichi Y., Ichida F., Tsubata S., Hashimoto I., Uese K., and Miyawaki T.FLow-dose dobutamine stress radionuclide ventriculography reveal silent myocardial dysfunction in Kawasaki Disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    6. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., and Miyawaki T.FDipyridamole stress cine MRI of coronary arteries in Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    7. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Futatani T., Kanegane H., and Miyawaki T.FVascular endothlial growth factor in acute Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    8. Hashimoto I., Ichida F., Uese K., Hamamichi Y., and Miyawaki T.FEvaluation of silent myocardial ischemia using dipyridamole stress acoustic densitometry in children with convalescent Kawasaki disease. The 6th Int. Kawasaki disease sympo.1999,2,Hawaii.
    9. Adachi Y., Onoue Y., Yamamoto J., Adachi YS., Seki D., Toyoda M., Morohashi M., and Miyawaki T.FCD30 expression on T cell is a better marker for role of Th2-type cell compared with soluble CD30 level in atopic dermatitis. AAAAI,1999,2,Florida.
    10. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFƒ[ƒ‰ƒ“ƒh”­ì‚Æ’èŒ^Œ‡_”­ì‚𓯎ž‚É”F‚ß‚œ‚PÇ—áB‘æ23‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1999,3,‹à‘ò.
    11. ŒIŒŽ–ƒ‹IŽqA–{‹œ˜a‹vA’|’J“¿—YA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêF—ǐ«“ûŽ™‚¯‚¢‚ê‚ñ‚Ì‚Q—áB‘æ23‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1999,3,‹à‘ò.
    12. ”‘òŽõŽqAŒ‘q—TŠìAŽs“c•™ŽqA‹{˜e—˜’jA‰ÆéˆŸ‹IŽqA“ˆ‘å“ñ˜YFEarly pre-pulseless phase ‚©‚çŠÏŽ@‚µ‚œ‘å“®–¬‰ŠÇŒóŒQ‚̈ê—áB‘æ265‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1999,3,•Ÿˆä.
    13. Kanegane H., Miyawaki T., Nomura K., Hashimoto S., Tsukada S.FGenetic analysis of X-linked agammagloburinemia identified by flow cytometric analysis in unrelated 36 Japanease families. 99' Experimental Biology,1999,4, Washington D.C.
    14. Yagi S., Konishi T., Matsuzawa J., Hongou K., Yamatani M., and Miyawaki T.: A infantile case with myoclonic epilepsy induced by eye closure. 2nd Conference on Seizures in Infancy and Early Childhood,4,1999, Tokyo.
    15. Matsuzawa J., Konishi T., Hongou K., Yamatani M., Yagi S., and Miyawaki T.: Recognition of 15 families with generalized epilepsy with febrile seizures plus(GEFS+). 2nd Conference on Seizures in Infancy and Early Childhood,4,1999,Tokyo.
    16. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA”‘òŽõŽqA‹{˜e—˜’jFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚š‚¯‚é‚s×–ECD30”­Œ»—Š‚ÆŒŒ’†soluble CD30’l‚ÌŠÖŒWB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    17. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF×‹Û«‘–Œ‰Š‚̍d–Œ‰º•a•ÏB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    18. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jAŠâ“c@—́A¬‹{ŽR~F•ª—Þ•s”\Œ^–Ɖu•s‘SÇ‚É‚š‚¯‚éBtkˆâ“`Žq‰ðÍB‘æ102‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1999,4,“Œ‹ž.
    19. ‘«—§—zŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«ŽŸŠ³“û—cŽ™‚É‚š‚¯‚é“úí“I‚ȃlƒR‚Ƃ̐ڐG‚ƌċzŠíÇó‚ÌŠÖŒWB‘æ35‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1999,4,•xŽR.
    20. ‹g“cärA¬Œ@“OA‹{˜e—˜’jA¡‘º”Ž–ŸF“–‰@‚É‚š‚¯‚é‚o‚u‚kƒnƒCƒŠƒXƒNŽ™‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ35‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1999,4,•xŽR.
    21. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFŒo‰ß’†‚ÉŒõŠŽŽó«“Ë”­”g‚ðŽŠ‚·‹ÇÝŠÖ˜A«‚Ä‚ñ‚©‚ñ‚̈êŒQ‚ɂ‚¢‚āB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    22. ŽR’J”ü˜aA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jF“û—cŽ™“«‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚鐇–°ŠoÁƒŠƒYƒ€‚̏áŠQ`—Տ°”­ì‚Æ‚ÌŠÖŒWB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    23. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jFEyelid myoclonia with absences‚ÌŒZ’í—áB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    24. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñƒvƒ‰ƒX‚ð‚à‚‘S”Ê‚Ä‚ñ‚©‚ñ‰ÆŒn‚ɂ‚¢‚āB‘æ41‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1999,5,“Œ‹ž.
    25. ‘«—§—YˆêF‹z“ü—Ö@‚̏¬Ž™‚Ɛ¬l‚É‚š‚¯‚é—˜“_‚ÆŒ‡“_|ƒÀŽhŒƒÜ‚̃^ƒCƒ€ƒŠ[ƒ†[ƒX`¬Ž™‰È‚©‚ç`‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ïƒVƒ“ƒ|ƒWƒEƒ€,1999,5,‘åã.
    26. ”öã—mˆêAŽRŒ³ƒŽqA‘«—§—YˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºAŒ“‡jŽ¡FƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚É‚š‚¯‚é––œŒŒ‚s×–Eã‚ÌŠeŽíƒPƒ‚ƒJƒCƒ“EƒŒƒZƒvƒ^[‚Ì”­Œ»B‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ï,1999,5,‘åã.
    27. ”ÂàVŽõŽqA‘ºãIŒ[AŽRŒ³ƒŽqA”öã—mˆêA‰ª•””üŒbA‰¡“cF”VA‘«—§—zŽqA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ‚ÌŠÖ—^[MxA’`”’‚ðŽw•W‚Æ‚µ‚ā[‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G‘å‰ï,1999,5,‘åã.
    28. Œ–쐳’mAˆÉ“Œ“¹•vA‹gZ@ºAŠâ’J‰ëŽqA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§Š°‰ð—á‚Ì‹C“¹‰ß•q«‚̐„ˆÚ-ÅI”­ìŽž”N—î‚©‚ç‚Ý‚œŒŸ“¢-B‘æ11‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,1999,5,‘åã.
    29. ‹àŒ“O˜aA‹{˜e—˜’jA{–è—ºA˜`@˜a”üA‹{“c—Y—SA–Ø‘º@GAX“‡P—YA–{“cŒiŽqAÎˆäžÄˆêA]Œû^—ŽqA‘Ÿ“c˜aGA’J“à]ºGF–{–M‚É‚š‚¯‚éX˜AœƒŠƒ“ƒp‘B«ÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ‚X‰ñEBƒEƒBƒ‹ƒXŠŽõÇŒ€‹†‰ï,1999,5,“Œ‹ž.
    30. ‚ˆä—¢AŒ‘q—TŠìAŽÂèŒ’‘Ÿ˜YArˆä”ü˜aŽqAŽðˆä—R‹IA’†–Ÿ‹žŽqA‹{˜e—˜’jFŒoŽž“I‚ɐt¶ŒŸ‚ðŽ{s‚µ‚œIgAtÇ‚ÉŠÖ‚·‚錟“¢B‘æ34‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1999,5,VŠƒ.
    31. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YArˆä”ü˜aŽqAŽðˆä—R‹IA‚ˆä—¢A‹{˜e—˜’jFæ“V«…tÇ‚É‚š‚¯‚éMRI urography‚ÌŽg—pŒoŒ±B‘æ34‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1999,5,VŠƒ.
    32. Œ‘q—TŠìA–L“ˆSˆê˜YA‹{˜e—˜’jFæ“V«…tÇ‚É‚š‚¯‚éMR urography‚ÌŽg—pŒoŒ±B‘æ44‰ñ“ú–{t‘Ÿ•aŠw‰ï,1999,6,‰¡•l.
    33. ‹{˜e—˜’jAŽRŒ³ƒŽqA‘«—§—YˆêFƒVƒ“ƒ|ƒWƒEƒ€u×–E“àƒTƒCƒgƒJƒCƒ“‚̗Տ°‰ž—p‚ւ̐헪Bv‘æ‚X‰ñ“ú–{ƒTƒCƒgƒƒgƒŠ[Šw‰ï,1999,6,ŽD–y.
    34. ’†—ÑŒºˆêAA‘º”ü‹IA‘ºãIŒ[A–{ŠÔˆê³A‹àŒ“O˜aF–{‘Ԑ«ŒŒ¬”ÂŒŒÇ‚Ì10Ë’jŽ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    35. “n粈»‰ÀAŒIŒŽ^‹IŽqA”ÂàVŽõŽqA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jAœAìTˆê˜YFŽ©‰Æ––œŒŒŠ²×–EˆÚA‚ðs‚Á‚œ—‘‰©”XŠà(stageE)‚̈ꏗŽ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    36. ŽRŒ³ƒŽqAFè@Œ’A”ÂàVŽõŽqA¬Œ@“OA¬ŒIˆºŽqFŒŒŽƒAƒ~ƒmƒgƒ‰ƒ“ƒXƒtƒFƒ‰[ƒ[‚’l‚É‚æ‚è‹ô‘RŒ©‚‚©‚Á‚œ‹ØƒWƒXƒgƒƒtƒB[‚Ì‚PÎ’jŽ™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    37. Œ‘q—TŠìA“n粈»‰ÀAŒIŒŽ^‹IŽqA‹{˜e—˜’jF“«‚ÌCAPD• –Œ‰Š‚𔜕œ‚µ‚Ä‚¢‚éˆê¬Ž™—áB‘æ‚R‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,7,•xŽR.
    38. ‹àŒ“O˜aA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA‘ºãIŒ[Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚ɂĐf’f‚µ‚œ‚w˜AœŒŒ¬”ÂŒž­Ç‚̈ê’jŽ™—áB‘æ15‰ñ•xŽRŒ§ŒŒ‰tŽŸŠ³Œ€‹†‰ï,1999,7,•xŽR.
    39. –{‹œ˜a‹vAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA¬Œ@“OA‹{˜e—˜’jFCongenital hypomyelinating neuropathy ‚ÌŽo–…—áB‘æ35‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,8,1999,•Ÿˆä.
    40. –쑺ŒbŽqA‹àŒ“O˜aAŽíŽsq’ˆA]Œû^—ŽqA¡hWìA‹{˜e—˜’jFT-lymphoblastic lymphoma with myeloid hyperplasia‚̈ê’jŽ™—áB‘æ41‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,1999,9,“Œ‹ž.
    41. ‹àŒ“O˜aA–쑺ŒbŽqA{–è@—ºAŒˆä@—zA˜`@˜a”üA‹{“c—Y—SA]Œû^—ŽqA–{“cŒiŽqAÎˆäžÄˆêA‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ41‰ñ“ú–{¬Ž™ŒŒ‰tŠw‰ï,1999,9,“Œ‹ž.
    42. Œ‘q—TŠìA‹{˜e—˜’jF“«CAPD• –Œ‰Š‚̈êÇ—áB‘æ‚V‰ñ’†•”¬Ž™t‘Ÿ•aŒ€‹†‰ï,1999,9,Œ–{.
    43. ”ÂàVŽõŽqA‘ºãIŒ[A”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§”­ì‚É‚š‚¯‚éƒEƒCƒ‹ƒXŠŽõ‚ÌŠÖ—^‚Ì‹Gß•Ï“®-MxA’`”’‚ðŽw•W‚Æ‚µ‚Ä-B‘æ‚Q‰ñ•xŽR¬Ž™šb‘§EƒAƒŒƒ‹ƒM[Œ€‹†‰ï,1999,9,•xŽR.
    44. ”ª–ؐMˆêA¬Œ@“OAL–ìŒbˆêAŒ‘òƒŽqA”öã—mˆêA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF“ÁˆÙ‚È”]‰ŠE”]Ç—ÞŽ—‚ÌŒo‰ß‚ð’悵‚œ’jŽ™—áB‘æ36‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,9,1999,‹à‘ò.
    45. –{‹œ˜a‹vA“n•Óˆê—mAŒ‘òƒŽqA¡‘º”Ž–ŸA”ª–ؐMˆêA¬Œ@“OA‹{˜e—˜’jFV¶Ž™Šú‚©‚çd“x‚̋؋ْ£’ቺ‚ðŽŠ‚µ‚œ‚QÇ—á`ŠÓ•Êf’f‚𒆐S‚ɁB‘æ‚V‰ñ•xŽRŒ§—Տ°¬Ž™_ŒoŠwŒ€‹†‰ï,9,1999,•xŽR.
    46. ‹àŒ“O˜aA{–è@—ºAŒˆä@—zA’J“à]ºGA‹{˜e—˜’jF–{–M‚É‚š‚¯‚é‚w˜AœƒŠƒ“ƒp‘B«ÇŒóŒQ‚̈â“`Žq‰ðÍB‘æ27‰ñ“ú–{—Տ°–ƉuŠw‰ï,1999,10,‰F“s‹{.
    47. ”öã—mˆêAŽRŒ³ƒŽqA‘«—§—YˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF“`õ«’PŠjÇ––œŒŒ‚s×–E‚É‚š‚¯‚éƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[iCXCR3j‚Ì”­Œ»‘‰ÁB‘æ27‰ñ“ú–{—Տ°–ƉuŠw‰ï‘‰ï,1999,10,‰F“s‹{.
    48. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jF‚w˜Aœ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚éD’†‹…Œž­B‘æ31‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1999,10,•Ÿ“‡.
    49. –쑺ŒbŽqA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jF‚RÜ•¹—p—Ö@‚É‚æ‚Á‚Ä’˜–Ÿ‚ȉü‘P‚ª‚Ý‚ç‚ê‚œ•êŽqŠŽõŒãAIDS‘Šú”­ÇŒ^‚Ì‚P—áB‘æ31‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1999,10,•Ÿ“‡.
    50. ‹{@ˆêŽuA–쑺ŒbŽqA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jA–Ø‘º@GAX“‡P—YF’†•_Œo•a•Ï‚ð‡•¹‚µ‚œEBƒEƒBƒ‹ƒXŠÖ˜AƒÁƒÂ-‚s×–EƒŠƒ“ƒpŽî@‚Ì‚P—áB‘æ31‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1999,10,•Ÿ“‡.
    51. ‘«—§—YˆêA‘ºãIŒ[A‘«—§—zŽqA”‘òŽõŽqA‰ª•””üŒbA‰¡“cF”VAŠâ’J‰ëŽqAŠžŒŽ¹ŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚鎩‘î‚Å‚Ì“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚œ”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽw“±ó‹µB‘æ49‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïA1999,10,L“‡.
    52. ŽRŒ³ƒŽqA‘«—§—YˆêA”öã—mˆêA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºAŒ“‡jŽ¡FƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚É‚æ‚蕪•Ê‚³‚ê‚é––œŒŒƒwƒ‹ƒp[T×–EˆŸŒQ‚̃TƒCƒgƒJƒCƒ“ŽY¶ƒpƒ^[ƒ“B‘æ49‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ïA1999,10,L“‡.
    53. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰¡“cF”VA‰ª•””üŒbA”‘òŽõŽqAŠžŒŽ¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚ւ̈ڍs‚ƃlƒR‚È‚ç‚тɐH•šƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ36‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ïA1999,10,ç—t.
    54. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêF¬Ž™“«‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚āB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    55. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aFŠááك~ƒIƒNƒƒj[‚š‚æ‚ÑŠá‹…ã“]‚𔭍쒆ŠjÇó‚Æ‚·‚é‚Ä‚ñ‚©‚ñÇ—á‚ɂ‚¢‚āB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    56. –{‹œ˜a‹vA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA’|’J“¿—YFŒo‰ß’†‚É’E–сAŒƒ‚µ‚¢ŽŒ]‚ð”F‚ß‚œMigrating Partial Seizures in Infancy‚Ì‚P—áB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    57. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF—ǐ«“ûŽ™‚¯‚¢‚ê‚ñ‚X—á‚Ì”­ìŽž”]”g‚ɂ‚¢‚āB‘æ33‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,10,1999,å‘ä.
    58. Itazawa T., Noguchi K., Ichida F., Hashimoto I., Seto H., and Miyawaki T.FMagnetic resonance imaging for early detection of Takayasu arteritis. The 27th Annual meeting of the North American society for cardiac imaging,1999,11,Atlanta.
    59. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–쏺GFCBFA1•ÏˆÙ‚ð”F‚ß‚œœœE“ªŠWˆÙŒ`¬Ç‚Ì‚U—áB‘æ20‰ñ–k—€æ“VˆÙíŒ€‹†‰ï,1999,11,‹à‘ò.
    60. ‘«—§—YˆêA‘ºãIŒ[A”öã—mˆêA‘«—§—zŽqA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚鎩‘î‚Å‚Ì“d“®Ž®ƒlƒuƒ‰ƒCƒU[‚ð—p‚¢‚œ”­ìŽžƒÀŽhŒƒÜ‹z“ü‚ÌŽÀÛ -ƒAƒ“ƒP[ƒg’²ž-B‘æ32‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,1999,11,•Ÿˆä.
    61. ‹àŒ“O˜aA{–è—ºAŒ‘q—TŠìA–쑺ŒbŽqA’J“à]ºGA’Ë“c@‘A‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘BŽŸŠ³‚É‚š‚¯‚é‚r‚`‚oˆâ“`ŽqˆÙíB‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    62. ŽRŒ³ƒŽqA‘«—§—YˆêAŒ“‡jŽ¡A‹{˜e—˜’jFƒqƒg––œŒŒƒwƒ‹ƒp[T×–E‚É‚š‚¯‚éƒPƒ‚ƒJƒCƒ“ƒŒƒZƒvƒ^[”­Œ»‚̗Տ°“IˆÓ‹`B‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    63. –쑺ŒbŽqA‹àŒ“O˜aA’Ë“c@‘A‰GŽR@ˆêAãŒˆê‰iA¬‹{ŽR~A‹{˜e—˜’jF‚w˜Aœ–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‚É‚š‚¯‚鍜‘‚a‘O‹ì×–E‚̉ðÍB‘æ29‰ñ“ú–{–ƉuŠw‰ï,1999,12,‹ž“s.
    64. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰Š“û—cŽ™‚Ìšb‘§‚ւ̐i“W‚ƃlƒRƒAƒŒƒ‹ƒM[‚ÌŠÖŒWB‘æ26‰ñ–k—€ƒAƒŒƒ‹ƒM[§˜b‰ï,1999,12,‹à‘ò.
    65. ‹g“cärA‹àŒ“O˜aA‹{˜e—˜’jA¡–쏺GFœœE“ªŠWˆÙŒ`¬Ç‚É‚š‚¯‚éCBFA1•ÏˆÙB‘æ‚S‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,12,•xŽR.
    66. ŒIŒŽ^‹IŽqAãšŒhˆê˜YA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–؁@–ŸAŠÛŽR–Ÿ•vF‰^“®ŽžŽž_”­ì‚Å”­Ç‚µ‚œ“Á”­«S–[‘e“®‚̈ê—áB‘æ‚S‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1999,12,•xŽR.

    1998”N

  • ’˜‘
    1. Žs“c•™ŽqFS‹Øãk–§‘wŒ`¬•s‘SBuAnnual@Review zŠÂŠí1998v,™–{P–Ÿ‘Œ•Ò,’†ŠOˆãŠwŽÐ,“Œ‹ž,179-184,1998.
    2. ˆîê@iA‰ª“c•q•vFEŠe˜_Et‰ŠBu¬Ž™”å”AŠí‰ÈŠw‘v,ì‘º@–ҁE¬–ö’m•F•Ò,‹àŒŽo”Å,“Œ‹ž,184-193,1998.
    3. ‹àŒ“O˜aA‹{˜e—˜’jFHermans syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘Œ•ÒAf’f‚ÆŽ¡—ÎЁA“Œ‹ž,620,1998.
    4. ‹àŒ“O˜aA‹{˜e—˜’jFNezelof syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘Œ•ÒAf’f‚ÆŽ¡—ÎЁA“Œ‹ž,630,1998.
    5. ‹àŒ“O˜aA‹{˜e—˜’jFOmenn syndromeBuÇŒóŒQŽ–“Tv‰Y•”»•v‘Œ•ÒAf’f‚ÆŽ¡—ÎЁA“Œ‹ž,631,1998.
    6. Žs“c•™ŽqFæ“V«SŽŸŠ³Bu‚í‚©‚è‚â‚·‚¢“à‰ÈŠwvˆä‘º—T•v‘Œ•Ò,•ªŒõ“°,“Œ‹ž,119-134,1998 .
  • ŒŽ’˜
    1. Ichida F., Uese K., Hamamichi Y., Hashimoto I., Tsubata S., Fukahara K., Murakami A., Miyawaki T.: Chronic effect of oral prostacyclin analogue on thromboxane A2 and prostacyclin biosysthesis in pulmonary hypertension. Acta Paediatr Jpn 40 : 14-19,1998.
    2. Futatani T., Miyawaki T.,Tsukada S., Hashimoto S., Kunikata T., Arai S., Kurimoto M., Niida Y., Matsuoka H., Sakiyama Y., Iwata T., Tsuchiya S., Tatsuzawa O., Yoshizaki K., and Kishimoto T.FDeficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection. Blood 91F595-602,1998.
    3. Mio T., Liu X-D., Adachi Y., Striz I., Magnus Skold C., Romberger D.J., Spurzem J.R., Illig M.G., Ertl R., and Rennard S.I. : Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am. J.Physiol. 274 : L119-L126,1998.
    4. Ichida F, Uese K, Tsubata S, Hashimoto I, Hamamichi Y., Fukahara K, Murakami A, Miyawaki T. : Beneficial effect of Beraprost Sodium, a stable analogue of prostacyclin, on pulmonary hypertension in children. Cardiol Young : 205-210,1998.
    5. Tsubata S, Ichida F, Miyawaki T.: Noninvasive diagnosis of coronary arterial fistulas using multiplanar cine magnetic resonance imaging. Cardiol Young 8:250-252,1998.
    6. Kasahara Y., Wada T., Niida Y., Yachie A., Seki H., Ishida Y., Sakai T., Koizumi F., Koizumi S., Miyawaki T. and Taniguchi N.: Novel Fas (CD 95/AP0-1) mutations in infants with a lymphoproliferative disorder. Int. Immunol. 10 : 195-202,1998.
    7. Adachi Y., Mio T., Takigawa K., Striz I., Romberger D.J., Spurzem J.R., and Rennard S.I. : Fibronectin production by cultured human lung fibroblasts in three-dimensional collagen gel culture. In Vitro Cell. Dev. Biol. 34 : 203-210,1998.
    8. Ichida F., Uese K., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Additive effect of beraprost on pulmonary vasodilation by inhaled nitric oxide in children with pulmonary hypertension. Am. J. Cardiol. 80:662-664, 1997.
    9. Ichida F., Uese K., Hashimoto I., Hamamichi Y., Tsubata S., Fukahara K., Murakami A., and Miyawaki T.: Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children .J. Cardiol. 29 : 217-224,1997.
    10. Hashimoto I., Ichida F., Okabe T., Miura M., Okabe T., Shimura S., Uese K., Hamamichi Y., Tsubata S., Miyawaki T., Fukahara K., and Murakami A.: Evaluation of left ventricular volume using automatic border detection system in children.: A comparison with conventional off-line echocardiographic quantification. Acta Paediatr Jpn 40:226-231, 1998.
    11. Kanegane H., Kishor B., Guiterres M., Kaneda H., Wada T., Yachie A., Seki H., Arai T., Kagimoto S., Okazaki M., Oh-ishi T., Moghaddam A., Wang F., and Tosato G. : A syndrome of peripheral blood T-cell infection with Epstein-barr virus(EBV) followed by EBV-positive T-cell lymphoma. Blood 91 : 2085-2091,1998.
    12. Mehrotra P.T., Donnelly R. P., Wong S., Kanegane H., Geremew A., Mostowski H.S., Furuke K., Siegel J.P., and Bloom E.T.: Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J. Immunol. 160: 2637-2644, 1998.
    13. Hongou K., Konishi T., Yagi S., Araki K.,and Miyawaki T.: Rotavirus encephalitis mimicking afebrile benign convulsions in infants. Pediatr Neurol 18:354-357,1998.
    14. Kanegane H., Yachie A., Miyawaki T., and Tosato G. : EBV-NK cells interactions and lymphoproliferative disorders. Leuk. and Lymph. 29 : 491-498,1998.
    15. Morikawa K., Nemoto K., Miyawaki T., and Morikawa S. : Deoxyspergualin preferentially inhibits the growth and maturation of anti-CD40-activated surface IgD+ B lymphocytes. Clin. Exp. Immunol. 112 : 495-500,1998.
    16. Wada T., Seki H., Konno A., Ohta K., Nunogami K., Kaneda H., Kasahara Y., Yachie A., Koizumi S., Taniguchi N., and Miyawaki T.: Developmental changes and functional properties of human memory T cell subpopulations defined by CD60 expression. Cell. Immunol. 187 : 117 -123,1998.
    17. Kanegane C., Sgadari C., Kanegane H., Teruya-Feldstein J., Yao L., Gupta G., Farber JM., Liao F., Lin L., and Tosato G. : Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J. Leuk. Biol. 64: 384-392,1998.
    18. Matsuzawa J., Konishi T., Masuko K., Hongou K., Yamatani M., Yagi S, and Miyawaki T. : SPECT and localized proton MRS of epilepsy in children with cortical dysplasia. Epilepsia 39 (suppl. 5):70-71,1998.
    19. Striz I., Mio T., Adachi Y., Bazil S., and Rennard S.I. : The CD14 molecle participates in regulation of IL-8 and IL-6 release by bronchial epithelial cells. Immunol. Letters 62:177-181,1998.
    20. Žs“c•™ŽqAŽÂèŒ’‘Ÿ˜YAà_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêA‹{è‚ ‚ä‚݁A‹{˜e—˜’jA¬–ìˆÀ¶A_’J“N˜YAÔ–Ø’õŽ¡A•l“c—m’ʁAL£CAˆé•”„ŽuAŒÃé¹“WA•”òr“ñAŽOŒË”ŽŽuAŽO‘îrŽ¡A‘ºã•Û•vAŒ@–ҁAŽÂŒŽ@^A£Œû³ŽjA“c‘ãT“ñ˜YA•xŒG•¶F–{–M‚É‚š‚¯‚鏬Ž™ŠúIsolated noncompaction of the ventricular myocardium‚̗Տ°‘œ`‘S‘’²žŒ‹‰Ê`B“ú–{¬Ž™zŠÂŠíŠw‰ïŽGŽ 14F402-412,1998.
    21. Î“c•¶GA¬—с@ŒõAÄ“¡@”ŽA“ñ’J@•A‹{˜e—˜’jAŽàVŒ€“¹Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚É‚æ‚éBtk’`”’Œ‡‘¹‚ɂĐf’f‚µ“Ÿ‚œ”º«—ò«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇŒÇ”­—áB—Տ°ŒŒ‰t@39F44-47,1998.
    22. ’ß‘ò³mCŽR–{‰ÃŽjC•Ð–ì’Œ”VCœA“c‹M‹vA‹{˜e—˜’jA–ö£‘ì–çA¬ò»ˆêA“àŠCŽ¡˜YAóŒ©ŒbŽqC“c’†@“āC”ž“‡G—YC’†ŽR‰ë•FA”š]–F˜YCŠÖª—E•vC“y’J‹ª‹`CŽR‘º‘׈êAŠâˆä’©KA‰Í–ì‰Ã•¶C‰º‰Í’B—YCŒìŒ’ˆêAŒ‰º’|ŽŸC—é‹{~ŽiC‘哇FˆêA‹e’r¹OAŽO‘î@“TC“n•Ó@VC‹àŽqˆÀ”äŒÃA’J“c•”“¹•vA“Œ@Š°C‰¡“cž•œC‹ïŽuŒ˜rŽ÷A‹e“c“ցAŽOŠÔ‰®~C‰ª“c@簁C_‰€~ŽiC“¡–{–Ð’jA]Œût•FF¬Ž™”ñHodgkinƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒ€‹†ˆê¬Ž™Šà”’ŒŒ•aŒ€‹†ƒOƒ‹[ƒviCCLSGjNHL855^890Œ€‹†‚Ì’·ŠúŽ¡—ЬÑ‚Æ“ñŽŸŠà‚Ì”­Ç—ŠˆêB—Տ°ŒŒ‰t@39F281-289,1998.
    23. ’Ë“c@‘A‹{˜e—˜’jF–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̐f’f‚ƌċzŠíŽŸŠ³B•ªŽqŒÄ‹zŠí•a 2 : 422-429,1998.
    24. ’ß‘ò³mA•Ð–ì’Œ”VAœA“c‹M‹vAˆÉ“¡m–çA–ö£‘ì–çAóŒ©ŒbŽqA¬ò»ˆêA’†ŽR‰ë•FA‹{˜e—˜’jA—é‹{~ŽiAŒìŒ’ˆêA”ž“‡G—YA–x‰z‘×—YA”š]–F˜YAŠâˆä’©KAˆ¢“쌒ˆêA‹e’r¹OA‘哇FˆêA‹àŽqˆÀ”äŒÃA•Ð‰ª@“NA“c’†@“āA’@Šî–ŸA‘œ‰ê@’A“n•Ó@VAì–ž@“OA‹ïŽuŒ˜rŽ÷Aìã@ŽA‹e“c@“ցAŽOŠÔ‰®ƒˆêA“¡–{–Ð’jF¬Ž™”ñHodgkinƒŠƒ“ƒpŽî‚ÌŽ¡—ÃŒ€‹†ˆê¬Ž™Šà”’ŒŒ•aŒ€‹†ƒOƒ‹[ƒviCCLSGj‚̐VƒvƒƒgƒR[ƒ‹NHL960‚Ì’·ŠúŽ¡—ЬÑˆêB—Տ°ŒŒ‰t 39F1092-1098 ,1998.
  • Ç—á•ñ
    1. Wada H., Akiyama H., Seki H., Ichihara T., Ueno K., Miyawaki T., and Koizumi S. : Spinal canal involvement in infantile myofibromatosis: case report and review of the literature. J. Pediatric Hematology/ Oncology. 20: 353-356, 1998.
    2. rˆä”ü˜aŽqAˆîê@iAŽÂèŒ’‘Ÿ˜YAŽðˆä—R‹IA•£‹žŽqAˆ¢•”KŽqAŒ‘q—TŠìA‹{˜e—˜’jF”A’†Podocyte‚̐„ˆÚ‚ð‚Ý‚œ¬Ž™Ž‡”Á•a«t‰Š‚Ì1—á|Ž…‹…‘Ì“à‹ÃŒÅ‚Æ‚ÌŠÖ˜A«|Bt‚Æ“§Í 44F120-124,1998.
    3. ‹àŒ“O˜aAŒ‘òƒŽqAŽs“c•™ŽqAFè@Œ’A¬’rŒ’ˆêA‹{˜e—˜’jFŽá”NŒ^–«œ‘«”’ŒŒ•a‚ÌŽ©‘RŠ°‰ð‚ð‚Ý‚œNoonanÇŒóŒQ‚Ì‚P’jŽ™—áB“ú–{¬Ž™‰ÈŠw‰ïŽGŽ 102F1102-1105,1998.
  • ‘à
    1. ”ª–ؐMˆêA‹{˜e—˜’jFŠŽõ–ƉuŒŸž`ƒƒ^ƒEƒBƒ‹ƒXR‘́A•Ö’†ƒƒ^ƒEƒBƒ‹ƒXRŒŽB‘‡—Õà¬47(‘)F1735-1737,1998.

  • 1998”NŠw‰ï•ñ
    1. ãšŒhˆê˜YA’ÔŠáÁˆêA‹Ž–{ˆè•vA•l“¹—T“ñAŽs“c•™ŽqA‹{˜e—˜’jA‹{è‚ ‚ä‚݁AŒ”ö‰ÄlF‚‘ψ³¬ŒŒŠÇŠg’£ƒJƒe[ƒeƒ‹‚ðŽg—p‚µ‚œBlalock-Taussing’Z—ŒŒŠÇ‚Ì‹·óA•ÂÇ‚ɑ΂·‚éƒoƒ‹[ƒ“Šg‘åpB‘æ‚X‰ñ“ú–{Pediatric Inter-ventional CardiologyŒ€‹†‰ï,1998,1,‹ž“s.
    2. ‹àŒ“O˜aA‹{˜e—˜’jAŠÛ”¢Œ\ŽqAŒÜ\—’“oAŠ}ŒŽ‘PmFEBƒEƒCƒ‹ƒXŠÖ˜AŽŸŠ³‚É‚š‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10. ‘æ‚Q‰ñŒŒ‰tŽŸŠ³‚ƃTƒCƒgƒJƒCƒ“Œ€‹†‰ï,1998, 2,‹à‘ò.
    3. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF×‹Û«‘–Œ‰Š‚̍d–Œ‰º•a•Ï‚ɂ‚¢‚āB‘æ33‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,1998,2,‹à‘ò.
    4. ŽRŒ³ƒŽqAŒ‘òƒŽqAŠ™’JˆŸ‹IŽqA”ª–ؐMˆêA‘«—§—YˆêA‹{˜e—˜’jFlHŠ·‹C‚É”œ‰ž‚¹‚ž External Chest Compressioni—pŽè‹¹Šsˆ³”—Š·‹C•â•j‚É‚æ‚芷‹C•s‘S‚©‚ç’Eo‚µ“Ÿ‚œ‹CŠÇŽxšb‘§dÏ”­ì‚̈ê’jŽ™—áD‘æ19‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï1998,2,•xŽR.
    5. ‹Ž–{ˆè•vAãšŒhˆê˜YA•l“¹—T“ñA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jFŒoŒûPGI2‚Ì‹}«Œø‰Ê‚š‚æ‚Ñ–«Œø‰Ê‚ª”F‚ß‚ç‚ê‚œŒŽ”­«”x‚ŒŒˆ³Ç‚Ì1“ûŽ™—áB‘æ‚S‰ñ¬Ž™”xzŠÂŒ€‹†‰ï,1998,2,“Œ‹ž.
    6. ¡‘º”Ž–ŸA…ŒûŽu‰êŽqAÂ–؉ëŽqAÎ‹àŒbŽqAœAãáÁ—ŽqA‘º“¡—ŠŽqA–kì—mŽqA‹«@”ü‘ãŽqA‹g“cˆèŽqAŽO‘º‘וFA“c“àŽ“TA—Ž‡@GA…“‡–LFNICU‚É‚š‚¯‚éMRSA‘΍ô‚ɂ‚¢‚āB‘æ13‰ñ“ú–{ŠÂ‹«ŠŽõŠw‰ï,1998,2,“Œ‹ž.
    7. ‘«—§—YˆêF‹C“¹‰ŠÇ‚ƃŠƒ‚ƒfƒŠƒ“ƒOD‘æ‚T‰ñ¬Ž™‹CŠÇŽxšb‘§•a‘ÔŒ€‹†‰ï,1998,3,‹ž“s.
    8. ¬Œ@“OAŒàVƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF—ǐ«“ûŽ™áz¹‚Ì’·Šú—\Œã|BECT‚ōĔ­H‚µ‚œ‚P—á‚𒆐S‚Ɂ|B‘æ14‰ñRDŒ€‹†‰ï,1998,3,‘åã.
    9. ŽÂèŒ’‘Ÿ˜YA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jAÀ“cŽOŽ}ŽqF¶‘lŒa•”ŒŽ”­ƒzƒWƒLƒ“•a‚̈ê—áB‘æ262‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1998,3,‹à‘ò.
    10. ‹àŒ“O˜aA‹k@çHA—с@ŒbŽOA‹{˜e—˜’jF•p‰ñ‚ɍĔ­‚ðŒJ‚è•Ô‚µ‚Ä‚¢‚éLangerhans cell histiocytosis‚̈ê—áB‘æ‚W‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,1998,3,‹à‘ò.
    11. Adachi Y., Onoue Y., Yamamoto J., Adachi Y.S., Seki D., Toyota M., Morohashi M., Miyawaki T.: CD30 Expression on T Cells as a Marker for Role of Th2-type Cell in Atopic Dermatitis. 54th Annual Meeting of American Academy of Asthma, Allergy and Immunology,1998,3,Washington DC, USA.
    12. ŽRŒ³ƒŽqA‘«—§—YˆêA‰ª•””üŒbA”öã—mˆêA‘«—§—zŽqA‹{˜e—˜’jA‘ºãIŒ[F‹CŠÇŽxšb‘§dÏ”­ìŒã‚Ɉê‰ß«‰º‚‘Ì‹@”\’ቺ‚ð’悵‚œ‚P’jŽ™—áD‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,1998,4,–ŒŒÃ‰®D
    13. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‘«—§—zŽqA‹{˜e—˜’jA‘ºãIŒ[AŒ–쐳’mFƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚É‚š‚¯‚éŒø‰Ê”»’è@-S””‚ÍŽw•W‚ɐ¬‚è“Ÿ‚é‚©-D‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,1998,4,–ŒŒÃ‰®.
    14. Œ–쐳’mAˆÉ“Œ“¹•vAŒŽ@³‘¥A–öŒŽr—YA‘«—§—YˆêFƒ_ƒj‚̍¬“ü‚µ‚œ‚šD‚ݏĂ«‚ðH‚ׂœŒãA‘SgÇó‚ð’悵‚œ‚P’jŽ™—áB‘æ10‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,1998,4,–ŒŒÃ‰®.
    15. ¬Œ@“OA‘ŽqDAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFƒtƒFƒjƒgƒCƒ“ŽUÜ‚Ì bioavailability FƒAƒŒƒrƒAƒ`ƒ“10”{ŽU‚ւ̕ύX‚ɍۂµ‚āB‘æ22‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1998,4,‹à‘ò.
    16. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jFŒõ—U”­«‚Ä‚ñ‚©‚ñ‚̗Տ°”]”g“Á’¥B‘æ22‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1998,4,‹à‘ò.
    17. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”M«‚¯‚¢‚ê‚ñ—\–h“Š—^’†‚Ì”­ìÄ”­-AEDŽ‘±“Š—^‚ÆDZPŠÔŒ‡“Š—^–@‚Ì”äŠr-B‘æ‚P‰ñ“û—cŽ™‚¯‚¢‚ê‚ñŒ€‹†‰ï,1998,4,“Œ‹ž.
    18. ”ª–ؐMˆêA¬Œ@“OAA‘º”ü‹IAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jFV¶Ž™Šú‚æ‚èŒQ”­‚·‚é•¡ŽG•”•ª”­ì‚ð”F‚ß‚œ“«‚Ä‚ñ‚©‚ñ‚̈ê—áB‘æ‚P‰ñ“û—cŽ™‚¯‚¢‚ê‚ñŒ€‹†‰ï,1998,4,“Œ‹ž.
    19. ˆÉ“Œ^—ŽqA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFŽ©•ÂŒXŒü‚ɑ΂·‚鑁Šú—Èç-—ÈçŠÂ‹«‚Ì’²®‚š‚æ‚Ñ•êe‰‡•‚ÌŠî–{-B‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    20. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«ŽŸŠ³“û—cŽ™‚É‚š‚¯‚éƒlƒRRAST—z«—Š‚Æ‚»‚̗Տ°“IˆÓ‹`B‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    21. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jFƒCƒ“ƒtƒ‹ƒGƒ“ƒU—¬sŽž‚É‚Ý‚ç‚ê‚œ”]‰ŠE”]Ç‚ɂ‚¢‚Ä.‘æ33‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1998,4,•xŽR.
    22. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA‘ºãIŒ[FƒAƒgƒs[«”畆‰ŠŠ³ŽÒ––œŒŒ‚s×–E‚É‚š‚¯‚éCD30”­Œ»‚ƍזE“àƒTƒCƒgƒJƒCƒ“”­Œ»ƒpƒ^[ƒ“D‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5.•ÄŽq.
    23. ‹àŒ“O˜aA“ñ’J@•A˜eŒû@GA‹vì_ÍA‘q‹Ù—²MAVˆä“c@—vAŠ}ŒŽ‘PmA‹{˜e—˜’jF–«Šˆ“®«EBƒEƒBƒ‹ƒXŠŽõÇ‚Æ‚µ‚Ä’·ŠúŠÔƒtƒHƒ[‚³‚ê‚Ä‚¢‚œFasˆâ“`ŽqˆÙí‚̈ê—áD‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5,•ÄŽq.
    24. ¡‘º”Ž–ŸA“ñ’J@•A¬ìŽŸ˜YA‹g“c˜aŽiA‹g“cärA‹{˜e—˜’jFNICU‚É‚š‚¯‚éMRSA‘΍ô‚̗Տ°“IŒŸ“¢`ƒsƒIƒNƒ^ƒjƒ“ˆŸ‰”‰Ø“îp‚ƃ€ƒsƒƒVƒ“•@o—p“îp‚ÌŒø‰Ê‚ɂ‚¢‚āB‘æ101‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1998,5,•ÄŽq.
    25. ‹àŒ“O˜aA‰ª•””üŒbA–쑺ŒbŽqA”ª–ؐMˆêA‹{˜e—˜’jAÎàV@LA”ö–ŽuA¬ò•x”ü’©AŒE“c”Ž“¹FEBƒEƒBƒ‹ƒXƒQƒmƒ€—z«angiocentric lymphoma‚̈ꏗŽ™—áD‘æ‚W‰ñ‚d‚aƒEƒBƒ‹ƒXŠŽõÇŒ€‹†‰ï,1998,5,“Œ‹ž.
    26. ¬Œ@“OA‘ŽqDAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF•”•ª”­ìÇó‚ð”F‚ß‚œŒ‡_‚Ä‚ñ‚©‚ñÇ—á‚̗Տ°”]”g“Á’¥B‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    27. ŽR’J”ü˜aA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqA”ª–ؐMˆêA‹{˜e—˜’jF‚Ä‚ñ‚©‚ñŽ¡—Ã’†Ž~—á‚É‚š‚¯‚éÄ”­“Á’¥-”N—îˆöŽq‚ÌŠÖ—^‚ɂ‚¢‚Ä-B‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    28. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF×‹Û«‘–Œ‰Š‚̍d–Œ‰º•a•Ï‚ɂ‚¢‚āB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    29. –{‹œ˜a‹vA¬Œ@“OAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jA’|’J“¿—YFMigrating partial seizure in infancy‚ÆŽv‚í‚ê‚é‚Q—áB‘æ40‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1998,6,‰¡•l.
    30. Œ‘òƒŽqA¬Œ@“OA‘ŽqDA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”]‰ŠE”]ÇŒãˆâÇŠ³Ž™‚É‚š‚¯‚éMRSŠŒ©‚ɂ‚¢‚āB‘æ40‰ñ“ú–{¬Ž™_Œo‰ï,1998,6,‰¡•l.
    31. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YBŽðˆä—R‹IArˆä”ü˜aŽqA•£‹žŽqAˆ¢•”KŽqAˆîê@iA‹{˜e—˜’jF‚W”NŒo‰ßŒã‚̍жŒŸ‚É‚Ähemispherical deposits‚ð”F‚ß‚œ¬Ž™IgAtÇ‚̈ê—áB‘æ33‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1998,6,‰¡•l.
    32. ”öã—mˆêA‘ê“cˆê˜NAŒ‘q—TŠìAŽRŒ³ƒŽqA‘«—§—YˆêAŽs“c•™ŽqA‹{˜e—˜’jFFontanpŒã‚É”­Ç‚µ‚œplastic bronchitis‚̈ê’jŽ™—áB‘æ263‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1998,6,•Ÿˆä.
    33. œA–ìŒbˆêAÝ“c—FŽqA‹g“cärA‘«—§—YˆêA‹{˜e—˜’jA‹àˆä‰pŽqF‰Œ«ƒNƒ‹[ƒv‚Æ‚ÌŠÓ•Ê‚É‹ê—¶‚µ‚œæ“V«‹CŠÇ‹·ïÇ‚̈ê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    34. ¬Œ@“OF“Á•Êu‰‰uŒõ—U”­«EŒõ‰ß•q«‚Ä‚ñ‚©‚ñ‚̗Տ°“Á’¥v‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,‚‰ª.
    35. ãšŒhˆê˜YAŠ™’JˆŸŠóŽqA•l“¹—T“ñA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA‘ºã@VA“¡–؁@–ŸFƒtƒ@ƒ[Žl’¥ÇpŒã‚ɐSŽº•p”‚𔺂Á‚œQT‰„’·ÇŒóŒQ‚Ì1—áB‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    36. ”‘òŽõŽqA•l“¹—T“ñA‹Ž–{ˆè•vA’ÔŠ^ˆêAŽs“c•™ŽqA‹{è‚ ‚ä‚݁A‹{˜e—˜’jA‘ºã@VA…–qŒ÷ˆêA‰ª“c‰p‹gAFè@Œ’F‰^“®‚É‚æ‚è“Ë‘RŽ€‚𗈂µ‚œ‹H‚Ȑæ“V«Š¥“®–¬‹NŽnˆÙí‚̈êÇ—áB‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    37. ‹{è‚ ‚ä‚݁AãšŒhˆê˜YA•l“¹—T“ñA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jA“¡–؁@–ŸFQT‰„’·ÇŒóŒQ‚É‚š‚¯‚éŒðŠŽ_ŒoŒnŽhŒƒ–òÜ•‰‰×S“d}ŒŸž‚̈Ӌ`B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998,7,“Œ‹ž.
    38. ‹Ž–{ˆè•vA•l“¹—T“ñAãšŒhˆê˜YA’ÔŠáÁˆêAŽs“c•™ŽqA‹àŒ“O˜aA‹{˜e—˜’jAŽOè‘ñ˜YAŽO‰Y³‹`A‰ª•”@ŒhA‘º“c“Þ”üA¬ò¹ˆêFAutomatic Border Detection‚ð—p‚¢‚œ¬Ž™‰»Šw—Ö@Š³Ž™‚É‚š‚¯‚éƒAƒ“ƒgƒ‰ƒTƒCƒNƒŠƒ“S‹ØáŠQ‚Ì‘Šúf’f‚̉”\«B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï, 1998,7,“Œ‹ž.
    39. •l“¹—T“ñA‹Ž–{ˆè•vAãšŒhˆê˜YAŽs“c•™ŽqA¬Œ@“OA‹{˜e—˜’jA…–qŒ÷ˆêA“¡–؁@–ŸF¬Ž™‚̐_Œo’²ß«Žž_‚ɑ΂·‚éHead-up tiltŽŽŒ±‚Ì—L—p«‚ÌŒŸ“¢B‘æ34‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1998, 7,“Œ‹ž.
    40. Œ‘q—TŠìA‘ê“cˆê˜NA”öã—mˆêA‹{˜e—˜’jA¡–쏺GAŽ…@áÁF•aŒŽ«‘å’°‹Û‚n26‚ÌŠŽõ‚É”º‚¢táŠQ‚ð”F‚ß‚œˆê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    41. ”ÂàVŽõŽqAFè@Œ’AŽíŽsq’ˆA”öã—mˆêA‹àŒ“O˜aA”ª–ؐMˆêF‰ºŽˆ‚Ìáu’É‚ðŽå‘i‚Æ‚µ‚œNeuroblastoma(NB)‚̈ê—áB‘æ‚P‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,7,•xŽR.
    42. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YA‹{˜e—˜’jA‹{è‚ ‚ä‚݁F‚RÎŽž‚É“Ë‘R‚Ì“÷Šá“IŒŒ”A‚É‚Ä”­Ç‚µ‚œAlport's syndrome‚̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–ŒŒÃ‰®.
    43. ‹g“cärA¡‘º”Ž–ŸA‹{˜e—˜’jA‰ê—ˆ–œ—R”üA”ª”Š‹`lF“ú—î‚P‚ÉŒðŠ·—AŒŒ‚ð•K—v‚Æ‚µ‚œˆâ“`«‹…óÔŒŒ‹…Ç‚̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–ŒŒÃ‰®.
    44. ’†—ÑŒºˆêA‹Ž–{ˆè•vA‹àŒ“O˜aA¬Œ@“OA‹{˜e—˜’jA—Sì˜aŽqFI-cell•a(ƒ€ƒRƒŠƒsƒh[ƒVƒXEŒ^)‚Ì‚UƒJŒŽ’jŽ™—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–ŒŒÃ‰®.
    45. •£àV—³–çA‹k@çHA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA¬—Ñ’B–çFŽc‘¶Žîᇂɑ΂µƒKƒ“ƒ}ƒiƒCƒt‚ªŒø‰Ê“I‚Å‚ ‚Á‚œ¬”]‘‰èŽî‚̈ê—áB‘æ34‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1998,8,–ŒŒÃ‰®.
    46. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YA‹{˜e—˜’jA‹{è‚ ‚ä‚݁F‚RÎŽž‚É“Ë‘R‚Ì“÷Šá“IŒŒ”A‚É‚Ä”­Ç‚µ‚œAlport's syndrome‚̈ê—áB‘æ20‰ñ“ú–{¬Ž™t•s‘SŠw‰ï,1998,9,VŠƒ.
    47. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚æ‚蓯’肳‚ê‚œV‚œ‚ÈXLAÇ—á‚ÆBtkˆâ“`Žq•ÏˆÙ‰ðÍBŒú¶È“Á’莟Š³ŒŽ”­«–Ɖu•s‘SÇŒóŒQ’²žŒ€‹†”Ç•œ¬10”N“x‘æ‚P‰ñ”ljï‹c‘‰ï,1998,9,Œyˆä‘ò.
    48. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jA“c’†’ŒŽqA–Ø‘º@GFƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒX‰ŠŽõ‚É‚æ‚é‚ÆŽv‚í‚ê‚œ‹}«ŒŒ¬”ÂŒž­«Ž‡”Á•a‚̈ê“ûŽ™—áB‘æ@‚U‰ñ–k—€ƒwƒ‹ƒyƒXŒ€‹†‰ï,1998,9,‹à‘ò.
    49. Matsukura H., Shinozaki K., Inaba S., Miyawaki T.: Long-term Follow-up of Steroid Responsive Nephrotic Syndrome in 86 Children.IPNA,1998,9,London .
    50. Takai R, Matsukura H. and Miyawaki T.: Glomerular podocyte vacuolation in childhood IgA nephropathy. IPNA,1998,9,London.
    51. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™“«‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚āB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,1998,9,‹à‘ò.
    52. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqAŽR’J”ü˜aA‹{˜e—˜’jF‹»–¡‚ ‚é”]”gŠŒ©‚ð’悵‚œeyelids myoclonia‚ÌŒZ’í—áB‘æ34‰ñ“ú–{¬Ž™_ŒoŠw‰ï–k—€’n•û‰ï,1998,9,‹à‘ò.
    53. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚ÌŠO‰È“IŽ¡—Ẩ”\«‚ɂ‚¢‚āB‘æ‚U‰ñ•xŽRŒ§—Տ°¬Ž™_ŒoŠwŒ€‹†‰ï,1998,9,•xŽR.
    54. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‰¡“cF”VAŠžŒŽ¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[«ŽŸŠ³“û—cŽ™‚É‚š‚¯‚é“úí“I‚ȃlƒR‚Ƃ̐ڐG‚ƌċzŠíÇó‚ÌŠÖŒWB‘æ35‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1998,9,‘åã.
    55. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YArˆä”ü˜aŽqAŽðˆä—R‹IAˆ¢•”KŽqA‚ˆä—¢A‹{˜e—˜’jA–L“‡Sˆê˜YFæ“V«…tÇ‚𔺂€Š®‘Sd•¡t᱔AŠÇ‚̐f’f‚ÉMR urography‚ª—L—p‚Å‚ ‚Á‚œˆê—áB‘æ28‰ñ“ú–{t‘ŸŠw‰ïŒ•”Šwp‘å‰ï,1998,10,“Þ—Ç.
    56. ¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éŒõ‰ß•q«‚ÌŒŸ“¢-Œõ‰ß•q«”]”gˆÙí‚ðŽŠ‚µ‚œÇ—á‚ɂ‚¢‚Ä-B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    57. ”ª–ؐMˆêA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA‹{˜e—˜’jF¬Ž™‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éŒõ‰ß•q«‚ÌŒŸ“¢-Œõ‰ß•q«”­ì‚ðŽŠ‚µ‚œÇ—á‚ɂ‚¢‚Ä-B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    58. ŽR’J”ü˜aA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vA‘ºã”ü–çŽqA”ª–ؐMˆêF“û—cŽ™Šú‚̓«‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚鐇–°ŠoÁƒŠƒYƒ€‚̏áŠQB‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    59. Œ‘òƒŽqA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF¬Ž™“«EÇŒó«‚Ä‚ñ‚©‚ñ‚É‚š‚¯‚éƒvƒƒgƒ“‚l‚q‚rŠŒ©B‘æ32‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1998,10,‰¡•l.
    60. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‹{˜e—˜’jFƒAƒŒƒ‹ƒM[«ŽŸŠ³“û—cŽ™‚É‚š‚¯‚éƒlƒRƒAƒŒƒ‹ƒM[‚̗Տ°“IˆÓ‹`B‘æ‚P‰ñ•xŽR¬Ž™šb‘§Œ€‹†‰ï,1998,10,•xŽR.
    61. Konishi T, Matsuzawa J, Hongou K, Yamatani M, Yagi S, and Miyawaki T.: Disturbance of sleep-wake rhythm in infants with intractable epilepsy. 2nd Asian Oceanian Epilepsy Organization,1998,11,Taipei,Taiwan.
    62. Matsuzawa J, Konishi T, Hongou K, Yamatani M, Yagi S, and Miyawaki T.: Proton MRS findings of children with intractable epilepsy. 2nd Asian Oceanian Epilepsy Organization,1998,11,Taipei,Taiwan.
    63. –쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jFEBVƒQƒmƒ€—z«ƒÁƒÂT×–EƒŠƒ“ƒpŽî‚̈ꏗŽ™—áB‘æ40‰ñ“ú–{—Տ°ŒŒ‰tŠw‰ï,1998,11,‹à‘ò.
    64. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jA‹Ž–{Í“ñA’Ë“c@‘AŠâ“c@—́A¬‹{ŽR@~Fƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚ɂĐf’f‚³‚ê‚œ‚w˜Aœ«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌBtkˆâ“`Žq‰ðÍB‘æ40‰ñ“ú–{—Տ°ŒŒ‰tŠw‰ï,1998,11,‹à‘ò.
    65. ”öã—mˆêA‘ê“cˆê˜NAŒ‘q—TŠìAŽRŒ³ƒŽqA‘«—§—YˆêA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jFFontanpŒã‚É”­Ç‚µ‚œplastic bronchitis‚Ì’jŽ™—áB‘æ31‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,1998,11,‰¡•l.
    66. •£‘ò—³–çA–쑺ŒbŽqAŒ‘òƒŽqA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jFGuillain-BarreÇŒóŒQ‚É‚š‚¯‚éŒoŽž“IƒŠƒ“ƒp‹…ƒTƒuƒZƒbƒg‚̐„ˆÚB‘æ30‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1998,11,Œ–{.
    67. –쑺ŒbŽqA•£‘ò—³–çAŒ‘q—TŠìA‹{˜e—˜’jAFè@Œ’F•aŒŽ«‘å’°‹ÛO-26‚É‚æ‚é—nŒŒ«”A“ŏǏnjóŒQ‚̈ê—áB‘æ30‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1998,11,Œ–{.
    68. Œ‘òƒŽqA¬Œ@“OAÝ“c—FŽqA‹àŒ“O˜aA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jF‹»–¡‚ ‚é—Տ°Œo‰ß‚ðŽŠ‚µ‚œƒqƒgƒwƒ‹ƒyƒXƒEƒBƒ‹ƒX‚UŒ^”]‰ŠE”]Ç‚Ì‚P—áB‘æ30‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1998,11,Œ–{.
    69. ‹àŒ“O˜aA˜eŒû@GFEBƒEƒCƒ‹ƒXŠŽõÇ‚É‚š‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10. ‘æ30‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1998,11,Œ–{.
    70. ‹àŒ“O˜aA‹{˜e—˜’jA‘Ÿ“c˜aGAŒÜ\—’@“oA—Sì˜aŽqFHunterÇŒóŒQ(ƒ€ƒR‘œ“œ—ށEŒ^)‚Q—á‚̈â“`Žq‰ðÍB‘æ19‰ñ–k—€æ“VˆÙíŒ€‹†‰ï,1998,12,•xŽR.
    71. ”‘òŽõŽqA‘ºãIŒ[AŽRŒ³ƒŽqA”öã—mˆêA‘«—§—YˆêA‹{˜e—˜’jF¬Ž™‹CŠÇŽxšb‘§‚É‚š‚¯‚éƒEƒBƒ‹ƒXŠŽõ‚ÌŠÖ—^[MxA’`”’‚ðŽw•W‚Æ‚µ‚ā[B‘æ25‰ñ–k—€ƒAƒŒƒ‹ƒM[§˜b‰ï,1998,12,‹à‘ò.
    72. Ý“c—FŽqA”ª–ؐMˆêA–쑺ŒbŽqA‹àŒ“O˜aA‹{˜e—˜’jF–«“÷‰èŽîÇ“ûŽ™—á‚É‚Ý‚ç‚ê‚œ‰ŠÇ«’°•a•Ï[’·ŠúƒXƒeƒƒCƒh­—Ê“Š—^‚Æ‘å’°ƒtƒ@ƒCƒo[‚É‚æ‚éŒoŽž“IŠÏŽ@[B‘æ‚U‰ñH×–E‹@”\ˆÙíÇŒ€‹†‰ï,1998,12,“Œ‹ž.
    73. ‹àŒ“O˜aA”ŒãˌŽËAãŒˆê‰iA‹Ž–{ÍŽiA’Ë“c@‘AŠâ“c@—́A¬‹{ŽR~A‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚ɂĐf’f‚³‚ê‚œ‚w˜Aœ«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌBtkˆâ“`Žq‰ðÍB‘æ28‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1998,12,_ŒË.
    74. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºFƒAƒgƒs[«”畆‰Š(AD)Š³ŽÒ‚É‚š‚¯‚é‚s×–ECD30”­Œ»—Š‚ÆŒŒ’†solubleCD30’l‚ÌŠÖŒWB‘æ48‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,1998,12,_ŒË.
    75. ”öã—mˆêA‘«—§—YˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‰ª•””üŒbA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºFƒAƒgƒs[«”畆‰Š(AD)Š³ŽÒ‚É‚š‚¯‚é––œŒŒƒŠƒ“ƒp‹…ƒTƒCƒgƒJƒCƒ“ŽY¶[×–E“àƒTƒCƒgƒJƒCƒ“‚ðŽw•W‚Æ‚µ‚ā[‘æ48‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ï‘‰ï,1998,12,_ŒË.
    76. ŽíŽsq’ˆA”ÂàVŽõŽqA‹àŒ“O˜aA‹{˜e—˜’jAA‘º”ü‹IA‘ºãIŒ[FD’†‹…Œž­Ç‚𔺂Á‚œ–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚̈ê—áB‘æ‚Q‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,12,•xŽR.
    77. Œ‘q—TŠìA‹{˜e—˜’jA–L“‡Sˆê˜YFæ“V«…tÇ‚É‚š‚¯‚éMagnetic Resonance UrographyiMRUj‚ÌŽg—pŒoŒ±‚ɂ‚¢‚āB‘æ‚Q‰ñ“ú–{¬Ž™‰ÈŠw‰ï•xŽR’n•û‰ï,1998,12,•xŽR.
    78. Hashimoto I., Ichida F., Uese K., Hamamichi Y., Miyawaki T.: THP-ADR induces lower degree of cardiotoxicity than ADR: Determination of cardiotoxicity by automatic border detection. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    79. Hamamichi Y., Ichida F., Uese K., Hashimoto I., Tsubata S., Miyawaki T., Ono Y., Kamiya T. : Isolated noncompaction of the ventricular myocardium -UFCT and magnetic resonance imaging- The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    80. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Miyazaki A., Fukahara K., Murakami A., Nakajima A., Futatsuya R., Miyawaki T.: Evaluation of pulmonary blood supply by multiplanar cine magnetic resonance imaging in patients with pulmonary atresia and severe pulmonary stenosis. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    81. Ichida F., Hashimoto I., Tsubata S., Hamamichi Y., Uese K., Murakami A., Miyawaki T.: Novel technique using biplane cine magnetic resonance imaging for evaluation of left ventri-cular volume in children. The 26th Annual Meeting of the North American Society for Cardiac Imaging,1998,11,Dallas,USA.
    82. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Futatani T., Kanegane H., and Miyawaki T.: Neutrophils and mononuclear cells secrete vascular endothelial growth factor in acute Kawasaki disease. The 71st Scientific Sessions of American Heart Association,1998,11,Dallas,USA.

    1997”N

  • ’˜‘
    1. Vˆä“c@—vC“ñ’J@•C‹{˜e—˜’jF‚w˜Aœ«–³ƒÁ-ƒOƒƒuƒŠƒ“ŒŒÇ‚̈â“`Žqf’fuAnnual ReviewŒŒ‰tv‚‹vŽj–›‘Œ•Ò,185-193,’†ŠOˆãŠwŽÐ,“Œ‹ž,1997.
    2. ‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇŒóŒQDu1997E¡“ú‚ÌŽ¡—ÃŽwj‘æ11”Łv–î“cƒˆê‘Œ•Ò,222,ˆãŠw‘‰@,“Œ‹ž,1997.
    3. ˆîê@iF—nŒŒ«”A“ŏǏnjóŒQ(HUS)Du1997E¡“ú‚̏¬Ž™Ž¡—ÃŽwj‘æ11”Łv–î“cƒˆê‘Œ•Ò,401-402,ˆãŠw‘‰@,“Œ‹ž,1997.
    4. ‹{˜e—˜’jFŒŽ”­«–Ɖu•s‘SÇDu¬Ž™‰ÈŠwv”’–ؘa•v‘Œ•Ò,695-700,ˆãŠw‘‰@,“Œ‹ž,1997.
    5. ¬Œ@“OFÒ‘ŽŸŠ³Du¬Ž™‰ÈŠwv”’–ؘa•v‘Œ•Ò,1431-1434,ˆãŠw‘‰@,“Œ‹ž,1997.
    6. ‹{˜e—˜’jF–Ɖu‹@”\‚Ì”­’BDu•W€–ƉuŠwv’JŒû@ŽA‹{â¹”V•Ò,480-486,ˆãŠw‘‰@,“Œ‹ž,1997.
    7. ’Ë“c@‘A“ñ’J@•A‹{˜e—˜’jF“ú–{‚ÌBrutonŒ^–³ƒÁƒOƒƒuƒŠƒ“ŒŒÇ‰ÆŒn‚É‚š‚¯‚éBtk•ÏˆÙu–Ɖu1997-98vŠÝ–{’‰ŽO•Ò,222-232,’†ŽR‘“X,“Œ‹ž,1997.
    8. “ñ’J@•A‹{˜e—˜’jFˆâ“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SDuÅV“à‰ÈŠw‘åŒnƒvƒƒOƒŒƒX‚Sv‹ààVˆê˜Y‘Œ•Ò,182-193,’†ŽR‘“X,“Œ‹ž,1997.
    9. ’Ë“c@‘A“ñ’J@•A‹{˜e—˜’jFu–Ɖu1997-98vŠÝ–{’‰ŽO•Ò,222-232,’†ŽR‘“X,“Œ‹ž,1997.
    10. “ñ’J@•A‹{˜e—˜’jF“û—cŽ™ˆê‰ß«’áƒÁƒOƒƒuƒŠƒ“ŒŒÇF¬Ž™“à‰È•Êûu¬Ž™ŽŸŠ³f—Â̂œ‚ß‚Ì•a‘Ԑ¶—v¬Ž™“à‰È•ÒWˆÏˆõ‰ï•Ò,963-965,“Œ‹žˆãŠwŽÐ,“Œ‹ž,1997.
    11. “ñ’J@•A‹{˜e—˜’jFˆâ“`ŽqˆÙí‚É‚æ‚é–Ɖu•s‘SDuÅV“à‰ÈŠw‘åŒnƒvƒƒOƒŒƒX‚Sv‹ààVˆê˜Y‘Œ•Ò,182-193,’†ŽR‘“X,“Œ‹ž,1997.
  • ŒŽ’˜
    1. Kasahara Y., Iwai K., Yachie A., Ohta K., Konno A., Seki H., Miyawaki T. and Taniguchi N.: Involvement of reactive oxygen intermediates in spontaneous CD95(Fas/AP0-1)-mediated apoptosis of neutrophils. Blood@89 : 1748-1753,1997.
    2. C. Sgadari., J. M. Farber., A. L. Angiolillo., F. Liao., J. Teruya-Feldstein., P. R. G. Gupta., Kanegane C., and Tosato G. : Mig, the monokine induced by Interferon-ƒÁpromotes tumor necrosis In vivo. Blood 89 : 2635-2643,1997.
    3. Kanegane H., Wada T., Nunogami K., Seki H., Taniguchi N., and Tosato G. : Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology : 95, 116-122, 1996.
    4. Kanegane H., and Tosato G. : Activation of naive and memory T cells by Interleukin-15. Blood 88 : 230-235,1996.
    5. Kanegane H., Wang F., and Tosato G. : Virus-cell interactions in a Natural Killer-like cell line from a patient with lymphoblastic lymphoma. Blood 88 : 4667-4675,1996.
    6. Angiolillo A.L., Kanegane H., Sgadari C.,Reeman G.R., and Tosato G. : Interleukin-15 promotes angiogenesis in Vivo. Biochemical and Biophysical Research Communications 233 : 231-237,1997.
    7. Kanegane H., Kanegane C., Yachie A., Miyawaki T., and Tosato G. : Infectious mononucleosis as a disease of early childhood in Japan caused by primary Epstein-Barr virus infection. Acta Paediatrica Japonica 39:166-171,1997.
    8. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., and Giovanna T. : Viral Interleukin-10 in chronic active Epstein-Barr virus infection. The Jounal of Infection DIseases 176 : 254-257,1997.
    9. Yamamoto S., Inaba S., Yoshida R., Takahashi T., Ishihara S., Sakai Y., Arai M., Kurose K., Matsukura H., and Miyawaki T.: Clinicopathological characteristics of the focal and segmental form of idiopathic membranous nephropathy: Comparison with the typical form of this disease. Acta Paediatrica Japonica 39 : 349-353 ,1997.
    10. Yagi S., Konishi T., Masuko K., Matsuzawa J., Hongou K., Yamatani M., and Miyawaki T.: Clinical features of patients with tonic spasms; Persistence beyond infacy. Epilepsia 38:77-78,1997.
    11. Miura M., Okabe T., Tsubata S., Takizawa N., and Sawaguchi T. : Chronic infantile neurological cutaneous articular syndrome in a patient from Japan. Eur J Pediatr 156 : 624-626,1997.
    12. Naganuma Y., Konishi T., Hongou K., Okada T., Tohyama J., and Uchiyama M. : Event-related Potentials (P300) and EEG activity in childhood partial epilepsy. Brain & Development 19 : 117-121,1997.
    13. Naganuma Y., Konishi T., Hongou K., Tohyama J., and Uchiyama M. : Epileptic seizures and event-related potentials (P300) in childhood partial epilepsies. Clinical Electroencephalography 28 : 106-111,1997.
    14. Ichida F.,Tsubata S., Hashimoto I., Hamamichi Y., Uese K., Fukahara K., Murakami A., and Miyawaki T.: Effect of oral prostacyclin and inhaled NO on pulmonary hypertension in children. J of Cardiology 29 : 217-224,1997.
    15. Ichida F., Uese K., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Additive effect of Beraprost on pulmonary vasodilation by nitric oxide in children with pulmonary hypertension. Am J Cardiol 80 : 662-664,1997.
    16. Tsubata S., Ichida F., and Miyawaki T.: Balloon angioplasty for isolated coarctation of the aorta with mirror image right aortic arch in an infant.Cardiol Young. 7 : 458-461,1997.
    17. Uese K., Ichida F., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Oral prostacyclin analogue enhances the pulmonary vasodilatory effect of nitric oxide in children with pulmonary hypertension. Cardiol Young. 7 : 362-369,1997.
    18. Murakami A., Fukahara K., Ichida F., Yahagi N., and Kumon K. : Significance of nitric oxide inhalation for reperfused lung. Artificial Organ. 21: 83-87,1997.
    19. Fukahara K., Murakami A., Ueda T., Doki Y., Tsubata S., Ichida F., and Misaki T. : Scheduled autologous blood donation at the time of cardiac catheterization in infants and children. J Thorac Cardiovasc Surg. 114 : 504-505,1997.
    20. Yokoyama Y., Narahara K., Teraoka M., Koyama K., Seino Y.,Yagi S., Konishi T., and Miyawaki T.: Cryptic pericentric inversion of chromosome 17 detected by fluorescence in situ hybridization study in familial Miller-Dieker syndrome. Am J @of Medical Genetics 71:236-237,1997.
    21. Y. Adachi, T. Mio, K. Takigawa, I. Striz, D. J. Romberger, R. A. Robbins, J. R. Spurzem, P. Heires, S. I. Rennard. Mutual inhibition by TGF-beta and IL-4 in cultured human bronchial epithelial cells. Am. J. Physiol. 273: L701-708; 1997.
    22. Feldstein J.T., Jaffe E.S., Burd P.R., Kanegane H., Kigma D. W., Wilson W. H., Longo D. L., and Tosato G. : The role of Mig, the monokine induced by interferon-ƒÁ, and IP-10 , the interferon-ƒÁ-Inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood 90 : 4099-4105,1997.
    23. ‘ŽqDA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFNIHŠÜˆÓ•¶(1980)A”M«‚¯‚¢‚ê‚ñ§˜b‰ïŽ¡—ÃŽwj(1988)AŽw“±ƒKƒCƒhƒ‰ƒCƒ“(1996)‚É‚æ‚é”M«‚¯‚¢‚ê‚ñ—\–h“Š—^‚ÌŽÀÛD¬Ž™‰È—Տ° 50F65-71,1997.
    24. ‰z“c—ŒbA‹Ž–{_”VA‰œ“c‘¥•FA¬ŒšõŽqA‘å–ìˆê˜YA’J“à]ºGA‹{˜e—˜’jFæ“V«ƒTƒCƒgƒƒKƒƒEƒCƒ‹ƒXŠŽõÇ|‘œÊ‚ȗՏ°‘œ‚Ì”äŠrŒŸ“¢‚š‚æ‚Ñ”D•w‚̍R‘Ì•Û—L—Š‚ƃEƒCƒ‹ƒXƒQƒmƒ€‚ÌŒŸo‚ÌŽŽ‚݁|D“ú–{V¶Ž™Šw‰ïŽGŽ@33:228-233,1997.
  • Ç—á•ñ
    1. Kanegane H., Wada T., Nunogami K., Seki H., Taniguchi N., and Tosato G. : Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. British Journal of Haematology : 95, 116-122, 1996.
    2. ˆîê@iArˆä”ü˜aŽqA•£‹žŽqAŽðˆä—R‹IAˆ¢•”KŽqAŒ‘q—TŠìA‹{˜e—˜’jF“÷Šá“IŒŒ”A”­ìŽž‚Ɉê‰ß«‚̐t‹@”\’ቺ‚ð”F‚ß‚œIgAtÇ‚Ì‚P—áB“ú–{¬Ž™t•s‘SŠw‰ïŽGŽ@17F39-40,1997.
    3. ‹g“c@–LA‰i“c‹`‹BAL“cKŽŸ˜YAŽÄ“cŒbŽOAÎ£@~A–k@‹`lA‹àŒ“O˜aF‘œ‘ŸŠí•s‘S‚ð‡•¹‚µ‚œƒCƒ“ƒtƒ‹ƒGƒ“ƒU‚`ƒEƒCƒ‹ƒXŠŽõ‚Ì‚PÇ—áD“ú–{W’†Ž¡—ÈãŠw‰ïŽGŽ@4F375-380,1997.
    4. ‰ª•”@ŒhAŽs‘ºž‰xA‹Ž–{ˆè•vA ŽO‰Y³‹`A’·’Jì@Œ’F"Growth without GH"‚ð’悵‚œRathke”X–E‚Ì‚P—áDƒzƒ‹ƒ‚ƒ“‚ƗՏ° 45F38-42,1997.
    5. ‹Ž–{ˆè•vAŽO‰Y³‹`AŽs‘ºž‰xA‰ª•”@ŒhAãšŒhˆê˜YA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–{@–ŸFƒJƒeƒRƒ‰ƒ~ƒ“—U”­«‘œŒ`¬SŽº«•p”‚Ì‚P—Ž™—áD“ú–{¬Ž™‰ÈŠw‰ïŽGŽA101F1616-1619,1997.
  • ‘à
    1. ˆîê@iF”÷¬•Ï‰»Œ^ƒlƒtƒ[ƒ[ÇŒóŒQ‚ÌŽ¡—ÁD¬Ž™‰È 38:221-227,1997.
    2. ˆîê@iFt‘ŸÇŒóŒQ|‚»‚Ì‘Œ‚̐t‘ŸŽŸŠ³‚ðŠÜ‚ß‚Ä(ã)|•ªßót’áŒ`¬D“ú–{—Տ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.16 397-399,“ú–{—Տ°ŽÐ,‘åã,1997.
    3. ˆîê@iFt‘ŸÇŒóŒQ|‚»‚Ì‘Œ‚̐t‘ŸŽŸŠ³‚ðŠÜ‚ß‚Ä(‰º)|‘̈ʐ«’`”’”AB“ú–{—Տ°—̈æ•ÊÇŒóŒQƒVƒŠ[ƒYNo.17 672-674,“ú–{—Տ°ŽÐ,‘åã,1997.
    4. ˆîê@iF–Œ«tÇB¬Ž™“à‰È 29:638-640,1997.
    5. ‹{˜e—˜’jF‚w˜AœƒŠƒ“ƒp‘BÇŒóŒQBˆãŠw‚Ì‚ ‚ä‚Ý 182:758-761,1997.
    6. ‘«—§—YˆêA‹{˜e—˜’jFTh2×–E‚ÆCD30B—Տ°–Ɖu 29F1533-1538,1997.
    7. Š}ŒŽ‘PmA‹{˜e—˜’jFEBVŠŽõ‚É‚š‚¯‚éT×–EŠˆ«‰»‚ƍזEŽ€DBIC Forum 2:79-84,1997.
    8. ¬Œ@“OFŒŸ—t‚Ì’x‚êD¬Ž™‰Èf—à 60(‘)F491-494,1997.
    9. ¬Œ@“OF‚Ä‚ñ‚©‚ñ‚̍ŐVf’fEŒŸž–@DŽ¡—à 79F1993-1999,1997.

  • 1997”NŠw‰ï”­•\
    1. ãšŒhˆê˜YA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA‚”©ÍŽiFŠ®‘S–[ŽºƒuƒƒbƒN‚ð‡•¹‚µ‚œS‹Ø‰Š‚̈ê—áD‘æ13‰ñ–k—€¬Ž™zŠÂŠí§˜b‰ï,1997,1,‹à‘ò.
    2. –{‹œ˜a‹vA¬Œ@“OA‘ŽqDAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF—ǐ«“ûŽ™áz¹‚̗Տ°‘œD‘æ31‰ñ–k—€¬Ž™_Œo§˜b‰ï,1997,2,‹à‘ò.
    3. Adachi Y., Onoue Y., Tamamoto J., Adachi Y.S., Seki D., Morohashi M., Murakami G.,and Miyawaki T.: CD30 expression on lymphocytes of patients with allergic diseases. American Academy of Allergy, Asthema and Immunology Meeting,1997, 2,San Francisco, USA.
    4. ¬Œ@“OA‘ŽqDAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jFRolandic discharge ‚ª“Ë‘RÁŽž‚Ü‚œ‚Í‘Œ‚Ì“Ë”­”g‚É•Ï—e‚µ‚œÇ—á‚̗Տ°“Á’¥D‘æ13‰ñRDŒ€‹†‰ï,1997,2,“Œ‹ž.
    5. –{‹œ˜a‹vA¬Œ@“OA‹g“c˜aŽiA‘ŽqDAŒ‘òƒŽqA”ª–ؐMˆêA‹{˜e—˜’jA‹àˆä‰pŽqF‹»–¡‚ ‚é‰æ‘œŠŒ©‚ðŽŠ‚µ‚œƒ‰ƒCÇŒóŒQ‚̈ê—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,3,•xŽR.
    6. –쑺ŒbŽqAÝ“c—FŽqA”ª–ؐMˆêA‹{˜e—˜’jA²“¡”üŒbA ‘ºãIŒ[A–{ŠÔˆê³Fœ‘üˆÛÇ‚𔺂Á‚œ‹}«‹Šj‰è‹…«”’ŒŒ•a(M7)‚̈ê—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,3,•xŽR.
    7. ‹Ž–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhAŽs‘ºž‰xAãšŒhˆê˜YA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA“¡–؁@–ŸFƒJƒeƒRƒ‰ƒ~ƒ“—U”­«‘œŒ`«SŽº«•p”‚Ì‚P—áD‘æ258‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,3,•xŽR.
    8. ”ª–ؐMˆêA ¬Œ@“OA‘ŽqDA–{‹œ˜a‹vAŽR’J”ü˜aA ‹{˜e—˜’jF•”•ª”­ìÇó‚ðŽŠ‚µ‚œWest ÇŒóŒQD‘æ21‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1997,3,‹à‘ò.
    9. Œ‘òƒŽqA¬Œ@“OA‘ŽqDA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF•¡ŽG•”•ª”­ìŒQ”­‚Å”­Ç‚µ‚œ‘€“ª—t‚Ä‚ñ‚©‚ñ‚Ì‚P—á|‰æ‘œŠŒ©‚𒆐S‚Ɂ|D‘æ21‰ñ–k—€‚Ä‚ñ‚©‚ñ§˜b‰ï,1997,3,‹à‘ò.
    10. Ý“c—FŽqA”ª–ؐMˆêA–쑺ŒbŽqA‹{˜e—˜’jAŽR‰º–F˜NAVˆä‰pŽ÷A‘Žq@—mF‰ŠÇ«’°ŽŸŠ³—ÞŽ—‚Ì’°ŠÇ•a•Ï‚ð’悵‚œ–«“÷‰èŽîÇ‚Ì‚P—áD‘æ18‰ñ•xŽR–ƉuƒAƒŒƒ‹ƒM[Œ€‹†‰ï,1997,3,•xŽR.
    11. à_“¹—T“ñA’ÔŠáÁˆêA‹Ž–{ˆè•vAãšŒhˆê˜YAŽs“c•™ŽqA‹{˜e—˜’jFIsolated Noncompaction of the Ventricular Myocardium‚̉Ƒ°“àWÏ—á`‚»‚Ìclinical entity‚Æ‚µ‚Ä‚Ì“Æ—§«‚ÌŒŸ“¢‚𒆐S‚Ɂ`‘æ61‰ñ“ú–{zŠÂŠíŠw‰ï,1997,3,“Œ‹ž.
    12. à_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêA“ñ’J@•A‘«—§—YˆêA‹{è‚ ‚ä‚݁Aˆîê@iAŽs“c•™ŽqA‹{˜e—˜’jA ‘ºãIŒ[AFè@Œ’Fìè•a‹y‚ÑŠeŽíŽŸŠ³‚É‚š‚¯‚錌’†ŒŒŠÇ“à”瑝BˆöŽq‚Ì“®‘ԂƗՏ°“IˆÓ‹`D‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    13. “ñ’J@•A¡‘º”Ž–ŸA‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[‚ð—p‚¢‚œX˜Aœ«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚ÌŠ³ŽÒE•ÛˆöŽÒf’fD‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    14. ‹{˜e—˜’jFƒVƒ“ƒ|ƒWƒEƒ€u–ƉuŒn‚ÌŠî‘b‚ƗՏ°v`‚w˜Aœ«–Ɖu•s‘SÇFˆâ“`Šw“I—‰ð‚ƐV‚µ‚¢•ÛˆöŽÒf’fD‘æ100‰ñ“ú–{¬Ž™‰ÈŠw‰ï,1997,4,“Œ‹ž.
    15. ’ÔŠáÁˆêAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vAŽs“c•™ŽqA‹{˜e—˜’jF“–‰È‚É‚š‚¯‚éìè•adÇS‡•¹‚𔺂Á‚œŠw“¶‚ÌŠÇ—D‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    16. ¡‘º”Ž–ŸA“ñ’J@•F“–‰È‚É‚š‚¯‚é’ŽE‹É’áo¶‘̏dŽ™‚̐g‘Ì”­ˆç‚ɂ‚¢‚āD‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    17. ˆÉ“Œ^—ŽqAÝ“c—FŽqA‘ŽqDAŒ‘òƒŽqA¬Œ@“OFŽá”N”­Ç‚̐ېHáŠQŽ™‚É‚š‚¯‚é—Տ°S—Šw“I“Á’¥D‘æ31‰ñ•xŽRŒ§¬Ž™•ÛŒ’Šw‰ï,1997,4,•xŽR.
    18. ‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‘«—§—zŽqA‰¡“cF”VA‹{˜e—˜’jA‘ºãIŒ[FCyclosporin A•¹—p‚É‚æ‚èƒXƒeƒƒCƒhŒž—Ê‚ðŽŽ‚Ý‚œ‹CŠÇŽxšb‘§‚Ì‚P’jŽ™—áD‘æ9‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ït‹G—Տ°‘å‰ï,1997,5,ç—t.
    19. Uese K., Ichida F., Tsubata S., Hashimoto I., Hamamichi Y., Fukahara K., Murakami A., and Miyawaki T.: Oral Prostacyclin Analogue Enhances the Pulmonary Vasodilator Effect of Nitric Oxide in Children with Pulmonary Hypertension. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery. 1997,5,Hawaii.(Young investigators award, The first Prize)
    20. Ichida F., Hamamichi Y., Uese K., Hashimoto I., Tsubata S., Miyawaki T., Ono Y., Kamiya T., Akagi T., Hamada H., Hirose O., Isobe T., Kojou M., Kurotobi S., Mito H., Miyake T., Nishi T., and Tomimatsu H.: Clinical Features of Isolated Noncompaction of Ventricular Myocardium in Japanese Children. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery, 1997,5,Hawaii.
    21. Hamamichi Y., Ichida F., Uese K., Hashimoto I., Tsubata S., Futatani T., Miyazaki A., Murakami G., Suzaki K., Inaba S., Murakami A., and Miyawaki T.: Increased Serum Levels of Vascular Endothelial Growth Factor in Kawasaki Disease. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery,1997,5,Hawaii.
    22. Hashimoto I., Uese K., Hamamichi Y., Tsubata S.,Miyazaki A., Ichida F., Murakami A., Miyawaki T., Arakaki Y., and Kamiya T. : A novel method for indexing angiographic left ventricular mass in normals and children with left ventricular hypertrophy. The 2nd World Congress of Pediatric Cardiology and Cardiac Surgery,1997,5,Hawaii.
    23. ‹àŒ“O˜aA‹àŒ“çtA˜eŒû@GA‘q”É—²MA‹à“c@®A˜a“c‘׎OA’J“à]ºGAŠÖ@GrArˆä@FAŒ®–{¹ˆêA‰ªè@ŽÀA‘åÎ@•×AGiovanna TosatoF–«Šˆ“®«Epstein-BarrƒEƒCƒ‹ƒXŠŽõÇ‚É‚š‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“10D‘æ‚V‰ñ‚d‚aƒEƒCƒ‹ƒXŠŽõÇŒ€‹†‰ï,1997,5,“Œ‹ž.
    24. ˆîê@iArˆä”ü˜aŽqAˆ¢•”KŽqAŽðˆä—R‹IAŽÂèŒ’‘Ÿ˜YA•£‹žŽqAŒ‘q—TŠìA‹{˜e—˜’jF¬Ž™t•s‘S•Û‘¶Šú‚É‚š‚¯‚éTJ-23‚ÌŒø‰ÊD‘æ40‰ñ“ú–{t‘ŸŠw‰ï,1997,5,VŠƒ.
    25. rˆä”ü˜aŽqAˆîê@iAˆ¢•”KŽqAŽðˆä—R‹IAŽÂèŒ’‘Ÿ˜YA•£‹žŽqAŒ‘q—TŠìA‹{˜e—˜’jF¬Ž™“«ƒlƒtƒ[ƒ[ÇŒóŒQ‚ÌCiclosporin—Ö@D‘æ40‰ñ“ú–{t‘ŸŠw‰ï,1997,5,VŠƒ.
    26. Ý“c—FŽqA”ª–ؐMˆêA–쑺ŒbŽqA‹{˜e—˜’jF–«“÷‰èŽîÇ‚É‚š‚¯‚é’°ŠÇ•a•Ï‚ÌŒŸ“¢D‘æ ‰ñ–k—€—Տ°–ƉuŒ€‹†‰ï,1997,5,‹à‘ò.
    27. ¬Œ@“OA‘ŽqDAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêFRolandic discharge ‚ÌŒo‰ß’†•Ï‰»‚Ì‘œ—l«‚ƗՏ°‘œD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–ŒŒÃ‰®.
    28. ‘ŽqDA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêF”M«áz¹‚É‚š‚¯‚é”­ìÄ”­‚ÉŠÖ‚·‚錟“¢ \—\–h“Š—^‚ðŽÀŽ{‚µ‚œÇ—á‚ɂ‚¢‚ā\D‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–ŒŒÃ‰®.
    29. Œ‘òƒŽqA‘ŽqDA¬Œ@“OA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêF‘å”]”玿Œ`¬ˆÙí‚ÌŠeŽí‰æ‘œŠŒ©‚ƗՏ°Çó‚ÌŠÖ˜A«‚ɂ‚¢‚āD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–ŒŒÃ‰®.
    30. ”ª–ؐMˆêAŒ‘òƒŽqA‘ŽqDA¬Œ@“OA –{‹œ˜a‹vAŽR’J”ü˜aF—Œ‘€Ž‹°•a•Ï‚ð’悵‚œ”]‰ŠE”]Ç‚̉摜ŠŒ©‚ɂ‚¢‚āD‘æ39‰ñ“ú–{¬Ž™_ŒoŠw‰ï,1997,6,–ŒŒÃ‰®.
    31. –{‹œ˜a‹vA¬Œ@“OA‘ŽqDAŒ‘òƒŽqAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF‚QÎ–¢–ž”­Ç‚̗ǐ«“ûŽ™áz¹‚Ì”­ì—\ŒãD|‚T”NˆÈã‚̒ǐ՗á‚É‚š‚¯‚錟“¢|D‘æ39‰ñ“ú–{¬Ž™_Œo‰ï,1997,6,–ŒŒÃ‰®.
    32. ‹Ž–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhA‘º“c“Þ”üAŽs“c•™ŽqA•l“¹—T“ñA‹{˜e—˜’jFAutomatic Border Detection System‚ð—p‚¢‚œ¬Ž™—á‚É‚š‚¯‚鍶Žº‹@”\‚ÌŒŸ“¢D‘æ4‰ñ–k—€zŠÂŠí’Ž‰¹”gŒ€‹†‰ï,1997,6,‹à‘ò.
    33. ¬ìŽŸ˜YA“ñ’J@•A¡‘º”Ž–ŸA‹{˜e—˜’jFæ“V«‹Ø‹Ù’£«ƒWƒXƒgƒƒtƒB[‚̈ê—áD‘æ259‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,6,•Ÿˆä.
    34. Œ‘òƒŽqA–{‹œ˜a‹vA¬Œ@“OA‘ŽqDAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF•”•ª”­ì‚ð’悵‚œWestÇŒóŒQ‚̈ê—áD‘æ259‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,6,•Ÿˆä.
    35. ˆîê@iA‹{˜e—˜’jA–öŒŽr—YAŒŽ@³‘¥A”óŒû@WA‚“cP˜YA’JàV—²–MF¬Ž™“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‚Ì’·Šú—\Œã‚ÆŽ¡—Â̍ČŸ“¢D‘æ32‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1997,6,‘åã.
    36. ŽÂèŒ’‘Ÿ˜YAˆîê@iAŒ‘q—TŠìArˆä”ü˜aŽqAŽðˆä—R‹IAˆ¢•”KŽqA•£‹žŽqA¬Œ@“OA‹{˜e—˜’jAŒE“c”Ž“¹A—é–؍D•¶FCockayneÇŒóŒQ‚̐t•a•ÏD‘æ32‰ñ“ú–{¬Ž™t‘Ÿ•aŠw‰ï,1997,6,‘åã.
    37. ŽÂèŒ’‘Ÿ˜YArˆä”ü˜aŽqAˆ¢•”KŽqA•£‹žŽqAŽðˆä—R‹IAŒ‘q—TŠìAˆîê@iA‹{˜e—˜’jFŒoŽž“I‚É”A’†Ž…‹…‘̏ã”ç×–E”‚ðŒŸ“¢‚µ‚œŽ‡”Á•a«t‰Š‚̈ê—áD‘æ27‰ñ•xŽRŒ§tŽŸŠ³lH“§ÍŒ€‹†‰ï,1997,6,•xŽR.
    38. Konishi T., Masuko K., Matsuzawa J., Hongou K., Yamatani M., Yagi S., and Miyawaki T.: Neuroradiological evaluation of cortical dysplasia in children with epilepsy. 22th International Epilepsy Congress,1997, 7,Dublin,Ireland
    39. ‹àŒ“O˜aA‰ª•””üŒbA–쑺ŒbŽqA‹{˜e—˜’jA¬ò•x”ü’©F’˜–Ÿ‚ȍœ‘üˆÛÇ‚𔺂Á‚œ‹}«‹Šj‰è‹…«”’ŒŒ•aiM7j‚̈ꏗŽ™—áD‘æ13‰ñ•xŽRŒ§ŒŒ‰tŽŸŠ³Œ€‹†‰ï,1997,7,•xŽR.
    40. A‘º”ü‹IA‰ª•””üŒbA‘«—§—zŽqA‘«—§—YˆêA”ª–ؐMˆêA‹{˜e—˜’jFƒ^ƒ“ƒiƒ‹ƒrƒ“•ž—p‚É‚æ‚èƒAƒiƒtƒBƒ‰ƒLƒV[ƒVƒ‡ƒbƒN‚ð‚š‚±‚µ‚œƒAƒgƒs[«”畆‰Š‚̈ê—áD‘æ33‰ñ•xŽRŒ§¬Ž™‰ÈW’k‰ï,1997, 7,•xŽR.
    41. ‹àŒ“O˜aA–쑺ŒbŽqA‹{˜e—˜’jAŒE“c”Ž“¹F‚d‚aƒEƒBƒ‹ƒXŠÖ˜A‚s×–EƒŠƒ“ƒpŽî‚̈ê—áD‘æ33‰ñ•xŽRŒ§¬Ž™‰ÈW’k‰ï,1997,7,•xŽR.
    42. à_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jAŽ…³ŽiA£ŒË@ŒõFìè•a‚É‚š‚¯‚éƒhƒuƒ^ƒ~ƒ“•‰‰×Sƒv[ƒ‹‚É‚æ‚鍶SƒpƒtƒH[ƒ}ƒ“ƒX‚ÌŒŸ“¢D‘æ28‰ñ–k—€zŠÂŠíŠjˆãŠwŒ€‹†‰ï,1997,7,‹à‘ò.
    43. ãšŒhˆê˜YA‹Ž–{ˆè•vAŽO‰Y³‹`A’ÔŠáÁˆêAŽs“c•™ŽqAà_“¹—T“ñA‹{˜e—˜’jFCathecho-laminergic polymorphic ventricular tachycardia‚̏¬Ž™—áD‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997,7,‹ž“s.
    44. ‹Ž–{ˆè•vAŽO‰Y³‹`A‰ª•”@ŒhAŽs‘ºž‰xAŽs“c•™ŽqA‹{˜e—˜’jFAutomatic Border Detection System‚ð—p‚¢‚œ¬Ž™¶ŽºŽûk”\AŠg’£”\‚Ì•]‰¿D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997, 7,‹ž“s.
    45. à_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jF“ûŽ™Šú‚Ìnative coarctation‚Ì‚R—á‚ɑ΂·‚éŒo”ç“IŒŒŠÇŒ`¬p‚ÌŒoŒ±D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997,7,‹ž“s.
    46. Žs“c•™ŽqAŽÂèŒ’‘Ÿ˜YAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vA’ÔŠáÁˆêA‹{˜e—˜’jA‹{è‚ ‚ä‚݁A¬–ìˆÀ¶A_’J“N˜YAÔ–Ø’õŽ¡A•l“c—m’ʁAL£@CAˆé•”„ŽuAŒÃé¹“WA•”òr“ñAŽOŒË”ŽŽuAŽO‘îrŽ¡A‘ºã•Û•vAŒ@–ҁA“c‘ãT“ñ˜YA•xŒG•¶F–{–M‚É‚š‚¯‚éIsolated noncompaction of ventricular myocardium‚̗Տ°‘œ`‘S‘’²žŒ‹‰Ê`D‘æ33‰ñ“ú–{¬Ž™zŠÂŠíŠw‰ï,1997, 7,‹ž“s.
    47. Œ‘q—TŠìArˆä”ü˜aŽqAˆ¢•”KŽqAŽÂèŒ’‘Ÿ˜YAŽðˆä—R‹IA•£‹žŽqAˆîê@iA‹{˜e—˜’jFCiclosporin associated arteriolopathy ‚ð”F‚ß‚œ“Á”­«ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áD‘æ‚T‰ñ’†•”¬Ž™t‘Ÿ•aŒ€‹†‰ï,1997,7,‹à‘ò.
    48. Œ‘q—TŠìArˆä”ü˜aŽqAˆ¢•”KŽqAŽÂèŒ’‘Ÿ˜YAŽðˆä—R‹IA•£‹žŽqAˆîê@iA‹{˜e—˜’jFƒtƒƒZƒ~ƒh‚Ƀƒgƒ‰ƒ]ƒ“‚𕹗p‚µŒ€“I‚È—˜”AŒø‰Ê‚ð”F‚ß‚œ¬Ž™ƒlƒtƒ[ƒ[ÇŒóŒQ‚̈ê—áD‘æ19‰ñ¬Ž™‘̉tŒ€‹†‰ï,1997,7,“Œ‹ž.
    49. ãšŒhˆê˜YA‹k@çHAà_“¹—T“ñA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jA‚”©ÍŽiA‹àŒ“çtFŠ®‘S–[ŽºƒuƒƒbƒN‚ð‡•¹‚µ‚œS‹Ø‰Š‚Ì‚QÇ—áD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    50. ‹àŒ“O˜aA‹{˜e—˜’jA‹à“c@®A’J“à]ºGAŠÖ@GrArˆä@FA‘åÎ@•×AMarina Gutierrez, Kishor Bhatia, Giovanna TosatoFŒo‰ß’†‚É‚d‚aƒEƒCƒ‹ƒXŠÖ˜A‚s×–EƒŠƒ“ƒpŽî‚ð‡•¹‚µ‚œ–«Šˆ“®«‚d‚aƒEƒCƒ‹ƒXŠŽõÇ‚Ì‚Q—áD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    51. Ý“c—FŽqA‘ºãIŒ[A–{ŠÔˆê³F“–‰È‚É‚š‚¯‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹Ž‘±‹z“ü—Ö@‚ðs‚Á‚œ‹CŠÇŽxšb‘§Ç—á‚̗Տ°“IŒŸ“¢D‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    52. ŽÂèŒ’‘Ÿ˜YAˆîê@iAŽðˆä—R‹IAˆ¢•”KŽqArˆä”ü˜aŽqA•£‹žŽqAŒ‘q—TŠìA¬Œ@“OA‹{˜e—˜’jAŒE“c”Ž“¹A—é–؍D•¶FCockayneÇŒóŒQ‚̐t•a•ÏD‘æ33‰ñ’†•”“ú–{¬Ž™‰ÈŠw‰ï,1997,8,•xŽR.
    53. ŽÂèŒ’‘Ÿ˜YAŒ‘q—TŠìAŠ™’JˆŸ‹IŽqAˆîê@iA‹{˜e—˜’jFBardet-BiedleÇŒóŒQ‚ÌŒo‰ß’†‚É‹}«Ž…‹…‘̐t‰Š‚𕹔­‚µ‹}«t•s‘S‚ɊׂÁ‚œˆê—áD‘æ45‰ñ’†•”t‘Ÿ•a’k˜b‰ï,1997,9,–ŒŒÃ‰®.
    54. Œ‘òƒŽqA¬Œ@“OA‘ŽqDA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”]‰ŠE”]ÇŒãˆâÇŠ³Ž™‚Ì‚l‚q‚rŠŒ©‚ɂ‚¢‚āD‘æ32‰ñ–k—€¬Ž™_Œo§˜b‰ï,1997,9,‹à‘ò.
    55. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YAŠ™’JˆŸ‹IŽqAˆîê@iA‹{˜e—˜’jAŒIŒŽ^‹IŽqA”šèŠì–FF’á•â‘ÌŒŒÇ‚ð’悵‹}«t•s‘S‚ð‡•¹‚µ‚œŽ…‹…‘̐t‰Š‚Ì‚QÇ—áD‘æ19‰ñ“ú–{¬Ž™t•s‘SŠw‰ï,1997,9,Œyˆä‘ò.
    56. –쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA’J“à]ºGAŠ}ŒŽ‘PmA˜a“c‘׎OA•zãFŽuF¶Œã‘Šú‚æ‚èŒÄ‹zŠíŠŽõÇ‚𔜕œ‚·‚é’jŽ™—á`CD3Œ‡‘¹Ç‚©HD‘æ25‰ñ“ú–{—Տ°–ƉuŠw‰ï,1997,9,“Œ‹ž.
    57. “ñ’J@•A‹àŒ“O˜aA‹{˜e—˜’jA’Ë“c@‘A‹Ž–{ÍŽiAVˆä“c@—vF‚w˜Aœ«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•ÛˆöŽÒf’f‚ƈâ“`“I”wŒiD‘æ25‰ñ“ú–{—Տ°–ƉuŠw‰ï,1997,9,“Œ‹ž.
    58. Œ‘òƒŽqA¬Œ@“OA‘ŽqDA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF‘å”]”玿Œ`¬ˆÙí‚ð—L‚·‚é‚Ä‚ñ‚©‚ñ‚ÌSPECTAMRSŠŒ©‚ɂ‚¢‚āD‘æ31‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1997,9,‹ž“s.
    59. ‘ŽqDA¬Œ@“OAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêA‹{˜e—˜’jF”ñáz¹«‚Ä‚ñ‚©‚ñdÏÇ‚Ì”­ìŽž‚r‚o‚d‚b‚sŠŒ©D‘æ31‰ñ“ú–{‚Ä‚ñ‚©‚ñŠw‰ï,1997,9,‹ž“s.
    60. ¬Œ@“OA ‘ŽqDAŒ‘òƒŽqA–{‹œ˜a‹vAŽR’J”ü˜aA”ª–ؐMˆêFPhenitoin ŽUÜ‚Ì bioavailability –òÜ•ÏXŽž‚̗Տ°“I—¯ˆÓ“_D‘æ‚T‰ñ•xŽRŒ§¬Ž™—Տ°_ŒoŒ€‹†‰ï,1997,9,•xŽR.
    61. ‹k@çHAŽRŒ³ƒŽqA‹àŒ“O˜aA‹{˜e—˜’jA¬—Ñ’B–çFŽc‘¶Žîᇂɑ΂µ‚ăKƒ“ƒ}ƒiƒCƒt‚É‚æ‚é’èˆÊ•úŽËüŠO‰È—Ö@‚ðŽŽ‚Ý‚œ¬Ž™‘‰èŽî‚̈ê—áD‘æ‚V‰ñ–k—€¬Ž™ŠàÇ—ጟ“¢‰ï,1997,9,‹à‘ò.
    62. ‘«—§—YˆêAŽRŒ³ƒŽqA”öã—mˆêA‰ª•””üŒbA‘«—§—zŽqA‹{˜e—˜’jA–L“c‰ë•FAŠÖ@‘Ÿ•ãA”‹Ž³ºA…“‡@–LFƒAƒgƒs[«”畆‰ŠŠ³ŽÒ‚Ì––œŒŒƒwƒ‹ƒp[‚s×–E‚É‚š‚¯‚éCD30”­Œ»|‘æ‚Q•ñ@—Տ°‘œ‚Æ‚ÌŠÖŒW-D‘æ47‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹G‘å‰ï,1997,9,‰¡•l.
    63. ”öã—mˆêA‘«—§—YˆêAŠžŒŽ¹ŽqAŠâ’J‰ëŽqA‰¡“cF”VA‹{˜e—˜’jA‘ºãIŒ[AŒ–쐳’mA•“¡“Ö•FF‰Æ‰®o’†ƒ`ƒƒƒ^ƒeƒ€ƒVRŒŽ—ʁ`’nˆæ“I·ˆÙ‚š‚æ‚Ñ‹Gß“I•Ï“®‚ɂ‚¢‚āD‘æ47‰ñ“ú–{ƒAƒŒƒ‹ƒM[Šw‰ïH‹G‘å‰ï,1997,9,‰¡•l.
    64. Š™’JˆŸ‹IŽqAŽÂèŒ’‘Ÿ˜YAãšŒhˆê˜YAà_“¹—T“ñA‹Ž–{ˆè•vA‹{˜e—˜’jA‘ºã@VA‚”©ÍŽiFFallotŽl’¥Ç‚̏pŒã‚ɐSŽº•p”‚𔺂Á‚œ‚p‚s‰„’·ÇŒóŒQ‚̈ê—áD‘æ260‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,9,‹à‘ò.
    65. à_“¹—T“ñAãšŒhˆê˜YA‹Ž–{ˆè•vA’ÔŠáÁˆêAŽs“c•™ŽqA‹{˜e—˜’jAŽ…³ŽiA£ŒË@ŒõFTc-99mƒhƒuƒ^ƒ~ƒ“•‰‰×Sƒv[ƒ‹ƒCƒ[ƒWƒ“ƒO‚É‚æ‚éìè•aŠ¥“®–¬áŠQ—á‚̍¶Žº‹@”\‚ÌŒŸ“¢D‘æ17‰ñìè•aŒ€‹†‰ï,1997,10,ŽD–y.
    66. ‹àŒ“O˜aA“ñ’J@•A‹{˜e—˜’jF–«Šˆ“®«‚d‚aƒEƒCƒ‹ƒXŠŽõÇ‚É‚š‚¯‚éƒEƒCƒ‹ƒXEƒCƒ“ƒ^[ƒƒCƒLƒ“10‚Ì”­Œ»D‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    67. Œ‘q—TŠìAŠÝ@—TKA‹{˜e—˜’jA‘ºŒû@“āFwhnˆâ“`ŽqŽY•š‚Ì‹¹‘BƒXƒgƒ[ƒ}×–E‚É‚š‚¯‚é‹@”\D‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    68. “ñ’J@•A’Ë“c@‘A‹Ž–{ÍŽiA‹àŒ“O˜aA‹{˜e—˜’jFƒtƒ[ƒTƒCƒgƒƒgƒŠ[–@‚É‚æ‚é‚w˜Aœ«–³ƒKƒ“ƒ}ƒOƒƒuƒŠƒ“ŒŒÇ‚Ì•ÛˆöŽÒf’f‚ƈâ“`“I”wŒi‚ɂ‚¢‚āD‘æ27‰ñ“ú–{–ƉuŠw‰ï‘‰ï,1997,10,ŽD–y.
    69. Ý“c—FŽqA‘«—§—YˆêA–쑺ŒbŽqAŒ‘òƒŽqA“ñ’J@•A‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jF”­Ç‘Šú‚ɏÁ‰»ŠÇ“÷‰è•a•Ï‚ðŠÏŽ@‚µ“Ÿ‚œ–«“÷‰èŽîÇ“ûŽ™‚Q—áD‘æ29‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1997,11,²‰ê.
    70. ‹àŒ“O˜aAŠ™’JˆŸ‹IŽqA–쑺ŒbŽqA“ñ’J@•A‹{˜e—˜’jA‘哇FˆêF––œŒŒ‚s×–EƒŒƒZƒvƒ^[ƒÁƒÂœ—z«T×–E‚Ì‘‰Á‚𔺂Á‚œ–«Šˆ“®«‚d‚aƒEƒBƒ‹ƒXŠŽõÇ‚̈ê—áD‘æ29‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1997,11,²‰ê.
    71. Œ‘òƒŽqA¬Œ@“OA‘ŽqDA–{‹œ˜a‹vA”ª–ؐMˆêA‹{˜e—˜’jAX“‡P—YFÄ”­Žž‚ÉŒ°’˜‚È•sˆÓ‰^“®‚ð’悵‚œƒwƒ‹ƒyƒX”]‰Š‚Ì‚P—áD‘æ29‰ñ“ú–{¬Ž™ŠŽõÇŠw‰ï,1997,11,²‰ê.
    72. Hamamichi Y., Ichida F., Tsubata S., Uese K., Hashimoto I., Miyawaki T., Miyazaki A., and Seto H. : Low-dose dobutamine stress radionuclide ventriculography for evaluation of left ventricular performance in Kawasaki disease. The 70th Scientific sessions of American Heart Association,1997,11, Orland,USA.
    73. Hashimoto I., Ichida F., Okabe T., Miura M., Nomura K., Uese K., Hamamichi Y., Tsubata S., Miyawaki T., and Misaki T.: Evaluation of left ventricular diastolic function using automatic border detection system in children after chemotherapy for malignant neoplasms. The 70th Scientific sessions of American Heart Association, 1997,11,Orland,USA.
    74. ‘«—§—zŽqA‘«—§—YˆêA”öã—mˆêAŽRŒ³ƒŽqA‰ª•””üŒbA‰¡“cF”VAŠžŒŽ¹ŽqAŠâ’J‰ëŽqA‹{˜e—˜’jA‘ºãIŒ[FƒAƒŒƒ‹ƒM[«ŽŸŠ³“û—cŽ™‚É‚š‚¯‚éƒlƒRRAST—z«—Š‚Æ‚»‚̗Տ°“IˆÓ‹`D‘æ34‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1997,11,“Œ‹žD
    75. ²“¡¹ŽqAŒ–쐳’mAˆÉ“Œ“¹•vAŒŽ@³‘¥A–öŒŽr—YA‘«—§—YˆêA“àŽR@¹F‹CŠÇŽxšb‘§dÏ”­ì‚ɑ΂·‚éƒCƒ\ƒvƒƒeƒŒƒm[ƒ‹­—ÊŽ‘±‹z“ü—Ö@‚̗Տ°“IŒŸ“¢D‘æ34‰ñ“ú–{¬Ž™ƒAƒŒƒ‹ƒM[Šw‰ï,1997,11,“Œ‹žD
    76. ŽRŒ³ƒŽqAŒ‘òƒŽqAŠ™’JˆŸ‹IŽqAŽÂèŒ’‘Ÿ˜YA“ñ’J@•A‘«—§—YˆêA‹{˜e—˜’jF‘}ŠÇŒã‚ÌSqueezingi—pŽè‹¹Šsˆ³”—Š·‹C•â•j‚É‚æ‚芷‹C•s‘S‚©‚ç’Eo‚µ“Ÿ‚œ‹CŠÇŽxšb‘§dÏ”­ì‚̈ê’jŽ™—áD‘æ30‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,1997,11,‘åãD
    77. Œ–쐳’mAˆÉ“Œ“¹•vA‘«—§—YˆêAŒÜ\—’—²•vF¬Ž™‹CŠÇŽxšb‘§‚ÌŠ°‰ð‚ÉŽŠ‚é‰ß’ö‚Å‚Ì‹C“¹‰ß•q«‚̐„ˆÚ‚ɂ‚¢‚āD‘æ30‰ñ“ú–{¬Ž™ŒÄ‹zŠíŽŸŠ³Šw‰ï,1997,11,‘åãD
    78. ŽRŒ³ƒŽqA‰ª•””üŒbA”öã—mˆêA‘«—§—YˆêA”ª–ؐMˆêA‹{˜e—˜’jA‘ºãIŒ[F’·ŠúŠÔ‚̐lHŠ·‹C‚ð—]‹V‚È‚­‚³‚ê‚œ‹CŠÇŽxšb‘§”­ì‚̈ê’jŽ™—áD‘æ23‰ñ–k—€ƒAƒŒƒ‹ƒM[§˜b‰ï,1997,11,‹à‘òD
    79. Kanegane H., Kamaya A., Nomura K., Futatani T., Oshima K., and Miyawaki T.: Epstein-Barr virus-bearing T cell receptor ƒÁƒÂ-positive T-cell lymphoproliferative disorder with recurrent oral ulcerations. American Society of Hematology 39th annual meeting,1997,12,San Diego,U.S.A.
    80. Futatani T., Tsubata S., Hashimoto S., Kanegane H., Kishimoto T., and Miyawaki T. : Flowcytometric detection of Bruton's tyrosine kinase deficiency and its carrier in X-linked agammaglobulinemia. American Society of Hematology 39th annual meeting. 1997,12,San Diego,U.S.A.
    81. A‘º”ü‹IA‹àŒ“O˜aA”ª–ؐMˆêA‹{˜e—˜’jA•£‹žŽqFŒ‹ß«g”Á—l”ç]‚ðŒ_‹@‚ÉŒ©‚‚©‚Á‚œŽá”NŒ^–«œ‘«”’ŒŒ•a‚Ì‚SÎ’jŽ™—áD‘æ261‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,12,•xŽR.
    82. Œ‘q—TŠìAŽÂèŒ’‘Ÿ˜YArˆä”ü˜aŽqAŽðˆä—R‹IA•£‹žŽqAˆ¢•”KŽqAˆîê@iA‹{˜e—˜’jFCAPD’†‚Ì–«t•s‘SŠ³Ž™‚ɐ¬’·ƒzƒ‹ƒ‚ƒ“‚ð“Š—^‚µ‚œ‚QÇ—áD‘æ261‰ñ“ú–{¬Ž™‰ÈŠw‰ï–k—€’n•û‰ï,1997,12,•xŽR.

    ƒAƒbƒvƒf[ƒg:2018.3.7 by X“àmŽu